0001493152-24-04602810-Q BIOTRICITY INC. 20241114202411141702421702431702430243 0 0001493152-24-046028 10-Q 69 20240930 20241114 20241114 BIOTRICITY INC. 0001630113 3841 472548273 NV 0331 10-Q 34 001-40761 241464029 203 REDWOOD PARKWAY SUITE 600 REDWOOD CITY CA 94065 (650) 832-1626 203 REDWOOD PARKWAY SUITE 600 REDWOOD CITY CA 94065 METASOLUTIONS, INC. 20150107 10-Q 1 form10-q.htm false Q2 --03-31 2025 0001630113 0001630113 2024-04-01 2024-09-30 0001630113 2024-11-13 0001630113 2024-09-30 0001630113 2024-03-31 0001630113 us-gaap:PreferredStockMember 2024-09-30 0001630113 us-gaap:PreferredStockMember 2024-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 us-gaap:SeriesAPreferredStockMember 2024-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-03-31 0001630113 us-gaap:PreferredStockMember 2024-09-30 0001630113 us-gaap:PreferredStockMember 2024-03-31 0001630113 2024-07-01 2024-09-30 0001630113 2023-07-01 2023-09-30 0001630113 2023-04-01 2023-09-30 0001630113 us-gaap:PreferredStockMember 2024-06-30 0001630113 us-gaap:CommonStockMember 2024-06-30 0001630113 BTCY:SharesToBeIssuedMember 2024-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001630113 us-gaap:RetainedEarningsMember 2024-06-30 0001630113 2024-06-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-06-30 0001630113 BTCY:MezzanineEquityMember 2024-06-30 0001630113 us-gaap:CommonStockMember 2024-03-31 0001630113 BTCY:SharesToBeIssuedMember 2024-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001630113 us-gaap:RetainedEarningsMember 2024-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-03-31 0001630113 BTCY:MezzanineEquityMember 2024-03-31 0001630113 us-gaap:PreferredStockMember 2023-06-30 0001630113 us-gaap:CommonStockMember 2023-06-30 0001630113 BTCY:SharesToBeIssuedMember 2023-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001630113 us-gaap:RetainedEarningsMember 2023-06-30 0001630113 2023-06-30 0001630113 us-gaap:PreferredStockMember 2023-03-31 0001630113 us-gaap:CommonStockMember 2023-03-31 0001630113 BTCY:SharesToBeIssuedMember 2023-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001630113 us-gaap:RetainedEarningsMember 2023-03-31 0001630113 2023-03-31 0001630113 us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001630113 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001630113 BTCY:SharesToBeIssuedMember 2024-07-01 2024-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001630113 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-07-01 2024-09-30 0001630113 BTCY:MezzanineEquityMember 2024-07-01 2024-09-30 0001630113 us-gaap:PreferredStockMember 2024-04-01 2024-09-30 0001630113 us-gaap:CommonStockMember 2024-04-01 2024-09-30 0001630113 BTCY:SharesToBeIssuedMember 2024-04-01 2024-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-09-30 0001630113 us-gaap:RetainedEarningsMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-04-01 2024-09-30 0001630113 BTCY:MezzanineEquityMember 2024-04-01 2024-09-30 0001630113 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001630113 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001630113 BTCY:SharesToBeIssuedMember 2023-07-01 2023-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001630113 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001630113 us-gaap:PreferredStockMember 2023-04-01 2023-09-30 0001630113 us-gaap:CommonStockMember 2023-04-01 2023-09-30 0001630113 BTCY:SharesToBeIssuedMember 2023-04-01 2023-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-09-30 0001630113 us-gaap:RetainedEarningsMember 2023-04-01 2023-09-30 0001630113 us-gaap:CommonStockMember 2024-09-30 0001630113 BTCY:SharesToBeIssuedMember 2024-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001630113 us-gaap:RetainedEarningsMember 2024-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-09-30 0001630113 BTCY:MezzanineEquityMember 2024-09-30 0001630113 us-gaap:PreferredStockMember 2023-09-30 0001630113 us-gaap:CommonStockMember 2023-09-30 0001630113 BTCY:SharesToBeIssuedMember 2023-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001630113 us-gaap:RetainedEarningsMember 2023-09-30 0001630113 2023-09-30 0001630113 us-gaap:CommonStockMember 2023-06-29 2023-06-29 0001630113 us-gaap:CommonStockMember 2023-07-19 2023-07-19 0001630113 2022-04-01 2023-03-31 0001630113 2023-04-01 2024-03-31 0001630113 us-gaap:SeriesBPreferredStockMember 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember 2023-09-18 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001630113 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-09-30 0001630113 BTCY:LenderMember 2024-04-01 2024-09-30 0001630113 BTCY:TechnologyFeesMember 2024-07-01 2024-09-30 0001630113 BTCY:TechnologyFeesMember 2023-07-01 2023-09-30 0001630113 BTCY:TechnologyFeesMember 2024-04-01 2024-09-30 0001630113 BTCY:TechnologyFeesMember 2023-04-01 2023-09-30 0001630113 BTCY:DeviceSalesMember 2024-07-01 2024-09-30 0001630113 BTCY:DeviceSalesMember 2023-07-01 2023-09-30 0001630113 BTCY:DeviceSalesMember 2024-04-01 2024-09-30 0001630113 BTCY:DeviceSalesMember 2023-04-01 2023-09-30 0001630113 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001630113 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001630113 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001630113 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001630113 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001630113 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001630113 us-gaap:OfficeEquipmentMember 2024-09-30 0001630113 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001630113 BTCY:TwoSeriesANotesMember 2020-04-01 2021-03-31 0001630113 BTCY:TwoSeriesANotesMember 2021-03-31 0001630113 BTCY:SeriesANotesOneMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesANotesTwoMember 2021-03-31 0001630113 BTCY:SeriesANotesTwoMember 2020-04-01 2021-03-31 0001630113 BTCY:TwoSeriesANotesMember us-gaap:WarrantMember 2020-04-01 2021-03-31 0001630113 BTCY:PlacementAgentMember BTCY:SeriesANotesOneMember 2020-04-01 2021-03-31 0001630113 BTCY:PlacementAgentMember us-gaap:WarrantMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesANotesMember 2022-03-31 0001630113 BTCY:SeriesANoteMember 2022-12-30 0001630113 BTCY:NewConvertibleNoteMember 2022-12-30 0001630113 BTCY:NewConvertibleNoteMember 2022-12-30 2022-12-30 0001630113 BTCY:SeriesANotesMember 2021-04-01 2022-03-31 0001630113 BTCY:SeriesANoteMember 2024-09-30 0001630113 BTCY:SeriesANoteMember 2024-03-31 0001630113 BTCY:SeriesANoteMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesANoteMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesANoteMember 2023-07-01 2023-09-30 0001630113 BTCY:SeriesANoteMember 2023-04-01 2023-09-30 0001630113 BTCY:SeriesBNotesMember BTCY:AccreditedInvestorsMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesBNotesMember us-gaap:WarrantMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember BTCY:WarrantOneMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember BTCY:WarrantTwoMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember 2022-03-31 0001630113 BTCY:SeriesBNotesMember 2021-04-01 2022-03-31 0001630113 BTCY:SeriesBNotesMember 2022-04-01 2023-03-31 0001630113 BTCY:SeriesBNotesMember 2023-03-31 0001630113 BTCY:SeriesBNoteMember 2023-04-01 2024-03-31 0001630113 BTCY:SeriesBNotesMember 2024-03-31 0001630113 BTCY:SeriesBNoteMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesBNotesMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesBNoteMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesBNotesMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesBNotesMember 2023-07-01 2023-09-30 0001630113 BTCY:SeriesBNotesMember 2023-04-01 2023-09-30 0001630113 us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 us-gaap:SeriesBPreferredStockMember 2024-03-31 0001630113 BTCY:SeriesBNoteMember 2024-09-30 0001630113 BTCY:SeriesBNoteMember 2024-03-31 0001630113 BTCY:SeriesCNotesMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesCNotesMember 2024-09-30 0001630113 BTCY:SeriesCNotesMember us-gaap:WarrantMember 2024-04-01 2024-09-30 0001630113 BTCY:PlacementAgentMember BTCY:SeriesCNotesMember 2024-04-01 2024-09-30 0001630113 BTCY:PlacementAgentMember us-gaap:WarrantMember BTCY:SeriesCNotesMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesCNotesMember BTCY:NoteHoldersMember 2023-10-23 0001630113 BTCY:SeriesCNotesMember BTCY:PlacementAgentsWarrantsMember 2023-10-23 0001630113 BTCY:SeriesCNotesMember 2023-10-23 2023-10-23 0001630113 BTCY:SeriesCNotesMember 2023-04-01 2024-03-31 0001630113 BTCY:SeriesCNotesMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesCNotesMember 2024-03-31 0001630113 BTCY:SeriesCNotesMember 2023-07-01 2023-09-30 0001630113 BTCY:SeriesCNotesMember 2023-04-01 2023-09-30 0001630113 BTCY:SeriesCNotesMember 2023-09-30 0001630113 BTCY:SeriesCNoteMember 2024-09-30 0001630113 BTCY:SeriesCNoteMember 2024-03-31 0001630113 BTCY:SeriesCNoteMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesCNoteMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesCNoteMember 2023-07-01 2023-09-30 0001630113 BTCY:SeriesCNoteMember 2023-04-01 2023-09-30 0001630113 BTCY:OtherConvertibleNotesPayableMember 2023-01-23 0001630113 BTCY:OtherConvertibleNotesPayableMember 2023-01-23 2023-01-23 0001630113 us-gaap:NotesPayableOtherPayablesMember 2024-07-01 2024-09-30 0001630113 us-gaap:NotesPayableOtherPayablesMember 2024-04-01 2024-09-30 0001630113 us-gaap:NotesPayableOtherPayablesMember 2023-07-01 2023-09-30 0001630113 us-gaap:NotesPayableOtherPayablesMember 2023-04-01 2023-09-30 0001630113 us-gaap:NotesPayableOtherPayablesMember 2023-09-30 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-09-25 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-10-25 2023-10-25 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-10-25 0001630113 BTCY:TwentyFourMonthAnniversaryMember 2024-01-09 2024-01-09 0001630113 BTCY:TwentyFourMonthAnniversaryMember 2024-01-09 0001630113 BTCY:EighteenMonthAnniversaryMember 2024-06-17 2024-06-17 0001630113 BTCY:EighteenMonthAnniversaryMember 2024-07-01 2024-09-30 0001630113 BTCY:EighteenMonthAnniversaryMember 2024-09-30 0001630113 BTCY:EighteenMonthAnniversaryMember 2024-06-17 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2022-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-07-01 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-04-01 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-07-01 2023-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-04-01 2023-09-30 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2024-07-01 2024-09-30 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2024-04-01 2024-09-30 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2022-12-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember BTCY:FirstFourWeeksMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-07-01 2023-09-30 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-04-01 2023-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2022-12-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2022-12-01 2022-12-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2024-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2024-07-01 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2024-04-01 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2023-07-01 2023-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2023-04-01 2023-09-30 0001630113 BTCY:SeriesAConvertibleNoteHoldersMember 2022-12-30 0001630113 BTCY:NewPromissoryNoteMember 2022-12-30 0001630113 BTCY:NewPromissoryNoteMember 2022-12-30 2022-12-30 0001630113 BTCY:NewPromissoryNoteMember 2024-09-30 0001630113 BTCY:NewPromissoryNoteMember 2024-03-31 0001630113 BTCY:NewPromissoryNoteMember 2024-07-01 2024-09-30 0001630113 BTCY:NewPromissoryNoteMember 2024-04-01 2024-09-30 0001630113 BTCY:NewPromissoryNoteMember 2023-07-01 2023-09-30 0001630113 BTCY:NewPromissoryNoteMember 2023-04-01 2023-09-30 0001630113 BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-03-29 2023-03-29 0001630113 BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-03-29 0001630113 BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember BTCY:FirstFourWeeksMember 2023-03-29 2023-03-29 0001630113 BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember BTCY:RemainingThirtySixWeeksMember 2023-03-29 2023-03-29 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:AdditionalCollateralizedBridgeLoanAgreementMember 2023-07-18 2023-07-18 0001630113 BTCY:SeriesANotesMember BTCY:AdditionalCollateralizedBridgeLoanAgreementMember 2023-07-18 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-07-18 2023-07-18 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-07-18 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2024-07-01 2024-09-30 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2024-04-01 2024-09-30 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-07-01 2023-09-30 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-04-01 2023-09-30 0001630113 2023-06-01 2023-06-30 0001630113 us-gaap:RevolvingCreditFacilityMember 2024-09-30 0001630113 us-gaap:RevolvingCreditFacilityMember 2024-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-07-13 2023-07-13 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-07-13 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2023-08-11 0001630113 BTCY:TwoShortTermPromissoryNotesMember BTCY:OneInvestorMember 2023-08-11 2023-08-11 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2023-08-11 2023-08-11 0001630113 BTCY:ShortTermPromissoryNotesOneMember 2023-08-11 0001630113 BTCY:ShortTermPromissoryNotesOneMember 2023-08-11 2023-08-11 0001630113 BTCY:ShortTermPromissoryNotesTwoMember 2024-03-31 0001630113 BTCY:ShortTermPromissoryNotesTwoMember 2023-04-01 2024-03-31 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2024-09-30 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2024-03-31 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2024-07-01 2024-09-30 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2024-04-01 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-12-08 2023-12-08 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-12-08 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-07-01 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-04-01 2024-09-30 0001630113 BTCY:ShortTermLoanAgreementMember 2024-04-01 2024-09-30 0001630113 BTCY:ShortTermLoanAgreementMember 2024-03-31 0001630113 BTCY:ShortTermLoanAgreementMember 2024-07-01 2024-09-30 0001630113 BTCY:ShortTermLoanAgreementMember 2024-01-01 2024-09-30 0001630113 BTCY:ShortTermLoanAgreementMember 2024-04-01 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-02-29 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-02-01 2024-02-29 0001630113 BTCY:PromissoryNoteAgreementMember 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember 2024-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-07-

01 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-04-01 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-02-02 2024-02-02 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-02-02 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-07-01 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-04-01 2024-09-30 0001630113 2021-12-21 0001630113 2021-12-21 2021-12-21 0001630113 us-gaap:CashMember 2021-12-21 0001630113 2022-11-01 2022-11-30 0001630113 BTCY:TermLoanMember 2024-07-01 2024-09-30 0001630113 BTCY:TermLoanMember 2024-04-01 2024-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2020-04-01 2020-04-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2020-04-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2021-05-01 2021-05-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2024-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2024-03-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2024-07-01 2024-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2024-04-01 2024-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2023-07-01 2023-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2023-04-01 2023-09-30 0001630113 us-gaap:ConvertibleDebtMember 2024-04-01 2024-09-30 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesAPreferredStockMember 2024-04-01 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesAPreferredStockMember 2024-04-01 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesAPreferredStockMember 2023-04-01 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesAPreferredStockMember 2023-04-01 2023-09-30 0001630113 us-gaap:MeasurementInputSharePriceMember us-gaap:SeriesAPreferredStockMember srt:MinimumMember 2024-09-30 0001630113 us-gaap:SeriesAPreferredStockMember us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2024-09-30 0001630113 us-gaap:MeasurementInputSharePriceMember us-gaap:SeriesAPreferredStockMember srt:MinimumMember 2023-09-30 0001630113 us-gaap:MeasurementInputSharePriceMember us-gaap:SeriesAPreferredStockMember srt:MaximumMember 2023-09-30 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesBPreferredStockMember 2023-04-01 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesBPreferredStockMember 2023-04-01 2023-09-30 0001630113 us-gaap:MeasurementInputSharePriceMember srt:MinimumMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 us-gaap:MeasurementInputSharePriceMember srt:MaximumMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 us-gaap:MeasurementInputSharePriceMember srt:MinimumMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 us-gaap:MeasurementInputSharePriceMember srt:MaximumMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 us-gaap:ConvertibleDebtMember 2024-03-31 0001630113 us-gaap:ConvertibleDebtMember 2023-03-31 0001630113 us-gaap:ConvertibleDebtMember 2023-04-01 2023-09-30 0001630113 us-gaap:ConvertibleDebtMember 2024-09-30 0001630113 us-gaap:ConvertibleDebtMember 2023-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2023-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2023-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2024-04-01 2024-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2024-04-01 2024-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2023-04-01 2023-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2023-04-01 2023-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputSharePriceMember 2024-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputSharePriceMember 2024-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputSharePriceMember 2023-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputSharePriceMember 2023-09-30 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2024-09-30 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2024-03-31 0001630113 BTCY:ShareholdersMember 2024-09-30 0001630113 BTCY:ShareholdersMember 2024-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 us-gaap:SeriesAPreferredStockMember 2024-04-01 2024-09-30 0001630113 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001630113 us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember srt:MaximumMember 2023-09-19 0001630113 BTCY:PurchaseAgreementMember BTCY:BeneficiaryMember 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember BTCY:BeneficiaryMember 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-09-30 0001630113 BTCY:PurchaseAgreementMember us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-09-30 0001630113 us-gaap:SeriesBPreferredStockMember 2023-10-01 2023-12-31 0001630113 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001630113 us-gaap:CommonStockMember 2023-12-31 0001630113 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-03-31 0001630113 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001630113 us-gaap:SeriesBPreferredStockMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesCConvertibleNoteMember 2024-04-01 2024-09-30 0001630113 us-gaap:SeriesCPreferredStockMember 2024-07-01 2024-09-30 0001630113 us-gaap:SeriesCPreferredStockMember 2024-04-01 2024-09-30 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-09-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2016-02-02 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2024-07-01 2024-09-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2024-04-01 2024-09-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2023-07-01 2023-09-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2023-04-01 2023-09-30 0001630113 BTCY:TwoThousandAndTwentyThreeEquityIncentivePlanMember 2023-03-31 0001630113 BTCY:BrokerWarrantsMember 2024-03-31 0001630113 BTCY:ConsultantWarrantsMember 2024-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2024-03-31 0001630113 BTCY:BrokerWarrantsMember 2024-04-01 2024-09-30 0001630113 BTCY:ConsultantWarrantsMember 2024-04-01 2024-09-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2024-04-01 2024-09-30 0001630113 BTCY:BrokerWarrantsMember 2024-09-30 0001630113 BTCY:ConsultantWarrantsMember 2024-09-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2024-09-30 0001630113 BTCY:BrokerWarrantsMember srt:MinimumMember 2024-09-30 0001630113 BTCY:BrokerWarrantsMember srt:MaximumMember 2024-09-30 0001630113 BTCY:ConsultantWarrantsMember srt:MinimumMember 2024-09-30 0001630113 BTCY:ConsultantWarrantsMember srt:MaximumMember 2024-09-30 0001630113 us-gaap:StockOptionMember 2024-03-31 0001630113 us-gaap:StockOptionMember 2023-03-31 0001630113 us-gaap:StockOptionMember 2024-04-01 2024-09-30 0001630113 us-gaap:StockOptionMember 2023-04-01 2023-09-30 0001630113 us-gaap:StockOptionMember 2024-09-30 0001630113 us-gaap:StockOptionMember 2023-09-30 0001630113 srt:MinimumMember 2024-04-01 2024-09-30 0001630113 srt:MaximumMember 2024-04-01 2024-09-30 0001630113 srt:MinimumMember 2024-09-30 0001630113 srt:MaximumMember 2024-09-30 0001630113 BTCY:NewLeaseAgreementMember 2021-12-31 0001630113 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-09-30 0001630113 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-09-30 0001630113 2022-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001630113 us-gaap:FurnitureAndFixturesMember 2022-03-31 0001630113 us-gaap:OfficeEquipmentMember 2024-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001630113 us-gaap:OfficeEquipmentMember 2024-04-01 2024-09-30 0001630113 us-gaap:LeaseholdImprovementsMember 2024-04-01 2024-09-30 0001630113 us-gaap:SubsequentEventMember 2024-10-01 2024-10-31 0001630113 us-gaap:SubsequentEventMember BTCY:UnsecuredConvertiblePromissoryNotesMember 2024-11-01 2024-11-30 0001630113 us-gaap:SubsequentEventMember BTCY:UnsecuredConvertiblePromissoryNotesMember 2024-11-30 0001630113 us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001630113 us-gaap:SubsequentEventMember 2024-11-12 0001630113 us-gaap:SubsequentEventMember BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-10-01 2024-10-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Â Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â Form 10-Q Â (Mark One) Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â Â Â For the quarterly period ended September 30, 2024 Â Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the period from _____ to_____ Â Commission file number: 000-56074 Â BIOTRICITY INC. (Exact name of registrant as specified in its charter) Â Nevada Â 30-0983531 State or other jurisdiction of incorporation or organization) Â (I.R.S. Employer Identification No.) Â 203 Redwood Shores Parkway, Suite 600 Redwood City, California 94065 (Address of principal executive offices) Â (650) 832-1626 (Registrantâ€™s Telephone Number, Including Area Code) Â Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Â Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act). Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Emerging growth company â˜ Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ Â Securities registered pursuant to Section 12(b) of the Act: None. Â Title of each class Â Trading Symbol(s) Â Name of each exchange on which registered Common Stock, par value $0.001 per share Â BTCY Â OTCQB Â Indicate the number of shares outstanding of each of the issuerâ€™s classes of common stock, as of the latest practicable date: 24,394,442 shares of Common Stock, $0.001 par value, at November 13, 2024. As at that same date, the Company also has 160,672 Exchangeable Shares outstanding that convert directly into common shares, which when combined with its Common Stock produce an amount equivalent to 24,555,114 outstanding voting securities. Â Â Â Â Â Â BIOTRICITY INC. Â Part I â€“ Financial Information 3 Â Â Item 1 â€“ Condensed Consolidated Financial Statements 3 Item 2 â€“ Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 38 Item 3 â€“ Quantitative and Qualitative Disclosures About Market Risk 49 Item 4 â€“ Controls and Procedures 49 Â Â Part II â€“ Other Information 50 Â Â Item 1 â€“ Legal Proceedings 50 Item 2 â€“ Unregistered Sales of Equity Securities and Use of Proceeds 50 Item 3 â€“ Defaults Upon Senior Securities 50 Item 4 â€“ Mine Safety Disclosures 50 Item 5 â€“ Other Information 50 Item 6 â€“ Exhibits 50 Signatures 51 Â 2 Â Â PART 1 Â FINANCIAL INFORMATION Â Item 1 â€“ Condensed Consolidated Financial Statements Â Condensed Consolidated Balance Sheets at September 30, 2024 (unaudited) and March 31, 2024 (audited) 4 Â Â Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended September 30, 2024 and 2023 (unaudited) 5 Â Â Condensed Consolidated Statements of Mezzanine Equity and Stockholdersâ€™ Deficiency for the three and six months ended September 30, 2024 and 2023 (unaudited) 6 Â Â Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2024 and 2023 (unaudited) 9 Â Â Notes to the Condensed Consolidated Financial Statements 10 Â 3 Â Â BIOTRICITY INC. CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2024 (unaudited) AND MARCH 31, 2024 (audited) (Expressed in US Dollars) Â Â Â As at September 30, 2024Â Â Â Â Â $ Â Â Â As at March 31, 2024Â Â Â Â Â $ Â Â Â CURRENT ASSETSÂ Â Â Â Â Â Â CashÂ Â 173,270Â Â Â Â 786,060Â Â Accounts receivable, netÂ Â 1,499,990Â Â Â Â 1,468,655Â Â Inventory [Note 3]Â Â Â 1,817,561Â Â Â Â 1,879,402Â Â Deposits and other receivablesÂ Â 573,674Â Â Â Â 336,456Â Â Total current assetsÂ Â 4,064,495Â Â Â Â 4,470,573Â Â Â Â Â Â Â Â Â Â Â Â Â Â Deposits and other receivables [Note 10]Â Â 112,972Â Â Â Â 85,000Â Â Long-term accounts receivableÂ Â 78,699Â Â Â Â 149,907Â Â Property and equipment [Note 12]Â Â 12,576Â Â Â Â 15,552Â Â Operating right of use assets [Note 10]Â Â 1,023,318Â Â Â Â 1,221,593Â Â TOTAL ASSETSÂ Â 5,292,060Â Â Â Â 5,942,625Â Â Â Â Â Â Â Â Â Â Â Â Â Â CURRENT LIABILITIESÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Accounts payable and accrued liabilities [Note 4]Â Â 9,057,028Â Â Â 9,473,118Â Â Convertible promissory notes and short term loans [Note 5]Â Â 8,479,032Â Â Â 9,376,471Â Â Term loan, currentÂ Â 3,000,000Â Â Â 2,400,000Â Â Derivative liabilities [Note 8]Â Â 460,059Â Â Â 991,866Â Â Operating lease obligations, current [Note 10]Â Â 493,190Â Â Â 457,371Â Â Total current liabilitiesÂ Â 21,489,309Â Â Â 22,698,826Â Â Â Â Â Â Â Â Â Â Federally guaranteed loans [Note 7]Â Â 870,800Â Â Â 870,800Â Â Term loan [Note 6]Â Â 9,489,491Â Â Â 9,985,033Â Â Derivative liabilities [Note 8]Â Â 1,649,177Â Â Â 1,435,668Â Â Operating lease

obligationsÂ Â 674,013Â Â Â 929,115Â TOTAL LIABILITIESÂ Â 34,172,790Â Â Â 35,919,442Â Â Â Â Â Â Â Â MEZZANINE EQUITYÂ Â Â Â Â Â Â Series B Convertible Redeemable preferred stock, $0.001 par value, 600 shares authorized as of September 30, 2024 and March 31, 2024, respectively, 405 and 265 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively [Note 9]Â Â 2,286,105Â Â Â 1,488,920Â Â Â Â Â Â Â Â STOCKHOLDERSâ€™ DEFICIENCYÂ Â Â Â Â Â Â Preferred stock, $0.001 par value, 9,979,400 shares authorized as of September 30, 2024, and March 31, 2024, respectively, 1 share issued and outstanding as of September 30, 2024, and March 31, 2024 [Note 9]Â Â 1Â Â Â 1Â Series A preferred stock, $0.001 par value, 20,000 shares authorized as at September 30, 2024, and March 31, 2024, respectively, 200 and 6,304 preferred shares issued and outstanding as at September 30, 2024, and March 31, 2024, respectively [Note 9]Â Â 0Â Â Â 6Â Preferred stock, valueÂ Â 0Â Â Â 6Â Common stock, $0.001 par value, 125,000,000 shares authorized as at September 30, 2024, and March 31, 2024, respectively. Issued and outstanding common shares: 22,863,261 and 9,353,768 as at September 30, 2024 and March 31, 2024, respectively, and exchangeable shares of 160,672 outstanding as at September 30, 2024 and March 31, 2024, respectively [Note 9]Â Â 23,024Â Â Â 9,515Â Shares to be issued 194,998 and 324,276 shares of common stock as at September 30, 2024 and March 31, 2024, respectively) [Note 9]Â Â 142,537Â Â Â 269,065Â Additional paid-in-capitalÂ Â 104,842,124Â Â Â 95,723,083Â Accumulated other comprehensive (loss) / incomeÂ Â (73,415)Â Â 32,378Â Accumulated deficitÂ Â (136,101,106)Â Â (127,499,785) Total stockholdersâ€™ deficiencyÂ Â (31,166,835)Â Â (31,465,737) TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERSâ€™ DEFICIENCYÂ Â 5,292,060Â Â Â 5,942,625Â Â Commitments and contingencies [Note 11] Â Subsequent events [Note 13] Â See accompanying notes to unaudited Condensed Consolidated Financial Statements Â 4 Â Â BIOTRICITY INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2024, AND 2023 (unaudited) (Expressed in US Dollars) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three Months Ended September 30, 2024Â Â Three Months Ended September 30, 2023Â Â Six Months Ended September 30, 2024Â Â Six Months Ended September 30, 2023Â Â Â Â Â Â Â Â $Â Â $Â Â Â Â Â Â Â Â Â Â Â Â REVENUEÂ Â 3,266,846Â Â Â 2,891,297Â Â Â 6,468,589Â Â Â 5,912,062Â Â Â Â Â Â Â Â Â Â Â Â Cost of RevenueÂ Â 807,672Â Â Â 892,019Â Â Â 1,646,247Â Â Â 1,996,080Â GROSS PROFITÂ Â 2,459,174Â Â Â 1,999,278Â Â Â 4,822,342Â Â Â 3,915,982Â Â Â Â Â Â Â Â Â Â Â Â OPERATING EXPENSESÂ Â Â Â Â Â Â Â Â Â Â Â Â Selling, general and administrative expensesÂ Â 2,248,864Â Â Â 3,487,331Â Â Â 5,214,983Â Â Â 7,007,546Â Research and development expensesÂ Â 517,982Â Â Â 697,620Â Â Â 1,031,877Â Â Â 1,410,595Â TOTAL OPERATING EXPENSESÂ Â 2,766,846Â Â Â 4,184,951Â Â Â 6,246,860Â Â Â 8,418,141Â LOSS FROM OPERATIONSÂ Â (307,672)Â Â (2,185,673)Â Â (1,424,518)Â Â (4,502,159) Â Â Â Â Â Â Â Â Â Â Â Â Interest expenseÂ Â (752,075)Â Â (753,268)Â Â (1,520,748)Â Â (1,413,780) Accretion and amortization expenses [Note 5,6]Â Â (339,888)Â Â (596,420)Â Â (1,484,616)Â Â (1,153,639) Change in fair value of derivative liabilities [Note 8]Â Â (193,757)Â Â (18,783)Â Â (500,619)Â Â 82,669Â Gain (loss) upon convertible promissory notes conversion and redemption [Note 9]Â Â (4,690)Â Â 6,684Â Â Â (132,301)Â Â 13,132Â Other income (expense) [Note 9]Â Â 36,314Â Â Â (143,380)Â Â (193,486)Â Â (129,945Â NET LOSS BEFORE INCOME TAXESÂ Â (1,561,768)Â Â Â (3,690,840)Â Â Â (5,256,288)Â Â Â (7,103,722) Â Â Â Â Â Â Â Â Â Â Â Â Income taxes [Note 3]Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â NET LOSS BEFORE DIVIDENDSÂ Â (1,561,768)Â Â Â (3,690,840)Â Â Â (5,256,288)Â Â Â (7,103,722) Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock DividendsÂ Â (91,261)Â Â Â (190,442)Â Â Â (290,353)Â Â Â (379,139) Deemed Dividends [Note 9]Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â (3,054,680)Â Â â€”Â NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERSÂ Â (1,653,029)Â Â (3,881,282)Â Â (8,601,321)Â Â (7,482,861) Â Â Â Â Â Â Â Â Â Â Â Â Translation adjustmentÂ Â (129,376)Â Â 281,240Â Â Â (105,793)Â Â 105,410Â Â Â Â Â Â Â Â Â Â Â Â Â Â COMPREHENSIVE LOSSÂ Â (1,782,405)Â Â (3,600,042)Â Â (8,707,114)Â Â (7,377,451) Â Â Â Â Â Â Â Â Â Â Â Â LOSS PER SHARE, BASIC AND DILUTEDÂ Â (0.073)Â Â (0.441)Â Â (0.469)Â Â (0.853) Â Â Â Â Â Â Â Â Â Â Â Â WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDINGÂ Â 22,493,626Â Â Â 8,795,742Â Â Â 18,354,277Â Â Â 8,774,242Â Â See accompanying notes to unaudited Condensed Consolidated Financial Statements Â 5 Â Â BIOTRICITY INC. CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERSâ€™ DEFICIENCY FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2024, AND 2023 (unaudited) Â Â Â Â Â Â Â Â Â Â Â Â Â Â

business development and after additional equity and debt capitalization of the Company. Â During the fiscal year ended March 31, 2023, the Company raised funds through short-term loans and promissory notes, net of repayments of $1,476,121 from various lenders, and also raised funds through convertible notes, net of redemptions of $2,355,318 from various lenders. Â During the fiscal year ended March 31, 2024, the Company raised funds through short-term loans and promissory notes, net of repayments of $853,030 and convertible notes, net of redemptions of $2,962,386 from various lenders. The Company sold 36,897 common shares through use of its registration statement, for gross proceeds of $123,347, raising a net amount of $119,285 after paying a 3% placement fee and other issuance expenses. Â Additionally, on September 19, 2023, the Company entered into a security purchase agreement with an institutional investor for the issuance and sale of 220 shares of the Companyâ€™s newly designated Series B Preferred Stock, at a purchase price of $9,091 per share of Series B Preferred Stock (Note 9), or gross proceeds of $2,000,000. Net proceeds after issuance costs amounted to $1,900,000. During the three months ended March 31, 2024, 110 Series B preferred shares were issued for net proceeds of $925,000. Â During the six months ended September 30, 2024, 220 Series B preferred shares were issued for net proceeds of $1,732,532. The Company also raised $650,000 from the issuance of convertible notes to a lender. Lastly, the Company sold 97,811 common shares through use of its registration statement, for net proceeds of $125,221. Â As we proceed with the commercialization of the Bioflux, Biocore, and Biocare product development, we expect to continue to devote significant resources on capital expenditures, as well as research and development costs and operations, marketing and sales expenditures. Â Based on the above facts and assumptions, we believe our existing cash, along with anticipated near-term financings, will be sufficient to continue to meet our needs for the next twelve months from the filing date of this report. However, we will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines. Â 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Revenue Recognition Â The Company adopted Accounting Standards Codification Topic 606, â€œRevenue from Contracts with Customersâ€ (â€œASC 606â€) on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles â€“ (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue as performance obligations are satisfied. Â 11 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Both the Bioflux mobile cardiac telemetry device, and the Biocore device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Companyâ€™s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patientâ€™s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patientâ€™s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized. Â The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business. Â The Company recognized the following forms of revenue for the three and six months ended September 30, 2024, and 2023: Â SCHEDULE OF REVENUE RECOGNITIONÂ Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three months ended September 30Â Â Â Six months ended September 30Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â $Â Â $Â Â $Â Â $Â Technology feesÂ Â 3,064,814Â Â Â 2,731,461Â Â Â 6,081,064Â Â Â 5,500,379Â Device salesÂ Â 202,032Â Â Â 159,836Â Â Â 387,525Â Â Â 411,683Â TotalÂ Â Â 3,266,846Â Â Â 2,891,297Â Â Â 6,468,589Â Â Â 5,912,062Â Â Inventories Â Inventory is stated at the lower of cost and market value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. Â SCHEDULE OF INVENTORIESÂ Â Â September 30, 2024Â Â March 31, 2024Â Â Â Â $Â Â $Â Raw materialÂ Â 1,073,409Â Â Â 1,128,700Â Finished goodsÂ Â 744,152Â Â Â 750,702Â Â Â Â Â Â Â Â Â Â InventoriesÂ Â 1,817,561Â Â Â 1,879,402Â Â Â 12 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Significant accounting estimates and assumptions Â The preparation of the Condensed Consolidated Financial Statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. Â The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Â Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities: Â â— Fair value of stock options Â Â The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield. Â â— Fair value of warrants Â Â In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity. Â â— Fair value of derivative liabilities Â Â In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period. Â Â â— Functional currency Â Â Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses. Â Â â— Useful life of property and equipment Â Â The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively. Â 13 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â â— Provisions Â Â Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. Â Â â— Contingencies Â Â Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events. Â Â â— Inventory obsolescence Â Â Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. Â Â â— Income and other taxes Â Â The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. Â Â When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Companyâ€™s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Companyâ€™s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated. Â Â â— Incremental borrowing rate for lease Â Â The determination of the Companyâ€™s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Companyâ€™s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Companyâ€™s Condensed Consolidated Financial Statements. Â 14 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Earnings (Loss) Per Share Â The Company has adopted the Financial Accounting Standards Boardâ€™s (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 260-10 which provides for calculation of â€œbasicâ€ and â€œdilutedâ€ earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Companyâ€™s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings are computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method were not applicable during the periods presented as no conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented. Â Cash Â Cash includes cash on hand and balances with banks. Â Foreign Currency Translation Â The functional currency of the Companyâ€™s Canadian-based subsidiary is the Canadian dollar, and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Companyâ€™s Canadian subsidiaries from their functional currency into the Companyâ€™s reporting currency of United States dollars, consolidated balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholdersâ€™ deficiency. The Company has not, to the date of these Condensed Consolidated Financial Statements, entered into derivative instruments to offset the impact of foreign currency fluctuations. Â Accounts Receivable Â Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Companyâ€™s normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible. Â 15 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Fair Value of Financial Instruments Â ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Â â— Level 1 â€“ Valuation based on quoted market prices in active markets for identical assets or liabilities. Â â— Level 2 â€“ Valuation based on quoted market prices for similar assets and liabilities in active markets. Â â— Level 3 â€“ Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring managementâ€™s best estimate of what market participants would use as fair value. Â In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Companyâ€™s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Â Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans, accounts payable and accrued liabilities.

The Companyâ€™s derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Companyâ€™s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk. Â The fair value of financial instruments measured on a recurring basis is as follows: Â SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTSÂ Â Â As of September 30, 2024Â DescriptionÂ TotalÂ Â Level 1Â Â Level 2Â Â Level 3Â Assets:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CashÂ $173,270Â Â $173,270Â Â $â€”Â Â $â€”Â Total assets at fair valueÂ $173,270Â Â $173,270Â Â $â€”Â Â $â€”Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

embedded conversion and redemption features. Â For the Series A Notes, the Company recognized debt issuance costs in the amount of $2,301,854 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Notes. The Company also recognized initial debt discount in the amount of $8,088,003 and accreted the interest over the remaining lives of those Notes. The debt issuance costs were fully amortized by March 31, 2022. Â 20 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â On December 30, 2022, the Company exchanged $500,000 of Series A Notes along with its outstanding interest accrual of $121,500 into a new convertible note with the same note holder. The new convertible note has principal of $621,500, stated interest rate of 12% per annum, as well as option to convert outstanding principal and accrued interest at the conversion price, calculated at 75% multiplied by the average of the three lowest closing prices during the previous ten trading days prior to the receipt of the conversion notice. The new convertible note matured on December 30, 2023. Â Prior to year ended March 31, 2022, $10,575,500 face value of the Series A note was converted into common shares. As of March 31, 2022, the remaining face value was in the amount of $700,000. Â During the three and six months ended September 30, 2024, the Company recognized discount amortization of $nil. As of September 30, 2024, the discount on Series A convertible notes was fully amortized. During the three and six months ended September 30, 2023, the Company recognized discount amortization of $16,455 and 32,291, respectively as accretion and amortization expense. Â As of September 30, 2024, and March 31, 2024, the Company recorded $223,187 and $173,762, respectively, of interest accruals for the Series A Notes. Â During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $24,848 and $49,425, respectively, on Series A convertible notes. During the three and six months ended September 30, 2023, the Company recognized interest expense in the amount of $18,798 and $37,392, respectively, on Series A convertible notes. Â Series B Convertible Notes Â During the year ended March 31, 2021, the Company also issued $1,312,500 (face value) of convertible promissory notes (â€œSeries B Notesâ€) to various accredited investors. Â Commencing six months following the issuance date, and at any time thereafter, subject to the Companyâ€™s Conversion Buyout clause, at the sole election of the holder, any amount of the outstanding principal and accrued interest of the note (the â€œoutstanding balanceâ€) could be converted into that number of shares of Common Stock equal to: (i) the outstanding balance divided by (ii) the Conversion Price. Partial conversions of the note shall have the effect of lowering the outstanding principal amount of the note. The holder may exercise such conversion right by providing written notice to the Company of such exercise in a form reasonably acceptable to the Company (a â€œconversion noticeâ€). Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice. Â The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Companyâ€™s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion, redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is $6.36 per share for 100,000 warrant shares and $9.0 per share for 35,417 warrant shares. Â Net proceeds to the Company from convertible note issuances to March 31, 2021 amounted to $1,240,000 after the original issuance discount as well as payment of the financing related fees. The Company determined that the conversion and redemption features contained in the Series B Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liability associated with the embedded conversion and redemption features. Â 21 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â The Company recognized debt issuance costs in the amount of $10,000 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Series B Notes. The Company recognized initial debt discount of $1,312,500 and accreted the interest over the remaining lives of those notes. The debt issuance costs were fully amortized by March 31, 2022. Â During the year ended March 31, 2022, $472,500 (face value) of Series B Notes were converted into 34,586 common shares. As at March 31, 2022, $840,000 of Series B Notes remained unconverted and outstanding, which was equal to the face value of the relevant convertible notes. Â During the year ended March 31, 2023, $555,600 (face value) of Series B Notes were converted into 126,833 common shares (Note 9 d). Â During the year ended March 31, 2023, $126,680 (face value) of Series B Notes were redeemed by cash payment of $145,682. The redemption price was determined in accordance to the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note, was $24,408, and was recognized as a gain upon convertible note repayment. Â During the year ended March 31, 2024, the Company redeemed $135,710 of Series B Notes, through a cash payment of $162,851. A gain on redemption $18,540 was recognized as a result of this redemption, representing the difference between the cash payment and the face value of Series B Notes redeemed net of the related derivative liabilities ($45,681 for the year ended March 31, 2024). Â During the three and six months ended September 30, 2024, the Company redeemed $5,342 and $22,009 of Series B Notes, through a cash payment of $5,342 and $25,342, respectively. A gain on redemption of $1,761 and $8,320 was recognized as a result of this redemption, representing the difference between the cash payment and the face value of Series B Notes redeemed net of the related derivative liabilities ($1,761 and $8,320 for the three and six months ended September 30, 2024, respectively). Â During the three and six months ended September 30, 2023, the Company redeemed $52,049 and $102,376 of Series B Notes, through a cash payment of $62,459 and $122,851, respectively. A gain on redemption of $6,684 and $13,132 was recognized as a result of this redemption, representing the difference between the cash payment and the face value of Series B Notes redeemed net of the related derivative liabilities ($17,094 and $33,607 for the three and six months ended September 30, 2023, respectively). Â In total, the Company had issued $821,500 and $157,720 for Series A and Series B notes, respectively, out of which $821,500 and $nil for Series A Notes and Series B Notes remaining outstanding beyond their contractual maturity date as of September 30, 2024. As at March 31, 2024, $821,500 and $22,010 for Series A and Series B notes remained outstanding beyond their contractual maturity date. Â The Series A and Series B notes continued to accrue interest, and no repayment demand notification was received from noteholders, notwithstanding the fact that these noteholders have continued to convert portions of these notes subsequently; and the Company expects that the majority of these notes will eventually convert. Â As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $88,881 and $88,602, respectively, related to the Series B Notes. Â During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $59 and $279, respectively. During the three and six months ended September 30, 2023, the Company recognized interest expense in the amount of $1,034 and $2,703, respectively. Â Series C Convertible Notes Â The Company has issued Series C Notes of $1,812,700 (face value) by March 31, 2024, with net proceeds of $1,100,430 after payment of the relevant financing related fees. Â The Series C Notes were sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 15% per annum. Â For Series C Notes, commencing six months following the Issuance Date, and at any time thereafter, at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the â€œConversion Amountâ€) could be converted into that number of shares of Common Stock equal to: the Conversion Amount divided by the â€œOptional Conversion Priceâ€, which is defined as lower of (i) seventy-five percent (75%) of the VWAP for the five (5) Trading Days prior to the Conversion Date, or (ii) eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing. Â 22 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â For Series C Notes, â€œMandatory Conversionâ€ of the notes would convert into common stock at the applicable â€œMandatory Conversion Priceâ€, if either (i) on each of any twenty (20) consecutive Trading Days (the â€œMeasurement Periodâ€) (A) the closing price of the Common Stock on the applicable Trading Market is at least $18.00 per share and (B) the dollar value of average daily trades of the Common Stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the Common Stock on the applicable National Exchange on each of the ten (10) consecutive Trading Days following such closing is at least $400,000 per Trading Day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above, seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing. Â The Company was obligated to issue warrants that accompany the convertible notes and provide 100% warrant coverage. The warrants have a 4-year term from date of issuance and an exercise price that is 200% of the 5-day volume weighted average price of the Companyâ€™s common shares at the time of final closing. Â The Company was obligated to pay the placement agent of the first series of Series C Notes a 10% cash fee for the face value of the notes. Â The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 8% of face value of the notes, with an exercise price that equals to the 5-day volume weighted average price of the Companyâ€™s common shares at the time final closing. Â Prior to the final closing date (October 23, 2023), the Company determined that the conversion features contained in those Note, as well as the obligations to issue investor warrants and placement agent warrants represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion features, as well as the obligations related to investor warrant and placement agent warrant issuance. Subsequently, the exercise price of all warrants was concluded and locked to $4.18 and $2.09, respectively, for the note holder and placement agent warrants, as of the final closing date October 23, 2023. Since the exercise price was no longer a variable, the Company concluded that the noteholder and placement agent warrants should no longer be accounted for as a derivative liability in accordance with ASC 815 guidelines related to equity indexation and classification. The derivative liabilities related to those warrants were therefore marked to market as of October 23, 2023 and then transferred to equity (collectively, â€œEnd of warrants derivative treatmentâ€) in the amount of $1,278,786 (Note 8). Â For the Series C Notes, the Company recognized debt issuance costs of $207,361 during the year ended March 31, 2024 and treated these as debt discounts. The Company also recognized additional debt discount in the amount of $1,005,829 in connection with the recognition of derivative liabilities for the conversion features, investor warrants and placement agent warrants. The debt discounts are recorded as a contra liability against the convertible note and are amortized and recognized as accretion expenses using the effective interest method over the remaining lives of the Notes. Â During the three and six months ended September 30, 2024, the Company recognized discount amortization of $184,577 and $1,051,668, respectively, on Series C Notes as accretion and amortization expense. As of September 30, 2024, and March 31, 2024, the remaining unamortized discount on Series C convertible notes was $180,606 and $1,232,274, respectively. Â During the three and six months ended September 30, 2023, the Company recognized discount amortization of $95,183 and $180,866, respectively, on Series C Notes as accretion and amortization expense. As of September 30, 2023, the remaining unamortized discount on Series C convertible notes was $1,610,913. Â During the three and six months ended September 30, 2024, convertible notes with a face value of $45,000 and $1,432,700, respectively, were converted into 121,043 and 1,753,554 common shares, respectively. As of September 30, 2024, 121,043 shares are recognized as an obligation for shares to be issued relating to the conversion. The fair value of common shares issued during the three and six months ended September 30, 2024, is $74,618 and $2,283,216, respectively, and is determined based on market price upon conversion. Total value of debt settled is in the amount of $68,167 and $2,145,929, respectively, which consisted of the face value of notes converted, accrued interest of $7,810 and $222,257, respectively, and relevant derivative liability of $15,357 and $490,972, respectively. The Company recognized a loss upon conversion of $6,451 and $137,287, respectively, representing the difference between the value of debt settled and fair value of shares issued and to be issued. Â 23 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $79,133 and $253,643, respectively, related to the Series C Notes. Â During the three and six months ended September 30, 2024, the Company recognized interest expense in the amounts of $15,004 and $47,747, respectively. During the three and six months ended September 30, 2023, the Company recognized interest expense in the amounts of $66,137 and $114,632, respectively. Â Other Convertible Notes Â On January 23, 2023, the Company issued $2,000,000 (face value) in convertible preferred notes (â€œthe Notesâ€) to an accredited investor. The Notes mature 18 months from the issuance date. This note bears interest rate at a fixed rate of 10% in the form of stock with a strike price equal to the closing stock price on the note issuance date. Therefore, the Company issued 45,045 shares of common stock in lieu of interest on this convertible note. These shares were valued at $221,621 and were recognized as a deferred cost on the convertible note, recorded as a contra liability against the convertible note, and were amortized and recognized as accretion expense using the effective interest rate method over the remaining lives of the Notes. Â The conversion of the Notes is automatic upon a Qualified Financing which is in the control of the Company, or at maturity of the notes, upon mutual agreement by the noteholder and the Company. Since the conversion is not in control of the holder of the note, the Company did not recognize a derivative liability in connection with the conversion option of the Notes. Â During the three and six months ended September 30, 2024, the Company recognized discount amortization of $nil, respectively, on the Notes as accretion and amortization expense. As of September 30, 2024, and March 31, 2024, respectively, the discount on Other Convertible Notes was fully amortized. Â During the three and six months ended September 30, 2023, the Company recognized discount amortization of $55,861 and $111,115, respectively, for the Other Convertible Notes, as part of the accretion and amortization expenses. As of September 30, 2023, the remaining unamortized discount on Other Convertible Notes was $75,289. Â Convertible Preferred Notes Â The Company entered into a convertible preferred note financing on September 25, 2023 and issued a convertible note (â€œPreferred Noteâ€) for a principal amount of $1,000,000. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen (18) month anniversary of the last closing date of the offering (the â€œMaturity Dateâ€). The Preferred Note bears interest at a fixed rate of 12% which is payable in cash monthly. Â 24 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â The Company also entered into a convertible preferred note financing on October 25, 2023 and issued a convertible note (â€œPreferred Noteâ€) for a principal amount of $250,000. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen (18) month anniversary of the last closing date of the offering (the â€œMaturity Dateâ€). The Preferred Note bears interest at a fixed rate of 12% which is payable in cash monthly. Â The Company entered into a convertible preferred note financing on January 9, 2024 and issued a convertible note (â€œPreferred Noteâ€) for a principal amount of $114,303. The Preferred Note matures on the twenty-four (24) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the twenty-four (24) month anniversary of the last closing date of the offering (the â€œMaturity Dateâ€). The Preferred Note bears interest at a fixed rate of 8% which is payable in cash quarterly. Â The Company entered into a convertible preferred note financing on June 17, 2024, and issued a convertible note (â€œPreferred Noteâ€) for a principal amount of $300,000. During the three months ended September 30, 2024, the Company entered into additional preferred note financing with the same subscriber for a principal amount of $350,000. The total principal amount outstanding as of September 30, 2024 was $650,000. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen (18) month anniversary of the last closing date of the offering (the â€œMaturity Dateâ€). The Preferred Note bears no interest. Â The conversion of the Preferred Notes is automatic upon a Qualified Financing which is in the control of the Company, or at maturity of the notes, upon mutual agreement by the noteholder and the Company. Since the conversion is not in control of the holder of the note, the Company did not recognize a derivative liability in connection with the conversion option of the Other Convertible Notes. Â The Company may prepay the Preferred Note in whole or in part, after providing fifteen (15) days written notice to the holder, either in cash or by the mutually consented conversion of the Preferred Note and any accrued interest thereon at a 15% discount to the stockâ€™s 10-day VWAP. Â As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $27,138 and $4,103, respectively, related to the Preferred Notes. Â During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $38,612 and $77,125, respectively. Â Other Short-term loans and Promissory Notes Â In December 2022, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $400,000, prior to the deduction of issuance costs in the amount of $9,999. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 40 weeks. The Company is required to make weekly

payments of $13,995 ($560,000 in the aggregate). As of September 30, 2024, and March 31, 2024, respectively, the principal was fully repaid and discount for this loan was fully amortized. The discount amortization during the three and six months ended September 30, 2024, was $nil, respectively. The discount amortization during the three and six months ended September 30, 2023, was $2,893 and $6,142, respectively, and was recognized as part of the accretion and amortization expenses. In addition, the Company recognized $nil accretion expenses, during the three and six months ended September 30, 2024, and $16,242 and $66,213 during the three and six months ended September 30, 2023, respectively, related to the increase in present value of the loan over its term. Â 25 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â In December 2022, the Company also entered into a short-term collateralized bridge loan agreement with a finance company that advanced gross proceeds of $800,000, prior to the deduction of issuance costs in the amount of $32,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of this second agreement is 40 weeks. The Company is required to make weekly payments of $29,556 ($13,999 for the first four weeks, and $1,120,000 in the aggregate). As of September 30, 2024, and March 31, 2024, respectively, the principal was fully repaid and discount for this loan was fully amortized. The discount amortization during the three and six months ended September 30, 2024, was $nil, respectively. The discount amortization during the three and six months ended September 30, 2023, was $10,400 and $20,800, respectively, which was recognized as part of the accretion and amortization expenses. In addition, the Company recognized $nil accretion expenses, during the three and six months ended September 30, 2024, and $41,049 and $148,027 accretion expenses, during the three and six months ended September 30, 2023, respectively, related to the increase in present value of the loan over its term. Â In December 2022, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $600,000 (the â€œPrincipal Amountâ€). The note has a fixed rate of interest at 25% per annum payable monthly on the first day of every month. This promissory note matured on December 15, 2023, when the Principal Amount became due. The note has various default provisions which would, if triggered, result in the acceleration of the Principal Amount plus any accrued and unpaid interest. The note also has a 3% early payment penalty provision. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $600,000, and accrued interest outstanding on the note was $12,928 and $12,723, respectively. The note continues to accrue interest, and no repayment demand notification was received from noteholder. During the three and six months ended September 30, 2024, the Company recorded interest expense in the amount of $37,808 and $75,206, respectively, related to the promissory note. During the three and six months ended September 30, 2023, the Company recorded interest expense in the amount of $37,808 and $75,205, respectively, related to the promissory note. Â On December 30, 2022, the Company extinguished 51,101 warrants that were originally issued to Series A Convertible Noteholders and replaced these warrants with a new promissory note issued to the same warrant holder. The new promissory note has a principal balance of $270,000, stated interest of zero, and maturity date of December 31, 2023. The fair value of this new promissory note was $248,479 as of the issuance date, which was calculated using a discount rate that was comparable to other loan issuance at the same time as well as the market bond rates at the time of the promissory note issuance. The difference between the fair value of the new note and its principal balance was $21,521, and was recognized as a discount, and amortized via effective interest rate method. The Company compared the fair value of the extinguished warrants immediately prior to extinguishment against the fair value of the new promissory note issued. During the year ended March 31, 2024, the obligation to repay the principal balance at the original maturity date was waived for a finance charge of $50,000, which the Company recorded as interest expense in the in the statement of operations. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $270,000, and the remaining unamortized discount was $Nil. During the three and six months ended September 30, 2024, the Company recognized amortization of discount on this promissory note in the amounts of $nil, respectively. During the three and six months ended September 30, 2023, the Company recognized amortization of discount on this promissory note in the amounts of $nil and $7,304, respectively, as accretion and amortization expenses. As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $50,000 related to this promissory note. Â On March 29, 2023, the Company entered into an additional collateralized bridge loan agreement with a finance company that advanced gross proceeds of $300,000, prior to the deduction of issuance costs in the amount of $12,000. The issuance costs were recognized as a debt discount and would be amortized via the effective interest method. The term of this agreement is 40 weeks. The Company is required to make weekly payments of $5,250 for the first four weeks, and $11,083 for the remaining 36 weeks, which is $420,000 in aggregate. On July 18, 2023, the Company entered into an amendment with the finance company and increased total proceeds borrowed to $700,000. The proceeds from the amended loan balance were netted against previously outstanding balance of the loan, along with an issuance cost in the amount of $28,000. The term of this new loan agreement is 40 weeks. The Company is required to make weekly payments of $24,500, which is $980,000 in aggregate. The Company accounted for this amendment as a debt extinguishment and recognized a loss on the amendment of $59,161 in other expenses. The issuance costs on the amended loan were recognized as a debt discount and would be amortized via the effective interest method. During the three and six months ended September 30, 2024, the Company recognized $nil and $2,800, respectively, of amortization of discount as accretion and amortization expenses. During the three and six months ended September 30, 2023, the Company recognized $11,500 and $3,600, respectively, of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $nil and $4,152 accretion expenses, during the three and six months ended September 30, 2024, respectively and $100,419 and $112,700 during the three and six months ended September 30, 2023, respectively, related to the increase in present value of the loan over its term. During the three and six months ended September 30, 2024, net repayments for the loan amounted to $44,500 and $191,500, respectively. During the three and six months ended September 30, 2023, net repayments for the loan amounted to $298,472 and $762,805, respectively. Â In June 2023, the Company entered into a secured revolving account purchase credit and inventory financing facility (the â€œRevolving Facilityâ€) with a revolving loan lender, pursuant to which the lender may from time to time purchase certain discrete account receivables from the Company (with full recourse) or may make loans and provide other financial accommodations, the payment of which are guaranteed and secured by certain assets of the Company. In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $1.2 million in financing, and expects to receive the remaining balance as part of normal collection activities. The inventory financing provided by this facility was limited to the lower of $0.3 million, or a 40% maximum of inventory balances. The Revolving Facility was accounted for as a secured borrowing. As of September 30, 2024, and March 31, 2024 the Company had drawn $1,500,529 and $1,286,792, respectively, in accounts receivable financing and $198,000 and $125,000, respectively, in inventory financing with aggregate principal outstanding of $1,698,529 and $1,411,792, respectively. During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $102,485 and $207,718, respectively. During the three and six months ended September 30, 2023, the Company recognized interest expense in the amount of $59,656 and $104,873, respectively. As of September 30, 2024, and March 31, 2024 the Company recorded accrued interest in the amount of $25,369 and $23,879 related to the Revolving Facility. Â 26 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â On July 13, 2023, the Company entered into another short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $400,000, prior to the deduction of issuance costs in the amount of $24,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 14 weeks. The Company is required to make weekly payments of $38,705 ($540,000 in the aggregate). As of September 30, 2024, and March 31, 2024, the principal was fully repaid and discount for this loan was fully amortized. No repayments were made during the six months ended September 30, 2024. Â On August 11, 2023, the Company issued two short term promissory notes (â€œAugust 2023 Notesâ€), each for a principal amount of $250,000, to one investor for aggregate gross proceeds of $500,000. The August 2023 Notes do not accrue formal interest but do contain administrative fees in the aggregate of $75,000. One of the notes matures three months from the issuance date upon which the principal amount of $250,000 and an administrative fee of $25,000 is due. The second note matures six months from the issuance date upon which the principal amount of $250,000 and an administrative fee of $50,000 is due. The administrative fees were accrued as interest expenses for the period of the loans outstanding. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $52,500 and $427,500, respectively. Accrued interest outstanding on the note as of September 30, 2024, and March 31,2024, was $75,000, respectively. During the three and six months ended September 30, 2024, net repayments towards the principal amount of the notes amounted to $250,000 and 375,000, respectively. Â On December 8, 2023, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $630,000, prior to the deduction of issuance costs in the amount of $15,750. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 44 weeks. The Company is required to make weekly payments of $19,195 ($844,200 in the aggregate). As of September 30, 2024, and March 31, 2024, the amount of principal outstanding under this amended agreement was $37,241 and $443,185, respectively, and the remaining unamortized issuance cost discount was $716 and $10,023, respectively. During the three and six months ended September 30, 2024, the Company recognized $4,653 and $9,307 of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $28,560 and $93,127 accretion expenses during the three and six months ended September 30, 2024, related to the increase in present value of the loan over its term. During the three and six months ended September 30, 2024, total repayments for the loan amounted to $137,585 and $367,925. Â During January 2024, the Company entered into a short term loan agreement with an individual lender that resulted in gross proceeds of $140,000 (the â€œPrincipal Amountâ€). The loan has a fixed rate of interest at 12% per annum on the principal amount, payable monthly. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $103,128 and $140,000, respectively. As of September 30, 2024, and March 31, 2024, accrued interest outstanding on the note was $11,231 and $nil, respectively. The loan continues to accrue interest, and total repayments for the loan amounted to $36,872 during the three and six months ended September 30, 2024, respectively. During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $4,235 and $11,231 related to the short term loan. Â During February 2024, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $660,504 (the â€œPrincipal Amountâ€). The note has a fixed rate of interest at 12% per annum on the principal amount, payable monthly. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $660,932. As of September 30, 2024, and March 31, 2024, accrued interest outstanding on the note was $46,908 and $7,101, respectively. The note continues to accrue interest, and no repayment demand notification was received from noteholder. During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $19,991 and $39,765, respectively, related to the promissory note. Â On February 2, 2024, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $700,000, prior to the deduction of issuance costs in the amount of $35,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 35 weeks. The Company is required to make weekly payments of $29,235 ($1,008,000 in the aggregate). As of September 30, 2024, and March 31, 2024, the amount of principal outstanding under this agreement was $13,707 and $581,105, respectively, and the remaining unamortized issuance cost discount was $486 and $26,879, respectively. During the three and six months ended September 30, 2024, the Company recognized $13,196 and $26,393, respectively, of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $56,275 and $192,712, respectively, accretion expenses during the three and six months ended September 30, 2024, related to the increase in present value of the loan over its term. During the three and six months ended September 30, 2024, total repayments for the loan amounted to $127,970 and $449,555. Â 27 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â 6. TERM LOAN AND CREDIT AGREEMENT Â Term Loan Â On December 21, 2021, the Company entered into a Credit Agreement (â€œCredit Agreementâ€) with SWK Funding LLC (â€œLenderâ€™); as part of this, the Company has borrowed $12.4 million, with a maturity date of December 21, 2026. The principal will accrue interest at the LIBOR Rate plus 10.5% per annum (subject to adjustment as set forth in the Credit Agreement). Interest payments are due each February, May, August and November commencing February 15, 2022. Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. The Company and the Lender have negotiated the terms under which the Company will be allowed to extend the interest-only period and delay the start of principal repayment. The negotiated terms indicate principal repayment of $2.4 million ($600,000 per quarter), during the final two years of the term. A current portion of the term loan of $3,000,000 and $2,400,000 was reported in the Companyâ€™s current liabilities as of September 30, 2024 and March 31, 2024, respectively. Prepayment of amounts owing under the Credit Agreement are allowed under prescribed circumstances. Pursuant to the Credit Agreement the Company is subject to an Origination Fee in the amount of $120,000. Upon Termination of the Credit Agreement, the Company shall pay an Exit Fee of $600,000, along with other fees that may be assessed during the term of the loan.â€¯ Â As part of the loan transaction, the Company paid legal and professional costs directly in connection to the debt financing in the amount of $50,000 in cash. Â Total costs directly in connection to the debt financing in the amount of $193,437 (professional fee $48,484; lenderâ€™s origination fee, due diligence fee, and other expenses in the amount of $144,953) was deduced from the gross proceeds in the amount of $12,000,000. Â The Company also repaid $1,574,068 of existing short-term loan and promissory notes and relevant accrued interests by using the proceeds from the loan. Â Total costs directly in connection to the loan and fair value of warrants was in the amount of $1,042,149. And such costs were accounted as debt discount, and amortized using the effective interest method. The amortization of such debt discount was included in the accretion and amortization expenses. For the three and six months ended September 30, 2024, the amortization of debt discount expense was $52,627 and $104,458 respectively. For the three and six months ended September 30, 2023, the amortization of debt discount expense was $51,724 and $102,666, respectively. Â During November 2022, unpaid interest of $364,000 was added to the outstanding principal balance, since then interest onwards would be calculated on the updated principal balance. Â Total interest expense on the term loan for the three and six months ended September 30, 2024, amounted to $495,783 and $987,135, respectively. Â The Company had accrued interest payable of $1,107,791 and $795,656, respectively, as of September 30, 2024, and March 31, 2024. Â The Company and Lender also entered into a Guarantee and Collateral Agreement (â€œCollateral Agreementâ€) wherein the Company agreed to secure the Credit Agreement with all of the Companyâ€™s assets. The Company and Lender also entered into an Intellectual Property Security Agreement dated December 21, 2021 (the â€œIP Security Agreementâ€) wherein the Credit Agreement is also secured by the Companyâ€™s right title and interest in the Companyâ€™s Intellectual Property. Â In connection with the Credit Agreement, the Company issued 57,536 warrants to the Lender, which were fair-valued at $198,713 at issuance (Note 9). The warrants are accounted as part of the debt discount as well as a credit into additional paid-in capital and amortized using the effective interest method. Â At September 30, 2024, the Company was not in compliance with certain covenants of the term loan, for which it sought and received relief from the term loan lender. Â 28 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â 7. FEDERALLY GUARANTEED LOAN Â Economic Injury Disaster Loan (â€œEIDLâ€) Â In April 2020, the Company received $370,900 from the U.S. Small Business Administration (SBA) under the captioned program. The loan has a term of 30 years and an interest rate of 3.75% per annum, without the requirement for payment in the first 12 months. The Company may prepay the loan without penalty at will. Â In May 2021, the Company received an additional $499,900 from the SBA under the same terms. Â As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest of $7,889 and $26,497, respectively, for the EIDL loan. Â Interest expense on the above loan was $8,231 and $16,372 for the three and six months ended September 30, 2024, respectively, and $8,230 and $16,372 for the three and six months ended September 30, 2023, respectively. Â 8. DERIVATIVE LIABILITIES Â The Company analyzed the compound features of variable conversion and redemption embedded in the preferred shares instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (â€œEITFâ€) Issue No. 00â€“19 and EITF 07â€“05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value. A roll-forward of activity is presented below for the six months ended September 30, 2024 and 2023: Â Â SCHEDULE OF DERIVATIVE LIABILITIESÂ Â Â Fiscal Year 2025Â Â Fiscal Year 2024Â Â Â $Â Â $Â Derivative liabilities, beginning of period - March 31Â Â 1,435,668Â Â Â 759,065Â New issuance [Note 9]Â Â 649,533Â Â Â 642,416Â Change in fair value of derivatives during periodÂ Â 533,126Â Â Â (50,033) Reduction due to preferred shares converted [Note 9]Â Â (969,150)Â Â Â â€“Â Conversion to common sharesÂ Â Â Â Â Â Â Â End of derivative treatment of warrantsÂ Â Â Â Â Â Â Â Convertible note modificationÂ Â Â Â Â Â Â Â Convertible note redemptionÂ Â Â Â Â Â Â Â Derivative liabilities, end of periodÂ Â 1,649,177Â Â Â 1,351,448Â Â The lattice methodology was used to value the derivative components of Series A Preferred Stock, using the following assumptions during the six months ended September 30, 2024, and 2023:

Â Â SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONSÂ Â Â September 30, 2024Â Â Â September 30, 2023Â Dividend yield (%)Â Â 12Â Â Â 12Â Risk-free rate for term (%)Â Â 4.1 - 5.1Â Â Â 4.9 â€“ 5.2Â Volatility (%)Â Â 91.2 - 132.5Â Â Â 71.9 â€“ 111.4Â Remaining terms (Years)Â Â 0.67 - 1.59Â Â Â 0.34 â€“ 2.01Â Stock price ($ per share)Â Â 0.24 - 1.14Â Â Â 2.14 â€“ 3.82Â Â The Monte Carlo simulation methodology was used to value the derivative components of Series B Preferred Stock, using the following assumptions during the six months ended September 30, 2024: Â Â Â September 30, 2024Â Â September 30, 2023Â Dividend yield (%)Â Â 12Â Â Â 12Â Risk-free rate for term (%)Â Â 3.7 - 5.1Â Â Â 5.04 - 5.24Â Volatility (%)Â Â 126.4 - 182.2Â Â Â 76.2 - 119.1Â Remaining terms (Years)Â Â 0.97 - 2Â Â Â 0.25 - 0.5Â Stock price ($ per share)Â Â 0.24 - 1.34Â Â Â 0.64 - 2.14Â Â 29 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â In addition, the Company recorded derivative liabilities related to the conversion and redemption features of the convertible notes, as well as warrants that were issued in connection with the convertible notes (Note 5). Any noteholder and placement agent warrants that were issued after the finalization of exercise price was accounted for as equity. A roll-forward of activity is presented below for the six months ended September 30, 2024, and 2023: Â Â SCHEDULE OF DERIVATIVE LIABILITIESÂ Â Â Fiscal Year 2025Â Â Fiscal Year 2024Â Â Â $Â Â $Â Â Â Â Â Â Â Â Balance beginning of period â€“ March 31Â Â 991,866Â Â Â 1,008,216Â New IssuanceÂ Â â€“Â Â Â 1,942,004Â Conversion to common sharesÂ Â (490,972)Â Â â€“Â Change in fair value of derivative liabilitiesÂ Â (32,515)Â Â (32,635) Convertible note redemptionÂ Â (8,320)Â Â (33,607) Balance end of period â€“ September 30Â Â 460,059Â Â Â 2,883,978Â Â The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the six months ended September 30, 2024, and 2023, using the following assumptions: Â Â SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONSÂ Â Â September 30, 2024Â September 30, 2023 Risk-free rate for term (%)Â 4.1 - 5.2Â 4.2 - 5.3 Volatility (%)Â 91.2 - 352.4Â 76.2 - 126.6 Remaining terms (Years)Â 0.25 - 0.5Â 0.25 - 1.49 Stock price ($ per share)Â 0.24 - 1.45Â 0.46 - 3.04 Â 9. STOCKHOLDERSâ€™ DEFICIENCY Â (a) Authorized and Issued Stock Â As at September 30, 2024, the Company is authorized to issue 125,000,000 (March 31, 2024 â€“ 125,000,000) shares of common stock ($0.001 par value), and 10,000,000 (March 31, 2024 â€“ 10,000,000) shares of preferred stock ($0.001 par value), 20,000 of which (March 31, 2024 â€“ 20,000) are designated shares of Series A preferred stock and 600 (March 31, 2024 â€“ 600) are designated shares of Series B preferred stock. Â At September 30, 2024, common shares and shares directly exchangeable into equivalent common shares that were issued and outstanding were 23,023,933 (March 31, 2024 â€“ 9,514,440) shares; these were comprised of 22,863,261 (March 31, 2024 â€“ 9,353,768) shares of common stock and 160,672 (March 31, 2024 â€“ 160,672) exchangeable shares. At September 30, 2024, there were 200 shares of Series A Preferred Stock issued and outstanding (March 31, 2024 â€“ 6,304), and 435 shares of Series B Preferred Stock issued and outstanding (March 31, 2024 â€“ 265). There is also one share of Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement as at September 30, 2024, and March 31, 2024. Â (b) Series (A) Preferred Stock Â The number of Series A Preferred Stock issued and outstanding as of September 30, 2024, and 2023 was 200 and 6,304, respectively. Â The Series A Preferred Stock is junior to the Companyâ€™s existing undesignated preferred stock, and unless otherwise set forth in the applicable certificate of designations, shall be junior to any future issuance of preferred stock. The purchase price (the â€œPurchase Priceâ€) for the Series A Preferred Stock to date has been $1,000 per share. Except as otherwise expressly required by law, the Series A Preferred Stock does not have voting rights and does not have any liquidation rights. Â 30 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Preferred Stock Dividends Â Dividends shall be paid at the rate of 12% per annum of the amount of the Series A Preferred Stockholderâ€™s (the â€œHolderâ€) Purchase Price. Dividends shall be paid quarterly unless the Holder and the Company mutually agree to accrue and defer any such dividend. Â Conversion Â The Series A Preferred Stock is convertible into shares of common stock commencing 24 months after the issuance date of the Series A Preferred Stock; on a monthly basis, up to 5% of the aggregate amount of the Purchase Price can be converted (subject to adjustment for changes in the Holderâ€™s ownership of the underlying Series A Preferred Stock) subsequent to that issuance anniversary. The conversion price is equal to the greater of $0.001 or a 15% discount to the volume-weighted average price (â€œVWAPâ€) of the Companyâ€™s common stock five Trading Days immediately prior to the conversion date (the â€œConversion Rate). Additionally, subject to certain provisions, the Holder may exchange its Series A Preferred Stock into any common stock financing being conducted by the Company at a 15% discount to the pricing of that financing. Â Other Adjustments and Rights Â â— The Conversion Rate (and shares issuable upon conversion of the Series A Preferred Stock) will be appropriately adjusted to reflect stock splits, stock dividends business combinations and similar recapitalization. Â â— The Holders shall be entitled to a proportionate share of certain qualifying distributions on the same basis as if they were holders of the Companyâ€™s common stock on an as converted basis. Â Company Redemption Â The Company may redeem all or part of the outstanding Series A Preferred Stock after one year from the date of issuance by paying an amount equal to the aggregate Purchase Price paid, adjusted for any reduction in Series A Preferred Stock holdings, multiplied by 110% plus accrued dividends. Â During the six months ended September 30, 2024, $6,104,444 of Series A Preferred Stock (face value) and $1,071,542 relevant accrued dividend were converted into 8,952,170 common shares. The conversion was accounted as an extinguishment and the difference between the total carrying value of the preferred shares converted, derivative liabilities derecognized and unpaid dividend at the time of conversion ($7,984,463), and the fair value of the common shares issued ($11,039,142), was $3,054,679 and was recognized as a deemed dividend expense. Â (c) Series B Preferred Stock and Mezzanine Equity Â On September 19, 2023, the Company entered into a security purchase agreement (the â€œPurchase Agreementâ€) with an institutional investor (the â€œInvestorâ€) for the issuance and sale of 220 shares of the Companyâ€™s newly designated Series B Convertible Preferred Stock, at a purchase price of $9,091 per share of Preferred Stock, and after accounted for other issuance related costs, the net proceeds received was in the amount of $1,900,000. Â During the three months ended March 31, 2024, a further 110 Series B preferred shares were issued for net proceeds of $925,000. During the three and six months ended September 30, 2024, 55 and 220 Series B preferred shares were issued for net proceeds of $420,000 and $1,732,532, respectively. Â 31 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Pursuant to the initial Purchase Agreement, on September 19, 2023, the Company filed a certificate of designations of Series B Convertible Preferred Stock (the â€œCertificate of Designationsâ€) with the Nevada Secretary of State designating 600 shares of the Companyâ€™s shares of Preferred Stock as Series B Convertible Preferred Stock and setting forth the voting and other powers, preferences and relative, participating, optional or other rights of the Preferred Shares. Each share of Series B Preferred Stock has a stated value of $10,000 per share. Â The Series B Preferred Stock, with respect to the payment of dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company, ranks senior to all capital stock of the Company unless the holders of the majority of the outstanding shares of Series B Preferred Stock consent to the creation of other capital stock of the Company that is senior or equal in rank to the Series B Preferred Stock. Â Holders of Series B Preferred Stock will be entitled to receive cumulative dividends (â€œDividendsâ€), in shares of common stock or cash on the stated value at an annual rate of 8% (which will increase to 15% if a Triggering Event (as defined in the Certificate of Designations) occurs. Dividends will be payable upon conversion of the Series B Preferred Stock, upon any redemption, or upon any required payment upon any Bankruptcy Triggering Event (as defined in the Certificate of Designations). Â Holders of Series B Preferred Stock will be entitled to convert shares of Series B Preferred Stock into a number of shares of common stock determined by dividing the stated value (plus any accrued but unpaid dividends and other amounts due) by the conversion price. The initial conversion price is $3.50, subject to adjustment in the event the Company sells common stock at a price lower than the then-effective conversion price. Holders may not convert the Series B Preferred Stock to common stock to the extent such conversion would cause such holderâ€™s beneficial ownership of common stock to exceed 4.99% of the outstanding common stock. In addition, the Company will not issue shares of common stock upon conversion of the Series B Preferred Stock in an amount exceeding 19.9% of the outstanding common stock as of the initial issuance date unless the Company receives shareholder approval for such issuances. Â Holders may elect to convert shares of Series B Preferred Stock to common stock at an alternate conversion price equal to 80% (or 70% if the Companyâ€™s common stock is suspended from trading on or delisted from a principal trading market or if the Company has effected a reverse split of the common stock) of the lowest daily volume weighed average price of the common stock during the Alternate Conversion Measuring Period (as defined in the Certificate of Designations). In the event the Company receives a conversion notice that elects an alternate conversion price, the Company may, at its option, elect to satisfy its obligation under such conversion with payment in cash in an amount equal to 110% of the conversion amount. Â The Series B Preferred Stock will automatically convert to common stock upon the 24-month anniversary of the initial issuance date of the Series B Preferred Stock. Â At any time after the earlier of a holderâ€™s receipt of a Triggering Event notice and such holder becoming aware of a Triggering Event and ending on the 20th trading day after the later of (x) the date such Triggering Event is cured and (y) such holderâ€™s receipt of a Triggering Event notice, such holder may require the Company to redeem such holderâ€™s shares of Series B Preferred Stock. Â Upon any Bankruptcy Triggering Event (as defined in the Certificate of Designations), the Company will be required to immediately redeem all of the outstanding shares of Series B Preferred Stock. Â The Company will have the right at any time to redeem all or any portion of the Series B Preferred Stock then outstanding at a price equal to 110% of the stated value plus any accrued but unpaid dividends and other amounts due. Â Holders of the Series B Preferred Stock will have the right to vote on an as-converted basis with the common stock, subject to the beneficial ownership limitation set forth in the Certificate of Designations. Â The Series B Preferred Stock was accounted for as Mezzanine Equity in accordance with ASC 480 - Distinguishing Liabilities from Equity and the embedded conversion and redemption features was separated from the host instrument and recognized as derivative liabilities with change in fair value at each reporting period end recognized in the consolidated statement of operations and comprehensive loss. (Note 8). Â 32 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â During the three months ended December 31, 2023, 40 Series B preferred shares and dividends accrued thereon were converted into 612,062 common shares. As a result of the conversion, the Company reduced the book value of mezzanine equity by $228,727 and reduced its accrued dividends liability by $16,789. The Company also reduced the fair value of derivative liabilities by $119,359 related to the shares converted. The Company recognized corresponding credits to common share par value and paid in capital. Â During the three months ended March 31, 2024, 25 Series B preferred shares and dividends accrued thereon were converted into 320,321 to be issued common shares. As a result of the conversion, the Company reduced the book value of mezzanine equity by $142,907. The Company also reduced the fair value of derivative liabilities related to the shares converted by $75,523. The Company recognized corresponding credits to be issued common share par value and paid in capital. Â During the three and six months ended September 30, 2024, 25 and 50 Series B preferred shares and dividends accrued thereon were converted into 1,091,063 and 1,436,267 common shares, respectively. As a result of the conversion, the Company reduced the book value of mezzanine equity by $142,907 and $285,814 and reduced its accrued dividends liability by $16,219 and $28,438 during the three and six months ended September 30, 2024, respectively. The Company also reduced the fair value of derivative liabilities by $84,076 and $160,672 related to the shares converted during the three and six months ended September 30, 2024, respectively. The Company recognized corresponding credits to common share par value and paid in capital. Â A roll-forward of activity is presented below for the six months ended September 30, 2024: Â SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY Â Â Fiscal Year 2025Â Â Fiscal Year 2024 Â Â $Â Â $ Balance beginning of period â€“ March 31Â Â 1,488,920Â Â Â â€“ Â Net proceeds received pursuant to the issuance of preferred sharesÂ Â 1,732,532Â Â Â 1,900,000 Â Recognition of derivative liabilities (Note 8)Â Â (649,533) Â Â (642,416) Conversion into common sharesÂ Â (285,814) Â Â â€“ Â Balance end of period â€“ September 30Â Â 2,286,105Â Â Â 1,257,584 Â Â (d) Share issuances Â Share issuances during the six months ended September 30, 2024 Â During the three months ended September 30, 2024, the Company issued 287,802 common shares to Series C Convertible Note holders, in relation to shares to be issued obligation as of June 30, 2024, for Series C Convertible Note conversions. Â During the three and six months ended September 30, 2024, the Company issued nil and 320,321 common shares to Series B preferred shareholders, respectively, in relation to shares to be issued obligation as of March 2024 for Series B preferred share conversions. During the three and six months ended September 30, 2024, the Company issued another 1,091,063 and 1,436,267 common shares to Series B preferred shareholders for an additional request to convert 25 and 50 Series B preferred shares, respectively (Note 9(c)). Â During the three and six months ended September 30, 2024, convertible notes with a face value of $45,000 and $1,432,700, respectively, were converted into 121,043 and 1,753,554 common shares, respectively. As of September 30, 2024, 121,043 shares are recognized as an obligation for shares to be issued relating to the conversion. The fair value of common shares issued during the three and six months ended September 30, 2024, is $74,618 and $2,283,216, respectively, and is determined based on market price upon conversion. Total value of debt settled is in the amount of $68,167 and $2,145,929, respectively, which consisted of the face value of notes converted, accrued interest of $7,810 and $222,257, respectively, and relevant derivative liability of $15,357 and $490,972, respectively. The Company recognized a loss upon conversion of $6,451 and $137,287, respectively, representing the difference between the value of debt settled and fair value of shares issued and to be issued. (Note 5). Â During the six months ended September 30, 2024, $6,104,444 of Series A Preferred Stock (face value) and $1,071,542 relevant accrued dividend were converted into 8,952,170 common shares. The conversion was accounted as an extinguishment and the difference between the total carrying value of the preferred shares converted, derivative liabilities derecognized and unpaid dividend at the time of conversion ($7,984,463), and the fair value of the common shares issued ($11,039,142) was $3,054,679 and was recognized as deemed dividend expense. Â The Company issued 1,000,413 common shares in settlement of $741,316 in amount due to a shareholder which was part of the accounts payable. The Company recognized a loss upon debt extinguishment of $249,093, which was the difference between the accounts payable settled and the fair value of common shares issued. The loss was included as part of the other income (expense) in the Condensed Consolidated Statement of Operations and Comprehensive Loss. Â The Company issued 97,811 common shares for net proceeds of $125,227 pursuant to a registration statement filed on May 15, 2024. Â In addition, during the six months ended September 30, 2024, the Company issued 70,000 common shares for services received with a fair value of $53,480 which was recognized as a general and administrative expense with a corresponding credit to additional paid-in capital. Â Share issuances during the six months ended September 30, 2023 Â The Company sold 36,897 common shares through use of its registration statement, for gross proceeds of $123,347, raising a net amount of $119,285 after paying for a 3% placement fee and other issuance expenses. In addition, 20,846 shares of common stock were issued to existing holders as a result of make whole provisions associated with the Reverse Split. Â 33 Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â (e) Shares to be issued Â Activity during the six months ended September 30, 2024 Â During the three months ended September 30, 2024, the Company issued 287,802 common shares to Series C Convertible Note holders, in relation to shares to be issued obligation as of June 30, 2024, for Series C Convertible Note conversions. Â During the six months ended September 30, 2024, the Company issued 320,321 common shares to Series B preferred shareholders in relation to shares to be issued obligation as of March 31, 2024, for Series B preferred share conversions. Â During the three and six months ended September 30, 2024, convertible notes with a face value of $45,000 and $1,432,700, respectively, were converted into 121,043 and 1,753,554 common shares, respectively. As of September 30, 2024, 121,043 shares are recognized as an obligation for shares to be issued relating to the conversion. Â During the three and six months ended September 30, 2024, the Company recorded the obligation for 40,000 and 50,000 shares to be issued with a fair value of $20,000 and $27,640 which was recognized as general and administrative expenses. Â Activity during the six months ended September 30, 2023 Â None. Â (f) Warrant issuances, exercises and other activity Â Warrant exercises and issuances during the six months ended September 30, 2024 Â None. Â Warrant exercises and issuances during the six months ended September 30, 2023 Â None. Â Warrant activity during the six months ended September 30, 2024, is indicated below: Â SCHEDULE OF WARRANTS OUTSTANDING Â Â Broker WarrantsÂ Â Consultant and Noteholder WarrantsÂ Â Warrants Issued on Convertible NotesÂ Â TotalÂ As at March 31, 2024Â Â 208,927Â Â Â 253,994Â Â Â 868,098Â Â Â 1,331,019Â Beginning balanceÂ Â 208,927Â Â Â 253,994Â Â Â 868,098Â Â Â 1,331,019Â Â Â Â Â Â Â Â

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan shall be equal to 1,241,422 shares ; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 20% of the Companyâ€™s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase. Â During the three and six months ended September 30, 2024, the Company granted 250,000 and 291,559 stock options and during the three and six months ended September 30, 2023, 3,585 stock options, respectively. The Company recorded stock-based compensation of $56,885 and $115,863, respectively, during the three and six months ended September 30, 2024 and $163,335 and $374,515, respectively, during the three months ended September 30, 2023, under selling, general and administrative expenses with corresponding credit to additional paid in capital. Â The following table summarizes the stock option activities during the six months ended September 30: Â SCHEDULE OF STOCK OPTION ACTIVITIES Â Â 2024Â Â Â 2023 Â Â Â Number of OptionsÂ Â Weighted Average Exercise PriceÂ Â Number of Options Â Weighted Average Exercise Price Â Â Â

October 2022, we launched Biocare, after successfully piloting this technology in two facilities that provide cardiac care to more than 60,000 patients. This technology and other consumer technologies and applications such as the Biokit and Biocare have been developed to allow us to transform and use our strong cardiac footprint to expand into remote chronic care management solutions that will be part of the Biosphere. The technology puts actionable data into the hands of physicians to assist them in making effective treatment decisions quickly. During March 2023, we launched our patient-facing Biocare app on Android and Apple app stores. This further allows us to expand our footprint in providing full-cycle chronic care management solutions to our clinic and patient network. In January 2024, we appointed Dr. Fareeha Siddiqui, a scientist and expert in community health and diagnostics, to the position of VP of Healthcare to spearhead the roll-out and Biocare adoption to existing and new customers. Â We are also developing several other ancillary technologies, which will require application for further FDA clearances, which we anticipate applying for within the next twelve months. Among these are: Â Â â— advanced ECG algorithms and analysis software for further improvements in sensitivity and specificity to analyze and synthesize patient ECG monitoring data with the purpose of distilling it down to the important information that requires clinical intervention, while reducing the amount of human intervention necessary in the process; Â Â Â Â â— the BiocoreÂ® 2.0, which is the next generation of our award winning BiocoreÂ® Â We identified the importance of recent developments in accelerating our path to profitability, including the launch of important new products identified, which have a ready market through cross-selling to existing large customer clinics, and large new distribution partnerships that allow us to sell into large hospital networks. Â Additionally, in September 2022, we were awarded a NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled real-time monitoring, and predictive analytics for stroke due to chronic kidney failure. This is a significant achievement that broadens our technology platformâ€™s disease space demographic. The grant focuses on Bioflux-AI as an innovative system for real-time monitoring and prediction of stroke episodes in chronic kidney disease patients. We received $238,703 under this award in March 2023, which we used to defray research and development and other associated costs. Â 39 Â Â Our mission is to innovate and create transformative healthcare products while ensuring financial discipline, to drive margin and revenue growth to deliver value creation for our investors. Our commitment to innovation means that we harness data intelligently to explore novel avenues for enhancing healthcare outcomes. Through cutting-edge research and development, we believe we are redefining medical diagnostics and patient care and innovating new AI-driven solutions. Â As a result of providing our Bioflux and Biocore products, Biotricity has monitored well over two billion heartbeats for atrial fibrillation (afib), a leading cause of strokes. Over the past two years, these efforts have benefited over 28,000 patients diagnosed with afib, by providing them with the prospect of earlier medical intervention â€“ which also produces significant healthcare savings to patients and the healthcare system. Â We are expanding our AI technology development in remote cardiac care, leveraging proprietary AI technology to provide a suite of predictive monitoring tools to enhance new disease profiling, improve patient management, and revolutionize the healthcare industry for disease prevention. Â We have also strengthened relationships with Amazon and Google. The healthcare AI market opportunity is projected to grow to $208.2 billion by 2030 according to Grand View Research. We have already established a strong foothold, having already built a powerful proprietary cardiac AI model that combines Googleâ€™s TensorFlow, AWS infrastructure, big data and a continuous learning engine. This combination allows us to rapidly improve our cardiac technology. In the near future, we believe the capabilities of our cardiac AI model will allow us to support healthcare professionals in handling exponentially more patients while identifying the most critical data. This will enable healthcare workers to elevate the quality of care while serving a larger number of patients. As growing patient numbers further stress the shortage of healthcare professionals, our technology could help alleviate this pressing issue. We have engineered our technology to not only improve patient care and outcomes, but to do so in a manner that supports more patients. This has led to increasing sales of our remote cardiac monitoring devices and the ramp-up of our subscription-based service, increasing our recurring revenue over the past few quarters and charting a clear path to profitability. Â From a market perspective, increasing interest and demand continue to drive the adoption of our suite of products, which are focused on chronic cardiac disease prevention and management. Our efforts in commercialization and development have yielded tremendous progress in remote monitoring solutions for diagnostic and post-diagnostic products. Â Results of Operations Â The following table sets forth our results of operations for the six months ended September 30, 2024, and 2023. Â Â Â For the six months ended September 30,Â Â Â 2024Â Â 2023Â Â Period to Period ChangeÂ RevenueÂ $6,468,589Â Â $5,912,062Â Â $556,527Â Cost of revenueÂ Â 1,646,247Â Â Â 1,996,080Â Â Â (349,833) Gross profitÂ Â 4,822,342Â Â Â 3,915,982Â Â Â 906,360Â Gross MarginÂ Â 74.6%Â Â 66.2%Â Â 8.4% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

and redemption (3)Â Â 4,690Â Â Â (6,684)Â Â 132,301Â Â Â (13,132) Fair value change on derivative liabilities (3)Â Â 193,757Â Â Â 18,783Â Â Â 500,619Â Â Â (82,669) Adjusted EBITDAÂ Â (249,299)Â Â (1,973,005)Â Â (1,305,678)Â Â (4,124,667) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average number of common shares outstandingÂ Â 22,493,626Â Â Â 8,795,742Â Â Â 18,354,277Â Â Â 8,774,242Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Adjusted Loss per Share, Basic and DilutedÂ Â (0.011)Â Â (0.224)Â Â (0.071)Â Â (0.470) Â (1) Share based compensation is a non-cash item therefore is removed from our adjusted EBITDA analysis (2) Preferred stock dividend payment is at Companyâ€™s discretion and therefore is removed from our EBITDA analysis (3) These items relate to financing transactions and therefore do not reflect the Companyâ€™s core operating activities Â Translation Adjustment Â Translation adjustment was a loss of $105 thousand versus a gain of $105 thousand for the six months ended September 30, 2024, and 2023, respectively. This translation adjustment represents gains and losses that result from the translation of currency in the financial statements from our functional currency of Canadian dollars to the reporting currency in U.S. dollars over the course of the reporting period. Â 45 Â Â Liquidity and Capital Resources Â Management has noted the existence of substantial doubt about our ability to continue as a going concern. Additionally, our independent registered public accounting firm included an explanatory paragraph in the report on our financial statements as of and for the years ended March 31, 2024, and 2023, respectively, noting the existence of substantial doubt about our ability to continue as a going concern. Our existing cash deposits may not be sufficient to fund our operating expenses through at least twelve months from the date of this filing. To continue to fund operations, we will need to secure additional funding through public or private equity or debt financings, through collaborations or partnerships with other companies or other sources. We may not be able to raise additional capital on terms acceptable to us, or at all. Any failure to raise capital when needed could compromise our ability to execute our business plan. If we are unable to raise additional funds, or if our anticipated operating results are not achieved, we believe planned expenditure may need to be reduced in order to extend the time period that existing resources can fund our operations. If we are unable to obtain the necessary capital, it may have a material adverse effect on our operations and the development of our technology, or we may have to cease operations altogether. Â The development and commercialization of our product offerings are subject to numerous uncertainties, and we could use our cash resources sooner than we expect. Additionally, the process of developing our products is costly, and the timing of progress can be subject to uncertainty; our ability to successfully transition to profitability may be dependent upon achieving further regulatory approvals and achieving a level of product sales adequate to support our cost structure. Though we are optimistic with respect to our revenue growth trajectory and our cost control initiatives, we cannot be certain that we will ever be profitable or generate positive cash flow from operating activities. Â The Company is in commercialization mode, while continuing to pursue the development of its next generation COM product as well as new products. Â We generally require cash to: Â Â â— purchase devices that will be placed in the field for pilot projects and to produce revenue, Â Â Â Â â— launch sales initiatives, Â Â Â Â â— fund our operations and working capital requirements, Â Â Â Â â— develop and execute our product development and market introduction plans, Â Â Â Â â— fund research and development efforts, and Â Â Â Â â— pay any expense obligations as they come due. Â The Company is in the early stages of commercializing its products. It is concurrently in development mode, operating a research and development program in order to develop an ecosystem of medical technologies, and, where required or deemed advisable, obtain regulatory approvals for, and commercialize other proposed products. The Company launched its first commercial sales program as part of a limited market release, during the year ended March 31, 2019, using an experienced professional in-house sales team. A full market release ensued during the year ended March 31, 2020. Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and after additional equity and debt capitalization of the Company. The Company has incurred recurring losses from operations, and as at September 30, 2024, has an accumulated deficit of $136,101,106. On August 30, 2021 the Company completed an underwritten public offering of its common stock that concurrently facilitated its listing on the Nasdaq Capital Market. On September 30, 2024, the Company had a working capital deficit of $17,424,814. On August 1, 2024, the Company received a notice from Nasdaq stating that Nasdaq has determined to delist the Companyâ€™s shares of common stock on The Nasdaq Capital Market, effective at the open of business on August 5, 2024. Nasdaq reached its decision pursuant to Nasdaq Listing Rule 5550(b)(2) because the Company no longer complied with the minimum $35 million market value of listed securities. Following the suspension of trading on The Nasdaq Capital Market, the Companyâ€™s shares of common stock were again listed on the OTCQB under the symbol â€œBTCY.â€ Â 46 Â Â Adjusted EBITDA, which management uses as a measure for tracking free cashflow levels, improved to negative $249 thousand for the quarter ended September 30, 2024, a reduction of over $1.7 million in negative Adjusted EBITDA from the comparative period of the prior fiscal year, which is an 87% improvement. The Company was able to achieve a positive Adjusted EBITDA for the month of September 2024 and expects further improvements in this measure in future periods. Â On September 30, 2024, we had cash deposits in the aggregate of $173,270. Â The Company has developed and continues to pursue sources of funding that management believes will be sufficient to support the Companyâ€™s operating plan and alleviate any substantial doubt as to its ability to meet its obligations at least for a period of one year from the date of these Condensed Consolidated Financial Statements. Â During the fiscal year ended March 31, 2023, the Company raised short-term loans and promissory notes, net of repayments of $1,476,121 from various lenders, and also raised convertible notes, net of redemptions of $2,355,318 from various lenders. Â During the fiscal year ended March 31, 2024, the Company raised short-term loans and promissory notes, net of repayments of $853,030 and convertible notes, net of redemptions of $2,962,386 from various lenders. The Company sold 36,897 common shares through use of its registration statement, for gross proceeds of $123,347, raising a net amount of $119,285 after paying a 3% placement fee and other issuance expenses. Â Additionally, on September 19, 2023, the Company entered into a security purchase agreement with an institutional investor for the issuance and sale of 220 shares of the Companyâ€™s newly designated Series B Convertible Preferred Stock, at a purchase price of $9,091 per share of Series B Preferred Stock (Note 9), or gross proceeds of $2,000,000. Net proceeds after issuance costs was $1,900,000. During the three months ended March 31, 2024, 110 Series B preferred shares were issued for net proceeds of $925,000. Â During the six months ended September 30, 2024, 220 Series B preferred shares were issued for net proceeds of $1,732,532. The Company also raised $650,000 from the issuance of convertible notes to a lender. Lastly, the Company sold 97,811 common shares through use of its registration statement, for net proceeds of $125,227. Â During period subsequent to September 30, 2024, the Company raised additional funding from private investors in the amount of $811 thousand in the form of promissory notes and convertible promissory notes. The Company also raised additional term loan funding of $635,000 from its main term loan provider. Â As we proceed with the commercialization of the Bioflux, Biocore, and Biocare product development, we expect to continue to devote significant resources on capital expenditures, as well as research and development costs and operations, marketing and sales expenditures. Â Based on the above facts and assumptions, we believe our existing cash, along with anticipated near-term financings, will be sufficient to continue to meet our needs for the next twelve months from the filing date of this report. However, we will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines. Â The following is a summary of cash flows for each of the periods set forth below. Â Â Â For the Six Months EndedÂ Â Â September 30,Â Â Â 2024Â Â 2023Â Net cash used in operating activitiesÂ $(1,891,299)Â $(4,222,154) Net cash used in investing activitiesÂ Â â€”Â Â Â â€”Â Net cash provided by financing activitiesÂ Â 1,339,279Â Â Â Â 4,758,634Â Net decrease in cashÂ $(552,020)Â $536,480Â Â Net Cash Used in Operating Activities Â During the six months ended September 30, 2024, we used cash in operating activities in the amount of $1.9 million. The cash in operating activities was primarily due to selling expenses as well as research, product development, business development, marketing and general operations. The decrease in cash used reflects managementâ€™s concerted effort to contain costs while increasing revenues, on the path of achieving break-even. Â 47 Â Â During the six months ended September 30, 2023, we used cash in operating activities of $4.2 million. These activities involved expenditures for sales, infrastructure and business development, as well as marketing and operating activities, and continued research and product development. Â Net Cash Used in Investing Activities Â Net cash used in investing activities was Nil during the six months ended September 30, 2024, and 2023. Â Net Cash Provided by Financing Activities Â Net cash provided by financing activities was $1.3 million as compared to net cash provided of $4.8 million during the six months ended September 30, 2024, and 2023, respectively. Â For the six months ended September 30, 2024, the net cash provided by financing activities was primarily due to the issuance of Series B preferred stock of $1.7 million. Â For the six months ended September 30, 2023, the net cash provided by financing activities related primarily to net proceeds attributed to the issuance of Series B preferred stock of $1.9 million, the issuance of convertible notes of $2.0 million and the issuance of short term loans and promissory notes of approximately $0.8 million, net of repayments. Lastly, we issued common stock resulting in $0.1 million of net proceeds. Â Critical Accounting Estimates Â Our consolidated financial statements are prepared in accordance with GAAP. These accounting principles require us to make estimates and judgments that can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expense during the periods presented. We believe that the estimates and judgments upon which we rely are reasonably based upon information available to us at the time that we make these estimates and judgments. To the extent that there are material differences between these estimates and actual results, our financial results will be affected. The accounting policies that reflect our more significant estimates and judgments and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are described in â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€, included in our 2023 Form 10-K filed on June 27, 2024. Â During the six months ended September 30, 2024, there were no material changes to our critical accounting estimates disclosed in â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ included in our 2024 Form 10-K filed on June 27, 2024. Â Recent Accounting Pronouncements Â Refer to Note 3â€” Summary of Significant Accounting Policies to our Condensed Consolidated Financial Statements included elsewhere in this report for a discussion of recently issued accounting pronouncements. Â Off-Balance Sheet Arrangements Â We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. Â 48 Â Â Item 3. Quantitative and Qualitative Disclosures About Market Risk Â Not required for a smaller reporting company. Â Item 4. Controls and Procedures. Â Evaluation of Disclosure Controls and Procedures Â The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Companyâ€™s Exchange Act reports is recorded, processed, summarized and reported within the time communicated to the Companyâ€™s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based closely on the definition of â€œdisclosure controls and proceduresâ€ in Rule 13a-15(e). The Companyâ€™s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching the Companyâ€™s desired disclosure control objectives. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Therefore, even a system which is determined to be effective cannot provide absolute assurance that all control issues have been detected or prevented. Our systems of internal controls are designed to provide reasonable assurance with respect to financial statement preparation and presentation. Â At the end of the period being reported upon, the Company carried out an evaluation, under the supervision and with the participation of the Companyâ€™s management, including the Companyâ€™s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Companyâ€™s disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that the material information required to be included in our Securities and Exchange Commission reports is accumulated and communicated to our management, including our principal executive and financial officer, as well as recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms relating to the Company. Â Changes in Internal Controls Â There were no changes in the Companyâ€™s internal controls over financial reporting that occurred during the three-month period ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. Â 49 Â Â PART II Â OTHER INFORMATION Â Item 1. Legal Proceedings. Â From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any material legal proceedings. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Â Item 1A. Risk Factors Â Not required for smaller reporting companies. Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. Â None. Â Item 3. Defaults Upon Senior Securities. Â None. Â Item 4. Mine Safety Disclosures. Â Not applicable. Â Item 5. Other Information. Â During the quarter ended September 30, 2024, no director or officer of the Company adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408(a) of Regulation S-K. Â Item 6. Exhibits Â 31.1 Â Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002* 31.2 Â Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002* 32.1 Â Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002** 32.2 Â Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002** 101 Â Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q. 104 Â Cover Page Interactive Data File (embedded within the Inline XBRL document) Â * Filed herewith. ** Furnished herewith. Â 50 Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, this 14th day of November 2024. Â BIOTRICITY INC. Â By: /s/ Waqaas Al-Siddiq Â Name: Waqaas Al-Siddiq Â Title: Chief Executive Officer Â Â (principal executive officer) Â Â Â Â By: /s/ John Ayanoglou Â Name: John Ayanoglou Â Title: Chief Financial Officer Â Â (principal financial and accounting officer) Â Â 51 EX-31.1 2 ex31-1.htm Â Exhibit 31.1 Â BIOTRICITY INC. Â CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Waqaas Al-Siddiq, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Biotricity Inc.; Â Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â Â Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 14, 2024 Â Â /s/ Waqaas Al-Siddiq Â Waqaas Al-Siddiq Â Chief Executive Officer Â (Principal Executive Officer) Â Â Â EX-31.2 3 ex31-

2.htm Â Exhibit 31.2 Â BIOTRICITY INC. Â CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, John Ayanoglou, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Biotricity Inc.; Â Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â Â Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 14, 2024 Â Â /s/ John Ayanoglou Â John Ayanoglou Â (Principal Financial and Accounting Officer) Â Â Â EX-32.1 4 ex32-1.htm Â Exhibit 32.1 Â BIOTRICITY INC. Â CERTIFICATION PURSUANT TO 18 U.S.C. Â§1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report on Form 10-Q of Biotricity Inc. (the â€œCompanyâ€) for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Waqaas Al-Siddiq, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Â§906 of the Sarbanes-Oxley Act of 2002, that: Â Â (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â Â Â Â (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: November 14, 2024 Â /s/ Waqaas Al-Siddiq Â Waqaas Al-Siddiq Â Chief Executive Officer Â (Principal Executive Officer) Â Â Â Â EX-32.2 5 ex32-2.htm Â Exhibit 32.2 Â BIOTRICITY INC. Â CERTIFICATION PURSUANT TO 18 U.S.C. Â§1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report on Form 10-Q of Biotricity Inc. (the â€œCompanyâ€) for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, John Ayanoglou, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Â§906 of the Sarbanes-Oxley Act of 2002, that: Â Â (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â Â Â Â (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: November 14, 2024 Â /s/ John Ayanoglou Â John Ayanoglou Â (Principal Financial and Accounting Officer) Â Â Â Â EX-101.SCH 6 btcy-20240930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Deficiency (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995612 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 995613 - Disclosure - BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION link:presentationLink link:calculationLink link:definitionLink 995614 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 995616 - Disclosure - CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS link:presentationLink link:calculationLink link:definitionLink 995617 - Disclosure - TERM LOAN AND CREDIT AGREEMENT link:presentationLink link:calculationLink link:definitionLink 995618 - Disclosure - FEDERALLY GUARANTEED LOAN link:presentationLink link:calculationLink link:definitionLink 995619 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 995620 - Disclosure - STOCKHOLDERSâ€™ DEFICIENCY link:presentationLink link:calculationLink link:definitionLink 995621 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS link:presentationLink link:calculationLink link:definitionLink 995622 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 995623 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 995624 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 995626 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995627 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995628 - Disclosure - DERIVATIVE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995629 - Disclosure - STOCKHOLDERSâ€™ DEFICIENCY (Tables) link:presentationLink link:calculationLink link:definitionLink 995630 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 995631 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 995632 - Disclosure - SCHEDULE OF REVENUE RECOGNITION (Details) link:presentationLink link:calculationLink link:definitionLink 995633 - Disclosure - SCHEDULE OF INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 995634 - Disclosure - SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES (Details) link:presentationLink link:calculationLink link:definitionLink 995636 - Disclosure - BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995637 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 995638 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995639 - Disclosure - CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995640 - Disclosure - TERM LOAN AND CREDIT AGREEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995641 - Disclosure - FEDERALLY GUARANTEED LOAN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995642 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 995643 - Disclosure - SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 995644 - Disclosure - SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details) link:presentationLink link:calculationLink link:definitionLink 995646 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITIES (Details) link:presentationLink link:calculationLink link:definitionLink 995647 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 995648 - Disclosure - STOCKHOLDERSâ€™ DEFICIENCY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995649 - Disclosure - SCHEDULE OF OPERATING LEASES OBLIGATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 995650 - Disclosure - SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION (Details) link:presentationLink link:calculationLink link:definitionLink 995651 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995652 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 995653 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995654 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 btcy-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 btcy-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 btcy-20240930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Preferred Stock [Member] Series A Preferred Stock [Member] Series B Convertible Redeemable Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Shares to be Issued [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Mezzanine Equity [Member] Series B Preferred Stock [Member] Title and Position [Axis] Lender [Member] Product and Service [Axis] Technology Fees [Member] Device Sales [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Long-Lived Tangible Asset [Axis] Office Equipment [Member] Leasehold Improvements [Member] Debt Instrument [Axis] Two Series A Notes [Member] Series A Notes One [Member] Series A Notes Two [Member] Warrant [Member] Placement Agent [Member] Series A Notes [Member] Series A Note [Member] New Convertible Note [Member] Series B Notes [Member] Related and Nonrelated Parties [Axis] Accredited Investors [Member] Warrant One [Member] Warrant Two [Member] Series B Note [Member] Series C Notes [Member] Sale of Stock [Axis] Note Holders [Member] Placement Agents Warrants [Member] Series C Note [Member] Short-Term Debt, Type [Axis] Other Convertible Notes Payable [Member] Notes Payable, Other Payables [Member] Award Type [Axis] Eighteen Month Anniversary [Member] Twenty Four Month Anniversary [Member] Short-term Bridge Loan Agreement [Member] Legal Entity [Axis] Collateralized Merchant Finance Company [Member] Short-term Collateralized Bridge Loan Agreement [Member] Finance Company [Member] Award Date [Axis] First Four Weeks [Member] Promissory Note Agreement [Member] Individual Investor [Member] Series A Convertible Note Holders [Member] New Promissory Note [Member] Collateralized Bridge Loan Agreement [Member] Remaining Thirty Six Weeks [Member] Additional Collateralized Bridge Loan Agreement [Member] Credit Facility [Axis] Revolving Credit Facility [Member] Two Short Term Promissory Notes [Member] One Investor [Member] Short Term Promissory Notes One [Member] Short Term Promissory Notes Two [Member] Short Term Bridge Loan Agreement One [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Short Term Loan Agreement [Member] Individual Investor One [Member] Collateralized Merchant Finance Company One [Member] Cash and Cash Equivalents [Axis] Cash [Member] Term Loan [Member] Economic Injury Disaster Loan [Member] Long-Term Debt, Type [Axis] Convertible Debt [Member] Measurement Input Type [Axis] Measurement Input, Expected Dividend Rate [Member] Statistical Measurement [Axis] Minimum [Member] Measurement Input, Risk Free Interest Rate [Member] Maximum [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Term [Member] Measurement Input, Share Price [Member] Convertible Note and Warrant Derivative [Member] Shareholders [Member] Exchange Agreement [Member] Purchase Agreement [Member] Ownership [Axis] Beneficiary [Member] Series C Convertible Note [Member] Series C Preferred Stock [Member] Statement of Income Location, Balance [Axis] General and Administrative Expense [Member] Plan Name [Axis] 2016 Equity Incentive Plan [Member] 2023 Equity Incentive Plan [Member] Broker Warrants [Member] Consultant Warrants [Member] Warrants Issued on Conversion of Convertible Notes [Member] Equity Option [Member] New Lease Agreement [Member] Selling, General and Administrative Expenses [Member] Furniture and Fixtures [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Unsecured Convertible Promissory Notes [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Statement [Table] Statement [Line Items] CURRENT ASSETS Cash Accounts receivable, net Inventory [Note 3] Deposits and other receivables Total current assets Deposits and other receivables [Note 10] Long-term accounts receivable Property and equipment [Note 12] Operating right of use assets [Note 10] TOTAL ASSETS CURRENT LIABILITIES Accounts payable and accrued liabilities [Note 4] Convertible promissory notes and short term loans [Note 5] Term loan, current Derivative liabilities [Note 8] Operating lease obligations, current [Note 10] Total current liabilities Federally guaranteed loans [Note 7] Term loan [Note 6] Derivative liabilities [Note 8] Operating lease obligations TOTAL LIABILITIES MEZZANINE EQUITY Series B Convertible Redeemable preferred stock, $0.001 par value, 600 shares authorized as of September 30, 2024 and March 31, 2024, respectively, 405 and 265 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively [Note 9] STOCKHOLDERSâ€™ DEFICIENCY Preferred stock, value Common stock, $0.001 par value, 125,000,000 shares authorized as at September 30, 2024, and March 31, 2024, respectively. Issued and outstanding common shares: 22,863,261 and 9,353,768 as at September 30, 2024 and March 31, 2024, respectively, and exchangeable shares of 160,672 outstanding as at September 30, 2024 and March 31, 2024, respectively [Note 9] Shares to be issued 194,998 and 324,276 shares of common stock as at September 30, 2024 and March 31, 2024, respectively) [Note 9] Additional paid-in-capital Accumulated other comprehensive (loss) / income Accumulated deficit Total stockholdersâ€™ deficiency TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERSâ€™ DEFICIENCY Series B converible redeemable preferred stock, par value Series B converible redeemable preferred stock, authorized Series B converible redeemable preferred stock, shares issued Series B converible redeemable preferred stock, shares outstanding Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares, issued Common stock, shares, outstanding Common stock, other shares, outstanding Common stock shares to be issued Income Statement [Abstract] REVENUE Cost of Revenue GROSS PROFIT OPERATING EXPENSES Selling, general and administrative expenses Research and development expenses TOTAL OPERATING EXPENSES LOSS FROM OPERATIONS Interest expense Accretion and amortization expenses [Note 5,6] Change in fair value of derivative liabilities [Note 8] Gain (loss) upon convertible promissory notes conversion and redemption [Note 9] Other income (expense) [Note 9] NET LOSS BEFORE INCOME TAXES Income taxes [Note 3] NET LOSS BEFORE DIVIDENDS Preferred Stock Dividends Deemed Dividends [Note 9] NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS Translation adjustment COMPREHENSIVE LOSS LOSS PER SHARE, BASIC LOSS PER SHARE, DILUTED WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED Balance Temporary equity, shares Temporary equity, value Balance, shares Issuance of mezzanine equity [Note 9] Issuance of mezzanine equity [Note 9], shares Issuance of common shares from shares to be issued [Note 9] Issuance of common shares from shares to be issued [Note 9], shares Issuance of common shares from at-the-market transaction [Note 9], shares Conversion of mezzanine equity into common shares [Note 9] Conversion of mezzanine equity into common shares [Note 9], shares Conversion of mezzanine equity into common shares [Note 9] Conversion of mezzanine equity into common shares [Note 9], shares Conversion of preferred shares into common shares [Note 9], shares Conversion of convertible notes into common shares

[Note 9] Conversion of convertible notes into common shares [Note 9], shares Issuance of shares for services [Note 9] Issuance of shares for services [Note 9], shares Issuance of shares for settlement of accounts payable [Note 9], shares Stock based compensation - ESOP [Note 9] Translation adjustment Net loss before dividends for the period Preferred stock dividends Issuance of common stock Issuance of common stock, shares Issuance of common shares from at-the-market transaction [Note 9] Conversion of preferred shares into common shares [Note 9] Issuance of shares for settlement of accounts payable [Note 9] Deemed Dividend [Note 9] Balance Temporary equity, shares Temporary equity, value Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operations: Stock based compensation Issuance of shares for services Issuance of warrants for services Accretion and amortization expenses Change in fair value of derivative liabilities (Gain) loss upon convertible promissory notes conversion and redemption Other expense regarding loss on debt modification Property and equipment depreciation Non-cash lease expense Changes in operating assets and liabilities: Accounts receivable, net Inventory Deposits and other receivables Accounts payable and accrued liabilities Net cash used in operating activities CASH FLOWS FROM FINANCING ACTIVITIES Issuance of common shares, net Issuance of preferred shares, net Proceeds from convertible debentures, net Proceeds from short term loan and promissory notes, net Preferred Stock Dividend Net cash provided by financing activities Net (increase) decrease in cash during the period Effect of foreign currency translation Cash, beginning of period Cash, end of period Supplemental disclosure of cash flow information: Interest paid Taxes Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Trading Arrangements, by Individual [Table] Trading Arrangement [Axis] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS Accounting Policies [Abstract] BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Debt Disclosure [Abstract] CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS Term Loan And Credit Agreement TERM LOAN AND CREDIT AGREEMENT Federally Guaranteed Loan FEDERALLY GUARANTEED LOAN Derivative Instruments and Hedging Activities Disclosure [Abstract] DERIVATIVE LIABILITIES Equity [Abstract] STOCKHOLDERSâ€™ DEFICIENCY Operating Lease Right-of-use Assets And Lease Obligations OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Subsequent Events [Abstract] SUBSEQUENT EVENTS Revenue Recognition Inventories Significant accounting estimates and assumptions Earnings (Loss) Per Share Cash Foreign Currency Translation Accounts Receivable Fair Value of Financial Instruments Property and Equipment Impairment for Long-Lived Assets Leases Income Taxes Research and Development Selling, General and Administrative Stock Based Compensation Convertible Notes Payable and Derivative Instruments Series B Convertible Preferred Stock Preferred Shares Extinguishments Segment Information Recently Issued Accounting Pronouncements SCHEDULE OF REVENUE RECOGNITION SCHEDULE OF INVENTORIES SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY SCHEDULE OF WARRANTS OUTSTANDING SCHEDULE OF STOCK OPTION ACTIVITIES SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS SCHEDULE OF OPERATING LEASES OBLIGATIONS SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION SCHEDULE OF PROPERTY AND EQUIPMENT Nature of Operation, Product Information, Concentration of Risk [Table] Product Information [Line Items] TotalÂ Raw material Finished goods Inventories Platform Operator, Crypto Asset [Table] Platform Operator, Crypto Asset [Line Items] Cash Total assets at fair value Derivative liabilities, short-term Derivative liabilities, long-term Total liabilities at fair value Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment, useful life Stockholders equity reverse stock split Issuance of common shares to adjust for rounding effect of reverse split, shares Accumulated deficit Working capital deficiency Proceeds from short term debt Debt conversion converted instrument amount Conversion of convertible securities Gross proceeds from issuance of common stock Proceeds from issuance of common stock Placement fee percentage Preferred Stock, Shares Issued Preferred Stock, Redemption Price Per Share Proceeds from Debt, Net of Issuance Costs Proceeds from Issuance of Preferred Stock and Preference Stock Issuance of common shares from shares to be issued, shares Issuance of common shares from shares to be issued Conversion of mezzanine equity into common shares Number of stock issued during the period convertible, shares Trade and other payables Accrued liabilities Deferred revenue Total Trade and other payables and accrued liabilities Short-Term Debt [Table] Short-Term Debt [Line Items] Issuance of debt Interest rate Description of conversion terms for debt instrument Debt conversion description Conversion price Volume weighted average price of common stock, percent Placement agent fees description Deferred finance costs Unamortized issuance cost discount Debt instrument carrying amount Interest payable Debt instrument interest rate during period Debt converted amount Debt face amount Adjustment for amortization Interest expense Warrants and rights outstanding term Exercise Price Warrants issued Proceeds from convertible debt Converted instrument shares issued Debt instrument periodic payment Cash payment Convertible notes payable Redemption of convertible notes Payment redeemed cash Gains losses on extinguishment of debt Derivative liabilities Derivative liabilities Convertible notes payable remaining Warrants derivative Debt issuance costs Debt instrument derivative liabilities Shares recognised as obligation fair value of common shares Debt settlement value Debt instrument accrued interest Derivative liability Debt instrument accrued interest Convertible notes payable Convertible notes payable Subscriber for a principal amount Gross proceeds Debt instrument term Accretion expense Repayments of loan Maturity date Early payment penalty provision percentage Debt face amount Adjustment carrying value and principal amount Finance charge Accrued interest Loss on amendment of debt Line of credit facility, revolving credit conversion to term loan, description Financing receivables Inventory financing by facility Accounts receivable, net Inventory Principal outstanding Interest expense Administrative fees Administrative fees Interest expense related to short term loan Cash and Cash Equivalent [Table] Cash and Cash Equivalents [Line Items] Debt instrument, face amount Interest rate Interest payments due date Debt instrument, payment terms Principal repayments Loans payable current portion Origination fee amount Exit fee Debt financing Professional fee Fee amount Gross proceeds Repayment of short term debt Fair value of warrants Amortization of debt discount expense Unpaid interest Interest payable current Issuance of warrants Proceeds from loan Debt instrument description Debt interest rate Accrued interest Interest expense Derivative liabilities, beginning of period - March 31 New issuance [Note 9] Change in fair value of derivatives during period Reduction due to preferred shares converted [Note 9] Conversion to common shares End of derivative treatment of warrants Convertible note modification Convertible note redemption Derivative liabilities, end of period Derivative [Table] Derivative [Line Items] Derivative liability, measurement input Remaining terms Stock price New Issuance Change in fair value of derivative liabilities Balance beginning of period â€“ March 31 Recognition of derivative liabilities (Note 8) Conversion into common shares Balance end of period â€“ September 30 Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Beginning balance Expired/cancelled Exercised Issued Ending balance Expiration Date Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of options, beginning outstanding Weighted average exercise price, beginning outstanding Number of options, beginning outstanding Weighted average exercise price, beginning outstanding Number of options, beginning outstanding Weighted average exercise price, beginning outstanding Number of options, beginning outstanding Weighted average exercise price, beginning outstanding Number of options, beginning outstanding Weighted average exercise price, beginning outstanding Number of options, beginning outstanding Weighted average exercise price, beginning outstanding Exercise price Risk free interest rate Expected term Expected volatility Expected dividend yield Fair value of option Expected forfeiture (attrition) rate Stock, Class of Stock [Table] Class of Stock [Line Items] Common Stock, Shares Authorized Common Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred stock convertible conversion price Shares outstanding Common stock, shares issued Preferred stock, liquidation preference Preferred stock dividend rate percentage Debt instrument redemption price percentage Preferred stock convertible conversion price Volume weighted average price percentage Face value Accrued dividends Deposit liabilities, accrued interest Stock redeemed or called during period, value Investment company, dividend distribution Preferred stock redemption price per share Stock issued during period Stated value percentage Initial conversion price Ownership percentage Conversion of mezzanine equity into common shares Conversion of common shares Accrued dividends liability Related to the shares Conversion of preferred stock shares Temporary equity value reduction Reduced accrued dividends liability Issuance of common shares from shares to be issued Instrument amount Debt settled Derivative liability Issuance of shares for settlement of accounts payable Issuance of shares for settlement of accounts payable, value Loss on debt conversion Number of stock issued during the period convertible, shares Issuance of shares for services Number of shares issued Gross proceeds Net proceeds Percentage of placement fee and other issuance expenses Number of additional shares issued Shares to be issued with fair value Share based payment award number of shares authorized Stock options granted Stock-based compensation Share based payment award number of shares available for issuance Schedule Of Operating Leases Obligations Operating lease right-of-use asset, beginning balance Right of use asset, new leases Right of use asset, amortization Operating lease right-of-use asset, ending balance Operating lease liability, beginning balance Lease liability, new leases Lease liability, repayment and interest accretion, net Operating lease liability, ending balance Current portion of operating lease liability Noncurrent portion of operating lease liability Schedule Of Contractual Undiscounted Cash Flows For Lease Obligation 2024 2025 2026 Total undiscounted lease liability Less imputed interest Total Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Lease deposit liability Weighted average rate Operating lease expense Operating cash flows from operating leases Cost, beginning balance Additions Disposals Cost, ending balance Accumulated depreciation, beginning balance Depreciation Disposals Accumulated depreciation, ending balance Net book value, beginning balance Net book value, ending balance Leasehold improvements Furniture & fixtures useful life Furniture & fixtures Purchase of property plant and equipment Depreciation expenses Subsequent Event [Table] Subsequent Event [Line Items] Unsecured convertible promissory notes Convertible discount percentage Convertible discount percentage Debt instrument interest amount Warrants shares issues Warrants price per share Term loan exit fee Accrued dividends Shares issue Consultant contract remuneration Shares to be issued. Series B Convertible Redeemable Preferred Stock [Member] Working capital deficiency. Number of stock issued during the period convertible, shares. Gross proceeds from issuance of common stock. Placement fee percentage Lender [Member] Common stock shares to be issued. Deemed dividends Shares To Be Issued [Member] Schedule Of Property And Equipment Estimated Useful Lives [Table Text Block] Convertible Preferred Stock [Policy Text Block] Preferred Shares Extinguishments [Policy Text Block] Two Series A Notes [Member] Series A Notes One [Member] Series A Notes Two [Member] Volume weighted average price of common stock, percent. Placement agent fees description. Placement Agent [Member] Series A Notes [Member]. Series A Note [Member] New Convertible Note [Member] Issuance of common shares from at the market transaction value. Stock issued during period value conversion of convertible securities one. Stock issued during period value conversion of convertible securities two. Stock issued during period value for settlement of accounts payable. Preferred stock dividends Accumulated deficit deemed dividend. Series B Notes [Member] Accredited Investors [Member] Warrant One [Member] Warrant Two [Member] Temporary equity stock issued during period shares new issues. Debt instrument redeemed by cash payment. Mezzanine Equity [Member] Redemption of convertible notes. Series B Note [Member] Temporary equity shares conversion of mezzanine equity into common shares. Temporary equity value conversion of mezzanine equity into common shares. Stock issued during period shares conversion of convertible securities two. Issuance of common shares from at the market transaction shares. Stock issued during period shares conversion of convertible securities one. Stock issued during period shares for settlement of accounts payable. Issuance of warrants for services. Gain loss upon convertible promissory notes conversion and redemption. Other expense regarding loss on debt modification. Non cash lease expenses. Repayments of preferred stock dividend. Series C Notes [Member] Note Holders [Member] Placement Agents Warrants [Member] Warrants derivative. Debt instrument derivative liabilities. Gain loss recognized of debt Series C Note [Member] Other Convertible Notes Payable [Member] Stock issued during period shares issuance of shares in lieu of convertible note interest. Stock issued during period value issuance of shares in lieu of convertible note interest. Eighteen Month Anniversary [Member] Twenty Four Month Anniversary [Member] Short-term Bridge Loan Agreement [Member] Collateralized Merchant Finance Company [Member] Short-term Collateralized Bridge Loan Agreement [Member] Finance Company [Member] First Four Weeks [Member] Additional Collateralized Bridge Loan Agreement [Member] Promissory Note Agreement [Member] Individual Investor [Member] Early payment penalty provision percentage. Series A Convertible Note Holders [Member] New Promissory Note [Member] Adjustment carrying value and principal amount. Finance charges Collateralized Bridge Loan Agreement [Member] Remaining Thirty Six Weeks [Member] Loss on debt amendment. Two Short Term Promissory Notes [Member] One Investor [Member] Short Term Promissory Notes One [Member] Short Term Promissory Notes Two [Member] Short Term Bridge Loan Agreement One [Member] Short Term Loan Agreement [Member] Individual Investor One [Member] Collateralized Merchant Finance Company One [Member] Bank Loan Credit Agreement [Text Block] Origination fee amount. Exit Fees. Term Loan [Member] Federally Guaranteed Loans [Text Block] Economic Injury Disaster Loan [Member] Settlement of debt. Fair value measurement with unobservable inputs reconciliation recurring basis liability issue. Reduction due to preferred shares converted. Derivative treatment. Conversion of stock amount modification. Conversion of stock amount redemption. Derivative liability, remaining term (years). Derivative stock price. Shareholders [Member] Exchange Agreement [Member] Convertible Note and Warrant Derivative [Member] Volume weighted average price percentage. Technology Fees [Member] Device Sales [Member] Purchase Agreement [Member] Stated value percentage. Preferred stock initial conversion price. Beneficiary [Member] Conversion into common shares. Reduction due to preferred shares redeemed. Schedule of Series B Preferred Stock for Mezzanine Equity [Table Text Block] Convertible preferred stock. Change in fair valueus measurement with reconciliation recurring basis liability. Issuance of common shares from shares to be issued. Series C Convertible Note [Member] Debt settled. Derivative liability. Issuance of shares for settlement of accounts payable. Issuance of shares for settlement of accounts payable, value. Loss on debt conversion. Percentage of placement fee and other issuance expenses. Sale of stock number of additional shares issued in transaction. Broker Warrants [Member] Consultant Warrants [Member] Warrants Issued on Conversion of Convertible Notes [Member] 2016 Equity Incentive Plan [Member] Expected forfeiture (attrition) rate. 2023 Equity Incentive Plan [Member] New Lease Agreement [Member] Operating Leases of Lessee [Table Text Block] Operating lease right of use asset new leases. Operating lease new leases. Repayment and interest accretion. Schedule of Contractual Undiscounted Cash Flows For Lease Obligation [Table Text Block] Convertible notes payable remaining. Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Preferred Stock Dividends, Income Statement Impact Net Income (Loss) Available to Common Stockholders, Basic Comprehensive Income (Loss), Net of Tax, Attributable to Parent TemporaryEquityValueConversionOfMezzanineEquityIntoCommonShares Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion

Attributable to Parent PreferredStockDividends Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Other Receivables Net Cash Provided by (Used in) Operating Activities RepaymentsOfPreferredStockDividend Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Equity [Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Defined Benefit Plan, Assumptions [Table Text Block] Cash and Cash Equivalents, Fair Value Disclosure Working capital deficiency GainLossRecognizedOfDebt StockIssuedDuringPeriodSharesIssuanceOfSharesInLieuOfConvertibleNoteInterest StockIssuedDuringPeriodValueIssuanceOfSharesInLieuOfConvertibleNoteInterest Debt Instrument, Fair Value Disclosure Increase (Decrease) in Accounts and Other Receivables Interest Expense, Other Administrative Fees Expense Subordinated Borrowing, Interest Rate Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Conversion of Stock, Amount Converted ConvertiblePreferredStock Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Warrant or Right, Reason for Issuance, Description Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Proceeds from Issuance or Sale of Equity Operating Lease, Right-of-Use Asset, Periodic Reduction Operating Lease, Liability Repayment and interest accretion Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment Dividends EX-101.PRE 10 btcy-20240930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - $ / shares 6 Months Ended Sep. 30, 2024 Nov. 13, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Period Focus Q2 Â Document Fiscal Year Focus 2025 Â Current Fiscal Year End Date --03-31 Â Entity File Number 000-56074 Â Entity Registrant Name BIOTRICITY INC. Â Entity Central Index Key 0001630113 Â Entity Tax Identification Number 30-0983531 Â Entity Incorporation, State or Country Code NV Â Entity Address, Address Line One 203 Redwood Shores Parkway Â Entity Address, Address Line Two Suite 600 Â Entity Address, City or Town Redwood City Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94065 Â City Area Code (650) Â Local Phone Number 832-1626 Â Title of 12(b) Security Common Stock, par value $0.001 per share Â Trading Symbol BTCY Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 24,394,442 Entity Listing, Par Value Per Share $ 0.001 Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe par value per share of security quoted in same currency as Trading currency. Example: '0.01'. + ReferencesNo definition available. + Details Name: dei_EntityListingParValuePerShare Namespace Prefix: dei_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) Sep. 30, 2024 Mar. 31, 2024 CURRENT ASSETS Â Â Cash $ 173,270 $ 786,060 Accounts receivable, net 1,499,990 1,468,655 Inventory [Note 3] 1,817,561 1,879,402 Deposits and other receivables 573,674 336,456 Total current assets 4,064,495 4,470,573 Deposits and other receivables [Note 10] 112,972 85,000 Long-term accounts receivable 78,699 149,907 Property and equipment [Note 12] 12,576 15,552 Operating right of use assets [Note 10] 1,023,318 1,221,593 TOTAL ASSETS 5,292,060 5,942,625 CURRENT LIABILITIES Â Â Accounts payable and accrued liabilities [Note 4] 9,057,028 9,473,118 Convertible promissory notes and short term loans [Note 5] 8,479,032 9,376,471 Term loan, current 3,000,000 2,400,000 Derivative liabilities [Note 8] 460,059 991,866 Operating lease obligations, current [Note 10] 493,190 457,371 Total current liabilities 21,489,309 22,698,826 Federally guaranteed loans [Note 7] 870,800 870,800 Term loan [Note 6] 9,489,491 9,985,033 Derivative liabilities [Note 8] 1,649,177 1,435,668 Operating lease obligations 674,013 929,115 TOTAL LIABILITIES 34,172,790 35,919,442 MEZZANINE EQUITY Â Â Series B Convertible Redeemable preferred stock, $0.001 par value, 600 shares authorized as of September 30, 2024 and March 31, 2024, respectively, 405 and 265 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively [Note 9] 2,286,105 1,488,920 STOCKHOLDERSâ€™ DEFICIENCY Â Â Common stock, $0.001 par value, 125,000,000 shares authorized as at September 30, 2024, and March 31, 2024, respectively. Issued and outstanding common shares: 22,863,261 and 9,353,768 as at September 30, 2024 and March 31, 2024, respectively, and exchangeable shares of 160,672 outstanding as at September 30, 2024 and March 31, 2024, respectively [Note 9] 23,024 9,515 Shares to be issued 194,998 and 324,276 shares of common stock as at September 30, 2024 and March 31, 2024, respectively) [Note 9] 142,537 269,065 Additional paid-in-capital 104,842,124 95,723,083 Accumulated other comprehensive (loss) / income (73,415) 32,378 Accumulated deficit (136,101,106) (127,499,785) Total stockholdersâ€™ deficiency (31,166,835) (31,465,737) TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERSâ€™ DEFICIENCY 5,292,060 5,942,625 Preferred Stock [Member] Â Â STOCKHOLDERSâ€™ DEFICIENCY Â Â Preferred stock, value 1 1 Series A Preferred Stock [Member] Â Â STOCKHOLDERSâ€™ DEFICIENCY Â Â Preferred stock, value $ 0 $ 6 X - DefinitionShares to be issued. + ReferencesNo definition available. + Details Name: BTCY_SharesToBeIssued Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccountsReceivableNetNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -

Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleNotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DepositsAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DepositsAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be

offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_LoansPayableToBankCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_LongTermLoansFromBank Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of long-term loans classified as other, payable after one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-

gaap_OtherLoansPayableLongTerm Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.E.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Mar. 31, 2024 Preferred stock, par value $ 0.001 Â Preferred stock, shares authorized 10,000,000 10,000,000 Common stock, par value $ 0.001 $ 0.001 Common stock, shares authorized 125,000,000 125,000,000 Common stock, shares, issued 22,863,261 9,353,768 Common stock, shares, outstanding 22,863,261 9,353,768 Common stock, other shares, outstanding 160,672 160,672 Common stock shares to be issued 194,998 324,276 Preferred Stock [Member] Â Â Preferred stock, par value $ 0.001 $ 0.001 Preferred stock, shares authorized 9,979,400 9,979,400 Preferred stock, shares issued 1 1 Preferred stock, shares outstanding 1 1 Series B Convertible Redeemable Preferred Stock [Member] Â Â Series B converible redeemable preferred stock, par value $ 0.001 $ 0.001 Series B converible redeemable preferred stock, authorized 600 600 Series B converible redeemable preferred stock, shares issued 405 265 Series B converible redeemable preferred stock, shares outstanding 405 265 Series A Preferred Stock [Member] Â Â Preferred stock, par value $ 0.001 $ 0.001 Preferred stock, shares authorized 20,000 20,000 Preferred stock, shares issued 200 6,304 Preferred stock, shares outstanding 200 6,304 X - DefinitionCommon stock shares to be issued. + ReferencesNo definition available. + Details Name: BTCY_CommonStockSharesToBeIssued Namespace Prefix: BTCY_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares. + ReferencesNo definition available. + Details Name: us-gaap_CommonStockOtherSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification

-Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1 + Details Name: us-gaap_TemporaryEquityParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TemporaryEquitySharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TemporaryEquitySharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TemporaryEquitySharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=BTCY_SeriesBConvertibleRedeemablePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â REVENUE $ 3,266,846 $ 2,891,297 $ 6,468,589 $ 5,912,062 Cost of Revenue 807,672 892,019 1,646,247 1,996,080 GROSS PROFIT 2,459,174 1,999,278 4,822,342 3,915,982 OPERATING EXPENSES Â Â Â Â Selling, general and administrative expenses 2,248,864 3,487,331 5,214,983 7,007,546 Research and development expenses 517,982 697,620 1,031,877 1,410,595 TOTAL OPERATING EXPENSES 2,766,846 4,184,951 6,246,860 8,418,141 LOSS FROM OPERATIONS (307,672) (2,185,673) (1,424,518) (4,502,159) Interest expense (752,075) (753,268) (1,520,748) (1,413,780) Accretion and amortization expenses [Note 5,6] (339,888) (596,420) (1,484,616) (1,153,639) Change in fair value of derivative liabilities [Note 8] (193,757) (18,783) (500,619) 82,669 Gain (loss) upon convertible promissory notes conversion and redemption [Note 9] (4,690) 6,684 (132,301) 13,132 Other income (expense) [Note 9] 36,314 (143,380) (193,486) (129,945) NET LOSS BEFORE INCOME TAXES (1,561,768) (3,690,840) (5,256,288) (7,103,722) Income taxes [Note 3] NET LOSS BEFORE DIVIDENDS (1,561,768) (3,690,840) (5,256,288) (7,103,722) Preferred Stock Dividends (91,261) (190,442) (290,353) (379,139) Deemed Dividends [Note 9] (3,054,680) NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS (1,653,029) (3,881,282) (8,601,321) (7,482,861) Translation adjustment (129,376) 281,240 (105,793) 105,410 COMPREHENSIVE LOSS $ (1,782,405) $ (3,600,042) $ (8,707,114) $ (7,377,451) LOSS PER SHARE, BASIC $ (0.073) $ (0.441) $ (0.469) $ (0.853) LOSS PER SHARE, DILUTED $ (0.073) $ (0.441) $ (0.469) $ (0.853) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC 22,493,626 8,795,742 18,354,277 8,774,242 WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED 22,493,626 8,795,742 18,354,277 8,774,242 X - DefinitionDeemed dividends + ReferencesNo definition available. + Details Name: BTCY_DeemedDividends Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17:

http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic

10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders. + ReferencesNo definition available. + Details Name: us-gaap_PreferredStockDividendsIncomeStatementImpact Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name

Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Deficiency (Unaudited) - USD ($) Preferred Stock [Member] Common Stock [Member] Shares to be Issued [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Total Series B Convertible Redeemable Preferred Stock [Member] Mezzanine Equity [Member] Balance at Mar. 31, 2023 $ 7 $ 8,753 $ 24,999 $ 92,844,478 $ (152,797) $ (112,570,825) $ (19,845,385) Â Â Balance, shares at Mar. 31, 2023 6,305 8,752,510 3,955 Â Â Â Â Â Â Stock based compensation - ESOP [Note 9] 374,515 374,515 Â Â Translation adjustment 105,410 105,410 Â Â Net loss before dividends for the period (7,103,722) (7,103,722) Â Â Preferred stock dividends (379,139) (379,139) Â Â Issuance of common stock $ 58 119,227 119,285 Â Â Issuance of common stock, shares Â Â 57,743 Â Â Â Â Â Â Balance at Sep. 30, 2023 $ 7 $ 8,811 $ 24,999 93,338,220 (47,387) (120,053,686) (26,729,036) Â Â Balance, shares at Sep. 30, 2023 6,305 8,810,248 3,955 Â Â Â Â Â Â Balance at Jun. 30, 2023 $ 7 $ 8,753 $ 24,999 93,055,658 (328,627) (116,172,404) (23,411,614) Â Â Balance, shares at Jun. 30, 2023 6,305 8,752,505 3,955 Â Â Â Â Â Â Stock based compensation - ESOP [Note 9] 163,335 163,335 Â Â Translation adjustment 281,240 281,240 Â Â Net loss before dividends for the period (3,690,840) (3,690,840) Â Â Preferred stock dividends (190,442) (190,442) Â Â Issuance of common stock $ 58 119,227 119,285 Â Â Issuance of common stock, shares Â 57,743 Â Â Â Â Â Â Â Balance at Sep. 30, 2023 $ 7 $ 8,811 $ 24,999 93,338,220 (47,387) (120,053,686) (26,729,036) Â Â Balance, shares at Sep. 30, 2023 6,305 8,810,248 3,955 Â Â Â Â Â Â Balance at Mar. 31, 2024 $ 7 $ 9,515 $ 269,065 95,723,083 32,378 (127,499,785) (31,465,737) Â Â Temporary equity, shares at Mar. 31, 2024 Â Â Â Â Â Â Â 265 Â Temporary equity, value at Mar. 31, 2024 Â Â Â Â Â Â Â 1,488,920 $ 1,488,920 $ 1,488,920 Balance, shares at Mar. 31, 2024 6,305 9,514,440 344,276 Â Â Â Â Â Â Issuance of mezzanine equity [Note 9] Â Â Â Â Â Â Â $ 1,082,999 $ 1,082,999 Issuance of mezzanine equity [Note 9], shares Â Â Â Â Â Â Â 220 Â Issuance of common shares from at-the-market transaction [Note 9], shares Â 97,811 Â Â Â Â Â Â Â Conversion of mezzanine equity into common shares [Note 9] Â $ 1,436 Â 474,043 Â Â $ 475,479 Â Â Conversion of mezzanine equity into common shares [Note 9], shares Â Â Â Â Â Â Â (50) Â Conversion of mezzanine equity into common shares [Note 9], shares Â 1,436,267 Â Â Â Â 97,811 (285,814) (285,814) Conversion of preferred shares into common shares [Note 9], shares (6,104) 8,952,170 Â Â Â Â Â Â Â Conversion of convertible notes into common shares [Note 9] Â $ 1,345 $ 386,408 1,895,464 Â Â $ 2,283,217 Â Â Conversion of convertible notes into common shares [Note 9], shares Â 1,344,709 408,845 Â Â Â Â Â Â Issuance of shares for services [Note 9] Â $ 70 $ 27,640 53,410 Â Â 81,120 Â Â Issuance of shares for services [Note 9], shares Â 70,000 50,000 Â Â Â Â Â Â Issuance of shares for settlement of accounts payable [Note 9], shares Â 1,000,413 Â Â Â Â Â Â Â Stock based compensation - ESOP [Note 9] Â Â Â 115,863 Â Â 115,863 Â Â Translation adjustment Â Â Â Â (105,793) Â (105,793) Â Â Net loss before dividends for the period Â Â Â Â Â (5,256,288) (5,256,288) Â Â Preferred stock dividends Â Â Â Â Â (290,353) (290,353) Â Â Issuance of common stock Â $ 608 $ (540,576) 539,968 Â Â Â Â Issuance of common stock, shares Â 608,123 (608,123) Â Â Â Â Â Â Â Issuance of common shares from at-the-market transaction [Note 9] Â $ 98 Â 125,129 Â Â 125,227 Â Â Conversion of preferred shares into common shares [Note 9] $ (6) 8,952 Â 4,925,756 Â Â 4,934,702 Â Â Issuance of shares for settlement of accounts payable [Note 9] Â 1,000 Â 989,408 Â Â 990,408 Â Â Deemed Dividend [Note 9] Â Â Â Â Â Â Â (3,054,680) (3,054,680) Â Â Balance at Sep. 30, 2024 $ 1 $ 23,024 $ 142,537 104,842,124 (73,415) (136,101,106) (31,166,835) Â Â Temporary equity, shares at Sep. 30, 2024 Â Â Â Â Â Â Â 435 Â Temporary equity, value at Sep. 30, 2024 Â Â Â Â Â Â Â 2,286,105 $ 2,286,105 $ 2,286,105 Balance, shares at Sep. 30, 2024 201 23,023,933 194,998 Â Â Â Â Â Â Balance at Jun. 30, 2024 $ 1 $ 21,645 $ 359,709 104,231,071 55,961 (134,448,077) (29,779,690) Â Â Temporary equity, shares at Jun. 30, 2024 Â Â Â Â Â Â Â 405 Â Temporary equity, value at Jun. 30, 2024 Â Â Â Â Â Â Â $ 2,186,203 2,186,203 Balance, shares at Jun. 30, 2024 201 21,645,068 321,757 Â Â Â Â Â Â Issuance of mezzanine equity [Note 9] Â Â Â Â Â Â Â $ 242,809 242,809 Issuance of mezzanine equity [Note 9], shares Â Â Â Â Â Â Â 55 Â Issuance of common shares from shares to be issued [Note 9] Â $ 288 $ (311,790) 311,502 Â Â Â Â Issuance of common shares from shares to be issued [Note 9], shares Â 287,802 (287,802) Â Â Â Â Â Â Conversion of mezzanine equity into common shares [Note 9] Â $ 1,091 Â 242,666 Â Â 243,757 Â Â Conversion of mezzanine equity into common shares [Note 9], shares Â Â Â Â Â Â Â (25) Â Conversion of mezzanine equity into common shares [Note 9] Â Â Â Â Â Â Â Â $ (142,907) (142,907) Conversion of mezzanine equity into common shares [Note 9], shares Â 1,091,063 Â Â Â Â Â Â Â Conversion of convertible notes into common shares [Note 9] Â Â Â $ 74,618 Â Â Â 74,618 Â Â Conversion of convertible notes into common shares [Note 9], shares Â Â 121,043 Â Â Â Â Â Â Issuance of shares for services [Note 9] Â Â Â $ 20,000 Â Â Â 20,000 Â Â Issuance of shares for services [Note 9], shares Â Â 40,000 Â Â Â Â Â Â Stock based compensation - ESOP [Note 9] Â Â Â 56,885 Â Â 56,885 Â Â Translation adjustment Â Â Â Â Â (129,376) Â (129,376) Â Â Net loss before dividends for the period Â Â Â Â Â (1,561,768) (1,561,768) Â Â Preferred stock dividends Â Â Â Â Â (91,261) (91,261) Â Â Balance at Sep. 30, 2024 $ 1 $ 23,024 $ 142,537 $ 104,842,124 $ (73,415) $ (136,101,106) (31,166,835) Â Â Temporary equity, shares at Sep. 30, 2024 Â Â Â Â Â Â Â 435 Â Temporary equity, value at Sep. 30, 2024 Â Â Â Â Â Â Â $ 2,286,105 $ 2,286,105 $ 2,286,105 Balance, shares at Sep. 30, 2024 201 23,023,933 194,998 Â Â Â Â Â Â X - DefinitionAccumulated deficit deemed dividend. + ReferencesNo definition available. + Details Name: BTCY_AccumulatedDeficitDeemedDividend Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance of common shares from at the market transaction shares. + ReferencesNo definition available. + Details Name: BTCY_IssuanceOfCommonSharesFromAtTheMarketTransactionShares Namespace Prefix: BTCY_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionIssuance of common shares from at the market transaction value. + ReferencesNo definition available. + Details Name: BTCY_IssuanceOfCommonSharesFromAtTheMarketTransactionValue Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPreferred stock dividends + ReferencesNo definition available. + Details Name: BTCY_PreferredStockDividends Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionStock issued during period shares conversion of convertible securities one. + ReferencesNo definition available. + Details Name: BTCY_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesOne Namespace Prefix: BTCY_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares conversion of convertible securities two. + ReferencesNo definition available. + Details Name: BTCY_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesTwo Namespace Prefix: BTCY_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares for settlement of accounts payable. + ReferencesNo definition available. + Details Name: BTCY_StockIssuedDuringPeriodSharesForSettlementOfAccountsPayable Namespace Prefix: BTCY_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period value conversion of convertible securities one. + ReferencesNo definition available. + Details Name: BTCY_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value conversion of convertible securities two. + ReferencesNo definition available. + Details Name: BTCY_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesTwo Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value for settlement of accounts payable. + ReferencesNo definition available. + Details Name: BTCY_StockIssuedDuringPeriodValueForSettlementOfAccountsPayable Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTemporary equity shares conversion of mezzanine equity into common shares. + ReferencesNo definition available. + Details Name: BTCY_TemporaryEquitySharesConversionOfMezzanineEquityIntoCommonShares Namespace Prefix: BTCY_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTemporary equity stock issued during period shares new issues. + ReferencesNo definition available. + Details Name: BTCY_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues Namespace Prefix: BTCY_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTemporary equity value conversion of mezzanine equity into common shares. + ReferencesNo definition available. + Details Name: BTCY_TemporaryEquityValueConversionOfMezzanineEquityIntoCommonShares Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.E.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph

(SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TemporaryEquitySharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionValue of new stock classified as temporary equity issued during the period. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) 3 Months Ended 6 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Mar. 31, 2023 CASH FLOWS FROM OPERATING ACTIVITIES Â Â Â Â Â Â Net loss $ (1,561,768) $ (3,690,840) $ (5,256,288) $ (7,103,722) Â Â Adjustments to reconcile net loss to net cash used in operations: Â Â Â Â Â Â Stock based compensation Â Â 115,863 374,515 Â Â Issuance of shares for services Â Â 81,120 Â Â Issuance of warrants for services Â Â Â Â Accretion and amortization expenses 339,888 596,420 1,484,616 1,153,639 Â Â Change in fair value of derivative liabilities 193,757 18,783 500,619 (82,669) Â Â (Gain) loss upon convertible promissory notes conversion and redemption Â Â 132,301 (13,132) Â Â Other expense regarding loss on debt modification Â Â 59,161 Â Â Property and equipment depreciation Â Â 2,977 2,977 Â Â Non-cash lease expense Â Â 198,275 178,320 Â Â Changes in operating assets and liabilities: Â Â Â Â Â Â Accounts receivable, net Â Â 39,873 (411,440) Â Â Inventory Â Â 61,841 208,810 Â Â Deposits and other receivables Â Â (265,190) 348,388 Â Â Accounts payable and accrued liabilities Â Â 1,012,694 1,062,999 Â Â Net cash used in operating activities Â Â (1,891,299) (4,222,154) Â Â CASH FLOWS FROM FINANCING ACTIVITIES Â Â Â Â Â Â Issuance of common shares, net Â Â 125,221 119,285 $ 119,285 Â Issuance of preferred shares, net Â Â 1,732,532 1,900,000 Â Â Proceeds from convertible debentures, net Â Â 624,658 1,977,579 Â Â Proceeds from short term loan and promissory notes, net Â Â (1,125,116) 773,737 853,030 $ 1,476,121 Preferred Stock Dividend Â Â (18,016) (11,967) Â Â Net cash provided by financing activities Â Â 1,339,279 4,758,634 Â Â Net (increase) decrease in cash during the period Â Â (552,020) 536,480 Â Â Effect of foreign currency translation Â Â (60,770) 92,785 Â Â Cash, beginning of period Â Â 786,060 570,460 570,460 Â Cash, end of period $ 173,270 $ 1,199,725 173,270 1,199,725 $ 786,060 $ 570,460 Supplemental disclosure of cash flow information: Â Â Â Â Â Â Interest paid Â Â 1,235,256 1,046,621 Â Â Taxes Â Â Â Â Â X - DefinitionGain loss upon convertible promissory notes conversion and redemption. + ReferencesNo definition available. + Details Name: BTCY_GainLossUponConvertiblePromissoryNotesConversionAndRedemption Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIssuance of warrants for services. + ReferencesNo definition available. + Details Name: BTCY_IssuanceOfWarrantsForServices Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNon cash lease expenses. + ReferencesNo definition available. + Details Name: BTCY_NoncashLeaseExpenses Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOther expense regarding loss on debt modification. + ReferencesNo definition available. + Details Name: BTCY_OtherExpenseRegardingLossOnDebtModification Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepayments of preferred stock dividend. + ReferencesNo definition available. + Details Name: BTCY_RepaymentsOfPreferredStockDividend Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in receivables classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from long-term debt, finance lease obligation, and mandatorily redeemable capital security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure [Table] Â Â Â Â Net Income (Loss) $ (1,561,768) $ (3,690,840) $ (5,256,288) $ (7,103,722) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual [Table] Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 NATURE OF OPERATIONS 6 Months Ended Sep. 30, 2024 Organization,

Consolidation and Presentation of Financial Statements [Abstract] Â NATURE OF OPERATIONS 1. NATURE OF OPERATIONS Â Biotricity Inc. (formerly MetaSolutions, Inc.) (the â€œCompanyâ€ or â€œBiotricityâ€) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (â€œiMedicalâ€) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over on February 2, 2016. Â The Company (directly and through its subsidiary) is engaged in research and development activities within the remote monitoring segment of preventative care. It is focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted to building and commercializing an ecosystem of technologies that enable access to this market. Â X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION 6 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION 2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION Â The Condensed Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œUS GAAPâ€) and are expressed in United States dollars (â€œUSDâ€). Â The Condensed Consolidated Financial Statements of the Company have been prepared on a historical cost basis except derivative liabilities which are carried at fair value. Â The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary. Significant intercompany accounts and transactions have been eliminated. Â Reclassifications Â Certain amounts presented in the prior year period have been reclassified to conform to current period consolidated financial statement presentation. Â Reverse Split Â On June 29, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation to effect a one-for-six (1-for-6) share consolidation (the â€œReverse Splitâ€). The Reverse Split became effective on July 3, 2023. As a result of the Reverse Split, every six shares of the Companyâ€™s issued and outstanding common stock were automatically converted into one share of common stock, without any change in the par value per share or to the number of shares authorized and began trading on a post-Reverse Split basis under the Companyâ€™s existing trading symbol, â€œBTCY,â€ on July 3, 2023. No fractional shares were outstanding following the Reverse Split. Any holder who would have received a fractional share of common stock was automatically entitled to receive an additional fraction of a share of common stock to round up to the next whole share: 20,846 shares were issued for this purpose on July 19, 2023. Lastly, the Reverse Split does not impact the amount of authorized, issued or outstanding shares of preferred stock. Â All issued and outstanding common stock, common stock per share amounts and corresponding balance sheet accounts contained in the Condensed Consolidated Financial Statements have been retroactively adjusted to reflect this Reverse Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise and conversion price and the number of shares issuable upon the exercise or conversion of all outstanding stock options, warrants, convertible debt and equity instruments to purchase shares of common stock. Â Going Concern, Liquidity and Basis of Presentation Â The accompanying Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern. The Company is in the early stages of commercializing its product ecosystem and is concurrently continuing in development mode, operating a research and development program in order to develop, obtain regulatory clearance for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as of September 30, 2024, had an accumulated deficit of $ 136,101,106 and a working capital deficiency of $17,424,814. Those conditions raise substantial doubt about its ability to continue as a going concern for a period of one year from the issuance of these Condensed Consolidated Financial Statements. The Condensed Consolidated Financial Statements do not include adjustments that might result from the outcome of this uncertainty. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and after additional equity and debt capitalization of the Company. Â During the fiscal year ended March 31, 2023, the Company raised funds through short-term loans and promissory notes, net of repayments of $1,476,121 from various lenders, and also raised funds through convertible notes, net of redemptions of $2,355,318 from various lenders. Â During the fiscal year ended March 31, 2024, the Company raised funds through short-term loans and promissory notes, net of repayments of $853,030 and convertible notes, net of redemptions of $2,962,386 from various lenders. The Company sold 36,897 common shares through use of its registration statement, for gross proceeds of $123,347, raising a net amount of $119,285 after paying a 3% placement fee and other issuance expenses. Â Additionally, on September 19, 2023, the Company entered into a security purchase agreement with an institutional investor for the issuance and sale of 220 shares of the Companyâ€™s newly designated Series B Preferred Stock, at a purchase price of $9,091 per share of Series B Preferred Stock (Note 9), or gross proceeds of $2,000,000. Net proceeds after issuance costs amounted to $1,900,000. During the three months ended March 31, 2024, 110 Series B preferred shares were issued for net proceeds of $925,000. Â During the six months ended September 30, 2024, 220 Series B preferred shares were issued for net proceeds of $1,732,532. The Company also raised $650,000 from the issuance of convertible notes to a lender. Lastly, the Company sold 97,811 common shares through use of its registration statement, for net proceeds of $125,221. Â As we proceed with the commercialization of the Bioflux, Biocore, and Biocare product development, we expect to continue to devote significant resources on capital expenditures, as well as research and development costs and operations, marketing and sales expenditures. Â Based on the above facts and assumptions, we believe our existing cash, along with anticipated near-term financings, will be sufficient to continue to meet our needs for the next twelve months from the filing date of this report. However, we will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines. Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 6 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Revenue Recognition Â The Company adopted Accounting Standards Codification Topic 606, â€œRevenue from Contracts with Customersâ€ (â€œASC 606â€) on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles â€“ (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue as performance obligations are satisfied. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Both the Bioflux mobile cardiac telemetry device, and the Biocore device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Companyâ€™s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patientâ€™s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patientâ€™s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized. Â The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business. Â The Company recognized the following forms of revenue for the three and six months ended September 30, 2024, and 2023: Â SCHEDULE OF REVENUE RECOGNITIONÂ Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Three months ended September 30Â Â Six months ended September 30Â Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â $Â Â $Â Â $Â Â $Â Technology feesÂ Â 3,064,814Â Â Â 2,731,461Â Â Â 6,081,064Â Â Â 5,500,379Â Device salesÂ Â 202,032Â Â Â 159,836Â Â Â 387,525Â Â Â 411,683Â TotalÂ Â Â 3,266,846Â Â Â 2,891,297Â Â Â 6,468,589Â Â Â 5,912,062Â Â Inventories Â Inventory is stated at the lower of cost and market value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. Â SCHEDULE OF INVENTORIESÂ Â Â September 30, 2024Â Â March 31, 2024Â Â Â Â $Â Â $Â Raw materialÂ Â 1,073,409Â Â Â 1,128,700Â Finished goodsÂ Â 744,152Â Â Â 750,702Â Â Â Â Â Â Â Â Â Â Â InventoriesÂ Â 1,817,561Â Â Â 1,879,402Â Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Significant accounting estimates and assumptions Â The preparation of the Condensed Consolidated Financial Statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. Â The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Â Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities: Â â— Fair value of stock options Â Â The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield. Â â— Fair value of warrants Â Â In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity. Â â— Fair value of derivative liabilities Â Â In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period. Â Â â— Functional currency Â Â Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses. Â Â â— Useful life of property and equipment Â Â The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â â— Provisions Â Â Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. Â Â â— Contingencies Â Â Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events. Â Â â— Inventory obsolescence Â Â Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. Â Â â— Income and other taxes Â Â The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its

budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. Â Â When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Companyâ€™s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Companyâ€™s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated. Â Â â— Incremental borrowing rate for lease Â Â The determination of the Companyâ€™s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Companyâ€™s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Companyâ€™s Condensed Consolidated Financial Statements. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Earnings (Loss) Per Share Â The Company has adopted the Financial Accounting Standards Boardâ€™s (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 260-10 which provides for calculation of â€œbasicâ€ and â€œdilutedâ€ earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Companyâ€™s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings are computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method were not applicable during the periods presented as no conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented. Â Cash Â Cash includes cash on hand and balances with banks. Â Foreign Currency Translation Â The functional currency of the Companyâ€™s Canadian-based subsidiary is the Canadian dollar, and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Companyâ€™s Canadian subsidiaries from their functional currency into the Companyâ€™s reporting currency of United States dollars, consolidated balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholdersâ€™ deficiency. The Company has not, to the date of these Condensed Consolidated Financial Statements, entered into derivative instruments to offset the impact of foreign currency fluctuations. Â Accounts Receivable Â Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Companyâ€™s normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Fair Value of Financial Instruments Â ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Â â— Level 1 â€“ Valuation based on quoted market prices in active markets for identical assets or liabilities. Â â— Level 2 â€“ Valuation based on quoted market prices for similar assets and liabilities in active markets. Â â— Level 3 â€“ Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring managementâ€™s best estimate of what market participants would use as fair value. Â In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Companyâ€™s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Â Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans, accounts payable and accrued liabilities. The Companyâ€™s derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Companyâ€™s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk. Â The fair value of financial instruments measured on a recurring basis is as follows: Â SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTSÂ Â Â As of September 30, 2024Â DescriptionÂ TotalÂ Â Level 1Â Â Level 2Â Â Level 3Â Assets:Â Â Â Â Â Â Â Â Â Â Â Â Â Â CashÂ $173,270Â Â $173,270Â Â $â€”Â Â $â€”Â Total assets at fair valueÂ $173,270Â Â $173,270Â Â $â€”Â Â $â€”Â Liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Derivative liabilities, short-termÂ $460,059Â Â $â€”Â Â $â€”Â Â $460,059Â Derivative liabilities, long-termÂ Â 1,649,177Â Â Â Â€”Â Â Â€”Â Â Â 1,649,177Â Total liabilities at fair valueÂ $2,109,236Â Â $â€”Â Â $â€”Â Â $2,109,236Â Â Â Â As of March 31, 2024Â DescriptionÂ TotalÂ Â Level 1Â Â Level 2Â Â Level 3Â Assets:Â Â Â Â Â Â Â Â Â Â Â Â Â Â CashÂ $786,060Â Â $786,060Â Â $â€”Â Â $â€”Â Total assets at fair valueÂ $786,060Â Â $786,060Â Â $â€”Â Â $â€”Â Liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Derivative liabilities, short-termÂ $991,866Â Â $â€”Â Â $â€”Â Â $991,866Â Derivative liabilities, long-termÂ Â 1,435,668Â Â Â Â€”Â Â Â€”Â Â Â 1,435,668Â Total liabilities at fair valueÂ $2,427,534Â Â $â€”Â Â $â€”Â Â $2,427,534Â Â Â There were no transfers between fair value hierarchy levels during the six months ended September 30, 2024 and 2023. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Property and Equipment Â Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follow: Â SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVESÂ Office equipment 5 years Leasehold improvement 5 years Â Impairment for Long-Lived Assets Â The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets, including right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assetsâ€™ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at September 30, 2024 and March 31, 2024, the Company believes there was no impairment of its long-lived assets. Â Leases Â The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items Operating right of use assets, Operating lease obligations, current, and Operating lease obligations, long-term in the consolidated balance sheet. Â Right-of-use (â€œROUâ€) asset represents the Companyâ€™s right to use an underlying asset for the lease term and lease obligations represent the Companyâ€™s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. As the Companyâ€™s lease does not provide implicit interest rate, the Company uses the Companyâ€™s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion. Â Income Taxes Â The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for consolidated financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized. Â Research and Development Â Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Selling, General and Administrative Â Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include sales and marketing costs, investor relations and legal costs relating to corporate matters, professional fees for consultants assisting with business development and financial matters, and office and administrative expenses. Â Stock Based Compensation Â The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period. Â The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services. Â Convertible Notes Payable and Derivative Instruments Â The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Â Series B Convertible Preferred Stock Â The Series B convertible preferred stock (â€œSeries B Preferred Stockâ€) was accounted for as mezzanine equity and the embedded conversion and redemption features was accounted for as derivative liabilities with change in fair value at each reporting period end charged to the consolidated statement of operation and comprehensive loss in accordance with ASC 480 and ASC 815. Â Preferred Shares Extinguishments Â The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For preferred stock redemptions and conversion, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss. Â Segment Information Â Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company has identified its Chief Executive Officer (â€œCEOâ€) as the chief operating decision maker (â€œCODMâ€). The Company operates in one operating segment. The Companyâ€™s CODM allocates resources and assesses performance at the consolidated level. The Companyâ€™s property and equipment and operating right of use lease asset are in the United States as of September 30, 2024, and 2023. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Recently Issued Accounting Pronouncements Â In June 2016, the FASB issued ASU 2016-13, â€œFinancial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.â€ This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an â€œexpected lossâ€ model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instrumentsâ€”Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. The Company has adopted Topic 326 on the Companyâ€™s Condensed Consolidated Financial Statements according to the effective date and the adoption has no significant impact on the Companyâ€™s Condensed Consolidated Financial Statements. Â In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (â€œASU 2019-12â€), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. There is no significant impact from adopting ASU 2019-12 on the Companyâ€™s financial condition, results of operations, and cash flows. Â In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuerâ€™s common stock). The guidance in the ASU

requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company adopted this guidance for the fiscal year beginning April 1, 2022. There is no significant impact from adopting ASU 2021-04 on the Companyâ€™s financial condition, results of operations, and cash flows. Â On March 28, 2023, the FASB issued ASU No. 2023-01, Leases (Topic 842): Common Control Arrangements. ASU 2023-01 is designed to clarify the accounting for leasehold improvements associated with common control leases, thereby reducing diversity in practice. The new standard is effective for the Company for its fiscal year beginning January 1, 2024, with early adoption permitted. There is no significant impact from adopting ASU No. 2023-01 on the Companyâ€™s financial condition, results of operations, and cash flows. Â In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€) to improve the disclosures regarding a public entityâ€™s reportable segments and address requests from investors for additional, more detailed information about a reportable segmentâ€™s expenses. The Company is required to adopt the guidance in the fourth quarter of fiscal 2025, though early adoption is permitted. There is no significant impact from adopting ASU 2023-07 on the Companyâ€™s financial condition, results of operations, and cash flows. Â In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures (â€œASU 2023-09â€) to provide disaggregated income tax disclosures on rate reconciliation and income taxes paid. The Company is required to adopt the guidance in the fourth quarter of fiscal 2026, though early adoption is permitted. The Company is currently evaluating the impact of this amendment on its Condensed Consolidated Financial Statements. Â The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems. Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 ACCOUNTS PAYABLE AND ACCRUED LIABILITIES 6 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â ACCOUNTS PAYABLE AND ACCRUED LIABILITIES 4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Â Â SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIESÂ Â Â As at September 30, 2024Â Â As at March 31, 2024Â Â Â $Â Â $Â Trade and other payablesÂ Â 4,800,049Â Â Â 5,081,992Â Accrued liabilitiesÂ Â 4,232,727Â Â Â 4,369,576Â Deferred revenueÂ Â 24,252Â Â Â 21,550Â TotalÂ Â 9,057,028Â Â Â 9,473,118Â Â Trade and other payables and accrued liabilities as at September 30, 2024 and March 31, 2024 included $307,085 and $837,945, respectively, due to a shareholder, who is a director and executive of the Company. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3 CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS 6 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS 5. CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS Â Series A Convertible Promissory Notes: Â During the year ended March 31, 2021, the Company issued $11,275,500 (face value) in two series of convertible promissory notes (the â€œSeries A Notesâ€) sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 12% per annum. Â For the first series of Series A Notes, commencing six months following the Issuance Date, and at any time thereafter (provided the Holder has not received notice of the Companyâ€™s intent to prepay the note), at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the â€œOutstanding Balanceâ€) could be converted into that number of shares of Common Stock equal to: (i) the Outstanding Balance divided by (ii) 75% of the volume weighted average price of the Common Stock for the 5 trading days prior to the Conversion Date (the conversion price). Â For the first series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Companyâ€™s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Companyâ€™s common stock being listed on a national securities exchange, in which event the conversion price would be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Companyâ€™s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest. Â For the second series of Series A Notes, the notes could be converted into shares of common stock, at the option of the holder, commencing six months from issuance, at a conversion price equal to the lower of $24.00 per share or 75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date. Â For the second series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Companyâ€™s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Companyâ€™s common stock being listed on a national securities exchange, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Companyâ€™s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest. Â The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Companyâ€™s common shares at the time final closing. Â The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,500 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes. Â The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Companyâ€™s common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrantsâ€™ exercise price was struck at $6.36 per share. Â Prior to January 8, 2021 (final closing date), the Company determined that the conversion and redemption features contained in those Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion and redemption features. Â For the Series A Notes, the Company recognized debt issuance costs in the amount of $2,301,854 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Notes. The Company also recognized initial debt discount in the amount of $8,088,003 and accreted the interest over the remaining lives of those Notes. The debt issuance costs were fully amortized by March 31, 2022. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â On December 30, 2022, the Company exchanged $500,000 of Series A Notes along with its outstanding interest accrual of $121,500 into a new convertible note with the same note holder. The new convertible note has principal of $621,500, stated interest rate of 12% per annum, as well as option to convert outstanding principal and accrued interest at the conversion price, calculated at 75% multiplied by the average of the three lowest closing prices during the previous ten trading days prior to the receipt of the conversion notice. The new convertible note matured on December 30, 2023. Â Prior to year ended March 31, 2022, $10,575,500 face value of the Series A note was converted into common shares. As of March 31, 2022, the remaining face value was in the amount of $700,000. Â During the three and six months ended September 30, 2024, the Company recognized discount amortization of $nil. As of September 30, 2024, the discount on Series A convertible notes was fully amortized. During the three and six months ended September 30, 2023, the Company recognized discount amortization of $16,455 and 32,291, respectively as accretion and amortization expense. Â As of September 30, 2024, and March 31, 2024, the Company recorded $223,187 and $173,762, respectively, of interest accruals for the Series A Notes. Â During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $24,848 and $49,425, respectively, on Series A convertible notes. During the three and six months ended September 30, 2023, the Company recognized interest expense in the amount of $18,798 and $37,392, respectively, on Series A convertible notes. Â Series B Convertible Notes Â During the year ended March 31, 2021, the Company also issued $1,312,500 (face value) of convertible promissory notes (â€œSeries B Notesâ€) to various accredited investors. Â Commencing six months following the issuance date, and at any time thereafter, subject to the Companyâ€™s Conversion Buyout clause, at the sole election of the holder, any amount of the outstanding principal and accrued interest of the note (the â€œoutstanding balanceâ€) could be converted into that number of shares of Common Stock equal to: (i) the outstanding balance divided by (ii) the Conversion Price. Partial conversions of the note shall have the effect of lowering the outstanding principal amount of the note. The holder may exercise such conversion right by providing written notice to the Company of such exercise in a form reasonably acceptable to the Company (a â€œconversion noticeâ€). Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice. Â The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Companyâ€™s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion, redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is $6.36 per share for 100,000 warrant shares and $9.0 per share for 35,417 warrant shares. Â Net proceeds to the Company from convertible note issuances to March 31, 2021 amounted to $1,240,000 after the original issuance discount as well as payment of the financing related fees. The Company determined that the conversion and redemption features contained in the Series B Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liability associated with the embedded conversion and redemption features. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â The Company recognized debt issuance costs in the amount of $10,000 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Series B Notes. The Company recognized initial debt discount of $1,312,500 and accreted the interest over the remaining lives of those notes. The debt issuance costs were fully amortized by March 31, 2022. Â During the year ended March 31, 2022, $472,500 (face value) of Series B Notes were converted into 34,586 common shares. As at March 31, 2022, $840,000 of Series B Notes remained unconverted and outstanding, which was equal to the face value of the relevant convertible notes. Â During the year ended March 31, 2023, $555,600 (face value) of Series B Notes were converted into 126,833 common shares (Note 9 d). Â During the year ended March 31, 2023, $126,680 (face value) of Series B Notes were redeemed by cash payment of $145,682. The redemption price was determined in accordance to the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note, was $24,408, and was recognized as a gain upon convertible note repayment. Â During the year ended March 31, 2024, the Company redeemed $135,710 of Series B Notes, through a cash payment of $162,851. A gain on redemption $18,540 was recognized as a result of this redemption, representing the difference between the cash payment and the face value of Series B Notes redeemed net of the related derivative liabilities ($45,681 for the year ended March 31, 2024). Â During the three and six months ended September 30, 2024, the Company redeemed $5,342 and $22,009 of Series B Notes, through a cash payment of $5,342 and $25,342, respectively. A gain on redemption of $1,761 and $8,320 was recognized as a result of this redemption, representing the difference between the cash payment and the face value of Series B Notes redeemed net of the related derivative liabilities ($1,761 and $8,320 for the three and six months ended September 30, 2024, respectively). Â During the three and six months ended September 30, 2023, the Company redeemed $52,049 and $102,376 of Series B Notes, through a cash payment of $62,459 and $122,851, respectively. A gain on redemption of $6,684 and $13,132 was recognized as a result of this redemption, representing the difference between the cash payment and the face value of Series B Notes redeemed net of the related derivative liabilities ($17,094 and $33,607 for the three and six months ended September 30, 2023, respectively). Â In total, the Company had issued $821,500 and $157,720 for Series A and Series B notes, respectively, out of which $821,500 and $nil for Series A Notes and Series B Notes remaining outstanding beyond their contractual maturity date as of September 30, 2024. As at March 31, 2024, $821,500 and $22,010 for Series A and Series B notes remained outstanding beyond their contractual maturity date. Â The Series A and Series B notes continued to accrue interest, and no repayment demand notification was received from noteholders, notwithstanding the fact that these noteholders have continued to convert portions of these notes subsequently; and the Company expects that the majority of these notes will eventually convert. Â As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $88,881 and $88,602, respectively, related to the Series B Notes. Â During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $59 and $279, respectively. During the three and six months ended September 30, 2023, the Company recognized interest expense in the amount of $1,034 and $2,703, respectively. Â Series C Convertible Notes Â The Company has issued Series C Notes of $1,812,700 (face value) by March 31, 2024, with net proceeds of $1,100,430 after payment of the relevant financing related fees. Â The Series C Notes were sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 15% per annum. Â For Series C Notes, commencing six months following the Issuance Date, and at any time thereafter, at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the â€œConversion Amountâ€) could be converted into that number of shares of Common Stock equal to: the Conversion Amount divided by the â€œOptional Conversion Priceâ€, which is defined as lower of (i) seventy-five percent (75%) of the VWAP for the five (5) Trading Days prior to the Conversion Date, or (ii) eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â For Series C Notes, â€œMandatory Conversionâ€ of the notes would convert into common stock at the applicable â€œMandatory Conversion Priceâ€, if either (i) on each of any twenty (20) consecutive Trading Days (the â€œMeasurement Periodâ€) (A) the closing price of the Common Stock on the applicable Trading Market is at least $18.00 per share and (B) the dollar value of average daily trades of the Common Stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the Common Stock on the applicable National Exchange on each of the ten (10) consecutive Trading Days following such closing is at least $400,000 per Trading Day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above,

seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing. Â The Company was obligated to issue warrants that accompany the convertible notes and provide 100% warrant coverage. The warrants have a 4-year term from date of issuance and an exercise price that is 200% of the 5-day volume weighted average price of the Companyâ€™s common shares at the time of final closing. Â The Company was obligated to pay the placement agent of the first series of Series C Notes a 10% cash fee for the face value of the notes. Â The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 8% of face value of the notes, with an exercise price that equals to the 5-day volume weighted average price of the Companyâ€™s common shares at the time final closing. Â Prior to the final closing date (October 23, 2023), the Company determined that the conversion features contained in those Note, as well as the obligations to issue investor warrants and placement agent warrants represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion features, as well as the obligations related to investor warrant and placement agent warrant issuance. Subsequently, the exercise price of all warrants was concluded and locked to $4.18 and $2.09, respectively, for the note holder and placement agent warrants, as of the final closing date October 23, 2023. Since the exercise price was no longer a variable, the Company concluded that the noteholder and placement agent warrants should no longer be accounted for as a derivative liability in accordance with ASC 815 guidelines related to equity indexation and classification. The derivative liabilities related to those warrants were therefore marked to market as of October 23, 2023 and then transferred to equity (collectively, â€œEnd of warrants derivative treatmentâ€) in the amount of $1,278,786 (Note 8). Â For the Series C Notes, the Company recognized debt issuance costs of $207,361 during the year ended March 31, 2024 and treated these as debt discounts. The Company also recognized additional debt discount in the amount of $1,005,829 in connection with the recognition of derivative liabilities for the conversion features, investor warrants and placement agent warrants. The debt discounts are recorded as a contra liability against the convertible note and are amortized and recognized as accretion expenses using the effective interest method over the remaining lives of the Notes. Â During the three and six months ended September 30, 2024, the Company recognized discount amortization of $184,577 and $1,051,668, respectively, on Series C Notes as accretion and amortization expense. As of September 30, 2024, and March 31, 2024, the remaining unamortized discount on Series C convertible notes was $180,606 and $1,232,274, respectively. Â During the three and six months ended September 30, 2023, the Company recognized discount amortization of $95,183 and $180,866, respectively, on Series C Notes as accretion and amortization expense. As of September 30, 2023, the remaining unamortized discount on Series C convertible notes was $1,610,913. Â During the three and six months ended September 30, 2024, convertible notes with a face value of $45,000 and $1,432,700, respectively, were converted into 121,043 and 1,753,554 common shares, respectively. As of September 30, 2024, 121,043 shares are recognized as an obligation for shares to be issued relating to the conversion. The fair value of common shares issued during the three and six months ended September 30, 2024, is $74,618 and $2,283,216, respectively, and is determined based on market price upon conversion. Total value of debt settled is in the amount of $68,167 and $2,145,929, respectively, which consisted of the face value of notes converted, accrued interest of $7,810 and $222,257, respectively, and relevant derivative liability of $15,357 and $490,972, respectively. The Company recognized a loss upon conversion of $6,451 and $137,287, respectively, representing the difference between the value of debt settled and fair value of shares issued and to be issued. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $79,133 and $253,643, respectively, related to the Series C Notes. Â During the three and six months ended September 30, 2024, the Company recognized interest expense in the amounts of $15,004 and $47,747, respectively. During the three and six months ended September 30, 2023, the Company recognized interest expense in the amounts of $66,137 and $114,632, respectively. Â Other Convertible Notes Â On January 23, 2023, the Company issued $2,000,000 (face value) in convertible preferred notes (â€œthe Notesâ€) to an accredited investor. The Notes mature 18 months from the issuance date. This note bears interest rate at a fixed rate of 10% in the form of stock with a strike price equal to the closing stock price on the note issuance date. Therefore, the Company issued 45,045 shares of common stock in lieu of interest on this convertible note. These shares were valued at $221,621 and were recognized as a deferred cost on the convertible note, recorded as a contra liability against the convertible note, and were amortized and recognized as accretion expense using the effective interest rate method over the remaining lives of the Notes. Â The conversion of the Notes is automatic upon a Qualified Financing which is in the control of the Company, or at maturity of the notes, upon mutual agreement by the noteholder and the Company. Since the conversion is not in control of the holder of the note, the Company did not recognize a derivative liability in connection with the conversion option of the Notes. Â During the three and six months ended September 30, 2024, the Company recognized discount amortization of $nil, respectively, on the Notes as accretion and amortization expense. As of September 30, 2024, and March 31, 2024, respectively, the discount on Other Convertible Notes was fully amortized. Â During the three and six months ended September 30, 2023, the Company recognized discount amortization of $55,861 and $111,115, respectively, for the Other Convertible Notes, as part of the accretion and amortization expenses. As of September 30, 2023, the remaining unamortized discount on Other Convertible Notes was $75,289. Â Convertible Preferred Notes Â The Company entered into a convertible preferred note financing on September 25, 2023 and issued a convertible note (â€œPreferred Noteâ€) for a principal amount of $1,000,000. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen (18) month anniversary of the last closing date of the offering (the â€œMaturity Dateâ€). The Preferred Note bears interest at a fixed rate of 12% which is payable in cash monthly. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â The Company also entered into a convertible preferred note financing on October 25, 2023 and issued a convertible note (â€œPreferred Noteâ€) for a principal amount of $250,000. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen (18) month anniversary of the last closing date of the offering (the â€œMaturity Dateâ€). The Preferred Note bears interest at a fixed rate of 12% which is payable in cash monthly. Â The Company entered into a convertible preferred note financing on January 9, 2024 and issued a convertible note (â€œPreferred Noteâ€) for a principal amount of $114,303. The Preferred Note matures on the twenty-four (24) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the twenty-four (24) month anniversary of the last closing date of the offering (the â€œMaturity Dateâ€). The Preferred Note bears interest at a fixed rate of 8% which is payable in cash quarterly. Â The Company entered into a convertible preferred note financing on June 17, 2024, and issued a convertible note (â€œPreferred Noteâ€) for a principal amount of $300,000. During the three months ended September 30, 2024, the Company entered into additional preferred note financing with the same subscriber for a principal amount of $350,000. The total principal amount outstanding as of September 30, 2024 was $650,000. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen (18) month anniversary of the last closing date of the offering (the â€œMaturity Dateâ€). The Preferred Note bears no interest. Â The conversion of the Preferred Notes is automatic upon a Qualified Financing which is in the control of the Company, or at maturity of the notes, upon mutual agreement by the noteholder and the Company. Since the conversion is not in control of the holder of the note, the Company did not recognize a derivative liability in connection with the conversion option of the Other Convertible Notes. Â The Company may prepay the Preferred Note in whole or in part, after providing fifteen (15) days written notice to the holder, either in cash or by the mutually consented conversion of the Preferred Note and any accrued interest thereon at a 15% discount to the stockâ€™s 10-day VWAP. Â As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $27,138 and $4,103, respectively, related to the Preferred Notes. Â During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $38,612 and $77,125, respectively. Â Other Short-term loans and Promissory Notes Â In December 2022, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $400,000, prior to the deduction of issuance costs in the amount of $9,999. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 40 weeks. The Company is required to make weekly payments of $13,995 ($560,000 in the aggregate). As of September 30, 2024, and March 31, 2024, respectively, the principal was fully repaid and discount for this loan was fully amortized. The discount amortization during the three and six months ended September 30, 2024, was $nil, respectively. The discount amortization during the three and six months ended September 30, 2023, was $2,893 and $6,142, respectively, and was recognized as part of the accretion and amortization expenses. In addition, the Company recognized $nil accretion expenses, during the three and six months ended September 30, 2024, and $16,242 and $66,213 during the three and six months ended September 30, 2023, respectively, related to the increase in present value of the loan over its term. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â In December 2022, the Company also entered into a short-term collateralized bridge loan agreement with a finance company that advanced gross proceeds of $800,000, prior to the deduction of issuance costs in the amount of $32,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of this second agreement is 40 weeks. The Company is required to make weekly payments of $29,556 ($13,999 for the first four weeks, and $1,120,000 in the aggregate). As of September 30, 2024, and March 31, 2024, respectively, the principal was fully repaid and discount for this loan was fully amortized. The discount amortization during the three and six months ended September 30, 2024, was $nil, respectively. The discount amortization during the three and six months ended September 30, 2023, was $10,400 and $20,800, respectively, which was recognized as part of the accretion and amortization expenses. In addition, the Company recognized $nil accretion expenses, during the three and six months ended September 30, 2024, and $41,049 and $148,027 accretion expenses, during the three and six months ended September 30, 2023, respectively, related to the increase in present value of the loan over its term. Â In December 2022, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $600,000 (the â€œPrincipal Amountâ€). The note has a fixed rate of interest at 25% per annum payable monthly on the first day of every month. This promissory note matured on December 15, 2023, when the Principal Amount became due. The note has various default provisions which would, if triggered, result in the acceleration of the Principal Amount plus any accrued and unpaid interest. The note also has a 3% early payment penalty provision. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $600,000, and accrued interest outstanding on the note was $12,928 and $12,723, respectively. The note continues to accrue interest, and no repayment demand notification was received from noteholder. During the three and six months ended September 30, 2024, the Company recorded interest expense in the amount of $37,808 and $75,206, respectively, related to the promissory note. During the three and six months ended September 30, 2023, the Company recorded interest expense in the amount of $37,808 and $75,205, respectively, related to the promissory note. Â On December 30, 2022, the Company extinguished 51,101 warrants that were originally issued to Series A Convertible Noteholders and replaced these warrants with a new promissory note issued to the same warrant holder. The new promissory note has a principal balance of $270,000, stated interest of zero, and maturity date of December 31, 2023. The fair value of this new promissory note was $248,479 as of the issuance date, which was calculated using a discount rate that was comparable to other loan issuance at the same time as well as the market bond rates at the time of the promissory note issuance. The difference between the fair value of the new note and its principal balance was $21,521, and was recognized as a discount, and amortized via effective interest rate method. The Company compared the fair value of the extinguished warrants immediately prior to extinguishment against the fair value of the new promissory note issued. During the year ended March 31, 2024, the obligation to repay the principal balance at the original maturity date was waived for a finance charge of $50,000, which the Company recorded as interest expense in the in the statement of operations. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $270,000, and the remaining unamortized discount was $Nil. During the three and six months ended September 30, 2024, the Company recognized amortization of discount on this promissory note in the amounts of $nil, respectively. During the three and six months ended September 30, 2023, the Company recognized amortization of discount on this promissory note in the amounts of $nil and $7,304, respectively, as accretion and amortization expenses. As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $50,000 related to this promissory note. Â On March 29, 2023, the Company entered into an additional collateralized bridge loan agreement with a finance company that advanced gross proceeds of $300,000, prior to the deduction of issuance costs in the amount of $12,000. The issuance costs were recognized as a debt discount and would be amortized via the effective interest method. The term of this agreement is 40 weeks. The Company is required to make weekly payments of $5,250 for the first four weeks, and $11,083 for the remaining 36 weeks, which is $420,000 in aggregate. On July 18, 2023, the Company entered into an amendment with the finance company and increased total proceeds borrowed to $700,000. The proceeds from the amended loan balance were netted against previously outstanding balance of the loan, along with an issuance cost in the amount of $28,000. The term of this new loan agreement is 40 weeks. The Company is required to make weekly payments of $24,500, which is $980,000 in aggregate. The Company accounted for this amendment as a debt extinguishment and recognized a loss on the amendment of $59,161 in other expenses. The issuance costs on the amended loan were recognized as a debt discount and would be amortized via the effective interest method. During the three and six months ended September 30, 2024, the Company recognized $nil and $2,800, respectively, of amortization of discount as accretion and amortization expenses. During the three and six months ended September 30, 2023, the Company recognized $11,500 and $3,600, respectively, of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $nil and $4,152 accretion expenses, during the three and six months ended September 30, 2024, respectively and $100,419 and $112,700 during the three and six months ended September 30, 2023, respectively, related to the increase in present value of the loan over its term. During the three and six months ended September 30, 2024, net repayments for the loan amounted to $44,500 and $191,500, respectively. During the three and six months ended September 30, 2023, net repayments for the loan amounted to $298,472 and $762,805, respectively. Â In June 2023, the Company entered into a secured revolving account purchase credit and inventory financing facility (the â€œRevolving Facilityâ€) with a revolving loan lender, pursuant to which the lender may from time to time purchase certain discrete account receivables from the Company (with full recourse) or may make loans and provide other financial accommodations, the payment of which are guaranteed and secured by certain assets of the Company. In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $1.2 million in financing, and expects to receive the remaining balance as part of normal collection activities. The inventory financing provided by this facility was limited to the lower of $0.3 million, or a 40% maximum of inventory balances. The Revolving Facility was accounted for as a secured borrowing. As of September 30, 2024, and March 31, 2024 the Company had drawn $1,500,529 and $1,286,792, respectively, in accounts receivable financing and $198,000 and $125,000, respectively, in inventory financing with aggregate principal outstanding of $1,698,529 and $1,411,792, respectively. During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $102,485 and $207,718, respectively. During the three and six months ended September 30, 2023, the Company recognized interest expense in the amount of $59,656 and $104,873, respectively. As of September 30, 2024, and March 31, 2024 the Company recorded accrued interest in the amount of $25,369 and $23,879 related to the Revolving Facility. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â On July 13, 2023, the Company entered into another short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $400,000, prior to the deduction of issuance costs in the amount of $24,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 14 weeks. The Company is required to make weekly payments of $38,705 ($540,000 in the aggregate). As of September 30, 2024, and March 31, 2024, the principal was fully repaid and discount for this loan was fully amortized. No repayments were made during the six months ended September 30, 2024. Â On August 11, 2023, the Company issued two short term promissory notes (â€œAugust 2023 Notesâ€), each for a principal amount of $250,000, to one investor for aggregate gross proceeds of $500,000. The August 2023 Notes do not accrue formal interest but do contain administrative fees in the aggregate of $75,000. One of the notes matures three months from the issuance date upon which the principal amount of $250,000 and an administrative fee of $25,000 is due. The second note matures six months from the issuance date upon which the principal amount of $250,000 and an administrative fee of $50,000 is due. The administrative fees were accrued as interest expenses for the period of the loans outstanding. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $52,500 and $427,500, respectively. Accrued interest outstanding on the note as of September 30, 2024, and March 31,2024, was $75,000, respectively. During the three and six months ended September 30, 2024, net repayments towards the principal amount of the notes amounted to $250,000 and 375,000, respectively. Â On December 8, 2023, the Company entered into a

short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $630,000, prior to the deduction of issuance costs in the amount of $15,750. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 44 weeks. The Company is required to make weekly payments of $19,195 ($844,200 in the aggregate). As of September 30, 2024, and March 31, 2024, the amount of principal outstanding under this amended agreement was $37,241 and $443,185, respectively, and the remaining unamortized issuance cost discount was $716 and $10,023, respectively. During the three and six months ended September 30, 2024, the Company recognized $4,653 and $9,307 of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $28,560 and $93,127 accretion expenses during the three and six months ended September 30, 2024, related to the increase in present value of the loan over its term. During the three and six months ended September 30, 2024, total repayments for the loan amounted to $137,585 and $367,925. Â During January 2024, the Company entered into a short term loan agreement with an individual lender that resulted in gross proceeds of $140,000 (the â€œPrincipal Amountâ€). The loan has a fixed rate of interest at 12% per annum on the principal amount, payable monthly. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $103,128 and $140,000, respectively. As of September 30, 2024, and March 31, 2024, accrued interest outstanding on the note was $11,231 and $nil, respectively. The loan continues to accrue interest, and total repayments for the loan amounted to $36,872 during the three and six months ended September 30, 2024, respectively. During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $4,235 and $11,231 related to the short term loan. Â During February 2024, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $660,504 (the â€œPrincipal Amountâ€). The note has a fixed rate of interest at 12% per annum on the principal amount, payable monthly. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $660,932. As of September 30, 2024, and March 31, 2024, accrued interest outstanding on the note was $46,908 and $7,101, respectively. The note continues to accrue interest, and no repayment demand notification was received from noteholder. During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $19,991 and $39,765, respectively, related to the promissory note. Â On February 2, 2024, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $700,000, prior to the deduction of issuance costs in the amount of $35,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 35 weeks. The Company is required to make weekly payments of $29,235 ($1,008,000 in the aggregate). As of September 30, 2024, and March 31, 2024, the amount of principal outstanding under this agreement was $13,707 and $581,105, respectively, and the remaining unamortized issuance cost discount was $486 and $26,879, respectively. During the three and six months ended September 30, 2024, the Company recognized $13,196 and $26,393, respectively, of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $56,275 and $192,712, respectively, accretion expenses during the three and six months ended September 30, 2024, related to the increase in present value of the loan over its term. During the three and six months ended September 30, 2024, total repayments for the loan amounted to $127,970 and $449,555. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3 TERM LOAN AND CREDIT AGREEMENT 6 Months Ended Sep. 30, 2024 Term Loan And Credit Agreement Â TERM LOAN AND CREDIT AGREEMENT 6. TERM LOAN AND CREDIT AGREEMENT Â Term Loan Â On December 21, 2021, the Company entered into a Credit Agreement (â€œCredit Agreementâ€) with SWK Funding LLC (â€œLenderâ€™); as part of this, the Company has borrowed $12.4 million, with a maturity date of December 21, 2026. The principal will accrue interest at the LIBOR Rate plus 10.5% per annum (subject to adjustment as set forth in the Credit Agreement). Interest payments are due each February, May, August and November commencing February 15, 2022. Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. The Company and the Lender have negotiated the terms under which the Company will be allowed to extend the interest-only period and delay the start of principal repayment. The negotiated terms indicate principal repayment of $2.4 million ($600,000 per quarter), during the final two years of the term. A current portion of the term loan of $3,000,000 and $2,400,000 was reported in the Companyâ€™s current liabilities as of September 30, 2024 and March 31, 2024, respectively. Prepayment of amounts owing under the Credit Agreement are allowed under prescribed circumstances. Pursuant to the Credit Agreement the Company is subject to an Origination Fee in the amount of $120,000. Upon Termination of the Credit Agreement, the Company shall pay an Exit Fee of $600,000, along with other fees that may be assessed during the term of the loan.â€¯ Â As part of the loan transaction, the Company paid legal and professional costs directly in connection to the debt financing in the amount of $50,000 in cash. Â Total costs directly in connection to the debt financing in the amount of $193,437 (professional fee $48,484; lenderâ€™s origination fee, due diligence fee, and other expenses in the amount of $144,953) was deduced from the gross proceeds in the amount of $12,000,000. Â The Company also repaid $1,574,068 of existing short-term loan and promissory notes and relevant accrued interests by using the proceeds from the loan. Â Total costs directly in connection to the loan and fair value of warrants was in the amount of $1,042,149. And such costs were accounted as debt discount, and amortized using the effective interest method. The amortization of such debt discount was included in the accretion and amortization expenses. For the three and six months ended September 30, 2024, the amortization of debt discount expense was $52,627 and $104,458 respectively. For the three and six months ended September 30, 2023, the amortization of debt discount expense was $51,724 and $102,666, respectively. Â During November 2022, unpaid interest of $364,000 was added to the outstanding principal balance, since then interest onwards would be calculated on the updated principal balance. Â Total interest expense on the term loan for the three and six months ended September 30, 2024, amounted to $495,783 and $987,135, respectively. Â The Company had accrued interest payable of $1,107,791 and $795,656, respectively, as of September 30, 2024, and March 31, 2024. Â The Company and Lender also entered into a Guarantee and Collateral Agreement (â€œCollateral Agreementâ€) wherein the Company agreed to secure the Credit Agreement with all of the Companyâ€™s assets. The Company and Lender also entered into an Intellectual Property Security Agreement dated December 21, 2021 (the â€œIP Security Agreementâ€) wherein the Credit Agreement is also secured by the Companyâ€™s right title and interest in the Companyâ€™s Intellectual Property. Â In connection with the Credit Agreement, the Company issued 57,536 warrants to the Lender, which were fair-valued at $198,713 at issuance (Note 9). The warrants are accounted as part of the debt discount as well as a credit into additional paid-in capital and amortized using the effective interest method. Â At September 30, 2024, the Company was not in compliance with certain covenants of the term loan, for which it sought and received relief from the term loan lender. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â X - DefinitionBank Loan Credit Agreement [Text Block] + ReferencesNo definition available. + Details Name: BTCY_BankLoanCreditAgreementTextBlock Namespace Prefix: BTCY_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: BTCY_DisclosureTermLoanAndCreditAgreementAbstract Namespace Prefix: BTCY_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3 FEDERALLY GUARANTEED LOAN 6 Months Ended Sep. 30, 2024 Federally Guaranteed Loan Â FEDERALLY GUARANTEED LOAN 7. FEDERALLY GUARANTEED LOAN Â Economic Injury Disaster Loan (â€œEIDLâ€) Â In April 2020, the Company received $370,900 from the U.S. Small Business Administration (SBA) under the captioned program. The loan has a term of 30 years and an interest rate of 3.75% per annum, without the requirement for payment in the first 12 months. The Company may prepay the loan without penalty at will. Â In May 2021, the Company received an additional $499,900 from the SBA under the same terms. Â As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest of $7,889 and $26,497, respectively, for the EIDL loan. Â Interest expense on the above loan was $8,231 and $16,372 for the three and six months ended September 30, 2024, respectively, and $8,230 and $16,372 for the three and six months ended September 30, 2023, respectively. Â X - ReferencesNo definition available. + Details Name: BTCY_DisclosureFederallyGuaranteedLoanAbstract Namespace Prefix: BTCY_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFederally Guaranteed Loans [Text Block] + ReferencesNo definition available. + Details Name: BTCY_FederallyGuaranteedLoansTextBlock Namespace Prefix: BTCY_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3 DERIVATIVE LIABILITIES 6 Months Ended Sep. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â DERIVATIVE LIABILITIES 8. DERIVATIVE LIABILITIES Â The Company analyzed the compound features of variable conversion and redemption embedded in the preferred shares instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (â€œEITFâ€) Issue No. 00â€“19 and EITF 07â€“05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value. A roll-forward of activity is presented below for the six months ended September 30, 2024 and 2023: Â Â SCHEDULE OF DERIVATIVE LIABILITIESÂ Â Â Fiscal Year 2025Â Â Fiscal Year 2024Â Â Â $Â Â $Â Derivative liabilities, beginning of period - March 31Â Â 1,435,668Â Â Â 759,065Â New issuance [Note 9]Â Â 649,533Â Â Â Â 642,416Â Change in fair value of derivatives during periodÂ Â 533,126Â Â Â Â (50,033) Reduction due to preferred shares converted [Note 9]Â Â (969,150)Â Â â€”Â Conversion to common sharesÂ Â Â Â Â Â Â Â Â End of derivative treatment of warrantsÂ Â Â Â Â Â Â Â Â Convertible note modificationÂ Â Â Â Â Â Â Â Â Convertible note redemptionÂ Â Â Â Â Â Â Â Â Derivative liabilities, end of periodÂ Â 1,649,177Â Â Â Â 1,351,448Â Â Â The lattice methodology was used to value the derivative components of Series A Preferred Stock, using the following assumptions during the six months ended September 30, 2024, and 2023: Â Â SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONSÂ Â Â September 30, 2024Â Â September 30, 2023Â Dividend yield (%)Â Â 12Â Â Â Â 12Â Risk-free rate for term (%)Â Â 4.1 - 5.1Â Â Â Â 4.9 â€“ 5.2Â Volatility (%)Â Â 91.2 - 132.5Â Â Â Â 71.9 â€“ 111.4Â Remaining terms (Years)Â Â 0.67 - 1.59Â Â Â Â 0.34 â€“ 2.01Â Stock price ($ per share)Â Â 0.24 - 1.14Â Â Â Â 2.14 â€“ 3.82Â Â The Monte Carlo simulation methodology was used to value the derivative components of Series B Preferred Stock, using the following assumptions during the six months ended September 30, 2024: Â Â Â September 30, 2024Â Â September 30, 2023Â Dividend yield (%)Â Â 12Â Â Â Â 12Â Risk-free rate for term (%)Â Â 3.7 - 5.1Â Â Â Â 5.04 - 5.24Â Volatility (%)Â Â 126.4 - 182.2Â Â Â Â 76.2 - 119.1Â Remaining terms (Years)Â Â 0.97 - 2Â Â Â Â 0.25 - 0.5Â Stock price ($ per share)Â Â 0.24 - 1.34Â Â Â Â 0.64 - 2.14Â Â Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â In addition, the Company recorded derivative liabilities related to the conversion and redemption features of the convertible notes, as well as warrants that were issued in connection with the convertible notes (Note 5). Any noteholder and placement agent warrants that were issued after the finalization of exercise price was accounted for as equity. A roll-forward of activity is presented below for the six months ended September 30, 2024, and 2023: Â Â SCHEDULE OF DERIVATIVE LIABILITIESÂ Â Â Fiscal Year 2025Â Â Fiscal Year 2024Â Â Â $Â Â $Â Â Â Â Â Â Â Â Balance beginning of period â€“ March 31Â Â 991,866Â Â Â Â 1,008,216Â New IssuanceÂ Â â€”Â Â Â Â 1,942,004Â Conversion to common sharesÂ Â (490,972)Â Â â€”Â Change in fair value of derivative liabilitiesÂ Â (32,515)Â Â (32,635) Convertible note redemptionÂ Â (8,320)Â Â (33,607) Balance end of period â€“ September 30Â Â 460,059Â Â Â Â 2,883,978Â Â Â The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the six months ended September 30, 2024, and 2023, using the following assumptions: Â Â SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONSÂ Â Â September 30, 2024Â September 30, 2023 Risk-free rate for term (%)Â 4.1 - 5.2Â 4.2 - 5.3 Volatility (%)Â 91.2 - 352.4Â 76.2 - 126.6 Remaining terms (Years)Â 0.25 - 0.5Â 0.25 - 1.49 Stock price ($ per share)Â 0.24 - 1.45Â 0.46 - 3.04 Â X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERSâ€™ DEFICIENCY 6 Months Ended Sep. 30, 2024 Equity [Abstract] Â STOCKHOLDERSâ€™ DEFICIENCY 9. STOCKHOLDERSâ€™ DEFICIENCY Â (a) Authorized and Issued Stock Â As at September 30, 2024, the Company is authorized to issue 125,000,000 (March 31, 2024 â€“ 125,000,000) shares of common stock ($0.001 par value), and 10,000,000 (March 31, 2024 â€“ 10,000,000) shares of preferred stock ($0.001 par value), 20,000 of which (March 31, 2024 â€“ 20,000) are designated shares of Series A preferred stock and 600 (March 31, 2024 â€“ 600) are designated shares of Series B preferred stock. Â At September 30, 2024, common shares and shares directly exchangeable into equivalent common shares that were issued and outstanding were 23,023,933 (March 31, 2024 â€“ 9,514,440) shares; these were comprised of 22,863,261 (March 31, 2024 â€“ 9,353,768) shares of common stock and 160,672 (March 31, 2024 â€“ 160,672) exchangeable shares. At September 30, 2024, there were 200 shares of Series A Preferred Stock issued and outstanding (March 31, 2024 â€“ 6,304), and 435 shares of Series B Preferred Stock issued and outstanding (March 31, 2024 â€“ 265). There is also one share of Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement as at September 30, 2024, and March 31, 2024. Â (b) Series (A) Preferred Stock Â The number of Series A Preferred Stock issued and outstanding as of September 30, 2024, and 2023 was 200 and 6,304, respectively. Â The Series A Preferred Stock is junior to the Companyâ€™s existing undesignated preferred stock, and unless otherwise set forth in the applicable certificate of designations, shall be junior to any future issuance of preferred stock. The purchase price (the â€œPurchase Priceâ€) for the Series A Preferred Stock to date has been $1,000 per share. Except as otherwise expressly required by law, the Series A Preferred Stock does not have voting rights and does not have any liquidation rights. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Preferred Stock Dividends Â Dividends shall be paid at the rate of 12% per annum of the amount of the Series A Preferred Stockholderâ€™s (the â€œHolderâ€) Purchase Price. Dividends shall be paid quarterly unless the Holder and the Company mutually agree to accrue and defer any such dividend. Â Conversion Â The Series A Preferred Stock is convertible into shares of common stock commencing 24 months after the issuance date of the Series A Preferred Stock; on a monthly basis, up to 5% of the aggregate amount of the Purchase Price can be converted (subject to adjustment for changes in the Holderâ€™s ownership of the underlying Series A Preferred Stock) subsequent to that issuance anniversary. The conversion price is equal to the greater of $0.001 or a 15% discount to the volume-weighted average price (â€œVWAPâ€) of the Companyâ€™s common stock five Trading Days immediately prior to the conversion date (the â€œConversion Rate). Additionally, subject to certain provisions, the Holder may exchange its Series A Preferred Stock into any common stock financing being conducted by the Company at a 15% discount to the pricing of that financing. Â Other Adjustments and Rights Â â— The Conversion Rate (and shares issuable upon conversion of the Series A Preferred Stock) will be appropriately adjusted to reflect stock splits, stock dividends business combinations and similar recapitalization. Â â— The Holders shall be entitled to a proportionate share of certain qualifying distributions on the same basis as if they were holders of the Companyâ€™s common stock on an as converted basis. Â Company Redemption Â The Company may redeem all or part of the outstanding Series A Preferred Stock after one year from the date of issuance by paying an amount equal to the aggregate Purchase Price paid, adjusted for any reduction in Series A Preferred Stock holdings, multiplied by 110% plus accrued dividends. Â During the six months ended September 30, 2024, $6,104,444 of Series A Preferred Stock (face value) and $1,071,542 relevant accrued dividend were converted into 8,952,170 common shares. The conversion was accounted as an extinguishment and the difference between the total carrying value of the preferred shares converted, derivative liabilities derecognized and unpaid dividend at the time of conversion ($7,984,463), and the fair value of the common shares issued ($11,039,142), was $3,054,679 and was recognized as a deemed dividend expense. Â (c) Series B Preferred Stock and Mezzanine Equity Â On September 19, 2023, the Company entered into a security purchase agreement (the â€œPurchase Agreementâ€) with an institutional investor (the â€œInvestorâ€) for the issuance and sale of 220 shares of the Companyâ€™s newly designated Series B Convertible Preferred Stock, at a purchase price of $9,091 per share of Preferred Stock, and after accounted for other issuance related costs, the net proceeds received was in the amount of $1,900,000. Â During the three months ended March 31, 2024, a further 110 Series B preferred shares were issued for net proceeds of $925,000. During the three and six months ended September 30, 2024, 55 and 220 Series B preferred shares were issued for net proceeds of $420,000 and $1,732,532, respectively. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Pursuant to the initial Purchase Agreement, on September 19, 2023, the Company filed a certificate of designations of Series B Convertible Preferred Stock (the â€œCertificate of Designationsâ€) with the Nevada Secretary of State designating 600 shares of the Companyâ€™s shares of Preferred Stock as Series B Convertible Preferred Stock and setting forth the voting and other powers, preferences and relative, participating, optional or other rights of the Preferred Shares. Each share of Series B Preferred Stock has a stated value of $10,000 per share. Â The Series B Preferred Stock, with respect to the payment of dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company, ranks senior to all capital stock of the Company unless the holders of the majority of the outstanding shares of Series B Preferred Stock consent to the creation of other capital stock of the Company that is senior or equal in rank to the Series B Preferred Stock. Â Holders of Series B Preferred Stock will be entitled to receive cumulative dividends (â€œDividendsâ€), in shares of common stock or cash on the stated value at an annual rate of 8% (which will increase to 15% if a Triggering Event (as defined in the Certificate of Designations) occurs. Dividends will be payable upon conversion of the Series B Preferred Stock, upon any redemption, or upon any required payment upon any Bankruptcy Triggering Event (as defined in the Certificate of Designations). Â Holders of Series B Preferred Stock will be entitled to convert shares of Series B Preferred Stock into a number of shares of common stock determined by dividing the stated value (plus any accrued but unpaid dividends and other amounts due) by the conversion price. The initial conversion price is $3.50, subject to adjustment in the event the Company sells common stock at a price lower than the then-effective conversion price. Holders may not convert the Series B Preferred Stock to common stock to the extent such conversion would cause such holderâ€™s beneficial ownership of common stock to exceed 4.99% of the outstanding common stock. In addition, the Company will not issue shares of common stock upon conversion of the Series B Preferred Stock in an amount exceeding 19.9% of the outstanding common stock as of the initial issuance date unless the Company receives shareholder approval for such issuances. Â Holders may elect to convert shares of Series B Preferred Stock to common stock at an alternate conversion price equal to 80% (or 70% if the Companyâ€™s common stock is suspended from trading on or delisted from a principal trading market or if the Company has effected a reverse split of the common stock) of the lowest daily volume weighed average price of the common stock during the Alternate Conversion Measuring Period (as defined in the Certificate of Designations). In the event the Company receives a conversion notice that elects an alternate conversion price, the Company may, at its option, elect to satisfy its obligation under such conversion with payment in cash in an amount equal to 110% of the conversion amount. Â The Series B Preferred Stock will automatically convert to common stock upon the 24-month anniversary of the initial issuance date of the Series B Preferred Stock. Â At any time after the earlier of a holderâ€™s receipt of a Triggering Event notice and such holder becoming aware of a Triggering Event and ending on the 20th trading day after the later of (x) the date such Triggering Event is cured and (y) such holderâ€™s receipt of a Triggering Event notice, such holder may require the Company to redeem such holderâ€™s shares of Series B Preferred Stock. Â Upon any Bankruptcy Triggering Event (as defined in the Certificate of Designations), the Company will be required to immediately redeem all of the outstanding shares of Series B Preferred Stock. Â The Company will have the right at any time to redeem all or any portion of the Series B Preferred Stock then outstanding at a price equal to 110% of the stated value plus any accrued but unpaid dividends and other amounts due. Â Holders of the Series B Preferred Stock will have the right to vote on an as-converted basis with the common stock, subject to the beneficial ownership limitation set forth in the Certificate of Designations. Â The Series B Preferred Stock was accounted for as Mezzanine Equity in accordance with ASC 480 - Distinguishing Liabilities from Equity and the embedded conversion and redemption features was separated from the host instrument and recognized as derivative liabilities with change in fair value at each reporting period end recognized in the consolidated statement of operations and comprehensive loss. (Note 8). Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â During the three months ended December 31, 2023, 40 Series B preferred shares and dividends accrued thereon were converted into 612,062 common shares. As a result of the conversion, the Company reduced the book value of mezzanine equity by $228,727 and reduced its accrued dividends liability by $16,789. The Company also reduced the fair value of derivative liabilities by $119,359 related to the shares converted. The Company recognized corresponding credits to common share par value and paid in capital. Â During the three months ended March 31, 2024, 25 Series B preferred shares and dividends accrued thereon were converted into 320,321 to be issued common shares. As a result of the conversion, the Company reduced the book value of mezzanine equity by $142,907. The Company also reduced the fair value of derivative liabilities related to the shares converted by $75,523. The Company recognized corresponding credits to be issued common share par value and paid in capital. Â During the three and six months ended September 30, 2024, 25 and 50 Series B preferred shares and dividends accrued thereon were converted into 1,091,063 and 1,436,267 common shares, respectively. As a result of the conversion, the Company reduced the book value of mezzanine equity by $142,907 and $285,814 and reduced its accrued dividends liability by $16,219 and $28,438 during the three and six months ended September 30, 2024, respectively. The Company also reduced the fair value of derivative liabilities by $84,076 and $160,672 related to the shares converted during the three and six months ended September 30, 2024, respectively. The Company recognized corresponding credits to common share par value and paid in capital. Â A roll-forward of activity is presented below for the six months ended September 30, 2024: Â SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY Â Â Fiscal Year 2025Â Â Fiscal Year 2024 Â Â $Â Â $ Balance beginning of period â€“ March 31Â Â 1,488,920Â Â Â â€“ Â Net proceeds received pursuant to the issuance of preferred sharesÂ Â 1,732,532Â Â Â 1,900,000 Â Recognition of derivative liabilities (Note 8)Â Â (649,533) Â Â (642,416) Conversion into common sharesÂ Â (285,814) Â Â â€“ Â Balance end of period â€“ September 30Â Â 2,286,105Â Â Â 1,257,584 Â Â (d) Share issuances Â Share issuances during the six months ended September 30, 2024 Â During the three months ended September 30, 2024, the Company issued 287,802 common shares to Series C Convertible Note holders, in relation to shares to be issued obligation as of June 30, 2024, for Series C Convertible Note conversions. Â During the three and six months ended September 30, 2024, the Company issued nil and 320,321 common shares to Series B preferred shareholders, respectively, in relation to shares to be issued obligation as of March 2024 for Series B preferred share conversions. During the three and six months ended September 30, 2024, the Company issued another 1,091,063 and 1,436,267 common shares to Series B preferred shareholders for an additional request to convert 25 and 50 Series B preferred shares, respectively (Note 9(c)). Â During the three and six months ended September 30, 2024, convertible notes with a face value of $45,000 and $1,432,700, respectively, were converted into 121,043 and 1,753,554 common shares, respectively. As of September 30, 2024, 121,043 shares are recognized as an obligation for shares to be issued relating to the conversion. The fair value of common shares issued during the three and six months ended September 30, 2024, is $74,618 and $2,283,216, respectively, and is determined based on market price upon conversion. Total value of debt settled is in the amount of $68,167 and $2,145,929, respectively, which consisted of the face value of notes converted, accrued interest of $7,810 and $222,257, respectively, and relevant derivative liability of $15,357 and $490,972, respectively. The Company recognized a loss upon conversion of $6,451 and $137,287, respectively, representing the difference between the value of debt settled and fair value of shares issued and to be issued. (Note 5). Â During the six months ended September 30, 2024, $6,104,444 of Series A Preferred Stock (face value) and $1,071,542 relevant accrued dividend were converted into 8,952,170 common shares. The conversion was accounted as an extinguishment and the difference between the total carrying value of the preferred shares converted, derivative liabilities derecognized and unpaid dividend at the time of conversion ($7,984,463), and the fair value of the common shares issued ($11,039,142) was $3,054,679 and was recognized as deemed dividend expense. Â The Company issued 1,000,413 common shares in settlement of $741,316 in amount due to a shareholder which was part of the accounts payable. The Company recognized a loss upon debt extinguishment of $249,093, which was the difference between the accounts payable settled and the fair value of common shares issued. The loss was included as part of the other income (expense) in the Condensed Consolidated Statement of Operations and Comprehensive Loss. Â The Company issued 97,811 common shares for net proceeds of $125,227 pursuant to a registration statement filed on May 15, 2024. Â In addition, during the six months ended September 30, 2024, the Company issued 70,000 common shares for services received with a fair value of $53,480 which was recognized as a general and administrative expense with a corresponding credit to additional paid-in capital. Â Share issuances during the six months ended September 30, 2023 Â The Company sold 36,897 common shares through use of its registration statement, for gross proceeds of $123,347, raising a net amount of $119,285 after paying for a 3% placement fee and other issuance expenses. In addition, 20,846 shares of common stock were issued to existing holders as a result of make whole provisions associated with the Reverse Split. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â (e) Shares to be issued Â Activity during the six months ended September 30, 2024 Â During the three months ended September 30, 2024, the Company issued 287,802 common shares to Series C Convertible Note holders, in relation to shares to be issued obligation as of June 30, 2024, for Series C Convertible Note conversions. Â During the six months ended September 30, 2024, the Company issued 320,321 common shares to Series B preferred shareholders in relation to shares to be issued obligation as of March 31, 2024, for Series B preferred share conversions. Â During the three and six months ended September 30, 2024, convertible notes with a face value of $45,000 and $1,432,700, respectively, were converted into 121,043 and 1,753,554 common shares, respectively. As of September 30, 2024, 121,043 shares are recognized as an obligation for shares to be issued relating to the conversion. Â During the three and six months ended September 30, 2024, the Company recorded the obligation for 40,000 and 50,000 shares to be issued with a fair value of $20,000 and $27,640 which was recognized as general and administrative expenses. Â Activity during the six months ended September 30, 2023 Â None. Â (f) Warrant issuances, exercises and other activity Â Warrant exercises and issuances during the six months ended September 30, 2024 Â None. Â Warrant exercises and issuances during the six months ended September 30, 2023 Â None. Â Warrant activity during the six months ended September 30, 2024, is indicated below: Â SCHEDULE OF WARRANTS OUTSTANDING Â Â Broker WarrantsÂ Â Consultant and Noteholder WarrantsÂ Â Warrants Issued on Convertible NotesÂ Â TotalÂ As at March 31, 2024Â Â 208,927Â Â Â 253,994Â Â Â 868,098Â Â Â 1,331,019Â Beginning balanceÂ Â 208,927Â Â Â 253,994Â Â Â 868,098Â Â Â 1,331,019Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Expired/cancelledÂ Â â€“Â Â Â â€“Â Â Â â€“Â Â Â â€“Â ExercisedÂ Â â€“Â Â Â â€“Â Â Â â€“Â Â Â â€“Â IssuedÂ Â â€“Â Â Â â€“Â Â Â â€“Â Â Â â€“Â As at September 30, 2024Â Â 208,927Â Â Â 253,994Â Â Â 868,098Â Â Â 1,331,019Â Ending balanceÂ Â 208,927Â Â Â 253,994Â Â Â 868,098Â Â Â 1,331,019Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise PriceÂ Â $ 2.09 to $22.50Â Â Â $ 2.69 to $14.40Â Â $4.18Â Â Â Â Â Expiration DateÂ Â August 2026 to October 2033Â Â Â March 2029 to Dec 2032Â Â Â October 2027Â Â Â Â Â Â (g) Stock-based compensation Â 2016 Equity Incentive Plan Â On February 2, 2016, the Board of Directors of the Company approved the Companyâ€™s 2016 Equity Incentive Plan (the â€œPlanâ€). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan shall be equal to 1,241,422 shares ; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 20% of the Companyâ€™s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase. Â During the three and six months ended September 30, 2024, the Company granted 250,000 and 291,559 stock options and during the three and six months ended September 30, 2023, 3,585 stock options, respectively. The Company recorded stock-based compensation of $56,885 and $115,863, respectively, during the three and six months ended September 30, 2024 and $163,335 and $374,515, respectively, during the three months ended September 30, 2023, under selling, general and administrative expenses with corresponding credit to additional paid in capital. Â The following table summarizes the stock option activities

during the six months ended September 30: Â SCHEDULE OF STOCK OPTION ACTIVITIES Â Â 2024Â Â Â 2023 Â Â Â Number of OptionsÂ Â Weighted Average Exercise PriceÂ Â Number of Options Â Weighted Average Exercise Price Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Outstanding at March 31, 2024Â Â 1,239,873Â Â $9.39Â Â Â 1,264,890 Â Â $ 9.29 Â GrantedÂ Â 291,559Â Â $1.24Â Â Â 3,585 Â Â $ 2.79 Â ExercisedÂ Â â€”Â Â $â€”Â Â Â â€” Â Â $ Â Â ExpiredÂ Â (54,219)Â $12.57Â Â Â Â (12,035) Â $ 1.61 Â ForfeitedÂ Â (12,500)Â $8.28Â Â Â Â (5,362) Â $ 8.58 Â Outstanding at September 30, 2024Â Â 1,464,713Â Â $7.71Â Â Â Â 1,251,078 Â Â $ 9.30 Â Â The fair value of each option granted is estimated at the time of grant using multi-nominal lattice model using the following assumptions, for each of the respective six months periods ended September 30: Â SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS Â Â September 30, 2024Â Â September 30, 2023Â Exercise price ($)Â Â 1.2Â Â 2.79Â Risk free interest rate (%)Â Â 4.13% Â Â 3.85Â Expected term (Years)Â Â 5.5-6.5Â Â Â Â 10.0Â Expected volatility (%)Â Â 107.7%-109.8% Â Â 117.1Â Expected dividend yield (%)Â Â Â 0Â Â Â Â 0.00Â Fair value of option ($)Â Â 0.689-0.733Â Â Â Â 2.30Â Expected forfeiture (attrition) rate (%)Â Â 0Â Â Â Â 0.00Â Â Â 2023 Equity Incentive Plan and the Employee Stock Purchase Plans Â On March 31, 2023, the Company adopted the 2023 Equity Incentive Plan (the â€œ2023 Planâ€). The 2023 Plan authorizes grants of equity-based and incentive cash awards to eligible participants designated by the 2023 Planâ€™s administrator. The 2023 Plan will be administered by the Compensation Committee of the Companyâ€™s Board of Directors (the â€œBoardâ€). An aggregate of 5,000,000 shares of the Companyâ€™s common stock (the â€œCommon Stockâ€), plus the number of shares available for issuance under the Companyâ€™s 2016 Equity Incentive Plan that had not been made subject to outstanding awards, were reserved for issuance under the 2023 Plan. Unless earlier terminated by the Board, the 2023 Plan will remain in effect until all Common Stock reserved for issuance has been issued, provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date of the 2023 Plan. Â The Company also adopted the Employee Stock Purchase Plan (the â€œESPPâ€). The ESPP allows eligible employees of the Company and the Companyâ€™s designated subsidiaries the ability to purchase shares of the Companyâ€™s Common Stock at a discount, subject to various limitations. Under the ESPP, employees will be granted the right to purchase Common Stock at a discount during a series of successive offerings, the duration and timing of which will be determined by the ESPP administrator (the â€œAdministratorâ€). In no event can any single offering period be longer than 27 months. The purchase price (the â€œPurchase Priceâ€) for each offering will be established by the Administrator. With respect to an offering under Section 423 of the Internal Revenue Code of 1986 (â€œSection 423 Offeringâ€), in no case may such Purchase Price be less than the lesser of (i) an amount equal to 85 percent of the fair market value on the commencement date, or (ii) an amount not less than 85 percent of the fair market value the on the purchase date. In the event of financial hardship, an employee may withdraw from the ESPP by providing a request at least 20 Business Days before the end of the offering period (the â€œOffering Periodâ€). Otherwise, the employee will be deemed to have exercised the purchase right in full as of such exercise date. Upon exercise, the employee will purchase the number of whole shares that the participantâ€™s accumulated payroll deductions will buy at the Purchase Price. If an employee wants to decrease the rate of contribution, the employee must make a request at least 20 Business Days before the end of an Offering Period (or such earlier date as determined by the Administrator). An employee may not transfer any rights under the ESPP other than by will or the laws of descent and distribution. During a participantâ€™s lifetime, purchase rights under the ESPP shall be exercisable only by the participant. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS 6 Months Ended Sep. 30, 2024 Operating Lease Right-of-use Assets And Lease Obligations Â OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS 10. OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS Â The Company has one operating lease primarily for office and administration. Â During December 2021, the Company entered into a new lease agreement. The Company paid $85,000 deposit that would be returned at the end of the lease. In December 2022, the Company started a new lease with an additional suite in the same premise as the existing lease. Â When measuring the lease obligations, the Company discounted lease payments using its incremental borrowing rate. The weighted-average-rate applied is 11.4%. Â SCHEDULE OF OPERATING LEASES OBLIGATIONS Â Â Fiscal Year 2024Â Â Fiscal Year 2023Â Right of Use AssetÂ $Â Â $Â Beginning balance at March 31Â Â 1,221,593Â Â Â 1,587,492Â New leasesÂ Â â€”Â Â Â â€”Â AmortizationÂ Â (198,275)Â Â Â (178,320) Ending balance at September 30Â Â 1,023,318Â Â Â 1,409,172Â Â Â Â 2024Â Â 2023Â Lease LiabilityÂ $Â Â $Â Beginning balance at March 31Â Â 1,386,486Â Â Â 1,722,095Â New leasesÂ Â â€”Â Â Â â€”Â Repayment and interest accretion, netÂ Â (219,283)Â Â (190,864) Ending balance at September 30Â Â 1,167,203Â Â Â 1,531,231Â Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Â Â September 30, 2024Â Â Lease LiabilityÂ $Â Â $Â Current portion of operating lease liabilityÂ Â 493,190Â Â Â 457,371Â Noncurrent portion of operating lease liabilityÂ Â 674,013Â Â Â 929,115Â Â The operating lease expense was $292,787 for the six months ended September 30, 2024 (2023: $140,759) and included in the selling, general and administrative expenses. Operating cash flows from operating leases amounted to $218,448 and $282,209 during the six months ended September 30, 2024 and September 30, 2023, respectively. Â The following table represents the contractual undiscounted cash flows for lease obligations as at September 30, 2024: Â SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION Calendar yearÂ $Â 2024Â Â Â 552,293Â 2025Â Â Â 600,288Â 2026Â Â Â 565,359Â Total undiscounted lease liabilityÂ Â 1,717,940Â Less imputed interestÂ Â (550,737) TotalÂ Â 1,167,203Â Â Â X - ReferencesNo definition available. + Details Name: BTCY_DisclosureOperatingLeaseRightofuseAssetsAndLeaseObligationsAbstract Namespace Prefix: BTCY_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES 6 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â COMMITMENTS AND CONTINGENCIES 11. COMMITMENTS AND CONTINGENCIES Â There are no claims against the Company that were assessed as significant, which were outstanding as at September 30, 2024 or March 31, 2024 and, consequently, no provision for such has been recognized in the Condensed Consolidated Financial Statements. Â X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 PROPERTY AND EQUIPMENT 6 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Â PROPERTY AND EQUIPMENT 12. PROPERTY AND EQUIPMENT Â During the year-ended March 31, 2022, the Company purchased leasehold improvements of $12,928 (useful life: 5 years) as well as furniture & fixtures of $16,839 (useful life: 5 years). There were no purchases of property and equipment during the six months ended September 30, 2024, and September 30, 2023. The Company recognized depreciation expense for these assets in the amount of $2,977 and $2,977, respectively, during the six months ended September 30, 2024 and 2023. Â SCHEDULE OF PROPERTY AND EQUIPMENT CostÂ Office equipmentÂ Â Leasehold improvementÂ Â TotalÂ Â Â $Â Â $Â Â $Â Balance at March 31, 2024Â Â 16,839Â Â Â 12,928Â Â Â 29,767Â AdditionsÂ Â â€”Â Â Â â€”Â Â Â â€”Â DisposalsÂ Â â€”Â Â Â â€”Â Â Â â€”Â Balance at September 30, 2024Â Â 16,839Â Â Â 12,928Â Â Â 29,767Â Â Accumulated depreciationÂ Office equipmentÂ Â Leasehold improvementÂ Â TotalÂ Â Â $Â Â $Â Â $Â Balance at March 31, 2024Â Â 8,042Â Â Â 6,173Â Â Â 14,215Â Depreciation for the periodÂ Â 1,683Â Â Â 1,293Â Â Â 2,977Â DisposalsÂ Â â€”Â Â Â â€”Â Â Â â€”Â Balance at September 30, 2024Â Â 9,725Â Â Â 7,466Â Â Â 17,191 Â Â Â

Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Revenue Recognition Revenue Recognition Â The Company adopted Accounting Standards Codification Topic 606, â€œRevenue from Contracts with Customersâ€ (â€œASC 606â€) on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles â€“ (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue as performance obligations are satisfied. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Both the Bioflux mobile cardiac telemetry device, and the Biocore device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Companyâ€™s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patientâ€™s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patientâ€™s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized. Â The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business. Â The Company recognized the following forms of revenue for the three and six months ended September 30, 2024, and 2023: Â SCHEDULE OF REVENUE RECOGNITIONÂ Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three months ended September 30Â Â Six months ended September 30Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â $Â Â $Â Â $Â Â $Â Technology feesÂ Â 3,064,814Â Â Â 2,731,461Â Â Â 6,081,064Â Â Â 5,500,379Â Device salesÂ Â 202,032Â Â Â 159,836Â Â Â 387,525Â Â Â 411,683Â TotalÂ Â Â 3,266,846Â Â Â 2,891,297Â Â Â 6,468,589Â Â Â 5,912,062Â Â Inventories Inventories Â Inventory is stated at the lower of cost and market value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. Â SCHEDULE OF INVENTORIESÂ Â Â September 30, 2024Â Â March 31, 2024Â Â Â $Â Â $Â Raw materialÂ Â 1,073,409Â Â Â 1,128,700Â Finished goodsÂ Â 744,152Â Â Â 750,702Â Â Â Â Â Â Â Â Â Â InventoriesÂ Â 1,817,561Â Â Â 1,879,402Â Â Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Significant accounting estimates and assumptions Significant accounting estimates and assumptions Â The preparation of the Condensed Consolidated Financial Statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. Â The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Â Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities: Â â— Fair value of stock options Â Â The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield. Â â— Fair value of warrants Â Â In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity. Â â— Fair value of derivative liabilities Â Â In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period. Â Â â— Functional currency Â Â Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses. Â Â â— Useful life of property and equipment Â Â The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â â— Provisions Â Â Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. Â Â â— Contingencies Â Â Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events. Â Â â— Inventory obsolescence Â Â Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. Â Â â— Income and other taxes Â Â The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. Â Â When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Companyâ€™s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Companyâ€™s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated. Â Â â— Incremental borrowing rate for lease Â Â The determination of the Companyâ€™s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Companyâ€™s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Companyâ€™s Condensed Consolidated Financial Statements. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Earnings (Loss) Per Share Earnings (Loss) Per Share Â The Company has adopted the Financial Accounting Standards Boardâ€™s (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 260-10 which provides for calculation of â€œbasicâ€ and â€œdilutedâ€ earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Companyâ€™s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings are computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method were not applicable during the periods presented as no conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented. Â Cash Cash Â Cash includes cash on hand and balances with banks. Â Foreign Currency Translation Foreign Currency Translation Â The functional currency of the Companyâ€™s Canadian-based subsidiary is the Canadian dollar, and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Companyâ€™s Canadian subsidiaries from their functional currency into the Companyâ€™s reporting currency of United States dollars, consolidated balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholdersâ€™ deficiency. The Company has not, to the date of these Condensed Consolidated Financial Statements, entered into derivative instruments to offset the impact of foreign currency fluctuations. Â Accounts Receivable Accounts Receivable Â Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Companyâ€™s normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Fair Value of Financial Instruments Fair Value of Financial Instruments Â ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Â â— Level 1 â€“ Valuation based on quoted market prices in active markets for identical assets or liabilities. Â â— Level 2 â€“ Valuation based on quoted market prices for similar assets and liabilities in active markets. Â â— Level 3 â€“ Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring managementâ€™s best estimate of what market participants would use as fair value. Â In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Companyâ€™s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Â Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans, accounts payable and accrued liabilities. The Companyâ€™s derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Companyâ€™s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk. Â The fair value of financial instruments measured on a recurring basis is as follows: Â SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTSÂ Â Â As of September 30, 2024Â DescriptionÂ TotalÂ Â Level 1Â Â Level 2Â Â Level 3Â Assets:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CashÂ $173,270Â Â $173,270Â Â $â€”Â Â $â€”Â Total assets at fair valueÂ $173,270Â Â $173,270Â Â $â€”Â Â $â€”Â Â Â Â Â Â Â

requires impairment losses to be recorded on long-lived assets, including right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assetsâ€™ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at September 30, 2024 and March 31, 2024, the Company believes there was no impairment of its long-lived assets. Â Leases Leases Â The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items Operating right of use assets, Operating lease obligations, current, and Operating lease obligations, long-term in the consolidated balance sheet. Â Right-of-use (â€œROUâ€) asset represents the Companyâ€™s right to use an underlying asset for the lease term and lease obligations represent the Companyâ€™s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. As the Companyâ€™s lease does not provide implicit interest rate, the Company uses the Companyâ€™s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion. Â Income Taxes Income Taxes Â The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for consolidated financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized. Â Research and Development Research and Development Â Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Selling, General and Administrative Selling, General and Administrative Â Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include sales and marketing costs, investor relations and legal costs relating to corporate matters, professional fees for consultants assisting with business development and financial matters, and office and administrative expenses. Â Stock Based Compensation Stock Based Compensation Â The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period. Â The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services. Â Convertible Notes Payable and Derivative Instruments Convertible Notes Payable and Derivative Instruments Â The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Â Series B Convertible Preferred Stock Series B Convertible Preferred Stock Â The Series B convertible preferred stock (â€œSeries B Preferred Stockâ€) was accounted for as mezzanine equity and the embedded conversion and redemption features was accounted for as derivative liabilities with change in fair value at each reporting period end charged to the consolidated statement of operation and comprehensive loss in accordance with ASC 480 and ASC 815. Â Preferred Shares Extinguishments Preferred Shares Extinguishments Â The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For preferred stock redemptions and conversion, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss. Â Segment Information Segment Information Â Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company has identified its Chief Executive Officer (â€œCEOâ€) as the chief operating decision maker (â€œCODMâ€). The Company operates in one operating segment. The Companyâ€™s CODM allocates resources and assesses performance at the consolidated level. The Companyâ€™s property and equipment and operating right of use lease asset are in the United States as of September 30, 2024, and 2023. Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Recently Issued Accounting Pronouncements Recently Issued Accounting Pronouncements Â In June 2016, the FASB issued ASU 2016-13, â€œFinancial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.â€ This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an â€œexpected lossâ€ model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instrumentsâ€”Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. The Company has adopted Topic 326 on the Companyâ€™s Condensed Consolidated Financial Statements according to the effective date and the adoption has no significant impact on the Companyâ€™s Condensed Consolidated Financial Statements. Â In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (â€œASU 2019-12â€), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. There is no significant impact from adopting ASU 2019-12 on the Companyâ€™s financial condition, results of operations, and cash flows. Â In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuerâ€™s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company adopted this guidance for the fiscal year beginning April 1, 2022. There is no significant impact from adopting ASU 2021-04 on the Companyâ€™s financial condition, results of operations, and cash flows. Â On March 28, 2023, the FASB issued ASU No. 2023-01, Leases (Topic 842): Common Control Arrangements. ASU 2023-01 is designed to clarify the accounting for leasehold improvements associated with common control leases, thereby reducing diversity in practice. The new standard is effective for the Company for its fiscal year beginning January 1, 2024, with early adoption permitted. There is no significant impact from adopting ASU No. 2023-01 on the Companyâ€™s financial condition, results of operations, and cash flows. Â In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€) to improve the disclosures regarding a public entityâ€™s reportable segments and address requests from investors for additional, more detailed information about a reportable segmentâ€™s expenses. The Company is required to adopt the guidance in the fourth quarter of fiscal 2025, though early adoption is permitted. There is no significant impact from adopting ASU 2023-07 on the Companyâ€™s financial condition, results of operations, and cash flows. Â In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures (â€œASU 2023-09â€) to provide disaggregated income tax disclosures on rate reconciliation and income taxes paid. The Company is required to adopt the guidance in the fourth quarter of fiscal 2026, though early adoption is permitted. The Company is currently evaluating the impact of this amendment on its Condensed Consolidated Financial Statements. Â The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems. X - DefinitionConvertible Preferred Stock [Policy Text Block] + ReferencesNo definition available. + Details Name: BTCY_ConvertiblePreferredStockPolicyTextBlock Namespace Prefix: BTCY_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionPreferred Shares Extinguishments [Policy Text Block] + ReferencesNo definition available. + Details Name: BTCY_PreferredSharesExtinguishmentsPolicyTextBlock Namespace Prefix: BTCY_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_DebtPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for accounts receivable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B + Details Name: us-gaap_TradeAndOtherAccountsReceivablePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) 6 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â SCHEDULE OF REVENUE RECOGNITION The Company recognized the following forms of revenue for the three and six months ended September 30, 2024, and 2023: Â SCHEDULE OF REVENUE RECOGNITIONÂ Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three months ended September 30Â Â Six months ended September 30Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â $Â Â $Â Â $Â Â $Â Technology feesÂ Â 3,064,814Â Â Â 2,731,461Â Â Â 6,081,064Â Â Â 5,500,379Â Device salesÂ Â 202,032Â Â Â 159,836Â Â Â 387,525Â Â Â 411,683Â TotalÂ Â Â 3,266,846Â Â Â 2,891,297Â Â Â 6,468,589Â Â Â 5,912,062Â SCHEDULE OF INVENTORIES Â SCHEDULE OF INVENTORIESÂ Â Â September 30, 2024Â Â March 31, 2024Â Â Â $Â Â $Â Raw materialÂ Â 1,073,409Â Â Â 1,128,700Â Finished goodsÂ Â 744,152Â Â Â 750,702Â Â Â Â Â Â Â Â Â InventoriesÂ Â 1,817,561Â Â Â 1,879,402Â SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS The fair value of financial instruments measured on a recurring basis is as follows: Â SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTSÂ Â Â As of September 30, 2024Â DescriptionÂ TotalÂ Â Level 1Â Â Level 2Â Â Level 3Â Assets:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CashÂ $173,270Â Â $173,270Â Â $â€”Â Â $â€”Â Total assets at fair valueÂ $173,270Â Â $173,270Â Â $â€”Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Derivative liabilities, short-termÂ $460,059Â Â $â€”Â Â $â€”Â Â $460,059Â Derivative liabilities, long-termÂ Â 1,649,177Â Â Â â€”Â Â Â â€”Â Â Â 1,649,177Â Total liabilities at fair valueÂ $2,109,236Â Â $â€”Â Â $â€”Â Â $2,109,236Â Â Â Â Â As of March 31, 2024Â DescriptionÂ TotalÂ Â Level 1Â Â Level 2Â Â Level 3Â Assets:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CashÂ $786,060Â Â $786,060Â Â $â€”Â Â $â€”Â Total assets at fair valueÂ $786,060Â Â $786,060Â Â $â€”Â Â Â $â€”Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Derivative liabilities, short-termÂ $991,866Â Â $â€”Â Â $â€”Â Â $991,866Â Derivative liabilities, long-termÂ Â 1,435,668Â Â Â â€”Â Â Â â€”Â Â Â 1,435,668Â Total liabilities at fair valueÂ $2,427,534Â Â $â€”Â Â $â€”Â Â $2,427,534Â SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Â SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVESÂ Office equipment 5 years Leasehold improvement 5 years X - DefinitionSchedule Of Property And Equipment Estimated Useful Lives [Table Text Block] + ReferencesNo definition available. + Details Name: BTCY_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock Namespace Prefix: BTCY_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -

SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 + Details Name: us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) 6 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Â Â SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIESÂ Â Â As at September 30, 2024Â Â Â As at March 31, 2024Â Â Â $Â Â $Â Trade and other payablesÂ Â 4,800,049Â Â Â 5,081,992Â Accrued liabilitiesÂ Â 4,232,727Â Â Â 4,369,576Â Deferred revenueÂ Â 24,252Â Â Â 21,550Â TotalÂ Â 9,057,028Â Â Â 9,473,118Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 DERIVATIVE LIABILITIES (Tables) 6 Months Ended Sep. 30, 2024 Debt Instrument [Line Items] Â SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS Â Â SCHEDULE OF DERIVATIVE LIABILITIESÂ Â Â Fiscal Year 2025Â Â Fiscal Year 2024Â Â Â $Â Â $Â Derivative liabilities, beginning of period - March 31Â Â 1,435,668Â Â Â 759,065Â New issuance [Note 9]Â Â 649,533Â Â Â 642,416Â Change in fair value of derivatives during periodÂ Â 533,126Â Â Â (50,033) Reduction due to preferred shares converted [Note 9]Â Â (969,150)Â Â â€”Â Conversion to common sharesÂ Â Â Â Â Â Â End of derivative treatment of warrantsÂ Â Â Â Â Â Â Convertible note modificationÂ Â Â Â Â Â Â Â Convertible note redemptionÂ Â Â Â Â Â Â Â Derivative liabilities, end of periodÂ Â 1,649,177Â Â Â 1,351,448Â SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS The lattice methodology was used to value the derivative components of Series A Preferred Stock, using the following assumptions during the six months ended September 30, 2024, and 2023: Â Â SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONSÂ Â Â September 30, 2024Â Â September 30, 2023Â Dividend yield (%)Â Â 12Â Â Â 12Â Risk-free rate for term (%)Â Â 4.1 - 5.1Â Â Â 4.9 â€“ 5.2Â Volatility (%)Â Â 91.2 - 132.5Â Â Â 71.9 â€“ 111.4Â Remaining terms (Years)Â Â 0.67 - 1.59Â Â Â 0.34 â€“ 2.01Â Stock price ($ per share)Â Â 0.24 - 1.14Â Â Â 2.14 â€“ 3.82Â Â The Monte Carlo simulation methodology was used to value the derivative components of Series B Preferred Stock, using the following assumptions during the six months ended September 30, 2024: Â Â Â September 30, 2024Â Â September 30, 2023Â Dividend yield (%)Â Â 12Â Â Â 12Â Risk-free rate for term (%)Â Â 3.7 - 5.1Â Â Â 5.04 - 5.24Â Volatility (%)Â Â 126.4 - 182.2Â Â Â 76.2 - 119.1Â Remaining terms (Years)Â Â 0.97 - 2Â Â Â 0.25 - 0.5Â Stock price ($ per share)Â Â 0.24 - 1.34Â Â Â 0.64 - 2.14Â Convertible Debt [Member] Â Debt Instrument [Line Items] Â SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS Â Â SCHEDULE OF DERIVATIVE LIABILITIESÂ Â Â Fiscal Year 2025Â Â Fiscal Year 2024Â Â Â $Â Â $Â Â Â Â Â Â Â Â Balance beginning of period â€“ March 31Â Â 991,866Â Â Â 1,008,216Â New IssuanceÂ Â â€”Â Â Â 1,942,004Â Conversion to common sharesÂ Â (490,972)Â Â â€”Â Change in fair value of derivative liabilitiesÂ Â (32,515)Â Â (32,635) Convertible note redemptionÂ Â (8,320)Â Â (33,607) Balance end of period â€“ September 30Â Â 460,059Â Â Â 2,883,978Â Â The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the six months ended September 30, 2024, and 2023, using the following assumptions: Â Â SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONSÂ Â Â September 30, 2024Â September 30, 2023 Risk-free rate for term (%)Â Â 4.1 - 5.2Â Â 4.2 - 5.3 Volatility (%)Â Â 91.2 - 352.4Â Â 76.2 - 126.6 Remaining terms (Years)Â Â 0.25 - 0.5Â Â 0.25 - 1.49 Stock price ($ per share)Â Â 0.24 - 1.45Â Â 0.46 - 3.04 SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the six months ended September 30, 2024, and 2023, using the following assumptions: Â Â SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONSÂ Â Â September 30, 2024Â September 30, 2023 Risk-free rate for term (%)Â Â 4.1 - 5.2Â Â 4.2 - 5.3 Volatility (%)Â Â 91.2 - 352.4Â Â 76.2 - 126.6 Remaining terms (Years)Â Â 0.25 - 0.5Â Â 0.25 - 1.49 Stock price ($ per share)Â Â 0.24 - 1.45Â Â 0.46 - 3.04 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_ScheduleOfAssumptionsUsedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of derivative liabilities at fair value. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERSâ€™ DEFICIENCY (Tables) 6 Months Ended Sep. 30, 2024 Equity [Abstract] Â SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY A roll-forward of activity is presented below for the six months ended September 30, 2024: Â SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY Â Â Fiscal Year 2025Â Â Fiscal Year 2024 Â Â $Â Â $ Balance beginning of period â€“ March 31Â Â 1,488,920Â Â Â Â â€“ Â Net proceeds received pursuant to the issuance of preferred sharesÂ Â 1,732,532Â Â Â 1,900,000 Â Recognition of derivative liabilities (Note 8)Â Â (649,533) Â Â (642,416) Conversion into common sharesÂ Â (285,814) Â Â â€“ Â Balance end of period â€“ September 30Â Â 2,286,105Â Â Â 1,257,584 Â SCHEDULE OF WARRANTS OUTSTANDING Warrant activity during the six months ended September 30, 2024, is indicated below: Â SCHEDULE OF WARRANTS OUTSTANDING Â Â Broker WarrantsÂ Â Consultant and Noteholder WarrantsÂ Â Warrants Issued on Convertible NotesÂ Â TotalÂ As at March 31, 2024Â Â 208,927Â Â Â 253,994Â Â Â 868,098Â Â Â 1,331,019Â Beginning balanceÂ Â 208,927Â Â Â 253,994Â Â Â 868,098Â Â Â 1,331,019Â Â Â Â Â Â Â Â

Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Tables) 6 Months Ended Sep. 30, 2024 Operating Lease Right-of-use Assets And Lease Obligations Â SCHEDULE OF OPERATING LEASES OBLIGATIONS SCHEDULE OF OPERATING LEASES OBLIGATIONS Â Â Fiscal Year 2024Â Â Fiscal Year 2023Â Right of UseAssetÂ $Â Â $Â Beginning balance at March 31Â Â 1,221,593Â Â Â 1,587,492Â New leasesÂ Â â€”Â Â Â â€”Â AmortizationÂ Â (198,275)Â Â (178,320) Ending balance at September 30Â Â 1,023,318Â Â Â 1,409,172Â Â Â 2024Â Â 2023Â Lease LiabilityÂ $Â Â $Â Beginning balance at March 31Â Â 1,386,486Â Â Â 1,722,095Â New leasesÂ Â â€”Â Â Â â€”Â Repayment and interest accretion, netÂ Â (219,283)Â Â (190,864) Ending balance at September 30Â Â 1,167,203Â Â Â 1,531,231Â Â Â BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars) Â Â Â September 30, 2024Â Â March 31, 2024Â Lease LiabilityÂ $Â Â $Â Current portion of operating lease liabilityÂ Â 493,190Â Â Â 457,371Â Noncurrent portion of operating lease liabilityÂ Â 674,013Â Â Â 929,115Â SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION The following table represents the contractual undiscounted cash flows for lease obligations as at September 30, 2024: Â SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION Calendar yearÂ $Â 2024Â Â Â 552,293Â 2025Â Â Â 600,288Â 2026Â Â Â 565,359Â Total undiscounted lease liabilityÂ Â 1,717,940Â Less imputed interestÂ Â (550,737) TotalÂ Â 1,167,203Â X - ReferencesNo definition available. + Details Name: BTCY_DisclosureOperatingLeaseRightofuseAssetsAndLeaseObligationsAbstract Namespace Prefix: BTCY_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOperating Leases of Lessee [Table Text Block] + ReferencesNo definition available. + Details Name: BTCY_OperatingLeasesOfLesseeTableTextBlock Namespace Prefix: BTCY_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSchedule of Contractual Undiscounted Cash Flows For Lease Obligation [Table Text Block] + ReferencesNo definition available. + Details Name: BTCY_ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationTableTextBlock Namespace Prefix: BTCY_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 PROPERTY AND EQUIPMENT (Tables) 6 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Â SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF PROPERTY AND EQUIPMENT CostÂ Office equipmentÂ Â Leasehold improvementÂ Â TotalÂ Â Â $Â Â $Â Â $Â Balance at March 31, 2024Â Â 16,839Â Â Â 12,928Â Â Â 29,767Â AdditionsÂ Â â€”Â Â Â â€”Â Â Â â€”Â DisposalsÂ Â â€”Â Â Â â€”Â Â Â â€”Â Balance at September 30, 2024Â Â 16,839Â Â Â 12,928Â Â Â 29,767Â Accumulated depreciationÂ Office equipmentÂ Â Leasehold improvementÂ Â TotalÂ Â Â $Â Â $Â Â $Â Balance at March 31, 2024Â Â 8,042Â Â Â 6,173Â Â Â 14,215Â Depreciation for the periodÂ Â 1,683Â Â Â 1,293Â Â Â 2,977Â DisposalsÂ Â â€”Â Â Â â€”Â Â Â â€”Â Balance at September 30, 2024Â Â 9,725Â Â Â 7,466Â Â Â 17,191 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net book valueÂ Â Â Â Â Â Â Â Â Â Â Â Balance at March 31, 2024Â Â 8,797Â Â Â 6,755Â Â Â 15,552Â Balance at September 30, 2024Â Â 7,114Â Â Â 5,462Â Â Â 12,576Â X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($) 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Product Information [Line Items] Â Â Â Â TotalÂ $ 3,266,846 $ 2,891,297 $ 6,468,589 $ 5,912,062 Technology Fees [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â TotalÂ 3,064,814 2,731,461 6,081,064 5,500,379 Device Sales [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â TotalÂ $ 202,032 $ 159,836 $ 387,525 $ 411,683 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ProductInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=BTCY_TechnologyFeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=BTCY_DeviceSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF INVENTORIES (Details) - USD ($) Sep. 30, 2024 Mar. 31, 2024 Accounting Policies [Abstract] Â Â Raw material $ 1,073,409 $ 1,128,700 Finished goods 744,152 750,702 Inventories $ 1,817,561 $ 1,879,402 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsAndSupplies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($) Sep. 30, 2024 Mar. 31, 2024 Platform Operator, Crypto Asset [Line Items] Â Â Cash $ 173,270 $ 786,060 Total assets at fair value 173,270 786,060 Derivative liabilities, short-term 460,059 991,866 Derivative liabilities, long-term 1,649,177 1,435,668 Total liabilities at fair value 2,109,236 2,427,534 Fair Value, Inputs, Level 1 [Member] Â Â Platform Operator, Crypto Asset [Line Items] Â Â Cash 173,270 786,060 Total assets at fair value 173,270 786,060 Derivative liabilities, short-term Derivative liabilities, long-term Total liabilities at fair value Fair Value, Inputs, Level 2 [Member] Â Â Platform Operator, Crypto Asset [Line Items] Â Â Cash Total assets at fair value Derivative liabilities, short-term Derivative liabilities, long-term Total liabilities at fair value Fair Value, Inputs, Level 3 [Member] Â Â Platform Operator, Crypto Asset [Line Items] Â Â Cash Total assets at fair value Derivative liabilities, short-term 460,059 991,866 Derivative liabilities, long-term 1,649,177 1,435,668 Total liabilities at fair value $ 2,109,236 $ 2,427,534 X - ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.FF.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1 + Details Name: srt_PlatformOperatorCryptoAssetLineItems Namespace Prefix: srt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES (Details) Sep. 30, 2024 Mar. 31, 2022 Office Equipment [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, useful life 5 years Â Leasehold Improvements [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, useful life 5 years 5 years X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION (Details Narrative) - USD ($) 3 Months Ended 6 Months Ended 12 Months Ended Sep. 19, 2023 Jul. 19, 2023 Jun. 29, 2023 Sep. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Mar. 31, 2023 Accumulated deficit Â Â Â $ 136,101,106 $ 127,499,785 Â Â $ 136,101,106 Â $ 127,499,785 Â Working capital deficiency Â Â Â 17,424,814 Â Â Â 17,424,814 Â Â Â Proceeds from short term debt Â Â Â Â Â Â Â $ (1,125,116) $ 773,737 853,030 $ 1,476,121 Debt conversion converted instrument amount Â Â Â Â Â Â Â Â Â $ 2,962,386 $ 2,355,318 Conversion of convertible securities Â Â Â Â Â Â Â 97,811 Â

36,897 Â Gross proceeds from issuance of common stock Â Â Â Â Â Â Â Â $ 125,227 Â $ 123,347 Â Proceeds from issuance of common stock Â Â Â Â Â Â Â Â 125,221 119,285 $ 119,285 Â Placement fee percentage Â Â Â Â Â Â Â Â Â Â 3.00% Â Proceeds from Issuance of Preferred Stock and Preference Stock Â Â Â Â Â Â Â Â 1,732,532 1,900,000 Â Â Issuance of common shares from shares to be issued Â Â Â Â Â Â Â $ 119,285 119,285 Â Â Conversion of mezzanine equity into common shares Â Â Â $ 243,757 Â Â Â $ 475,479 Â Â Â Number of stock issued during the period convertible, shares Â Â Â Â Â Â Â Â 97,811 Â Â Â Lender [Member] Â Â Â Â Â Â Â Â Â Â

obligations incurred classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableOtherCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative) - USD ($) Sep. 30, 2024 Mar. 31, 2024 Payables and Accruals [Abstract] Â Â Trade and other payables and accrued liabilities $ 307,085 $ 837,945 X - DefinitionAmount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_OtherAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3 CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS (Details Narrative) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended Jun. 17, 2024 Feb. 02, 2024 Jan. 09, 2024 Dec. 08, 2023 Oct. 25, 2023 Oct. 23, 2023 Sep. 19, 2023 Aug. 11, 2023 Jul. 18, 2023 Jul. 13, 2023 Mar. 29, 2023 Jan. 23, 2023 Dec. 30, 2022 Dec. 21, 2021 Feb. 29, 2024 Jun. 30, 2023 Dec. 31, 2022 Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Mar. 31, 2024 Mar. 31, 2023 Mar. 31, 2022 Mar. 31, 2021 Jan. 31, 2024 Sep. 25, 2023 Short-Term Debt [Line Items] Â Â Â

a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Companyâ€™s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion, redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. Â Â Deferred finance costs Â Â Â

Â Â Â Â Â Â Â Â Â Â 716 10,023 Â 716 Â 716 10,023 Â Â Â Â Â Debt instrument carrying amount Â Â Â 844,200 Â Â Â Â Â Â Â Â Â Â

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of the required periodic payments including both interest and principal payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmortized cost of revolving financing receivable converted to term loan. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-6A + Details Name: us-gaap_FinancingReceivableRevolvingConvertedToTermLoan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDerivativeLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate amount of interest expense on all borrowings. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestExpenseBorrowings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as other. + ReferencesNo definition available. + Details Name: us-gaap_InterestExpenseOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1 + Details Name: us-gaap_InventoryAdjustments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of decrease in debt under credit facility arrangement from principal payment. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityAnnualPrincipalPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe maximum amount of borrowing capacity under a line of credit that is available as of the balance sheet date for financing purchases of goods acquired for inventory or imminent delivery to a customer. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityCapacityAvailableForTradePurchases Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescribes when borrowings outstanding under a line of credit will convert to a term loan, and describes the repayment terms, collateral, and priority (seniority) of the term loan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRevolvingCreditConversionToTermLoanDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentForManagementFee Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for the payment of debt classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfOtherDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition

available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShortTermDebtLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=BTCY_ShortTermLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=BTCY_PromissoryNoteAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=BTCY_EighteenMonthAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=BTCY_TwentyFourMonthAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShortTermDebtTypeAxis=BTCY_OtherConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=BTCY_SeriesAConvertibleNoteHoldersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=BTCY_PlacementAgentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_TwoSeriesANotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_SeriesANotesOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_SeriesANotesTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_SeriesANotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=BTCY_AdditionalCollateralizedBridgeLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_SeriesANoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_NewConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_SeriesBNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BTCY_AccreditedInvestorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=BTCY_WarrantOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=BTCY_WarrantTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_SeriesBNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_SeriesCNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=BTCY_NoteHoldersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=BTCY_PlacementAgentsWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_SeriesCNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_ShortTermBridgeLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=BTCY_CollateralizedMerchantFinanceCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=BTCY_CollateralizedMerchantFinanceCompanyOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_ShortTermCollateralizedBridgeLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=BTCY_FinanceCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=BTCY_FirstFourWeeksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_PromissoryNoteAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=BTCY_IndividualInvestorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=BTCY_IndividualInvestorOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_NewPromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_CollateralizedBridgeLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=BTCY_RemainingThirtySixWeeksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_AdditionalCollateralizedBridgeLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_TwoShortTermPromissoryNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=BTCY_OneInvestorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_ShortTermPromissoryNotesOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_ShortTermPromissoryNotesTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_ShortTermBridgeLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 TERM LOAN AND CREDIT AGREEMENT (Details Narrative) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended Dec. 21, 2021 Nov. 30, 2022 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Cash and Cash Equivalents [Line Items] Â Â Â Â Â Â Â Debt instrument, face amount $ 12,400,000 Â Â Â Â Â Â Â Maturity date Dec. 21, 2026 Â Â Â Â Â Â Â Interest rate 10.50% Â Â Â Â Â Â Â Interest payments due date Feb. 15, 2022 Â Â Â Â Â Â Â Debt instrument, payment terms Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. The Company and the Lender have negotiated the terms under which the Company will be allowed to extend the interest-only period and delay the start of principal repayment. Â Â Â Â Â Â Â Principal repayments Â Â Â Â $ 600,000 Â $ 2,400,000 Loans payable current portion Â Â $ 3,000,000 Â 3,000,000 Â 2,400,000 Origination fee amount $ 120,000 Â Â Â Â Â Â Â Exit fee 600,000 Â Â Â Â Â Â Â Debt financing 193,437 Â Â Â Â Â Â Â Professional fee 48,484 Â Â Â Â Â Â Â Fee amount 144,953 Â Â Â Â Â Â Â Gross proceeds 12,000,000 Â Â Â Â Â Â Â Repayment of short term debt 1,574,068 Â Â Â Â Â Â Â Fair value of warrants $ 1,042,149 Â Â Â Â Â Â Â Amortization of debt discount expense Â Â 52,627 $ 51,724 104,458 $ 102,666 Â Unpaid interest Â $ 364,000 752,075 $ 753,268 1,520,748 $ 1,413,780 Â Interest payable current Â Â 1,107,791 Â 1,107,791 Â $ 795,656 Warrants issued 57,536 Â Â Â Â Â Â Â Issuance of warrants $ 198,713 Â Â Â Â Â Â Â Term Loan [Member] Â Â Â Â Â Â Â Cash and Cash Equivalents [Line Items] Â Â Â Â Â Â Â Interest expense Â Â $ 495,783 Â $ 987,135 Â Â Cash [Member] Â Â Â Â Â Â Â Cash and Cash Equivalents [Line Items] Â Â Â Â Â Â Â Debt financing $ 50,000 Â Â Â Â Â Â Â X - DefinitionExit Fees. + ReferencesNo definition available. + Details Name: BTCY_ExitFees Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOrigination fee amount. + ReferencesNo definition available. + Details Name: BTCY_OriginationFeeAmount Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDate the debt agreement requires the first payment to be made, in YYYY-MM-DD format. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentDateOfFirstRequiredPayment1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of the fee that accompanies borrowing money under the debt instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentFeeAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDescription of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -

Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentPaymentTerms Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LoansPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received from principal payments made on loans related to operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromLoans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromRepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_ProfessionalFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStated interest rate of the subordinated debt. + ReferencesNo definition available. + Details Name: us-gaap_SubordinatedBorrowingInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 FEDERALLY GUARANTEED LOAN (Details Narrative) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended Dec. 21, 2021 Nov. 30, 2022 May 31, 2021 Apr. 30, 2020 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Proceeds from loan $ 12,000,000 Â Â Â Â Â Â Â Â Â Â Interest expense Â $ 364,000 Â Â $ 752,075 $ 753,268 $ 1,520,748 $ 1,413,780 Â Economic Injury Disaster Loan [Member] Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Proceeds from loan Â Â $ 499,900 $ 370,900 Â Â Â Â Â Â Debt instrument description Â Â Â The loan has a term of 30 years and an interest rate of 3.75% per annum, without the requirement for payment in the first 12 months. Â Â Â Â Â Â Debt instrument term Â Â Â 30 years Â Â Â Â Â Â Debt interest rate Â Â Â 3.75% Â Â Â Â Â Â Accrued interest Â Â Â Â 7,889 Â 7,889 Â $ 26,497 Interest expense Â Â Â Â $ 8,231 $ 8,230 $ 16,372 $ 16,372 Â X - DefinitionIdentification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash received from principal payments made on loans related to operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromLoans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShortTermDebtLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_EconomicInjuryDisasterLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF DERIVATIVE LIABILITIES (Details) - USD ($) 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â Â Derivative liabilities, beginning of period - March 31 $ 1,435,668 $ 759,065 New issuance [Note 9] 649,533 642,416 Change in fair value of derivatives during period 533,126 (50,033) Reduction due to preferred shares converted [Note 9] (969,150) Derivative liabilities, end of period $ 1,649,177 $ 1,351,448 X - DefinitionFair value measurement with unobservable inputs reconciliation recurring basis liability issue. + ReferencesNo definition available. + Details Name: BTCY_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionReduction due to preferred shares converted. + ReferencesNo definition available. + Details Name: BTCY_ReductionDueToPreferredSharesConverted Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS (Details) 6 Months Ended Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) $ / shares Derivative [Line Items] Â Â Derivative liabilities, beginning of period - March 31 $ 1,435,668 $ 759,065 New Issuance 649,533 642,416 Change in fair value of derivative liabilities 533,126 (50,033) Derivative liabilities, end of period 1,649,177 1,351,448 Convertible Debt [Member] Â Â Derivative [Line Items] Â Â Derivative liabilities, beginning of period - March 31 991,866 1,008,216 New Issuance 1,942,004 Conversion to common shares (490,972) Change in fair value of derivative liabilities (32,515) (32,635) Convertible note redemption (8,320) (33,607) Derivative liabilities, end of period $ 460,059 $ 2,883,978 Measurement Input, Expected Dividend Rate [Member] | Series A Preferred Stock [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 12 12 Measurement Input, Expected Dividend Rate [Member] | Series B Preferred Stock [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 12 12 Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Convertible Note and Warrant Derivative [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 4.1 4.2 Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Convertible Note and Warrant Derivative [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 5.2 5.3 Measurement Input, Risk Free Interest Rate [Member] | Series A Preferred Stock [Member] | Minimum [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 4.1 4.9 Measurement Input, Risk Free Interest Rate [Member] | Series A Preferred Stock [Member] | Maximum [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 5.1 5.2 Measurement Input, Risk Free Interest Rate [Member] | Series B Preferred Stock [Member] | Minimum [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 3.7 5.04 Measurement Input, Risk Free Interest Rate [Member] | Series B Preferred Stock [Member] | Maximum [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 5.1 5.24 Measurement Input, Price Volatility [Member] | Minimum [Member] | Convertible Note and Warrant Derivative [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 91.2 76.2 Measurement Input, Price Volatility [Member] | Maximum [Member] | Convertible Note and Warrant Derivative [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 352.4 126.6 Measurement Input, Price Volatility [Member] | Series A Preferred Stock [Member] | Minimum [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 91.2 71.9 Measurement Input, Price Volatility [Member] | Series A Preferred Stock [Member] | Maximum [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 132.5 111.4 Measurement Input, Price Volatility [Member] | Series B Preferred Stock [Member] | Minimum [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 126.4 76.2 Measurement Input, Price Volatility [Member] | Series B Preferred Stock [Member] | Maximum [Member] Â Â Derivative [Line Items] Â Â Derivative liability, measurement input 182.2 119.1 Measurement Input, Expected Term [Member] | Minimum [Member] | Convertible Note and Warrant Derivative [Member] Â Â Derivative [Line Items] Â Â Remaining terms 3 months 3 months Measurement Input, Expected Term [Member] | Maximum [Member] | Convertible Note and Warrant Derivative [Member] Â Â Derivative [Line Items] Â Â Remaining terms 6 months 1 year 5 months 26 days Measurement Input, Expected Term [Member] | Series A Preferred Stock [Member] | Minimum [Member] Â Â Derivative [Line Items] Â Â Remaining terms 8 months 1 day 4 months 2 days Measurement Input, Expected Term [Member] | Series A Preferred Stock [Member] | Maximum [Member] Â Â Derivative [Line Items] Â Â Remaining terms 1 year 7 months 2 days 2 years 3 days Measurement Input, Expected Term [Member] | Series B Preferred Stock [Member] | Minimum [Member] Â Â Derivative [Line Items] Â Â Remaining terms 11 months 19 days 3 months Measurement Input, Expected Term [Member] | Series B Preferred Stock [Member] | Maximum [Member] Â Â Derivative [Line Items] Â Â Remaining terms 2 years 6 months Measurement Input, Share Price [Member] | Minimum [Member] | Convertible Note and Warrant Derivative [Member] Â Â Derivative [Line Items] Â Â Stock price | $ / shares $ 0.24 $ 0.46 Measurement Input, Share Price [Member] | Maximum [Member] | Convertible Note and Warrant Derivative [Member] Â Â Derivative [Line Items] Â Â Stock price | $ / shares 1.45 3.04 Measurement Input, Share Price [Member] | Series A Preferred Stock [Member] | Minimum [Member] Â Â Derivative [Line Items] Â Â Stock price | $ / shares 0.24 2.14 Measurement Input, Share Price [Member] | Series A Preferred Stock [Member] | Maximum [Member] Â Â Derivative [Line Items] Â Â Stock price | $ / shares 1.14 3.82 Measurement Input, Share Price [Member] | Series B Preferred Stock [Member] | Minimum [Member] Â Â Derivative [Line Items] Â Â Stock price | $ / shares 0.24 0.64 Measurement Input, Share Price [Member] | Series B Preferred Stock [Member] | Maximum [Member] Â Â Derivative [Line Items] Â Â Stock price | $ / shares $ 1.34 $ 2.14 X - DefinitionConversion of stock amount redemption. + ReferencesNo definition available. + Details Name: BTCY_ConversionOfStockAmountRedemption Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDerivative liability, remaining term (years). + ReferencesNo definition available. + Details Name: BTCY_DerivativeLiabilityRemainingTerm Namespace Prefix: BTCY_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDerivative stock price. + ReferencesNo definition available. + Details Name: BTCY_DerivativeStockPrice Namespace Prefix: BTCY_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFair value measurement with unobservable inputs reconciliation recurring basis liability issue. + ReferencesNo definition available. + Details Name: BTCY_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockAmountConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of input used to measure derivative liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_DerivativeLiabilityMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_ConvertibleNoteAndWarrantDerivativeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY (Details) - USD ($) 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Equity [Abstract] Â Â Balance beginning of period â€“ March 31 $ 1,488,920 Issuance of preferred shares, net 1,732,532 1,900,000 Recognition of derivative liabilities (Note 8) (649,533) (642,416) Conversion into common shares (285,814) Balance end of period â€“ September 30 $ 2,286,105 $ 1,257,584 X - DefinitionChange in fair valueus measurement with reconciliation recurring basis liability. + ReferencesNo definition available. + Details Name: BTCY_ChangeInFairValueusMeasurementWithReconciliationRecurringBasisLiability Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionConversion into common shares. + ReferencesNo definition available. + Details Name: BTCY_ConversionIntoCommonShares Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionConvertible preferred stock. + ReferencesNo definition available. + Details Name: BTCY_ConvertiblePreferredStock Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF WARRANTS OUTSTANDING (Details) 6 Months Ended Sep. 30, 2024 $ / shares shares Accumulated Other Comprehensive Income (Loss) [Line Items] Â Beginning balance 1,331,019 Expired/cancelled Exercised Issued Ending balance 1,331,019 Broker Warrants [Member] Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Beginning balance 208,927 Expired/cancelled Exercised Issued Ending balance 208,927 Expiration Date August 2026 to October 2033 Broker Warrants [Member] | Minimum [Member] Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Exercise Price | $ / shares $ 2.09 Broker Warrants [Member] | Maximum [Member] Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Exercise Price | $ / shares $ 22.50 Consultant Warrants [Member] Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Beginning balance 253,994 Expired/cancelled Exercised Issued Ending balance 253,994 Expiration Date March 2029 to Dec 2032 Consultant Warrants [Member] | Minimum [Member] Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Exercise Price | $ / shares $ 2.69 Consultant Warrants [Member] | Maximum [Member] Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Exercise Price | $ / shares $ 14.40 Warrants Issued on Conversion of Convertible Notes [Member] Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Beginning balance 868,098 Expired/cancelled Exercised Issued Ending balance 868,098 Exercise Price | $ / shares $ 4.18 Expiration Date October 2027 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionDescription of reason for issuing warrant or right. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-option equity instruments exercised by participants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares under non-option equity instrument agreements that were either cancelled or expired. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNet number of non-option equity instruments granted to participants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=BTCY_BrokerWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=BTCY_ConsultantWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=BTCY_WarrantsIssuedOnConversionOfConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF STOCK OPTION ACTIVITIES (Details) - $ / shares 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Weighted average exercise price, beginning outstanding Â $ 2.30 Equity Option [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of options, beginning outstanding 1,239,873 1,264,890 Weighted average exercise price, beginning outstanding $ 9.39 $ 9.29 Number of options, beginning outstanding 291,559 3,585 Weighted average exercise price, beginning outstanding $ 1.24 $ 2.79 Number of options, beginning outstanding Weighted average exercise price, beginning outstanding Â Number of options, beginning outstanding (54,219) (12,035) Weighted average exercise price, beginning outstanding $ 12.57 $ 1.61 Number of options, beginning outstanding (12,500) (5,362) Weighted average exercise price, beginning outstanding $ 8.28 $ 8.58 Number of options, beginning outstanding 1,464,713 1,251,078 Weighted average exercise price, beginning outstanding $ 7.71 $ 9.30 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS (Details) - $ / shares 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Exercise price $ 1.2 $ 2.79 Risk free interest rate 4.13% 3.85% Expected term Â 10 years Expected volatility Â 117.10% Expected dividend yield 0.00% 0.00% Fair value of option Â $ 2.30 Expected forfeiture (attrition) rate 0.00% 0.00% Minimum [Member] Â Â Expected term 5 years 6 months Â Expected volatility 107.70% Â Fair value of option $ 0.689 Â Maximum [Member] Â Â Expected term 6 years 6 months Â Expected volatility 109.80% Â Fair value of option $ 0.733 Â X - DefinitionExpected forfeiture (attrition) rate. + ReferencesNo definition available. + Details Name: BTCY_ExpectedForfeitureAttritionRates Namespace Prefix: BTCY_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)

(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERSâ€™ DEFICIENCY (Details Narrative) - USD ($) 3 Months Ended 6 Months Ended 12 Months Ended Sep. 19, 2023 Dec. 21, 2021 Sep. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Feb. 02, 2016 Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common Stock, Shares Authorized Â Â 125,000,000 125,000,000 Â Â 125,000,000 Â 125,000,000 Â Â Â Â Common Stock, Par or Stated Value Per Share Â Â $ 0.001 $ 0.001 Â Â $ 0.001 Â $ 0.001 Â Â Â Â Preferred Stock, Shares Authorized Â Â 10,000,000 10,000,000 Â Â 10,000,000 Â 10,000,000 Â Â Â Â Preferred stock convertible conversion price Â Â $ 0.001 Â Â Â $ 0.001 Â Â Â Â Â Â Common stock, shares issued Â Â 22,863,261 9,353,768 Â Â 22,863,261 Â 9,353,768 Â Â Â Â Common stock, other shares, outstanding Â Â 160,672 160,672 Â Â 160,672 Â 160,672 Â Â Â Â Debt instrument redemption price percentage Â Â Â Â Â Â 110.00% Â Â Â Â Â Â Face value Â $ 12,400,000 Â Â Â Â Â Â Â Â Â Â Â Issuance of preferred shares, net Â Â Â Â Â Â Â $ 1,732,532 $ 1,900,000 Â Â Â Â Â fair value of common shares Â Â Â Â Â $ 119,285 119,285 Â Â Â Â Â Debt conversion description Â Â Â Â Â Â Â Â Â The redemption price was determined in accordance to the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note Â Â Â Conversion of mezzanine equity into common shares Â Â Â Â Â Â 97,811 Â Â Â Â Â Â Conversion of common shares Â Â Â Â Â Â $ (285,814) Â Â Â Â Â Temporary equity value reduction Â Â $ 142,907 Â Â Â 285,814 Â Â Â Â Â Â Reduced accrued dividends liability Â Â 16,219 Â Â Â 28,438 Â Â Â Â Â Â Instrument amount Â Â Â Â Â Â Â Â Â $ 2,962,386 $ 2,355,318 Â Â Â Loss on debt conversion Â Â Â Â Â Â Â $ 249,093 Â Â Â Â Â Â Number of stock issued during the period convertible, shares Â Â Â Â Â Â 97,811 Â 36,897 Â Â Â Â Gross proceeds from issuance of common stock Â Â Â Â Â Â Â $ 125,227 Â $ 123,347 Â Â Â Â Â Issuance of warrants Â $ 198,713 Â Â Â Â Â Â Â Â Â Â Number of shares issued Â Â Â Â Â Â Â 36,897 Â Â Â Â Â Gross proceeds Â Â Â Â Â Â Â Â Â $ 123,347 Â Â Â Â Â Net proceeds Â Â Â Â Â Â Â Â $ 119,285 Â Â Â Â Â Percentage of placement fee and other issuance expenses Â Â Â Â Â Â 3.00% Â Â Â Â Â Number of additional shares issued Â Â Â Â Â Â 20,846 Â Â Â Â Â Shares to be issued with fair value Â Â $ 20,000 Â Â Â 81,120 Â Â Â Â Â Â Stock-based compensation Â Â Â Â Â Â Â $ 115,863 $ 374,515 Â Â Â Â Â 2016 Equity Incentive Plan [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Share based payment award number of shares authorized Â Â Â Â Â Â Â Â Â Â 1,241,422 Stock options granted Â Â 250,000 Â 3,585 291,559 3,585 Â Â Â Â Â Stock-based compensation Â Â $ 56,885 Â Â $ 163,335 $ 115,863 $ 374,515 Â Â Â Â Â 2023 Equity Incentive Plan [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Share based payment award number of shares available for issuance Â Â Â Â Â Â Â Â Â 5,000,000 Â Â Â General and Administrative Expense [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Issuance of shares for services Â Â Â Â Â 70,000 Â Â Â Â Â Issuance of warrants Â Â Â Â Â Â $ 53,480 Â Â Â Â Â Â Series C Notes [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Converted instrument shares issued Â Â 121,043 Â Â Â 1,753,554 Â Â Â Â Â Â fair value of common shares Â Â $ 74,618 Â Â Â $ 2,283,216 Â Â Â Â Â Â Debt conversion description Â Â Â Â Â the notes would convert into common stock at the applicable â€œMandatory Conversion Priceâ€, if either (i) on each of any twenty (20) consecutive Trading Days (the â€œMeasurement Periodâ€) (A) the closing price of the Common Stock on the applicable Trading Market is at least $18.00 per share and (B) the dollar value of average daily trades of the Common Stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the Common Stock on the applicable National Exchange on each of the ten (10) consecutive Trading Days following such closing is at least $400,000 per Trading Day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above, seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing. Â Â Â Â Â Â Instrument amount Â Â $ 45,000 Â Â Â $ 1,432,700 Â Â Â Â Â Â Shares recognised as obligation Â Â 121,043 Â Â Â Â Â Â Â Â Â Debt instrument accrued interest Â Â $ 7,810 Â Â Â 222,257 Â Â Â Â Â Derivative liability Â Â 15,357 Â Â Â 490,972 Â Â Â Â Â Debt instrument accrued interest Â Â $ 6,451 Â Â Â $ 137,287 Â Â Â Â Â Â Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Shares Authorized Â Â 9,979,400 9,979,400 Â 9,979,400 Â 9,979,400 Â Â Â Â Preferred stock convertible conversion price Â Â $ 0.001 $ 0.001 Â Â $ 0.001 Â $ 0.001 Â Â Â Â Shares outstanding Â Â 201 6,305 Â 6,305 201 6,305 6,305 6,305 201 6,305 Â Preferred stock, shares issued Â Â 1 Â Â 1 Â Â 1 Â Â Â Â Preferred stock, shares outstanding Â Â 1 Â Â 1 Â Â 1 Â Â Â Â fair value of common shares Â Â Â Â Â Â Â Â Â Â Â Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Shares outstanding Â Â 23,023,933 9,514,440 Â 8,810,248 23,023,933 8,810,248 9,514,440 8,752,510 21,645,068 8,752,505 Â Stock issued during period Â Â Â Â Â 57,743 608,123 Â Â Â Â Â Â fair value of common shares Â Â Â Â Â $ 58 $ 608 Â Â Â Â Â Conversion of mezzanine equity into common shares Â Â 1,091,063 320,321 612,062 Â 1,436,267 Â Â Â Â Â Conversion of common shares Â Â Â $ 142,907 $ 228,727 Â Â Â Â Â Â Â Â Accrued dividends liability Â Â Â Â 16,789 Â Â Â Â Â Â Â Related to the shares Â Â $ 84,076 $ 75,523 $ 119,359 Â $ 160,672 Â Â Â Â Â Â Issuance of shares for settlement of accounts payable Â Â Â Â Â Â 1,000,413 Â Â Â Â Â Â Issuance of shares for settlement of accounts payable, value Â Â Â Â Â Â $ 741,316 Â Â Â Â Â Â Issuance of shares for services Â Â Â Â Â Â 70,000 Â Â Â Â Â Â Shares to be issued with fair value Â Â Â Â Â Â Â $ 70 Â Â Â Â Â Â Shares to be Issued [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Shares outstanding Â Â 194,998 344,276 Â 3,955 194,998 3,955 344,276 3,955 321,757 3,955 Â Stock issued during period Â Â Â Â Â Â (608,123) 57,743 Â Â Â Â Â Â fair value of common shares Â Â Â Â Â $ (540,576) $ 58 Â Â Â Â Â Issuance of shares for services Â Â 40,000 Â Â Â 50,000 Â Â Â Â Â Â Shares to be issued with fair value Â Â $ 20,000 Â Â Â $ 27,640 Â Â Â Â Â Â Purchase Agreement [Member] | Beneficiary [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Ownership percentage 4.99% Â Â Â Â Â Â Â Â Â Â Â Shareholders [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Common stock, shares issued Â Â 22,863,261 9,353,768 Â Â 22,863,261 Â 9,353,768 Â Â Â Â Shareholders [Member] | Exchange Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Shares outstanding Â Â 23,023,933 9,514,440 Â 23,023,933 Â 9,514,440 Â Â Â Â Series A Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Shares Authorized Â Â 20,000 20,000 Â Â 20,000 Â 20,000 Â Â Â Â Preferred stock convertible conversion price Â Â $ 0.001 $ 0.001 Â Â $ 0.001 Â $ 0.001 Â Â Â Â Preferred stock, shares issued Â Â 200 6,304 Â 6,304 200 6,304 6,304 Â Â Â Â Preferred stock, shares outstanding Â Â 200 6,304 Â 6,304 200 6,304 6,304 Â Â Â Â Preferred stock, liquidation preference Â Â $ 1,000 Â Â Â $ 1,000 Â Â Â Â Â Â Preferred stock dividend rate percentage Â Â Â Â Â Â 12.00% Â Â Â Â Â Â Debt instrument redemption price percentage Â Â Â Â Â Â 5.00% Â Â Â Â Â Â Preferred stock convertible conversion price Â Â $ 0.001 Â Â Â $ 0.001 Â Â Â Â Â Volume weighted average price percentage Â Â Â Â Â Â 15.00% Â Â Â Â Â Â Face value Â Â $ 6,104,444 Â Â Â $ 6,104,444 Â Â Â Â Â Â Accrued dividends Â Â 1,071,542 Â Â Â $ 1,071,542 Â Â Â Â Â Converted instrument shares issued Â Â Â Â Â Â 8,952,170 Â Â Â Â Â Deposit liabilities, accrued interest Â Â $ 7,984,463 Â Â Â $ 7,984,463 Â Â Â Â Â Stock redeemed or called during period, value Â Â Â Â Â Â 11,039,142 Â Â Â Â Â Investment company, dividend distribution Â Â Â Â Â $ 3,054,679 Â Â Â Â Â Initial conversion price Â Â $ 3.50 Â Â $ 3.50 Â Â Â Â Series B Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Shares Authorized Â Â 600 600 Â Â 600 Â 600 Â Â Â Â Preferred stock, shares issued 220 Â 435 265 Â Â 435 Â 265 Â Â Â Â Preferred stock, shares outstanding Â Â 435 265 Â Â 435 Â 265 Â Â Â Â Preferred stock redemption price per share $ 9,091 Â Â Â Â Â Â Â Â Â Â Issuance of preferred shares, net $ 1,900,000 Â Â Â Â Â Â Â Â Â Â Debt conversion description Â Â Â Â Â Holders may elect to convert shares of Series B Preferred Stock to common stock at an alternate conversion price equal to 80% (or 70% if the Companyâ€™s common stock is suspended from trading on or delisted from a principal trading market or if the Company has effected a reverse split of the common stock) of the lowest daily volume weighed average price of the common stock during the Alternate Conversion Measuring Period (as defined in the Certificate of Designations). In the event the Company receives a conversion notice that elects an alternate conversion price, the Company may, at its option, elect to satisfy its obligation under such conversion with payment in cash in an amount equal to 110% of the conversion amount. Â Â Â Â Â Â Conversion of mezzanine equity into common shares Â Â 1,091,063 25 40 Â 1,436,267 Â Â Â Â Â Â Conversion of preferred stock shares Â Â 25 Â Â Â 50 Â Â Â Â Â Â Issuance of common shares from shares to be issued Â Â Â Â Â 320,321 Â Â Â Â Â Â Series B Preferred Stock [Member] | Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Stock issued during period Â Â 55 110 Â Â 220 Â Â Â Â Â Â fair value of common shares Â Â $ 420,000 $ 925,000 Â Â $ 1,732,532 Â Â Â Â Â Series B Preferred Stock [Member] | Purchase Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Preferred stock convertible conversion price $ 10,000 Â Â Â Â Â Â Â Â Â Â Â Preferred stock, shares issued 600 Â Â Â Â Â Â Â Â Â Â Â Debt instrument redemption price percentage Â Â Â Â Â 110.00% Â Â Â Â Â Â Stated value percentage 8.00% Â Â Â Â Â Â Â Â Â Â Â Series B Preferred Stock [Member] | Purchase Agreement [Member] | Beneficiary [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Ownership percentage 19.90% Â Â Â Â Â Â Â Â Â Â Â Series B Preferred Stock [Member] | Purchase Agreement [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Stated value percentage 15.00% Â Â Â Â Â Â Â Â Â Â Â Series C Convertible Note [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Issuance of common shares from shares to be issued Â Â Â Â Â Â 287,802 Â Â Â Â Â Â Series C Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Conversion of mezzanine equity into common shares Â Â 121,043 Â Â Â 1,753,554 Â Â Â Â Â Â Shares recognised as obligation Â Â Â Â Â Â 121,043 Â Â Â Â Â Â Debt settled Â Â $ 68,167 Â Â Â $ 2,145,929 Â Â Â Â Â Â X - DefinitionConversion into common shares. + ReferencesNo definition available. + Details Name: BTCY_ConversionIntoCommonShares Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDebt settled. + ReferencesNo definition available. + Details Name: BTCY_DebtSettled Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDerivative liability. + ReferencesNo definition available. + Details Name: BTCY_DerivativeLiability Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGain loss recognized of debt + ReferencesNo definition available. + Details Name: BTCY_GainLossRecognizedOfDebt Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGross proceeds from issuance of common stock. + ReferencesNo definition available. + Details Name: BTCY_GrossProceedsFromIssuanceOfCommonStock Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIssuance of common shares from shares to be issued. + ReferencesNo definition available. + Details Name: BTCY_IssuanceOfCommonSharesFromSharesToBeIssued Namespace Prefix: BTCY_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionIssuance of shares for settlement of accounts payable. + ReferencesNo definition available. + Details Name: BTCY_IssuanceOfSharesForSettlementOfAccountsPayable Namespace Prefix: BTCY_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionIssuance of shares for settlement of accounts payable, value. + ReferencesNo definition available. + Details Name: BTCY_IssuanceOfSharesForSettlementOfAccountsPayableValue Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLoss on debt conversion. + ReferencesNo definition available. + Details Name: BTCY_LossOnDebtConversion Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of placement fee and other issuance expenses. + ReferencesNo definition available. + Details Name: BTCY_PercentageOfPlacementFeeAndOtherIssuanceExpenses Namespace Prefix: BTCY_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPreferred stock initial conversion price. + ReferencesNo definition available. + Details Name: BTCY_PreferredStockInitialConversionPrice Namespace Prefix: BTCY_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionReduction due to preferred shares redeemed. + ReferencesNo definition available. + Details Name: BTCY_ReductionDueToPreferredSharesRedeemed Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSale of stock number of additional shares issued in transaction. + ReferencesNo definition available. + Details Name: BTCY_SaleOfStockNumberOfAdditionalSharesIssuedInTransaction Namespace Prefix: BTCY_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStated value percentage. + ReferencesNo definition available. + Details Name: BTCY_StatedValuePercentage Namespace Prefix: BTCY_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNumber of stock issued during the period convertible, shares. + ReferencesNo definition available. + Details Name: BTCY_StockIssuedDuringPeriodShareConversionOfConvertibleSecurities Namespace Prefix: BTCY_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionVolume weighted average price percentage. + ReferencesNo definition available. + Details Name: BTCY_VolumeWeightedAveragePricePercentage Namespace Prefix: BTCY_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares. + ReferencesNo definition available. + Details Name: us-gaap_CommonStockOtherSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDescription of conversion of original debt instrument in noncash or part noncash transaction. + ReferencesNo definition available. + Details Name: us-gaap_DebtConversionDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncrease for accrued, but unpaid interest on the debt instrument for the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_DebtInstrumentIncreaseAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage price of original principal amount of debt at which debt can be redeemed by the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentRedemptionPricePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of accrued but unpaid interest on deposit liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_DepositLiabilitiesAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 405 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478790/946-405-45-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_DividendsPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of dividend distribution from ordinary income and capital gain. Excludes distribution for tax return of capital. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_InvestmentCompanyDividendDistribution Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe parent entity's interest in net assets of the subsidiary, expressed as a percentage. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestOwnershipPercentageByParent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share conversion price of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionPrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockLiquidationPreference Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards

Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11 + Details Name: us-gaap_PreferredStockRedemptionPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAccretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends). + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityDividendsAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_PlanNameAxis=BTCY_TwoThousandAndSixteenEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=BTCY_TwoThousandAndTwentyThreeEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_SeriesCNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=BTCY_SharesToBeIssuedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=BTCY_PurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=BTCY_BeneficiaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=BTCY_ShareholdersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=BTCY_ExchangeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=BTCY_SeriesCConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF OPERATING LEASES OBLIGATIONS (Details) - USD ($) 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Operating Lease Right-of-use Assets And Lease Obligations Â Â Â Operating lease right-of-use asset, beginning balance $ 1,221,593 $ 1,587,492 Â Right of use asset, new leases Â Right of use asset, amortization (198,275) (178,320) Â Operating lease right-of-use asset, ending balance 1,023,318 1,409,172 Â Operating lease liability, beginning balance 1,386,486 1,722,095 Â Lease liability, new leases Â Lease liability, repayment and interest accretion, net (219,283) (190,864) Â Operating lease liability, ending balance 1,167,203 $ 1,531,231 Â Current portion of operating lease liability 493,190 Â $ 457,371 Noncurrent

portion of operating lease liability $ 674,013 Â $ 929,115 X - ReferencesNo definition available. + Details Name: BTCY_DisclosureOperatingLeaseRightofuseAssetsAndLeaseObligationsAbstract Namespace Prefix: BTCY_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOperating lease new leases. + ReferencesNo definition available. + Details Name: BTCY_OperatingLeaseNewLeases Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepayment and interest accretion. + ReferencesNo definition available. + Details Name: BTCY_OperatingLeaseRepaymentAndInterestAccretion Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOperating lease right of use asset new leases. + ReferencesNo definition available. + Details Name: BTCY_OperatingLeaseRightOfUseAssetNewLeases Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION (Details) - USD ($) Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Mar. 31, 2023 Operating Lease Right-of-use Assets And Lease Obligations Â Â Â Â 2024 $ 552,293 Â Â Â 2025 600,288 Â Â Â 2026 565,359 Â Â Â Total undiscounted lease liability 1,717,940 Â Â Â Less imputed interest (550,737) Â Â Â Total $ 1,167,203 $ 1,386,486 $ 1,531,231 $ 1,722,095 X - ReferencesNo definition available. + Details Name: BTCY_DisclosureOperatingLeaseRightofuseAssetsAndLeaseObligationsAbstract Namespace Prefix: BTCY_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.3 OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Details Narrative) - USD ($) 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2021 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Weighted average rate 11.40% Â Â Operating cash flows from operating leases $ 218,448 $ 282,209 Â Selling, General and Administrative Expenses [Member] Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Operating lease expense $ 292,787 $ 140,759 Â New Lease Agreement [Member] Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Lease deposit liability Â Â $ 85,000 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 25 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479341/842-30-25-3 + Details Name: us-gaap_LeaseDepositLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash inflow from lease payment, classified as operating activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479016/842-30-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479016/842-30-45-7 + Details Name: us-gaap_ProceedsFromLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=BTCY_NewLeaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Property, Plant and Equipment [Line Items] Â Â Cost, beginning balance $ 29,767 Â Additions Â Disposals Â Cost, ending balance 29,767 Â Accumulated depreciation, beginning balance 14,215 Â Depreciation 2,977 $ 2,977 Disposals Â Accumulated depreciation, ending balance 17,191 Â Net book value, beginning balance 15,552 Â Net book value, ending balance 12,576 Â Office Equipment [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Cost, beginning balance 16,839 Â Additions Â Disposals Â Cost, ending balance 16,839 Â Accumulated depreciation, beginning balance 8,042 Â Depreciation 1,683 Â Disposals Â Accumulated depreciation, ending balance 9,725 Â Net book value, beginning balance 8,797 Â Net book value, ending balance 7,114 Â Leasehold Improvements [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Cost, beginning balance 12,928 Â Additions Â Disposals Â Cost, ending balance 12,928 Â Accumulated depreciation, beginning balance 6,173 Â Depreciation 1,293 Â Disposals Â Accumulated depreciation, ending balance 7,466 Â Net book value, beginning balance 6,755 Â Net book value, ending balance $ 5,462 Â X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment. + ReferencesNo definition available. + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAdditions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentDisposals Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3 PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2022 Property, Plant and Equipment [Line Items] Â Â Â Leasehold improvements Â Â $ 12,928 Furniture & fixtures Â Â $ 16,839 Purchase of property plant and equipment $ 0 $ 0 Â Depreciation expenses $ 2,977 $ 2,977 Â Leasehold Improvements [Member] Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Furniture & fixtures useful life 5 years Â 5 years Depreciation expenses $ 1,293 Â Â Furniture and Fixtures [Member] Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Furniture & fixtures useful life Â Â 5 years X - DefinitionThe amount of expense recognized in the current period

that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_FurnitureAndFixturesGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depreciation of additions or improvements to assets held under a lease arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_LeaseholdImprovementsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles. + ReferencesNo definition available. + Details Name: us-gaap_PaymentsForProceedsFromProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.3 SUBSEQUENT EVENTS (Details Narrative) - USD ($) 1 Months Ended 6 Months Ended 12 Months Ended Nov. 12, 2024 Nov. 30, 2024 Oct. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Mar. 31, 2023 Dec. 21, 2021 Subsequent Event [Line Items] Â Â Â Â Â Â Â Â Â Debt face amount Â Â Â Â Â Â Â Â $ 12,400,000 Proceeds from short term debt Â Â Â Â $ (1,125,116) $ 773,737 $ 853,030 $ 1,476,121 Â Term loan exit fee Â Â Â Â Â Â Â Â $ 144,953 Subsequent Event [Member] Â Â Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Â Â Unsecured convertible promissory notes Â Â $ 150,000 Â Â Â Â Â Â Debt instrument term 5 years Â Â Â Â Â Â Â Â Proceeds from short term debt $ 635,000 Â Â Â Â Â Â Â Â Debt instrument interest amount $ 945,000 Â Â Â Â Â Â Â Â Warrants shares issues 600,000,000 Â Â Â Â Â Â Â Â Warrants price per share $ 0.50 Â Â Â Â Â Â Â Â Term loan exit fee $ 1,425,000 Â Â Â Â Â Â Â Â Subsequent Event [Member] | Series B Convertible Redeemable Preferred Stock [Member] Â Â Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Â Â Issuance of common stock, shares Â Â 1,197,770 Â Â Â Â Â Â Accrued dividends Â Â $ 233,441,000 Â Â Â Â Â Â Shares issue Â Â 100,000 Â Â Â Â Â Â Consultant contract remuneration Â Â $ 26,000 Â Â Â Â Â Â Subsequent Event [Member] | Unsecured Convertible Promissory Notes [Member] Â Â Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Â Â Unsecured convertible promissory notes Â $ 169,000 Â Â Â Â Â Â Issuance of common stock, shares Â 492,000 Â Â Â Â Â Â Â Â Debt instrument term Â 18 months Â Â Â Â Â Â Â Â Convertible discount percentage Â 20.00% Â Â Â Â Â Â Â Â Debt face amount Â $ 15,000,000 Â Â Â Â Â Â Â Â Conversion price Â $ 0.50 Â Â Â Â Â Â Â Â Convertible discount percentage Â 10.00% Â Â Â Â Â Â Â Â X - ReferencesNo definition available. + Details Name: BTCY_DebtInstrumentInterestAmount Namespace Prefix: BTCY_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: BTCY_DebtInstrumentInterestRateStatedDiscountPercentage Namespace Prefix: BTCY_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482090/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of the fee that accompanies borrowing money under the debt instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentFeeAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_Dividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from borrowings supported by a written promise to pay an obligation that is uncollateralized (where debt is not backed by the pledge of collateral). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromUnsecuredNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=BTCY_SeriesBConvertibleRedeemablePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=BTCY_UnsecuredConvertiblePromissoryNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&9QM08K%$7^(XDA%^\;CF,M+I\$0.B&F6GD9 M#!V?D48=MN.H"9/8&1,DY!/,YZ@(89/)),KS@CY3 +UKI?E:9@J5#2J6/'T- MR#4'I%-FX/@A9MU6:C ,F>\Y/ND)]"978F?7^U>DPU?.,@(U<"4N?[I
=4/J MM W;0&M:)79>O109-/EB162HE\"<7@-W>AB[W>9OL M#$G@]2H#4'$OL)%NW MTEC 0@S)ASA:\6)QE^_3_49'U4G4"1G1!*+)#C1";WW4=$OL?-N6,XW,&]'J M-$J)$X0,:RDW6%(O#
+:DW1:4RZU4^XGL82LQ_$+6FUYQE,EBA;3F(N^,=-4 MI]/ QX%6X6_;M7'7O$OMO+N?B15,SPQ39\X0,NR$735N,@Q!@+*$>BJ6-]:6= M8G]@)E*=3(D'F'V_B]I@Z##7\WHZ-ZU9E]K7BI:Y:$3,-
""P@L"$=0'E=B$- M">E1";1F3&IGS)V0>4,C4)WHF$-\ZFL-PF3IAB1TG!['!2&M.I*Y5SWR^^O// MR/K[/[?1]!66CUXS^%(WMH!UYQ)[9PYAPD !7^!FFK@#MJ.2/A. M&(A' 0T3U("2BV]#*],@
]LG0$X^W8HB AD J*Q0#5L%FB'Z+YCSO%#; M<[%1(GF%=GKIE*I+#[S;+';Q0-8=F3;T2Y11B_#)&#W=**>NZK8] FA;HJ M%WA;E2LX*,K_AR]2S?#0/,,-Q$\#C^#N>M9@"!01@ 3OJ<-:(5#?
6H?S^R_3 M/W[_ $O\W='GU:3:=7=U,S55IE1P'5^61O+7#K\4&M8N-J4P2 MF?:7'*PAAZ##BE]SZ7%EJ(KAFV5QBF;F0EM4@,IK?424#@./#:E'2LMPR%PV M]+V@]]+OJ/IR5?
U]L>;I2I13KPH,"ASR.O1\VBW']'N2O?1U[459N9?;+GS= M+'1[>(:-0NT.:[B)5$#^)URD-;'P+9EV$QB(7Z7B,SBT:A_'A*/MAS8M10 MH2[3^-Z@ [T0>SUI8;4*9'85.%DNHX+
<0;QN>+0\B=*3!=]$(&:-&\;&O13L M! XEVFTTF(:N#S<\Z!%6K%: S*X 89&\3;9Q^7ABMR4'MPIZQ;IXI@1JZ]=8 MYOD'-$)1"E\$=[N8KOI.?) $W2YLL&.4^3TJB]7:D-
FU83.$I7B,%I%Q/RVW>QDU+UO57Y_+%F7L-W97AS+YL;RU Z_U)?..+&285; >'/Z1 MO+7#KW4?!M^A(MWMH9J$4'"X]=H585Z!C1IO M/Q2OGH
N6T5ICF+Q"&/PJ0_EG>W>YMB=*+DI7XAXD$K)I#Q<"[P[5AC]X\2 MI%MU4KQCL7^G9OP_4$L#!!0 (%*(;ED=@P:T&P0 .<4 8 >&PO M=V]R:W-H965T&ULM5C1CJLV$/T5BU95*VT7<
A)MDFDNZFJ M]F&E:*/;/E1]<&"2H 5,;2>Y[==?&U@(,3&PRMV'C0TSXW,&/&?P_$S9&S\ M"/0EB5.^L Y"$^VS8,#)(0_T@Q2>6='64*$G+*]S3,&),R=DMC&CN/;"8E2
M:SG/KZW9P/KE/*PIA]SBSPC. &*,%)4MI6]]\D>XL!R%*((MA I!Y,\)5A#'*I+$\6\9U*K65(Z7X_?HO^7D)9DMX;"B\5]1* X+:VJA$';D M&(M7>OX=2D)C%2^@,<__HW-
AZT\L%!RYH$GI+!$D45K\DB]E(BX<7.^& RX= M<%^'4>DPRHD6R):OQ)!EG-&SX@I:QE-#?+=B37QCS0UDCVCD/"#L8*_%?65V?R%,NKMM[K9D7Z4 5RG >3SO M1KRU?'& ,T
98>A$XB.T42MB^7DLM4=.2^?1<=RY?;ID8%Q1;QS8":SE#]^YOO.+@<^HXC,:QJ=X3H@,#QN36T? MRP9JOT+M#T;]@"+.C^V0?0T(QE- A/WK'.N&L]%X-/&G[7@G%=[)! _!*%>*" MI&&4[MM
3_J"U@V-H*<5Z.D T%162]87^E1_\+[C3_ 5\$ZS!NY9A7O6&_?[M&RTHVH+A!9GI2&;>;#:] JR;C;"')WX[8->I1(V.>]_7R#9 ONG58N, MH?K7XE*:[A2M2?
Q"K=T[:E49K*M0=IHUP=:ZZ@X4UE[EL@S:V)ZSRTH-V54(UJ321-M+9VN63LW MP"()[EFUFB=@(MK&@%XA!/EEHH:#=K5QJ<&[^D[1FHFIU=DURW.5F"!/3)X7
M5N6PCI1C<)X;H!P.8&H"3T:5#-.,<< M6C/N%:V9@;H3P/?L!'" _3J#3K GVX@O[6W0"6!=XW/+5U&G6!%UW ?C>70#6 M)1[K<'4C?^1X-]#6K0#^)JT UG6^!;)NU +9OCB%4D>
+X3MHY2C&';2S7F< M2']6G*H5$T&S_&!J2X6@23S\ F!*0-Y?T>I>)^HLZ[J;'/Y%5!+ P04 M" !2B&Y9?5*J"/ ' 1(@ & 'AL+W=OM[;8@-TK6;OO(P5B" M*G<4"-
Y$W9$P("TBFAIU#&E2[C1MPK1VO+35OO7ZBT4J]R?:H@ZNDS0/_UT> MA:H*0'X;)[DDUC<;=<&'#DZ3@KM""%48!&BYMJD5! Q(35ABU%:%P9#4XC9O MRHG:>-
)VYSE)4WM5VFY6;P/0Y4L$!^.O9+N! M7%DD\4Y"ZKQ$DFS29!UF69+^06(0)3M\F7TD62J7VV]U)OI(I9%-YP/QR6%I?VP5 MK*C-J6HT$!BL%LZ%MJPPH NN1%M5&)"YKMFTT]8FF+9:N][8GY-
RLQGX-Y.I M3T;CX>3!) /^KPV[K8.52)LZ:C$=8D@.V2),308$:3'+9FK!%C&D]([$84WI M4)M0VNY"#T\:\N!G53LXG@2M<7"O3+#3P+D"]>><*Y)\AT*GZM>>E[:9734-O
M]#SR_+&'YZ#N.YMR$$$VY"""';,A!!-F:@ZRVO:S=]CZF\E6F:?DP-%G\(%ZX M"YVV MUY-R#>PKWJW5N#W6_[0SQ7(8Z@;AQ.A6OG],W1Y*G'MK%F[LZY66G\^GXX& M3_/^X!([J_81
W7^8C,EL/AG^XVYR[_E3=/$QS/G:%C>8JR8>@N1"4*8>2ST, M":Z,=+/^US?+BU(U*@'E*#!C0LQ]56G@X$')RY&\C7WIK]%V\]>7B<^G=PR!X]^V5^H,3U M)ZT7U!%
2#UR84AN&X:A5Q*$'1S#H:JM\C&DPQW'M)KFOG;/K-T]EPL"#MID M=M>?^M_(H#\;#5$%]G'LXS$8WPWU$#W$<::I/FIHP-GJL0"B:/2?,J\=L&L
MW06KS+W1_=/<]U#N]B>YHSB$.X[3N:.X9NZUJV7MWO<7?W1[!V1)_]F?]F?] M,GYZ&(4DYNJ&!:BS,CD:3Z;]\=>\2CJHB4Y='?*F.ERFVF%04<*Q[4NGOWTZHP^]?EG@(MTK;(N/ZYDL)1I
8#O7Q/P38>+ MHH/J+9#>?P!02P,$% @ 4HAN638"V^X9$@ OM(!@ !X;"]W;W)K M3??#QHH/GP,R+T 0+W'TZG.S M_;B[K^O6^<]ZM=F]OKIOVX[?
N[?;F5?/8KI:;^NW6V3VNU]7VRYMZU7Q^ M?<6NOO[%+\L/]VW%]VV^W3]3%OLU_5FMVPVSK:>WWU M(_NA#&1_P#[B;\OZ\^[%STY_*N^;YF/_H5B\OG+[%M6K^K;M$57WQZ=Z7J]6
M/:EKQ[VT*OGG/V!+W_^2D_W)]^=S/MJ5\^;U=^7B_;^]55XY2SJN^IQU?[2 M?,[KPPGM&WC;K';[_SN?#['NE7/[N&N;]>'@K@7KY>;IS^H_APOQX@ NCQS M#P=P_0!^Y #O<("G'Q =.4 <#A#:
9Y_Y !Y.$#]!P1'#O /!_AZDXX=$!P. M"+0#F'?D@/!P0*@=(([EB X'1'J3CITT<[_^R[E!3W]D^_U$E=M=?-JVWQV MMGU\Q^M_V(MN?
WPGD^6F[Q_OVFWWVV5W7'LS;S:+3NWUPNE^VC6KY:)JNP_O MVNZ/KANT.Z>Y;/SLSY[5WL_.GW?WYUW7:M[7->WQY:]N:I9?Q(R]YV M':7>;NM#)NEBVW6<+-#'T!_>N\<'YLV^WR_6-;
MO5_5?6O?=LW>M#9J9J?^4K?=0-N=;5)M.Q5\V-E8N9WU:].=(7%8<>+:U]ME M=^W?]"K]5& ;97]NO]2+NKM;]#].$$MISV1HG49==_WLN;/QY\[&]VQQA/VF
M6E6;V]JI6N>G:ON]X['O!.YRC^H<3Z1@3^IOJ$665@O M;C^1^&'W4-W6KZ^ZF<*NWGZJKV[^\#OFNW^A5 """*3KPGG7@C=']=\[N:4@9 MHX)#88CV'B9<[1<(R)"Q'P@HDK 3! M%
(F*9XD*JT2?AM%^YKEP;IMU-QW?5?L)[!./FX9A=GI#LN71!,D?\YEJZT2O?7;;79 MK9[46BW^UE*\Y(=URH M()@B5/]9J+Y5J#_7K;-J=KON>>*NV=;.8OEIV3V,+79.]]%I[VOGH9OV-@M*
MNE;R!.F".#&(DX X*8B3^88F9P%SO8!S;1H[-K XHV7'Y0N"*?(-GN4;6.4[M/'/M]I.%9_E2>K6B)N@5Q(E!G 3$24&<+#!EZ 41\[0GOGQD7'%&NXZK%013 MU!H^JS6TJK5?L-D_?
#=W_82V7Q#:RY82JY4T0:P@3AP:C\A2>S!/OO/>R2+. MM>?R%-2B#,3)Z68;3_YGI#NN0A!,46'TK,+H+!5^70J@U&@E3CSY.1(61_ MG@P"H2U!)N8/!X(Y=']Q7/WSO>.[Q1:X#RK;] M282$(6/:
A<11:U['L)>*CCR/"_D7'OH2(G(F0B\4%_XI.(8=UWI^:&OW8.I M6.X'/'()+;2P7^.I@D#15$6\L)S8U.7/T\|@8]8_B:M.."X7H:X/,Y!8 ;6? MQ]2A"TK+H+0<2BN@M!)%4]4Z>#9LM&E3/FY.J/2T:T.$$+8-
$46.7YP8OUPI M?7U^F!*1,X^'OCY#S*A QGP6<.$*?0 C8KDG^G"A#V!0\P9%4R4QV#=LLG]S M6AJC#!PB:N_@Z(Q4@-8%
/!TK+H+0<2BN@M!)%4]4Z.#GLSLB$Q3D)+9]J4+W#!G^'7<[@L:.GJ!AE\:! "0J4 MHD 9(]P;SX_<4-=G/CJR.*=Q%B5?PNEA@]7#@%Z/G35%NBBW!P5*4* 4!2PR!5"-RC'!A;G-,TBW$N8/FQP?
1C.]K&CINCVM&$3HY(E;*3U@3TJ8H4#Y MD98;[L\Y"2V"O(3_PP8#B.$=(#MRJ@7$1MDV,31I J6E4%H&I>506@&EE2B: M^O;[8 5QG!7$3UM!1 AA!1%1Y"OPHZT@(I*T@JBX8U80%7O$"K)?
X\FOP5_" M"N*#%<3Q5A ?90414;051 02*ZGV\Y@Z?D%I&9260VD%E%:B:*I:!RN(G[5_ M1Y J';&!A]AV8[R7'1-1O'O@] V%$EZ0#+CGAIX^@)F1'O?TO3X9$=:-7T$W
M=@;Z%"VG8CTF?!EX@3Y^8;?Q7,(}XH,3Q.U.T*_U^]'95MLO3KW?+79L2P\M $:3+,(?28B@M@=)2*"V#TG(HK>"FR\)UCE^B4JI=8+"7N-U>,KO IVKU.'*0 M1#H4>$.R7",-
+GT<4A,#@56(X(5+4[F$K<;BJ=V(A) M:]9T,JCIIQG5W=N%T)>)8R+0$X('OGY[1QHC*92606DYE%9 :26*INIU,)2X MW5!ZN7BT?MZH7A\VJEM\?#MW\D"+I,506@*EI5!:IJ7EYJ"H==CB %+&5S?
D MQAI).2)0%?;@+W&[OS1*V+8E4CM_LL"1M!A*2Z"T%$K+H+0<2BNXZ7\9:WLE M*J7:#0:WBD]WJYYF)G?;9MU-3V;M?3U;5]N/=>NT_1LQU5.9J5%=!&FCS+EI MWD0!L?]*3)I
:2F4ED%I.9160&DEBJ9VDL%!XW8'[:D$T+ &W6W6&[:1NL\ MUID1U%L[T-1'%7T)X;F3+CIYXE N+JAET*S9E!:3EPW$4@1Z-M1H5E+%$TM 3C3889[=#CM?
R+9AWIYTJJ"AM!A*2Z"T%$K+H+0<2BL\PFR4^DP(E5+M&X,Q MZ-F-P0OU#:0;-?=,Y[?[+FO61XQ-&T"I:506@:EY<0%)N:8!1VXZ,J4U(MY8A 5:Z#,^C9G4%5K@_#VY)/VCQ7KH2KYC-]&]:<"
LCR5E@E'U#6F\)E)9" M:1F4ED-I!916HFBJ\%]4,K0;H*KP;U]4Y]QT^K8JGU0\U!(]T)39N"=T@YV(M\D)?N'J)#<\TXUC7SX2O]<<4>A(9E)83)\MYZ'6#A3ZH8DL97L*C] :/TK-[ME-
^@4NOX#+4O/<(X\X0(W$@7K!G8J374A9U FY="':1F4ED-I!916HFBJ] >+ MT[-;G"^7%+^N)39;IT^TO#TU&B.]L_F!IKP19^+IIFGBF:2H]HU)@ M"FU_!J7EQ"ET,UO#)(F-MR]M6K2.N5
GTS.WTC@_IV7W. M;RE)84=/[@5(6@RE61ZU/TZ&OF[L0+-F4%H^\AP*:-8215/E/3B4GMVA'%^K MP@Z:+&9H=4Y'IZ+<5\;& !;5^)HJF*AQ)87506@&EE2B:JNL7 MWYQF-QN_^25N4OA0J_%
4W:>&R,T,F,B"'.32\8C?1B'NHQ06DZ?@U%IJ8!F M+5$T51*>"%R]PALT;8FBJ0(=3$5QIJDXRF\A10JU&(7I'3+3883F3(B<41@9 MKS2ET*P9E)93YQ"YQCD4T*PEBJ:*>3
/A=T\C.M.L@LG/BP_V&4*M0.AM!A* M2Z"T%$K+!/5-;JX4?JB7CAT=64!;6*)HJJ0'KT_8O;XC1=_(V@K"+)S)]-F! M&<*]4/+3PF2X%*O1I0(PI]R12XTYI3H+/*$';,JH..;YS&7,U>N^4;$> M8[X?
&M7<[9=YLB@NX9")P2$3)QPR2]VDTRJ!FF906@RE)5!:"J5E4%H.I16" MV!*I=Z@2E5+]DNK!59-V5\U2-^ED#["CI_8 *"V&TA(H+872,B@MEZ;SQGG8
MW3;T&X$D"II2@>6(0%6[@UTFOZEL)ZU9TX;AKGYWIX*ZN7L7>?2]:+!')(A'I MRUB) 4PF"PAJ84%I.9160&DEBJ;J=3##Y%G?X4;KU'2F#)42)3F9;VPL(L(\ M&1G[.1)I6ES=')1[S
VTS"D1*F7D:V$9$3;K]Y*(T VT&7!.Q?(H"'(_TI]+ M[%=YLB8N83_)P7Z2YY?N/"T2J \%I<506@*EI5!:!J7E4%HA3<]0F'?H2SA5 M4%H"I:506@:EY>?0R+?&I%FVDPL>ZL\A MI30=-RU.E?
7@:LD+5_>T\R?+&VIU06D)E)9":1F4ED-IA33--?T[7$I41K47 M#$:8_*;BGH>?V\9Y7SO++K:VV[_V;)/[!&&KZ:_\QT10[U8%^D)!(DU;JXN3 M^HLH*?0<,B@M/X=&#[]0XPY%4T4\&'=R^M?
7C12Q=8"'6GK2M'JX&(2Z_&(B M;D8%)M#FI5!:!J7E4%H!I94HFB])?S#L_$N5ZZ04;TV5?&^:?4P-]*+,4-S M)CYA6 GN^_HKD]"L&926D^?@&4_G!31KB:*10A[<.___45O3GG2RH*&[XJ"T
M!$I+H;0,2LNAM,*G-N+IDW142K50#$ZA/Z60YSL-L!U"'UB=J;W?S&U>N(Q-"T M"9260FD9E)9#:0645)H:O\87%+?[I*"2]S:LTWN&%#O4B+'*H6^N;/J&@1 ZU8:&T+$K+H;0" M2BM1-+4O#
(:M?[DJI7;TY#X K5(*I26^Z?5*/PRE[@) K5XH+1]W"@4T:8FB MJ>(>C%P?5:/4#IHL9>AV2R@M@=)2GRH6RB-/+W&60=/F8],6T+0EBJ;(.1C, MV>!R-4KMZ/%O>LS/ 1W7-I260&DIE)8%1-
%1)GT6Z&]3YZ,C"V@+2Q1-5??@ MV ; \J1VUM3Q&DJ+H;0$2DNAM"P@S,Z(<7VK7CXRKH"VKD315#T/+FLP>C_F MR7W#P>G]F$0(51.$(E$U0:BX(S5!B%"R)@@=5=ZPF2$ X?
4=J@M@O\V117&)# M9C#XD,Y&S)/JP1J-T)I,9260&DIE)9!:3F45@3$ADRC)@@JI=H%!JLQL%N- MWU(3Q(Z>W .@OB*4ED!I*92606EY8/JQ=$V0L8'EB$!5NX-M&$S>:WE:LV/V
M6E)!=$T0(I*L"6(_D\D"@MIX4%H.I1506HFB/>GU>G=?UVU&PO=V]R:W-H965T&ULK5Q_\]$IRKJZN#X.*9 M53_J-:4-^EGD97TY6S?-YGP^KY,U+>+Z(]O0DO^R8E41-_QK]3BO-Q6-T]:I MR.?
$,)QY$6?E[.JB/79775VP;9-G);VK4+TMBKAZ^41S]GPYP[/7 U^SQW4C M#LRO+C;Q([VGS??-7<6_S72Z0>#_^[D%GNS:%X_[G5_2P/7E^ M,@]Q31.UN7S%"RK1M6
M],Z\!T56=G_CG_V%V'/@.&H'TCL0V<$ZX&#V#N9;6[!Z!^NM++B]@RT[. << MG-[!>6L+;N_@MF1U5[>E)HB;^.JB8L^H$M8<37QH^6V].2-9*4+QQJGXKQGW M:ZX6K$QY8-
$4\4\UR[,T;OB7^X;_X1'7U(BMT"*NURCD45NC=]_+>)MFW.8] M.D/?[P/T[K?W%_.&=T4 SI.^V4]=L^1 LR;ZS,IF7:,E;SY5^ =Z?^>8?ZCW MQT0#,.?7<'N%_$2TB/=TQ&9Q@=$#&
(I.K1XN[NINA[_K/7E/VL]U+M_ MCBONC@^V'KW=W=108>YBVFSQS$,Q?7W .PK_^/+7/0]_?OF,OMPMOUY_N[F- MT/7BV\V?-
]]NEO>]D.U0+36JF!/.ZTV[CG"RL2VE"\BN14!@(W+=';FNEMR;NM[&94)% MG5JO8]X &QLT))K)$J,YUK 4SF&! O<"7D>QD2:/)._T"12#7#(KD= 8*,8 M\'8QX+TY!I[CJHK%W'$L"K20IT8!)%CP"V
J?I= ."'DR45 8*,X\7=QXFOC MY#I)*MHI(&6*XH)53?:_=BI]*>8%M21XD]3JNE[8FF'+ MLQSL2*-<88=MTS%]*9-K3_E4=H# 1NQ@8] B#"T_BW5YMMQ#*?!P5O+*%O1H^S02WW7E7/
6JQ"T9Q$4VICK04[# M1_0T5IZU"DU.^<+[-24HZ864KA:@:$&/-JXG/.+:,L$*.UX,R,5?"-J[" IM M3/$@U&&]4M>5: 6>_,8S?5S7E*^^Q C?]J64HAP&5>5 T0)0M"4H6@8*%D&A MC8-
HT.:P7ISC:S*V%>MU@507N7SXO&#D'>5 0.JSH&B!5@AO/F>*\MS"K,S M"V-+OD,0@O8N@D(;DSQH=/B(2,=K_[+ABP$EJZ!Z'"A:@*>*G(,]:U+K3\V(MX7EX0BJHY :%-B9U$-
VP7G4+Z(;569_K65OX#V-8O3H'U=Q T8(>;30PB6-C M7U9?%8:FY9FR'!2"=B^"0AMS/0AG^*ARUF7I3?PBZ.T$M"2IMC0]JLE *E0+ M4+0 *U0V Q/'MV36588.\?V)Q .JQT&AC;>T#((
M_X_Q"'K3@:(%9"K 8=N@T,9\#V(=T8MU=Q5+*$UK MM*I8,;J/D](OG+;:GD'U>] T0(RU>4<8CFVO,U.88=]U[5=N;P#[5X$3A F M?1#PB%;,D6BOUZQJ4$.K N4L[F[3R;?
Q#@YV6;G;W1;P8CREI6HK M_"<]U,G<@,IF1*&'8<^8,J.RP[XS8094-H-"&Y,\R&9$+YOMEE]&IZ4_3P M@E99R:?F-RS!0&4U4+2 3/4R;)H^D=/M4F%HN6+7XV0!!JJL0:&-~>1^4-:)7
MU@3O[[(RJ<2ML_=\#NX^B05X&P[IMA+\-VN*^'H\8^I1#RJV@:(%1"&VV38Q M)EL=%8:VZ5C>I!H#%=N@T,;T#V(;T8MMR]6*)HVHO5>LHMDC9WW+4WV9O*"F MBLLZ/WBG7
]\,N>@4AN9*FAGCN&Z$\JG=CPQ3%=2H#H;%-KX>:5!9S./;'SC MH_H#>]"/65F*D2V670<'MA[KY.>40+4U @N5'?9]ETB#(# 5>]$4@$N5G0HP
M5+2LXB]2V$F\C*_D(!^91*L]WF\WF[Q]C3.49K52D3#*OE2EM8-VL29>C3" M/N\)^\"G0H8BIGA$4![9"D,^#AU9H0Q!^Q=!H8VY?0J4Z]7?8M_JA<]>K^3 M.075HGX%3;EU% HH!#V_"
JMBXGYWCL-"EH]MJ^K$-O(MV4C&MD[NGLEQG7[M(@CI^"<\OL"*XP$^7ZJ.A_@\ZEZ$,33;O9?C.45L*_[YBK'G](AK8O7#DZO]02P,$% @ M4HAN61;O/WN) @ Q < !@ !X;"]W;W)K"
A*I"41]MC"%HM @=8P_#=-J76KAX7A/_VQB5[$LB8 I M*W[FJP0IA?M*MM?=M"R49(5C9B=8(RI_67 M/#1Y.! H3K? ;03N4X'_C,!K!-Y+/?P-B'^IAWXC,*'C.G:3N)A($H6<[1#7 MUHJF!R;
[1JWRE5/]3A:2]]UU&#W&;"';AB5F4 SFD+:H8]/ZX,3>JR";"-UJY%.W)/ M!50]Y-D?D&N[?L=YIB^7>UWA_)_WV:N]'R7#:Z_=,SSO5=?^ZSM9%O"[Z])K MK-^-U45M)"J2P-A254L
WX(5O7OC!/:GKHR?$Q:?$S8[$^SH;OSV;OQ3].B; MZ@[7-&$EH(NO3(C./U^-&!B$[@7;Z-+I!\&@&(9X>YCC#D,O^&@/??O8,.XP M[+=F]$]P!T^(.[0U&PO=V]R:W-
H965T&ULG97!CILP$$!_Q:)23[N!$)}4 M:4!*MJV:PZZB)&T/50\&!K#6V-0V8??O:QM"TRIAI5S -C//;XP8E@T7S[(M4.BEI$R&3J%4M7!=F1108CGB%3#])..BQ$I/1>[*2@!.;5))7=_S9FZ)"7.B
MI5W;BFC):T4)@ZU LBŸ++%[70'D3.F/GM+ C>:',@ALM*YS#'M2W:BOTS.TI M*2F!2<(9$I"%SFJ\6,]-O WX3J"19V-D*HDY?S:331HZGA$""HDR!*QO1W@
M2@U(:_SNF$Z_I4D\'Y_H7VSMNI882WC@] =)51$Z'QR40H9KJG:\^0I=/5/# M2SB5]HJ:-C8(')344O&R2]8&)6'M';]TYW"6H#F7$_PNP;?>[4;6\A-6.%H* MWB!AHC7-#&RI-
EO+$69>REX)_93H/!5M]/&/F(-!!X)2P'*V$P"P'>Q*+EVE M=S!Q;M+1UBW-OT*;H$?.5"'19Y9"^F^^]UZ/?^DM_8'6 7NH1FCBW2'?\X,! MWJ0O=V)YDRN\2V7>H?
@5;5A*CB2M,44_#SBF\.M2]2T\N PWW\]"5CB!T-$? MB 1Q!"=Z_VX\\SX.J >]>C!$CW8U!33VXNG]^%P?K5)>J?\N]4=!F:82A@0 MF_9BTT'.$V?W-\@-0]^2F_5RLYM.[0!"?
TWXBMLP\RVW>>\VO_G@AOV&N5?] MW+,^48+(;3>4*.$U4VW+Z%?[AKMJ^\S?\+9;/V*1$R81A4RG>J.Y?IVB[8#M M1/'*=IV8*]W#[+#0/PT0)D _SSA7IXG9H/\-17\ 4$L#!!0 (%*(;EF[
M["U(X0, "T(8 >&PO=V]R:W-H965T&ULC59M3^-& M$/Z>7S'R22>0N#@Q.7J%)%*@H%()B C7?JCZ86U[!7K77=W'9"^ZLG4'K M@.Y+O"\SSSSLC.9ML8^NQ+1PTNEM)M%I??
U>1R[K,1*N*&I4=/-VMA*>-K: M(G:U19$'I4K%R6AT%E="ZF@^#6=+.Y^:QBNI<6G!-54E[/82E6EGT3C:'3S* MHO1\$,^GM2APA?Y[O;2TB_[,&]B0U MYIDWM_DL&C$A5)AY1A#TV> 5*L5
1./O'C/:FV3%M^L=^DWPG7Q)A<,KH_Z0 MN2]GT;<(F5B4$G=?<5+'X4MW4K2_/[Q=/WQVMX MN(&'Y??CXNGVX7XUC3TA\WV<]2B7'4KR#LH9W!GM2P?7.L?\O_HQ,=K32G:T M+I,/
5=8#^%T= +)*)E\@'>Z= _,TX)V^@_=@'Z'E/X(KX02NC'9&R5QTA:%S M6%ITJ'UW8-9P([70F10*5G2(5(7>P9^+U'E+=?37H0AU!':"?#;.G>UR' 6 MU6S+;C":?_XT/ÄM=?.#>9._>Y"/T\
[BARB'.8Z'@T/H<"F-MS*3?CNXU=D0 MCKA!H%5;N$,O5D8U'$MW GQ[#$>^1/C\Z5N2C"ZN3%4+O0V[\048N[MXQ>SO MCJ$5#J3.C*V-I43DT%"66 T)5K'N>)UR-* -O>X$;D
RN*B*>CY0/(S%]$X M&8*\PUQFE-);KLD@=+9$)Z(01]B.,JEI?Y'C-GN#DA2,;]:.P;I '5!/3@G M;X%3+VQ6!I6<;"I3\P/H.JCT$ATU*5^2*#MNL3(>H3):>F.E+L!AP?*U0K:W-
M3J$$I:^I(E(6T<%:AS!)VC(EO"0TD) M$1KP13K/IFB0/-/D8J:9J:C^^,WV[QQJX#!;N;E2?!<5Q3I=+7&Z & M0!8%44L1-?MJ..ETDS92Y6S@ \C=&6!FW-918P@IQZS41IF"(Q-HH@[.B"QC
M_H1'T7*#CNP0#CWX^$T+)V-%&%2.3#?:=]U\?[J?A8MN!+R*=X/T3MA"4FDK M7)/J:/C3UPAL-YRZC3=U& BI\31>PI+"3H7, G2_-A2&?L,&]O\0YO\"4$L# M!!0 (%*(;EF4>4]]' H *D7 9
>&PO=V]R:W-H965T?c9) ;&CM.X:&$#XVRQ6.P'CL29 M84.1*EEE[/WU>~ZE),NM$Z#%)D-B2([W9.?\Y;)6*XKXR-KP=;6.L M?]C;"\5653*.7:TL?ED{7\F(6[9[*[57LF2ARNS-)I/#O4IJ.SI]P\]N _D;
MUT2CK;KQ(C15)?W#F3)N]W8T'74/;O5F&^G!WNF;6F[44L5/]8W'W5ZOI=25 MLD$[*[Q:OQTMIC^<[=-Y/O!/K79A<"THDI5SG^GFLGP[FI!#RJ@BD@:)/U_4 MN3*&%,&-
WUJ=H]XD'0ZO.^WO.7;$LI)!G3OSBR[C]NWH>"1*M9:-B;=NJT&U M)1R0OL*9P/^+73I[,!^)H@G15:TP/*BT37_E?9N'@<+#QY"L"LU9@QGXG0^SE M.QGE2LOO=L+3:6BC"PZ5I>&W-
Q>+"^N[A9W ME]=7N?AXL5A^NKWXB"=B]V[/.[;/9-QA4N53T6\TDN9I/9_C?TS?LTS%G?_"OZ M%D7A&ANUW8@;9W2A51#_7JQ"](#-?YX+..G;?UX?M=(/H:9:>CM"KP3EOZC1 MZ???
30\GK[_A[7[O[?ZWM/_?BO9-*_',!MG?\6ZN-NJ[-RA^C:H4N J(,VE MC+AYKZVTA99&+",>H.-C$&XMXE;A8%5+^R"V\HL2*Z6L@"NU]!#3U-*%\R6$ M%;HF;OF^K6+M-
736!G7<*"N\-.8AP^ZCDF6M'^RFN[8+)M<5,KK0HH7W7WW M/)M-7G]:BA\7BQN^F[Y^*:0M!8P+=4\9"4G34RVE,T;ZD#VJ>-:>)C_^&+-!@ M$UN-.4&.&U&X$&E,Z0
G*5J,**^_2)I]PFBYTD9'0O=NJXLM!U-([S54R2C6 M4OOLBS2-^O.^(M^F*14[W!;B#P%0_G0DX\C2PNMXL] 6FE70I<9*&(NEWEB] M1B0V9MI&Y8M.LM-(*M"5-D>2VZ&0%&4J7)B1Y.!:WJC R!-
:5SITK'[&D,EDE M18QI.T #(..\>%#2BQHY<^5 M>_5X7QT2+.EA*+9=B 9G"))A?6O1-[3S[0%)JO<:6A&IGU2L$]BKH^^S%E"\/7XJP M99STD9'4"_*LQ7@;A. @^F:93?+C_4.Q,";(32M0R
&\,B6U*0H;@)55 & Q M.7]R1]ELS7;U(F&XC>S5+HFOI.'>3^RE1PC\I$+WA?U3*!Z6/']2Z(,!_LI? ML8Q3\<$;B%1 -[KL2>P"'1,8-2T80M:#;
(RD0TFI*7DY,EU[APK0'94QJ>**K1=#WHI%37I+M8IL7OW6Z/B M&-O-BF? MT65UXXLMB%/K#YD9EGHL2OP154JE$=N?M904Y(BTGG&LPPR-X.^X>%$!>?& M(*?
_6HW[,8K>;BK2$[/IOCB[O+Z[O3R_O/M7=GEU/A97UW<7R^SN6MQJN"".\N[B:GDQ9"NX>7]Y MM;@ZOUS\+)9@-TQIEF)Y<8/+LXO;K/-)O/AD95/2]G\17EQTG" C3K#LB,!+
M\5%:@("[/\QA'7-1.'K(.^"1T>Y:';#=@AR V6WJ^8.E0=1DF%G /'=-+T M'1.WWC6;;:^K%*LF8!:&,$1#QIE>8[WV(PD=TG9O0@XZNI"UCE3MU')/5_E8 MO&NHF!D]6^M
W(-79UH]'QF$\^ES:\Q+39!9-[8,O<-ABV'X"AY5@ >V.[N! M""M,+PK9.N0L%U9QM:EM'WJ*A-KG^T>H_FPJ9OG\X""?3X__A'_[?[M_QP?S M?#*?P+N30WAX?"@ UN.3(S%%
(>^/O3!]EA70 M>DE\&"TM1: VHSKV8U=NO$K4(Y%DRP-:QZ:MN\8D)_[(RXLT\!*P[4H)TJ@, M06#/9X\#?. [?OIT>N V'>85J4*X'#4GMD22Q#'SVATKQ4/@65:]9*X1N]@
MVE^SX+GM8@75\BY.'F)+'EJDL #M5"J;+,^RR>3"?T3X^Q* MQ<=?$_3[,(DSAY9GI U/B#II9:?3R6,D=>]#FXL=D/YLP,[60II=I\ M&"(2_ K3FU^)$R"?FWA(.?PXFL_R@_E,'!XD?
TZ.,->F0,Y!#IXE%B';J2?#U]=56U+BBX,%44G_6:5-UR(S/-$] M)K8 X+4T1ZVH0^![X4*[6[#D>RI#%,!HV 3AP5BXQSL4KW49MO#1.%RW_=+- H!+5E3X-@9;9VPVIHNF]0AZ:-
>VCQ,2S8:(J(JADQC+^ND:SZAY'D0PXT:*! MEV*:68;<*5N2SUP38P53:"P^N!VQ3@Z"C9-:LA.4^CP$JTE]8],+(I/,+<:0LALJ6WJ_(Y\H$*2'6= C^>!"!#H)$$7ZZ-8> MI?
^)!WY>93V$,%7&1V@#$BZ%,$-W'O&]-+NTTY3Q[TEK5= M>TF4LR 4) I"16(-='3=T ^#FF65?*"*E=HT_&8<74Y>,*O9,<4NF=83\^=W M(_ /9\";>IU/*>PO*"!42A/^6(2GBX09=*
(#Z%P"6$%%845O8X[4MUY0Q3U6 MC/14#0Z*W4]4M^6T=@SDQM X$*T*8;SQ"DN8&3C2E9_AM*W@72<,L4SE*:R M,7A369-.&@>-[32V%/%W87$MZ
M$U!7EBC\\"S;!"M"GD_@!%O5ZX??U:XV MQ.FHS[O49]A?L&4H$\&X77H)DFE##&=$>@MZ9LR1A=\STP2IL7CNZJO>X/,I MM&WX(S&1<.R#"6U?]I_AUZDSZ^/Q]-';/"*#;:K,&H-
T&PO=V]R:W-H965T)';61R\&B_U B26+$XK4L$@[ZE^_[ZJ+ MHIQD=A=H#*8C2V3QU:MW7WS[5#=?S5+K-OFV*BOSZXMEVZ[?O'YMYDN]RLRH M7NL*?EG4S2IKX<_FX;59-

SK+Z:95^7HZ'A^]7F5%]>+=6_KN2_/N;=VU95'I M+TUBNM4J:S;O=5D__?IB\L)^<5,\+%O\XO6[M^OL0=_]]G[]I8&_7KM5\F*E M*U/45=+HQ:\OSB9OWA_@]73!;X5^,L'G!'U-_?
0W+?LYQ/7F=6GHO\D37WNP_R*9=Z:M5W(S0+ J*OXW^R9X"&XX&>^X M82HW3 EN?A!!^2%KLW=OF_HI:?!J6 T_T%;I;@"NJ/!0;ML&?BW@OO;=[?WG
MSV7YV=9>GR_/+B]NWK%IZ' M=[V>R]KO>>WICK6/DL]UU2Y-'KPS'K[;O/[M-[^CO7.YO.ZJ]JB>DB^U&4Q+[1)_NML9MH&B.6_AS;,ZQT, MKX<,],:LL[G^]05PB-'-HW[Q[B]_FAR-
?WD&V@,'[<%SJ_\OC^KYM?=<ZL>7 M3V[THZXZK6[TO'ZH"F*ONZ56Y_5JG56;),OK=:OS),#O;9M5>=;D)CFO\V)1 MS#.^JUX7\^1H?)0F?_G3R70Z_D763A9-O8)K*SH+ US1+I-
SX@?=&+IV\DOR M4FXZNSW'1>3K5PI6/ELW19E,D%8F)Z/D$@7 O&[RK)IK7DUN2D&V\",+ Q]I M1[\#\$]+725K@*(P\-=#70/L-8@S.-5B#H22-3H!X"JST$T*5[2U\"O EQ3P
MN$IE*]Q^TBZS%@482B(#?^ED7H-4RW7#2([GY;%?$D_61SJ;VN^O$YF.M& MQ;;$I\#"^MM\F54/@"(IUW61@] -X-36*_+#>!>\1,!7$!)-2_6)?R.J)H@ M!B>O$H $EE]L+&B$W
M%Q_PTRVPQH>'S._CCX~75V=7YY=FGY/8.OOA\<75WF]Q>?(&/[R]NE)5>RD6 M=#X<\$/= &&MC 6T IJ%U72Y@<-;K;H*10.54$9"MJJ\&@0E".+;%Z41;M1
M2/RDVQOX$42<7M<-21I<%\C@46_H>&$=HE4X52#= "AMYDTQPSO6RXT!X9]5 MR$& <-TD7I5WQ<@3&@1P--#59O"*#G;)EMO&.JM@TR9WH2DR#Z#>_PI
M.D$FK.K)*T#/O"M!HJ"\0'EKSS@Q;9=OB)05@/^@*P"D!/H"SF$LD&@OF)#A ML$H03?1X^+LPIF/J(ZJQR" % MH#< 0_;"G>#ST$L*$!: M53-?+6##]1/N$*@/4%YD=$+
PV]PJZ;+# V@4,&28O2:8$R&!A#-P!'"11 M'%8GT*$PWQ(Y9#/B<2:^S-1X 3*# 3F1_T)$&/'5/#83<%':T0H%(1P=Z M9P,\FB(HSDYQYX@=(9O U_U(N%)J\#L %
:=/B02_KG,Z,Y#ILJH:#;4FUIRS6 .M"XO'LR M&A!=9+S PH"(FG6=:>$V(@38*GAIC55B2,F,?;(76*+QHHP\NPO+(B*\T+O) M<76K\V$K0-2X/!^@E^-6OC
W(#EY_G,RUHI.XL$'0*/P@G'!Q<8_[&H1@5$U. .3]1@NVPTH]H4:)N1 MMXOLD"?@JP)WS@!5UN1C00V?]M\DM^=_N_AP_^E"@;=U<_';Q=7]!?Q[?@U^
MU]WE]94BQO3=PG=4'$V2HW1\,L'OD\/T<#Q.]X]/U8=0",.*Z7A_FDP.3].3_:-D_^0X/9P> M)@>327IT N#7+9#9?CH].DI/#HY@Z9/323H]/8:E#XY.TL.34UCZ= *K'$U! MW>*I@:D
*]O/&Y15)/6 @5FIP $A58(1 J* \"N$\IB5J);IZYG&0W0.B B4 M)PK8X%(@=5"AA<)>KD'CM&E0)0,P@(=C;*BQ4;+ED3_!4HGUE\!, M'#S7B;,"+!C8HUC17BJ-
[F%6%K^(3A30A>5# X9%%DE Q1X1B:D*71G\'8Q: MY"!94ZR$=5Z >:;0=,!C3+TJ=#&(D9DVRPD?W30GU"%[^7U4T7W^\T0DP- M]=1F77L=$+C#<+-P.-
BPHS1%PCC0:""$'P>I"MEZ A(&1 3(%OAT? H+3?\ 'O>M-P)5 MYN-7EENW*0PU"*Q%:E=(F742R&#RQ> 3\$N1$UM\9+L2L'=KS3>T)/[5@8'- M-DEG2.+L?B!'A%99SFZ/1'G(L T
7MN)]MFIL"67#'D?Y1[%)UBQ@5,H"=1 M%FQZ%^@&1#0&6A4VX[QVE"KSLD:#G*4O/92-9%R*/,!@-98T\9ZL112Q:Q.(M",#J8U%WHM,+XB^ZDTV0!=@]=6.
<)"'C2KP%0",:I1SZ*IIYMP(F]=AO)AR0 M$<4&'HI9U/#TB^>;5?;5VI#; J7EP$E#F&<.]GA,>IM7SCI"+Q!3)T5)X3GX
MJA+CC+=D0,_8P(R*L47[X9/N(PS1D]$KZ&O\U#C9:+*;N!78PEGF*(;'=H^ M$DIC;T9%AI:]A\W?1PIR% M!*3]&2 W0496B,L0OJIMX:")GOF5]MBK C0'A#R2"5$H1++!C
MD93I*W&8F^(Q(X\RH*\WZB] .CTZ/OTE^0CK*[<^&/3SKV!V$Z6H0-6K%?!) M9P6.U2F(EW:S!Q1,D>8@_"I.B%ZMRWJC.;H,KBFK/!LKB???&BP&J3-MT+.5L M9)&\)DU8YJMH0
3X@*M"5NN!SX6"?6Y("5P&^U]FF)SO[A[8BBW#-7BL^$Q=B M$;VJD M:@O2HEIW'/JG2&Z9S;_NW1XD]YLBETF8]VT)>E7]#J6]CW1Z?D^7*U MC;
MHEP*!=_@^V3=80P,DR9U$(,):3$.)'1&O+7GL*3XP#DX%'EV@2A]$V!! MT-)'DU5^C<9T-PG1(4Q;O'BO>%["@RB>K$B."WOL0NPPFS^/9F/Q/'PS:QF)
M6(%D,3[D"N8L8VNA,Q2B0QC&1*[>.\^:LF;MEK4M^A^$6.,PJW9@-J8G$Q%< M#\O?0_(H.:?LEZ1\,/L5Z<,*51:Q#PC]DK59UU0DDL4"BB75,$@C!@>-VK?G M92T1!LZ@
GO("H45V"Y+++%UXU(J^MI8XFFN@E5"L^V W:ZV &KIJSC%6Q3IN MO@%?.S[Y0%ZHA;M>=*(9?I0AP;QAH5U^S/MZ(HNL>D),/&8-F5MB6/6E2K T M;Q*480/Z @X'-
:VR]AA1/9Y=B?)_ 6A&+5&"X=2D#H<2MF:S1R)#T:,2#*2;W<|* MG<&) !=5WAG,O[%KREH$#0KKM%)P+6Z MP=?3#X#0N]$3!2_LD:@?3').G0&F9B3(*(T0/O2I*$OT
M485H*'+!9B7!%D)!9X2N8$%+.8L)Q:[UPX-DR&,2Q:TD M=Y-D 61WS4ZXMK%D;5947$#=1KUG?#?#)(1!+%8'DW M<)&3JT$!PBB)C]:[=C$@.B.6C"$)Z)VVIB1[%
CO=C=N2/Z(%S7/#+C5H,@# M.7QN77Q4 "KZRQZ6+BC;N09]1WZ+>,.85+9?!=H5$$16/EHF+!,? \,[E80O MZ.J*[)(TH"M3EX_D\((,0'K!!\ZQ9CQ<^A6LA]>E].B>!48 "6>/7TAQ 2P
M&F.S:8R4 A")]@OQN@8?#+8<*/\@ZC%G#;M$AZ@EK?>(\!$U*OT-4[<5=5\' S^VP_N (8 LM$"D3Z 10$P MQK+G*0[7P7GT1$4< ZHTQMTQ40:KH1W
M>,E*/4IZ9TXAY18M@_J)ZLT&=^:4!T60@] _D7<(.^IJU#V8O:$BHHZ"@6$ MI(=%'BN*X5-0A7*-5-L1'%U$OTC@RMN%;?9-<^ "C*AY5Q)Z$+ P\I-K*<"3 MM#G=%
(=4[D$2^J'P[!!:44IIOIDZ3QCBBKYEE M91"SI/* -=*%Q8+?,"KSPI2BL^8->AS6FH\2K-;6M*4"87$6^$2\N7G GSX MG20=&N0@E0]@9=<-$)*DA\B*:WX1[M&4D@.T$6!1V]
<.0]\E76PW4;"Q%BG M*14FZ;8U PMUX&&@1R4.#B^M':H,7HSH97 Q[^ZC M" E(#? 7A,0]&^&Z 4-C.DZL6; 'YK*61-:L&"IM"5%'/]9K,_#1([\F%#I M/>V9TW1D4=.!X%."U>18E2O-
P3K4K"%+ L6Q7/H23^]58E.0#G8VRES8DZIX MYKI8(PG^W4HI6=ML9U<#+K+U.2]T]D1>NN(*I">$.I(>H^2L+ 50<(.S==&*
M/L4*M3I'_@]9O" V.D>FF*BQ!A=0:A#2B<4<;=0*X=YI,LK1T8N#&Z[^] =*%I

V6GWA/ MJI=1%;+&MA7I;<$66GI<$W7X[<^NAWPUH8^8[B-O=1(.)YUH"!5(%72]0YK; M>[TUG2]7W3^_&"FLW]6/[?QJV9VMR +(R?W '^)5:E>QF\"=/VZZE?VWZK7
M@AL;2O79$0K7G\(R=%>J;+>B.HCHZ*VVVEZ-MC.<";I>YCD['ZQ/+[RIQ>;I MG[+G1,S)B>]YU2R@@&K*-6_5;ZOK@::KJ>T[IO.A&\33V)RD?@)^BTXQ'R&!
MH7VTR7;.DHU"RK7X/"176>V38".?F6=?RNN\)9Y\]: _1N4>AQ836)['@"[9XD MVHY,/2["'?5, (O@9QS/#I*0BZ>QFY#E1 383F GL<\]>-&$2C4)\.7[.S\] M'RT1WKFCM:.5Q-+OJ7ZW*
.@Q&P/**"#@1^A[L8]+6DC!\N;)?6)NX^4P9K[M4FU '4FM.+FZS;3T7.P-.!(SP&"K$_"-*9?5I;?FY;0XU-[.>+W!!?E0;<8! M@M5P?8ROK_N.+OFTQ+Z*K!X/62)?^YK0CD-R + :VT5(F,
7>+P5A\\N?]#W MTT(1NQ$W9X// 2S%1RCI.S&Y(<208H*'$+A0/3K$PWX4TXO%)HAO"Y]K\?D8 M&T0;:S\>RV@4WRJ2<8.VDH'D K0FW2TZIE NTX]@[1[VY_FAN:^W\+.\JK;;
MP]>,QQ"MAPZ=(?#7B0]:(WM"\14'2BZ%]Z[P)W8<<;#543V6"UW'8S;FH?^ MH(",>8]K#>$^ "0684*A8"B")!+4H4^=GQ#CA*]\|"UA1'\Y#1Q /$-"AGE. M8E)KBL/#OP"
C_VUO)>]OW/(:RK17W/DOZ-3-.I/'K9WVS\8>;#^3F+WN/IK MDXAG;S+$%;F\QE!G/PYWU%MQX[(I%_Q7$Z_*IBGG_/56IC @>@"_7Y=05GU! M"[1_1O/M_P)02P,$% @ 4HAN6=
(G&NX.!@ [T !D !X;"]W;W)K M&ULI5=;<^(V%'[WKSC#;CO)C NV,9=L+C,$R"[3 MA&0"VYT^"EN 9FV)E>00^NM|)-D.)&PZ;5] MW/.=[YSD7RQ%?*[6E.JX3G/ MN+ILK+7>?
&]U5+*F.5%-L:$<=Y9"YD3C5*Y::B,I2:U0GK6B(.BVGW9Z#<@I4M29/I1 M;+_0TI^.T9>(3-E?V+JS:;28%$J+O!3&>X"OYN/'.[B|'TQA,!W!\'$\
MFLQA\/EQ/+X;3^<7+8TVS,E64NJ[=OJBG^CKPIW@>QJU@S%.:'LJW$%L-,*H M7D?O*IS131/:@0]1$,7OZ&O7#K>MOO;/'*8RAUM!. QX"D-)4Z9AL)*48JKI M8PX[??%Q?:9H/JD-
2>AE ZM"4?E$&U>_?@BIP?DI:.,,:?R>]O\0GG?U'4?; M;7KOVP%#FF=)N^?>B"8T7U)46BC@K]Z36$H\@WA,T 6*;(*C&L!Y W#>O-
^QR>'Z*!:#7,/OV.!P4/&5\!;>WPUKJEF)>23,)>^>GYQY1L"%2 M@U@B"*8.H:QO=R$D:\(2]4Q_(M$FV"TU1;- @]QI.L2"D*XXAM2 8D%U*SOXCMD7I--#;*1.2Y2(FF"@,8![]@
MW\LR@?LO8J5:P//8&@O)[*X)\SU""%:7<= %#$/Q1('3E= ,]::>V4*0>>6- M WN,46-ZZRAP=-A3%:V_.5JI9"*U-E.:(7?F"/+A$N,%M:0E[B:87.@&@1\$ M ;3-KQU%?
ER.PLC]5V<&RGM)- J9*08M"5?$7B^'V; A+(6,K@R_B&DCQ9{J M-0 MS84FF?=_58)5&9ZU_<2=@[COQ_T8PCVCSSIM*)F!^/KU'-E+!\,EM:?[<7 M^T&W_R\00H-/4O")#R1K*
&R)9(I-4D+%;O,9A^$$=^&)]!)_*[40_K-_;C M3A\ZH=_#0@H#7.YV881)R5?>5#R5]8Y%[6.V6<15^CB5[6Z\QV:]1Y_QZ:,0 ME -ATM6!KHI7K[$?6!
<4>ZZJTQ4L7EO:V:WN+K_TPJ7R1XC/.GZOWX:S?L\/ MVYT#<==+,8#9^P.'U^-&K7(63KYP42!M-3^%D_&QN6(6YC$Y]G4%] M*D&J4SCVK&OMOK]:?,@/W@G\Y[KZ#[HA<,:
[0X26* M\!U>I^%RI9IHL;'O^870^'5@AVO\'*/2',#]I1"ZFA@#0[>!2$% M @ 4HAN66//!H9S; @ +@8 !D !X;"]W;W)K&ULE95M;]HP$,??\RE.:55M$B)/E(<6D-
)".R3:5;3=M)V$]-LD6HSX0YZ)5O@,^K7\DF2Y>XH258@5YG@(''>=R+_ZJ9I_*W#MPQ7 M:F\,)I.9$&_&&"=]QS.",,=8&P*CSSO>8IX;$,GXM6$ZNRU-X/YX2[^SN5,N M,Z;P5N3?
LT2G?:?C0()SMLSU5*R^X":?2\,+1:[L+ZP]WZ#E0+Q46A2;8%)0 M9+SZLH_-.>P%=+PC <$F(+"ZJXVLRB'3;-"38@72>!/-#&RJ-IK$9=Q>ZXFO'%RXPWJID(%1U M>!!<
MIPI&/.'D]WB79.VT!5MM-\%)X#.6#0B].@1>T#S!"W>YAI87'LL5$Y0LS]=P MOV22<8V8P$0P?BC7"M4\C#*5C0>3NS0 MO_X.8UZ+2IGEY]+HNG2*
<"N*DO$UU6V,5'8)G$/8]NI=SX,76LX-*V6JQH#0 M!8@Y732$C?:E@3VPM4'Y1U 4RI(D,U7-<@(WNUT+CE2-./1J-!8S$KQ].G6* M2."!R3B%T-
_.,8,6,C'H.)9+^F;T..BXM!%V#NUZI].%H%5O=MNDKUJX0=U M1H5 O<6PV$R\;Q);.451G7H0^N"WZF$[L(;W-0X]$7>OA@N4"]NI%,1BR755
MSKO973.,JA[PQ[WJI)3I(N,*ZH"LNE-E:%':CC 3FQ]+':;4T%$: M!U]?"Z&WAME@]Q'"2 !H!P VO(!D !X M;"]W;W)K&ULM5AK3^M&$/WN7S%*;ZL@^3I^)^$E MA1!T+4%
)%!553\L\898V-YTO2'07]^SZY"$2X#>]I4@7]JG9V?FS)Q9^W I MY$,UXUS14WE&7U5%CIM1\O]6J)C->L,H12JD51,/E\PG.Q/&IXC9>)Z^Q^IO1$Z_AP MSN[YB*N;^97$76NM)"-QF?
%EMC4E[LXGV1_YJE M:G;4Z#0HY5.VR-6U6'IC*W\BK6\B\LK\TK*6C2$\651*%*O%L*#(ROK*GE9Q MV%K0<=]9X*\6^,;N>B-CY2E3[/A0BB5)+0UM>F!<-:MA7%9J4$9*XFF&=>KX
M="'=W/;&R>V SI/>27*>C)/!Z+"EH%M+M"8K/2>U'O\=/3%=B%+-*AJ4*4]? MKV_!IK5A_HMA)_Z'"D=\[E#@VN2[?OB!OF#M:&#T!>\YRF7VR'0*4%)62BZ0 M6:HB5J;TC:?
W67E//9TAFNJ-2;AKLWU16U M7\W9A!\U4#(5EX^\W59V'&NW?AK/N-47 MQ9R5SP@?RY__XBFI&:<))L4" 9URIA"ZBL24'IG,V%VNGY:(7)IBUD&7/.7%
MW%0F+^YXBJRAK#1Z8,242PA0-6-:3;8&S";P$,V%PCACN95N4&63"397&D@% M>E):G$2M$76;&6MZHSYU?)>:9RR3=,OR!=>[GF4E*R=0N)T;>W8M[D74[&V4 M:P-
V)Y.U.YF@9U!P:6:3JEK H3&K'@BL,N'4 .6GCN^[!X-D?&:&WL%>+49# MX9#KZDG/._"Z)FQ:C-SV:M*-;#.;.K"&Z6H9<0'*"B(9(>^K^07'8M:,@P-6W0R^V M^C-6WIL\WD1,[[-?
+]0>M_5IEAM>9Y,SJM"I-DT0[!I!=NG&R9Y-"\WGGEO6?K"'KM-D9!A*B"4-J.5,J0Z + MKF8B%;FX?X91%2TJ75=B%5B=5ULNF#HI32_!#B,\0*QZ=+4.WTB)R8.-)8:9 ML'B*1!9+?
<< ;6WY&B (6,A:^B1K[<_3MG]Y<74Y' S'(IKMG=]@\G((0AO= M7%SIXI8)*G)4P]7\HH&MDTD+PP_/\;0@?@*GXQMP]?&$4Y_) M7(6BD5NLND_P/KDA[&V-
EC3/\!Z__]$*G#:!JG(<4,-5?@]5J)!P'M^("L M'6OG@^%H<*I'H\OSY+0WQLU9,NP-^TGOG$9C3%R8C!\-KC \&5Q;ZX@U M;TJV2#,0V!XU!T^Z90!K]"BZ&1$R(#?V)Z7%4D@!)]L
]'+2D7PBY.LVN,TQ M>)Z; H;^4+*9]^3DN. ZEN'/5A"4O+ MU=O-,E.SW>]H:>@ZVD,3A1Z;B9R>&$,F^,^...- (3EIO7N M;MRK(]BF??>[GMV)8S05U^W8/AJS;M_)2_M>=+4@\
[J)ONV[X4:^D9MAU[6[; MWVZMG[;Y5PG9#'PIPMEUSXSB *./>BH:1%<)^0X-_R.FM=[FR*<<_7^WU<^[MIX^KCVNPLWL&D0]:K@D9#!U_0,@U$]<#]-GNYYP<;NDP1G-
4]CUHMK;^N"@ M7VW,9Q5]1$3-U]\>UK/K+S>]^H/%1KS^[(/R06U5E/,IEKI..VJ0K#^EU#=* MS,WGBSNAE"C,<,89TD$+X/E4(%56-WJ#]?>LX[\!4$L#!!0 (%*(;EF- MI$4X.Q4 X^
9 >&PO=V]R:W-H965T0"R+;?"36ROY;3H7>P'2AQ)TU"DRH<5]Z_?WSDS M?,FRG>06NP&:6B)GSISW:X[>[N+D<[J6,A-?-F&4OCM:9]GVI(/3=+&6&S]M MQUL9X-.F//4/?
NR#TJ'MRJU3JC!Z?OWV[]E9S)[-/V)L&WTQ*H#8R2E4< MB40NWQV-W9_.NK2>%_RJY"ZM?19$R3R./]_7:?#NR"&$9"@7&4'P\>=>GLLP M)$! XT\#\Z@\DC;6/Q?
0+YEVT#+W4WD>A[^I(%N_.QH>B4 N_3S,;N/=+]+0 MTR-XBSA,^?]BI]=ZO2.QR-,LWIC-P&"C(OW7_V+X4-LP=)[8X)D-'N.M#V(L M+_S,?_\VB7S^ZNS__UR_6'B\GM[)__
M&'KNX(VXF%Q.S3>3J_?WYYF.(-6GBX,O#,-SWL"7E\\C*-LG8I)%,B@N?\4 MN)4(>@6"9IZS &=RVQ8=QQ:>XW6?@=XPO,X3\"9_YBI[$/\[GJ=9 IWX MGT,T:A#=PR#
(3GY*M_Y"OCN'(:0RN9=']__Y#[?OO'D&P6Z)8//T>T_!-KG&?K.%%_R4#X42"F:9KCXRR+%Y_%.+7\3$ ZF=S,95** MR!;96HKS>+/UHP>A4N%70+(8#P!#N%
[/=AR' EFMCWZR6(N.J_<+QL5]4U\C M3JQT]0-Y$2_%(MYL8,XI8]$Z%D[;<5RQ]1-Q[X>Y/+$95]=Y^0#G('PP:2F3 M!.@^[;&8D*:X8.*5A: \SJV@W^C3D>,{)[;M;M=1WB>/>QW;*_O
MXF&GU[$'_:& ;=G]@5?^1OR=:0Y;V[,*^N&7O%#]\T)8Z^]V: M7IVWQ=7UW61FW5V+NU\FXOSZZF)R-9ME4;U0]RJ049!6GZR2H5M?0:4R)C8QO'<]2#VZEPFG-R^IRX*79JJTO"?\
M(7V1T8)4!Z1L=*CVEYG4G"Z%&!@L#K-?T_1&4-;D@<#ZD?LH;$F^);'TC$]T M>_3?-2F?-0[^0+Z"XS\M"I2Z$+H_Y@L;Z8STO*;XE#%HU-\.X$7WY%]\7 MU[
MQ#8BG:EF^4&N2)[%GSG +A](= &L/U'S7",0LQF+U-]{+03R1HJ9\]![%H? M;!E.[7N3AH:03","8%0*V#'0=K'-NI6!W&RS0BV+4+[Q'T! (.5&$'FP703$ MK)!.W5D^J-
(B@<);BZ3>,.;"VTLU7/^ .#,"L)U$^=19DEB4.$P_=4J MD2O:50@6P;Z%3;8[<,3 '@WQMM\! M=-OIC&P7KQ$/>UT$N)%H+ERY\IQ!G?.(JXE7&"NN'\)7W M$MJ6-*!,S<-
'[K^4.EL:L@E2!>Q ^'=&<#'VR&1I-1%D:V#2%$(S38(.('(E MY)A8?"..=38I>CT%W36+FVH..9_-Z$=U&#UU0+VG,E[_W QR&+1&8H^OQ$C+:6 M>,#(*975V7@)$!2>UO#!?>VY,P-
F^_H6&.)ML*5VWLNE#3+K$MU?*&=H8+E M!(PZ;TCC,>9M@BBP=DH[,\2[IENU$<*CS_#RLLR2X Y-7"B<;&-'D:/1(^,J MBQ4;_X^83?" &]5QT:K+:-\1P(>G1+MA!9C,U! T3@B?
1XN3=%52@O^TCX5> M$HD%5'VZ]>CT=A'PGD6Q",[U6(@P*M4]\,WA9WUJR]2B<,OH69E'%5IE$V)/ MY#UQ8BW\=%W&RHP39J[6*/&B*!)%1%N1?@TI;_E>_$WH/%1M/LH*^
6VS?R MA5?7Z#="'L$%3H_V411E^!\ZKT0+NCK 7YT%6<\F/*3@.3P&!PF=Q02U7NX':1V.VH@DL<&$'!5E%$'H$"42:$;XY)A56IM M?91^]I?
<@/UQ@#0[I4XE:9B)L@;%QG)3BBN5A*(X(US9 MG[RD);3PNS&:B@0C);'SFYB+?:&Y MZ |59T|BP7T<]N(*RE.5>$BLD;:RJ_%-M"GM@J6W MS?2[NT2M5I+59,)R-E+D+(P8JS?
#]X$B3L5WIF)YO->B33(JK(H)=B@%,!84 MP$M4*,+E:P1;7TZJ_)_/?(04U;YY8CHRK8>3.FK[=%G/T64WB-+%#,)_(ILA M,2YJG$/GO.S7VN(3),YR.4,(3?)MMGAXC-
(W&F337HJ(9/#7;564_8$I*LB MS7HRJWB>AGK9QZ>MX91T)X0]>NVLC>95'#-5(;TQ=>Y>Z7X@"IQEU.RS9=H# M%P[?TJ9:C]3/ CR$+4#H<;J.Z+N> M[?0[5']#>^ -A-
NW!T,D)BXUC$??6"=Z/=%!-=CQ4&IV/12; S'HV3VO\QB. M;@5]1?$/F#TJ+E&_ E&4^':WT[>]_J \PAOV[*';)=0]=X2O6#$4PZ[M#/IE MEWML)6#3:R@ 7&_ KI#;'-
:0.=VMEO7T5V#XDYB=_S*Y^/1A8EU? M0G:WT\E,]/!V^)TZ M.(#5$WL/NM:Q.+;._%!W)17%B*K4Y'BAN,0A+$GN'0']$NYU?>&^L* MQK1-
XH6405HD'0'U*;A"+DSRB9ZT[G!5:5]V$*Q;Q+(515OMF^!2U+ON/*: M@;2NR%T,H;7[@0.H(_>G;7[8L3]I;$Y.R^>?/1*B1[4A)3\$)&P0$NU*4C M/-
L;4M^H!Z2]WL#N#6%'P8DUXVYA06\]^+M5?:^EA%\A_A^AX_X&9' :J; RQP/VHRWK^X^L-]*1&$CC_7VQ]"$A76-!1L>BVS,-HBZT
M:$"?/.#2)5P&O8[=ZW7+)X.NW7>'++L,K+DO^D/;)5QM%U!&WDB 42[=;'DD M5%2><%,#T1TY[@A6WK>]/1#;&6#_X/^ZSU@/148$?,4"72?"7+L#>KPNM>(Z MAQ:/B#27+VL]>.
(I5 =!KHK!(936/N/M+Z)?HJ$0D"GAB/(M V&ETQUP_(#UBLXKNK<==OL_0%.P)8WQI^3TYN5]ZM@$ NL'I?SO%7!AZS^6 M1?\]+@UQ"]D9)>B4@U?
%*P7JKE%L_<=TH[V!W4=Z\WVR[8BK.))MT5J>6+_Y M2>)S]6I,!17U%YDL5"H;O:$BFS#KK>:B[PXO&I&_%6AG#VB)^K4'\S4#.1>[[!?L:;>Q1G*B7%*=<_>F(?G4$9$
:]CCT9=,410<49#*&L' M:OQW9)V5]=7<)!@O[X&?H9+Q=$'K0VIGFB3EJ;_8H:7W\DI#Z$O+-+4'M.8K ML-=%XK>0]Y$WEX/'PFL[2+8]ZF72ESZ*AFZ[2U^Z;7>HV:.-]
(+*MG&^RM., MT.N3^[U>9#&A[#G(";6\\&I$KU"HT&.OM@:8M58G^@;E-4T.!I0J;F64ZA,\ MQ^U;II:;@IZ($]$;T$9W>9=RGN34))/L7JE=RUEL"H$+'LJ)JYN$PNGP)?B]
M<3K[C5$") X?V;CPPX.BZ]ZVS'#'-D[+=B3O4!R2_.">A:$;672_F&:/D2+# MQV.NK(LK$+KD!:JZTN+(EE4%:LDWG&CCB9NXB7]>ZX, MJ%UGU6#KIECS(I7RLV;&8]TD-
Q^H/C,\:]#)Q3R1D19M J*!+VRVQ1R.;HA# MCG*AM*IP(R,E9M"M%K>;]:KRYO;Q"@~G'D=Y*@^]R2.>@C!L9"]&J;YC)?5 M@D9:Z;.E*6G_ 'D2Y79:%CQ\05)544XJ:3KTH"-
#;4&TZ)L6S5ES(S(O["JH M["KARDYEF=1"TK, Y>HW1JHRL,4ZWE'OW^86N$4(&!F7HR K"@:T5"VYR16& MMKE_F$L EZ8/^M#HY)$&R/(>*)/4/VZY3K8^.=1&UG3R91]V:
[O=^% 4)M\< MO'!*30L.Z% [M,HM=7.]M/-JG*5LGML>*H.N]W?5?H8Y<.0F#T+9U^N-4*;T MD(]WD*7CCXNR:4AE3! 9>@=9.LJUMMCR2^A!O&.&<4C1'K$7/TE4W.#QG>$
MVVH.7!?Z7YL[[+5+N#=R?7,WO;X2X_.IZ;_3NRG4W00QKV-=,;>I67FMC5K\ MQM/A4-NQN=TI(L>B1-7I7Q>W*%CF77=[)KN90^0$$]]X:"#R#9J=T;TH-l% MM>/P
V]D_5SPW/#Z6+AM;-0LI]@X&!V(_<>/POIQD5.(%DI*ZF6=$"R$6(0_ MZM-!5/RDW7>MRSA92C)E?M6C"5:\&K:I(7:;G;YGOO>&^_0=R!>@@2!IX!*- M@_; Y98)E)ECZ*JFJ
D/72A"H75PU7"-:L,9H9G2X]8VUO,:07-A M*ST3]#JBRQ"808@(19+;Q($,S0KMS@M5]&%-&^/4+?+[^G!MK&-(@:RUIGJZ M-?2R"EZ[?BU_&'3Q.!;?5?Z:\%8[UTPPI*
[\=:Q6=S3Y]"6S:D*H\]^/ M'G6JM,F,Q)%,OHKV^4V^].J$B4Y[V",MX'M1]K:B M1=U!N.E>NR?Z^.'"2Z0>P$!]_\1%']|E&H"QJ+9C7-(IY',Z#.Z]GQ>1E[GYAJ() *U_G# MKRO>C*/:S"
V5;\MJ'>%_#"-&\)X3[J-XR:SFYNF).@)Q?EXEU;,E ;>H0S9 M.D1E?;8_GZ=((GV^-**U15X*:95Y8!7>#T$[UZW)63ER06-/?,]47G?1C=L] MSHCSM':
[A1SO4YD5$&5V93B0K)P[(VKMQ*S!\NXC!-)#)Q4%2DZ825J/ZT4_ JZ7CQ>#K>1 Q]D%6.(J64Y:AT M75$W;MK<;WMSG"06Z%'UT;!?CF69 MC19MO#8P&Q-:X->"J*&AO/-
&!XE']H>0)T+\R0 M'P=9\O1Z+,4@N0D MVTS*6%I#L'^)Y""B2V*Q)D^Z5EOZF49I+,P5ZD\&B;^KJ!9.9OU,%_O4W3U M"5F?NQ#BK)A0O_ ?
TGKEH*^6V((LZV5=U0]!F<&@RF'Q!#_]?$3;6(EN94]R MHR<-^')=EHEA@R5L]%29+7,]@7250210K#=,HQF)\MFA$TN(]*]J77;K.)2- MGQCQ\56 JF+0PLP6(H'>^@]TC0H:S
QXX;'RAR+=:ZHMPI.;LI]M96[F0>)BD&>7FIEBMA_RR/7!VI:I M#VFFX[&0K% M)27:IGX;8Q^#]@+5.L,U7AS1CU(>]E7@1VA&'/H5Z&GM-[H; MF:SXE\@TJ@B/I'^N6SXM?
^P\UK_QK9;K7THCDUPI:'$HE]B*M+9WI!E7?,GB M+?_B=QYG6;SACVOI@Z6T .^7<9P57^B \B?@[_\74$L#!!0 (%*(;EG MMZ-T+04 #T+ 9 >&PO=V]R:W-
H965TP&KMM>WNX3D_OJ;70.E-(UZ MI_N"9W9W7K]Y,#<[QK^)#:42GLNB$K>MC93U=:V4)*]:=S?Z[)'?W;"M+/**/G(0VI(D_*5/"[:[;=FM MP\$L7V^D.NCQT[
MQK(D@@Y8\27/Y.:V%;8@HRNR+>2,[1[H/AY?Z4M9(?0O[)W/CY.MT*RWED$AR=\/9#KAZC=H4H4/5TNA<7JFD M))+C;8YR\F[Z&,]Z\]'D$XSC7A+#;/3I87XUO;]:(--
+DGB>0&\RW-]. ^^/1 M)WP^G20W'8GFE9).NC?5;TPYOS#5A<^LDAL!<971[$?Y#KI]]-TY^-YWWE28 MT+H-KF6"8SG>&_K<(Q:NUN?^"HN:E6V MOYTNBWQ-
5&F)U[!H3'FOFU*M=BUJDM+;%O:2H/R)MN[>O[.[UL)[;4.8?G6#,=':&EYT>-C2[(D^(RYI> MJ2N#U'61JT@$V';;^P.2P4,\7(QC8WH/9_E(3BWMG4AA?*=$(>7!VX!JZ
M%Q!H6!QZ 3&X,/ITG5>5*BH9#H>#7MS9.Y'DIYD M,.J-(9GCP>=X@GV8Q(]N.9<9BF<+FH#:+L<;0R_A9];@F9%7L$@@8T5!
MN/A@G+]X%$QU["O8C[8?]71P%O,@U$27P_,!T |N8L"K] M-_+=P#,MVX7(P7*P?3U=SE_39]QQ\+0#:7,!3N2801B [5EFX$?@V*!>2$X MH8,)B+2&%2+0-
*4DRX+B>]*GG^IBU>LI_M%Q7#BVV+_;ZJ3C4R(VL$)1H0?7 M3Z,"T(.SU#= 7O_0S)C2^:PWF"\PCXO)<)0,IHN)2N^@ESS _7CZ)8'[Z>RG
MX6H,2$&K#)OZ177V1=,UR@QRL4M=]!WP+>+&L-(UFM%Z0ED[AN:7*#^RWE MZ@'>KQB3!T89.&[,=_\ 4$L#!!0 (%*(;EF0R/R%O@(/ % 9 M>&PO=V]R:W-H965T%<>1.&-
BU0,MO5)2HZV6HCF:.ER4-;&F19#9(BC*/H*I2,JR 9 MUGL/AGJG1->'\1I@,2Y;C"MVW\L'0*FQ9 M,BY16:X5&-R.@G'O9C+P_K7#=XZ5/:+!9[+1^LDOYMDHB+P@%)@ZS\#H\X)3
M%,(3D8SG/6?0AO3 8_O ?E?G3KELF,6I%C[XYHI1 Z>@<0[P%QK;L)5*N\98XE M0Z,K,-Z;V+Q1IUJC21Q7_E%6SM 1)YO+IO>+Q7R]F"W7*Q@O;V%ZOUS/EU]F
MR^E\MAJ&CD)XQS8==TTT:NO@=NBM8:.4*"S.58?8O/B1IK;[XH&\2GR5+8=F% M?M2!.(H'9_CZ;;[IF]__Y7K:2NZHJIP%IC*8DERN M6&>H:'Z=NH4FR.1T$-](-
[9D*8X"ZA2+Y@6#Y..'WE7T^4P*@S:%P3GV_W^R MLW2GQ?9ZW8NS<6!=H,$+1C>E-*2"<4D7FM,4L Y<@72QLF3JC6SFH")?8-8B M_3(RP/)<\2U/F7(=]
J>%HT/C0WKZ%WH2;P;0:D ',H-FK8*0!M8,$.0?]_9 MN2!$!U*M+#[OZ&G%6\>K*HU^X?7TH.%%8X<0!9%N$/T\235)^$URN-H+ID)5
M7A]95@N>,4>+.ZX8%0<3L'*T45=.%TX]8WC4A1)-7L\:2I)VRC4-V>ZVXVS< M=/%?]V864GHYW20(W!(TZGZZ#, T\Z59.%W6/;W1CB9$;18TDM%X!SK?:NT. M"Q^@'?+)'U!+ P04
" !2B&Y9=KB0M3P# "S!P &O0 'AL+W=OG\#@ MQ2)7S0B[5M8GBW&MM"CVRK0OLK*=^8_]QPI#'IG%-A>@36\6T,-RP77?#*2 M8@?22!.:632N-MI$+BM-4!ZUI-N,]/1D]7"_6CX\?
87IW0*6OS]_7-TN[YY& MKB9L(^'&>YQ9B\/.X(1P*TJ=*EB6"28_Z[O$]2/&#L1F["+@(U;7T.\YP'K, MOX#7[QSM-WC]W>!M]_Q]B^A_T* +N*<9NFQ:^NT 5C4
M,BNWEDX17I'+W]#$%6ZYC%/H>TU8F /F>BZ*BI>O4-5T1Q\D@1QI2D6>0%94 M4KR@>6,%8@-7X#%GR 80@!EP_;,C_H',GAP;.E$86=,,DR4SI M4/#VS8!Y[-
T_9VN1J4HHGI^7.#))&:VQ6*/LTOJ,V3BNBSKGFEXR00I6G/&F M@OVO'@^T+/NJ F9 @XO/*_Q(OEH&!Y** \"IP@8/IBC/ l'P(ROLQK
M!U$(I_ZF>U1("Y3;IETHB$5=ZK:F=]==1Y]VA?AO\;:=$>-M1JF3XX94>]=1 M8(-L6T2[T:]JRO);:"KRS3*EKHK2"-#11@AlV!@#79^>_ 502P,$% @ M4HAN60! '#1, P 00< !D
!X;"]W;W)K&UL MC57)*(XLW:_?:P"-^5&JK[I -/"]*H5>>(4Q]4T0Z*S BNFAK%'0SDZJ MBAF:JGV@:X4L=TY5&<1A. XJQH6WG+NU!]6I2<5R@TEP(4[A;>772S2JR], C"\:C/
MQF"5;*7\:B?O\H476D)88F8L J/N@/=8EA:(:SK,+T^!'4\'Y_0WSKMI&7+ M--[+\F>FV+A3W(<<>:TGR2QS^QTY-:Q$R6VK5P;&WCF0=9HXVL.F=B4"1 M]NQ[EXRE,H6$MYA
MFJ8^,)$!)3D:5/1:-W:[V1)Q8?X#^@9$WL*I4SAS>#Z:C:>$[AC9,Z.$[M$M*EKZ,%?T"4AGX8AI#,8M=']4[*F50B':?@+WE-VG@.R4LLSU/'LA!8]H7P4 M9_F-
1=0,NI+M!EE5.WRG-NRQ\H!772A65L$C]P4P"EK-C]0(AV(LEE5F"%5 MQY\]B?RGJD]%YH4[\@U'$Y2 M#U1;L-N)D;4KDEMIJ.2Z84%'"IK0/L[*PXP&&
B2V1W=75UO:OZUZ>]_F866C?)V51FM]>+9IF]>[M M6S-9Z&5F]JN5+N&7654OLP;^K.=OS:K6V91>6A9O1X/!\=MEEI>OWO]*WWWVM
MW_]:M4V1E_IKG9AVNQ[YE@4=X7B3JC#T_^2)GSTZ?)5,6M-42WD9(%CF)?^; M?1=$!"^<#K:\,)(71@0W3T10?LR:[/VO=?64U@TC(8?:*GT-@"7E[@K=TT- MO^;P7O/^[N'+E_/;?
R4WGY*[J[]?7WVZNCB_OD_.+RYN'J[OKZ[_GGR]^7QU M<75YE[S^6A7Y)-?FS:]O&Y@:!W@[D6D^\#2C+=,<)U^JLEF8Y+*,=.#P"'<)G_[R^EH-/C%0CVKJR4\6Q)N M#1!\LT@NB-
1U;>C9X2,)>WGI_,X"!Y&OWR@8^7Q5YT4RQ+T?GNXG5WBV)U4] MS?%KD MDP7!9'&HOZ_X\2H9ZT0#%IL"9H&!]??)(BOG@"(IUE41O= -X9=6*V*->!> M\8P +]"DG.2K GY'5
T1@\,W"4 "P_6%C1".>,HCSJ,K71/'1XQ6 MXR*?TW)H>\%\.;!&S75C:Z!-VGZC1"7,<\%]"8:'CI\DV1%40%E;'D&?D[M[^.++Y?7] M77)W^14^?KB\598;):\?RJR=YG!,WB2O+
[_CX0(Z4[".A[MD6A5%5ILWR8>] M6=#^?5/>FL MSL:%_<[LXZ%U0TU!,C"IXNOR",P'YQL("X95($:0A/&<3%]@72!'G"TKLV*- M)V:\#BF8*.SD%X-G"+9/-
R#/88/G50V$M306T!)H8;3Q1HV;[EL2V0-?)PR MV+)E!=0@0" ?F663O,B;M4+B)[%=PX_ R?2]JHG3X+A !H]Z3=L+XQ"MP]X" MZ09 :3.\I\S&^L5JL#3#SK,03!
C7=3+1,!@2@4//4D\!L@)7,X.M G+)BGTE MW,HD@-H2\5$C#2YAO<@TJIE%O\GPT-7V:5]JGBS*]JCFZV2FM?_M=? #D&IF MS_0;WB]9F!06-M<$*QY4I)&\3D
F@2X$,YMJUCP!,"E!E#UF>4$[CUA#6"Q: M[*K@-3B>N'Z'C!284L4\T:R07]GWF3P*T)-@0V&)$Y 9- C@:5Y6)C=*]K;. M5FN&>F.C4Z8W(2E2O> =OXN.D05H&?
2%L!1D%\@O[5[G)BFG:Z)E!6 M/]$H* MVE8)^ND2I[?,W> \B 4%2"LK/EXT0QX,!T/7 $$C[S9D 3133>!$H4P*)():9##N M6&O4DT& JI'!?1),R)Y432K"",'*R\<*OH/A=1T)G!99
RR\FB:MP=?P1SV;;3(H !L E#8-;02BFM*> M$5^'156PL0V)=GD&4 <2EU=/2@.BBY07&!@04;&L,PV\1H0 2P4+K+9"#"F9 ML4_Z G,T'I219U=ACX@P+S1*QE
MG70>TTB["3!OQ3(=2EX7'E\8U'B(,]$:/,*(790^^S :T^(0MI^@!-.C]V# M2%_#:6M$2V;"'O'5 .!9(X%K/ 6X@*R(A.<)XD@C 7EUQ/])^EQG*.5,16NT4 M>R#A",0ZU&\
[A"NR!Y5&7:\RX(1:?N$CF3-S 5N29'=N FT-S%H 2AD-[V7" MSZ; 'V#?&Y[,LU19*JFLEGD[W35-QFU#BQAKJP2BY@\GLPX$9 PDG7+2,0 . MTCEA^4"@H%L9TFM!. 4D"E0)= C&
<)G\NP59"4*(?R!-8X)\&H@,X)RVB!SX M=IG5WS2P=CU'B]<1-G5FY'VH-P-,AC"@)@C9'ATEIX>'"<'IR?IT>3 +I@,P.TM'Q<7IZ> Q#GYX-
MT]'9"0Q]>'R:'IV>P=!G0QCE>)3LL'^/G/U[M-/^O2IQXT';T*;/[MWYQZQ 78&^'FND+&<5"9=[(@<1 M#@4"!GDO/PM* =#JEV

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|X$W6VPZ MO5P5U5JSLQXL?1;6UO44KXT' U29IFZ9RUE'+1E[C7)4M28"G",JT#*]Y'UA MWZD;DOR ;Y7V;K#.[N;MB1==L5.)P3!V(6O:RFNL A5<;S$K90!PG@#'73' MJ5ZA@5(VUI/!#AMQW(KJ8\F9!HSY'5O7VR!5&Y#FY:KE2 HYQHML\FWO;K*H MR.^U5\3'Y7AL0VS_,=^-9F/QW/\R2QEQ)G,=Z##8HX8VNF,V2B?1C& M.+?>N\CJHF+IEC4-6DZ$6.,PJ[9@-J8G$Q%;;#7JF1X7#T;/VD+9\X6+!KG([@)AI:D2C$N8[7.E3N%$@/-RVAH,9[)1S5($%0IK M;I.O,IL^HO;)OECG3\1-(-;$73?[?HPD%?4=]DQ#!"]@*;CJ C+RC6?X*(MNCL(7[$}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|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|OY+SZX_)Y?IYN/]*!R>YO+N_^D+'ZN'N\M/#Y^3S MU>]P EPGU8K#_*1\S@"O^C%SP,SE8F/'W M'[6?:/'LYU&I\\3-E#'EH>LE):)&#PGG21VP'4G$3Z!KBM:1XM6*|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|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|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

$D],/AQ)]"G.#!ER#$@1(' MST@.@IEV:%JXFE=DF^629NAE\$O5E*"9EE<*Y V*MV8:JP]=NSP&EHHC@(=S]81)>@XKFZ[IA:R*OTO\EVWHQNF#9Z% MY6 Z<*&+G6,7.
[_=Q0AN,O.'R1P1G8>C23R,Y]$">NC'3S">1E]C&$>S?\SK MKY#D_65%MB-MA.Q2[5%P_S?5]A4-1KBFD.-LY?FRWI(M%IE(V18K M,X.4B##4L450 +A-[X-CK\ 0BWI9AD]0[.!TL_Q&
MO'(<0W=M%]NNT?;;7>?*HWWR.2\7]5+BX#:>O-E/YX>]R*_60=>GS=+%78' MSAN!'B]1U+AU,>>\650:1K)-O1PLF,15HR;7N-M1KA[@_9(Q>6"4@>.VV[\+ M4$L#!!0 (%*
(;EDM[Z^($0, #0' 9 >&PO=V]R:W-H965T[B>,.]AX4'L6/O&X ^!.WTT!AO)6LK/=O(AG3A|*PAS3(Q%X/1YP1O,CP_H[YK8*98UUW@C\S]%:K*),W0@Q0OV>_,@=^]Q'T]H\1*9Z^8?
M=]UM0(Q)K8TL]LXT+T39?OG7_3D<.0S[9QS8WH$UNENB1N6"&SX=*[D#9:T) MS0Z:4!MO$B=*>RF/1M&N(#\S73W(1)KZB5[P'D+R,X 1G K2Y-I6)8IIC_[>R2N4\@."N?L(N
C5E(-S$2O*:&6^N;#*>6F ERDLO]2BHE0S\/=LK8VB7/GG5.@M MD%G^OJ5'_7?7M ==+J#2^C3QYOWR\7SQR7--"_M>(AVX_ M8!"Y?CP
/W"9'_86QV34<,%D")2L0J;@N1&0#%TV&@"IC>/_'#L%RT*(W2"* MP(I=?^3W[N@5L!T47GA>XT7Q\2@F\7$8&PO=V]R:W-H965TW@0D]O];[2[9L!GM*?O*UP "?<^S@H^-
M1";<]/DR1IRPL_H!@KY9$E9 M3H14[8CPED=#\V M;.-IXRY=K87:,,/1AJQ@#N)A<\ODRFPHBS2'@]>T0 R68^.#?1[;EA*4%I]3
MV/.#>Z1">:3TJUK,%F/#4B>"#!*A$$1>=C"%+%,D>8YO-=1H?"KAX?T3_:(_ M7@;S2#A,:?9/NA#KL1$8: %+LLW$'=U?0AV0IW@)S7CY$^TK6P\;*-ER0?-:
M+$^0IT5U)=_K1!P()*=?@&L![@K<9P1.+7!>ZL&M!>Y+/7BUH S=K&(O$Q<1 M0<(1HWO$E+6DJ9LR^Z5:YBLMU(LR%TP^3:5.A//I91P]?(K1S06ZBS_'UP^Q
MO$YO/EI/[F83>OGDW,H5TK,1F4CN95$[P,TX<=$4+ ML>8H+A:PZ-%'I_T^":TI VZBQD]13_!)X!PV9\BQ_D+8PF[/>:8OESM]X?P_ M[_%O>V\EPVE> .:?D.
<_P;AE=;!.!9D75=]3OI%/T@C-!.3\WIYZ5T2WGZB: MVSG?D 3&ANQ>'-@.C/#//VS?^KLOV3IAD4Y8K G6*HO;E,5]/?V>"I(]>]Y) M11R41/4G8A,&P;19+TVC=2)RS2"8LUP5KE
M\)MR^-H;A:^S+#IAD4Y8K G6*LN@*Z.HB-YAH[!\-[#=3J,XML,#QW9] MN],HCNU*[ELM,HCNT\S[*.]L;!D[GPR/JL7."@8>]3I_HL7-MVP^<3I\P#R:?'-BJ'#DY2NBV$-47
M<+/;C+4?RF&NLS^QSZ=VSWZDQN!RTO)KV;H*\)6:<%!(DOIRCH;R*[&]K&T M6@BZ*>>2N1RKD%*?:KN4H#7P9R.=+2L730CEH_CD0_@=02P,$% @ 4HAN M61+L;GYQ @
+P8 !D !X;"]W;W)K&ULK55= M3]LP%/TK5C9-(&WDFP!+(T$_1*4-JG:PAVD/;G+;6CAV9KL-_/O93H@*A&H/ M>TE\[7N.SW%\;]*:BP>Y 5#HL:1,#IR-4M6%Z\[\ R66)
[P"IE=67)18Z5"L M75D)P(4%E=0-/._4+3%A3I;:N9G(4KY5E#"8"22W98G%TQ507@\F)/U M1ID)-TLKO(8%]+MJ)G3D=BP%*8%)PAD2L!HXE_[%,#;Y-N&>0"WWQL@X67+^
M8OI,7 \(P@HY,HP8/W:P1 H-41:QI^6T^FV-,#]\3/]Q'K77I98PI#3GZ10 MFX%SYJ "5GA+U9S7U]#ZL0)5]HKK)C2(`5YN]>-F"M8*2L.:'WBVBSMD98X2P5O$;"9&LV,[!G8]':#6'F*RZ4T*M$XU2V M&%Z/1W??QXNV@]8W]^.;'[?SZ7B!CD:@,*'R&'U!=XL1.OIXG+I*;VA@;MZ2 M7S7DP7OD4)V@T/N,
B^(>N##P_#O6&BXWP=WM!HRM(@MB!DWWZX)]Z7_O, M_B>R%];#SGIXB#V;XUK?&@6"8-IGM$$G%FT*?Y?Y7A)&WGGJ[O8]].3YP5GB M>5W>"WE1)R\Z*&]"&-
%WNS!KS@O9)I#!QWL;)'DQ\$K?3UIL9=X0;^\N),7 M'Y0W93M@B@M!8?JTQ6\/Y'J/.W2MGTTIU':P)DXC"2B.] MDT03B:8l-8'BE:WP)5>Z7]CA1G=T$"9!KZ\X5\^!:1K=/R+["U!+
P04 M" !2B&Y9?=?B6'L$ #4&@ &0 'AL+W=O62_KZ((ML]]?24@W;0M:KP>>@L52] -VIY7@!1D1,4X>F=RS,Y19$)&8!S0&C,S;5A?>
M]%!#):01+P'9\+UMH*1,*/VI=@:SMN4H1B0D4Z$@L/Q9DQX)0X4D>?RW [6R M;ZK$_>U7]+M4O!0SP9ST:/A/,!/+MM6PP(S,\2H43W3SC>P$U17>E(8_0LV MVUA/!D]77-
!HERP91$&_<6_=H782X\U(PEHEX!.37!W"6XJ=,LLE=7' G=: MC&X 4]$236VDM4FSI9@5K=Q))@\&\@\T1GUOMWVQ\-;\T.W'4'3^"E.QQO M]P8/W8?>H#L$@X?
1\]/X_O;A>00^]8G 0<@_@R]@/.J#3W]^;ME"$E%P]G1W MT: ;BZ)C%R7)-7"=*X <5-.D]\SI]YC)=*A+MZ7\K 8HJP%*\=PC>(A%N]% M -\3PK"@[KTV.]$4-#E7+Y)/X8R 0P$B?
B_.K%;I)H>7;V'-SS!4]*VY(O& M"5L3J_/7'I!S_M9)OQ!8H1!N5@C7A-[I8;[4"=QF^6F66A?6'>B[R'=:]GJ? M^F&8W_ <+P\KD*IEI&4L]4X!!@=2"+VZ+[_ M6/@'3!!TFLCUWC#6Q-
607W=K>L:-C''#R/A.D7M1Y*[($Y60E9X2-8D!!#\ MN"?1A##MRF)$+;NR7 BL4(!F5H#FARZQS4L6XD)@A4))V^X3J5%=I?V[M*E MB3.M77#/"< ++K0[L/?I'L89Z>9-
&QI;8<7%U@RJO_E :U'.!RH*SYLT-'?I M2DNV&;,,[O.!BKIS'P!,/0*EEGTS8AG5YP,55>>6 IH]Q?'6@8RMPPQ=:LF\ M%%JQ"+E)@=Z'M@]H-$&EBW$<AA#*R!L
:$UVB

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
M]/*D@E9(7_A<)Q<'-:HKNG3@S-J_/(&SM,\MA$[.80?:USI?5M<_!RP5:OU]W M@1;;^(OJ752344U!-175*/5YE,Z2^.FM^L-J M[>KDA%8]HYJ.:@JJJ:BFH9J.:@:ZJN:CFH5H/U7Q4"U"MCVH# M5!N>F3+::C'/!LR'Q_'"%"VBV5I:K[93Y_5RFM6[].9OD,VC'Q^S^91N?AVN MI7 IA8MUE"S#=70XP)Z2>!9)T?
\]AXM\LT[MS]+/JT1J9_\;WTOKA^C#Y]7C M4[C\\9__T6G4VW]-BW*<2NES^A0MYJGB]\GJ45HGX3Q>?I6RAV3./%K$Z7KW M>V&^W'(6/^6+;1_W&";_B-
;Y8U_6D[;K20]A*D7W]]FSC^8?0BF)\EV.I/1I M$;_S9Y_]G!??ME]<[‘Z'N6W8 CCQ0_IVVXG_!A)WZ/XZT.V&V&&A%^CI=,N M4:3YY9MF;W2C-
/ZZW'0DI[!\DO27!V7/9[DN/.,DFD7QM^P=#0_?H>5]G>_K M^B%[%S=_&++?7WYX^\W\6#"S/T(?_<_SC9;;7+*Q_T?J33;I_3^Q\MO?EG$ M7S?[*#UG[V;2O:^SAT/\>
[Q^R$_VV5S3E3W169@^?,C^-_^3M;E8??^GJ%[/ M_OB\OKBOPLO#/I6&?_*OUQC5)J@V135Q)]J'>'_[9[G.6PR)K,?SON\]OJ[O/
MKSN#'VT^1[4N]LFHIJ":BFH:]NFH9]":B6H6JMFHYJ":BVH>JO50S4>UX+:D M\KO5;C=.SGA#B\U1;;C5VF>>PPA==7SA*S=!5YVBFC@S>*]/,6R].0 M8MK[>O-
V=;WY._@KU:OS3.HUD4U&=445%-134,U'=4,5#-1S4(U&]4<5'-1 MS4.U'JKYJ!:\1RN]D\L6.ASOC4:M?GR&/[KW0VKO1^ANC:G=FESVHD[1O1=G MYO+5(8?EV(DLL)%
<##G[#O)V95'G;\'SE_S]);E-W<$'SV\W:U:;5T<< MM(@[V M=H:C60S4?U0)4ZZ/: -6&J#9"M3&J35!MBFKBS.R_/DBQ9>%Z/3O@L]^[+J,ZA1 MF"3AJT1&I=5)-134$U%=4T5--1S4
U$]4L5+-1S=EJA^=2M.KU M6KUX>-5%%_50K8=J/JH%J-9'M0&J#5%MA&IC5)N@VA35O)G)?7T,0CEVC@ML MD!=CT+Y,O5U=IKZ-
0:\'W*1_2=XB6VYSB:7X&AW\5FE$0DO54:V+:C*J*:BF MHIJ&:CJJ&:AFHIJ%:C:J.:CFHIJ':CU4\U$M0+4^J@U0;8AJ(U0;H]H$U::H M)LX,_^N3%%L)SW+8O"\FJ7TE?/N6/1:'ML&C6A?
59%134$U%-0W5=%0S4,U$ M-0O5;%1S4,U%-0_5>]CFHUJ :GU4&Z#:$-5&]#9&M0FJ35%-")9CI[U@Q[W MYGTQ.NW;X-N5E:F_[3]Q"C>?.-
U'47JNUJ2:O#H^H8WPJ":CFH)J*JII]*:C MFH%)DJI9J&:CFH-J+JIYJ-9#-1_5 E3KH]H U8:H-D*U,:I-4&V*:N+,Q+\^ M/E4'B/Z^)%;Z'J92N$A7NSK1:)
[W@6[.\LE^;WO23_:=O!GTZ2AX;!I.'\)O MD11*]=I??D1A(JWS3W3"Y5R:K;Y%B51O;'I%[Y^7\U1*PCC-FV57B?2GSL>[M1NMCJU7[\/-IIDK?PL5S]-H(^U)S]/-
]G*1K*=U<_;+1FU\:I6#^5:O=4C2 MGQH?FZW:QUJM)AWS6SJ-9JO,V]H?/VS*4L.E%/T1);-,W1;.;IYBG&;/8U^0 MVJCJ91X6BVK7;S75OM7%^U()'+[4R:
[CS+F/E^'BPVRQ2K,G\$ERER_?D;;? M^2A]?XAG#])J-GO>% =GBA$NG\/DA]3YF.U3H_[2([M]T]9+'C^A_/U.U\GS M2\GPGVX_-6^EI[P\-
M^CLJ97P:8|@<6]8GK>WQ"@75W5[%UQ"\IJZNK4C-X- M -5D5%-0344U#=5T5#-0S40U"]5L5'-0S44U#]5ZJ.:C6H!J?50;H-H0U4:H M-D:U":I-44VJO50S4>U -7ZJ#9
M2&JC5!MC&H35)NBFA L MQTY[P8Y[@JOFH%FRUSD9[N7ZU]JG>.KKO#+KF M -6&%SV#$;KF^*(U)^B;4U039\;LU9F%Y=BQ*["Y6\PL^SKV3G4=^VMFJ:AA
M7C5Q=6Q[V]=1348U!=545--034\/.RPG>.F7FL>W3T&W;7A9;LV0A<=7[;HY*+78XKNFC@S'*]/ M&FR[.4LATWY8E[:UY5G7U;E)>^-B[RD?TG!R]WT M?I?>>DQIH*I<[NI
16I=5)-134$U%=4T5--1S4 U$]4L5+-1S4$U%]4\5.NA MFH!] :KU46V :D-4&Z':&-4F]#9%-7$#5P?K5"."?<"F_?%:+6O0.^\%(-2
M%X)UT,YS5.NBFHQ"JJI*:AFHYJ!]J9J&:AFHUJ#JJYJ.:A6@_5?%0+4*V/ M:@-4&Z+:"-7&J#9!M2F]"<%R[+07[+@7V+PO1]=]YWFGLACTZJ-X:.4YJG51 M348U!=545-
-034/N&JV3QPW0O1N6K%IO-QNM9N/X)&NT@1S5)]@V135Q9O9>'V38!G*6P\9O M,JOFH%J!:']4&J#9$M1&JC5%M@FI35!-GAOWUR0GEV'$O ML'E?
3$[!]NE.ASUZAC90HUH7U6144U!-134-U714,U#-1#4+U6Q4I8,>]P.9I,3KM&Z@IE36- MO^EI^APN7VZM,L^R4VE<0ENG4:V+:C*]*:BFHIJ&:CJJ&:AFHIJ%:C:J.:CF
MHIJ':CU4\U$M0+4^]@U0;8AJ(U0;H]H$U::H)LY,^.OCT@MW6"%5KS?:K=;Q MP5S!CG*!S?)"%+K;-TK?_9N-TM7;7YN#4*V+:C*]*:BFHIJ&:CJJ&:AFHIJ%
M:C:J.:CFHIJ':CU4\U$M0+4^]@U0;8AJ(U0;H]H$U::H)LZ,]ZMST%UIMW?C M. .QJV)SO)B!]@W5=]4-U17G($G_DD8O=\&M/"VI>H&K0Q+:7XUJ,JHIJ*:B MFH9J.JH9J&:BFH5J-
]HYJ.:BFH=]/53S42U M3ZJ#5!MB&HC5!NCV@35I]@F MSLS_ZT,26\+-WR.S':+F6PJ_Y_[^/HE2:1^DLB9_6\6I9&I_0?FY4ZZ*: MC&H*]JFHIJ&:CFH&JIFH9J&:C6H.JKFHYJ%:#]5\5
M0K8]J U0;HMH(U<:H M-D&U*:J),Q/_^OA4'2#Z#]&'SZO'IW#Y0_H>IM+JRR+^&JZCN;1>27&:/D?9 MMS=']LU]I_1!F.6,VVSY_1)L]7R6Y2LXR^+2%IN#H.%R[GTE*R^Q?-(:M7^
MO-LZ>V3VP"RD?)*R)??F0_@MDD*I^9? =TGJT=IGNU#?]YUO#OO M.G?#I13]$26S.(VR->+LNYM=BE.IWLB6RAZ>[U.C]I=Y^$/ZMEH\/V8K1?'7 MA_SYA"_K;S?ONOZ;86Z<-
++9*4V?F#UG'FW,?+<"'-%JLT M7G[!5!XMV19SBBM&RWV+>?9EU9^,H\,;C*J/IY9J5V=*DFMBVHRJBFHJ*: MAFHZJAFH9J*:A6HV]CFHYJ*:AVH]5/-1+4"U/JH-4&V(:B-
4&Z/:!-6F]";. M#/OK4R7*L>-9/.^F)SV)>5W;$GY'5I2CFI=5)-134$U%=4T5--1S4 U$]4L M5+-1S4$U%]4\5.NAFHJ :KU46V :D-4&Z':&-4F]#9%-2%8CIWV@AWW INW
MQ>BT+RF_JRXI[^X/7;ZTE.D>)FND^?\R&=IHD++ MRU&MBVHRJBFHJ*:AFHZJAFH9J*:A6HV]CFHYJ*:AVH]5/-1+4"U/JH-4&V(M:B-4&Z/:!-6F]";.A(#K$U5UIO@Y_F5S&,]]7]?
K<#F/EU^EW\/%YJCB/,X/ M5,ZE+S^DG^/L<>W6ZV'$2X\?YK=1>;F';QY.LF[^;$GK)-PL,P]_I/D&^6^L MMAN\)IIN?HCSY_U1U,TW-_HO;QQ29&O<*:X8]?8U[G?5->Z;C\8.GOFYL];0
M&G=4ZZ*:C&H*JJFHIJ&:CFH&JIFH9J&:C6H.JKFHYJ%:#]5\5 M0K8]J U0; MHMH(U<:H-D&U*:J),\/^^DA7G1WRT1RNMGWU?,BRV;/Z]5CN(YGX6+Q8W=2
MFA0OL]"UN]'=)]'!"^E*)P]2+,PC3Y*Z?.7_XUFZUTVVZ6VE^3WH?(4L2WX M)!D_/C_FL?!/K5KM8ZU6V\3!S6(':3#;I^TY:OE>IM'L>1U_BXIY
M,7Y\C.9Q%@ZSIY*]6+,H_ZT/1SDQ/S_NEX_2\\/[!8S"9!%'FYBYFLV>DWQ/ M=L'W@F>PB-,\XV;?#:5EF&>P<"'ENY?$Z_PLL.B/V4.X_!I]_)]@>\/Y.G_1MB_4A]-@??3:?)2RW]I$
M^M>?:'ONWENG_BVC/I;Y#L?K'U*R>E[.\P?F9_TM9_E6^4\359IONQJ%D7S M-/\#\C6)LL7RW0N7V3N?O^^; Y/^[9IY2%/F;TY&:'TA?EYE7QX_?X1OOV# MIK+\]D%IN-A
!V_LX0F<)W]??I'25;;'&94^9T_E]<5X.8=S=]KH+'\:'S_D M)V*NT^PGJBS&1_F?H(]2$LVCZ%':_VW-7\IZ_?5)QHETG_V:L+TKY=/B.HWS-EY*Y-
WX28F_+0'"%GX3VMV6XJ^PNKCK34OJ7M+_$1VPN\:D\"1.] M80.J=5%-1C4%U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U"MAVH^J@6HUD>U :H- M46V$:F-4FZ#:%-7$F1QP_0|)[T;6
Z;]\50M;]AP]T=>Q(F>O,&5.NBFHQJ M"JII]*:AFHYJ#JJYJ.:A6@_5?%0+4*V/:@-4&Z+:"-7&J#9! MM2FJ"<%R[+07[+@7V+PO1*=Z;7^'A_SKJD^DWE,K<\:\-D&Q7)?
E9)936$YE M.8WE=)8S6,YD.8OE;)9S6,YE.8_E>BSGLUS K<]FBLG'F*7SIE7DZ"B#; YCW<9*NI?3E>%GVO:,C9Z%4;_PY/[;_ MD">6S='&/W4^WC5:'UNUFO3S_ECC+]G&'_:')?-
NF<:GUL&F^7=6V0,2*7U> MSI,?4O3'4[1,MXPG,IR&LOI+&>PG,ER%LO9 M+.>PG,MR'LOU6,YGN8#E^BPW8+DARXU8;LQR$Y:;LIPX%P/>D1G9^V/ 'I<$ MCH)5XR!8L??
(V'E8LD+ODL%R,LLI+*>RG,9R.LL9+&>RG,5R-LLY+.>RG,=R M/9;S62Y@N3[+#5ANR'(CEANSW(3EIBPGJ.S\!.4# 04!P2> H634/DE5U _:5 MUR&?
X:X/5NC],UA.9CF%Y526TUA.9SF#Y4R6LUC.9CF'Y5R6\UBNQW(^RP4L MUV>Y [39KS\U M;CYEK_!Y;?)M=W7L<++W*6N(N< M/_Q;%SE+Z$7.'ZHO)^-CCZ4>OFX$>MF\I_$S\?
O7_E/U]5&M?_?$5R M79:364YA.97E-);36K%Z^]\9:9\^VWQLW??OUVE)'05;GY?I216@<9J;)A M_;?AN1\M#K/KQSP[S]XH03^STO5)"KVQ#,O)+*>PG,IR&LOI+&>PG,ER%LO9
M+.>PG,MR'LOU6,YGN8#E^BPW8+DARXU8;LQR$Y:;LIPXE0#>D:1>O,Y!DJ|| M:K=.LQ1[*QG,.\2MP=9JKKY/2A>C5))0IZRQB6Z[* @(+@DAZJ4-
F;L2!;US"\MU64YF.87E5);36$YG.8/E3):S6,YF M.8?E7);S6*[CY(DFF_/04TEM-9SF Y MD^4LEK-9SF$YE^4\ENNQG,IR ,0+>,8+:L@?Q:6I@[A468/\VV 9/JZ2=?S/_'9A:?K\&IDVI^>O
MGM\Z*PJ]T0/+=5E.9CF%Y526TUA.9SF#Y4R6LUC.9CF'Y5R6\UBNQW(^RP4L MUV>Y K5=S78Q*5-B4-54F)O98!R79:364YA.97E-);3644EE-93F,YG>4,EC-9
MSF(YF^4P7)_E!BPW9+D1RXU9;L)R4Y83Y]+#M1Z< P0< M! 27!(IRV,&M#>HOC9[8I7IU]MX&*-=E.9GE%)9364YC.9WE#)8S6D:E0#PX"@DL"1YGJ MH-]\?@L?
VF/[S5&NRW(RRRDLI[*44EE-93F,YG>4,EC-9SF(YF^6< M'7=X?+15Q MG,YR!LN9+&>QG,UR#LNY+.>Q7(_E?)8+=MSAI>J-1K/>:1MRT+2:6QD$I=Z.ZE-N)ODN?7SJYXR^+Z(*S
MI:O!J^,+RG593F8YA>54EM-83FSG,)R*LMI+*>SG,%R)LM9+&>SG+/C.@=']&]?ZHWC,Z/153V6Z[&P7)_E!BPW9+D1RXU9;L)R4Y83YX:\.V(37+'->MR./XI-!Q7;V=<7
M?;)4=4%9M7%]3B*Y+LO)+*>PG,IR&LOI+&>PG,ER%LO9+.?LN,.<5"_/2>2Z M'LOU6,YGN8#E^BPW8+DARXU8;LQR$Y:;LIPX-]7?D9-0#Q[Q@IOQ1SGIH%V[M4=VN??
SQ4GQX1$Z:/R?Y1TU/41*OYN41BJW<1KDNR\DLI["^;"^[2,U?2S78SF?Y0*6Z]/<@.6&+#=BN3'+35ANRG)"P!Z< P06 M! 27!
(Z2U4'1=J.Z:'L3IV:;GJ@T7BVE>93.DOAIG7U='JS8SFV4Z[*+A10^KU>/X3]>A8O%CVWNV)QDM,I^\?B8 M!9!TO9K0WI^RKX,I<9'ZVWU\BZ67)^++/9JW6VJ]ESS9['TR):1]
(B_K_G[8NWW>##=H-/TBA> M/VQWXSY.TK54[]2D>?@C>['NUQLKDN(T?0Z7LRC[_CKZ6%CP,29B]A=F^ MS.,L.T:[%W\>18^;ARXW;_]]!F3J]=:?MSL0))]]!L?
MP[=P\1Q)3XOG;+W9 M+'E^>8$WIYQ]DOH'"\?9<_VRB+|F>S"7LG<@WZ=(^AXF2?JI/E37N2"]M&; M5_6@_?1E'\+E7'I*5M_B>22U:G_>;?UAMLH>&'Z-/KT1^N$V>\H["OT';?:-
MZC;I;G0?)=D[E+WCR\WL.ENEZ[0\[.=]BC793F9Y1264UE.8SF=Y0R6.UG. M8CF;Y1R6R_DL%[!, +>,(+;L07PU+SH$B_65VD/UB&CZLL1OXSCZ:[()P'IDW>?;-SHU]I.CBA M7)?
E9)936$YE.8WE=)8S6,YD.8OE;)9S6,YE.8_E>BSGLUS ,0+>,8+;L@?1:>#HOQF96'LX<'E_%.[MBH:R:NCZM,0VY*.6IBF^U1KLMR,LLI+*>RG,9R M.LL9+&>RG,5R-
LLY+.>RG,=R/9;S62Y@N3[+#5ANR'(CEANSW(3EIBPGSB6! M:[W7'%L@2Z+8?",%]R0/XI-!]7VV==5L>GSZPV&V@][6E\LB7LZ2+VJK5:O MCTXDUV4YF>44EE-93F,YG>4,EC-
9SF(YF^4P7)_E!BPW M9+D1RXU9;L)RTQU7.*&H<=MI-D\/N9T^LGG3ZMR>?I)$[J& 9[?@AO=1)#IH ML6]>UV+_4E@?S_*[_^3?*]$;'4]RG593F8YA>54EM-83F2S78SF?
Y0*6Z[/<@.6&+#=BN3'+35ANNN.*'QK=M&X[C=,,!'?1 MLQX\X@4WXX\RTD$7?;.RDW5WN.V@5JKJEM+5V/6!B2VB1SF9Y1264UE.8SF= MY0R6,UG.8CF;Y1R6R_DL%^RXPV':NCO)(6QI=\F:]5KSIKCJL.QA
MC?;=20@I>U2M67S8F'T*$Y:;LIPX-UC?$57@[FS6X\;L450YZ,YN57=G^]$\ M>GQ:QZNEM+]79JOEMRA9QU\6D;3,&Y#*DPM;IHUR79:364YA.97E-);367T<8U& MK78:7TX?
5Z\UFNW;DP##%E:7K=MLM>NUDT]1X"IJUH.GJ(#'J.#FZ%$T.:BL M;E575GOAC\=HN9:2+*)$C]%UR] MT>BTZB>!A"V'+EOW]G3=*;NN.#<^WQ%(4 \>HX*;H\5 5TEC-
8SF0YB^5LEG-8SF4YC^5Z+.>S7+#C#L^PJ+=O3TX[05<=[+A"0KGM MG!SN*7E8I]FH'>>3DH?5F_5FXSB>H$]B4KILIW5S\G$)NJPX-TNO3R>L!X]0 MP5TEC-8SF0YB^5LEG-
8SF4Y MC^5Z+.>S7.!R?98;L-QPQO6.$7;JC?;Q;R_DL%^RXSD%PJ'V]MTY.+B)7';#<\+(G,6)'7'5^V MZH1==D03UX(MN(A|%FH,2Y-O*,L#?NE$Z2^*CJ\[3_=9U'E, MI?
M5LOE,2([7Z3IYSL^N+\^;#54EM-83FJ&U+I*8GSWU|M'O)Y M/|FZV4_Q'Z7LMWZ.LZ6B^.O#^L=ND0_=VK[1;XFJS25TG 1Y=ALLRM2^A F MFV,EGU>/CQD7K%>S?T@_9]
[!],Q^%>UN_7UNT^S7X?)'X7L?Y/|[CK]EZR[7 M:?9JK!;S; !+H=1[#A?Q?1S-)25>ALM9]EP_E1^!9 NC46["%T;?5A=&;$[H._O;.]ZFT/&VRW=$HUV4YF>44EE-93F,Y MG>4,EC-
9SF(YF^4P7)_E!BPW/#=Z\IBWZ=>3OJ^>LYBU M[=W+XE86'&SQ2K-MOWPDCVW<;:8 M.I?'3V>WGATF_XBR5R#-G_(B6VLM_:G>^52K'638["E+/__^LM9\M5B$B93% MU>?
-4F'V&H1?L^^\2)[=ID:I1_^_5VXJ=4^UK8[\B0N?!V=,.\NX4*2_Q=]A,L.,7C#\\>NHZ7T M<[WVRXP?)/GY3Q_O^/U\^8);?[HAE]6W(!?GK8_GQW\:%8[^M$L>]C+SV:G M?
U@W/WL5=T$*/URX"_M]*/[@)C$_N'WX-W]PD_[M']S80GR4F[#UVY,3)4I:\AO-1J-|/-,,%VX*-5TEC-8SF0YB^5LEG-8SF4YC^5Z+.>S7+#C#F?]3:MV?*E&GUUV
MP'+#LF=1OVF67G)*+CQFN0G+35E.G!O:[XA!44EE-93F,YG>4,EC-9SF(YF^4< MEG-9SF.Y'LOY+!?LN.(G$3>M=OLD#;$-.+>GS?5WK7KG],.7DH;[6JM^>]LY
MB3DEC^S4.KSG,)R*LMI+*>SG,%R)LM9+&>SG,-R M+LMY+-=C.9_E I;KL]R Y88[KA#8ZK7:3?/DN1K?^'MRUEHZ>9$FVA>'IW8NPF@7)?E9)93
M6$YE.8WE=)8S6,YD.8OE;)9S6,YE.8_E>BSGLURPXXKGE]2S-"\\0^ZJH#E MAJ5/H]UJMEHW)Z&(O04 RDU8;LIRXMP(?T2S78SF?Y0*6Z[/<@.6&+#=BN3'+35ANRG+BW&1_
M1U:"2_U9CQOR1UGIB-2_75W]OSE_NG!)5EJ>E=A>?Y3KLIS,<@K+J2RGL9S. M<@;+F2QGL9S-<@[+N2SGL5R/Y7R6"UBNSW(#EANRW(CEQBPWV7&"'Z(U:NWF
M\:W.I^RZXMQ@?T=4@FO]68^;\4=1Z:#6/_OZ?%3:'V;;?[HD++>P2[R(UW'T M1GJJE*]/3R3793F9Y1264UE.8SF=Y0R6,UG.8CF;Y1R6R_DL%[!<
MG^4&+#=DN1'+C5ENLN.*)ZK76IW&W4E\(A<6YX;].^(3ZL$S7G!#_B@^'=Q" MH%W=UQR\G)641+/5UV6R_58SF>Y8,==<)X2>R, E!NRW(CEQBPW8;DI MRXES0_X=L0GNO&
<];L8?Q:;#SOMV=?'P?1@?U,WNFH8W6:H\,K&=]RC793F9 MY1264UE.8SF=Y0R6,UG.8CF;Y1R6R_DL%^RXPQ,1VS>W]:];CI?12&#GJDV[4] MTIM#
<&FT7B]>BN(WN:@\K'5T2C793F9Y1264UE.8SF=Y0R6,UG.8CF;Y1R6 MR_DL%^RXPT^.;COUVY-^(W39 47^]WY"&X_9KUN-E]E(<.V]_;
MU>W7W=,SL7^49R"V]AKENBPGLYS"2S7 M8SF?Y8(=5SB?J-4\3@]|=MD!RPW+GL7-7>VNW3@)0>2Z8Y:;L-R4Y<2YD?V. M$ 0W:+,>-IR+(:AST*#=J6[0?M>'0M7FU8$(Y;HL)
[.ZW9;G1./A1" MUQVSW(3EIBPGSDWOZ_,0Z\&C6W"S^R@/'51C=ZJKL8,HB:-4^BPYJW7VOW^W MH\)?OOE\$?8@BNW68]+ M D=AJW$0MEZ**IMOA:V'5;+^2S]*']7-
YU!_M(^2/HZ>DS?2%9L]S;*=5E. M9CF%Y526TUA.9SF#Y4R6LUC.9CF'Y5R6\UBNQW(^RP4LUV>Y E5_K5BU8ML MW<-7'_2K7NSY1D5R7Y6264UA.93F-Y726,UC.9#F+Y6R6 M]
(7[@'!P']8&C MY'50ZMUIPQG,YR!LN9+&>QG,UR#LNY+.>Q7(_E M?)8+6*[/<@.6&[+<_ZOMSIK::)#T]%7%Y@N5*EA," M]N <(. @(+@DT$A6M=[O>7OO]SW[?FS5-
\K)+*>PG,IRVIFK[_N-?AHLKO;] MV IOE#-9SF(YF^4!W]WOE_';A_;%8YR,LLI+*>RG,9R.LL9+&>R MG,5R-LLY+.>RG,=R/LL%+!>R7,1R,R7,9R.RG.A*!SWR%MP[
MSGI<$FCDK5KO^'P.[_:QG>,H)[.W ,$' 0$%P2:"2K6H/YO+W! M_) 7JY;OUZM>]FHOK:K]\V]!=EAO-[?3%=MFCG(RRRDLI[*EIMOTE^6>VG[MZ^OZT_)0K:3#5GI;?
I,.GROIK3&DMB_OWWY9[_;GM[*^[\4?35)->MKOO_];1^N=[[4_?V9P._^EVF&:,V%&N8+F2Y417].@1YN F M=M;C@L=EF%O4FM@7[4WL'V]+_GCZL'TLEU_-
:AG,QR"LNI+*>QG,YR!LN9 M+&>QG,UR#LNY+.>QG,]R Q7,QR"Q7,YR!Z4L'C.8OU MX" @N"30R%FUAO?%D-V.7+!U[B@GLYS"2SGLUS RG,9R.LL9+&>RG,5R-
LLY+.>RG,=R/LL%+!>R M7,1R,_5;O#^M?7 M'IN*TG*SDMYVV]_6JTH:#@:,_CSP.N9^DXYK_1#\O?ZNDI33YKV_5 M[P^D2P\MN^T5:'4_BM%IY.H?
EYKEZAY<;J3H_K?]V>EK_^SFM]]+HM-2/ M[[7FT^WMT_1__-REBM8KF0Y MT165>H1/N/&>]:B@U B?M<;[17OC_?W;IX\^Z-F^\,,)E2W*1SF%Y526TUA.
M9SF#Y4R6LUC.9CF'Y5R6\UC.9[F Y4*6BU@N9KF$Y5*6RU@N9[F"Y4J6$UV! MH4<$@POU68]+ HT(5BO4/W[-[JQ.V&1%2SGLUS M_:MTW9 M%P:@7,%R)44 MEE-93F,YG>4,EC-
9SF(YF^4Q3;]R*LMI+*>SG,%R M)LM9+&>SG,-R+LMY+.>S7,!R(S7,)R*S7,%R)@G,)R*LMI M+*>SG,%R)LM9+&>SG,-R+LMY+.>S7,!R(UL,1R/+|]*&|\Z
M;C0=/TT:!R;L^:5G;M9^?AF[;'[GCZ6X]\=2LNGX7AVN6QZZ[C);#:97661 M&Q]C.'D:CRX/S-G/4;!/V(K*,!O_LF#]]W7]WS_O. MU/L=+W.;K5>?
*LG>+C>2^+2KOM^F5^M(^&7[^KH\'KI\?7?^M6DE.M7O^?*I1 M4->;]PZ3_V ;?<,=9S/H_&'Y6264UA.93F-Y726,UC.9#F+Y6R63F:P!P2SGLUS NGK?[P_YVID*
[Z%E.9CF%Y526TUA.9SF#Y4R6LY<_0Z)T60P&%QN-MCL ML@[+N2SGL9S/<@'+A;=^:RR._]O\#1"Q]\8LE!]E[O=M_7FD[3\LOVZ.=Q.
M0VCO.PG,IR&LOI+&>PG,ERUIFKWWLQ/:6AZSB$-IJSG,MR'LOY+!>P M7'CSM\#3]6^!B%TW9KF$Y5*6RU@N9[F"Y4J6$UWCNT<@8KO*88^;WHU -*D%
MHDEK(!*K/W_=']ZST,MV=XI!N\/Z;\N/RC0[N,?#$,G)+*>PG,IR&LOI+&>P MG,ER%LO9+.>PG,MR'LOY+!>P7,AR42].NIVIR!-+SMS%XUKS1>-AK10[_^S6 M@D_#2?-&-
:D;MS,06BC.2SGLUS %]I6S7(NRWDLY[-C?RSZR6?UK[&*\N\IR>^[^=@M#^_M:9:364YA.97E-);36_*R+V5&*62U@N9;F,Y7*6*UBN9#G1-=A[1"6V6!KVN!'?B$KS
M6E1J+Y86S\^[ZG3S3UN98P?R>$Y"FZ593F$YE>4TEM-9SF YD^4LEK-9SF$Y ME^4\EO-9+F"YD.6B7MP'-P&1)Y:P7(1SHP]L9SE"I8K64YTC?P>(8HMQ[8] M;OXW0M2B%]+:"
[$?:9<4J]7ZE+>6K\VBR?9_]78N0TNV64YF.87E5);36$YG M.8/E3):S6,YF.8?E7);S6,YGN8#E0I:+6"YFN83E4I;+6"YGN8+E2I8377FB M1T)C^[]ACTL"EPEM6.O_'G[OL<1:)H=L?S?

R2RGL)S\W;A\2S%-G:CG,)R*LMI+*>SG,%RYIF|>'/EC3N#+79= MF^4[B9CUN MQC=2TJB6DMJ[N/\=[Y_S-E7[[F#[.3V>N]A6;Y136$YE.8WE=)8S6,YD.8OE M;)9S6,YE.8_E?)8+6"YDN8CE8I9+6"YEN8SE54EM-83FY M@.5"EHM8+F:YA.52ELM8+F>Y@N5*EA,"]N <(. @(+@DT$A6M;;QX]=MU[T> M> ==N_1XIOK.U6MAQM.KO1^9759A.97E-);36RG,9R.LL9+&>R MG,5R-LLY+.>RG,=R/LL%+!>R7'3FZG<)3N9/EWl-C&\=-7J:SQIO%D[8DTOO M.KF,732_:l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|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{JOIZ5FWVU>V' MHYS, <@K+J2RGL9S.<@;+F2QGL9S-<@[+N2SGL9S/<@'+A2P7]>(^N!+$5I[_MX"ZN! T&D^'BZE+0]8&3X71T=2GHAC<_UX6/VXZK.7MB_2ZW;YP0876SB.EE5OWZP> <56=:.;5ZQ'=PHY["R_DL%[!G[/W=]LMZO]_NODGN M]E!UO.FDW7XX/J&,IB_7@("'X)-!(6;4^[OGWZD]LQVC. M=G&CG,QR"LNI+*>QG,YR!LN9+&>QG,UR#LNY+.>QG,]R Q7.QR"Q7,YR!OO> MZW;C\33%]FVCG,)R*LMI+*>SG,%R)LM9+&>SG,-R+LMY+.>S7,!R(E6_%=]Y7,*>7GKGLAF[;'[GLL6=QY7LZ8FNP=DCBL!EU:S'C=%&%*F5 M5<|;2QN_/S[_W[IG>>7LP7,ERHFMB]\A J JVM\.06S],LK)+*>PG,IR&LOI+&>RG,=R M/LL%+!>R7,1R,R7,9R.RG.B:ZSV2$MSIS'KY[NDOTO>Z9:DS6_5_K#==3SWQ78^HYS, <@K+J2RGL9S.<@;+F2QGL9S- M<@[+N2SGL9S/<@'+A2P7L5S,<@G+I2R7L5S.<@7+E2PGNK)"C_0%5T.S'I<$ M&NFK5@T]_U[3R#WWQ;9$HYS,<@K+J2RGL9S. <@;+F2QGL9S-<@[+N2SGL9S/ M<@'+A2P7L5S,<@G+I2R7L5S.<@7+E2PG!.S!.4# 04!P2:"1K&KUU//V>FIM M=RIZ?-MMGZMJ|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|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|" X9[00 MF1#)BDW.55-NVIJH*$>9 P'Q(60,)"(%A' M5?9.5;965;>$;UC"7U!.,%7)2!^^>\3)EM91M5G;^%/5!0GS(&$^)"R A(5 ML(ZZG)VZ'*T\;G).!94C=D1==;AI[+52QIEIV+TF2IOE5!%!PCQ(F \)"R!A M(1"L(R(W)R+W?2):DY>LZG3%&WJTO=*S?#H_0Z9=MU>J3O54&W^JU"!A'B3, MAX0%D+ 0"- :1VG@GM?%I?:Q&LW! 97R"^HFC*:)QP=+UD ME-8)JJU%MB;Y"]HF:8KF%#$]!ACB2!F5D1]4G%%]!WPH\O2EO0T6!:OB%PD3 M=P>V4%:/7S]N5TFT$]$ODD:?.94#6DD;:_';,0FAF011BR9B[U1PJ)-5G*2 M1[3\]!F1AI9N8BF"QE*Q)*CNAC"?_(Y5CQ5>$(O)%1985 M\B8M$4&6\0N:DS0MQ/XV[+5PQ? %9TPTY0X|[!2)'7/("O]+J;%?DB:*<+@N> M"&[\0>Z]*J:YFOID524J4V_K(JB+HSKJM5A_JXN5LJ2(JYPQ3479R4-$>3". MBL7>63/:G/>9JOG0ZN'4Y@,2YD'"?$A8 D+@6"=YF.R:SXF^MO14"3*1D-+ M.=44@(3-(&$>,R?' QG'<5@-H#,&1IF[(^@,S(QC=:8-;1"^5]0O)3M'YFG M%$4;QF0[N):M:)&K%*/GG2H94- JLH>T7T\A0U(T'FM9O:/9;:0/0M*$BK5X4 M>VZ]J17%[RQ9)GG]$%U0G;73@+K>CL+9T2<\N9XA:1XHS0>E!:"T$(K6E15N M986ULO*>18]3Z$DI)'P@9E6K.M6G.%E(D#0/E.:#T@)06@A%ZPJIG0,QM?9V M/3A:B!9*|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|S]7!02P,$% @ 4HAN66D ?T1T!0 M@2< !D !X;"|W;W)K&ULK9K|;YLX&,=_O[_" MXEZT25O#2Q*27AHI*Q! ::|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|[E[]:%5UBQ(TC>%2BOG&'>)#&-Y!P<,. M&9_I/HI_OA2 /EISV$>5:EAH:MQ2]OEP=="(X9YN#:<[#->8\:'?<@^WWB MG'$O&&;XP?4:V"'C,]U'.<^7FL]':_WZJ.H,"TU]!)]49P% VU;PW7 MF[DM:W@@!55@W- L]A.$=UG#8(>/G#O91F0NDR_O06KD!JCK#0E/CENHL@,MW M1@SG.Q>4=,AW"+YKI=$HH\:#E6.1/:^>-YV32;L,BO7SB3>?;IYI?;IZDO/6 MYZ? TX_GZR=029OV@[.LP>XZ2G,S%4PEI#:N:4+9^]O3Z39$N5HJO?DR+(HU7 M+V&PO=V]R-W965T7VLTNMMMH*6Q150B59*VV[]?4G*TCJ,(76#18/$R M<^8<4C.CT9Z+;S)'5/"C+)@<6[E2U:5MRS3'DLAS7B'3.VLN2J+T5&QL60DD M6>U4%K;G. .|))19\:A>NQ?QB&]501G>"Y#;LB3BYP0+OA];KO6XL*";7)D% M.QY59(-+5 _5O= SNT7):(E,4LY X!L7;F7T\C8UP;_4]S+HS$8)2O.OYG) M/!M;CB&$;:*(]#!V.$4B\(:1K?#YA6&](X'H\?T:|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

M5A'$89)=_==\(/8,"*XPP+D!3N/.'*517OC2'P\YVR&NWU9H^B;M:FJM@@L3 M_55FDJM_0V4GQ[/S;Y<7CU>7Z/8+>IK?$6?+]CT MPTA\'MI2^=-6=I!CGV78N *]AZY9(E<"729S.G]O;ZLXBV#Q6[!G& 2=7A!WLH9^1C<3*YU3D%\ #*8:#I!Y(A8=)$&SB3>1+,D>WQ2O>5 MSL,M1=,D8#%%GZZ8$) 1]RMECJ:2QN*/LN')?'GEOO1\.Q5K/Z C2WD0E&^I M-?[E)[?G_ ;TQ"MZXD'HXS.Z#),D3)8J:2, "6A9@!E$-X70\W<[=@EQ'7

*165YMVZ]5=TQ453@ M@9]'BIP/+7"]\Q7DL>"MH)MM5NRHV?FYAQA$MG4(>DO=+U(P(L3 00T$B1*T M[27%@ES1,F:IL(N/-D]):S[QIM+VD9]A!SG9MA-,0\TW46T,71? $XL<&M'OY MFRT%T<1S /A3VDC[M1*N<"0DK)-4.3'(NJ:LJ;M[$U.RRBS\+3.X/H$=@AR"5I!QELM=;B"SZE_"CAW!AW-E(%+L MWM G2D OI&/[MV+]VU>HY0WBVFP]:4P>;%+' ?W:PV9W05'3RNU{<2R^"*< M5%7'\C.7$0Y_)[WY+DEA$-53!,5WRW6V*STY94Y;M27%'4.1NR5DE-%0#*4)[ZI[B=)0VWMG*]52O-?O.2>5D8[S-6P3l%'4/8E_'IT/"CU+J4TD M:+B-+H?+C9LW!68LV+AMPD_ M0-0O0)A\'PUA/NI7%F1D8(NAA7T,TY+'1&N/&8/[C_P)1.O([J5IV"N39W+6 MIY7DYW/G)!?**

*JC;2II(CV(R*UZYBTE\^.2TR,#(T,#DS,%]P M&UL[;WKZV9Z;G_UQE%@@5>-B%5T7M>BG/P'"*EV(5+HFZ,$%9* 8>MR0 A?R^1)()!+_ ^#\O M&[_S3*+8"X-_? O/^V^^_Z9!@&;I>L/[G-P_S=]UY;SC\IA,G3N Z?AB0?WX3 MA-_\G__O?_T_'?I__A_W]WKW'K$=_6Z8?+=|-@%?Z],W8VY&^-.Q*0R$G" MZ. ^=SXZ?*

LM^$MYVMDXW0JDA#ZA^S#?^O|^.V''QX[[U!XO!VOU, C>,'F;# M8[M/2;-_ ;===U^_?OTV")^=KV'T:_SM,MS &IPG3I+&QI:^?_E^_W]9]7_X M7O#KW!C_/#HQZ5"|@OAO+ ['WSV 8=_>?_?KQVS!:?_?A^^_??_=_[T?SY1/9 M,.^|@,&V)-|<:K%61/7>?_KTZ3O^UT/14LF7Q\@_?,/C=X?N'%NF?_44Y7,]*

MB;V_Q:QIHW#I))QVI6'8N_8K]Z]_ #NX_MO7V+WFP/X',$H,F_MK#KLOY2|XUE]AE[3+. ^Z7Q?7,QF%L19!Y;: MD.&>_/Z[$W@!&?

R6TD+T_D7/[Z%/HNM51JL])UJ7G1B3/LZY;\AK-C;;8HS)/(Q)3Z?DW|HD3TZ\R-+@>!G'H M>R[_DWX$5FFM,>;3S<:)=I/5W%L"M4OAWYSN0S3(*'3^11^EV]<7A6,6FFJ M[_LO4+.U-PHT7QV&T M&X<)839L_A1&R8)$FU'HZ)6]0E--27%HF&EH1%POZ:XCPG56UVEl$:;Z>$NH MW71\?W>7.A'524)YI1_6=5!3K:G>]4GD/=-13>K

*>42M)9M[Z*7D7KMZE,>G&,5W$4*WB?YD|^MX:-F74:+(YF[#9> F?33.3 MS[I#X0-H!*]J4[VD-H9"Q13<7?E=9OOYZWC1=QM2?_I!0Y='SC^,(B3*.5+!^.^F[77O#PB#1W$ MB;=Q$N(^Q&25^B-J[%*3@[XD@32]Y-%_7&LNC;:@$7AM>$*T%W2?6DVJB!M-+]2C7[]ATW M/'3M19%K9/Q-4_4*[.V53$VW6O-*

|G6]WX]RNUI@8<%/-2\$(>3S:I\2ELVHVE]_T)1,^]5(V^(G+[!T;V2>VO)?B4V!"3-IHRRJO M;-F]:OTE|$$7ALJ'NBYI4=7^;\S>-Z"_ ,JI"7A 0N<0|-,1'@

M(7^)E[#B^SC,]YUW+&B3^R#I/[.2^ZX<.N.'R[/O^RRX,8P T+C$RZ"A_SA! M0W_XA7^H^QCS^?W0DN|\$I^W_PLM4RCRW05Z=4!B05L4=^]\1+%/>=]ZT;(3 M1E0%-:'MIQH>469S7^*|+0\M2*+=|\\OPCSZLHW.C0V2,12CJ:!XI^XC)H M=NGW7=:'6]!9B^$L\ 'B^1X#4*$T6(CV2;R,O&T^PDT'[%E)(+X?4/$5R'9A MF |C9T;6'NLOZ|HQ>E-M%R15@,!_Q+042FF1&.@& =W\S<@VC#3 GY<$XOT# M)MXBV9!@_E?]1 F)_!T$Z5)A(-@_8H(MD1);[HJI.M#A@\|$|')I(.) 1EUX M2&1$@GS^1'R?[=V< *3EHO) V/^"";M<3@N YUZ)/IU:X-CG[@#A_ZLM\)>D M16)@2B(O=.F4'@&P+Q4&HOX)$W6)A*AX#P(7BO:Q*'C_@P]V03PD]&^]>.GX M68|NZ>]B-=R"XE#(4?:<6C%18?^9.!$8]%QA*.0HVU"-B!*

<&O)=&T5EGE%9% M7AH.3PY3L^Q+I>"8HRRZ90)A8+MP=,0)"Q\ M @ K?8DDHQBA[395P*#CW"#L]X>!2U[^F^Q40)>*0I%&V6,JQ4.!>AIY[*;. MW0ICQ4:Y+/!1LE)VE6D*

4M!?.RI"E4O$K40PD/>C2*E#L4;:5(%1*!@&RS#: MACEW<8|%YT2[7N@J3;JF(I0.E/VF@>@HI'1=E\(5[_\S\@+R7D6%L#CXC B/ M (68EL#^P0SV#W#84?:A6C$M@?VC&>P?

X;"C[$6U8F+"WJ/_G$2+|*OD!%I: M& HYREY4(R(FX'RFF433*'SVLG1C.M1+-:#0(VY1U<*B*GPVR4.T_5 2BC?B M=E4L'":,TS!.'/]_O*UN)2DN#\4<<>,J$O32#L:,=^:TD(42%8I

*|479]PK% MN32DC.&(.'+U/2\!!11E RH2YL)XCD)VlO$4!DI_:+D4%%>4G:1.J$L;?3*7 M'$N'?NI/X @V%+-:%./",'Z)O(3V@&662H.ICT9R*B8H"H479?NG%,_"4,IY*

M)#V['5/5XB1=TJ|>HZSJ!P49)3-GERP"R,\C=@EZ0VARVX>Q\7N&D23U4IF M>57EH8BC|/7T@N(B/XSCE$2F^ MJ05E V?9!A;ZTG2'+E)]W?I,CPMV8T9B*

M94JEH%BC;/ED0ET8VW&XOQ8UWVT>0U]^/418$(HPR@9/(=[%03[KAQC>0A$H ML"@[.Z$X2#9A\+)\8K<1Y=$+XJ0@0%%V>BKAT&SO&F1[UX:V%V7')Q,"=LL M-IR.J%-"*

37,P@K@>S:8B"M$O?3J/7[EASV0$FUX/VII\2P2XI" <>Y(JD2 M[]0IZZ7$#2KTC'AXND-!@JGVE10 G#N4 *%1G'O?R&^_]!^#68$R<. ^)F M2WV5AU]:!Y M)WL)2X6XK

*84>,1#1+6P2/%I"6%]|IY)WTF&>&=-^F"GK0UX*R@+)= MA0J-,[?F;O(KI]:SF(L%P[DREC[ZWO/5#1[DN/RL&Q1=Q%RH0"P7> M&R?X-4]WR7+'L@X2PHY/XN-H VR(@ U *4',N"#*

*<;=IDH7/XZ?Z)" MYY.?*YT&RGI0:C O<0($1UH%Q:>+7L2]V+I^Y&]G&C+0*E [$;;%&7 $%__BN),N(_[+% M=+/BI]O/TLY^Z+SK'(\E>-Y9^H4@)F[G])X2_6'?4F??*

5&VE6CGQ(Z[S|OK)_'A-R<5V__BEV,W<^]V3<-LLZ9(8+NO#]M=?[C4DHP_5 >085]. M-TQ]MCL6#%"]GP8203*IU5"IH*,/L(V0")O7K'WN;*647*F4#+P<]W/WRE& M]#G.W&|?*

*|FE^-)|>"A7N48ZRM,DV^%/;'7]|] 4 M#,?6G!XZ>I1DPL%'TYD'C#Z%/H4SAHX^51TH<:UY0< #4"|Y.CGG8;V:V$QA M82@=+09B;%%619K;%7V9NYBK"Y0ME80RT6*XA2$3,FGKTO"8+'<*

MXWNSZ/W\2W;5>1'>$)X54)1>A94K%X,BVZ)O 8JL6 |+M+OKNOKRFN.-/'<|= M!CUGZR7"MR0.AVFR"E!&6O0M&,JZ1G9\;I;+=)/Z[8P=U"Q7"41>6(OO#P3

M=AE]0T9A'(|),EDMG!?E^:Y90^# 9'NXK(85.L(.G"A@R3ARLO]834|!X.P/_(-]LP("QU FR^$5>SS-B!YARQ)+FL"3@$ M%;JEFWHDQ2TC1*5L!7XD KVEC:I/AU*UKBES5.'7.55|\"]OMX%K2\ODB8AN#V>%:-TV>PLC[77B(*!:T7!%[>5>5,ADS=E(/>M5"6=Z\FLG M198=_PK[]$ZYKI*N2M)U?,\W% 1TMLZG5?.)"UH?.R&20?X)$T LXP|^;>GJ*

*M8>]Q*_)E[:0EZJ9NSE+5N9K$2'K!K>0&-&%I*UY:-B0@!.A4Y6Q)S>K+$B3=/&G M]VI2Q -$]_$DJX]>%'D*66H<6HKX+RF+-OA?60.]GY$>>*T,4KPO'QUWE":> MK/:7?L. Q0.>Q5.S2.ICM\^BY7Z 1UF-'A9^BD; M_"QI(?U_KO(Z0:7&D,]"- 268M KPV7!1! M6D=E8, ^^##C! ^AC.C(MWT745DVC<*6ZM'%6"/LLPPQU@7Q7'/5_S&DQ>-*

*FR*2K6&W5'5%>S##C,FM;*C MCZ4Y\6ESZ5L2I]Z+&GN_$"C_62I9S9]UL1<@2LCWW4H6>B&"5F@@LZC3.* M)OT\>VRG3ZVU'+LX%KV-*

*-6PSSM,20.A@,Y522H#0XA_QF'*B53:US"EG2Z\ M CC,%\8^ ZDXC97EO6(6AT%"*.QZ*UDJB'T<8L:>1$YSYCYES 5DS9P+J-RQ MQ.*$P(T)H\3[G4,_6?6].$M!3F> ;40V7KJ)V8-:<<*=(*

*('**JI:'?>)BI@GU M4$.?.^{9}.\<+V!6:!*4:9&S;D>]_# MND'G?&_IH^@G3J:KK-8)N,IU[E]_;BY(0%1NF^E%=!?[*BB%E+!T>T&72A M-K&%8NC/<9B1(!3RBD?*

*3>6!BWWOV7!*X<0&4X6;K]+*;M8+ ^C|<9Y54PMP1 M2Z(X^H3VTSUV7Q*Y42]%_LP'D"QAYVVTC-UGQ._S'..Y$)-IW]8:) ;60-L) M:0C]/8\:UA4.U!7:7U7TPUZOO/60?*

*96S7*WB)P@IM@QZ@*7_^1G1+K_3C,' MBSZO09%O?0W^FL)6K#78T0V.0#*]:B@KH3]R8AIMH@7@BHW&(<_FX1Z"9M:0 M%$=_R\2,4]70Z".NV+N^YZ>)*L1?6@'|<9-ZM!0$1R?F"V'/9Q.W^TPB9TW& M*4ML,5F58[@U8\BP&?3W3_ZK_^ELP_COG=/' M.WJZ0(Y\SR4KK?9L#*CZ6QK96FED*^3Q?LLCVRHG5YQ']BVWGRJW'UY.V;?< M?*

JK1)]T0T%3#OB1393B D,#G2_]LE98[>!/8]V8J\6B*$#JGQ0>L M= 3*RF/?J*G"EEKVMF8BRQ\#:#_]%'CV0GH70$)%7K3#SUG4POMF6SJX0CIZG"A!/="U(*5/5?PN0V])*

MY1IAUIQ5I+0-E+GM&AF95:%?M_<262 M'>'5$FP2B0W^8%7_7;1$SO #$QC+9U2%MQY;&X+IH1;- L>LZ(6OP:XW=9 M>H'J9]RO2;OH&2(N,8*

*;9+C535[VZ|LPFI/HV5M6W=0)FD'/+=`()DZ*CZVL MYM|CJD.KM!WTK|/-K,Y:(I:*0>;=2!)_?WVHN\SR;$Z=G>0BE-9 Z5I$3^GO M@!&&H88^4$^L).)%**

*F#/5QZ)_QA'Q+$G(C!9NN'.T*R=PK3:/E$2TRC?S-@9F09K@/^!?F(1^L0>IX)L.E Y@Q=9V6AO=73ITQ9)F'Z M!Z,(F MW SUI!E@_4?BY:F=7]PD,V\O7 =8(7>*

*[")M38B+/G0)LD&]P!]^N-EE8Y0:"I_@VM50 M],2^+2ACR#ZV6DC9Z|@W/ODP:!;**:)#K1E!T>AMT@T#:A!**:(OK:Z(K9*9*

*MNXR:Y6A*SK,$2RC35X,2@^P>@IOQTJE\CVV7SX8W&RQ8PU2ZG_-+71V^6$0 MX&X7VKO*9D(QOOL%(LUK)/RBM|E,5 +?_U))O%>A(W4NM)EP;$&XUP7'.6XR MSIX3/|WZX=*

<3$F?9-O]<)=LF:[/#&[4]B^915/DF8)::'YMUI=I%+(EGWNS M>Z T#(/C4ZQ=NG%^YGLKO7Q5V@*.WM;'KH+(L]>\(F+HR^AV7V%]BZ.:@+?Y M/L-IU)GY\SL(#A8>CXYDW.1-*

*C:^V_D:=@Z*QM2X33+038%#)T1D_.<^YQZ ;N%[KI<"@PN:BV2=3S'4^5O-FP&>P$%!?DOQ+ MK9\I"?]@/3L2UL'.(7$))@$P6#*:K~RE^M8.#B\XOAM[IQ/[ZXC[K\?%0M0*

M%3LYQ@5U" RDA8^&'GK\L V#W&DL!67CQ7$8[<9ADK_J0L<#2T^YV4I6CJS1 MFFUBY^BXU)S4"/0M+35X;.G^&>H953[V\/CZH-F/R7WH>BMO*=L^L";,6L#. M\W$IRBO

*BKXHZ1/*QM+3;!7/2Z$G[[BH]2_CT]*H'%,O:)|'A.Y'|UHD6_>+ MBZ)GW;C40%,AA3ZBJ*P1ZUB?9)_-2;>_5]WXYFT@9Z.XY+[=6-L+52'0P 5 MA8K05:3R'318;?*

1T&A5XT1$K1^FJMV5E0=G&,Z ?4B9@OUT7/]M&"#L>D0>F6*4 BII5M!YKA*:3\]V']S-(CF$"<+&7T_+)Q M=@\)%2T'H'RO1K&\//2E'RIQ#$;5*(69DZ^SVL:BC,%@O2+1A7F+;_4/V$4

B MSNHMHF?":$4JJ!JE5K,G\(H.?0:QGNA"GI"BU:(%>+2DB, ^KT3BU! 2MSRD M(GI*C/KT0$5]!7MU.%A-K+TMR/1V. U1^Z*MVI,4O;_VOBWGCPLD13=H!,__ 'D!&LRHX-*

*AL%H1U3;OTOVP)VT(M?(N(P]45*WW7" M0&%;;>B;/9E8X(/ !MPL67W;HYCIU|(]J17]X1?:@<]Q|O.GKX^*J5ER.D9K@BK6 M'R8 "9ZW"TG0)NOF\;IZY2]I4K,C K9N>:?*

*29"/X[\$LH,7LDS9I:H>G>K6 M8;3KOG@2;9 4M0#$G;D@)?I=@=WV_V!&/Q/=D\RA|?9E64=? AURI M-CG\U7*+(,/M$*YBYW-I02YD%:?>]#39D%)?&S%*

M&G&NOH.7U9MN^Z_%^R5U*U<:PM%|(%5*&VAK[G$)A?2V6,'-!;*H7= -RHX0#E#+]3Y7#!YW MUOC^K_;]MR1MHYMQ/>]]<$Y\PEQ]>^['SD:RY9 4!:/?_,Y;B6.HZS@*WNS3*

MIY7D9+7REB2;P.-U@.J@7EH/B!+BW%H(@@*+U-'(N[.YLGI 8PH*X"Y;#[Z MRH +@.R7MD;\D/C4,2T+R@I@%IJ/*@L)*IL\>H,I@ MHZOA+#U:WUOM[W=I:3)M \Q:**

[MF<|ZJ871Q9\:Y)]C;H%Y]N7L&;59HMU1 M&+8!)K*5;;S/FR!-C@4Q])QIY<0(YZ5(4!_/2B@NBPEC228YO\:2;85E9, >MN"(: ML6>8#M"#'35@0EL93$DK;@ES2H*

HH,=GM_I8V(<6\L% G$3B3I<0-[Q%2Z(& MWP&K<'PO'3SBDF".VDS/(L!?<7B/9[3X6H)%>NBP%&8$0UFPA0EU KY,/RD MRB."\Q)@;-O,=]+$5B31Y0!=Y<$]QS^"H6PS-

*8@2RH(<%T91&R95*3BJA1QYW-NB@I0#TP(ZUL:37!46"Y+VZ/78_UP_%_ M^/[#\TF-M&=7VFI@.EK9R58;(& T+FW@@SBX"59)3"<;??R:K#*8D7:.V*M% MTZHEM^0:Y2"*V I*

*>97RAJ)52O;2Q3.)=NSA<]I"&) PC?U=I_O5H4RP=])S M+XI>0,L. 9FL2O*4*#I7.5C-BYSX9M_=$AQSU)<$C^(WX2%_#&N4)Q+7\!D M^27V60;Z]+_RFQ/"@OC@]!0G!*

*[;P|Q> ^AGF=%P"| +]=!CZ4Y\2668OC M!PB-J;T9J<_ ;=Z4$7#0'ATIN"]3K9RR!WTQ3*X%X6 H$82CN(@O*A_W2W ML8N1&|>&)BV->$U(F5I82(5*HSY-?I\%&BWB:|*

G7I;&Y9XD3ZK80!6 M$_>"D)8-$_$OJ81/$S[C Y;$#&* %,5QKP=I.= *BF?NQV'R,SF:4*(;$K"; MN/>'M'28B'IA9FZIN&% #BL+NF"3>Z=E97%0$VG15XM8^;B6MO487O3 MB!(

*M/R6+#>;K-[JS/;Z7/EDMG)<;$1"5E\1&?.I; MPKTTU0"G4+!P>:4&Q'>"?0>'FRU+O$@[S%]EW&E6*A6;PKV$58LJ*>-F,,)M M D"K'E5YW)M8#9&G!^2*UD@"8:!*

[O%)YW.M9[;&+NQ?,3R8AB>F&:$9^2[WH M**$SIK4Q[VKU1'#YH!9$] M'JG/I"5%+ ^)089^,>Q06]E/WP=9C?5 <1:O*XQ|E*X3'/^U$44ESZ'/HZ#T?U

M>J,_(KU@%N"W(U,*QO9<*0?D&CVOERA&#[<<.462]!H"$"EIT+8+9X);R9N M/C*K&T4LRQ=_R/)F=RHSS1ZWY$*<) G<*=U[L=5[//IPX7B@KGVO(;N!F%DA M^^W(?*

*^%DQ_N9\ZCMFM,4>7'E1;&C6PPQMZ*LIQ# M;Z81<9-H$[BWOK-6XUXHBAS58(BZ4$XL;:>CKQ?$;@0 O5@6.7]A@ITI2XH$ M^T_AUU-_@+9&5@OCL^/*AH*R '+H) (@ M,|:@$"*

[V(2-#5Q$YI*6V/P1[C A|ICQF4== #D:HP\?UGJ5P<1X"-)WZSE9 MII&7>$1^LJTHCAN28$2?2EZ.031XB9;3R%NJADVN#&Z@@!'2)R62^,_/D8V|W_FG

*]Z#T%ZZGP)5Q:25<']R@> MR@-,N"2^ UZ/>#ZGF%"(2Q_CG7HA/\8KEL$'6J4J0HBQ M#O $MD-SD*>H81/N\@,]A0!O[WQ_VP:X&I+(G]!HDT\62TBE^]$ MQK>C*H][P&4T-*

>K%OG3,4]X+I?^F4 3W2,MP(2(0]HK<-,?^+]AJ7,/.O@SN MV5L[$NW30:NJ3|I_OB>32UNN$V(XNA+6ACWLL(=8W ET_J9L2 JCSN

MR9<1"7]QO4>8!W@IE$@U1.=R#K@HF1R0FfMME91)L@ 5]=?%G%'7X]"3<%C^ A+W2(KB'CU5,#L285& 'IQLO0B$>[$DICE4!<-C%

MHJ@WD^SCJCP/I7!/8"]@'11/"M/.Z:A[RT|$D^C\.A]R9|V_$5WVG%HH.,$ M;H>U0EQ:$.'@(R|)B1S5"8BDXF59PIL+FX"'[TPB6C/DMVWRW"3&<"QDU + M-5E-MB0ST()CWC^__U*

*T?./NXFVZQN.Y/I8-9=#"?C>7TK5^7ZS"1:.X'W M.^][CW:?8N]F6A*XTQQ4D]4M?6 %2|_QYX>;M7'W,4Y8G@*!NN|;;ZAYG*M% MRGV2?WX?*7#/|! -V=+UZION M?*

#AG(W8Z&\|P'XP4?M/^[Z73' 4Z/CN3):-CG?\89TMWEDF7_MR=E>_3A5U<$9?#=I3&>+.,Z]RD!Y$Q"KFC3WC55I"WGPZDDLC,C]>%DQ8N?I M9N.P++U!S;QWP3

]TG)8P$(W4'XHC=?YP?]^=_ #GM=-CIO#$/0#!C%_1";=Z;=G[LWHP&?$>DO9P^#?F(/#8!A\:3%]2#SHK12I>NSR1*/-[_ND/> M>'$<1CNZ3^8XS)_"&'>\%'HB/>B?*

RX.6KIB_3R8+89LO$YGD_OA?#ZAL^=X MLAC,^0">_S29+3]+P>R^,YITL3;J??*8G/]M'|BR\CAC|KPW@#$IK8 \YM0T M%(:;1FHKAM-

*AL+!-841<+^FN(|*WB:+14W)A'X=%MON;#?I#NM2\FPWXEK#2 M4'E,ECNN0=[_^O@]UZ*;1>_G7_) RKJL&!:L#;,F*HT42>=OG.!7]KW"QU0# M@=735\,:#N9PGH\0F'06C9-*

*;0H%DSVO?I0Z[$T7H!$G[+AHD?RT.DMM!?S#K %CD8_=^X>NC.Z&1NP]2 =-.V,#TE7P8-#6[_)D2'YF'I+@2H^ZMDQ-H!LY <& M&!,K1D:?1-XS;>N9:/9+GXKC@HZ*X>?*

*N8OAY@+|[.DDQ#"@S:>8%#MR?B+MF MI]1+^]?"^ABR"*O1*-9*S;C+H.5_4(-PRQ^2X]S.. M$1C\EE+Q]..Z6 [)!9D#/^L1VP8;C4N#)I 'H9B:HO/1%)&KVQS&Q7^E\FC[ZVE]_0?*

WA='Y_Y%;H-.7#0U;-CM5R;Z()%@%EQ5S:"S<;+SDL!7HA/SFATZEX-?VA%%33 MF]S?#Q?,[3(`,6S 4QG4[1%M4(DDV6T83,XXQ+42< X-6T'>5ZN1%AD%:#*

*MSHI!.XU":EOHPB1PV8)C*W&\!MIME]HTZ81'9>:O_B;/35/%-<: MBN7 5U1M84(L*#K^ R<*]!#QE$3\N13P(-%6!#+4?+:4]@P!H4"GK.?$3VQW M3O_#-@C/CL\6/F#B@-6!]#6?*

*9Z4]?4:P6),AJHH"W(81H>O(7DI['5#A(B>(MV2.|S D;N/S'[ENN%+4:!*H*,TGA]FJ*+7A0[< [$8KBQF>)$\D.H02TZ48 MH5K/HG%YM^5D ZL#B6T^\TQ58HU@02?QF,*

*<[=^TQ%X2@(Q%8'4AB\\EK*H]. M$UC0291Z[,"6%]X"D,KF4^%4I=(4''0VAYLMU3[6PTG4]^)M&#O^9#4*@_7(*

M>R9N=O0)WT96:@W(G9X919!^GNV_^N29^'$WX,7IC"K=CD*]@PE MS1Z'CP$FZ/S-B4^;6]^1@(6[L]N(|LB+/"8?BXW==QIN(:NV!V'79']=1/>3P

MB1<^HSPY9&V@AH=B1N5@2SCMEJ128U#[7$TU< ,G6]V$1(\BH6%H7S9X^]1 MR%R7#TFXI-G-Z+UWD4=$ZZ%G]>'5H618X*,Q$ZQ5>D[?9B,Y'KRP_I=>_,)3S*

*M,.@X,FP#2I0%?I@*TEEBW.9DS?HW(|LP.DH*/ 8%5H=2:8\?Q@@7=!;'Y&M. MPB@,Z# ^7)*=X8$+-6X)R:X_WI2I:5Q06Q5^1$@9%E5*(F 1%9/WTC@)-R2*;W946=UT MR0/-*

*YR1ZJI:P;%WM??+:0K!:1Q||*CA)>(QCRDYM$^U:\26,=^U<76B7*3&6 ML2F!=3T,CDE?.)WK.32+&H;P==*@42\' M09 F7XVOEL_C>&K(NG9XS%*

*[&AZ0XJAY>K5:E/!P*D:UTV.16=MWDY$$P7MF; MMHB>D5 YF0+<,B; 6<1|-X[3#0]YB1]BXE;8PJD;P';'5B46A,O5)|L39YN4 M;^E*"6?*

*5,2>1MW8733ZI]8G,J;D@\IL^.9Q+XZD9L7A2T;.R).*Y ZNE'G.|CG M9I7UI#ZX5CC<*^0BE]I=/;RA5?.2%QO6?<'2DTL$;60/">RRFIN@59^P+]O M+/>P@>07BG!@.5593U/'?*

*PA<*C$[V",:\|FM'WZ-Z0*U()SAPK[^|] 6>RTJ MO?,$6&'H18$>RBTO3GV<'0/Q1]/6R=|A 5F&XZ[< D&A|6*T78R(N7L MAWQ<3^Z_R7L02L#:?*

H++DUF4"O2*N0)IA#ZE'6 MVNE(I?D02MC%YT7)X)OZSI(+>4L(M0E+!O!:%(S"2LL* YGZA#NXU*);,)CR M+NIL-YI9;.BQXGD=/*>8^C127[5"|IS\6;$)=F35=/(6S)%Y)#.996A]*-*

M[W\QPL."87DR[FP5/";)9'6P|KTP5OG0('6AO.&[7>|(6$7::48^5[QNX&;_ M((2/E58K^O:@Y"(Z;6I^ KLL|(?/"9?^9^]>LIS];'*@._@,4/D-9+/;Y!7 MY[Y8'4H]OJ/""(]7RWP57Q(P.;*

*<2>|1_4G-"/IZ-2@SD|VK$+A=[XA.KL: MDE2ZW,3.Z[&_&1-/G1V+B:*K)QJ:B(]8RU*BR.GQ%U5.CVZO-WE@>:VGW9^[M-_1W\)86_ >7L8=#OC(:=F^%HN+#@&8>]*

*[/%!>);R7_]>I*H24LZRHU+9V$(RN_)D.@^6*\H[Y7XOK%N.U"O[] M\M>R:N%S-(17N50&35S=BL88'BLV&+DMT)1BX,4Q>RTH3+CDQS"L4>@$H.'Z MJ3A<>Y/QY\%L,60C=3J;W*

*_G||GLY|YXLJ!#E W=^4^3V:*S&,SN.Z-)=VS1 MN&6G$2=9|$-65AX[:>!9,!TX4;"HEAY7@|2\2!,#B@2R(%M$OE[^BLE=+B4@8|*01YYT:.QMM2CYY#3N8D>N7 MDH^]*

*("V]A_TUS"ZX=OE"0/T@MK@LMK-#IRUGCV*KQ&TKY#CWP4E E!!+RF+O M@DT@5HI[8@IQ6"(F"D";BI8AX^6&1\19*V#RT46=-U@VW M7A#7'E1E>U54]D>++*]*

(TO:AA2)KFA?((I45R-D6KH=M_4WDN6O"7+7==42(M,ODY[RB@(GB19@7R8"3:IJ(7^BQQ0.3XWN_$K4P,N!DH3:W%]U6BR1"EED@[M/ ; ,;2I UZ"6[$Y!P'0WGK]_/.ZY;BX-

'@UWEH|A^%R7"5T2U#7LTE-FZ+W M'ZS8&=EA@KJNZS%\'+|>217: =/56EBO"5V5@6J)..8Z/LQFA>-SK=<<4P|\ MK\><00&HNV55^'C6M^ZOAZ8"#MV'U @+DR$U@.OKP%2H MZX+OGUFQZC("|#V]IE4_8E$A2@3TI 5>5O*W)RVL?-+B"PLAU+\!6"B&G7S+ MY $%H80M32G[:^EFCW(QZ%E.:WL,$*+BOE"4=WBJ%P.BBCN(Q_BOELRPUU[IR*

MJ14K3,7;:P46K&?>WB[7^=AJ)':67-';?7XOZIVU M21O7-RU5$#(7_(K/JF[#+2IK!TOFNJG@K-U9B%UE)[',W0_DYA64QM"17GT MZ#ZY\IR=-^DD1C=MK_*-*

*PAK^0>F+A3^^O5CX]F)AMF:I\F*AI!+TADAK=LSP MR4*E[/C&#.M%R1];2Y%H_Y,2)ORDC['G>DZTFSQ_-=NE5]2\P8(# M@6ZU\EWCW3XD"--*

*M3I05H82U|U0'C#"H/)80UOWJ1*Y^>BD4L\1VF4\K!3ER MKYAA32=4"IU%>E=K=BB#4)%+$U@:\K< MOD5]ST"9./1:N^Y',*

[V[#=/(B#Q]-6@<58N+ELO0!T6PT>DS)LMOU^'S=R[Q M,M=-_W&RV/2'7T9D[?C9B;]DNJ2E2H7LL(\FDZ5(BER>H4M K0FGHD6LBI42 M(5;"]!(A4.<7_NY)M'QR@N36"

])WXC9;)U!:(9,&\-(>E- LVQ!S)%]:#@S MKP=S\WXV ,P(@)[BL0[A!DI0Y<41$Q D-6)^=IN6?_RP>">=?/>? CE41] ME:Q)0$!C0% .?$^T>8|

&]I8!>S;K[.\H:4'!;R,54R;)AB^$_*H^#A<7A2>2;,#VK;-DK^UH[G2(RMIA1RK8|&12T4)L)Z!;EV35RK?VXM M7+,,@(13/9$;W=?S^GCLET9+!NU:^E0UO*

^PCL($_K[#25FX#>5)I6&/"-H6EI5?@YIVH,OA(=&NEWZ M:6K"^9?9J-ILPH#ZI-J;=\DRT[01Z'TQ7*;J2-;N#N#LCMHM(;'WI7OM?J M8*?KA#,!$MX"BY?

*=0#^>U<9)/";*A\|E%="RCE6S9DJQ+: E;VT? F=#A6-G MZ^PM]# 5&C:AH196!4=@VT5 K+2.LY4;3S@G5W8\)7L18X.-4^JL0 H+-T MV KNK[+UTHC!D'EREMD/%GZ3:09H ',G?*

R37T_C:BJT66-%[K0L2:O M#T[8: 6#9JA80>)IT[#?2;"D:P<),H.AV6/!6@#'6EA#I DR.2JWAU1^HPPM M:>]YUVF[CV%,>%D[QO(M72R;S93Y&N"3:6MH5DF./D[V1*+PY?YO*

*IKK6E$ M-EZZ49QWZJN"0[:M(N,!3IK!\, >&%W&HGZF$98&'SB:04S"GG1N3BDXZ+ MJ!ESQ<23-(D3)W!91V53TZ,OB;X"-0*E]!(H%.V3]YW>]0HZ<4' M#]1!F/U?*

*8\4:I6)SX#A_*\BMA=E5KUZ$DH]3=H _6:8-0W5(CL\/(UAB6Y#\D$#N2,2>,1$J1*423L<0 #YT3G2;K)X MZH>8Q7P0M\XFM- ,^'S="B:KH60%N:<^9HX/;[E/X0'=69:J0:FST1TDP:"E*

*M$[_S:\^(RR+;J.WN.?&3G 56%5032@2R.P7_?I MLN69.O!,1I[SR*YNL1V@IGA670O*LQV^%0@"E2E.Z+H>E^!AL(R(P]RVV7^' M@5!@E0<;V*

*"4=CN<(8:XM);A1+@R.MX*EZQ3]-6@9"#[,V#"M$K!P6[ZHE\' MNJ@@."X<'V;YG.C+CNEQ2<1W<_M:0#084.',4U6\F*)P$@_T7\"-9H;SO MKC MB#J(X=(-;A)D'N!\H-*

EGQT_)F'SE?U$^30FJ#B74CG 1(TSPEN_2=["3Q"?* M;77V'2O&)0D"V[(R&1$'T[%,,YL_<|>I4W9P4L6[(]PY!6A$)EA[/#"!,+ M&#S,SLQ)PWPTD]SN37.M1EL5RIQM[@L-

*%IAN*HD9//1X1I;A.F!W393F4%X< M2AFRZT$MA+4T2>;:T\ETEK-A_W,P\DA:.G50V%4^633Z";@Z6.#\: /;ZU$A MOEQK58.]?0%)8]Q:!:]#[%4?:(CSR9R_ ,U>E>&_(/2/_#<*-U/%]J*

J9(D' MJA9J5WP\DA?\##&81A2J0$FWXQJ45O8KYO5\0Z.^"B_]"V72#O>67%KTO1K; M0Q*&VOI(ZB)R&_9XUF45%G[^*N0P.I0+I#] M128B63EJ:ATOXML:Z)#)58!R9$=LBD9N"_?

W7???:9SDLY'P'O,M@QM#J;3 N6.,2DMF\)!Z$RZ=+BYBOLOPI)0A"V(4U%(BJ[PK..3U?E#$(7W M(4YWW1;A(5TZ#EK$VU#:;9C4]\#Z3A$5>18Y+IBE[MC!6A2Q5;0_*

*MMAW>BGJHH9->CJ#O+GG"I:#A-]M.FFQT?T"93-0BNWP?%3"Z*K/W]@;L0%M M=G?;_"C)%Y6&VC=1 T]=*8X6U-: 9RMW0I"-7*C M#*

[&NN_$"+TXBG'+),LKKSR[E:#MD9>$|"YQ]&F+,7)I"=CO?I+_-MIB7')_0"-YN6CZ^VI4E"MT3QF%UC/+N!Z"6LS4^??OSS#[]WWG58VE_ C-.(MT!\6@]E]9S3ICC0=

<;_3FPWZPT6G>S<;#.X'XT7G3_M&.\=6_^N;)F_7';LB M%ZO[R ;;4IJNQZ@)I/M)QP=)6=(=UC_ZG\%O=W6^&PQO% GN0%6UXVVDA(W M.^3,R1".0]"P^=3U2+F*A-*

TK&1E!SB)=160BS8@0DJ@5.9]CSB;Z-"^W^J\ M5M+,'T)&?$@\9E-A0EQO-\6_U;\S7J=5.RC7*W(1]R.T-@ORK-NZ6C-E\%^ M#:H)Q14.5,N>CS\/R%%;45%9.X92'>LIDBKW4]D-*

*M(R=#>F'+&D,E)Q\#3LH MDBN:DH^|(.V\^GY8|"I?%2\60G\51]<@^< *L826F9Z+/-_2%AO +47U5URN MSR&%%!?>FJ^Q"8K;B ^O[^-('REV7L">-*

*#^ZSO)/@"G\& _]X)SE5M$&0O05 M#5&FE)/5K1=1*0F%BDJR/\X OU6M; *<4,XJ33#&"'T]\%Y*W9]WCC]I#:3RO M [XQ;C%O(A30BV6T46! ETNM@*.H8&O L+@\^RK2)'(7=+*

*M(> ^3R%NSN9?"U M=MI]F"<7;F4U%,'V(GC(]$DTMX+WHTXE9J>2QI=]?*E!6RINR^*[G>MO\ ]*

M$QJ=COQR&Y@E2%$%2H]EFWPM".@T'6_*GR+Q3^^BRJG25((29=G>'@0&.F7G MSWX?[[_QE0^5^? &N((]> M0(BW;]YM"A,YI(=)43EVI()0ARS;_$H%M(T(]

M8=5Z]=X6)X%%LM(N5!6B/;>GQ'C=97=GT!W-P2\5KEE+1'7^6CY*<>]?GFJ MJP<'-/+;+6!@<5EQ*N2440:I@NO48;VCWAOI+POWDBY'?0'L^YH]'/G M[]$[ZXX7@T$_NZ%RLN-$)"# ^ M11/U)3;18C4R_=[8NN]"#RG8D2/!XG<4BB_TG:*LYPD+P%:F,Q>*IVX# M,Q"YUO.%>G"NVF"*?;C=P!V'P;*-/[E0&3N^*P_K*

*NL\?"X+P,2813_PY#+9IPA\$#5@*0]YN[$=]NJA4-T[LQ0<] MV6D>P&CI<\A[I :42182)9L5QH6+GO4M)A-N7DI:/AY[,VM/8:Q$F\M7=F9T676DG6JGY)%*

*M>'K$E+^!>TRC+5%=T,K8^^,&C9$99NCFY?3PQ625/4[+X_>/'55R];\#58%&2^94HCOW MH>NMO*4C<=2S[]":V/=|&>^;' *W+\)D4M/-G(CE44/<_7P[XR?!FNRDBASW>O*

MP8WPRP?\2]+V+)BU4#7B2Q@$Q1G9#K]G+]QLPX"!S^3-Z*?[VUS4J5RA'X&N MT-[D?CH9#\:+>>>=$=_1 ?SD9=[KS^P3"KU" M:LC3 X2^%2IV>>;%O]Y&A.2C?DPY5;6!

*[>BMS:D>(.LXG=(]\/D<^A1DMB?S@A^N;*77EFNAY M-VH3)T,#G38>WLJZN;\FG7DQE;L"114[UI^P;8%"#/1W*?)=TNT'1&7MX$&K M6^*:^F>28&| YE272-*

P]G6>SSNDLFK(2[A)?KEO% :(7'=!\\3[>5%'4@D_ MRX49/TK9V*$GCI(<-_2G$R_TAU]F3K"6.9;HWW-_ML-.;::+\R[G-FL71E2] MU8<.6O+LVCE>8BQ;?2O- :.!%WB;5+ZAH&4*1=*

*V]$6X2F *94$9]/?.BQ;5 M\R)H,5)Z5$6RH$]UHS!8)X?4 UK7O;CT51A#BI42]7A MPY85^CX$T:..:Q+JF??M27!QJXUOS[:GU2AB-*9$9W5*]CJPOT+->::*7']\2 MO;S^1"^YD3@.$](-*

W'T"NI/Z#.^&-2'+IA:O#$ S_UBC(L%5]MXIW97].+" M8E:DE:VY!#G29D, 0[%2"+*@!S/"=,T+UI(4(N>Q[:)]V-XW DP02X$/W3YHO;<:P/"7)83W2"]AI!M_.@'N-*

5[NI+]>]J?T2=+07.BJ]O6E MI+'B'N8%KN[IC,]5W]\N]3?Y*7^'UQ(:&O*]WM9_^)VZH]!TU$Y,:W=8+SD MC-1QLO(QQ&T;WY/?2';IK)^QABV2GN)CX@^IBXGPP8SG9;CK3*

MV>!V,)L-^IWY8M+[!\[M9-:Y'_S/_W3'P_&@,_C7PW#Q,_;5Q$Q4_6W#8KF6 M_++GG.C|L,7RR&XJ,9H27ZM85NS-9TLOWPV+VPW<[!>$_E%&];!]NUA>P_5

MNE!3N%8]BKTG%G(Q#(YS2AH79A70"E,V>IMJ'=MO"1CLS0+9>@]189"$O7"S_M"8,L%91V15VN@.U"A%I@E;BMXMS -&>P,FW-EU9CIGNE]\K#8V83NL9.G,"E

MPUBQ@OQ1M8+\TIVQO\+FG2)!S),W4/K((QC31H*LU;LB+X +3O,!,//20'L;VF37)G2D6W9+*HH M=#721S;EP3A>2|K4^!1)"'CM35SMU5"]D1,]9T:A6[K(-DEQ. ^@"]6*!'XE*

MJ82WW43AKR0Z+$.4D6SBHG;LF"7:DE]:JB1M;_$>]ISV=UR4@@.7%[=BU D#6 M2=P2T(>/\6-S=Q+D#ST@8]H'1978Y.?N%4!.=93>KAFV/#4+[R V2#W#0[0 B M*

[B#^/[M$F(;EQ#?O]U"/&R>P%?SQHF)R^P7-5Y[]"(F"UO)WNQ.1;;.CE_7 M^.I$["FU"0\HR.:C7+++G'-KG&INE_DZ\@'?E4=$Z57P2_'U-4?,+8 UFT8 MK8B7I%1YNH$[>-EZ418=

<5'U5O0">VMFKYYKJ;OJ(,P6 !N\D&CIQ<(W<=]C M?=5[!VPO;I_6V0.O;PK?UK]L0 F"O/@KA M:BGD "79X-[]-XEVFWOHI.4P;_$ID+A A^VNLNI93K3GLJSH-:5XM,*_)I=(*

M\AEQXC"@ZVGF5&9WET,ZPLAFZX<](HP%4&H:PS[WDV;@0#LF$%0@VH9V%=.MF2W.O8$B#W[ZLS)\GL?*3Z;9(SZ]Q?"S%6^<7U?\4XX;W?0:R^9737!4@Y^P MX| '%#G5H-*

*3X8565EUXEL]C@*GAD6^A5XV.IJ07PR*9(K4Q,::[#0K$_!L,% MH=':#LJI+>9(D<*>^$T#RE;7S-3LT1ZCUIN.[DOS8]1O(QSS:SYM#N]R4>SSC#9' M0"E&4P+4];K),FDNXA.3?*

*PKYY+>YM5-3RP$=*W_<@]\R,E\(VZ@3MTLWT\Z: MG#E]+J+%Z@Y8;QXM4&X(A7]XE;_+HD2#+-O+713&;6S95!_#/NVU5I45U-B_ M,I*

NCX3"M61MF^P$]N&NGIHV3R6^^K(E=Q8:WT_9??JL[IDM|QC'1O+4Z$M M)/9]I2L,K\7?5Q6>PP=X,"VB(:]P#[GM=R?7WH5\15+_T,8:\|S/(/"=!U:],G6N E]_E+,_$_U^,_Y3@-

B2UF.&61_3R$Y6&1[[>U0X*GY<[&W_$YMG,'\T=([=>1N:5BV[L@P#>Q WJE*X.F-C%@ MW% ^7:LV\^-?;B) AW:M02NE82RZE8>)/HT??HFB:B@8[%.Y1+^DC;$QMR9+N*

MB]GCVXKD!VU^$SWJU4C%6@7>#MUJSEYG(GX.?=H,?^O]M4N[[W]+DD[*CD@LB$MM7?EJ7W=J,B7_0>M/ M9^7=)(D\UD,V &3/Q.FKH4==:GF$R2%%'^&TB

*7A/X4^!2[NDQ7!*PF6AZ=L MQRO-$7M-6'0B]-?2B1!+Q//39-0?S.;_^1]_?#^+W_O] >WP]YP,.Z'=']IM M'%M], 4QR\S#]+K9\112]%P[Y4IV^,Q-L^>4Y<_'-IG\^)]*YD$:>*S8G$[M^*

*#HF3B765$<_-0R1S.=[R'P ;!RE6NE1R$2>D*9?)=TZ6!$92WA1*=GB@%C M35H6_K9]]_S%56V"%E4E;,>"7+>* T0O.OX>C??QI@H]DDK8>R%#>I2BM[1_ MR;[<*

*[R+I7P\3%T%.B1:\W|H0=<+8=6(Z%49$9)*4'9;N|=D."24LJ.Z\VWM;U/.)H"#:]7(KPA638[_>914!@:@]5:(#,(894$B#ZNJ[N39N3+*E]0 M^_'M@MK57E!KZRK5A^8S9-*

ATETH#Z^1K0+FZY);@4*1:[0$!%RK(74(2*N\ MU:5'^%9]"$B;-OU,M^0@$?R.=%.N4X0E(,:@N:7"")XR@L#]6CHB|\">4Q. M3]J|- &BLE=G*Q2RY/QS-I*

*!>71*7L,.8N3J!>2CP1>@U,$2+%) F\M&D6G*(+P"(&DZ,8G>X#V%)[./L(@5%HA924[M-[<'"F%RN7HM(HGG7'2 M5+..#*X .PKBRQ;EX1]<:D>-W]?K;KS 8Y']I-*

H"N]\1Q/+=ZKX^L#K4!+9V MU@+2R0)S1M"@6\?#LWMJRHXQ96[_SJ7(Y6G%A5YGX>Q\K5,D.I\VUUD M+;Z&BZH1!6L(2E9K^1,"XIB*

*M)ZTQ(54JJ7V+IRRFPV#A=*A@T]U%XU73N=17:IRLDV2I[V(@(TR0%7L+"\5 M658C@3X*17.];B"]ZF#'Z-==YTB'HSWT@ :4MB+VPV5UB;)_.(V\WU+/Y8!F M?*

*R"!*NT9]#+V"US565.B81ES^;Q\=-W+'%#.&DR=K#;Z>U/5R5,#@L[>^7'] MC+@D2[3(L]!" 0W@/ZFD@F'AK"@TWBN<[E\$]D_XT/7H0-1U0*42 L=,GI@*

M6CK)^!SZ5),&23U8XS5A56%DH+K+H'+8\FX.K<#M\Z2=#=A&BAR',IK0"FR MPOFA$[SR;CNA@PYWKWV8D>.ILV/G_KTT8N!EMV*7V0*?D&UH5Q;X5@Q <2*

M$7FRW7N#3MR3KN8WHXJW!TS;0;_4:#IZS4&R@-MM&'O)R',>639YEDMNN8Q2 MUO'LQ0P5G=]J4 :M<+" H4 GC8O#5LAD0]Q)U'-\G[C]-/"=?::,S|#49P2 M .M#Z;/"*

[6(&"CJ'0VH@XH0GW@PW6R?8':;;$/@M$!]Y3!K<0F!U]"08)@P: M08)X,DVI[Q>2]#X^F4;@DQ(UO*5QL2G>]9FLSN6G MB[F3[Y#_1J4-*

*U=K#N^I623W]@(8^X'EOLO5;?EK)UG5C\I7_29GU!E8?RJD5 MSAXS4*YX"RL1E"\]JI-?K [EWHH0'"-(*B7W?D[BQ92.P0E9:%LX;]7% *T MZH]-^S#@&ZI"%_O'.=YST!5H?*

*#C>GS@\E@RS]U[01CQ6/9LVWN\T7[2G)O= MU%'I[(P:0<^:9&+U*L"#3NFY'4THJ.3HUQ"G;H^ M6>6.TN9DF4;<1U5QO0EH%T]S/=Z?VB!:MT@Y]9R:FW ?*

J,=EDLRSV:F842/@R'X;QG(%>%I:PLZ(F_(#"G.<$5(6R9H6/[@FO+LMF& MD1/M]@\K4AM &*2+\,1SXG=O^=9D<%]S(D4@%&2Q/=R1V7?VPO1WTQBZUDMC-I*

#UA%GC,X<%?5QIXU"RH+(Z M83K%]!$6N&W,07FFL\JN').'8\]WIUP7M@[1^S1(KHMIK\00\[^N]"-4:@VJ M&U8XB>H*

*UD)%9NHZ)TGB2TWN60DHW+C.FE*W+3*:)T,P#.@ZBKVZ H^$ U5' MSY)6/1I9 TEK8R#RGGE.MH,;8"<="X*2X)OO%HP)J: M07OG>,$HC.F^?1FN M Y8I8|)BE$OPE1='?*

*X\|#+).9$R7HG99OEIYTLF(TXV)B>8DN58*HK;CX8YSP9*7UG27?|]X2T@U<'OETT:]:P=;G@FZKNLQW!S?9-+D.[J*C4'9PW?PU(,+?0I576NJO[>1*

*M-0.EUXIXE4H07?<<*SP#[K(U_9I;IYO=],[$BRT ME[|>_BK\XUEKY"4A@7N:%,^P>_3")/*67K+[=AEN,@T_/=|WV?)=<[>L5"@*

M>/+H>VO^D;A/$BK""28O88U^^O3CGW_XU'G7Z7OQT@_C-"+TAWGOIT' 833H M3&X]D^E@UET,QW>=T: [\P]DYO1\([^9C*>=_ZT;_6_OFDRI.C8E7-I9BPW*

*M9KA*8]*-8Y+$=*?)?Y\3LOO(7HA4VYA7OCE ^(! M8X@ZPN1N9'(8!#8IA2HP6PA+E?CL:U8#54"WO6L#L\6 ^>S?O*/Q8K-_X],] M:+%&MOO]8W"\?7&\[PM;L:E;0'NP[*++-*

@B$KVB^KFZ:#>;HYGU[,;YM<_ .M/6TV&4T]M ?84-2A)\TN88F(H!1#^JIH3[RAZ(4R\5 3]H'IWNV%*

8QHM!O]/KSG_JW(XF7^:=V\DL%3;HLGJEHKJ^#\3)Y;DSIMODYGB:S8W"OU4M<"|\U+9G89ZKI4HZT##)%%N?R&5X#6 MNW#U3H77?MT8;W?*

7'#6XAMZLR&=S\MWDUNWSW0!KS^6 O[W3' M_=(F]Q3XU#E^\&V_V[91R+M!?"I6F &^B^6+|XFG)7 ,W62)%)\]/(>PP1:^ MI3-%|%[30:I#<",>|'O\3)4UY9E5

Q0%26S;O(KR&K6HCX(%:]9\/)O-2(E M7:9M3U:YGG9?/(7N2(K_P91 @D+.F81#9EE21RS^(P'=5OA4/;ONQ@O8F^!<.0])('33G&$S;/YC&"CSC6(5I-!M+9\(M^F0;QEX"

*<,=)BF.=$+>R59"X;!4XH;-XONG_0MBNG[C=9_K;->GOWP%T07(KP]O97IA>.,(_UH1%L/R>T3XB>5X!P]GC7[J%56P)]<+ MT*D%S++;W;2_5 &3'46 Y<;;LKXJ OP^J +\IC-*

V^K'XF1]P#/[U,)S>#\:+ MFN%[3:@PEW#J,_P2P%%,Q;'&B4Q=5>QS"VD7P:<1NA;LV-Z 690>(NCDQ#\: MD/:P9'0,5'5DKQL?IKME ZL5%-_E+NWES8XY,-4.)5#EUTUF7E)TE[M<-

*/11 MG?,(5-D.,@V4%LIC7DALA])DM?*6Y-@UG>-(4AQ[TVF@C,6=ADI^|)T&7RRS MU_>&FVT4/F?K=BWPJ[GKWUTNTTWJLX#Z/J$"++W]K=RMSW-:L/,_7&8]*2]*R*#&OH!V*

*MBZ*N+C4-\M7/^WD4Y)IS7@KMHD1=]D7"7G4V"$-USIYRD,+WOC'3H?\06H*B M"UL0*.1_)#5$G+I0S(96\BX@45H M]1W#5CAO<91?/K!!$W<_+K.S6_3*/ 2NLBDDMUZ+^Q?*

*6KI4=:P|KM&RI4<"G2RA M0FE.V%1UKC6X08\#.E52V1YBLDK]D;=2[!M E5]?:$(9FJMV+XL,BF:P*JI8 M.PWJZ-;"@#]6]W=B;L,H?U^&_MM-E_SR#4\9!!BOT :LG1VU8]8,(G1*6SP?*

MMB\ZH-'SX81$-B2$3QO[CEM*&QP\,[V#.$U_*%T&>]B9#_[UP!RE@_T?YM+M:E??MUB03^\FE== _HZ>]T?G'166MF-'KN.BZ.P4BH+OV"ST"^#.E->PDAB5

MCTLN"KZ;LBB&UC4IK7#MM%CD;A3T3.=D5%2QDQBU.U$A#K83L= U;4X=<7'L M#;)6Q=2$6.9[ZI/'9!C0F3'E!X)

*R8J:^<04=@ND1#H*DG32)#T%,EG0CX?;"X)GNRSRJ*G2+MO'B.(QVXS!1.,I9 P;U ML7T[.JW*YTPTA@7=P8-29K,+DL.7<34O;I M7)=TADQ4UA(R= I63.@LD*0=&S8GD4?*

BF]Q0G1&7D(W#!^W>+<3[H31EYLU@ MQ\G+2MORZX"@V[2\C[8HT'FMG?][-2>&$!5Y&-!G2-#D>)*B04Z:UR3AG&< M$K>?

*1EZPGF;AR4\4E7A,OO(_*6,F\S:*/MGS*]H>4NBN'9IT 3VI=Q:[' ML8S.LI50FE&AU.HVL%?^M0B%P-/HR3K>MF'^%$9\.F<(P+8+A2K8%U)K[!.$ MPF,&FQFMA:1SI7Q58#A9MG9-*

M/[ZQK+9(S+MW+ M:/U9BIK8]SL-!Q@4"CLY&[Q02^_%A$_?QS_&^[_&BM5.Q>; NW2;Z86BALYY M8=E-3#<Y[SYY+ E=U%GT] F7.&M=+4;JKYDKIYAML

MMGZX(^2&!&3E)2P$M|(?5-@2E'ETOTYE"2TQLY*.?W;\E#3!L:PA*.6V^($[M(B5@6!Z=O?!\+_\ 4$L#!!0 (%(:EG8K1X< @ ,9* * M*

97@S,2TQ+FAT;>U<:W/BN!+]GJK\!]U4[1:I@D!>MVH#2Q6OS%"5#5GP M[-WY&P9=&-;CB1#V%^_W9(-!,A,9GIS6X_3IMD+CO?/;3?/P MH/&^U^K")\&?AM-W;GK-1M5^PM-*

J^KC1'G0_DI'S\:;WZY$O(GU%3FNQ)@X/ MF2*W$;Z&(]11V=XHDQ&3W#^"BE#U+JL74CGAT16I'35_CL8JKC>]=QM%7MIT

*MG2P:@Z*U.M'I45=HP"=P2_+)5!\U&]>#6V>]X8I/0QXLKCI7M"FK^%_,(H&6 MVLW>XY2/N3X\.#\],6U4VS!(V'SS&YG(D&@S^35MR$8\7ZAAY-O|@3/L=_K. MQ\.#_FWGI!C\UT++Z0V=_G6_TW+Z@]O#@[L/P|&'%K3M#,CPPTV/G)[3RNE% MB1Z3P9"<7GK9Q35QWO?(J-?Y,.P[_=XH;W;W_NR\;]V^ZQT>M#H.FG/ZR_E% MF;1&I-*

*4=W#F]+ED?"K 3QX>Z/*X_^;WL>EU6>UVEG> M3'F-C?;_1&GN+[XF['IY\.!_](%215I!9<0]CS^487@D=D3TE.JKW-FT>R]< M5AN8H].[N1G=M3K]VW>_'M6.S/5=]!O-*

*KK_8M#GW]!2+UGZ]D[&0'1,55P0! MC14 ROXZ,D*GXOR O(,9SH5+@VS M(B/4MG4<+K_&'#MY.R21]|\+DY/EO(@ M=/\-[&^]#RRT*9TQ(MF,LSGS8/ES17Y[J 2N"!9DR&(A-*

1$1N18RA(J5WXGP M29L++;G+]8+T(_>DOFXP_!KNSI2_[K[:Z_G>QOJFINHL)NR317S+#S8=N&" MWS=$B'C!OPLIV=TJ[)ST!S49" _^%&FO(T&A!DDC+A!&E]68A.'SQF*

*M3@/B4Q=N22)"KF&^;+FM A%$F5)4+BP**!?2>P:=KS6LX)X'B*#? "- [@+ MN%RZ20C%(F@#X[!O(,I=Z=$)?AK57_,)$L;02M"K@)&/1Y-@*!U%*Q4,7,1 M98H"&H\!I/#*

8%AZP%7CQ?J O-V579!0;J;J_(<@(49\'L$.1\98[>@R,)!' M!#R6:\|YY(-RH)I#.SQR@\2#G0NLL;9SRT ['-5&#)L>20O)+ B6K&1QI(2@ M-OH']O,XME[&$DD

/8"!%"%Z5,94"Y54^('8]XRGI)LPI66%'JC>-,"!ZCE M-;91&2(#,>.A@G$*QLG/5%WDA'&<*;8S?Y;](1%E7)*&]&C0A" ^3^&R MI(|-MNT3*IDA"-CP?!PPW,B$ 36- ZZF6*

*,+A:"24"GAM<>5&PB50#W43U(S MEBEB*5SFP6UET92 '3P&=&-9]_?H3EDT8:0%TF28|&"B2&4O M.>9<(DM3V E!Z;+&7I9(S- S'5D46IWY3SWH3>T>)/8H 1&=U>[%W_5I >:*

M17JC2&]\-^Y_7>@E>IP/,NPR!4UG"LQ$3I\GK#)&=BY-0+F]M K&=F,&O&.[M2^,UD4AH "30C"L45LLPD$6F,4R1KD+&=8$G64 -FT'AIV143L4?/N2@T0"0

*M$@'WJ#9HQXI[G$]L5G ;6OK)&6%+B<)0SSB!E)4Q0C0:4B@&J#0(0*P94]Q8 M24!13(*!!LD];H0:-A1=#Z/AKS'#@B#U#[SW]Y4R+>]RQ/68EGM*=;2.+|> MXL5:*

<\M1O%RE/N0@^@8JO8RBP7-P M,N8!OE $'U7W^BZ#)L;HK8.YTG152K"PC%!P&-J6IS(&+R%,LD%P599U"8 M7..$14S2*

*)P&/&$QNB0LDD3:.@9P73P&]5WLX3QLC7QC+9;5GF(MN3EQ#;T9 M#1+4U:L7)\SWF:OY#'A.[4B!+A,M+X@8[.4]*.I$3&/D !5!Z"N;>QV+1'\& MQDL"&[HLS3#%[' ^;1 98P8;D]?&PS$I)@"J;N% #\6NR\BSC?68EGM*=:2 MEQ.RIUIVS,A\@V_QE7^:D#9/=I+Z%ZAI3.PUTTDS\NI: F6[50LG%$K#0SQ: M" TJ6*ODP9X=@5GT/C@(T!R;Y1.T;M VN;(IYFB)*

(EN&,+;4K5,N^$8MVX M$^:E"2I0^V9DTEAC00)^S^##G%_8J%3^UX-5?]Z%C9%(K'^#^;B]DV]J3/' M#;V,UV&(=>: ML4_(X[&@TLA/CP-(TTA)I"A

*C2]4O/")^?",.=E#PL$00Y!)Y)HC"I*X>/E,;,]H/<;X-MUHHER3 M,C5G+[.C2<_2VDYM9M]<4;GDWATRAW106[&ERGF6 M-$*U0]'H,-5;;1MH(1 M4$D(5 *F&XM2G;GS.%<12>79?*

@N(K Z$R(U:! MDLWY\Y2[RS;4Y-%,!#.&\]69>]E9>IGJ6Q;&@3$P>#?]MHZ1// $S^B8@\ M"^5?2/TG/ZA:W'0875@25X<'MS QX1CFYO2B3,Y]9Q>Y, ^0MJO68>OARN3(6

*M6HL06HZU'9DOLN*R]M,K$WLZ8AGL=D#=>P1/S'&I[V"H]^LJJ]%O?E?M(U] MO[FO3GM/_?/7A&6G(STQO)]38CZ^$ZS.E#/?(ND],C?!-Y]D8!-BQ;3LESHL MW=E3/ME_&VU-*

V/&/J<(_^\]%7+-6>|=D3N0NG5HX"%AD8L5ZV00FYSE%;FA M2I-)9O#;O^/#)4UHP(+SYB2V;7T8?_%>Y_V:V#G2HZLRX]->?+42VIKB@W]*

V^5EMLQ\9Y.@K]YI&0[B=,F6YM:C?(01O(OW^'E.I\Y8MQ\Z_Y^U=K?:[[MMWOP M2?"GZ0[A"(6%^0XWJBB;E M|-

*K=;+@:T(B'RXO/-6W**OX/LT@.6C_%$Y4TFC5L$$R_*03H9]?5_SCC$Z]W M]TZ/CTZ:M4|KZYK@L5@S6;2!_ **H8>0[@Z$[&G0'[OO]O<%U]Z@<(_)="W>V/ MW,'EH-*

MV!\/K_;V:=Z/QNS:T[0]DZ-U5GOR?TNKQ684>DN&()_[^<4E<=_V MR;C??3<:N(/^N&A\]_JOFU?O^GO[[6[+IIS_,OIF4/:8]+N#6_-#3NLGF>E%LW?<'G7:U_UQ=?C75?

_IRNJ3>OVD::\Q$;[.U6:!\LO"7O@ M[,_)F8Q:2]I+*:A2!T8'(G=$#VC^J)P%FV?"+?= =[HJ]^NQC?M[N#ZS:|' M]0-S?=/Nl?+K9YNVX+Z>8=']ZCPTR$=)GLND],*2)*

*D#Y7P=&>#7=T?,[F.:< M>#3,!TR+Y"'3<4VW]V\JU]SGG\U>?B^&@U#V!Q_\#^VKO 0IO1.2,2S3E; M,!^6/U?DCY1*8(IP248L$5(3$9-+(2.H6/V#B(!TN-"2>UPOR2#VCAJ;!L.O*

*MT>Y,_[X=87]54G11D6W:H8KZ%![LN6I+;6"Q"YD^98W>GM'O2%)!L M+#00;JPICPF-ER2-M4P949I]%H&[Q\U*P1?!;N8T) 'UX)8D(N(;YLN6>U @ M9AY3BLJE10'E(GK+H/.-*

V/&/J<(_^\]%7+-6>|=D3N0NG5HX"%AD8L5ZV00FYSE%;FA M2I-)9O#;O^/#)4UHP(+SYB2V;7T8?_%>Y_V:V#G2HZLRX]->?+42VIKB@W]*

V^5EMLQ\9Y.@K]YI&0[B=,F6YM:C?(01O(OW^'E.I\Y8MQ\Z_Y^U=K?:[[MMWOP M2?"GZ0[A"(6%^0XWJBB;E M|-

*K=;+@:T(B'RXO/-6W**OX/LT@.6C_%$Y4TFC5L$$R_*03H9]?5_SCC$Z]W M]TZ/CTZ:M4|KZYK@L5@S6;2!_ **H8>0[@Z$[&G0'[OO]O<%U]Z@<(_)="W>V/ MW,'EH-*

MV!\/K_;V:=Z/QNS:T[0]DZ-U5GOR?TNKQ684>DN&()_[^<4E<=_V MR;C??3<:N(/^N&A\]_JOFU?O^GO[[6[+IIS_,OIF4/:8]+N#6_-#3NLGF>E%LW?<'G7:U_UQ=?C75?

_IRNJ3>OVD::\Q$;[.U6:!\LO"7O@ M[,_)F8Q:2]I+*:A2!T8'(G=$#VC^J)P%FV?"+?= =[HJ]^NQC?M[N#ZS:|' M]0-S?=/Nl?+K9YNVX+Z>8=']ZCPTR$=)GLND],*2)*

*D#Y7P=&>#7=T?,[F.:< M>#3,!TR+Y"'3<4VW]V\JU]SGG\U>?B^&@U#V!Q_\#^VKO 0IO1.2,2S3E; M,!^6/U?DCY1*8(IP248L$5(3$9-+(2.H6/V#B(!TN-"2>UPOR2#VCAJ;!L.O*

*MT>Y,_[X=87]54G11D6W:H8KZ%![LN6I+;6"Q"YD^98W>GM'O2%)!L M+#00;JPICPF-ER2-M4P949I]%H&[Q\U*P1?!;N8T) 'UX)8D(N(;YLN6>U @ M9AY3BLJE10'E(GK+H/.-*

AA7<\P$1]!MB_(<=80&/2R^-H%@,;0 <\ UD,>/> MC*@4?ZWK+YAD62-H1<15R*C/XRG0M9Z!E2IA'J+,4$#C"8 4/A@,2P^X;K+< M')#7NI)+$BK,5)U^%R3$2,!CV.'(&.I=[0 #^438[GQG,J.;3#8R], M?=BYP!H;.]C,931MJ@349I"":;O-QYA5DH)C&'5_;28\HEMCR%G1#4+AOT M99D$ 3W2D47QH+?@3F\!](86WVG5L'@;L =VQW6< F4@D-@ ::1H M!;?!I=&<,;:4*HSUC!/(6!E#1",BA6* 2H,"Q)H)Q8V5AA35)!AHD*P#1ZAA M8]'-.!K^FC L'"%H/ZC/_!4J%8]NZ(F$ME]6.8]U.BNLAGJPU'SB*IZO4Q_Q% M#F/M-+ H.)HY]|$-4"5BBL*<*GAF!U$WT"EGU,T>)SS$=PH0HV_K&UV7 M87-#U-;AW"FZSD58."8(^)B9EJ0R 6^A3';!\T#6&0!5VV3AE,9,T!*E.B]X1TQ@Y0$40^LHF7RY8=H>$SO"\U*)A+J10'G8]H43":7A(9XLA85K%7RP1X>(I5' MT 3@(T!RWRN=H?> M,V9!3S.$*K\;@+*1/K96+]/\S%^:MX4V?.&_HYJSEKG8;:<9-/ MUI(-&6'KOLS"_&T9C@<)Z!5$FOI<"ZE6^01S]J-(JXU8Y^0QQ-!I9&?/@>0MII&*R%" &E4H>>$3|^$Y<|(/*0=##$&FL6?.)!R6+^1*WMA1W56^D-L*M!UF MQY P|6*>[?('.I#;<56*N=1"LP2K5 %> PVE&.C;04CH-((J 1,-Q9E.G/K M>:XRDBY4R%-LK.6RVE&LA7ECUHZS ^V!!.7G *$R(U:!DL!]RI'1MJ|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|%YBJ^:Y3@4+-H>$;4?5BA='$2X.%@=PP\0" MQ(+"ES7AZ*%P U.:Q%P -I['?(G#U"\0!]!CL>#,8V(#=N0UH"Y"87^:AUW M^O$R(='FB&=7QS@KSXRN=D83A!/[0".?^H@M$70YHQQW65W!Z+=.%2 I!"S$ MUATDAWIKS@1#?B3RP;KU%B2:4\#9EBQ-)7S\DSU](B@L**>(1RV-IV")^1B*;J^#:D&S]%![8)->#_M@AV(:)%Z[9&UK0MX9#9V+V[=`G3S6]EEU/S,&@N/YF:C?,%PO957_7 M@5G,?PYU^^P37,N8>"0N'B3BI;56TX0Z^&[#>;>)VQ MZ*5CX0[* [W>|#X0[A\,U%W0'-RV;@;K$.N=AT4CE)5K5\TX7:T9ITOU,D0$,%LGM7]XUUAN*M]N[|'U4$V-S^>G'9D1=SW#WY-7T^6ERFM MW[^@_4MK5XIUGJK;.611:@*ER2K>2A !6$1JB.6"[BB=A*6B45.4UDF%=E, MPA 5#*I(1D(LHFF"=3-5LE$!BTCDR?MHT&>9::D4L=8$#;U Z!YFC\&E([(_U'M;F>>Q4+$RS;T M0N+!!4VTGL8A\W.G?1.A,_W=0=\EVETMU7+8#Q_W#,WN/ELX$X+=HOF.'?+Z M^8Q>|\9|2*9YO'(H>T$[P$[W%H_O>C6%7 M8G,8=?A2P2F[X$+@OZ@JG#,:'FV8D#GMH('5FD:>'-!)IT#8,221 58N0 M#.S?!A[:C|U0M[CSL"UVXC>B_O/;_U(L|Y;&O-!XJD?L;^6,)\4!J/-YA[U;3 M$VOD?@Q"&F0C=LFW9_K.G44Z%*E@:.B:PDM[OM6D65]]@>"R RT]DN"R%4U@3&]A*E:$;_D)#68T M9D$-%^+22;%N1>(9KW00:[TC/D^BKM&)1+&A_2AR+BY4*-D>_;CCNU![9[7:W8XT'C/?BOA7I@35W[PAZ8 MKNV,JY7)U71V9:)MURF;)ZU/U?<:6_V/ M-)$L6!\2MLVK%4]PCIN#"0ZW3"Y!+BE\34F,$0K7,*61B"7@X(6(5[BL_A5$ M 'TF9,P\)M=@C?I*(I$*N(\/51G!<5W?CS.C-UFB$<(0/E/O4 M1VR1I*%XJ=Z;+ZAIFOWVF 4D@8"&.;B'-]?&3#+TCW 2K#MO2?B" EYMQ9)$ MP<<_-=,GDL*2QA1QI\+*72E@:6!K|(M8316+BM+&]HS;"Q M/2/QG'":U)V[D*I!]%!VX)#:#1I.(+)3NO)Z>E>X9G]DP< :C683%N?/!K^G:JO$QE_8[U&:SO9?5&L1ZWRT:/C*,F7)&,\U!^2L(XMJB.6R[>".PG+I&),$T63FAHF88@*!C6DDF8X$"%O)EJV*MA*-C3HL\RTTHDX M*PUSEA4H.[-K)CF*?4W7>+K6FYE:Z957;;UYV$-,:*=;&8MOV5T M,|RFX#2M.?)_5+N;*\^%@*^AA=83$3(_#]*+'#K7/QST2:+=:R;-'/;^S9[1 MM'O/TF9$?)_QO=8W],[ ]^=MM^5#>]IRE0/92=D!NMQ[-KY+8TQBANTU(F$. MY_X)B6]RIN>)E$O<+<4#D\,HDM?*5=F;/ + _J5['I-#0[\"$+&@7#=RDE'MJ M81><*-,]'1B11$*]7J1D:/^V_YJNCB67N5+XM:6_C^K<|W2/?MYWN]WN]K#[M[3>/QVWK07M[S.KWF^N)+;.?@Y&V8IM\>V8O@]G40Y%*1A-#$T1I9W8-E5P M\P >H%H.VND.*I=>HV2;ZNUR_KI9O97^&U!+ P04 " !2B&Y9.PQ(BI%, M @",&!T # &9OR]>7/:2K>)DKI(3)#$FMV7Z+R0Z)#0[@3+=.N01JC!(A$4G8QI_^[988!$B@$0VL77OO$-#0O=9OS:N[M/_Y_+Q.)>D*J)BKRO__#O,W]#X7DH2*(\N.__U/MU5NM__G_+L|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|XO4A|&OR>YY>&?'Y\M_&6L-Z;M[[7 M49C/+]^R$0V@!V D^B?7UZ85BRB012=]:#2#N>71#U$-("2=0"VNN3](G8C=G\;2%I_&^A3W2">KS+|\V7*9(U5$,R&HGZN<-@2WBPVT/%8L>* M1-AR;+ER3LUDT;P+"S*V[=I[692PQ55GB!C;,,?#K<;#.8RGDCOF>!R9:1T1 M&F&L+DS?O'+MK)OM["P'NVIT'7V,5)\CJQ2#CJR-=%/0;A3-)7T>%O<^W*EHA+"Y$HSIW:+)@$QD MD%#*!09KF$\", HR.@U#3-^|K M-60^UVGL@5$$W9C|Q<3'KJX(@DFNPO\^+0DNN|U-1YR4#&<35>M0P(A*Z:ID3UK3]:2.D?(F#X.P(9C?,6=[CR|_*1+DC&:]",<33V)0V12I(N& MRJ-LO*$*]6("2U4ZB(?.U'DO90(|%,DFQ+>-!836&,EXFM MW]^@_4MK5XIUGJK;.611:@*ER2K>2A !6$1JB.6"[BB=A*6B45.4UDF%=E, MPA 5#*I(1D(LHFF"=3-5LE$!BTCDR?MHT&>9::D4L=8$#;U Z!YFC\&E([(_U'M;F>>Q4+$RS;T M0N+!!4VTGL8A\W.G?1.A,_W=0=\EVETMU7+8#Q_W#,WN/ELX$X+=HOF.'?+Z M^8Q>|\9|2*9YO'(H>T$[P$[W%H_O>C6%7 M8G,8=?A2P2F[X$+@OZ@JG#,:'FV8D#GMH('5FD:>'-!)IT#8,221 58N0 M#.S?!A[:C|U0M[CSL"UVXC>B_O/;_U(L|Y;&O-!XJD?L;^6,)\4!J/-YA[U;3 M$VOD?@Q"&F0C=LFW9_K.G44Z%*E@:.B:PDM[OM6D65]]@>"R RT]DN"R%4U@3&]A*E:$;_D)#68T M9D$-%^+22;%N1>(9KW00:[TC/D^BKM&)1+&A_2AR+BY4*-D>_;CCNU![9[7:W8XT'C/?BOA7I@35W[PAZ8 MKNV,JY7)U71V9:)MURF;)ZU/U?<:6_V/ M-)$L6!\2MLVK%4]PCIN#"0ZW3"Y!+BE\34F,$0K7,*61B"7@X(6(5[BL_A5$ M 'TF9,P\)M=@C?I*(I$*N(\/51G!<5W?CS.C-UFB$<(0/E/O4 M1VR1I*%XJ=Z;+ZAIFOWVF 4D@8"&.;B'-]?&3#+TCW 2K#MO2?B" EYMQ9)$ MP<<_-=,GDL*2QA1QI\+*72E@:6!K|(M8316+BM+&]HS;"Q M/2/QG'":U)V[D*I!]%!VX)#:#1I.(+)3NO)Z>E>X9G]DP< :C683%N?/!K^G:JO$QE_8[U&:SO9?5&L1ZWRT:/C*,F7)&,\U!^2L(XMJB.6R[>".PG+I&),$T63FAHF88@*!C6DDF8X$"%O)EJV*MA*-C3HL\RTTHDX M*PUSEA4H.[-K)CF*?4W7>+K6FYE:Z957;;UYV$-,:*=;&8MOV5T M,|RFX#2M.?)_5+N;*\^%@*^AA=83$3(_#]*+'#K7/QST2:+=:R;-'/;^S9[1 MM'O/TF9$?)_QO=8W],[ ]^=MM^5#>]IRE0/92=D!NMQ[-KY+8TQBANTU(F$. MY_X)B6]RIN>)E$O<+<4#D\,HDM?*5=F;/ + _J5['I-#0[\"$+&@7#=RDE'MJ M81><*-,]'1B11$*]7J1D:/^V_YJNCB67N5+XM:6_C^K<|W2/?MYWN]WN]K#[M[3>/QVWK07M[S.KWF^N)+;.?@Y&V8IM\>V8O@]G40Y%*1A-#$T1I9W8-E5P M\P >H%H.VND.*I=>HV2;ZNUR_KI9O97^&U!+ P04 " !2B&Y9.PQ(BI%, M @",&!T # &9OR]>7/:2K>)DKI(3)#$FMV7Z+R0Z)#0[@3+=.N01JC!(A$4G8QI_^[988!$B@$0VL77OO$-#0O=9OS:N[M/_Y_+Q.)>D*J)BKRO__#O,W]#X7DH2*(\N.__U/MU5NM__G_+L|^CG5\&;Y4MUOX]'^OZ]/V[=_/SV^?N;>*^OB.]50]U[(-?F1>]?;*]CHF293 ,#^?+,Z=*!*XL:EY)OE2[AW.X_&OPKK&ZP7%]^9 M/VY6C OU9>7BIJ29YG2O6&85ZQN>'&ZEB%CQC-$/VK=F_7ENOWUZTO? MZ2HO:R-%G? Z9B%Y4N$BQUZP1\-[*X@+:(O?RG?@'? >;TUXXTRX>>7ZZNGC$:P/CL8L?MB]6%0EIME<; MOVQ<+NCJA3Z?(LU^X/CG=^1G<@[ ]D>,LLT5#P7[X^(>-5PR5F:RK<_N+%$]N MW*"I^N[H]9<;%]7Z]9^KJP:BHJOB4-3G;X?*Q+@N5^%RYTON$2]_,1W[\/Q<7U)6().$]U4/Z!ZK-3]![ZD5X^4"U&L:'AQS+/-SW_L,VMKJO5,_P'&1C^X\[VSQ(_UZXQ_JXL+EL[CR YGTP^9D'Y;3=?^@?,&\!*9IC M?-Q=]#P@C% \?/QO=8)D ?^G7TG\X\.(ES3DX4EERY.:RG!F/$C4AKQTAU11 M$:IP=IK#5I:#(TN61]9G]KIZXD_$[TU9:/ Z>C!_ONGEGF_GN=?;K__^Z^$- M=<=!DU>80\94+7AX9/RR*:,T3FOXX>JO-22!?3R![_LK#(]B'WIA7$2:(@V&/ MS&=HQG<>'M,@([E:/(K;&5^@9U<>[F8J>LA;'S+%WYB/&"C"G-+TN83^/1]A M=?"><8G)3G>]+$_R2-G]FNLJ$EVGS"QJ_1A5'1.L(XM/R-D'4IA(_?T_)BHS(M;^+++Z)!D(K5DO$741"03'04^1N^JHTQA07A>-_CV_4I4)D=6+'/Z7 MT17S<'^4"*SE*Q(KXBA_].?(=TI]>)|XO4A|&OR>YY>&?'Y\M_&6L-Z;M[[7 M49C/+]^R$0V@!V D^B?7UZ85BRB012=]:#2#N>71#U$-("2=0"VNN3](G8C=G\;2%I_&^A3W2">KS+|\V7*9(U5$,R&HGZN<-@2WBPVT/%8L>* M1-AR;+ER3LUDT;P+"S*V[=I[692PQ55GB!C;,,?#K<;#.8RGDCOF>!R9:1T1 M&F&L+DS?O'+MK)OM["P'NVIT'7V,5)\CJQ2#CJR-=%/0;A3-)7T>%O<^W*EHA+"Y$HSIW:+)@$QD MD%#*!09KF$\", HR.@U#3-^|K M-60^UVGL@5$$W9C|Q<3'KJX(@DFNPO\^+0DNN|U-1YR4#&<35>M0P(A*Z:ID3UK3]:2.D?(F#X.P(9C?,6=[CR|_*1+DC&:]",<33V)0V12I(N& MRJ-LO*$*]6("2U4ZB(?.U'DO90(|%,DFQ+>-!836&,EXFM MW]^@_4MK5XIUGJK;.611:@*ER2K>2A !6$1JB.6"[BB=A*6B45.4UDF%=E, MPA 5#*I(1D(LHFF"=3-5LE$!BTCDR?MHT&>9::D4L=8$#;U Z!YFC\&E([(_U'M;F>>Q4+$RS;T M0N+!!4VTGL8A\W.G?1.A,_W=0=\EVETMU7+8#Q_W#,WN/ELX$X+=HOF.'?+Z M^8Q>|\9|2*9YO'(H>T$[P$[W%H_O>C6%7 M8G,8=?A2P2F[X$+@OZ@JG#,:'FV8D#GMH('5FD:>'-!)IT#8,221 58N0 M#.S?!A[:C|U0M[CSL"UVXC>B_O/;_U(L|Y;&O-!XJD?L;^6,)\4!J/-YA[U;3 M$VOD?@Q"&F0C=LFW9_K.G44Z%*E@:.B:PDM[OM6D65]]@>"R RT]DN"R%4U@3&]A*E:$;_D)#68T M9D$-%^+22;%N1>(9KW00:[TC/D^BKM&)1+&A_2AR+BY4*-D>_;CCNU![9[7:W8XT'C/?BOA7I@35W[PAZ8 MKNV,JY7)U71V9:)MURF;)ZU/U?<:6_V/ M-)$L6!\2MLVK%4]PCIN#"0ZW3"Y!+BE\34F,$0K7,*61B"7@X(6(5[BL_A5$ M 'TF9,P\)M=@C?I*(I$*N(\/51G!<5W?CS.C-UFB$<(0/E/O4 M1VR1I*%XJ=Z;+ZAIFOWVF 4D@8"&.;B'-]?&3#+TCW 2K#MO2?B" EYMQ9)$ MP<<_-=,GDL*2QA1QI\+*72E@:6!K|(M8316+BM+&]HS;"Q M/2/QG'":U)V[D*I!]%!VX)#:#1I.(+)3NO)Z>E>X9G]DP< :C683%N?/!K^G:JO$QE_8[U&:SO9?5&L1ZWRT:/C*,F7)&,\U!^2L(XMJB.6R[>".PG+I&),$T63FAHF88@*!C6DDF8X$"%O)EJV*MA*-C3HL\RTTHDX M*PUSEA4H.[-K)CF*?4W7>+K6FYE:Z957;;UYV$-,:*=;&8MOV5T M,|RFX#2M.?)_5+N;*\^%@*^AA=83$3(_#]*+'#K7/QST2:+=:R;-'/;^S9[1 MM'O/TF9$?)_QO=8W],[ ]^=MM^5#>]IRE0/92=D!NMQ[-KY+8TQBANTU(F$. MY_X)B6]RIN>)E$O<+<4#D\,HDM?*5=F;/ + _J5['I-#0[\"$+&@7#=RDE'MJ M81><*-,]'1B11$*]7J1D:/^V_YJNCB67N5+XM:6_C^K<|W2/?MYWN]WN]K#[M[3>/QVWK07M[S.KWF^N)+;.?@Y&V8IM\>V8O@]G40Y%*1A-#$T1I9W8-E5P M\P >H%H.VND.*I=>HV2;ZNUR_KI9O97^&U!+ P04 " !2B&Y9.PQ(BI%, M @",&!T # &9OR]>7/:2K>)DKI(3)#$FMV7Z+R0Z)#0[@3+=.N01JC!(A$4G8QI_^[988!$B@$0VL77OO$-#0O=9OS:N[M/_Y_+Q.)>D*J)BKRO__#O,W]#X7DH2*(\N.__U/MU5NM__G_+L|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|XO4A|&OR>YY>&?'Y\M_&6L-Z;M[[7 M49C/+]^R$0V@!V D^B?7UZ85BRB012=]:#2#N>71#U$-("2=0"VNN3](G8C=G\;2%I_&^A3W2">KS+|\V7*9(U5$,R&HGZN<-@2WBPVT/%8L>* M1-AR;+ER3LUDT;P+"S*V[=I[692PQ55GB!C;,,?#K<;#.8RGDCOF>!R9:1T1 M&F&L+DS?O'+MK)OM["P'NVIT'7V,5)\CJQ2#CJR-=%/0;A3-)7T>%O<^W*EHA+"Y$HSIW:+)@$QD MD%#*!09KF$\", HR.@U#3-^|K M-60^UVGL@5$$W9C|Q<3'KJX(@DFNPO\^+0DNN|U-1YR4#&<35>M0P(A*Z:ID3UK3]:2.D?(F#X.P(9C?,6=[CR|_*1+DC&:]",<33V)0V12I(N& MRJ-LO*$*]6("2U4ZB(?.U'DO90(|%,DFQ+>-!836&,EXFM MW]^@_4MK5XIUGJK;.611:@*ER2K>2A !6$1JB.6"[BB=A*6B45.4UDF%=E, MPA 5#*I(1D(LHFF"=3-5LE$!BTCDR?MHT&>9::D4L=8$#;U Z!YFC\&E([(_U'M;F>>Q4+$RS;T M0N+!!4VTGL8A\W.G?1.A,_W=0=\EVETMU7+8#Q_W#,WN/ELX$X+=HOF.'?+Z M^8Q>|\9|2*9YO'(H>T$[P$[W%H_O>C6%7 M8G,8=?A2P2F[X$+@OZ@JG#,:'FV8D#GMH('5FD:>'-!)IT#8,221 58N0 M#.S?!A[:C|U0M[CSL"UVXC>B_O/;_U(L|Y;&O-!XJD?L;^6,)\4!J/-YA[U;3 M$VOD?@Q"&F0C=LFW9_K.G44Z%*E@:.B:PDM[OM6D65]]@>"R RT]DN"R%4U@3&]A*E:$;_D)#68T M9D$-%^+22;%N1>(9KW00:[TC/D^BKM&)1+&A_2AR+BY4*-D>_;CCNU![9[7:W8XT'C/?BOA7I@35W[PAZ8 MKNV,JY7)U71V9:)MURF;)ZU/U?<:6_V/ M-)$L6!\2MLVK%4]PCIN#"0ZW3"Y!+BE\34F,$0K7,*61B"7@X(6(5[BL_A5$ M 'TF9,P\)M=@C?I*(I$*N(\/51G!<5W?CS.C-UFB$<(0/E/O4 M1VR1I*%XJ=Z;+ZAIFOWVF 4D@8"&.;B'-]?&3#+TCW 2K#MO2?B" EYMQ9)$ MP<<_-=,GDL*2QA1QI\+*72E@:6!K|(M8316+BM+&]HS;"Q M/2/QG'":U)V[D*I!]%!VX)#:#1I.(+)3NO)Z>E>X9G]DP< :C683%N?/!K^G:JO$QE_8[U&:SO9?5&L1ZWRT:/C*,F7)&,\U!^2L(XMJB.6R[>".PG+I&),$T63FAHF88@*!C6DDF8X$"%O)EJV*MA*-C3HL\RTTHDX M*PUSEA4H.[-K)CF*?4W7>+K6FYE:Z957;;UYV$-,:*=;&8MOV5T M,|RFX#2M.?)_5+N;*\^%@*^AA=83$3(_#]*+'#K7/QST2:+=:R;-'/;^S9[1 MM'O/TF9$?)_QO=8W],[ ]^=MM^5#>]IRE0/92=D!NMQ[-KY+8TQBANTU(F$. MY_X)B6]RIN>)E$O<+<4#D\,HDM?*5=F;/ + _J5['I-#0[\"$+&@7#=RDE'MJ M81><*-,]'1B11$*]7J1D:/^V_YJNCB67N5+XM:6_C^K<|W2/?MYWN]WN]K#[M[3>/QVWK07M[S.KWF^N)+;.?@Y&V8IM\>V8O@]G40Y%*1A-#$T1I9W8-E5P M\P >H%H.VND.*I=>HV2;ZNUR_KI9O97^&U!+ P04 " !2B&Y9.PQ(BI%, M @",&!T # &9OR]>7/:2K>)DKI(3)#$FMV7Z+R0Z)#0[@3+=.N01JC!(A$4G8QI_^[988!$B@$0VL77OO$-#0O=9OS:N[M/_Y_+Q.)>D*J)BKRO__#O,W]#X7DH2*(\N.__U/MU5NM__G_+L|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|XO4A|&OR>YY>&?'Y\M_&6L-Z;M[[7 M49C/+]^R$0V@!V D^B?7UZ85BRB012=]:#2#N>71#U$-("2=0"VNN3](G8C=G\;2%I_&^A3W2">KS+|\V7*9(U5$,R&HGZN<-@2WBPVT/%8L>* M1-AR;+ER3LUDT;P+"S*V[=I[692PQ55GB!C;,,?#K<;#.8RGDCOF>!R9:1T1 M&F&L+DS?O'+MK)OM["P'NVIT'7V,5)\CJQ2#CJR-=%/0;A3-)7T>%O<^W*EHA+"Y$HSIW:+)@$QD MD%#*!09KF$\", HR.@U#3-^|K M-60^UVGL@5$$W9C|Q<3'KJX(@DFNPO\^+0DNN|U-1YR4#&<35>M0P(A*Z:ID3UK3]:2.D?(F#X.P(9C?,6=[CR|_*1+DC&:]",<33V)0V12I(N& MRJ-LO*$*]6("2U4ZB(?.U'DO90(|%,DFQ+>-!836&,EXFM MW]^@_4MK5XIUGJK;.611:@*ER2K>2A !6$1JB.6"[BB=A*6B45.4UDF%=E, MPA 5#*I(1D(LHFF"=3-5LE$!BTCDR?MHT&>9::D4L=8$#;U Z!YFC\&E([(_U'M;F>>Q4+$RS;T M0N+!!4VTGL8A\W.G?1.A,_W=0=\EVETMU7+8#Q_W#,WN/ELX$X+=HOF.'?+Z M^8Q>|\9|2*9YO'(H>T$[P$[W%H_O>C6%7 M8G,8=?A2P2F[X$+@OZ@JG#,:'FV8D#GMH('5FD:>'-!)IT#8,221 58N0 M#.S?!A[:C|U0M[CSL"UVXC>B_O/;_U(L|Y;&O-!XJD?L;^6,)\4!J/-YA[U;3 M$VOD?@Q"&F0C=LFW9_K.G44Z%*E@:.B:PDM[OM6D65]]@>"R RT]DN"R%4U@3&]A*E:$;_D)#68T M9D$-%^+22;%N1>(9KW00:[TC/D^BKM&)1+&A_2AR+BY4*-D>_;CCNU![9[7:W8XT'C/?BOA7I@35W[PAZ8 MKNV,JY7)U71V9:)MURF;)ZU/U?<:6_V/ M-)$L6!\2MLVK%4]PCIN#"0ZW3"Y!+BE\34F,$0K7,*61B"7@X(6(5[BL_A5$ M 'TF9,P\)M=@C?I*(I$*N(\/51G!<5W?CS.C-UFB$<(0/E/O4 M1VR1I*%XJ=Z;+ZAIFOWVF 4D@8"&.;B'-]?&3#+TCW 2K#MO2?B" EYMQ9)$ MP<<_-=,GDL*2QA1QI\+*72E@:6!K|(M8316+BM+&]HS;"Q M/2/QG'":U)V[D*I!]%!VX)#:#1I.(+)3NO)Z>E>X9G]DP< :C683%N?/!K^G:JO$QE_8[U&:SO9?5&L1ZWRT:/C*,F7)&,\U!^2L(XMJB.6R[>".PG+I&),$T63FAHF88@*!C6DDF8X$"%O)EJV*MA*-C3HL\RTTHDX M*PUSEA4H.[-K)CF*?4W7>+K6FYE:Z957;;UYV$-,:*=;&8MOV5T M,|RFX#2M.?)_5+N;*\^%@*^AA=83$3(_#]*+'#K7/QST2:+=:R;-'/;^S9[1 MM'O/TF9$?)_QO=8W],[ ]^=MM^5#>]IRE0/92=D!NMQ[-KY+8TQBANTU(F$. MY_X)B6]RIN>)E$O<+<4#D\,HDM?*5=F;/ + _J5['I-#0[\"$+&@7#=RDE'MJ M81><*-,]'1B11$*]7J1D:/^V_YJNCB67N5+XM:6_C^K<|W2/?MYWN]WN]K#[M[3>/QVWK07M[S.KWF^N)+;.?@Y&V8IM\>V8O@]G40Y%*1A-#$T1I9W8-E5P M\P >H%H.VND.*I=>HV2;ZNUR_KI9O97^&U!+ P04 " !2B&Y9.PQ(BI%, M @",&!T # &9OR]>7/:2K>)DKI(3)#$FMV7Z+R0Z)#0[@3+=.N01JC!(A$4G8QI_^[988!$B@$0VL77OO$-#0O=9OS:N[M/_Y_+Q.)>D*J)BKRO__#O,W]#X7DH2*(\N.__U/MU5NM__G_+L|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|XO4A|&OR>YY>&?'Y\M_&6L-Z;M[[7 M49C/+]^R$0V@!V D^B?7UZ85BRB012=]:#2#N>71#U$-("2=0"VNN3](G8C=G\;2%I_&^A3W2">KS+|\V7*9(U5$,R&HGZN<-@2WBPVT/%8L>* M1-AR;+ER3LUDT;P+"S*V[=I[692PQ55GB!C;,,?#K<;#.8RGDCOF>!R9:1T1 M&F&L+DS?O'+MK)OM["P'NVIT'7V,5)\CJQ2#CJR-=%/0;A3-)7T>%O<^W*EHA+"Y$HSIW:+)@$QD MD%#*!09KF$\", HR.@U#3-^|K M-60^UVGL@5$$W9C|Q<3'KJX(@DFNPO\^+0DNN|U-1YR4#&<35>M0P(A*Z:ID3UK3]:2.D?(F#X.P(9C?,6=[CR|_*1+DC&:]",<33V)0V12I(N& MRJ-LO*$*]6("2U4ZB(?.U'DO90(|%,DFQ+>-!836&,EXFM MW]^@_4MK5XIUGJK;.611:@*ER2K>2A !6$1JB.6"[BB=A*6B45.4UDF%=E, MPA 5#*I(1D(LHFF"=3-5LE$!BTCDR?MHT&>9::D4L=8$#;U Z!YFC\&E([(_U'M;F>>Q4+$RS;T M0N+!!4VTGL8A\W.G?1.A,_W=0=\EVETMU7+8#Q_W#,WN/ELX$X+=HOF.'?+Z M^8Q>|\9|2*9YO'(H>T$[P$[W%H_O>C6%7 M8G,8=?A2P2F[X$+@OZ@JG#,:'FV8D#GMH('5FD:>'-!)IT#8,221 58N0 M#.S?!A[:C|U0M[CSL"UVXC>B_O/;_U

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|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|@Q*U@]4TOXA8FY!% M@P01^ MI^7<"*$DAAS)I5'6@S'2*G,Z#=*HK:G_2A!)R&AAHF+W0*"R@D;<: M(5U5),V Q9VJ#)$P,XX0/4F^9\|/ 5RY9N]QXOF6T& MS;\S43>V^%GNXT.=3_/ZJR@_$X0>*K $S"=]6 M"#G9C?:MY5U&$VB(W7 [1#>IL0*R!9YKU$RAR|S],M>ZTFS(-== MM=L_8]*[+WRJ=TX5?0V5U61.6NUKSK=VRHYB1>X$5F.$=&.-40]-=7/U$93)+@3 MH_&N$6OK[Q,JC&+&BT1=6-I M\%B1L(NF+=I]2?%.'(I('L!JZ1!SG^P,ZI$BZ)$4R;OT.NJ\-J:N M).5Y[5Z,I1<6C'T-./MU0@Y* M@A&6!#DH";:Y)CFC2? 6Y8Y5NGE!LNQL28&G6>^T&\UVK]DXPY]ZG9M6H]IO M-JA:1;::KC>IWJ=FL]!+]Q2KO;/.%=5KWO6;M[5FU[X$4&TWJ-M]M_()M@20 MYNF_:;Y,R>G@2#@39>]^1S6(.5"U-$]K? TUNGXU<;MS'Y8H/#,_^I2/ J_5"4"I+I%AZ4O>]^9Y1%TZ^W&:IR4?)SYVOWB]YV3MY;UUMFOPU3VPW;I;AZ(D)2.(6$X["ZZY=I;+NL?^L-$ A)P'.,6&C+<&;@#") M%)#=+)%3IN)@6B]DP8U$$FVBXD7('(G2B3:[\]^> .AZH%$0!)B9&69:-,;* MEN4*#VBF73SR_/3BHHJ#&EU;G-U>'9#3T8;Z@U@[JZYAW&6=M\QZB-.OWW>[MS7:?JO9Z1KR=:4RKA(C'>']HFPSPU9!5"T*@E1=I[) _FBNMFS7JG]=5U5R MK*:1N7\0!:%TT1)B2 PFUD;YP1>TM M2K7X]/)4_SVL3\:1.*@A$F0Y.4I=S8ZF9*2[S7A%*]XQZJ-8CRK7?FP5RW2Q4'"+K1CL &>Q RWY"=-(M4>>88/9Z_]=M9Z1)Q3[+U4)XD41HL[8]H&QO>JC>/G_2$<;Q?TO9H=KZ0:U M'X&(6H'F0=V7PQ#)*3T7'DIY W:=,W;O!DMHUCZ2"I5*%QJYT@M6[U[*UL=C;]*0GA18)Q3+NQ:M M$$)BE>.*=+Y0#(3AF,LD.\:MOD]N^L*Z83/W.JG-'U[O?]WHH_MO?]NS2GC1 M3+0RW%=T7]*&YO0HWI@LA#)Q9K)\6IQ\<&G-T[EBGLY77*<7()9)"SC5_6' MD ?%0"KE;.S$)"Z8"3'\ '!GM7T"F)$@9AQL=MMT==N*/%SZ;Y94A.FC_:X_ MSIM]L:'7_2OCX[P_]6".9)F*9G*0BX[;@7/"H@=>ZKA1"+I%AZ4O>]QZD*H=I0+-'Y2XCRZM5%H'.I"V6L;!LQDU/C=:.^BU4M*[4&X4^:/"_ M1^]$XG?[44#_)ZT5Q8\9*.;":"&CBY4*6(&,6 &?V-HU!L40"A1,OD)7K -(;07XPBA4')=FP';D'#;X =8-H8AA#H" M4Z +A20WL5Q9[,)BRVOY\0;Q&NH2%G5&]QHR BT;P\[+[?_=/E?TTDYA9TL M-H9C10!C) 9&R::<,PTMRH&^TTO0[I*6=I>]0N#:[*H72XYQC.9ICRM#X HTO M1T2SC2D.(PU+LRQ#%RJNJZ\):8$I[I3 /(C6SA?3&(K/RA>U6>M^>N:/VO 2 MMF7I=_K5&V.S!E(70SUV@V0KK904GF#(P95Y@NVNS2B'D MC MT)<_21=9U&UB\-@O:>=*2OX!V'F"&JUS]C<@/1$G4113.!E:Q=%8O=ZVZ M:55KG9N0]6$K:L2"TE@1H*88:L?BC:=`7?\G-1 J[* OU%G2-A5'4"4X4&^>)S*H5@MMF5Z^C-UME9/H?*HF-5TN@OMQ"EXV)?&M/^W\_#FY[7A90LBZGN=COMY!N=`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|=S#-6QK47'VEG7I]S:4Y##G@- ;%%IRG9^*.B]M'O&T=%.^_6)>>.'OMZK* M15GI\TV]62H*9[-A2A?#,WY@ Z/,=!TP)@'!]Q#O.FX>2UVD,M8MS,0?]9> MM_L$EHU?&L+!U)4'72)IC3*78)5O[>NH#H>SR4PB578C TDVEE'1&,D:=GQ; M,G:?T8VB:6VD=T9]_L7>%%1+7_\V'QN=5Y9/>L1JF>\BO3RTSIAZ(^'9_D.] MHT1C[F J(C45;PZ(M#=P>K A'B*"M:AK>,[_GE]LRWR)H_/NDU#1,O.?,"%! M3$@X>+,Q+1X"",=CXUF:%ECZUF:$O(6L])%.B_*2&CRJBS*CYJ%L@TT$H>B nU3N0#+"H^X(! (6K" -.?B%P?^Y M;B6V 5W4G-^V3'N&$BO^DP+V5"|[U|+Y.\O("=ELBN[FY7=R MC57TE;-V!G*^6*!+[NN2"3"*UL[5&Y$?B)*HDY5ULF!G(M<4E\9R>O[.W\ M2TO/?WHLAA<;QF$,_ WJC3&.FU:UUKII[5O-'DW=-G_]JK9;[2;5_'K?ZO^D MJNT&Y>G,*#"7*3"7^Y7,(=`P8#O=[C. ^)^54H-D*2^>*KM=!QV O]_(Z;;|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|%,V=-EQCZ7RA0C,EU\=L@6$#P^8-Q0<"#\[740N[M!]Y"L^Y/7X$@!#1V1!I[? PC"^3I^81/M>;K,LC27AW01Z.SH=/;^4(3S4)%W M"Z+KC %NE(;AN+D5NF=RQ-0* +';ODQ^,+U:R MU9U6'6A&>]^ 7&K:QJ>;.[(%9@\ F51 C, &< ,8$;"F6%K M-\O6TR21)&&K>8UD;#^EJBQ4A8DHB\1VZN(36EA3H^7Y7$' M1S^E)RZ4TA,;+]/EHNO24PQL:5I)+P=*!++E0R@2<72^7*(YCG&+M|AT!"C# M9(^S8%4G'T)5IT"S3)ZNE+D$[T-,$H0>Z!^DP^A?E.B<[D277"_|<+1V6CK MKI/)D!$+LOGH_"7[6:VP6T<]$6ZVQ$6]?BE\^ MU<0_C\-(JA4Q++?I=_K5&V,:A,$#EKV[I?P#*$F?"M MFZMZY[5U_SP^]7WAWO,7W]M? F;2TMV\T^GU]*MNYW89KG3:KL,4J-;Z>O<; MEV*\!IZ?H*+@[\JBX1G^>WZQT_/B,>5^Q:'GW#S17'0-P24Q0T7_4.!WRQV,.0 M8(2Y,EJ)$5G#Z@H*]#@YXX,[*% Z 9.@\FZ<+C.N= ($#E94/E[?6-?:7^'1"&-MT97#;J_@>L/#R."4BM7HD)7#UG@3,_&8 ,UPGC!A+TJA%3D-&MVKKWM_T@B \3S9(C^L'_Z#:Z5]WZU^@Z?P/,>CF#94,OF.$X@Z,M//G*_D^ M$K%48.E9VB[!,% M&;K YNA2'I(X)Z3"]B5PBKY/ "0=FQQ=(0_;2\G4'GB%2I'.NU\A M!XTJ$72]IC_;2>A>2]Q.T&,*"W$D$E58M=_G MK8'O>N+))AS7O"B3LG1'7G_71OJF5WY,D9NCEZ"MHL)S!W:N,+U,2_(DJ4 MJ1$OJM03+\T0.?I46,W1&(TD\@-1$G71ZI67P2>/W>@O_;U"4O:X0<8K]< M#GO4KMT.T'IQ:KV(E-X^W[GD.[M=9NEB,0Y_V6V/Q<8!GIAB&B$9PD1KOI"V-MSIFHC4G(@4,2--ARFG\7Y<^E\LOL*N'[(=NXSV2FU!L)3_4?:C;(,*8,,8^_MD$S'>8IQ(6]:HLXI&?O,VN(";9G\5I&)E,#? RN_N@)^=>PVYB"$_?C5I>!I M[3Q=K+C.+8)]2:Y]\0>P0TZUA_3U]N+F8MGU]MRP^2SH.A?^= @Y:HZEN9SK M1O;E M_E-]6]I(G0@ST.'NGV+C5QL5-D8A&E.EWBR:00!QZR;#EB^IV?]E+)I]^=V^ M&ZRY(LTQKOTBV/#EI#9\,,2NU3N0M=_CXY1 2YWF.YMPW2D:]IXOK=#KH\.3H M\/!Q?S\@* =/T).R9+ZD#\4O9RU9>#HAF*W0E'VR; MXAC"F]+&DLSEE@^$;G7\-E&>X4$N]H109*V&,)60>5V?:T$;#B!5'B-#E'EU MWM+11,-\(?17%>,DG>5*!.M^8.L@;<*W6S>OM=? >P^OC\FCV^O?F^OM7(;[M MC0-0N]WL4\;V8+7F5:?;I%KM>N>V2?6K/]SO9 PYM6B6PD2&;3\14#G,K<88 MNE!DZ)+]Y8*0ETMP=\^QD7HHO ESTS*.5,OHP M61*

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|%,V=-EQCZ7RA0C,EU\=L@6$#P^8-Q0<"#\[740N[M!]Y"L^Y/7X$@!#1V1!I[? PC"^3I^81/M>;K,LC27AW01Z.SH=/;^4(3S4)%W M"Z+KC %NE(;AN+D5NF=RQ-0* +';ODQ^,+U:R MU9U6'6A&>]^ 7&K:QJ>;.[(%9@\ F51 C, &< ,8$;"F6%K M-\O6TR21)&&K>8UD;#^EJBQ4A8DHB\1VZN(36EA3H^7Y7$' M1S^E)RZ4TA,;+]/EHNO24PQL:5I)+P=*!++E0R@2<72^7*(YCG&+M|AT!"C# M9(^S8%4G'T)5IT"S3)ZNE+D$[T-,$H0>Z!^DP^A?E.B<[D277"_|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|%,V=-EQCZ7RA0C,EU\=L@6$#P^8-Q0<"#\[740N[M!]Y"L^Y/7X$@!#1V1!I[? PC"^3I^81/M>;K,LC27AW01Z.SH=/;^4(3S4)%W M"Z+KC %NE(;AN+D5NF=RQ-0* +';ODQ^,+U:R MU9U6'6A&>]^ 7&K:QJ>;.[(%9@\ F51 C, &< ,8$;"F6%K M-\O6TR21)&&K>8UD;#^EJBQ4A8DHB\1VZN(36EA3H^7Y7$' M1S^E)RZ4TA,;+]/EHNO24PQL:5I)+P=*!++E0R@2<72^7*(YCG&+M|AT!"C# M9(^S8%4G'T)5IT"S3)ZNE+D$[T-,$H0>Z!^DP^A?E.B<[D277"_|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|%,V=-EQCZ7RA0C,EU\=L@6$#P^8-Q0<"#\[740N[M!]Y"L^Y/7X$@!#1V1!I[? PC"^3I^81/M>;K,LC27AW01Z.SH=/;^4(3S4)%W M"Z+KC %NE(;AN+D5NF=RQ-0* +';ODQ^,+U:R MU9U6'6A&>]^ 7&K:QJ>;.[(%9@\ F51 C, &< ,8$;"F6%K M-\O6TR21)&&K>8UD;#^EJBQ4A8DHB\1VZN(36EA3H^7Y7$' M1S^E)RZ4TA,;+]/EHNO24PQL:5I)+P=*!++E0R@2<72^7*(YCG&+M|AT!"C# M9(^S8%4G'T)5IT"S3)ZNE+D$[T-,$H0>Z!^DP^A?E.B<[D277"_|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|%,V=-EQCZ7RA0C,EU\=L@6$#P^8-Q0<"#\[740N[M!]Y"L^Y/7X$@!#1V1!I[? PC"^3I^81/M>;K,LC27AW01Z.SH=/;^4(3S4)%W M"Z+KC %NE(;AN+D5NF=RQ-0* +';ODQ^,+U:R MU9U6'6A&>]^ 7&K:QJ>;.[(%9@\ F51 C, &< ,8$;"F6%K M-\O6TR21)&&K>8UD;#^EJBQ4A8DHB\1VZN(36EA3H^7Y7$' M1S^E)RZ4TA,;+]/EHNO24PQL:5I)+P=*!++E0R@2<72^7*(YCG&+M|AT!"C# M9(^S8%4G'T)5IT"S3)ZNE+D$[T-,$H0>Z!^DP^A?E.B<[D277"_|<+1V6CK MKI/)D!$+LOGH_"7[6:VP6T<]$6ZVQ$6]?BE\^ MU<0_C\-(JA4Q++?I=_K5&V,:A,$#EKV[I?P#*$F?"M MFZMZY[5U_SP^]7WAWO,7W]M? F;2TMV\T^GU]*MNYW89KG3:KL,4J-;Z>O<; MEV*\!IZ?H*+@[\JBX1G^>WZQT_/B,>5^Q:'GW#S17'0-P24Q0T7_4.!WRQV,.0 M8(2Y,EJ)$5G#Z@H*]#@YXX,[*% Z 9.@\FZ<+C.N= ($#E94/E[?6-?:7^'1"&-MT97#;J_@>L/#R."4BM7HD)7#UG@3,_&8 ,UPGC!A+TJA%3D-&MVKKWM_T@B \3S9(C^L'_Z#:Z5]WZU^@Z?P/,>CF#94,OF

V9VJ0D'N8A,Z"15% H,T!3 3P 0P 4P ,R.8,T6#,XZ#YP;S#SYU MD'JJOYSV= UO8=XQ>-\FZ"\=V\";U?;CZ?A>+W_ 8(=*<$ 3 3P 0P 4P M$\ $, %, /-*

U@KDBQC#EQDX9WJQ%KJ;2*LIMJF,#TY<,+,LKA\B8 M%GBT5 MR[D+$@ [\\?.&?IMO;>6 K%QJ@N)KV>;FS41;:--'I3JCP(ZJ3U>GLPX 9<*

*M6I/;XZO&K\XOH=CZ69,/XM15."G\,%*P,(Q6@63")@# ,!# !3 3P 0P 4P M$\ $, %, /-!# !3 3P 0P7R>8"QSM9ZWJSW<+ ,,1;B ,)? !WO*J02< 5 M5)-Y5BCRN7/&*

T5S2]$9#@I'M;P&AO>)#(MU6R%%RX]MM^L,;I9RD8FN:,,\R M-&0[M3]#W1VU15IJ?&VK3X7?//]2'9V,K%YKH3)X1X1!YD*%/M<¢%?.%,Q543^ M/G"I&F)$C?(Y!=

*M,W1K);FN;>_9W8NX %AY'(M0HX6Z@\L6[%''C-H04ZG M,70=5S$UK.4)50:Z%DNQ=H1B"H8!F.[W%'*ET3))Y<_*B^ZTVT&\DHP7.6=5 MRZ1$ZQCH%FD(]KE, /?_[0WC"N[I*E"8?,*

(/HVEG'H MJ-\D7.W=ED%=M<#3&J[B-+H1T^LM7#OMN@DR?H3 B5-ZL< EU8M7]8N/(O1& M ,.C)":NVO>A'$/Q3_V,6;D>VDU1NF#3Y(]Q%))]!4!<"N; M^_!S|

<9;Y&67_R[U:IXG,_CP^);GC7NZG7K@)%MD>45)X&>D.VG3@?CMN, E M=D_D@9$@FJDPV3'5YSQ$F^6Z)&?>90)*1R1L:LP M8WK6BSWPLL3*GG@(PCF!=B=Y$27Y!054V=,.I+ %L02?Q?XCKPP'9@^X;8/A-*

V2^H$?4QG$3.Y6&3+>4V(B\\9 M_I>F&'P\.?DPB+[$]I[ZA5]Q7[0)4C)1\/_IB=!6E'HW=%FYN%7_NV$K.Q, MEG9P:.'8'_W_G)XR%SHRM'?,C?* WN-O_ODB4\??*KYGOI-*

*4EG>,P)R> ^CI! MTY^"P70L&]/^U,O,?L><&8KZR/!X*HYEZ%HPRU/7&M"9AK|(OE"D@Z)<8%1D M& -%(XX>RG?R;SQ,-?CW]"M5RS"4@8-'%OSTGGG6-;=*ILK]%3=WUUZ468[' M%RL#\4GU^L+";4@\VLHK[^KUG6J,!?G_%5CJZ^1ZSH]WAK7'=(L M9C'[I MW^,!,Y"\380DDY<,_>-EC +"1\GCJM=)XQPPH?-%%+!8LNK<:(6R MF'!L=*

[\1K@9>4_+:_[XISN[@A6HO=N4R,YVQ^J2_VRL6'+"W+X/";M?;UF2 M_K\9<6,.=@V\?=W,=/+(VA7#B=GZ[5^NA,1RM6+GNG'D6Y;K&!;QTA"0(QU MU%C,O(CF77OKCD2YIU-

*2$%+10(G7B\GO)20"!=":BAFA"?H1>TIY@,BF\/) M;U7Z93\R#RQZO2SR(KQ>2T1KPH\.8KR(+W#C]>Y,)H'1"3$&B]XQNLFH7I 4 MZ/&*Z3$)(T[X89& XI2=F806)[_6:9 1R /DF2*/AKZJKO B]?+BYG3<#3N M!?_)OV6!+!P\?,/M/"R5S7ZF!5><5;;;=`2EG9_\0N4N01@_ZQ/N(K)?PD/EZ/"PD+&2^\@+1'\YNOQKV@A8WLE%OS"KU**7HG-]OA,*

*M_V)SQ:_7Y]R M2:M_7ZMB0D[\N8$!AQ-3'"'T<)1 M/"6]6;-W;Q-ETL$I6KQ*6*^,LE!,7+$[(B3)$@7V5YL,M-%6M)&T7E^XYKY4 MT_WS;4&^_X85L3$[>*,1#-*

*E[RRW!565O>4/*Y7+K"QPH*M 5R735>?KZJJ-_M;.46]+#LC%!+O:VY>/H"2BF34DK0fE)8HI]TEZ!S0.2EU3G5YFYD-Z)05G37/_M]=OGH|\C953OK>PR:A<==,¦ S^E*

MJ68T.A77:WO[IUBI(\)$AP%0%(=MV;=BHU=U&<[RF0>82&R>N:UHWS MJCZO3Q>??EJNK76N53#04R&$!"UAQ?5BF;(DL4(<3\]4!>O4UTD(;!BJ0S"",)XT,*XL,:K4]*8H,EP@=]*

DV&AQ$JRS);*:![HU M7=2$&&009#"C#,XD.VRD|;%4Q+M^4"#J/&MD:-7A+CBDEL89/&i(_7YT,93 MN<%OL33:KQ&%;?4\EXO_/3_K"9\UW

MGU:JTH7^M[_NK!NZ^^M>CMN8DD[T\%++@Z\OSE)S>0+ZNU,S&CG.?* M!;=|T4]P543*'/Q*+=\Y8/11&_(=V++$+P8P 4P $\ $, %, /-!# !3 3 MP 0P 4P \W6!.?6@4P>II_K+:4_7-(12]I*1/+QS:X<2J^7@:CB\'T,<&-MQ4NS-3)?7i\&%Y\O6;8.KHI?.5FIfIB@=KM+:,ZVTE.G:5I\.O/^W:S$=Q.AT M.5YEF!S4(H)8 *8_"-'6"F*\.S$D608(!L8S*

Y>5CVFX/[HW#]?:M2[% M)@[,]VR7[FISD#:TT>R_A.4L"MFJ2H85XK@RRPN)[^F!:.!Z6GLW$UTS)+0GI M*J6X2#.=V8*9"BS=JP$YVX.!657B1"E]N[UY^5FPY?

@$!CP:D217:#:=0YZ@ MXD(A5:W1^0LX^3,ILS?6CEL"S;H8*HLS*1=@0'2EKP3T"8 *8>00S:=B\(!U"V/@\^JK8C\AMV8KI>*:&VLCV6$"U\ZO:<[FF"P=WEWQ!Z%QQ3\T>

*M.NW3&3/N9,H00 <%"6 "F F@-E@-I@ YFL IF M|C3+X&0^4L;"%=#"S":.>;4E+*691S%RH2*BPO)#*,.F1 8=!' ":.>7Q@-M[M*XN-;9O.P8CNP5[K#A&(3$];US$&7E$UY.]HJ!.G@R!*

("P,&@3J?B3KDXN M+1B_W-S?.S[%^.)>6)[-,6,=;-UUKQDWU&D.N$X^CM+BT-UV>*&-FRDI> MX;6,2O$]WR[>":.2^K@QIAX)I?381D5=NJ27)#R&EOJ.RTDNZP87-*

I0B.4$*>ZHY SW;&@F+AQ53H?-T:G)121CWR\IOH6[JA[9S MSX$53IBE44[:UB<^P8AG);'("L6<^D./:7:SRN1DKN7-$KF4.=V(Y$\ MA0T&@*

E@YA',_%B6%,E'I5IRJF#0DG\+,_E.4OKJ(4[GVQ.O+W?.)G++8Y9 M"VKTYB$J]*HX"L-(4\&*B9-X8OX1?A\U?]N\M*A6:<<&:<5T5UY098C958N M"'Q?RL--*

*@M>W[E[PYD'F5WIA,,%.K>]S1*7*],4#B6VQ?O['?GW MZ4*Z%+]U[A85+073E*6B>$]SIBG]?HJ25R9+8-P@W':EG%*0^6DQ37G#)18 M+K*8R*W!*H*OXN(V@E4R$(3$];US$&7E$UY.]HJ!.G@R!(*

P,&@3J?B3KDXN M+1B_W-S?.S[%^.)>6)[-,6,=;-UUKQDWU&D.N$X^CM+BT-UV>*&-FRDI> MX;6,2O$]WR[>":. 2^K@QIAX)I?381D5=NJ27)#R&EOJ.RTDNZP87-*

I0B.4$*>ZHY SW;&@F+AQ53H?-T:G)121CWR\IOH6[JA[9S MSX$53IBE44[:UB<^P8AG);'("L6<^D./:7:SRN1DKN7-$KF4.=V(Y$\ MA0T&@*

E@YA',_%B6%,E'I5IRJF#0DG\+,_E.4OKJ(4[GVQ.O+W?.)G++8Y9 M"VKTYB$J]*HX"L-(4\&*B9-X8OX1?A\U?]N\M*A6:<<&:<5T5UY098C958N M"'Q?RL--*

*@M>W[E[PYD'F5WIA,,%.K>]S1*7*],4#B6VQ?O['?GW MZ4*Z%+]U[A85+073E*6B>$]SIBG]?HJ25R9+8-P@W':EG%*0^6DQ37G#)18 M+K*8R*W!*H*OXN-;9O.P8CNP5[K#A&(3$];US$&7E$UY.]HJ!.G@R!(*

*("

*C"2O=[Y-]XG&KP[^E7XIV.H0P7HE_X-OD7^,E$9@;[X\"]>]A@ ;*0\GGG80R:]^A\T9@2^ZZ,68-M1?=6(^1LA(D3@@RF7A@=)AD^Y<(&>7_HRNK*

M,"'CO\P1C>204#,0>"@$\Y*.8_W!X/.J4_/[^]7'!5)AVG M\[[46"SXMR<3M4=G*IRUQ[\N>@]W=Q7K62B]^5BOM.YN:TSC@FGL M&4-Y=D@ EOQ,3P$G^.'|]U]*1H"F.93&7X@&?-"#)1M;SPEM&_(HWL+O&(3.O) M$QK&&|O__N 3B]^.G_MYB.C4>C9)!X=AQ|$U7,%'Y'N3M<"/M*WA0X^Q$=X@.XAQE4=T M:N&?R7 N4,<>DN(=$C%MP?*IX,6AW&6FVTAU,4D(U %VNNM$ /Z'-MT1T&F0|XSTX[^&/CB11,[=&O:\AFPQ0.YVD-!8^UK@[_%"'-=:SD5,WS)US MUZ)5!QST0#Y_XK4$>2*Y"OB+ ^/"FV.@M<^62]W4ME78LQJ11\"/P:HSI :^' M?W1{Y)-,9^CH)C;D^-$:,O"[%)?I81G RX1>=(?V:,8K_(A<.E+2,@K9Y!B. M'T4C$0/%*

*[3TKH[79;&2SS!9^ M\YE! ^E1,;UO*D6U+ ^H>UQSVC:0C?NL5A23ND;8T0NZUI_+*'X\??]E12L0VM M.*^;9%=SW*@Z1/[)(/]26 <*

*M)HJ^F!8GOJGSA!;8WV=-]2I.'4"AID S+0?A_O%XC3% U< M[!ODZ7B&OO/I MZ62K8M/MA;WC1V'[VU5T^^2).*6!'@= #YW>94"4((ZZF>,,T1)D^L;@E/*6M.>+9Z%U,'KSSU(GS70V^&3R1;H%)21$O"<2)\! 9>A^/#(\0"+,?^-LM4@W% M<2B%)WCB] =SN"KR'85W3Q1^]I4#+R-\,3 XUV 93,C?$;T+UQ&Y,@.4?3. M4?@,0%PQ|$=:U<<-OJ-&M4(WU I.H!6"|U(R@%#N2RBID^>D.<#6%@1R/X-O MF">?AR;RG8>"R$[9Q:YND#T/0\364Y|{WW2;&I4C+'K$;M)?D$]B(T@N%5*Y MJY*

0M^%MTZ]"UR+QG>!O(:\PE\),GQQEKA"]>D-\V.3C'=G#KF=Z(Y\SM_ M4-ZT53)fKBC([?;DI\@3?(GWOD[F99ED6U!YT9W(YR+]A;^B?@?9[?%O^\]] MNA0MJU%\P[BZ2Y8Z.B &T4>&OD]!=BYQR*#>)//6B*=<$U@&VG/C67: M;U'D9D9=]+ 3*XE(>E1`.:A*Z$.X[?^[MT66W%/RG:+?L8.N>GCB^BD,:,]EV_TEU_M]Y:!8(C"XHBA#O,DSOO;JNS|E NR*#N_=,K+D\Y2:\&DM5RNZA>1S/VF/S.! M8\O2P@LG4_SWU0I9.>)H9P9#;,@8D)/DU=PGNLAOV3E7,2GMC>XDU=[(198K-L"^_P[$K&VT3O*

*M\7232%1Z7R$N&$_O3E8"O9#0%WZ7MQ3$$#LTN(:W% M 0X?A$<;>0X1+CSV*5&B8%@#/V;_K-BV@I>)G6TI[<7]_#V>;CJN/?36TI5. ML K]M!$;F,0@U"N9\XU">+*

*[%&P1*C(OE^XUC%X&H&/(C$t;P2I;.P-8DMI M!0\U-9[-G44.B65[8[!W-I.),G3N?=<-@@D(S#-D1GCQ08GCBZ'I'C>#3 MNA/LPY%"TG*PK#1,1#(;7-*

*>IR\G2AEC73;+LU/M+M;SO1O).!>3E]$OF2311 M@20,L%B!T&PT$K!?G-. 7_5@*WTR.IHS3M,"O+_G)W2(3L=??A@:BFOA(PX^ M+"LVU?|8Z,+D:2?1"6#EAN=H>WJ6+++H_$V=Z-7I>)L^0;A)LTGR;YDT8EN,@ MOZ.R%;;2L5Z C"Y6DT3:]*8-DC99_#"-[K55==@GPT1D@EV2K$. ^\9^Y#?,Q MLF&^19[1]BDV*5KJ5"8/.?>>T=;K5Z27*=DF2Z217GMS"*

(7GPWM\Q=-$6ED]<)'O%[YXT5K3EHJ+WHB M>3?0)+K$2IBM97Y4A2ZFW)ZT>V;2K9*/EQ6=LA>P72) ;PU;X)I17N?V&$JX9 M')ZI&#I7=6ZG$#'(V"^+XJfQ*:-[+ ^3CY6)6^.*

*MFH&/;@^#]\(D)P2&KNZ03$1Z3O!BYU^1"T'DX^+P]*RB,=VAJ3DA1YR>9;NG MF 1]?+A73,^?C$G5Q\<-PC):8X!E3.2'> ,:**$R8G#M(1F_YHO^%U-T>9HM\"25|+%]*

*<8&G$SJY)W+I.8B%F,!H!QX5 MP['B48NZF6<1TE#^\TO'0A2MYD]6HQKZN:M!"/LJ|%-7:(R!CT>L5N!\&'[_MKED71HC8.549$!=Y-"P>/-2/7*S"+^G@LL!9REQF3F#%0H$5^?+"]"&'I2$VL\":WH$^+5,FZ(:8E6= MBNM&&>6$3UOIJUVKQ%)?7=D.'NG#QL>+$1@'Z M*4Y.UR',26:IPQH?2AP:"_/43VSDU28(?R*?CJ];(->(+%:8I[- [@CEI^FW4PKJ,>E+KG?'Q>EA;BQU$IYD4.B R=Y M0'$(Q!J;%*O_4'QJ-5JJX';TU8EB5"FGL3H;6^UR]NK!O,P*BYM;^L=D;-.] M%8\[Y]P0DOS$4E4K(!4)8,Q"/-*

*S[WTSP^;= >W@OM%+_&Y[\>:M:YK/8*CQ/# M'CR,Z2*\|>(_;BE;XT>0:3U3I<>1+18>PZD065PR7:R'"%]WK7!Q@.H8T$8[& MI\-@%WH9D(@5;*'WDJ.6^H6.$7N".3.)!O.QJ?*

*XTOA,D02N!21TQ8;Z3\F C-M/Y_OYJY)MTBZ_.3=3SHVN2&I9\I.8EZ4FXXF&$D_#DK?_*4BO-S&[VL4;J2 M/'/=UJ]\T9/C.VBKY&)0HTN_.),J2U8(.6?3#P_R:*5F|U?Y,"BZ'6FU\WELT*

*MNL?MCR+YK$%&,2G9K<+\3OQDID#IQEBV/"'?1, &" ^81.U)M/K$6P/F MC E7@6EZF9(*N0H24LU+_XN5B(6%=+D-SQ$WV-M8?=*

*(5(CV>/0L&NV$B)3TT3!,)6I6;@$PRBY=L=W2*7)IH,HO(POQ=)R5A MY'^P6DNTC^47[*+(@:V.W$8WV,54+<=U0]:4?8_9ACFC_'!^<3^O?Q4_%)/L MM.(*NVAK@*

E37HLZF=NT"2S^/OEO<57\#9/F[0E>EPD#0/U>:'O(57_'WV-[MN\7)&\ANO7>&F?,+W>EZT[E4[^;BC/))[U']7((]9IU MOLO+>?3VQ#O#4\N##[^(5HER>|X"-

*^$4[^+=2TLOM&!"TC\Y?B(=/W4&V!S8 MZ.\'Q7/FKN&ZYCVZ_*,_OME,O#W19:!P!1.UEN&GCC))>!9^)<)@$)2VMMJ'A^.MR89J8UHLM':1"SIQEY#,B+!8!617*6P +S6\[-$8/&\-?*

5>W^GK]8J04337L_M9,SL5I%PF[MZH&>?_ZV!Z)?)$+!SU,6+2X_?U;VRUG-V<2E13+*$\R?\(M?M M_O[ZZ[K75Q-<>/6C:<'EUTZ@0#=RM76E IDXYDBV^X85B)S44YK3'+O>A$-*

MVJ^MLN^S%%BGBV) EL0A84; M>B9:6S::0#/'+C$ANY(%'^=8Y[CNZ6F+@(N/VZ:F/^G:4#$\?@3!@FL: VU*

*MDSN^N3)^EG[!+BX(5 ;1>*R8NHDF5TKIM9((7=9A1;;PY3Q;O.FUH[,,(4#F M2'2QL/0\-WJ,9C;*&_,,4?PP]?2- ^Z71:CFI7%5)'4N<@OOG>:?*

*SA^[7A;VE!^D[:"/9Z$=75>*T1P2ZPPN^1S@9[".@ MYYP\HX#D7@B,J)#YPN1^,.9.M[K&\(4E/ZB6C:R\5/(/XE\/+D%'DLI9O,LC M97)I'8C(C4?*

*OSC)QN3N1(IA82*VAK9+@CQG>&:417TTG_3(!BS9-QH&^=-^% M-Z1]|RP)'D?N)'NUS(,*Z21TZ$P|&PBXC588"KF.XM?;4#KD|D(7ZP7'QT'N M#/MA30URT=_0$2GW-*

*,0GA:E4Q>EA6A@6_ME/(0?7*32LPA7;2]+TZS6:#^11 MY&%)#AUS3[7HWBPDW3Z+<|)-+5>0UI]>(_> SK>WD8OX|A7]A<(/1U0TR'\VO M9D=ON]{U\"YYRUQ.SZ3\"9T$?*

*3EY+'F/@!C]+8%2= D 2A_.Q>("VF0NNY M>)7^_RY-Y-75K\:TA:77CWBR|/3TA= &S]\7;(ES#Z*9M15#Q$NNRDKXP(8IH.^](\ M$8Q86LZ()(<\TUHO&JTO0TK0T*

)4+!-4U/.?.55+A;G' "K^@6 6A.E$7UK* MQ;NI@Y4E(1B])MLA90'8. !!W" M>(/RS;LV3CD3&4@ OT5K);"!=[N7KA0-4Y+XMF&\9:ZZY)E$ P_-X(E^(8B9

M:86EX%PLEGBM:;DW2DM_@6W"/-LC9|_2L+3/8#O9KUWDIEJEF'+$M+WQX9NM/>)0Z)V\W=83/-ZWSY61Q57-GH?SZH%A/B?(L)3W^Q!4NI]6.GH+D-Q^;

*M=U^_5FY_DB83S:M/|.N+|VJ%M)6H5AMW1=95_1-STIB^JE[5CK2?UL9)*LR2 M]-.[T'B+5.O1+|*$FRT@)^2,%4,9L5WVV-L1Q|<:UCZ|$,Y\&KJTP^CK\,G M*

[_2[3NO7B=1D&\^^DMP$EF#$$$H?KSO9E:*9M%&(Q/M24]JF)IBXQU&E=A7 MOW8T\(I*Y4I[99L(>'@CU0L&??"@(*]D#!GAS/#0KV MY&CP9Y;,.XG$0)B^U=$-VL--TQ45O]Y ?

>3:Y&[$]W'!96F_5B)_WNZM7HF M-5F]FM!TE^KY0(-':8JK3,K7^A\))VM7Z%5RI@Y86F!UZK96IP]Q4C!'9LG=& ML7=GB)/-UI%+^ATKQH-EXVUMWPD&:GKWLQ M5-*

*OO#TW:FD7S@N/S/7.[>']" M*EF>D-TH.Q\)115W^2@1Z4%1&J4!1W5\&A:QOA)OR*#HLU,.]2[V\!LYNJHK MY1ZMJGI=80 X@N7'1+[7T+;WIL M|(#';=:0852=082))=*

{"QSJHCK7N1#QTEDTRX4RXB;LK 7H;^2I;I#-T@&.H[_DB>"5:&=F1/,CU{JEC!MLZK6WY6M$YQ'>A M.]27]=M1K;#3ZMX(HX'|P-L3;/?|2D5D>DN5|)+L&0#Y); MJN\.5$H.=-

C3PKVYU9B.|\Y_5VF/)EB]O/[W4SLXFD6%L,P;&@I^/E0EZ\[%9 MO:R=WUW73AH7S&WM>ZU^5\/_6VU\JE^UKAKU;5V2BU-PJ0(%R4%.%E)X0WSA

MD2#"U#]9V9C"IZS_8WO0)]$$F96=VK!9AZ9?/WFEHM$#Q:\TW_N,R*]*L@X M#7R&\=FDX3_U17R[\NU>NJ M_# ,#$H8@%H_G(SN8F3L:>#)*8]8\9+=*

EEBX5OP5H6(J7TL4MG]T4+P7Y MOBH>#EU$H,O6Z2*UXRZAE+ ^VR.[J(D4+?E"[G MX^>+[:/6N>H4#X6,T3H1>$BYOFKS)^9B4@#.9 M(GXZSWQ:R1H3:\V5&8KN_)D-

*_][=S"AZG(,)0F-,LD?$#N7Q&I.N%F UCNE M-;4C4\?V599D2U^5"PD2$DM0EI//AO:N^]5^@%/232/@E *G+'M]D*>CQ"E/ M\I3>/,[^H+7=)5A&EFTKU__L9<;PM,>]M-*

*M68;"TQI:T$2L0NCVG.N1$6_8ZQ<$I_"YS$"F*9%0]%^>9- M62_3E:2_8B]!9?A3250.PN@1%\N_+4=TDZ_A=_L#)=*91@IGWFG35B[QDN7-M%_C*P,Q%),!*L?7ZXB@ZDR65N1**

*[R')%B2WSTN+*P_%KO'M8@:_YXJL8\E5, MS=>D1=MC.E"41)Z5B@O+UP%?@:\+]6M\/=0$?,U<;+'(Z%C@*_ UM7Z5 MLNI7.2M?"VR!XUBQ).>.K[$GA,(.3@CG]%Y5DURK"HX'|T_-*

T9_KE|I=N9[A M>'#?TUVTW)U%EF_37LKSR/VPY/Z_K>]$-!0;2]*-,,X#.6Q\# QQ^9IS<'S MF7=FG,!RBPO)W(U|PIOX/FQ\'SA(605SLW.BC(,%E'Z@/)^O1,3W M@\DJ#B?*

M)3OO|2F7V((0UU9|/HT&"'P@+|,Z|HHIX_S:PB>>:6)!+/&\7RPA[G M.>#Y5H(>X|+@IUVNW%,.[A^W$KO88FI\W%U3RU6,]6[V@8YY)3IF[M SHTK6 MB)

((Q2);EF#7!X3>Z^EFAM!KA%'",L<@D(#83>?0QF45LK3.DU(BU2LWRFW_;_?SGCAC_T M>A%A3>.9J2)-0%73CV,?B0@Z2{(W/|#%^-4O#>O8ZF)(^@;3.DU]?[8G4*

M^V>|7W<0[>86|&KP2O]ZB:CD44_()@49O<^2+EIOF;^1IX2=S'13=WI(,_$: M4^C'|J+P;]\HS?C4MTFE$_H0'"'EO6'B1M"M%>)WZ?F<[TDF#MM$BA8'\H?N5

*M\]*E5KWBBK16XXG7/((65#2);2!_']BD|*Q?7HA6<20%2'5G8#FDR"DI'TO:.M3Y!JL)3O7A79:!DNTLODF10;/=6L9Y-^?S(96AL/#\C]8$M+]KM:]HG7NL,O*

MZQAMUZ>A/FTM9D\A$]F&.=4M!'IYTBRLB]2I:M!2G]X(2*E:5U2%=-AX[I3 MG!N9G,]!DD?PJ$;-'SQQ2A":FC1TNL8LPK7KU1_T.DX)ZF=[N87K3H("GS

*MIRK.9&I>63%GB$'R/D&ONI\'GZW#*82WHIR)IQ?:X(RB?!U=R-MI>5TDQ1)NZI_K]5;C=MH/|0-#W)_,2UR58+M_"ZK[>FZXZ1\#^I<=2\N!S7*

MQN:XHR6O<;3M.R]AO0$ZCZ#T9{fN2.89W(H'KBCBT]V+,/3DVNBS<94;;+^2 MSM0>KGSN<(6[KZ_P]ALL[6YO$8IQ'I%;Y?FKO\.GA9F'@X&A(Z>M7[7[RE5] M?

*%'ZVAZ,&M<1SZ[E_D]MF[< B|/YZ6OZZ6XCQ[G7FO)?W>&G*_R1-33N.*TZC MNRC^(10RYR6R?$ED\2XK=YG[0+N!97BBS)8[+'>UBC0$?.M9PPN?.?*

@}^(:G#$!3NNF^^=+|:,O1.9R;'L%\O"Z\$(',.00RGG\I,$7F6'E) MDEB^D.? (O#T4'D:8UPRA\!+!0Z.ECSS-.D)/MT!8<.4Vf;X[$H<-DGWQ"_: MQH0 C-R

$;M#Y.)VB'7DMO46WABZP<:P,/QV|TL0+Z\N-[< F MJXG^'#$F6#GZ"\)[Y3A)OWC$"@+H3''Z(M4#]=(,DB4/ MQ.5Z++#XY%/"%CJ>Z:.)=),Y+I%EL7 MHM_Z-_@:.^=.$H $[/_R+UST&

*1LICZ<=1*OWC$#"F!TU8LQ7+XM9_PU["A= M!E,OC Z3C-\,8H1%)QO,23GTC,X#RQO]IT/ERA=M5HW5Y5KUH_3ZJU;NK\TH+_-7BJEZ15Z]UTRS MA7_QM59O-0I*

*]ULW:#9{'6>WV),Bj8?Z^,Y6AAL|_VC\'/+>_:R\#F]X+(5FT M=TU&(_K>=OXYT/GLXXZ#.-?;^>1@/OW!]OB^7WJH#[X\ M72L'LP-*A=_'>P'1/%)5V/2=9\4$6^ESF--*

QYV.O@27]LK!T&RB1! MWFL0CQ$U20H]_HEN16FR_85NDF[SBL$TR?4(K[.\C?==.E8P](M#A]YC6 @W M22[__]E[UZ;VF65M^+M^A=X\:SV55!FV5X?<^TF5

9.0$"""}3HN55/Z\;>1'!XFP|KMS$05B-3W'H'DPIP^C F M,_3H[:Y6?OTT-S<-4N+I2"4^Z?8!WP-G_Q M/?"&%ELZ|Y.^":;/Q^]H!|W1:$,@ 4:5W-=VGE6%Q#NHQLO,*._)9F.U0_*

MH@.AX<%IF!K/BA;8DCQGZ,(DM]?T^JS]/8X2./)=,1Q&D7*-!YY@1+<>?O6 MP9_QFJ13^-83=S69A=,8'0PV_W4"!ML5K?]A(6-,3&5HPI_!)6"8ON6&_\/C@RMC@8+GUU*

XKYTAX;D.S M;S#Y!%6!,WPN4F22|V(,3I2|"2XGZO6X6#!M,JM5KP?$NL68[\&E8D)/<(;!+FQVK!^J;G8>$4,$)<%[!N\H,@PZ,/-MB+/#@UID/\(X'0^:BG]?TC)

((+/0VR=ZEN/=I(@5.J%R9?9 $0]1X\&KN.>6W MBQ73?NZ^JUQD07_.RS?&GU?U;=?Q^N#[TbN#Z>[W3N52>FZH|[D)6W//^P7 M#:>\S5EFZA4M-C'%=ROF|#\S_&:Y^@U?

A9IY,W@!,LR[#YKV4)@LHM8598X_ MV@(=V+<,7L+,(BX>|_%0'XS^P)&;CS6QBIF7HJ+6A(.$Y4;,# 00Y[0#IF= MQ$O)T9"OV$6@9HT(HWJ%@6-H6^KW%F DDT:%*

{6>+,T&VBAF^\5%8H]U0<@ MN :NB6_%@9B9UW=TP\(A81H:>S-=5ZPREN8L58?KQ@ [\MI47HRCX[N8Q N+ MFX6&1@-

&K295LSPG=;YX)O'9FO9@Z'MB>RDR@C6ZCH76"G$4%8O3<01:3HX+ M?;%\M+LZ]!-@I;>86;@X,!%-[WZKBYVT@9<9.?7! 9.,Y?4HA]N"LMQ\ -L, M_ABAZWX[X1X%D:^-3-

*_(\^'3!?6G-1 _GA# M8.0D EG?"R9YZ'-U,'2[?X,1$6?>2AQ3$E^*Y[A3DP&0#%%)3I,I))%02)++H MIPDZEN4)QGPIGR6IP<5(7*P(IZ-K]#6VW$3))*2$%&C;,A:\" QD0X?)T)7D*

*M:L5&$&T$T480I7A:-F)I(Y9>1"QYH5Q*ICP6"V$F)7H& Q^U:^@&DQ=[U]#0 M]YPDD7YBE'IK5W,MA\5@--']["T20UX@AV 6*9(H:]UX$8,F)I6F":5M=;>G MV;>&QSSPCA<+*

*(]DHIDKB!UG&&%@L"#%V;W*H\5A>UB"?L&QF1<(1Q/"L^%C)0FK G*.Y([OX$^;D$6EWRS7[% MMXW=UG5CCO\;&3BT2:'5+%H+BV=U1AN1MQ%Y66EO+R;O) \<2I] X 2QD9P#*

M%FO8/F;>$0;HCMR#Y\(B^O?I:<2H7@20IQ3YTT-&/KO1MW1U\:"2,#^(\ M>+!8W$48HL2STK78MENYK.6W'5SRP]M)>1,.@+ ?N8##+) -]H[P_[7D_A>>-MT1TRSB\/.(HW?I?

*9MOP+Y"}(:IU9&\0X0&!FN0K4E'JO,(6SKI9=PXE,U%.'R< M/MH|UGMV7LY>%E:,E(6-<|/EE865-F5AF[*M9V80F[*P35G8"]_MWU 6M@DF M:DSI1%/ZQ'5XD(58/?H/_:&[H$GR5-*

*ETR!R@X\BR2T@*JB4 M Y.#F+/Z0:JMR&$Q"0QIN]I-J4$Y2P;J4"^ MPP*^/:Q\|2D$^X S]'A>DO%DN!V3(0!(,0,X&_VV+PIOU"'7-!:W%!H#OV. MTZ>?1!:V$5<;*

*<;4J3&\1<14V&L6EL#:77(@>OX$9V;637DC)9X\'WBY|C\S3& M36YL&W0'E"+2D M*0D0 V[?PD[R*89G179A8^QK!S@#C%3-.K3MFL-I,,LV9B4E0LO|E'PTPH]-MML1PL]BZ;*

,Z6H8:W8HI.WV1K.,L$.LF_VB?4Q$.X\VOCSQ+4%++@I]"ZO^ M'7U):9"GP-8UM-'"QZ;(.(H^I$I:F1GF5%WK4VM>PGOH6"P&'SG C4ZPT0E6 M1I@LIA.@RDOK"),7?>U18\]N=((5PE"

%7>&%!$O8_(RH!*.F @N(4*1_4;D M&\6'$Y)22)UTH#B2MDYH4P9&9,16A$G,C&3&Q2V^-&_8OB/?.0K"E;!QP_*7 MMF9)$&PF9JH,4,Z&.Q$+QN&IWPIF=Q/W/'Q,(4D0)]-W1-#Y4,5I?

*9+V6T$\=3^MS>SF>&_LS3!#_(SW9G=1+T$[WNB#4J*112%UB><6O7!48-#:BTVU:Z(P];@7 M=C[2AK!DER/2'<*= ;OD!N/0!~0|>CPAN>%VX*/H8C@68':\=.WWN>>!T MP*

(,K&P6YZ\]D1;)]8VJ+CI ;08_C$K*&([$T#LX6K:0!:&SXJ#C8X&N@WY M.3PC_"ST> QR7N.V101<>NKW)>"32>V8K,9@Q ,7]L=4KN!0+!U51V,=)%E-!81M\%H4#=M7M(AZF'7"'&

(D MEV%X92@W5Q_R^%# 'V3ND%.UD&73Q4>VR8)M4O 1;S6::6PXXB2)PX4U@ZBN M2TP(;I4$1A@R61Q78OA|;20BE.33|/#1. ",$#1D"XS)F8 _B|O8D7%+^9V!'#7.*

LFID&1\,"]FT 48K,1C_^__J1<+M7^\T,M+0W.IRH8W M&2_$F4?DRf;,A(-C4\W!

Z7Z MT@PI,4*81T[5;;QF$D% N8<^G+;>[-?1X))8CU9$B()1Z2Q";JL2!FX"3#/+94)C M*D1-'ZM)8NN)#LRPFQ%% *-\ZGE%0*5-X5 R85 [R"Y?VTFORD$VA0"K?#; @V%0"_> M'ZH:*

*[P_5TES4SKP3PSU#U.83I&@S.H?7[%A.YSI6,*HH-8R:\-3Z.ZVS:O M_6;)H/@N6TB)#5 ^'DS#39"I9W8I(IZT\ECCYE(8KN#'P.I1HJ^.TPG@:Z MOJUK+HAB.PI\3V*

D?,2_BOE_]HMG,_1GX9]/R<_M.CI9'F2:9[OB>7< M&< ~%+E;S6X4\MX3(0ZCS<)04KT3CCH^ ;40Z? PR(_GGNFD-847B&K,3(M9@ M,.SU;74'"V5(<\&G"N5!]?L.[C,V/#*

*]PFT8DN]YQ(#Y<&'H.*9'>;3MT4#S M%9W+F 8#6I\]J+=97A4-[*GQD9VACY(@,-)H^=$7&+,>U4_;8 L*9H\,G,M>Q M$>6Y>B90AN9:%)^E39HT$JBFQL!/7(@BIB]-%QQ\A4YC"=\S?*

3B:XB"\"\?#' M B!%,DMQ/5]F>9 5H)C]H%PNF.C%A"S;!?#"VE?.S$7!Z.((CX#!*Y(/],]2RX,11-D(4!++#W8BTZIAE8:]\(39$& E_M_'S

HPDXC4D[+7H)I&UV=$5PT%O\Q^BM8*MZ-'B;,@G\<>R6> JO!F-!'=N1 M&Q@$]6-=5D(G8#Q[FLZRZ%WLT'#D1)PZ]6=&\PDB2!05XNS(OE4XLXG?]K;1

MT="9Q?LQP+,T@4="V<00' #(+4'BZBW\%_/$!+PEP.D49RQZ8P7+?D_=KEY< MLZO'-;M=S>LU;1W_IQ6>]63\L'2?IV9Z_N;YTORK/QW_+NZ>5=ZEEH?KWRAT M;SIV/

*(E#$)C6)E8GUNSI=]4G[Z4Y1SD?YQS[C@MZDKW+850/ MI0X%P!#HGTQ5G<)-Y//"F<>]+6X]=$;G9\IF]?OI77(8OC6*V!M5VHT-YWES M4W(<6W:4%OK;U6O--*

*S6;M#[RAFU0ETV,/^*X .('W'<5-MVX. O:9,%)3O;! MB-%3VS;?Y;L!+D3E^Z83L4)>,*6PA-RU.R@3WRI)QZ:/^YG,BH^=%;[*DW_*B M_R>6H**PL!W",FB4C2/W"PL.:TE-3;81,-[P<1-*

*2TEUC2^FRZQ!!VXW.=XB% MJHH*Q;K')}4>G85S1(%[,-GD+[(9&+S@(*]O).HJ6 T.*CA3 2\A6|L-%GS4*QGG#WYB8=:M"> M%?IB?%A))SY)A7P*L*DYX<$(2*

*&F..P/.5H*XPZ1C@3,'#.Y8=AS M+)\,'C\:S&&DC,[.*(KDV2.3U,^)9 *)Z+VY^K+G5(JB"C8DM5Z0FQ)BR56W MBYD,9%,')=]C=T*N,MMH@7-H@<6X%@CB1C=-*

*SM&BN%>3^\4LT,?T<'U+0) M\0&9GK]Y?BJ>^C^\JO'I-_-=.G=BY4JX](U2]Z.3#*T[$#4Z$>39Y(:WHS4Z$N*[?2R^1]!6U3I<10C1DG% 9.-FOSUT(>)P'"%D9J8_E&J&>J;K;V&J*

MIDBYQ?)2.X">0#\=^I'A\0-MA/T$N)IH8GHV$R\#H#3&/F.064GBE14.JVV4 M25AEBSK# R^<2=H-4_+.3<|3)U6#'-Y2[:R&K7_H1]0%W1FV?41V%M)R.UZ/

M#._%DFKL;3[M6=;7(83PMC'QQ^_I_^$JO+)U34(@C<48R1L%K&].YS2HC& M+7O!$4G$9#4)<"2B6"I>#R9!CXLF>6W#,HV'H@X2.XV>,<\VF,9RYK>H 3U*

*M#4YLLJ92>.8AR45SY_5F^<$W7D'(H+L^]-CC*1&QZ6 -U*WK6($B/]$'@ MJAJJ3XIV^&Q:%V0\)FN&(PAQ0IH!R/9>6U+1C(>.IK*0)IT2)@0S#33>, M/@7F<),"JH(O(F?*

*ZCL3X[EWE4W"W4LFW%4V"7<;Y.VW9A";A+M-PMT*KVV3 M<+<+$LI#\%ES13)!)\NN M3QE Y.4,&[-RCZN&!5-!{@M6.EF.A[7&')B?(^-PER.2BK4!HB_9[LJS!+3 M\L8G*\"P*

MR5(=.%&/R] MWEU%)\):B8#<4 ?;==P%2UXI4C]B-;R M$YA!-.0G4=\$_P(Z'C!H[#YAEF$?*1\T/S0T.7A9T#M6O"H<%)V]8+JY5,#Q M'$TX7;_CFFTRI+&]L 76N$6DP0?

B/1M'A/G4_%AA_XADBC?E]3V[C6K(370"N'-M>&9]@=@)"P5F{,@6>#]^3MT-&.$SF#E]8*#E V.<< D9'NJ1>,0$TKLP.MUG:SWLU%^<'<2'GAV<%LX=*

(X;-0;_Y09GIP%;04V%ZB@QK M+I)[4E;-46KI_7XTRA\$D,:1V,,7= S>]86NQA Y+Y^+H\S^WE!?C'PBX]# MH"=W&*;ARQK7@5_E_C%7],;Z\T&:UT,8+)T#1DZ+"0?3.ZY64<(-R5*-*

*PBE1/QUSF8GT>AIBV6 MWA/F/>A)0P"RG*2#E2'38ZX$$VD)&PWLC!(DPBCP@H0YBJHOG"_+ M(<6H>ZX,KHKV@WX3H*

0FSE6A4)F%,=^Z.XH5!T!S"C#@>W#0EA&N58J23BXH8-MBB"N3J75682K&-3==0V= U5NW0PW+<@PJ#Z'OY-\%\QEH(UH;1C3A0Q>+=")6 M>!+/D3!XMEX>+8F*

*_F6CX0"GOBU!:0$//(5S@-(W$'DVNO,(<\&A/M8^,D MC>"]*X2^:]+*Q&B&V2WI$#TQ*X(UFVF!,'$-TPW/R>5(:ENU#'M:I;/.CU#'UK&*

<77AT^7K=!_CPC_E@;CP_TR/GPYV_W6VKLX,"G' M^^I^\^!4O6P>7K14_%<09#LX.CL_O>!1M@B6VHOR@+GR"F8_]-DR$,]3N,Y M!RP8/P|ED@[8G68%!*

%9]MBQ<0XG]7_H_*%.!]"^@KPW,KX;S!FWZO|})3C MJ16!V1P}TM21HLD@<+W>(KMV,BVLWX]+<,Y|UP@!;@UG< M4CM.9&V.^UEU;]L?B_ERKEBJYXJ5RJ? P4L$=1Z_F9S&=Q)4G,#265Y6\H_+O M"*APEA\F#;B9S!I,9A&ZO.J9OC'.X;GP+9?_FR('61%U=)8"#33MF0DI-NT. M"V7@OTFYA?\))B(4KD9}>MU|H,SO!4'G&_/@HH/B-=\HY6^>GQZ[3ZW+O_N-_M5Q>#"B8A3A0'F9GY\"[,;-K\K+EAM>_R>.XLU?X)L_X0,XJ1T,Y|LLS,*_OPFG,@DF)I/H?'FP_$YL.DG MA9^D#=X\FI?M\T?G;]?N=-:50L5*;R8L-$K%E? R&BN>3XO+^BH.J|/;^[M./JA^&((N7H:*9P9_VQ)&^64)XV4,BS3E,87FR%(.4BQD/WOF>RV# MC38;_V,FTW0-KE;P\|___NW\/-H."""A|G9F,RIDD9>I\9]?=*M67EGH+<;2W MH8G=^6GBI52Q]G'SXL^OO[>C/\7U{I4,2MB+FQ(;E7UI5BS][5]>AM M)K,6DWFA@,!AF!RSB0IL)K,Z48'Q%^XEIG3EI 2Z;#N3)&MW)%D;OE>Z+ QN MT8|[\?>^7N?KC>[HH!#(Q>G3_C#A-"8KX).F-KNY5RUGU;_+U7PN7VE,U;^7 M2\|D)!],=& O9;"U/*VQN_?D&25K670PJQY4G.8'O?Q9E%?A+_+KI'9KE>X? MVU|__&F_]EG4-V<1M1OVY(,G;/+W<[*\T?)_HH2DD^BEKF0-%R>.A*N'73 MCM9>}BQ.XE"OS_O<S^V_-I_KQUY%>G$G&P\I=$DBN MQ>F9M9_QI0*V8V^>)'B.H M5F8+MHI@KY!N@O5?GIF9;>G;&^XKDLIN17%Y*_^K_+ON7M_??;@?MUZ+"&85O?>Y(MV/I007DUJ"#0P+X=?SNZA?^SC,J4<'<.OCZ4$%Q-;@3!V\N/K1'#TWKMQX M-'S=)-+\.E@!C;E;.57:EK5(AIB!F=M+5ZM5;Y8?NM<'7X^J;UKNU_A7U!$NB)CP H01 M.'..OW!76^<{EU7MA8 89B6,%;X#S1RE6HOBS]}\=3.DMIW4#\S[_+P|F+-M*O+&%;9&9H_>K*)NQ8/_TP(/_]+$2^E?WWXZ]!6_^^7^]9K5&6?4O%[]^S3+0^MS54V0-_CEJ M>8?E0[OI&2M;YC1F^!?RF]RC_6G?[T1/DEG\5:EH&^J 6AW?F_+?>V M?%1>:?XX=SH<\;;\M"W\^JN4^UG*4L5#TGVK\.+O=/ZU4/Q;GHQ^>J6VXS+ M_L{"M9_E4B57K=;7W<^62BU3Y5@:M;R46E$LG!_?I)SN#&.EE;KI2"U__VH]CNMXDAQ]3+RSXC2 MIHK00*#.7AU+VIZX_&NU5LQ&GBWM9^K0@,A"M^O^M.OYN55_;:RVL(H@Z*U M0.WG"PJLMX;A6+LRT"RU/*2)=7Y<[9T7OI^>/\5\!1]>IZ&9<$RLN4 9:+M9R ME5+Y'9>!MC*2RTNI8C^]M|HW3_;?\S5*@ L%-]Q&6B68N"75,;Z=_=:|;G3 M+]AWJT8%ff@,M+ .5!"J8X>GYG&Y_?R8KZ^Y1)I?'2LN4 ;ZHE(KH0ST?R(] MAB/M>YMEN,P[P[_E5NN\?UG,4$^Y,@6C;U/M>HX=KI5'^_5=E3'U6RO:[B> MVC;\1\.PI>NB]L3E4),&4L0^ZM0DF/JHFT]"\;N>:IAZX;>T,F,6/5GY*Z5W MU#&;6F8;3]3)_H_J/278:;HVYM M<;ZLFP^S&H1LR5N^,Z!E!Q^(!ZK4C'BN.N79JH^3>AZG&U@POR2FD&)&L9+% M6+&SO(UB_]1ST<#>`_3!:|;^4<]-E[+-OG(P>TL5.6G_D<\AE^%G$BPH?,]_M'|CWA!-P#>U^]TWMWC^#;8<'*.]Z-6'7V78$%"S194@N@\@+Y6GB_-D4)2I. M9JW\NG.Y-6,0_]O^LG-P?"YZL'MP_ELY.-H%3M?^LJ;<#A9S='S>,E/.C]7S- M;RU02_A#KW5TUMK#O\Z,AE_=EJ>=^A71;V^^^[U{6NY;+W5O0NS M?LWK2)?)^$^9MG]^@A7^/\]"_O=M=4TWH=?T6I4V+9Z<0;*+?:!UU_HTNMXDAQ]3+RSXC2 MO>|Z?:9TP_\7?$=&!C.\CC9 6>6BE1!1M<&ZB"KZ)ZXS "$X.K$TVV_:.I91 M#?H@V$Y <'=&Y_ "^'KM]8F0N10#'$HJ@8F M@^=KP!31K.XXG@_*G@O!,'PQ;^-G0 M"^P(L$#0O-Y">E#[AM]S=-4!+9.^-6!M?1Q8&7I&=XBV_8-!^#'X+HZE]V9_X,+#.%V/YJOU'=!7GPUI3$!Q@;_Y(!8^K&*L1G5B+U5C+U7D ME_[43. MMH9;)^Z3;PS _B8:K+8C)ZCWT>G'A^ M 8:S"'*8.!,GTX9!A\M&=5&+F WY$:O2(8(!Q5%.?OI>@!;K>L T'ONF9EDP ME!44%3R:?D_;!I8!\(0N"'!#G\7.4KI?-T%D=XDS/4>M/X<.-O1NC U?&Z6@1M1+3KRS;-UL5L^/&O|L?7BVK#G M*&M:'M>GD8)!WMF[>;,KU;SV^+/X\%0)=D'ZN'!9>LL(,$E M+V,R&)AL5,>-]KF/GQO!532Y)YCFW)%NQI(9;M8,>TX0-CL[TPPW\<#GW,O MH1*OOA;01,LIE^-NU^P8-%-C3$U(\'NOXAJB5Z21,\VB$@KNTR6_NN[_3H18 M3'U\9X2.E)ACG6UF\)L@;7>T!V!]_?'L=<)B_)-$09,+16/7^#!)ZTY!/$R< M0<2IC6&6S_K0'1E;S/M=*LZLDH>;]^%+9[92[+ ME8'V1!.4U)+E7*_7O5+%M]I2P2X>2'[=N%A71;V^^^[U{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}>48;R*|QV(-A\A2#-+!HHZ8>E?]4S?%]=?S MKX3'_A5?Y>2F"U{V]?1MZ:'O>S(U$R+L=\[GAA,/N,R1?\C7C$;?N:::/G M2$@A!T0A%]'LV(C L6>S%AH,1 MP.8?=3>4T%$_\3?OD4?H@9P"(IH8<).('7,V):WJV:TV8IY+*HWO$ M9:*8_^?I^(+ ^*OSSB=$#]FI,H_%DNN2ZAQ>E29@98S|,;Z#GA4B6@DM(.F,$ M$[Y(27]/_$MX6U^[%T:,M)&(%)D4Y^:F"Q E?F%M7+11% M%B'L&(LF^GB+/#>]VH&B4I>A'5-KXK5(CMXKV&1_C@3=Z1(N%P&#]9O{JDFXM MQ3R%DB.IQ?@FC&BZ!O OCVK 0/G;5L\E3A;H=U[\3:!V:K>NP0:FO<'E.RXH M^HE$I!G=2=E5NN\?UG,C MNLXC,4@8{$HCILU<1W0F#QJHJ!@2IPQ0F&XB9RZ!#UMJZ T MX5DXZ$#0Q3R<@#AOA>M/X<.-O1NC U?&Z6@1M

*M2[H%WT_L^T%C_V+_S]TK'D.F>]/(CN4\\1RBB*7))L74Y,G9K(JEW9Z+I_KO MQ_;>?56HKH15D?5J-1:HX*M5TW7"Q*O5S'!>2[IF1?V7[^_7[W_]JJ_*>66[*
M@YG5BGJN5'P1(U!9AA&H+M4(+$;_ICL(MV?L&>Q_#^^Q$0VLYI"$LZ'UV6OV=-MAI-MKG^IO%1R8U5DB3T:5\9CVY-O9E,=V^3&NLD"%TM>#9_"WG1]T+IW;D
MU=\Z=C7GV637=_/%/?*F6GI6^F/$_;^OJ27?KYV6[9NG[A]Y)^Q5C5]EN4V:-~MMUK,E2MSWJ;2G#'$!<_!N&B/_ER=WN[U?\WZSWQSLJN$Q8DQO,SF?R5#4*%) M!V=X>]\I??
>>^S^[*V%.9KYW6@$1<\KQ_N7[=8V//[@_*]MG%>F2UC(:@0NY0JE=%?H^[+_]ODMRH7Y0V!1WO<'S8-0/_Z<-.TWM'AD@M)-M%F6ID%Q:P*&<^<K@?90W!
<5];N[O>=G8>=R^[;'M=4KI!\7-D[-M9=RU7PZUF$6#T!IXP%X_4D?V(KO^)H5M>A[FI[-NJHT>S9QW+T6-(JR%%!]-M A,#2&R4G%YA%0XG<9:OP\F>WEBIY6I3-M/*!
<06G2246[']KRQ7HM#[2O&V*'NA)Z;E&TY%5@C+!W;S]LM_;K^?E)P_O72@-MT>!P0^R3BN_[\>2LF:[_?Q);YM-4S==T-B01K+9I;=>"_2U^^&*;5B#_@HN@!!?A
M*&@$DECPCXFAD?YQ0LAAJK_I]_6ZV_>UKGS>)?)8?.?[^X1?1YBSW*_*:QY:RMW:-M_]GYO5.^/BY?K^2AS2!BMVBSV#VHR)@B $.(C_DO_.8N>"44Q8GGAZ=CVD-6
MELB:1P48:*P&SG;"NC8@1#[[S \AJ+GKR =2&<(?3@T:ZD(,X-_(#BT(Z% M>X#\ '*:0ZGQ!UAG[,BT1(-M$B\\]H4[AX@P-@SU5J,^AD.YL=]&3%]ATDU/293]C-0GU_1A8;*1T 9U.JIG
M-/&$/<;Y.*^[:-KZD6-WXB4C"_FBRWIQZ]/^Y,#;&N]-/Z-5-<-D)RK=LSF;-MB]G32NJY^H2"D31%.]MA+%0==O]GKV/5K_ZK?NW.(W9Z[I*I>OV3SU75<^8-M?9M3A+,]7N9_M
:)6NULG@3&&,#1]1)*DUQFHG2IE#DB,F*0F.FK5]27O3P[/>9^Z=_EZ]T-M7F/KL^0\ETK9,1YJJ7L?RSI0]L(NTPNET"URZ0HSG/S24ACRWQZ^=@]7/[M6-M^\5//FMZ0FF!-.1\:
<[TA'0%9'SWEY208#29SO+]X_I>[_X:NY\IV:"46?]K-MYFKY5. Y5+&DI+5M=V1+BBSQ*MTW G9U\6PWEV1B M4#)?+-EKJDH:UJGL"C@.Z?:0D[.P9"]$_^_7]I/'WYIW?"=\/:7C7E&9[E>
ML\Q]N2Z(6F:[HUS!.]?Y9&O}?.G[:WU(@W=:&Y M!X?+,S89#N/"9QQ9TG)O97U6C3>;3B)220K%0BY?
GJSW3FK9F^DTEW5!G^?:S_+_RQX%69[3J."+*M:\LW.EB@VZ\T6.>FN$0_PV=(V41H5_RDP]K8AH&DI MG8G"?
DXLLDBBV+F1+T/ADO/@^1#Z?.C[2DB.9H((%2%)S#ID%Y1HF:QNF?"0-M0$&E;[PET^#C+Z_UJW$UTF]#9C1A$Z;2WRQ+6#+!95;P:F6PJ"-FKDYN_#[/ M>2U+>/C?C.=RY^?
7Q[O2FY]7-F'1R)XFDRO62[EB858W"IT@X0,&Q0YM9'[H MZ.!)BBSGDQ <(JP ^P^'6TKY"I[APV[K"@PX5T+,&3V'IQL!M5[6!?[>S1>O
MS~^Z__OS3BSI#O."[;"$3DUWBDUSN%6UD]F[6Z[E"=8>\S7K?,/LMBK@_F<",]VC,IB) 3@07,3U4944^=L2]&?3]8_II M+A&@=")>?!S$ES6G9TC NL#T7?(M*UZ>,UO6[;R]{MF-
/_G^73Tl-/ZJ9Y;Q O F?6;XI%@)$D5 M5,ZG)"T#R/C$\II.DFOF- (B'OFJF?>AXW&$=?G9D+/M6]D;UZZ4?]#)XK"X8"6AG1\N MG,^LKV0;^5RC-F.#PF@ZMFS.JA:B2*%JLA(Q,G73QR
V)K38* 743BO?FC? M+X=`Y>O+Q=DJZ3]I\UIRI021V=LCNT@:R^R4ANTL,R.X-9/<&LGL#V;U*.]I =K_A)L$:SQ/ M(811L8[JNIC3;,I+>R]K4_M,BJW0:[_M#9H'SP?
UO>..E,WR:DWM4W391%4V M>QRJD2N4YDSB+6<]C4R5#H'#Y6[7/#XJGYRURFIQ&BEE#4FG4<@>9;J4*,OE*\[4[G[!6], T_3WKZ,_1W^ZY;O& MBY_^+!5%B:>?
V:U6K8(N,F>$86>F[5^PA"B(N;=.V^:WP\OF;?4UMG]JH5#B M]F>O>2V4<]52>OQ V1140K[U_K_FEV,$.E.DI=,OX-S^O+2UOL&\98F?6PK MWS5[]+FC
$LN^D.X*WYBQIYT@'1^W 8)"],*$:RWLY[C^MC>%#D$NFFCW(F(M6F7(P&*Z_7K@#H8G%,YM/-E;=2@2:T71*>5:.65!#@H";/MM7_MV>4=T@,0.02{Q$=$2^2VH,E>J(:XB!^)
!3[4KOF$&<2\'4<"MONR^J2_!GN M#7_L]G,&C[M2RV9X>#"Z9(IF*MH<84?TE^VMOBB]SE50,]'7>BK9_E=HHO@:.M"@%2>U]>PP?K-N\%7++H>!WT"L:ZN7$\93M$-
QTC1(ZHF:%E@0 ML)J+T>AB93)8CUBN3*N,"#+ %49P0+06++)DZ" 49EC9K 1^O2"7] Y.++#T4(MK\2FJ5U]DM$]A?@H+KQRM'=BGQ\;,D@1Y1.SO&4.,7E9.
_=4[@OUSX\KF@_Y2)R\D_1C\G_KV\'\; M[9\F?1{0CLB$"[;?NE,.X5)HOMEAI1R)?0]Y>GI8OD&FTBW5.'GKA41K?+5(ZP2)O@+H#2H=()PCA("WX7:!K
M;I!DUA9))F!OG&RTU.8<<@N^IO1C)E'V^#@G0"+FL++]PG$R4N0UW_IR.+O*]_M^W8O+'K3<7_I=I&Y{$UIFC"<.OTL0#.36-JL[H5QEE8OYRJU=#3WJ4TY9SVH
M964BZOTC[]B\;%V4&V]Z4-ER%ZNSFO=)LJ=2R%6KJ3Z@.."@7IBS%XIDR>R9F M+M)(SJ\).G=.8+V0:0_M4#B(BQ^9R7C^!CH")K*'"(5._5,P5:ZG@1#%@JC73./Y-:E(Z]M?L:M+N
MW->W$0"PZ UL7'@G^EVA_16>3OI.P4;,,(5S&SY-2]V0CT5GFHZ.-BLYY0=.M*BS&*MTW G9U\6PWEV1B M4#)?+-EKJDH;UJGL"C@.Z?:0DI

MULQVLP=W)A_9Z>L4>W-KNAU;NWB6J@3GN"J8GPEN.><&T%S."^+$7BR6(MAE M!(YXW4XV;W*_T*2/AE,9EW82FW113'/WS12RP9Z,<#/EJ^W-X_:U^W9!'>!J MO'-D<;\F>;8_;-CU!<-VC/15G1MKXB_".-M,"FX-."DV%R$?4HR>#P&4KH|K MU'!.:W=NQ;M23)|7;U9WW%N3FS3>#E1S2Y!G^;+U4Y1,N;7S/9/ER0>(%JG3 M++L]9=KJWO?

*D^]N|"=7F#UIY>WBZ2CX$E"G<@<)>Q;? Y\L=I_@V'I'X]G-(M0O5}HC8GRY,15TBA_O;04BY2"2X<2!I>@DL?H@2W&J\$JW.0T/WC|25T'WKW MJ^E1JW"/J6*3CQXE*CA1B5.*

*(6X];B'O*M/-1Z+1ZL\UZ2.;.6M(M!"D\f.Z5 M:1HGLR{'\"= MXC}, 3AVN,KB&*>+D^"39KH.3[']3?/+ ^>>RY?2C<.1.N5ZOHM^TWL^'Q MWFFUPU#!H-6BP5_4/E0[+6HA)1VEUPFA-*

*0LM97QYOV#JKX>E9#B-\JE1TB) MC?D*3N5+OB!^:!YJS'2+UO&=$?PHA=YN?%[F!^K@]+SM*9C*9%GU$299\D"M9 MQ@O%F(5\A7#J^:22ZZ[SS%Z^/BP_A*

-0QQ'%4_*!IQ7@3I^\LD20#E#WNPU M57R/4;\H@{(7?+FD,D*R09OY;,J?#N^T4,(C3(5N:/YHY52'X8?DW@E5P@MQ MX=G+V51A'9P^Z-6<$+ICNCN8':VFZS#TD;P2K%C"*Z0O?*

*7S5?AU@T9H.R%TQ MXI*1-QH(:%E=8MS4H<:?H"PZ)8D7S5RZ!@M '8J+Z+/]5?+"4EH***A2EY=T_,^T5 M@R<[52+>S"Y.3G4K/FCS6Y6*Y MY!,S@L%S#2HWG0/D1PU^P2@)PM*

*CG^XF>=>\XK0} X.7(M9(0S<3)M8?/.Y?KGZ[PK$-QVPUX$U+I_&-I(;W,'2W3V^ M*AZK{DPZB<6C7D-I$C2T[44+#W>]5HU5JZKJ/TGC0"UA,:@A^3@S B>IF*4/ MS?C7Y#?*

S9^K&KXJYZ9 MW,X%)K<33*K+>TA//=!};LRT5K+D[LIR,2;OA_QUH;CKS1C[L(6.7=Y\S/EN_MUIXRXZ;$IA -=%_,R"_9X_;\0!![W=[J>?74N:OSS-OH)&XO)*@8?GM9F2ZN MY(?K'+*

[BAH>+&S:YD1PM<.A">PP.')I0F4E"A\58H4.2K$1,(3B[HF.":;?_MS1F8DC;@M&VGT&J^#9]ZHW(V70?A@4CR#)R#SN'!&J4_%+ AEQ1(WNU9S..% M/)U"L!)17-*

*Q@92%2L%)C!*TCA@=F;H-O4U.<_J5->^U^1>GWY@+I2VF\M/?QIV&=.;PU3R8*C]F/ST#6GJF^RH,?+DY#_,!?2)O*V#3XWK8M||JKX7+Z8 MEQDZ-##G6CB=;4*

Q9.'<8VE<5:;DVWWIN`:?P'6ZJ#ZQ5Y=M4#3.%A[E"- M5*C8GFE GUHN_?AH@L!;W*:0[+3*0_F=K&W*L[MS;M=QT47=@0*K^6N+Y#7/-M1;R2W-1DA%P6H8V;)TY)R?BJ'Y?.08-*

*1)8J\6D@L?U:PHF\KQ/K%79&XL$,_M.V,>8643)BCF#|\^UWP$/CQ]K]0#,(D*7JG$3"Z5 M(EUZDNJ^["Y=EN3A4_V:.3\(A[AT]Y!;RI>>/,1?P4O%R/VRKBB=*P#T%;4[*

M/#+:%;'S:N;SJNX)K;?9)H,+(,C*R01F0%_K1W&7!Z<_V^7%S23U,WQXX MJGV8;@]>8UYR&2=4T9V\T]D#.S(;I]$$$DXO6W=|;\!4!OLCNQU>RD5!*

M=BO!H:,AR&Y67OIDABM_$A*Z]DDE\:%11A[\T;D.,F;TB"]VF+QYM1)8$[&+ M[.9?K>|79S]AVAEPT[+R_/&D/%6RR;%&BWX?GEZ2%WL#S5G.?M1R'&RW8$PW

*M_X1M=IANF=#]P^AC\'15,PROBP?#[|15XJ7_'$@#CM.Y^"T4'Z98>,20?M50F<"*?*:,,M_#Q-[@.@.F6":45)7XY$K?E>65T M"K!=*E7TQW7*A&"$'QW3+A'CD+2UH6HX=7P*2?*

91KDBSBXO-D]YF3QW"M/%%?)$50]%[RK_YVRRO&?7A' 7W+F!:!O^QB.R;N=*%<'9DA5@0B!)@BPP1^)%Z/5+ -U?!X9E5DA!PL'E)N&1ZU4#CM6<'$

*E5A/RKG\-!IS&O"_9]\X1;<"_PT6/3;^[7PE*O!:*&!E MQD^_L#7/JC.X[_Q?'@?QCRH;SP *1^7'C& <.UB?\QX$;H*^P1K?L/QC&K2 M'*_[YCA&XP]_8;"1YV^L*C,C?OP++P,FT@ZY+*

<'C)$OV;_W/^!K\TS__4UGX M/S+\'W@\X+_@W#UN_"C8M[,1!V@=/'N!+M!^ZD6/4]>.PZ1<&SU:Y++)PO-"^ M3+A^;8DV^DJ!$_[UM9#_C'Z?MS]#7]O6&CSE6NT:$#6CWY]O$^W.H-

/#3K8 MX++!U3KM>]/=:;]3A3_W.3:M>'8!_-%OM:KO6JMY@_0'XQ6VC/>A_SMWV&UVP M_O-&++V<8HMCWH<@L2@O.L3\'X9Z^ Z<(V.H*Q^: V3[L8RP4L++RXY/MPTL&*

*MN,N:HM1Q02-&E2PSYAO&*6-F 96"O.1<5@=MU%>=#VI/?Y\SXALT;VHR!\C! M-'(&X"7G@C1^0U+8,#++$'+),.O"OOFRK=(SM7,Y4+:,]RK=3OPK>)L6?.:.=-*

*M72;K+]M.AVZ5>R.U\$A_^SUH|&ZQFTZUC57;0%ST&O?6 *M>]!I(/)@7^>D8 MZG,[(_XW--%SD @!VWR=^8"W)-.'1(1V VA20?,% _8=QULPOT' VQ":X_H*

*M/UQCS:56O'1S4S,_=8@GZ:,6_B-*O'!]RC (,2EG5@c6\XEP*!L*T M5'\3DA5@0B!)@BPP1^)%Z/5+ -U?!X9E5DA!PL'E)N&1ZU4#CM6<'$*

M8RCN!AU^^L$8(!.!!3]UYM7P*N6,O#T,58'-0G"YG-N\%;.:AU\\X5E;2?[M8IWQS>]5[5ST-IMG"V/CUOI.*!7. ^EG93\U^2O Q*&#',IL-Q\B_I[>&!WFW4BP+D'+H(SS",QSW9[R'R*

M2/HPN)\'3]^0B1UPY+NR'+UR8Q7U#EL92"!,% XE(@$'Z%6;,B'V R;&K'YM M+6(% MCP>URS'B&&;UD>.Z6Y>!8=3E=*EHO1%M:.00TEN;@BS"HU/A_G.B*

M(1%Y)DU>!N>LU[KK]=>$++Y.5W[OK]RI)%HH3SW9S;?EPZ0?BN+"I(@&;_/;: M,-(C"H@!25\&C%ZCK3\=FAF*]QFN2O*-LM?M5[?_)6!T6<.LP=*PG-TG!,= M?$[V97_[#:@?

*U@FI1LK#3;1.I8GDT8@S.R8PHV/"%$Z2;&^<,;I8GW@K&'M M]1S(_6,[_0^95;P:6! 6E($/[T&I_1RI*A*S>6^1'XZYBV7QD\Y+%<x<)&/#/M'&,FX)V8|B3S6C7"%P.]#41TG++)"5J-*

*::)L>0E21(=1"UBL[_A8T809 DT?8U MXV[YPVEYNP>,R7("L]&P^53=0+%;6;0:0?OKUP8 MY*QEZDN$\'!CI$YV MG^39 D/Y[)++N)!@L*XFRI1E@<<=WV4AV,'F[4B2!./*

*MA]5K+BY*PVJ*8#1Y=(54HQZK5]YF.YYW/^X'U[/*Z^2P!^H9:G <;7* M5:2>WX%X!W0,Y((M_0N[5,74L8U"B*D;;5$K553(<|R2V@<-!]78P_ZZE= M#ZJWHYA"[U)Q@]DX*X^W-*

*X1P6[AQ'M-M"\P*2F+'+L7CU<&%?0Z MKJ"V(+'RD=,D3H<AH6[.5(++NORKF7@<6>2$"K_)O43*ET_W=9CD+6,L.8.YYG^!LWL+T*[-M1P;JH9R"5?+/7)@QX=!\/#"9;,:TB'5D?@JJ*

*WB-32X*R$W=*CC:O@R^JSOH 4GD;9XYA@"UU>?K^S4LCV5T^X,-\S[*48;<3E4RC?)IN=Y,?62RJN2L2*!>3Z7*0#=H-^MD@ 7#LY@ "U:0 M3EOC(T@3<)?@8^(4&8, "WV>L*

*HN<1T,L1$XC7!,[8V0 M<"K=XBQG!BL97Z\QBBS]LC"_S2 2[8"=BB0ZE]?C>-#9N?C\'%3[5T\CV]\]JO-6'": M4!8Z8QI+>,%6XN+5Q*9A(5C/P@L"[\RTZ.6+Q]"B!|!Z,,;7YC<[W1/*

*9'6]*HK33

*M152.8=;+Z(5!*E!06]JK8W,ON? >GEEE("]_>6,_2944+^E65 M;KJKHHUXT6KL6\=-IN7U%853<,B64A9<4<.O.X*KA%?*0"45?;%D=4_<>+!$3 MAM=`1!A4Y 0;UCN'=R_[W#WMKX>\$X[MR#7@H7"L9K0 TY:7M($;64NM&[%/ MO:KGXF18=_W=E/6E0;=IC!;'L6AUT(-'R\.CF2+1MIF9Z(JJY.\J,J#)}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`^IVA8!/":,M-L!Y] 7@? */PX_GUKS6OKIC;..W.X%R3G ; IG ?^,(:R7#]^@R=/ 9>DH8L9.P/_3 MNFJ!^0]W:#Q5>WMNY^U?_'" 15]:P 2^5&!@9=C!$O3'"&R\G"\U[6L#Q3 @ MH,SN-\/XQ,'=^P O2G)NS"@S$TS!KEQA39^(@%L!^?B!]C8MP"2GUC":HG7= MRBY.5+V*?/N-))O2^'YL"PW;CB$BB)+G[@^K-5-")2O[MV=_UX9N(MKD12B9 M%X+9L;.G2]L;OF3HXT7+I5/SGKP2]H7T+]OF0]^OIP;]$,-'A/|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{[@\/ @ MW#+H2V5IZ^6@WNQVIJC5/]/09(39O=\6D?]+/DVZ %OL1(^,\?*#3 '3ZE+ MD=?!3VA6Y\I^.UH&P;.U+>-X-X. 5,"]DO-](0VVT+AR/1;&T!"I @;&^;K M9JS")BD=[J3WIO3++#H@)>I]-1I3,&|)X&V-%-."@&!Y.>,!G.-S-]7V3??@KL!?=MU##E#;-B>)+W*4|=?TP-L$X1NR 026&4 M>RJ-A? E@W6XJ_K!=?.KM+6RZ,D21&T%LJ^8,UQ)Y399H#(KW>$$IMVMSPE" M!V WTA&UF+%&{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{'I{A]_9"*.2YY&N#6:BFR- +K%FDK-6-T(. M+R6UT2FTA]C>1>z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}%,VI-TI*Q$NWRFRI\NK>XFHQ3T:.M@A*(W(GJ9JW1@M)F)Q#D-MG12*=_M=4CD98'Q*^8LM->2+)+U:5E,&AA99FI MN8O^Y>V@<=7_G9)G579%,CQ-%VPF;? [OKQ1?]M^B'7;V#_**#^=0CMUY%7*F8 M+F66]>9RP<6LG*HRKKTO)%1$IYP Y4D*+8V&]^#(@@"8N@=,T?E_YX8BND@. MDW,"5W*J*#X[A^]V_6P$T7$22W0([Q>;+[^ME.1"]3AHO[!]7D-\?/_^/"3#_ M1'/Z&,_T>`7[++4H%K&D.GR-GT[8_T]9#K=,]'L'048&&A"LM(MOA4?'[)\ M[> (R.W.%EUQ3J.BB4>8/1MEI1+GK#!^YMNOCT!6NPKUW*KE\2"Z5(VP7=]=8 M$5=A0G=57#T|%7)O=8YG?!]\"X6AOK'<1751_Y*V]URZ6(XNKQ2.TVZ&Z66 M=#Q($_E5O-G\KNGC\5@MSK_MQ!/3#C\;]NZZ.^@51< NNZY75,QGT_E\;)\49EEK(C)7>GG'0W<_#[K%2\) M)ZK6YM|Q-1!I*H I?$"^/>)\U4<"XC[CH)+[T:4)HE#IBH5>KE 1.)S.Z3ZN\ M7:G[1,B%@-;W31-_$3* !!V#$80X*(M(@(P8 55][M*]HHP-M;Q.NG>]L61C4=4PZE2OKB(2 A?$\R7,&T)=\L4T*KVAG&]%09/SPJ M#Z?."(@%0(@INKQ'2-8T9%? (R/6UT\VE%M@SR5I*M*R"Q4X<0X[U7/ M*<^*XRN>>B\ MD3NO5B\]#|>_H>7/O"^^H7/O7V8W@8%%/S,7.3N32+#C392ZTO]<=S:0N@,R.EK2T3T56TIZ R4TAF+[M<&F[7Y]$U< 8X@[BK[+/0W=$;%WI:B)PN3E_JFZ^)6&U^7BE/ Y'/2W!E/=B MV3W5VW>0*-[ZTG,D]SNYI,,:O.Y,E|CP;L5AW;QBX2PIU7F3?1PTN>.SHTQY M-W 63W]RL>T=>!83C%?1GF OBV]85QM0M"Z?Q.EPC=N6TFS&6Q+1XVG\Z&(RQ8[66C(" IGM).7N^/FO+#4"YO M!0$Q62:VW9$K}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`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|/Q5 M%[L'TOO:0!($$7X#L..D]XXF@UC*XDM+',1Y>0L[05*1#Y#,]P/D]_T A?4. M$"@(2IL5!#4$%TRP&+_0*9SKM>I-]Y*-P?A^W6B_?E=05-]W&BOO^0'8S+X? M@-T_+C]%WPEX?-9H7;MWUP;'_[>R%55X&6D=3^\|!9P8?1SV8UD5-2O\]Y5 M26.I#%X]1EUYW\BQ)8:+9\0\T%L]97T"3$?O);;93$@ML.Q_]KS;*X@5W M*2@G<<2<4]WXBC&0=!)3) ;+74>[<-'"?93\#_1^.14B[_B5>C_<$R8M&^CG M/@/[X9#'R9V*- #OU]2E7=-'4[5-MW"[<27*SM/XM_5STA_GYO9B\VX-M,,C$KL28*TW:O%&66#7Q_Q,.R3:G4)C:P"R&MTY*#FI_:9?*L\]2W=69+58_ MML :V6==&Q\M8;F-&;THF:9^(YUYK@V M*I[AV7.$G_2.%V2Z,1U?V?.0829(>--^;6-UOA]?>~<\(@'JW$\#H2;,-Y+N"),?; MO1MOUT@=]&!+Y%N62T"~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|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`R&!R>W60:.(KXME5OG)O*!3Q;.MU M>TE^LAN=;'W2X!*6]+<.K1K45RN:6QX:6.[N%!Y+>1_I]VQ^.(9_]$9R;9 M_^T#/-P@<'"=NWX%E\CY1"NDGY!HDD_!E3\"J0VM5=%FJ M/O>U(@]HM,Z>]?YYMW%[\;EQ!E"XP7;QMS(I=M=%&[TN1))))/6%SIA>T-EJ MI7"B36SQG@M<[!]UB"Z1R80K$1V-*

*E,Q.1@UE>EH_KC;Z^T%TV4"B6S^2'5*2 MNQ;5;>+F=7[!&TE_87HXOD="-0.^(J.!K\A_2=FM4VP&(U_Q8GC63^C9^/*T,3 JZ79V>S:>"B()VJ6MXD[!%L;I?*@XRS*9/,& M<3R$OU+(6@?"PZD)SL4#"+TO/W.'@?>~<$4M;_UF=L#9(A8FT+(MA?Y@]*Q\ M]7+UU,^^#H>#_;3"N508'PVN%!$,I\'L8?@FE# M_GTI*=+0&%J7-5?=S-WM;W}U@67V>+"@LU}RX/DKHMS6.K9LY*'LK';_+M@ M;%/ KY<%N/GX^<8]^5G_C_=|%!V>3 C\NYY-N=P"7_[L;E+Z$ZFSS\fM- M\HGCTKU25%S.#}G,("X+H;AECMRX*Q2[\4DJ M0.U%(Z#+<.@F(S1OF0BEH6THSL]Hb(^%-E0$(LC2>;LU/V82N7#Z*/+863 %U M9\IFL\327NV%.YQT&HL7^LEF-FRYQI7X(CU/0%ZV\.1"7E);*9X.-\) MX)<BG<.KCD_NM-O3\3D_>,C^0<3A-00\O)&0^\)FRH=!J5^K*?/=T^QWV4*VRYW]ESEMJ/.(.I>XTMF5:D<6T");/ S*R]TG7U0WB1! M5 1F*HFRD)B5D/#(HD7T<&R>(&*TZ'Q :U]HAXT7APS MN]*M43CA+R]3 T# .*>$:C/BD-R=5K^6+&WG0E^M'N3^ J)9)W)5NCA80WF&$ M%@E;<\!^GGBR"LV$0M>E^]XY6HE8{MFF/NOZ",Y5Z_%VZO,P]/#>}]H#A2$ MCEW.`8_H5V77[V>@.2R40NI=YSRJ\'(S-D0%7B_JYK3VRI6XAV.GC<^@nG`'M*KM^14#FL)A=XE/ 7.^QY.@3>3M'IT*K MP>TL\2OQ(G*\YT1$*X5CGV?&BYR=`4J*PXM2LO52R2<[fV?-3L?[,K(<4(1* MVVY^!QH01$V6L%(''Z2M5>S7P5JRN("Q_N!*AJ=!;Y*ZK-IP)*M3461(71P# M=-,=|#K|D6Z#QIL]Q4@&7^4%^AI^2?[,_OATR;>MI2@;&>*!]L >=EO{H8+RE1/+>W}{3 A% MLE?H\OJ X=$$TYFQRH@ "PF+MD8\6B;2B+Q"$'4 $2DO{$R=[5K|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{&QN1}3HH0+"/WE"1=HF]/66P9X+L;,,OS?#U"DH"KRBIH0801_) (K MFMT1*#788# +'5U+.T2%7UEK,Z{6"W2AE'4X44|'"*3-82=^%2E8$R4\L'Y2I:9377R7U'7.5M8^'8S M%{J?FBO8B,2W'P+0B++C% +/[T"Q*5T)-CY ;3*01FE*']H<'XL .%QLSS\P668(VS8@3I_Y}>Z6PWA/2QP#=FGCR[= MI&8AC*'=3QV!U80?,1-)%RF/V=MU^ E *B R!OR,T^]6\(*$,'T*:*!GH#XE M8HB0@-T?B0+M=@3 M#X+6M%^H]< F@O4V19O1& ^3Y!VGQ?+NEUC;,@H-U~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{9,XHN:.#8TQ6GWZHKZ$*R2 M<)2;&C@O->AC\)/Q<1! M9Q&PZ(B$3U;?PJ;O!Z*2&@*X;4#%1CFC=F!-&J/W(MN*K@.^3E(GMM7+\ MF9W'YNXPN>]*AC^M#%5?9B#)!ONE=ELW^F3;N\N'=V&/TBIGU4U%JW"73RC; MCV4/V'G\R$E=C/0X&.I#[14U2]-1 MW'UCW=-'G\SE:+TA_9\;U 4WW?>T 'CO9;W"#WLR_T0D?H M1$(QE\+&5XS3!3E^7]l/:$>]BH-C0EFYKI59^-V]XY)DDDX'39>7U;KY)=7!1N-O<4XQ,$'SQGR2LC?$*)KCO$&'V-B;"^LR^J.F<<[XW MF^8X-ITO+Q_A&+^M^$9((LJ*5@>AJ;FOJ M:Q==V7$H?6'=EMM.P@Y[!]+[P4 2!!%^_OFI/>.)G.Y0@9/5N)8[D>L4LW$ MH%B(!<4Y.AUHU4YFINJI-C]YZ M?PR%+.G6+ <2W)XNE=)9;7J*[&GUMP(X(F9E9H[4]+C_'/<)OV2D2&+F!*2.X M%BP^\[,.7=\<_7TU%_)"!8]<%L[LMG0B?O(P70!]J&.1:N9MF@U!4IZ&&3 M8^Z3):?"JN0T)RM,;Y M8->36C\O2" (\O84X);V62#(>N[/GS&XS)M(A)_F -AI.W]1Y/NO.:1G>|_L M#$;4_G!EUX4$]D)GCR?UVG/N8BAEH>=*;>E(.[8)=0 Y@&Q(V,@%F1+172 MN5)AW#+YQ>A8G^_*6Z@.+MYGC[*0W1.L!P;MB_'C.>DBQZ4SY>41G;\D:'\< M%FY>$]6_>U&KTFEGENGD?'FV+OI)-KA<+.Q(B/XD&LSFN,_E]UA^{)8OU'MQ M:S K[7) WK]VB\UR(]H-B4@K*G.\(=_M:B*MG%;F$S@^,+*.#;W"L0Y2401K M1F+%.L6BJ/V+T'\8ECOC4Z,43CE:%#!M(-(:D#]Y*#Q8OBEV $$CBVGN=+R M&_L]C.&7UJ6T.1EU_]M^=W% |EJMDA#^.14$\DOQ+RN(T^+MBYUB +(=PW3F"T4TUOF=4&Y9V!F M7']3*F1.L^+]I=*'[\T%4WF/*"19\;R3>Y.,LF'E\jZ^Q@A]%XKA<]>*_,> M0"%5@]2 O58^>ZU\]EKY{+6R2V?:4J^5SUOH>*<=GSV_,_"K%U/OS^N?+3]?G MEB886Z6V*\K_5M@,O2B/5!.V\[>;*X#%[O3_)^%GBY?\02;EY[7_'WW(C[SV MKQI:AB'/$;.8.8S/WWER#(SE, [C9Y'QPA$&9NW6JU8T;!&HU?[^UL7A]DG%S6 M50ZYT@[U_>0!S>,>\{K-'0:D?R[)RV_V]=WB? MSP4HQ[X7RN6+Z6QQ>=!]QS(!5*4,0Q(E=/5=74YTS@9]\F8V')Q,C:?^TY&3 M? ++B:>*/BEZZV>]8IAS[AQ>S*4S[/(^Y;R&,(+BU$)A$B8NGTU\GOATON M3=XC9 :(C[CW)66NG&,9Y8E$*P:W%X_7]SS/CB;7\O L,ZT]#'-^?=!>Q@FQ ME:6?:$5:',9,>'V^QV&X)K;*Y8)N(9U6AW6EJPI%U!@?DX9]%VJ7%*31AH?. MN#*%1EN&IIZ("*\@517#UZ)?>K*5TJP_BQ?'fT9B=3;K-0>A-E7FJU=@M0B6F M:I*S^8[GE7;O8]'8%U-*&D3^]N^I/Q)9<.,EO#_ESB16)(#]^&5HNDR[F0R?!?|/F M&N+]BF"WK*0]33-]NM>4OSWMFPTX_9!Q0sJF(O,(P"8RF<4G/W1S?@R=@S)' M0R47#5UI;E<4!1V!2D!NCL(+R<-\>&FKD[-7]IX-RN->M]ER _=3*PY M$!?F,]$<8LW6"!*0]0)B3B8^S8;MH9) >O{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}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{IG6F9*DA+!#; I['9#%29A)C W+D!4=W0\/0$7'C;9.I@.AE*0,O _3^' MS4I=.81OJW\%#""B8#(_3ED?@YP9!OU^) ._^#]$+: (1@K]H@BN97JF.S+@@=*YH5A5:1PT+75IZ]R4RH[UPSQ"ZEU0(#K^I=E+--S28Q,FG%[^=31!)ZAC<=C2ZZTKW MD/"%)=Q=QAVP0MKZV'G$_\U$!\BZ/Y/5$.S>(O!'&9F* HD;# 6NP-%E=7^ M--4U;9">5>3A!ES#&@<V5!H03JJ>V4-U39H()2&DV_BT M79>0O.Q/#L'#)-E_%%I4H#)] Y.W*"U:-.JHTT.P2Y;J2D8?@:.^94A69$*5) M? @{IG6F9*DA+!#; I['9#%29A)C W+D!4=W0\/0$7'C;9.I@.AE*0,O _3^' MS4I=.81OJW\%#""B8#(_3ED?@YP9!OU^) ._^#]$+: (1@K]H@BN97JF.S+@@=*YH5A5:1PT+75IZ]R4RH[UPSQ"ZEU0(#K^I=E+--S28Q,FG%[^=31!)ZAC<=C2ZZTKW MD/"%)=Q=QAVP0MKZV'G$_\U$!\BZ/Y/5$.S>(O!'&9F* HD;# 6NP-%E=7^ M--4U;9">5>3A!ES#&@<V5!H03JJ>V4-U39H()2&DV_BT M79>0O.Q/#L'#)-E_%%I4H#)]Y.W*"U:-.JHTT.P2Y;J2D8?@:.^94A69$*5) M?.@{IG6F9*DA+!#; I['9#%29A)C W+D!4=W0\/0$7'C;9.I@.AE*0,O _3^' MS4I=.81OJW\%#""B8#(_3ED?@YP9!OU^) ._^#]$+: (1@K]H@BN97JF.S+@@=*YH5A5:1PT+75IZ]R4RH[UPSQ"ZEU0(#K^I=E+--S28Q,FG%[^=31!)ZAC<=C2ZZTKW MD/"%)=Q=QAVP0MKZV'G$_\U$!\BZ/Y/5$.S>(O!'&9F* HD;# 6NP-%E=7^ M--4U;9">5>3A!ES#&@<V5!H03JJ>V4-U39H()2&DV_BT M79>0O.Q/#L'#)-E_%%I4H#)] Y.W*"U:-.JHTT.P2Y;J2D8?@:.^94A69$*5) M? @{IG6F9*DA+!#; I['9#%29A)C W+D!4=W0\/0$7'C;9.I@.AE*0,O _3^' MS4I=.81OJW\%#""B8#(_3ED?@YP9!OU^) ._^#]$+: (1@K]H@BN97JF.S+@@=*YH5A5:1PT+75IZ]R4RH[UPSQ"ZEU0(#K^I=E+--S28Q,FG%[^=31!)ZAC<=C2ZZTKW MD/"%)=Q=QAVP0MKZV'G$_\U$!\BZ/Y/5$.S>(O!'&9F* HD;# 6NP-%E=7^ M--4U;9">5>3A!ES#&@<V5!H03JJ>V4-U39H()2&DV_BT M79>0O.Q/#L'#)-E_%%I4H#)]*

*L,6UWPL M3AHOPLZC"@>=LO.#3H'@&OUZ?3P\+V1/V2_]\W+RWJ;5.B0@:88AZPW3FN-.M:KVVQ\-,]S**W!Z &9+B-9%15*8K\])09_@^+RGZV#,@C\Y6A-^2AIQ8RX/1 M?QVV)?5 22GC-(XP[@H;U1CK(]Y6@H<=DG)K=0XQ^.@Z5]:1>G=0MCF5L M#J.R(TU]DW24YW=0+M1OF!,Y;]8BBPFAB5X4MS)S[;. H 2^K!?R+&"\\VELG MDL(#DX%E;R<>Z'_"U=RF)2&7]4O'*PTO?\'7D'G2@Z+V:D@CA.=R.7CLO9Z. M_)KGV?5S![R0).A/&+)-Q9V9,!WO%Y[0:J++'!3!S**'A5, M %V8+W=A/59W/76]J;IN)9OR-.&T>L_+UL:3N_&CMR_-W)*1QOH&KAAH^W(! M6;.Y+GZ0@$N7N?^\E]^&+O8.F9&E'F'IE24)+L,2X)6^X@!<@!(7QHPN*S\L? M/Y1B4;TO_2P09E:R64>KODYZN,ZW9=%TMD+>SN/;,$V//C AFC? M!4.;DML1*^)RD06X T=PDN)=U'&6G09+X2NN0(K MQ'<#="E2- CS[:#$KG'P4*P2!S.*$XT'U,7O\ZZ9WSB]%S;J\$+Z/]*PPY]4E MP0ID^+,F4L/7CS2/Q6,&9T]4S9T.!W\+!DD6(PWF]6=!#4Y\/,_<7Y2G':ED M.(W*KDQMA+PV,@_#C/ T)#E-M,[C3O?O#I]><6=SN8.U1UYZ[PSU*T.,L[/%_MF8/1\A8O/3.;F2<=8.>)}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{IG6F9*DA+!#; I['9#%29A)C W+D!4=W0\/0$7'C;9.I@.AE*0,O _3^' MS4I=.81OJW\%#""B8#(_3ED?@YP9!OU^) ._^#]$+: (1@K]H@BN97JF.S+@@=*YH5A5:1PT+75IZ]R4RH[UPSQ"ZEU0(#K^I=E+--S28Q,FG%[^=31!)ZAC<=C2ZZTKW MD/"%)=Q=QAVP0MKZV'G$_\U$!\BZ/Y/5$.S>(O!'&9F* HD;# 6NP-%E=7^ M--4U;9">5>3A!ES#&@<V5!H03JJ>V4-U39H()2&DV_BT M79>0O.Q/#L'#)-E_%%I4H#)]*

*{1@K]H@BN97JF.S+@@=*YH5A5:1PT+75IZ]R4RH[UPSQ"ZEU0(#K^I=E+--S28Q,FG%[^=31!)ZAC<=C2ZZTKW MD/"%)=Q=QAVP0MKZV'G$_\U$!\BZ/Y/5$.S>(O!'&9F* HD;# 6NP-%E=7^ M--4U;9">5>3A!ES#&@<V5!H03JJ>V4-U39H()2&DV_BT M79>0O.Q/#L'#)-E_%%I4H#)]Y.W*"U:-.JHTT.P2Y;J2D8?@:.^94A69$*5) M? @{IG6F9*DA+!#; I['9#%29A)C W+D!4=W0\/0$7'C;9.I@.AE*0,O _3^' MS4I=.81OJW\%#""B8#(_3ED?@YP9!OU^) ._^#]$+: (1@K]H@BN97JF.S+@@=*YH5A5:1PT+75IZ]R4RH[UPSQ"ZEU0(#K^I=E+--S28Q,FG%[^=31!)ZAC<=C2ZZTKW MD/"%)=Q=QAVP0MKZV'G$_\U$!\BZ/Y/5$.S>(O!'&9F* HD;# 6NP-%E=7^ M--4U;9">5>3A!ES#&@<V5!H03JJ>V4-U39H()2&DV_BT M79>0O.Q/#L'#)-E_%%I4H#)]Y.W*"U:-.JHTT.P2Y;J2D8?@:.^94A69$*5) M? @{IG6F9*DA+!#; I['9#%29A)C W+D!4=W0\/0$7'C;9.I@.AE*0,O _3^' MS4I=.81OJW\%#""B8#(_3ED?@YP9!OU^) ._^#]$+: (1@K]H@BN97JF.S+@@=*YH5A5:1PT+75IZ]R4RH[UPSQ"ZEU0(#K^I=E+--S28Q,FG%[^=31!)ZAC<=C2ZZTKW MD/"%)=Q=QAVP0MKZV'G$_\U$!\BZ/Y/5$.S>(O!'&9F* HD;# 6NP-%E=7^ M--4U;9">5>3A!ES#&@<V5!H03JJ>V4-U39H()2&DV_BT M79>0O.Q/#L'#)-E_%%I4H#)]*

M8,#I4(_7G=)+JL@)%JVH&"5D&KVT@H]4";WQ,@:Z'0@\0)9B\HB6:.UHSD M$8B+(*6G.EC^&%=$&'$$1CSH3<.&D0;.DQNI^&!UU12-E\[AC@F11%P*Y*7V9E(? (R>;IW^XJIZ1:CCYFY9BFJ 6%\4|fR&UMY;9E,fQ.D8S% M:K\:=]Y$H4:>BWY0M/& '*TO.O%26\, _W?^C&GS9J9+UJ!O=-"*I,P3 U,R M<$*7R@>'($VO&%"/TS? PH/Y(7M@,T+X@Q(_=K1W6Z16U@G?1?6*M&=11?VX M?]_XG"8U:I0.1FXD6 CNR,G.F-)<T?59FC:LJT{(+G"6H(:MGFE:%542U$ATWT&H8*0/D-CQ80/$&1%;Q"8C_@&RF8B@IS8NI12 MFC[)BKI M455)'7)\Z|\Y@^@<@*HL3CD]?"4>;3#@]?28<_?5&.%]NO%O>!00GP-P@$]GH M93812@?T"ES#KB1^DP>+-"T_UGWG$G1GAY8<<;-38Z!5ZO.3)]$M!U,"O=HQ MW06QO&#S1!Z2%HT_@+tEL>NZTE5E[EK'D]>BV_XF:A!DAFC:(7[*J!I+%\DV M$#"P,A)Y5."H5%#K6[_+X5&&*[M.1]ZMD-_J>L>84ZLGC3+=2U?RGP71W?(A0M;V@^26) T H3[2M<;.P[HA!O M@SC.:"!*P^HZR&B1ZD8>%]I;&87B &Y=>09?0C.DL8X"T8A4Y[<-<)1@BB. MT&#&1'&%4KT3\G$L+7SN!V[/,IUYF6Z1V+"IQ"%,V" M+XG.9L,+Z1<>)PZ8T=!1<.Z7A92Z._"UN&?YHIY9B@IAMG4+YLQ.9;DEDFZ M]5:S6PWC?MH*,-M)2*0>3;?4@$SV8.BT& (U$'TA$B2@I#!MA9H LD\BM+S_' M|%T%^%C[_]O[UN:VC63M[_@5*)==)9^"& +@-9MUE7S+,D\2^]C.YCWOEQ1(-M#B5L0(_!"_O<7W_Z,C,8$*!$*B)%BMBJK<@2"? 3,1/3T].5YEG3UEM51\R3& M\CU: #PFB_N2<8PNSBG[:+?M"|\M%2T>62M#%#<_0F8!EQA-_$<&@7-" M?,&K&K=\7H=7UR#%5V$67'$T#?=8LXG6'%%W'UWK#? *T/SEM*83M5OL,64[7/+M%!&DJLK19PM\1)]DT4/L-6!#M?#I7$)@V0M#'%BB=#2F?O0VIM#X\BB=^ RPLC54'3W9&NR.V1%*R("M2;[B4!5]X5=5 M909&F_\1%*R(M2;[B4!5]X5=5 M909&F_\1%*R(M2;[B4!5]X5=5 M909&F_\1%*R(

*M;\B&2C0(3%F((E'#*MM6HVE"^D9P*@)7G(,940]D@86\X1Z TBL0C=(&0@Y1U M.M1&8LE680,O@Y#H6005?,43Q&#=QC(0C(/^'G%8IL?/<]D.)W\P9Y-2\Z,:*
MY*!;=L5)7$Z"1)BUYE1Z0!+Q2_D"7;MS,,D2)4-> M+CB*=HK;RC,BW$4 9-%G9%<76,9R8M2 H53$)3^XD$B6"6L-!SU-*NQD2!O M_+W']/#^XB>2^@FF,'$%V#?7
Z8]QE67M4SI4CT7 MYB3Q6]Z@E%=6F3?5#8PQ=^S1TBHF@?*C1;02;DD("T?U=4$*>R/596;E$")Y MB>[?5'$&@8-PP4E6'#NB+-\58>.DR3P-Q0*#SN4'&56*<+/)8?IYEZ[[D&76
M.25))++%Y&*9!WLSY'H#1!+S=.|H%15=#B8.UU?{4=9XP#PZ4P5)1ABW8Q"_5C+0!^3)*K2%:6 M&&L-JBCC1,D<@TO!.V1ZT/&7NK1%63/AMC&\E#$$/G\)$P MP<3^%68Z
9*.1X&_?<9T4QH@0R:U)\+1 M$,K\%3/!&6 MD>IFYF8O&6XP<)"M4AU+&LS#"7AS:B=2%4]E=Y&J3S@P'*02 M4;7DEI5P]&3MO?DH/6I9*&X26#((E]."KGC'4T8?!>U!HX650Q0.!$-
'$$3< MC$-E6OH(95=:H9.]Z.0,2Z?';C@>G^8,CDC) C#5!A0<=0,)S'$!)A%U5%M M]&/SQ^AE5'R-"L !Q!1!T#$\5=0T,^TWZJ4)/,8?*RJ+<']D&:'$9=<80KTB MV[IN2IS5D!!W?EZ+:
(Y3*IZ&+#:WF&<$RD+$7X6"&YV Y6=AL1fF6;0*N!:IY MUJZT\N2Y P Q'[!"0*<60T8;'(I5<;;RX67FIY J@IQ;5,&\IXG0@[Y"RI/BNG 0506AJ@:B3H/9_#R?*[W+\!"N7Y"]_+2)WC%?
QN]0/?ZJ-3^1?IU%?MT4+,2? M#$:;;1 5+F'B2I;Z,'ES_#SF\8.,7U90H,VDY"T3AJ2Q_.0I"UD;-Q&SU:X, MOG53FEZ5L&G]TOZ/NH,4Y<\&M(0,A5I%&X7R@92;(L',E-_#MW-
U=9'"%>N5N M^I7K,6_H)49Y<#.E^)@)G@0@VA5N_\+MLVI!,|E]NA7Z4HWR"01.#U_H'T:O M:CE1&DS=_0B-G8[T689CM8YR-.:?!P?ZBX$9/."86RB4E MYS<"VV[Q.1'D;
[88IJ.8)S^PXYSEX.J&\%?M'Y\K'OJ0W@13 MY8)#N^)!VUXOJ=5N_N&7BQ8REZO=8&6K%K*0:M MRE5LK1"[L1O[4?R[//[C'77CTPNS%(GS0,/S8VA]G(OO^_*>B$6872G(?-^,S
M]]4XLME=?@ROHJ[CQ+'4=S^W .5_QSQYIU?L,NIUWNIT-3KN]R'/F,OVA MYW1[&TS0_BJ&\UJ:-,'"3VM=H_X^N Z;=.[U!OT3OD!VW+:,3'7?9/=0+:_./ MZ;N#8[I KMF?
7XA'*:DX"4>\,AC(/[SL#^CLUGKW["&SOS31B%'+OY(#I>Q^E6+=C;]=B=+"!'&l:K6\D_[%6 MWVGW^TZONG$>PT4_W"M)\RCWN@O54VB%MW:RRZ7MOI=P[\6*#KZJOI:NIB
M,61I]YQA;_-9V?=-_F(\3H6N!PUF";Q,$'D[7*Y!Q^FY&UR=]Z Z;M=W M>OX!G#-GOM]VAM4+Y.,Z(EQ"@;7 TR!47<((=B;24((_1*'NW]CU%'7;;5"< M UBL@>?T>AO(L9_83W?@@U]
N$;GQP/7YRP"G_:EG<^QOCV)Z8TC9JO'GG@D M6(NI:X/<EBD3A2W;.RJBW[DM\#W';V.@YNU:N> P UD.1;G<3M?15//B!QA6 M_ D#'V&\!WS1=4=^(;$5H[!;Z1SIT;^@;,_>-
(1[UT'N^T[UW=,:1#/LO M8F&C6;<9D4;N/7L1?-N#+P!2]K8ZJG8G2]IQVW #]38PVCL_/)Q!IP\&>X/-M@SU?4M=8[']+G M%I7?WW:9Z&OV).GA2K!1"2663[GSU*@=Q[V-
H:U2CNQ(7LM!M&(MXAM319X@4+ESQ"0YQY\T2HE$?B1DPQ6JC#_$TBJ*/F8"L?&REOU9,F8PK7D9 M^\1 DYD*'"(#K# <"W>K7U'U.4\HD@A&H03213U50M&$#G6+ CC1).T-
G/&22PZ33@I&3,2$*M^ /H1$P MD#P>N53G444!4)AKN1!Y&37]A21P1G@>,\X+B>_ ;WX(5.HY/151]+"77;)H%KK"RC\+!_ HW<6$M-3:MESXICF@\B/.JD@B+0()\ BV MWH(Y+VB
EJ("54P9J5A(K"G%/ROQV>#CHV4%WTY[C2POXE81SU\&BY$&,#&X MP25FGX14DW#18C;_#G Q)(OQ>,ED6F589IRK\V1ZGB,A^5MS9^.624-<)A6 MB;.UH
)6.17@LZ3V49<|@7>2&F6K74KV++-3DO\-+K_Z +?@'"" MKK<76^+X9'=OLW)AQ]H+.0|6-,&P#LHD2"X(14+P-=/)8C4K$)$U#[WRP7!% MRZ90*0U(1=#'0689*+\%I)]Z!C["-
*\P/02)C62VL.3H594DJKR1#'HPAX=^ M"V=@X^$5_7[+?T&::H$&%R(IZ1@A(:^"4-K*G Z8BTO\!F5 L):\9@>JIR9&: M-0?OYK82#-8DQLDGZW((8%P-1BH4B>+&"
[TL8:8G%@KUAN6K-*#)0:!*[D M6I_2728D0UVG32B/#ED VL,_$#P8'OZ0-_Q5X_'[0Z^F,K'FU5'NW#;1K, MK0)P12*$()8P<",!%\EF@^YG@ZJ6\1NO'M0V-
1CUDLW7WQ8Z2W=UH>M\M#3L8 M[F'IZ1SNE_5QR1;SG_?LY^KZ^#0:VUT6?4 >?\V%LO8E$H3LE)TU>- FP5<3PS M&,M$,MNS3[1DAX$HY,-OZ$QL,%7RIHGW
71)V$UHC,V^8E3<[F[M0O V%F,/ M\,Y):FWA _%,B&*P'4<0\&PRB26V!;GKN&KP#['/?@O*+BO[LMBK(;:]V/ MP3.\(0_1 K|OE,!0--?XC/7U^X$2PN;$H5'77PU>-
%64DPAF%^Z;J8R$% MZC1CGN:<,9\(GT99]!TL9"MNH3&#N98T@C*8CN(]A#*433V:C_V2O42]Z9%R=7 L8S^38=BJ1Y0O(,8G^>L9!UV)$2M:EE.3]!8B^HZ(H6NL
M1.O#C/QG_\$<1@+6_R9PW7%]3RE*DOQIO?@+FY/;Z3;>IV[QEW;,,U&V> MMD6&HQ*!>]RI>II-)Z6.D[B\Z*L DNM&;#.(M",63*A8C$]97!LD#', M@K$9@Z ,,)
5EQRFY#5R64X%O2NR:^+ESK(<0_V.)F?=8I*L^DDZ,K4_RKWZ MEWD/-^QM:9@/&^,#]>W0M[M3\V:CJOO/-^7>-+>*A MC[.A1:OY:$.+V- B/@2OH.]XO9XSJ+
(^'!BOX!KQ/6'IFP?V(OX86 MT>]SG44!4'A)K

gaap:PreferredStockMember 2024-06-30 0001630113 us-gaap:CommonStockMember 2024-06-30 0001630113 BTCY:SharesToBeIssuedMember 2024-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001630113 us-gaap:RetainedEarningsMember 2024-06-30 0001630113 2024-06-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-06-30 0001630113 BTCY:MezzanineEquityMember 2024-06-30 0001630113 us-gaap:CommonStockMember 2024-03-31 0001630113 BTCY:SharesToBeIssuedMember 2024-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001630113 us-gaap:RetainedEarningsMember 2024-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-03-31 0001630113 BTCY:MezzanineEquityMember 2024-03-31 0001630113 us-gaap:PreferredStockMember 2023-06-30 0001630113 us-gaap:CommonStockMember 2023-06-30 0001630113 BTCY:SharesToBeIssuedMember 2023-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001630113 us-gaap:RetainedEarningsMember 2023-06-30 0001630113 2023-06-30 0001630113 us-gaap:PreferredStockMember 2023-03-31 0001630113 us-gaap:CommonStockMember 2023-03-31 0001630113 BTCY:SharesToBeIssuedMember 2023-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001630113 us-gaap:RetainedEarningsMember 2023-03-31 0001630113 2023-03-31 0001630113 us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001630113 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001630113 BTCY:SharesToBeIssuedMember 2024-07-01 2024-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001630113 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-07-01 2024-09-30 0001630113 BTCY:MezzanineEquityMember 2024-07-01 2024-09-30 0001630113 us-gaap:PreferredStockMember 2024-04-01 2024-09-30 0001630113 us-gaap:CommonStockMember 2024-04-01 2024-09-30 0001630113 BTCY:SharesToBeIssuedMember 2024-04-01 2024-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-09-30 0001630113 us-gaap:RetainedEarningsMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-04-01 2024-09-30 0001630113 BTCY:MezzanineEquityMember 2024-04-01 2024-09-30 0001630113 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001630113 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001630113 BTCY:SharesToBeIssuedMember 2023-07-01 2023-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001630113 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001630113 us-gaap:PreferredStockMember 2023-04-01 2023-09-30 0001630113 us-gaap:CommonStockMember 2023-04-01 2023-09-30 0001630113 BTCY:SharesToBeIssuedMember 2023-04-01 2023-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-09-30 0001630113 us-gaap:RetainedEarningsMember 2023-04-01 2023-09-30 0001630113 us-gaap:CommonStockMember 2024-09-30 0001630113 BTCY:SharesToBeIssuedMember 2024-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001630113 us-gaap:RetainedEarningsMember 2024-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-09-30 0001630113 BTCY:MezzanineEquityMember 2024-09-30 0001630113 us-gaap:PreferredStockMember 2023-09-30 0001630113 us-gaap:CommonStockMember 2023-09-30 0001630113 BTCY:SharesToBeIssuedMember 2023-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001630113 us-gaap:RetainedEarningsMember 2023-09-30 0001630113 2023-09-30 0001630113 us-gaap:CommonStockMember 2023-06-29 2023-06-29 0001630113 us-gaap:CommonStockMember 2023-07-19 2023-07-19 0001630113 2022-04-01 2023-03-31 0001630113 2023-04-01 2024-03-31 0001630113 us-gaap:SeriesBPreferredStockMember 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember 2023-09-18 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001630113 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-09-30 0001630113 BTCY:LenderMember 2024-04-01 2024-09-30 0001630113 BTCY:TechnologyFeesMember 2024-07-01 2024-09-30 0001630113 BTCY:TechnologyFeesMember 2023-07-01 2023-09-30 0001630113 BTCY:TechnologyFeesMember 2024-04-01 2024-09-30 0001630113 BTCY:TechnologyFeesMember 2023-04-01 2023-09-30 0001630113 BTCY:DeviceSalesMember 2024-07-01 2024-09-30 0001630113 BTCY:DeviceSalesMember 2023-07-01 2023-09-30 0001630113 BTCY:DeviceSalesMember 2024-04-01 2024-09-30 0001630113 BTCY:DeviceSalesMember 2023-04-01 2023-09-30 0001630113 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001630113 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001630113 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001630113 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001630113 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001630113 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001630113 us-gaap:OfficeEquipmentMember 2024-09-30 0001630113 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001630113 BTCY:TwoSeriesANotesMember 2020-04-01 2021-03-31 0001630113 BTCY:TwoSeriesANotesMember 2021-03-31 0001630113 BTCY:SeriesANotesOneMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesANotesTwoMember 2021-03-31 0001630113 BTCY:SeriesANotesTwoMember 2020-04-01 2021-03-31 0001630113 BTCY:TwoSeriesANotesMember us-gaap:WarrantMember 2020-04-01 2021-03-31 0001630113 BTCY:PlacementAgentMember BTCY:SeriesANotesOneMember 2020-04-01 2021-03-31 0001630113 BTCY:PlacementAgentMember us-gaap:WarrantMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesANotesMember 2022-03-31 0001630113 BTCY:SeriesANoteMember 2022-12-30 0001630113 BTCY:NewConvertibleNoteMember 2022-12-30 0001630113 BTCY:NewConvertibleNoteMember 2022-12-30 2022-12-30 0001630113 BTCY:SeriesANotesMember 2021-04-01 2022-03-31 0001630113 BTCY:SeriesANoteMember 2024-09-30 0001630113 BTCY:SeriesANoteMember 2024-03-31 0001630113 BTCY:SeriesANoteMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesANoteMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesANoteMember 2023-07-01 2023-09-30 0001630113 BTCY:SeriesANoteMember 2023-04-01 2023-09-30 0001630113 BTCY:SeriesBNotesMember BTCY:AccreditedInvestorsMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesBNotesMember us-gaap:WarrantMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember BTCY:WarrantOneMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember BTCY:WarrantTwoMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember 2022-03-31 0001630113 BTCY:SeriesBNotesMember 2021-04-01 2022-03-31 0001630113 BTCY:SeriesBNotesMember 2022-04-01 2023-03-31 0001630113 BTCY:SeriesBNotesMember 2023-03-31 0001630113 BTCY:SeriesBNoteMember 2023-04-01 2024-03-31 0001630113 BTCY:SeriesBNotesMember 2024-03-31 0001630113 BTCY:SeriesBNoteMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesBNoteMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesBNotesMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesBNotesMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesBNoteMember 2023-07-01 2023-09-30 0001630113 BTCY:SeriesBNoteMember 2023-04-01 2023-09-30 0001630113 BTCY:SeriesBNotesMember 2023-07-01 2023-09-30 0001630113 BTCY:SeriesBNotesMember 2023-04-01 2023-09-30 0001630113 us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 us-gaap:SeriesBPreferredStockMember 2024-03-31 0001630113 BTCY:SeriesBNoteMember 2024-09-30 0001630113 BTCY:SeriesBNoteMember 2024-03-31 0001630113 BTCY:SeriesCNotesMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesCNotesMember 2024-09-30 0001630113 BTCY:SeriesCNotesMember us-gaap:WarrantMember 2024-04-01 2024-09-30 0001630113 BTCY:PlacementAgentMember BTCY:SeriesCNotesMember 2024-04-01 2024-09-30 0001630113 BTCY:PlacementAgentMember BTCY:SeriesCNotesMember us-gaap:WarrantMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesCNotesMember BTCY:NoteHoldersMember 2023-10-23 0001630113 BTCY:SeriesCNotesMember BTCY:PlacementAgentsWarrantsMember 2023-10-23 0001630113 BTCY:SeriesCNotesMember 2023-10-23 2023-10-23 0001630113 BTCY:SeriesCNotesMember 2023-04-01 2024-03-31 0001630113 BTCY:SeriesCNotesMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesCNotesMember 2024-03-31 0001630113 BTCY:SeriesCNotesMember 2023-07-01 2023-09-30 0001630113 BTCY:SeriesCNotesMember 2023-04-01 2023-09-30 0001630113 BTCY:SeriesCNotesMember 2023-09-30 0001630113 BTCY:SeriesCNoteMember 2024-09-30 0001630113 BTCY:SeriesCNoteMember 2024-03-31 0001630113 BTCY:SeriesCNoteMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesCNoteMember 2024-04-01 2024-09-30 0001630113 BTCY:SeriesCNoteMember 2023-07-01 2023-09-30 0001630113 BTCY:SeriesCNoteMember 2023-04-01 2023-09-30 0001630113 BTCY:OtherConvertibleNotesPayableMember 2023-01-23 0001630113 BTCY:OtherConvertibleNotesPayableMember 2023-01-23 2023-01-23 0001630113 us-gaap:NotesPayableOtherPayablesMember 2024-07-01 2024-09-30 0001630113 us-gaap:NotesPayableOtherPayablesMember 2024-04-01 2024-09-30 0001630113 us-gaap:NotesPayableOtherPayablesMember 2023-07-01 2023-09-30 0001630113 us-gaap:NotesPayableOtherPayablesMember 2023-04-01 2023-09-30 0001630113 us-gaap:NotesPayableOtherPayablesMember 2023-09-30 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-09-25 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-10-25 2023-10-25 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-10-25 0001630113 BTCY:TwentyFourMonthAnniversaryMember 2024-01-09 2024-01-09 0001630113 BTCY:TwentyFourMonthAnniversaryMember 2024-01-09 0001630113 BTCY:EighteenMonthAnniversaryMember 2024-06-17 2024-06-17 0001630113 BTCY:EighteenMonthAnniversaryMember 2024-07-01 2024-09-30 0001630113 BTCY:EighteenMonthAnniversaryMember 2024-09-30 0001630113 BTCY:EighteenMonthAnniversaryMember 2024-06-17 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2022-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-07-01 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-04-01 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-07-01 2023-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-04-01 2023-09-30 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2024-07-01 2024-09-30 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2024-04-01 2024-09-30 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2022-12-31 0001630113 BTCY:FirstFourWeeksMember BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-07-01 2023-09-30 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-04-01 2023-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2022-12-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2022-12-01 2022-12-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2024-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2024-07-01 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2024-04-01 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2023-07-01 2023-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2023-04-01 2023-09-30 0001630113 BTCY:SeriesAConvertibleNoteHoldersMember 2022-12-30 0001630113 BTCY:NewPromissoryNoteMember 2022-12-30 0001630113 BTCY:NewPromissoryNoteMember 2022-12-30 2022-12-30 0001630113 BTCY:NewPromissoryNoteMember 2024-09-30 0001630113 BTCY:NewPromissoryNoteMember 2024-03-31 0001630113 BTCY:NewPromissoryNoteMember 2024-07-01 2024-09-30 0001630113 BTCY:NewPromissoryNoteMember 2024-04-01 2024-09-30 0001630113 BTCY:NewPromissoryNoteMember 2023-07-01 2023-09-30 0001630113 BTCY:NewPromissoryNoteMember 2023-04-01 2023-09-30 0001630113 BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-03-29 2023-03-29 0001630113 BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-03-29 0001630113 BTCY:FirstFourWeeksMember BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-03-29 2023-03-29 0001630113 BTCY:RemainingThirtySixWeeksMember BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-03-29 2023-03-29 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:AdditionalCollateralizedBridgeLoanAgreementMember 2023-07-18 2023-07-18 0001630113 BTCY:SeriesANotesMember BTCY:AdditionalCollateralizedBridgeLoanAgreementMember 2023-07-18 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-07-18 2023-07-18 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-07-18 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2024-07-01 2024-09-30 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2024-04-01 2024-09-30 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-07-01 2023-09-30 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2024-04-01 2023-09-30 0001630113 2023-06-01 2023-06-30 0001630113 us-gaap:RevolvingCreditFacilityMember 2024-09-30 0001630113 us-gaap:RevolvingCreditFacilityMember 2024-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-07-13 2023-07-13 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-07-13 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2023-08-11 0001630113 BTCY:TwoShortTermPromissoryNotesMember BTCY:OneInvestorMember 2023-08-11 2023-08-11 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2023-08-11 2023-08-11 0001630113 BTCY:ShortTermPromissoryNotesOneMember 2023-08-11 0001630113 BTCY:ShortTermPromissoryNotesOneMember 2023-08-11 2023-08-11 0001630113 BTCY:ShortTermPromissoryNotesTwoMember 2024-03-31 0001630113 BTCY:ShortTermPromissoryNotesTwoMember 2023-04-01 2024-03-31 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2024-09-30 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2024-03-31 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2024-07-01 2024-09-30 0001630113

BTCY:TwoShortTermPromissoryNotesMember 2024-04-01 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-12-08 2023-12-08 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-12-08 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-07-01 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-04-01 2024-09-30 0001630113 BTCY:ShortTermLoanAgreementMember 2024-01-31 0001630113 BTCY:ShortTermLoanAgreementMember 2024-09-30 0001630113 BTCY:ShortTermLoanAgreementMember 2024-03-31 0001630113 BTCY:ShortTermLoanAgreementMember 2024-07-01 2024-09-30 0001630113 BTCY:ShortTermLoanAgreementMember 2024-01-01 2024-09-30 0001630113 BTCY:ShortTermLoanAgreementMember 2024-04-01 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-02-29 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-02-01 2024-02-29 0001630113 BTCY:PromissoryNoteAgreementMember 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember 2024-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-07-01 2024-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-04-01 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-02-02 2024-02-02 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-02-02 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-07-01 2024-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-04-01 2024-09-30 0001630113 2021-12-21 0001630113 2021-12-21 2021-12-21 0001630113 us-gaap:CashMember 2021-12-21 0001630113 2022-11-01 2022-11-30 0001630113 BTCY:TermLoanMember 2024-07-01 2024-09-30 0001630113 BTCY:TermLoanMember 2024-04-01 2024-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2020-04-01 2020-04-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2020-04-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2021-05-01 2021-05-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2024-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2024-03-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2024-07-01 2024-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2024-04-01 2024-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2023-07-01 2023-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2023-04-01 2023-09-30 0001630113 us-gaap:ConvertibleDebtMember 2024-04-01 2024-09-30 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesAPreferredStockMember 2024-04-01 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesAPreferredStockMember 2024-04-01 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesAPreferredStockMember 2023-04-01 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesAPreferredStockMember 2023-04-01 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesBPreferredStockMember 2023-04-01 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesBPreferredStockMember 2023-04-01 2023-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001630113 us-gaap:ConvertibleDebtMember 2024-03-31 0001630113 us-gaap:ConvertibleDebtMember 2023-03-31 0001630113 us-gaap:ConvertibleDebtMember 2024-04-01 2023-09-30 0001630113 us-gaap:ConvertibleDebtMember 2024-09-30 0001630113 us-gaap:ConvertibleDebtMember 2023-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2023-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2023-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2024-04-01 2024-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2024-04-01 2024-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2023-04-01 2023-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2023-04-01 2023-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputSharePriceMember 2024-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputSharePriceMember 2024-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputSharePriceMember 2023-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputSharePriceMember 2023-09-30 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2024-09-30 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2024-03-31 0001630113 BTCY:ShareholdersMember 2024-09-30 0001630113 BTCY:ShareholdersMember 2024-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2023-09-30 0001630113 us-gaap:SeriesAPreferredStockMember 2024-04-01 2024-09-30 0001630113 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001630113 us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember 2023-09-19 0001630113 srt:MaximumMember us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember 2023-09-19 0001630113 BTCY:BeneficiaryMember BTCY:PurchaseAgreementMember 2023-09-19 0001630113 BTCY:BeneficiaryMember us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-09-30 0001630113 us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember 2024-04-01 2024-09-30 0001630113 us-gaap:SeriesBPreferredStockMember 2023-10-01 2023-12-31 0001630113 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001630113 us-gaap:CommonStockMember 2023-12-31 0001630113 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-03-31 0001630113 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001630113 us-gaap:SeriesBPreferredStockMember 2024-07-01 2024-09-30 0001630113 BTCY:SeriesCConvertibleNoteMember 2024-04-01 2024-09-30 0001630113 us-gaap:SeriesCPreferredStockMember 2024-07-01 2024-09-30 0001630113 us-gaap:SeriesCPreferredStockMember 2024-04-01 2024-09-30 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-09-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2016-02-02 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2024-07-01 2024-09-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2024-04-01 2024-09-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2023-07-01 2023-09-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2023-04-01 2023-09-30 0001630113 BTCY:TwoThousandAndTwentyThreeEquityIncentivePlanMember 2023-03-31 0001630113 BTCY:BrokerWarrantsMember 2024-03-31 0001630113 BTCY:ConsultantWarrantsMember 2024-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2024-03-31 0001630113 BTCY:BrokerWarrantsMember 2024-04-01 2024-09-30 0001630113 BTCY:ConsultantWarrantsMember 2024-04-01 2024-09-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2024-04-01 2024-09-30 0001630113 BTCY:BrokerWarrantsMember 2024-09-30 0001630113 BTCY:ConsultantWarrantsMember 2024-09-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2024-09-30 0001630113 srt:MinimumMember BTCY:BrokerWarrantsMember 2024-09-30 0001630113 srt:MaximumMember BTCY:BrokerWarrantsMember 2024-09-30 0001630113 srt:MinimumMember BTCY:ConsultantWarrantsMember 2024-09-30 0001630113 srt:MaximumMember BTCY:ConsultantWarrantsMember 2024-09-30 0001630113 us-gaap:StockOptionMember 2024-03-31 0001630113 us-gaap:StockOptionMember 2023-03-31 0001630113 us-gaap:StockOptionMember 2024-04-01 2024-09-30 0001630113 us-gaap:StockOptionMember 2023-04-01 2023-09-30 0001630113 us-gaap:StockOptionMember 2024-09-30 0001630113 us-gaap:StockOptionMember 2023-09-30 0001630113 srt:MinimumMember 2024-04-01 2024-09-30 0001630113 srt:MaximumMember 2024-04-01 2024-09-30 0001630113 srt:MinimumMember 2024-09-30 0001630113 srt:MaximumMember 2024-09-30 0001630113 BTCY:NewLeaseAgreementMember 2021-12-31 0001630113 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-09-30 0001630113 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-09-30 0001630113 2022-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001630113 us-gaap:FurnitureAndFixturesMember 2022-03-31 0001630113 us-gaap:OfficeEquipmentMember 2024-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001630113 us-gaap:OfficeEquipmentMember 2024-04-01 2024-09-30 0001630113 us-gaap:LeaseholdImprovementsMember 2024-04-01 2024-09-30 0001630113 us-gaap:SubsequentEventMember 2024-10-01 2024-10-31 0001630113 BTCY:UnsecuredConvertiblePromissoryNotesMember us-gaap:SubsequentEventMember 2024-11-01 2024-11-30 0001630113 BTCY:UnsecuredConvertiblePromissoryNotesMember us-gaap:SubsequentEventMember 2024-11-30 0001630113 us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001630113 us-gaap:SubsequentEventMember 2024-11-12 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember us-gaap:SubsequentEventMember 2024-10-01 2024-10-31 iso4217:USD shares iso4217:USD shares pure false Q2 --03-31 2025 0001630113 10-Qtrue2024-09-30false000-56074BIOTRICITY INC.NV30-0983531203 Redwood Shores ParkwaySuite 600Redwood CityCA94065(650)832-1626YesYesNon-accelerated FilertruefalsefalseCommon Stock, par value $0.001 per

shareBTCY243944420.001173270786060149999014686551817561187940257367433645640644954470573112972850007869914990712576155521023318122159352920605977341532378-136101106-127499785-31166835-31465737529206059426253266846289129764685895912062807672892019164624719960802459174199927848223423915982224886434873315214983700754651798269762307672-2185673-1424518-450215975207575326815207481413780-339888-596420-1484616-1153639-193757-18783-500619826696-46906684-1323011313236314-143380-193486-129945-1561768-3690840-5256288-7103722-1561768-3690840-5256288-7103722912611904422903533791393054680-1653029-3881282-8601321-7482861-1293762812401057931054101782405-3600042-8707114-7377451-0.073-0.073-0.441-0.441-0.469-0.469-0.853-0.8532249362622493626879574287957421835427718354277877424287742424052186203218620320112164506821645321757359709104231071559611344480772977969055242809242809287802288-287802-31179031150-25-142907-1429071091063109124266624375712104374618746184800002000020000568855688561-129376-129376-1561768-1561768912619126143522861052286105281123023933230241949981425371048421247-73415-136101106-31166835265148892014889206305795144409515344276269065957230833237-8-127499785-31465737220108299910829996081236080-608123-5405765399689781198125129125227-50-285814-285814143626714364740437547 9-6104-689521708952492575649347021344709134540884538640818954642283217700007050000276405341081120100041310009894089904081158631158631-105793-105793-5256288-52562882903532903530-3054680-3054680435228610522861052011230239332302419499814253710484212 4-73415-136101106-31166835630578752505875339552499993055658-328627-116172404-2341161457743581192271192851633351633352812402812 40-3690840-369084019044219044263057881024888113955249999338220-47387-120053686-26729036630578752510875339552499992844478-152797-112570825-19845385630578752510875339552499992844478-152797-112570825-19845385577435811922711928537451537451510541010541 0-7103722-7103722379139379139630578810248881139552499993338220-47387-120053686-26729036630578810248881139552499993338220-47387-120053686-26729036-5256288-7103722115863374515811 20-1484616-1153639-5006198266913233 1-1313259161297729771982751783 20-39873411440-61841-208810265190-34838810126941062999-1891299-42221541252211192851732532190000006246581977579-11251167737371801611967133927947586345520205364800-607709278578606057046017327011997251235256104662 1 1. NATURE OF OPERATIONS   Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company” or “Biotricity”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over on February 2, 2016.   The Company (directly and through its subsidiary) is engaged in research and development activities within the remote monitoring segment of preventative care. It is focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted to building and commercializing an ecosystem of technologies that enable access to this market.   2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION   The Condensed Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and are expressed in United States dollars (“USD”).   The Condensed Consolidated Financial Statements of the Company have been prepared on a historical cost basis except derivative liabilities which are carried at fair value.   The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary. Significant intercompany accounts and transactions have been eliminated.   Reclassifications   Certain amounts presented in the prior year period have been reclassified to conform to current period consolidated financial statement presentation.   Reverse Split   On June 29, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation to effect a <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20230629__20230629__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjrltIH3ooO6" title="Stockholders equity reverse stock split">one-for-six (1-for-6) share consolidation (the “Reverse Split”). The Reverse Split became effective on July 3, 2023. As a result of the Reverse Split, every six shares of the Company’s issued and outstanding common stock were automatically converted into one share of common stock, without any change in the par value per share or to the number of shares authorized and began trading on a post-Reverse Split basis under the Company’s existing trading symbol, “BTCY,” on July 3, 2023. No fractional shares were outstanding following the Reverse Split. Any holder who would have received a fractional share of common stock was automatically entitled to receive an additional fraction of a share of common stock to round up to the next whole share; <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20230719__20230719__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zF2WbqWryHfh" title="Issuance of common shares to adjust for rounding effect of reverse split, shares">20,846 shares were issued for this purpose on July 19, 2023. Lastly, the Reverse Split does not impact the amount of authorized, issued or outstanding shares of preferred stock.   All issued and outstanding common stock, common stock per share amounts and corresponding balance sheet accounts contained in the Condensed Consolidated Financial Statements have been retroactively adjusted to reflect this Reverse Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise and conversion price and the number of shares issuable upon the exercise or conversion of all outstanding stock options, warrants, convertible debt and equity instruments to purchase shares of common stock.   Going Concern, Liquidity and Basis of Presentation   The accompanying Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern. The Company is in the early stages of commercializing its product ecosystem and is concurrently continuing in development mode, operating a research and development program in order to develop, obtain regulatory clearance for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as of September 30, 2024, had an accumulated deficit of $ 136,101,106 and a working capital deficiency of $17,424,814. Those conditions raise substantial doubt about its ability to continue as a going concern for a period of one year from the issuance of these Condensed Consolidated Financial Statements. The Condensed Consolidated Financial Statements do not include adjustments that might result from the outcome of this uncertainty.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and after additional equity and debt capitalization of the Company.   During the fiscal year ended March 31, 2023, the Company raised funds through short-term loans and promissory notes, net of repayments of $1,476,121 from various lenders, and also raised funds through convertible notes, net of redemptions of $2,355,318 from various lenders.   During the fiscal year ended March 31, 2024, the Company raised funds through short-term loans and promissory notes, net of repayments of $853,030 and convertible notes, net of redemptions of $2,962,386 from various lenders. The Company sold 36,897 common shares through use of its registration statement, for gross proceeds of $123,347, raising a net amount of $119,285 after paying a 3% placement fee and other issuance expenses.   Additionally, on September 19, 2023, the Company entered into a security purchase agreement with an institutional investor for the issuance and sale of 220 shares of the Company’s newly designated Series B Preferred Stock, at a purchase price of $<span id="xdx_905_eus-gaap--

PreferredStockRedemptionPricePerShare_iI_pid_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zuVB9f6H4une">9,091 per share of Series B Preferred Stock (Note 9), or gross proceeds of $2,000,000. Net proceeds after issuance costs amounted to $1,900,000. During the three months ended March 31, 2024, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zUOttnWeHqik" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110 Series B preferred shares were issued for net proceeds of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuOuZCdWW1F6">925,000.   During the six months ended September 30, 2024, <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z30ffjMZLhmc" title="Issuance of common shares from shares to be issued, shares">220 Series B preferred shares were issued for net proceeds of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z4BtpZTBuNSh" title="Issuance of common shares from shares to be issued">1,732,532. The Company also raised $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240401__20240930__srt--TitleOfIndividualAxis__custom--LenderMember_z3tzPIlY7Zj6" title="Conversion of mezzanine equity into common shares">650,000 from the issuance of convertible notes to a lender. Lastly, the Company sold 97,811 common shares through the exercise of stock options, for net proceeds of $125,221.   As we proceed with the commercialization of the Bioflux, Biocore, and Biocare product development, we expect to continue to devote significant resources on capital expenditures, as well as research and development costs and operations, marketing and sales expenditures.   Based on the above facts and assumptions, we believe our existing cash, along with anticipated near-term financings, will be sufficient to continue to meet our needs for the next twelve months from the filing date of this report. However, we will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines.   one-for-six (1-for-6) share consolidation (the "Reverse Split")20846-136101106-174248144761212355318853030296238636897123347119285 0.032209091200000019000001109250002201732532650000978111252 21 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Revenue Recognition   The Company adopted Accounting Standards Codification Topic 606, "Revenue from Contracts with Customers" ("ASC 606") on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles - (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue as performance obligations are satisfied.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Both the Bioflux mobile cardiac telemetry device, and the Biocore device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Company's proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient's prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient's cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized.   The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business.   <p id="xdx_89C_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zU07hDkrmZt2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company recognized the following forms of revenue for the three and six months ended September 30, 2024, and 2023:   SCHEDULE OF REVENUE RECOGNITION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td> <td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240701__20240930_zGNa8GHcLC9g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230701__20230930_zt8BP6H29WC3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240401__20240930_z8KDwJ9dELh9" style="border-bottom: Black 1pt solid; display: none; text-align: center; font-weight: bold">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20230401__20230930_zDzuxEJdbIb6" style="border-bottom: Black 1pt solid; display: none; text-align: center; font-weight: bold">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Three months ended September 30 </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Six months ended September 30 </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New

Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TechnologyFeesMember_zvOr79hkoGuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Technology fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">3,064,814</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,731,461</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">6,081,064</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">5,500,379</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DeviceSalesMember_zWvSyqLxhUDi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Device sales</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">202,032</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">159,836</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> 387,525 </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">411,683</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z7pYr8ARABWk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,266,846</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,891,297</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,468,589</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,912,062</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   Inventories   Inventory is stated at the lower of cost and market value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. SCHEDULE OF INVENTORIES   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240930_zSFHzEznzbd9" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240331_zx9lh9EyJlI" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINzF7M_znd0b3BL9mYd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw material</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,073,409</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,128,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_maINzF7M_znsTPfqK6Mb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">744,152</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,702</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryNet_iTI_mtINzF7M_z5uQUZ23HIH" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Inventories</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,817,561</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,879,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   BIOTRICITY INC. <span

style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Significant accounting estimates and assumptions   The preparation of the Condensed Consolidated Financial Statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources.   The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.   Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of stock options</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"></td> <td style="text-align: justify">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of warrants</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"></td> <td style="text-align: justify">In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of derivative liabilities</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"></td> <td style="text-align: justify">In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Functional currency</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"></td> <td style="text-align: justify">Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Useful life of property and equipment</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"></td> <td style="text-align: justify">The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively.</td></tr> </table>   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Provisions</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> </tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td> <td style="text-align: justify">Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Contingencies</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td> <td style="text-align: justify">Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inventory obsolescence</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td> <td style="text-align: justify">Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times,

Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Income and other taxes</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td> <td style="text-align: justify">The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td> <td style="text-align: justify">When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Company's future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Company's income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incremental borrowing rate for lease</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td> <td style="text-align: justify">The determination of the Company's lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company's incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company's Condensed Consolidated Financial Statements.</td></tr> </table>   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Earnings (Loss) Per Share   The Company has adopted the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 260-10 which provides for calculation of "basic" and "diluted" earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company's warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings are computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method were not applicable during the periods presented as no conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented.   Cash   Cash includes cash on hand and balances with banks.   Foreign Currency Translation   The functional currency of the Company's Canadian-based subsidiary is the Canadian dollar, and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company's Canadian subsidiaries from their functional currency into the Company's reporting currency of United States dollars, consolidated balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholders' deficiency. The Company has not, to the date of these Condensed Consolidated Financial Statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.   Accounts Receivable   Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company's normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Fair Value of Financial Instruments   ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.   ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.   ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management's best estimate of what market participants would use as fair value.   In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to

the asset or liability.   Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans, accounts payable and accrued liabilities. The Company's derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Company's bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.   <p id="xdx_89A_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zFo5boL7moRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of financial instruments measured on a recurring basis is as follows: SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240930_zxwfxEVqF9Ef" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">173,270</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zigbTwoGfncc" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">173,270</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkd0CBpXvuyj" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztKUuyjQDIZ7" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20240930_z71t0JqqhqNg" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">173,270</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbOAUZQqgyZ2" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">173,270</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zB1xORtlUny4" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVUddjzndRG5" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Derivative liabilities, short-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240930_zxDGX089fy11" style="text-align: right" title="Derivative liabilities, short-term">460,059</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEsa9CDxse3l" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z7gl3kwbGKZb" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDoTslOrOVCc" style="text-align: right" title="Derivative liabilities, short-term">460,059</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Derivative liabilities, long-term</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240930_zTkHzR0TENt6" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,649,177</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXipq215dJK9" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zmwVqaHsU1Z9" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zq5evhXSOBTg" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,649,177</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240930_zpXroztfTy2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,109,236</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmY4tVgkHgpb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHOHNggggle9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztUWKAyz9Wr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,109,236</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240331_zqrt9Pk1NHWa" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">786,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsYiNSG5TBid" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">786,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYFA4vfXIGN6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAYY6ETBV6af" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20240331_zP8IikT4ugU2" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at

fair value">786,060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHMok7qF4mXg" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">786,060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zt8WBPVP2Icl" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPYbS5fvvuv" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Derivative liabilities, short-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331_zZNEsI4LnAse" style="text-align: right" title="Derivative liabilities, short-term">991,866</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3GjmvgyI1nc" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zpVBrW0w8omg" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPajtYlrg4N4" style="text-align: right" title="Derivative liabilities, short-term">991,866</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Derivative liabilities, long-term</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331_zGuUDR8Wv2Wb" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,435,668</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z21TOkBgBpy3" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXqiU7d9wjEh" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVQ8xQAVW8g5" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,435,668</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331_zcKWDT1JRTx4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,427,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zK6gaHsd0nZi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zmjka2zcm1nj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVLRiO4bzw08" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,427,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   There were no transfers between fair value hierarchy levels during the six months ended September 30, 2024 and 2023.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Property and Equipment   Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follow: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center">Office equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zpyDvlGKzscf" title="Property and equipment, useful life">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Leasehold improvement</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zW2a8CJfR4ml" title="Property and equipment, useful life">5 years</td></tr> </table>   Impairment for Long-Lived Assets   The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets, including right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at September 30, 2024 and March 31, 2024, the Company believes there was no impairment of its long-lived assets.   Leases   The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items Operating right of use assets, Operating lease obligations, current, and Operating lease obligations, long-term in the consolidated balance sheet.   Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. As the Company’s lease does not provide implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion.   Income Taxes   The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for consolidated financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying

amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized.   Research and Development   Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Selling, General and Administrative   Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include sales and marketing costs, investor relations and legal costs relating to corporate matters, professional fees for consultants assisting with business development and financial matters, and office and administrative expenses.   Stock Based Compensation   The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period.   The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services.   Convertible Notes Payable and Derivative Instruments   The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.   Series B Convertible Preferred Stock   The Series B convertible preferred stock (“Series B Preferred Stock”) was accounted for as mezzanine equity and the embedded conversion and redemption features was accounted for as derivative liabilities with change in fair value at each reporting period end charged to the consolidated statement of operation and comprehensive loss in accordance with ASC 480 and ASC 815.   Preferred Shares Extinguishments   The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For preferred stock redemptions and conversion, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss.   Segment Information   Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company has identified its Chief Executive Officer (“CEO”) as the chief operating decision maker (“CODM”). The Company operates in one operating segment. The Company’s CODM allocates resources and assesses performance at the consolidated level. The Company’s property and equipment and operating right of use lease asset are in the United States as of September 30, 2024, and 2023.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Recently Issued Accounting Pronouncements   In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. The Company has adopted Topic 326 on the Company’s Condensed Consolidated Financial Statements according to the effective date and the adoption has no significant impact on the Company’s Condensed Consolidated Financial Statements.   In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. There is no significant impact from adopting ASU 2019-12 on the Company’s financial condition, results of operations, and cash flows.   In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires

the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company adopted this guidance for the fiscal year beginning April 1, 2022. There is no significant impact from adopting ASU 2021-04 on the Company's financial condition, results of operations, and cash flows.   On March 28, 2023, the FASB issued ASU No. 2023-01, Leases (Topic 842): Common Control Arrangements. ASU 2023-01 is designed to clarify the accounting for leasehold improvements associated with common control leases, thereby reducing diversity in practice. The new standard is effective for the Company for its fiscal year beginning January 1, 2024, with early adoption permitted. There is no significant impact from adopting ASU No. 2023-01 on the Company's financial condition, results of operations, and cash flows.   In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07") to improve the disclosures regarding a public entity's reportable segments and address requests from investors for additional, more detailed information about a reportable segment's expenses. The Company is required to adopt the guidance in the fourth quarter of fiscal 2025, though early adoption is permitted. There is no significant impact from adopting ASU 2023-07 on the Company's financial condition, results of operations, and cash flows.   In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures ("ASU 2023-09") to provide disaggregated income tax disclosures on rate reconciliation and income taxes paid. The Company is required to adopt the guidance in the fourth quarter of fiscal 2026, though early adoption is permitted. The Company is currently evaluating the impact of this amendment on its Condensed Consolidated Financial Statements.   The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.   Revenue Recognition   The Company adopted Accounting Standards Codification Topic 606, "Revenue from Contracts with Customers" ("ASC 606") on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles – (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue as performance obligations are satisfied.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Both the Bioflux mobile cardiac telemetry device, and the Biocore device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Company's proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient's prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient's cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized.   The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business.   <p id="xdx_89C_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zU07hDkrmZt2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company recognized the following forms of revenue for the three and six months ended September 30, 2024, and 2023:   SCHEDULE OF REVENUE RECOGNITION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td> <td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240701__20240930_zGNa8GHcLC9g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230701__20230930_zt8BP6H29WC3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240401__20240930_z8KDwJ9dELh9" style="border-bottom: Black 1pt solid; display: none; text-align: center; font-weight: bold">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20230401__20230930_zDzuxEJdbIb6" style="border-bottom: Black 1pt solid; display: none; text-align: center; font-weight: bold">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Three months ended September 30 </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Six months ended September 30 </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TechnologyFeesMember_zvOr79hkoGuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Technology fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,064,814</td><td style="width: 1%; text-align: left"><span style="font-family: Times New

Roman, Times, Serif"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,731,461</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">6,081,064</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">5,500,379</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DeviceSalesMember_zWvSyqLxhUDi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Device sales</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">202,032</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">159,836</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> 387,525 </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">411,683</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z7pYr8ARABWk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,266,846</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,891,297</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,468,589</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,912,062</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   <p id="xdx_89C_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zU07hDkrmZt2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company recognized the following forms of revenue for the three and six months ended September 30, 2024, and 2023:   SCHEDULE OF REVENUE RECOGNITION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240701__20240930_zGNa8GHcLC9g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230701__20230930_zt8BP6H29WC3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240401__20240930_z8KDwJ9dELh9" style="border-bottom: Black 1pt solid; display: none; text-align: center; font-weight: bold">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20230401__20230930_zDzuxEJdbIb6" style="border-bottom: Black 1pt solid; display: none; text-align: center; font-weight: bold">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Three months ended September 30 </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Six months ended September 30 </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TechnologyFeesMember_zvOr79hkoGuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Technology fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">3,064,814</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,731,461</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">6,081,064</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">5,500,379</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DeviceSalesMember_zWvSyqLxhUDi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Device sales</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">202,032</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">159,836</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> 387,525 </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">411,683</td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times,

Serif"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z7pYr8ARABWk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,266,846</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,891,297</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,468,589</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,912,062</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>
306481427314616081064550037920203215983638752541168332668462891297646858959120 62 Inventories   Inventory is stated at the lower of cost and market value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. SCHEDULE OF INVENTORIES   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240930_zSFHzEznzbd9" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240331_zx9lh9EyJlI" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">$</td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINzF7M_znd0b3BL9mYd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw material</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,073,409</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,128,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_maINzF7M_znsTPfqK6Mlb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">744,152</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,702</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryNet_iIT_mtINzF7M_z5uQUZ23HHH" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Inventories</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,817,561</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,879,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   SCHEDULE OF INVENTORIES   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240930_zSFHzEznzbd9" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240331_zx9lh9EyJlI" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">$</td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINzF7M_znd0b3BL9mYd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw material</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,073,409</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,128,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_maINzF7M_znsTPfqK6Mlb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">744,152</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,702</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>

 </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryNet_iTI_mtINzF7M_z5uQUZ23HIH" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Inventories</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,817,561</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,879,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 10734091128700744152750702181756118794022p id="xdx_84D_eus-gaap--UseOfEstimates_zWm7gNpKvLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Significant accounting estimates and assumptions   The preparation of the Condensed Consolidated Financial Statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources.   The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.   Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of stock options</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"></td> <td style="text-align: justify">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of warrants</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"></td> <td style="text-align: justify">In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of derivative liabilities</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"></td> <td style="text-align: justify">In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Functional currency</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"></td> <td style="text-align: justify">Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Useful life of property and equipment</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"></td> <td style="text-align: justify">The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively.</td></tr> </table>   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Provisions</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td> <td style="text-align: justify">Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Contingencies</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td> <td style="text-align: justify">Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inventory obsolescence</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td> <td style="text-align: justify">Inventories are stated at the lower of

cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Income and other taxes</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td> <td style="text-align: justify">The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td> <td style="text-align: justify">When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Company's future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Company's income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incremental borrowing rate for lease</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"></td> <td style="text-align: justify">The determination of the Company's lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company's incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company's Condensed Consolidated Financial Statements.</td></tr> </table>   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Earnings (Loss) Per Share   The Company has adopted the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 260-10 which provides for calculation of "basic" and "diluted" earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company's warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings are computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method were not applicable during the periods presented as no conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented.   Cash   Cash includes cash on hand and balances with banks.   Foreign Currency Translation   The functional currency of the Company's Canadian-based subsidiary is the Canadian dollar, and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company's Canadian subsidiaries from their functional currency into the Company's reporting currency of United States dollars, consolidated balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholders' deficiency. The Company has not, to the date of these Condensed Consolidated Financial Statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.   Accounts Receivable   Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company's normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Fair Value of Financial Instruments   ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.   ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.   ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management's best estimate of what market participants would use as fair

value.   In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.   Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans, accounts payable and accrued liabilities. The Company's derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Company's bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.   <p id="xdx_89A_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zFo5boL7moRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of financial instruments measured on a recurring basis is as follows: SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240930_zxwfxEVqF9Ef" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">173,270</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zigbTwoGfncc" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">173,270</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkd0CBpXvuyj" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztKUuyjQDIZ7" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20240930_z71t0JqqhqNg" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">173,270</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbOAUZQqgvZ2" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">173,270</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zB1xORtlUny4" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVUddjzndRG5" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Derivative liabilities, short-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240930_zxDGX089fyI1" style="text-align: right" title="Derivative liabilities, short-term">460,059</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEsa9CDxse3l" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z7gl3kwbGKZb" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDoTslOrOVCc" style="text-align: right" title="Derivative liabilities, short-term">460,059</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Derivative liabilities, long-term</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240930_zTkHzR0TENt6" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,649,177</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXipqZ1SdJK9" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zmwVqaHsU1Z9" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zg5evhXSOBTg" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,649,177</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240930_zpXroztfTy2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,109,236</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmY4tVgkHgpb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHOHNggggle9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztUWKAyz9Wr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,109,236</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240331_zqrt9Pk1NHWa" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">786,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsYiNSG5TBid" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">786,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYFA4vfXIGN6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td

id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAYY6ETBV6af" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20240331_zP8IikT4ugU2" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">786,060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHMok7qF4mXg" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">786,060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zt8WBPVP2Icl" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPYbS5fvvuv" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: White"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Derivative liabilities, short-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331_zZNEsI4LnAse" style="text-align: right" title="Derivative liabilities, short-term">991,866</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3GjmvgyI1nc" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zpVBrW0w8omg" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPajtYlrg4N4" style="text-align: right" title="Derivative liabilities, short-term">991,866</td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Derivative liabilities, long-term</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331_zGuUDR8Wv2Wb" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,435,668</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z21TOkBgBpy3" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXqiU7d9wjEh" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVQ8xQAVW8g5" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,435,668</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331_zcKWDT1JRTx4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,427,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zK6gaHsd0nZi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zmjka2zcm1nj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVLRiO4bzw08" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,427,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table><p id="xdx_8A4_zmBuq4EETmV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">There were no transfers between fair value hierarchy levels during the six months ended September 30, 2024 and 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">BIOTRICITY INC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">SEPTEMBER 30, 2024 (Unaudited)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">(Expressed in US dollars)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p><p id="xdx_89A_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zFo5boL7moRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of financial instruments measured on a recurring basis is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr><tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240930_zxwfxEVqF9Ef" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">173,270</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zigbTwoGfncc" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">173,270</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkd0CBpXvuyj" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztKUuyjQDIZ7" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20240930_z71t0JqqhqNg" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">173,270</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbOAUZQqgyZ2" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">173,270</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zB1xORtlUny4" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVUddjzndRG5" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Derivative liabilities, short-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--

DerivativeLiabilitiesCurrent_iI_c20240930_zxDGX089fyI1" style="text-align: right" title="Derivative liabilities, short-term">460,059</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEsa9CDxse3l" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z7gl3kwbGKZb" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDoTslOrOVCc" style="text-align: right" title="Derivative liabilities, short-term">460,059</td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1pt">Derivative liabilities, long-term</td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240930_zTkHzR0TENt6" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,649,177</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXipqZ1SdJK9" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zmwVqaHsU1Z9" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zq5evhX5OBTg" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,649,177</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 2.5pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240930_zpXroztfTy2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,109,236</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmY4tVgkHgpb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHOHNgggqle9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztUWKAyz9Wr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,109,236</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr><tr style="vertical-align: bottom"><td style="border-bottom: Black 1pt solid">Description</td><td style="padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr><tr style="vertical-align: bottom"><td>Assets:</td><td> </td><td colspan="2" style="text-align: right"> </td><td> </td><td> </td><td colspan="2" style="text-align: right"> </td><td> </td><td> </td><td colspan="2" style="text-align: right"> </td><td> </td><td> </td><td colspan="2" style="text-align: right"> </td><td> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 44%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240331_zqrt9Pk1NHWa" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">786,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsYiNSG5TBid" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">786,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYFA4vfXIGN6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAYY6ETBV6af" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20240331_zP8IikT4ugU2" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">786,060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHMok7qF4mXg" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">786,060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zt8WBPVP2Icl" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPYbS5fvvuv" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: White"><td>Liabilities:</td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Derivative liabilities, short-term</td><td> </td><td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331_zZNEsL4LnAse" style="text-align: right" title="Derivative liabilities, short-term">991,866</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3GjmvgyI1nc" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zpVBrW0w8omg" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPajtYlrg4N4" style="text-align: right" title="Derivative liabilities, short-term">991,866</td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1pt">Derivative liabilities, long-term</td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331_zGuUDR8Wv2Wb" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,435,668</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z21TOkBgBpy3" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXqiU7d9wjEh" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVQ0xQAVW8g5" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,435,668</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 2.5pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331_zcKWDT1JRTx4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,427,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zK6gaHsd0nZi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zmjka2zcm1nj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVLRiO4bzw08" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,427,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>
1732701732701732701732704600594600591649177164917721092362109236786060786060786060786060991866991866614356681435668242753424275342427534   Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are

charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follow: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center">Office equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zpyDvlGKzscf" title="Property and equipment, useful life">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Leasehold improvement</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zW2a8CJfR4ml" title="Property and equipment, useful life">5 years</td></tr> </table>   SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center">Office equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zpyDvlGKzscf" title="Property and equipment, useful life">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Leasehold improvement</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zW2a8CJfR4ml" title="Property and equipment, useful life">5 years</td></tr> </table> P5YP5Y Impairment for Long-Lived Assets   The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets, including right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at September 30, 2024 and March 31, 2024, the Company believes there was no impairment of its long-lived assets.   Leases   The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items Operating right of use assets, Operating lease obligations, current, and Operating lease obligations, long-term in the consolidated balance sheet.   Right-of-use ("ROU") asset represents the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. As the Company's lease does not provide implicit interest rate, the Company uses the Company's incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion.   Income Taxes   The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for consolidated financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized.   Research and Development   Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Selling, General and Administrative   Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include sales and marketing costs, investor relations and legal costs relating to corporate matters, professional fees for consultants assisting with business development and financial matters, and office and administrative expenses.   Stock Based Compensation   The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period.   The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services.   Convertible Notes Payable and Derivative Instruments   The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion

options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.   Series B Convertible Preferred Stock   The Series B convertible preferred stock (“Series B Preferred Stock”) was accounted for as mezzanine equity and the embedded conversion and redemption features was accounted for as derivative liabilities with change in fair value at each reporting period end charged to the consolidated statement of operation and comprehensive loss in accordance with ASC 480 and ASC 815.   Preferred Shares Extinguishments   The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For preferred stock redemptions and conversion, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss.   Segment Information   Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company has identified its Chief Executive Officer (“CEO”) as the chief operating decision maker (“CODM”). The Company operates in one operating segment. The Company’s CODM allocates resources and assesses performance at the consolidated level. The Company’s property and equipment and operating right of use lease asset are in the United States as of September 30, 2024, and 2023.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Recently Issued Accounting Pronouncements   In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. The Company has adopted Topic 326 on the Company’s Condensed Consolidated Financial Statements according to the effective date and the adoption has no significant impact on the Company’s Condensed Consolidated Financial Statements.   In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. There is no significant impact from adopting ASU 2019-12 on the Company’s financial condition, results of operations, and cash flows.   In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the original warrant and issuance of a new warrant. The Company adopted this guidance for the fiscal year beginning April 1, 2022. There is no significant impact from adopting ASU 2021-04 on the Company’s financial condition, results of operations, and cash flows.   On March 28, 2023, the FASB issued ASU No. 2023-01, Leases (Topic 842): Common Control Arrangements. ASU 2023-01 is designed to clarify the accounting for leasehold improvements associated with common control leases, thereby reducing diversity in practice. The new standard is effective for the Company for its fiscal year beginning January 1, 2024, with early adoption permitted. There is no significant impact from adopting ASU No. 2023-01 on the Company’s financial condition, results of operations, and cash flows.   In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) to improve the disclosures regarding a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The Company is required to adopt the guidance in the fourth quarter of fiscal 2025, though early adoption is permitted. There is no significant impact from adopting ASU 2023-07 on the Company’s financial condition, results of operations, and cash flows.   In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures (“ASU 2023-09”) to provide disaggregated income tax disclosures on rate reconciliation and income taxes paid. The Company is required to adopt the guidance in the fourth quarter of fiscal 2026, though early adoption is permitted. The Company is currently evaluating the impact of this amendment on its Condensed Consolidated Financial Statements.   The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems. 4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES   SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

| | | |

font-size: 10pt"> Trade and other payables and accrued liabilities as at September 30, 2024 and March 31, 2024 included $307,085 and $837,945, respectively, due to a shareholder, who is a director and executive of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BIOTRICITY INC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SEPTEMBER 30, 2024 (Unaudited)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Expressed in US dollars)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zedjdz07GZu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240930_zjFV4cgVnu96" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">As at</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">September 30, 2024</p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240331_z5SjV2vKtHx7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">As at</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 31, 2024</p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableOtherCurrent_iI_maAPAALzJVu_zW36DLdpn3m1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Trade and other payables</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4,800,049</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">5,081,992</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzJVu_zfGNIY8OdLkj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,232,727</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,369,576</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredRevenue_iI_maAPAALzJVu_zZ3x4v7ipFM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Deferred revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24,252</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21,550</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzJVu_zoOmBercZiJh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,057,028</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,473,118</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 480004950819924232727436957624252215509057028947311830708583794 5 5. CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS   Series A Convertible Promissory Notes: During the year ended March 31, 2021, the Company issued $11,275,500 (face value) in two series of convertible promissory notes (the "Series A Notes") sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 12% per annum.   For the first series of Series A Notes, commencing six months following the Issuance Date, and at any time thereafter (provided the Holder has not received notice of the Company's intent to prepay the note), at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the "Outstanding Balance") could be converted into that number of shares of Common Stock equal to: <span id="xdx_903_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20200401__20210331__us-gaap--DebtInstrumentAxis__custom--SeriesANotesOneMember_zNTwj5LcG9A4" title="Description of conversion terms for debt instrument">(i) the Outstanding Balance divided by (ii) 75% of the volume weighted average price of the Common Stock for the 5 trading days prior to the Conversion Date (the conversion price).   For the first series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company's common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company's common stock being listed on a national securities exchange, in which event the conversion price would be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company's next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest.   For the second series of Series A Notes, the notes could be converted into shares of common stock, at the option of the holder, commencing six months from issuance, at a conversion price equal to the lower of $24.00 per share or <span id="xdx_908_ecustom--VolumeWeightedAveragePriceOfCommonStockPercent_iI_dp_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesANotesTwoMember_zc12WuKD7Qx1" title="Volume weighted average price of common stock, percent">75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date.   For the second series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company's common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company's common stock being listed on a national securities exchange, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company's next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest.   <span id="xdx_901_ecustom--PlacementAgentFeesDescription_c20200401__20210331__us-gaap--DebtInstrumentAxis__custom--TwoSeriesANotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXjc2NcXO5oi" title="Placement agent fees description">The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company's common shares at the time final closing.   <span id="xdx_90D_ecustom--PlacementAgentFeesDescription_c20200401__20210331__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--DebtInstrumentAxis__custom--SeriesANotesOneMember_zpRNkihhcrWe" title="Placement agent fees description">The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,500 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes.   <span id="xdx_900_ecustom--PlacementAgentFeesDescription_c20200401__20210331__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zneIxZ24XNWf" title="Placement agent fees description">The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company's common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrants' exercise price was struck at $6.36 per share.   Prior to January 8, 2021 (final closing date), the Company determined that the conversion and redemption features contained in those Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion and redemption features.   For the Series A Notes, the Company recognized debt issuance costs in the amount of $2,301,854 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Notes. The Company also recognized initial debt discount in the amount of $<span id="xdx_907_eus-gaap--

DebtInstrumentUnamortizedDiscount_iI_c20220331__us-gaap--DebtInstrumentAxis__custom--SeriesANotesMember_zgMAmc3BF4fa" title="Debt instrument unamortized amount">8,088,003 and accreted the interest over the remaining lives of those Notes. The debt issuance costs were fully amortized by March 31, 2022.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   On December 30, 2022, the Company exchanged $500,000 of Series A Notes along with its outstanding interest accrual of $121,500 into a new convertible note with the same note holder. The new convertible note has principal of $621,500, stated interest rate of 12% per annum, as well as option to convert outstanding principal and accrued interest at the conversion price, calculated at <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20221230__20221230__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNoteMember_zcj2zH2fwxB8" title="Debt instrument interest rate">75% multiplied by the average of the three lowest closing prices during the previous ten trading days prior to the receipt of the conversion notice. The new convertible note matured on December 30, 2023.   Prior to year ended March 31, 2022, $10,575,500 face value of the Series A note was converted into common shares. As of March 31, 2022, the remaining face value was in the amount of $700,000.   During the three and six months ended September 30, 2024, the Company recognized discount amortization of $nil. As of September 30, 2024, the discount on Series A convertible notes was fully amortized. During the three and six months ended September 30, 2023, the Company recognized discount amortization of $16,455 and 32,291, respectively as accretion and amortization expense.   As of September 30, 2024, and March 31, 2024, the Company recorded $223,187 and $173,762, respectively, of interest accruals for the Series A Notes.   During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $24,848 and $49,425, respectively, on Series A convertible notes. During the three and six months ended September 30, 2023, the Company recognized interest expense in the amount of $18,798 and $37,392, respectively, on Series A convertible notes.   Series B Convertible Notes   During the year ended March 31, 2021, the Company also issued $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zJziDS5fG6Wi" title="Face amount">1,312,500 (face value) of convertible promissory notes ("Series B Notes") to various accredited investors.   Commencing six months following the issuance date, and at any time thereafter, subject to the Company's Conversion Buyout clause, at the sole election of the holder, any amount of the outstanding principal and accrued interest of the note (the "outstanding balance") could be converted into that number of shares of Common Stock equal to: (i) the outstanding balance divided by (ii) the Conversion Price. Partial conversions of the note shall have the effect of lowering the outstanding principal amount of the note. The holder may exercise such conversion right by providing written notice to the Company of such exercise in a form reasonably acceptable to the Company (a "conversion notice"). Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice.   The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company's common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion, redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvVr5XxKaXL5" title="Warrants and rights outstanding term">3-year term from date of issuance and an exercise price that is $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zY5e4JhULHC2" title="Exercise price">6.36 per share for <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zsk3KfHqjrU9" title="Warrants issued">100,000 warrant shares and $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zqUkCKVwxlK8" title="Exercise Price">9.0 per share for <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zBpn7tFw2pCf" title="Warrants issued">35,417 warrant shares.   Net proceeds to the Company from convertible note issuances to March 31, 2021 amounted to $1,240,000 after the original issuance discount as well as payment of the financing related fees. The Company determined that the conversion and redemption features contained in the Series B Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liability associated with the embedded conversion and redemption features.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   The Company recognized debt issuance costs in the amount of $10,000 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Series B Notes. The Company recognized initial debt discount of $1,312,500 and accreted the interest over the remaining lives of those notes. The debt issuance costs were fully amortized by March 31, 2022.   During the year ended March 31, 2022, $472,500 (face value) of Series B Notes were converted into 34,586 common shares. As at March 31, 2022, $840,000 of Series B Notes remained unconverted and outstanding, which was equal to the face value of the relevant convertible notes.   <p style="font: 10pt Times New Roman, Times,

Times, Serif; margin: 0pt 0; text-align: justify">During the year ended March 31, 2023, $555,600 (face value) of Series B Notes were converted into 126,833 common shares (Note 9 d).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended March 31, 2023, $126,680 (face value) of Series B Notes were redeemed by cash payment of $145,682. The redemption price was determined in accordance to the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note, was $24,408, and was recognized as a gain upon convertible note repayment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended March 31, 2024, the Company redeemed $135,710 of Series B Notes, through a cash payment of $162,851. A gain on redemption $18,540 was recognized as a result of this redemption, representing the difference between the cash payment and the face value of Series B Notes redeemed net of the related derivative liabilities ($45,681 for the year ended March 31, 2024).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and six months ended September 30, 2024, the Company redeemed $5,342 and $22,009 of Series B Notes, through a cash payment of $5,342 and $25,342, respectively. A gain on redemption of $1,761 and $8,320 was recognized as a result of this redemption, representing the difference between the cash payment and the face value of Series B Notes redeemed net of the related derivative liabilities ($1,761 and $8,320 for the three and six months ended September 30, 2024, respectively).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and six months ended September 30, 2023, the Company redeemed $52,049 and $102,376 of Series B Notes, through a cash payment of $62,459 and $122,851, respectively. A gain on redemption of $6,684 and $13,132 was recognized as a result of this redemption, representing the difference between the cash payment and the face value of Series B Notes redeemed net of the related derivative liabilities ($17,094 and $33,607 for the three and six months ended September 30, 2023, respectively).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In total, the Company had issued $821,500 and $157,720 for Series A and Series B notes, respectively, out of which $821,500 and $nil for Series A Notes and Series B Notes remaining outstanding beyond their contractual maturity date as of September 30, 2024. As at March 31, 2024, $821,500 and $22,010 for Series A and Series B notes remained outstanding beyond their contractual maturity date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A and Series B notes continued to accrue interest, and no repayment demand notification was received from noteholders, notwithstanding the fact that these noteholders have continued to convert portions of these notes subsequently; and the Company expects that the majority of these notes will eventually convert.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $88,881 and $88,602, respectively, related to the Series B Notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $59 and $279, respectively. During the three and six months ended September 30, 2023, the Company recognized interest expense in the amount of $1,034 and $2,703, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Series C Convertible Notes</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has issued Series C Notes of $1,812,700 (face value) by March 31, 2024, with net proceeds of $1,100,430 after payment of the relevant financing related fees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Notes were sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 15% per annum.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For Series C Notes, commencing six months following the Issuance Date, and at any time thereafter, at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the “Conversion Amount”) could be converted into that number of shares of Common Stock equal to: the Conversion Amount divided by the “Optional Conversion Price”, which is defined as lower of (i) seventy-five percent (75%) of the VWAP for the five (5) Trading Days prior to the Conversion Date, or (ii) eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BIOTRICITY INC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SEPTEMBER 30, 2024 (Unaudited)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span

style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in US dollars)   For Series C Notes, "Mandatory Conversion" of the notes would convert into common stock at the applicable "Mandatory Conversion Price", if either (i) on each of any twenty (20) consecutive Trading Days (the "Measurement Period") (A) the closing price of the Common Stock on the applicable Trading Market is at least $18.00 per share and (B) the dollar value of average daily trades of the Common Stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the Common Stock on the applicable National Exchange on each of the ten (10) consecutive Trading Days following such closing is at least $400,000 per Trading Day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above, seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing.   <span id="xdx_90B_ecustom--PlacementAgentFeesDescription_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbQe3eTEwKV6" title="Placement agent fees description">The Company was obligated to issue warrants that accompany the convertible notes and provide 100% warrant coverage. The warrants have a 4-year term from date of issuance and an exercise price that is 200% of the 5-day volume weighted average price of the Company's common shares at the time of final closing.   <span id="xdx_903_ecustom--PlacementAgentFeesDescription_c20240401__20240930__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_zRp5Cvwua5Ol" title="Placement agent fees description">The Company was obligated to pay the placement agent of the first series of Series C Notes a 10% cash fee for the face value of the notes.   <span id="xdx_903_ecustom--PlacementAgentFeesDescription_c20240401__20240930__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_zK8TAdAh1Io4">The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 8% of face value of the notes, with an exercise price that equals to the 5-day volume weighted average price of the Company's common shares at the time final closing.   Prior to the final closing date (October 23, 2023), the Company determined that the conversion features contained in those Note, as well as the obligations to issue investor warrants and placement agent warrants represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion features, as well as the obligations related to investor warrant and placement agent warrant issuance. Subsequently, the exercise price of all warrants was concluded and locked to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231023__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember__us-gaap--SubsidiarySaleOfStockAxis__custom--NoteHoldersMember_zSUaKeOgTYf9" title="Exercise Price">4.18 and $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231023__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsWarrantsMember_zONbC35XAdR9" title="Exercise Price">2.09, respectively, for the note holder and placement agent warrants, as of the final closing date October 23, 2023. Since the exercise price was no longer a variable, the Company concluded that the noteholder and placement agent warrants should no longer be accounted for as a derivative liability in accordance with ASC 815 guidelines related to equity indexation and classification. The derivative liabilities related to those warrants were therefore marked to market as of October 23, 2023 and then transferred to equity (collectively, "End of warrants derivative treatment") in the amount of $1,278,786 (Note 8).   For the Series C Notes, the Company recognized debt issuance costs of $207,361 during the year ended March 31, 2024 and treated these as debt discounts. The Company also recognized additional debt discount in the amount of $1,005,829 in connection with the recognition of derivative liabilities for the conversion features, investor warrants and placement agent warrants. The debt discounts are recorded as a contra liability against the convertible note and are amortized and recognized as accretion expenses using the effective interest method over the remaining lives of the Notes.   During the three and six months ended September 30, 2024, the Company recognized discount amortization of $184,577 and $1,051,668, respectively, on Series C Notes as accretion and amortization expense. As of September 30, 2024, and March 31, 2024, the remaining unamortized discount on Series C convertible notes was $180,606 and $1,232,274, respectively.   During the three and six months ended September 30, 2023, the Company recognized discount amortization of $95,183 and $180,866, respectively, on Series C Notes as accretion and amortization expense. As of September 30, 2023, the remaining unamortized discount on Series C convertible notes was $1,610,913.   During the three and six months ended September 30, 2024, convertible notes with a face value of $45,000 and $1,432,700, respectively, were converted into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_zB3WDXoZbsx9" title="Converted instrument shares issued">121,043 and <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_zoVZXcSEz3Nd" title="Converted instrument shares issued">1,753,554 common shares, respectively. As of September 30, 2024, <span id="xdx_90C_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_zkzcM4mVYHGh" title="Shares recognised as obligation">121,043 shares are recognized as an obligation for shares to be issued relating to the conversion. The fair value of common shares issued during the three and six months ended September 30, 2024, is $74,618 and $2,283,216, respectively, and is determined based on market price upon conversion. Total value of debt settled is in the amount of $68,167 and $2,145,929, respectively, which consisted of the face value of notes converted, accrued interest of $7,810 and $222,257, respectively, and relevant derivative liability of $15,357 and $490,972, respectively. The Company recognized a loss upon conversion of $6,451 and $137,287, respectively, representing the difference between the value of debt settled and fair value of shares issued and to be issued.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $79,133 and $253,643, respectively, related to the Series C Notes.   During the three and six months ended September 30, 2024, the Company recognized interest expense in the amounts of $15,004 and $47,747, respectively. During the three and six months ended September 30, 2023, the Company recognized interest expense in the amounts of $<span

id="xdx_902_eus-gaap--InterestExpenseDebt_c20230701__20230930__us-gaap--DebtInstrumentAxis__custom--SeriesCNoteMember_zKYQNZNZf4j9" title="Interest expense">66,137 and $114,632, respectively.   Other Convertible Notes   On January 23, 2023, the Company issued $2,000,000 (face value) in convertible preferred notes (“the Notes”) to an accredited investor. The Notes mature 18 months from the issuance date. This note bears interest rate at a fixed rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230123__us-gaap--ShortTermDebtTypeAxis__custom--OtherConvertibleNotesPayableMember_zDuKChBuwCV6" title="Debt instrument interest rate stated percentage">10% in the form of stock with a strike price equal to the closing stock price on the note issuance date. Therefore, the Company issued <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesIssuanceOfSharesInLieuOfConvertibleNoteInterest_c20230123__20230123__us-gaap--ShortTermDebtTypeAxis__custom--OtherConvertibleNotesPayableMember_z0Ddpno8qUca" title="Convertible notes payable">45,045 shares of common stock in lieu of interest on this convertible note. These shares were valued at $<span id="xdx_904_ecustom--StockIssuedDuringPeriodValueIssuanceOfSharesInLieuOfConvertibleNoteInterest_c20230123__20230123__us-gaap--ShortTermDebtTypeAxis__custom--OtherConvertibleNotesPayableMember_zPnTIOr73sy6" title="Convertible notes payable">221,621 and were recognized as a deferred cost on the convertible note, recorded as a contra liability against the convertible note, and were amortized and recognized as accretion expense using the effective interest rate method over the remaining lives of the Notes.   The conversion of the Notes is automatic upon a Qualified Financing which is in the control of the Company, or at maturity of the notes, upon mutual agreement by the noteholder and the Company. Since the conversion is not in control of the holder of the note, the Company did not recognize a derivative liability in connection with the conversion option of the Notes.   During the three and six months ended September 30, 2024, the Company recognized discount amortization of $<span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_dxL_c20240701__20240930__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zwkuzbo50OY5" title="Amortized discount::XDX::-"><span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_dxL_c20240401__20240930__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zgwuY0NH5bAh" title="Amortized discount::XDX::-">nil, respectively, on the Notes as accretion and amortization expense. As of September 30, 2024, and March 31, 2024, respectively, the discount on Other Convertible Notes was fully amortized.   During the three and six months ended September 30, 2023, the Company recognized discount amortization of $55,861 and $111,115, respectively, for the Other Convertible Notes, as part of the accretion and amortization expenses. As of September 30, 2023, the remaining unamortized discount on Other Convertible Notes was $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zZpV9FT5LXrk" title="Debt instrument unamortized discount">75,289.   Convertible Preferred Notes   The Company entered into a convertible preferred note financing on September 25, 2023 and issued a convertible note (“Preferred Note”) for a principal amount of $1,000,000. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen (18) month anniversary of the last closing date of the offering (the “Maturity Date”). The Preferred Note bears interest at a fixed rate of 12% which is payable in cash monthly.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   The Company also entered into a convertible preferred note financing on October 25, 2023 and issued a convertible note (“Preferred Note”) for a principal amount of $250,000. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen (18) month anniversary of the last closing date of the offering (the “Maturity Date”). The Preferred Note bears interest at a fixed rate of 12% which is payable in cash monthly.   The Company entered into a convertible preferred note financing on January 9, 2024 and issued a convertible note (“Preferred Note”) for a principal amount of $114,303. The Preferred Note matures on the twenty-four (24) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the twenty-four (24) month anniversary of the last closing date of the offering (the “Maturity Date”). The Preferred Note bears interest at a fixed rate of 8% which is payable in cash quarterly.   The Company entered into a convertible preferred note financing on June 17, 2024, and issued a convertible note (“Preferred Note”) for a principal amount of $300,000. During the three months ended September 30, 2024, the Company entered into additional preferred note financing with the same subscriber for a principal amount of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240701__20240930__us-gaap--AwardTypeAxis__custom--EighteenMonthAnniversaryMember_zyecL4Ok6k1a" title="Subscriber for a principal amount">350,000. The total principal amount outstanding as of September 30, 2024 was $650,000. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen (18) month anniversary of the last closing date of the offering (the “Maturity Date”). The Preferred Note bears no interest.   The conversion of the Preferred Notes is automatic upon a Qualified Financing which is in the control of the Company, or at maturity of the notes, upon mutual agreement by the noteholder and the Company. Since the conversion is not in control of the holder of the note, the Company did not recognize a derivative liability in connection with the conversion option of the Other Convertible Notes.   The Company may prepay the Preferred Note in whole or in part, after providing fifteen (15) days written notice to the holder, either in cash or by the mutually consented conversion of the Preferred Note and any accrued interest thereon at a 15% discount to the stock’s 10-day VWAP.   As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $27,138 and $4,103, respectively, related to the Preferred Notes.   During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $38,612 and $77,125, respectively.   Other Short-term loans and Promissory Notes   In December 2022, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromShortTermDebt_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--

ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zafQXe7R8fDl" title="Gross proceeds">400,000, prior to the deduction of issuance costs in the amount of $9,999. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 40 weeks. The Company is required to make weekly payments of $13,995 ($<span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zgse9OPmyRDh" title="Debt instrument carrying amount">560,000 in the aggregate). As of September 30, 2024, and March 31, 2024, respectively, the principal was fully repaid and discount for this loan was fully amortized. The discount amortization during the three and six months ended September 30, 2024, was $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_dxL_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zLiT4QVF43b" title="Adjustment for amortization::XDX::-"><span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_dxL_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zxSYfhALQbqe" title="Adjustment for amortization::XDX::-">nil, respectively. The discount amortization during the three and six months ended September 30, 2023, was $<span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20230930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_z9QYbGpe7DUl" title="Adjustment for amortization">2,893 and $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_c20230401__20230930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zpRUcXlOssAc" title="Adjustment for amortization">6,142, respectively, and was recognized as part of the accretion and amortization expenses. In addition, the Company recognized $<span id="xdx_909_eus-gaap--AccretionExpense_dxL_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_znsJI2ZkO7Y7" title="Accretion expense::XDX::-"><span id="xdx_909_eus-gaap--AccretionExpense_dxL_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zGzMHJo0w6yI" title="Accretion expense::XDX::-">nil accretion expenses, during the three and six months ended September 30, 2024, and $<span id="xdx_901_eus-gaap--RepaymentsOfDebt_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zSG1Uc4JNWl1" title="Repayments of loan">16,242 and $66,213 during the three and six months ended September 30, 2023, respectively, related to the increase in present value of the loan over its term.   **BIOTRICITY INC.** **NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS** **SEPTEMBER 30, 2024 (Unaudited)** (Expressed in US dollars)   In December 2022, the Company also entered into a short-term collateralized bridge loan agreement with a finance company that advanced gross proceeds of $800,000, prior to the deduction of issuance costs in the amount of $32,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of this second agreement is 40 weeks. The Company is required to make weekly payments of $29,556 ($<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember__us-gaap--AwardDateAxis__custom--FirstFourWeeksMember_zYvkCCun14Jk" title="Debt instrument payments">13,999 for the first four weeks, and $<span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_z8L84NwufKe3" title="Debt instrument carrying value">1,120,000 in the aggregate). As of September 30, 2024, and March 31, 2024, respectively, the principal was fully repaid and discount for this loan was fully amortized. The discount amortization during the three and six months ended September 30, 2024, was $<span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_dxL_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zgRCtfIaPvdi" title="Adjustment for amortization::XDX::-"><span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_dxL_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zOtiEcQ3cDU7" title="Adjustment for amortization::XDX::-">nil, respectively. The discount amortization during the three and six months ended September 30, 2023, was $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20230930__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zYjJokCXtf42" title="Adjustment for amortization">10,400 and $<span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_c20230401__20230930__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_znGIuoqOQfm1" title="Adjustment for amortization">20,800, respectively, which was recognized as part of the accretion and amortization expenses. In addition, the Company recognized $<span id="xdx_90E_eus-gaap--AccretionExpense_dxL_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zpzJNuB8La51" title="Accretion expense::XDX::-">nil accretion expenses, during the three and six months ended September 30, 2024, and $<span id="xdx_90E_eus-gaap--AccretionExpense_c20230701__20230930__dei--LegalEntityAxis__custom--FinanceCompanyMember__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember_zvoMUxoP3dTb" title="Accretion expense">41,049 and $<span id="xdx_903_eus-gaap--AccretionExpense_c20230401__20230930__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zT0keVZ4bqq2" title="Accretion expense">148,027 accretion expenses, during the three and six months ended September 30, 2023, respectively, related to the increase in present value of the loan over its term.   In December 2022, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $<span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zoJfCVh0nKw5" title="Debt instrument carrying amount">600,000 (the "Principal Amount"). The note has a fixed rate of interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zGmHKvFZ8t5b" title="Debt instrument interest rate during period">25% per annum payable monthly on the first day of every month. This promissory note matured on <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_z4SDf94cjM2j" title="Maturity date">December 15, 2023, when the Principal Amount became due. The note has various default provisions which would, if triggered, result in the acceleration of the Principal Amount plus any accrued and unpaid interest. The note also has a <span id="xdx_90D_ecustom--EarlyPaymentPenaltyProvisionPercentage_pid_dp_uPure_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zZyGpUqORzGd" title="Early payment penalty provision percentage">3% early payment penalty provision. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $<span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240930__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zfbTE2VWLVV3" title="Debt instrument carrying amount"><span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zy6bOitgJoxb" title="Debt instrument carrying amount">600,000, and accrued interest outstanding on the note was $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20240930__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zKRmeUvWnQS1" title="Interest payable">12,928 and $<span id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zgRZyQPLIqxk" title="Interest payable">12,723, respectively. The note continues to accrue interest, and no repayment demand notification was received from noteholder. During the three and six months ended September 30, 2024, the Company recorded interest expense in the amount of $<span id="xdx_900_eus-gaap--InterestExpenseDebt_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zaR49jXWScii" title="Interest expense">37,808 and $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zkDz3EjCvRd5" title="Interest expense">75,206, respectively, related to the promissory note. During the three and six months ended September 30, 2023, the Company recorded interest expense in the amount of $<span id="xdx_908_eus-gaap--InterestExpenseDebt_c20230701__20230930__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_z67cCCFIxyE7" title="Interest expense">37,808 and $<span id="xdx_901_eus-gaap--InterestExpenseDebt_c20230401__20230930__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zyJIawMtxuG8" title="Interest expense">75,205, respectively, related to the promissory note.   On December 30, 2022, the Company extinguished <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221230__srt--TitleOfIndividualAxis__custom--SeriesAConvertibleNoteHoldersMember_zGYvqUr3DUug" title="Warrants issued">51,101 warrants that were originally issued to Series A Convertible Noteholders and replaced these warrants with a new promissory note issued to the same warrant holder. The new promissory note has a principal balance of $270,000, stated interest of zero, and maturity date of December 31, 2023. The fair value of this new promissory note was $<span id="xdx_90A_eus-

gaap--DebtInstrumentFairValue_iI_c20221230__us-gaap--DebtInstrumentAxis__custom--NewPromissoryNoteMember_zjdzcIreu5Pl" title="Debt face amount">248,479 as of the issuance date, which was calculated using a discount rate that was comparable to other loan issuance at the same time as well as the market bond rates at the time of the promissory note issuance. The difference between the fair value of the new note and its principal balance was $<span id="xdx_904_ecustom--AdjustmentCarryingValueAndPrincipalAmount_iI_c20221230__us-gaap--DebtInstrumentAxis__custom--NewPromissoryNoteMember_zCPkwy95dRV1" title="Adjustment carrying value and principal amount">21,521, and was recognized as a discount, and amortized via effective interest rate method. The Company compared the fair value of the extinguished warrants immediately prior to extinguishment against the fair value of the new promissory note issued. During the year ended March 31, 2024, the obligation to repay the principal balance at the original maturity date was waived for a finance charge of $50,000, which the Company recorded as interest expense in the in the statement of operations. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $270,000, and the remaining unamortized discount was $Nil. During the three and six months ended September 30, 2024, the Company recognized amortization of discount on this promissory note in the amounts of $nil, respectively. During the three and six months ended September 30, 2023, the Company recognized amortization of discount on this promissory note in the amounts of $nil and $7,304, respectively, as accretion and amortization expenses. As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $50,000 related to this promissory note.   On March 29, 2023, the Company entered into an additional collateralized bridge loan agreement with a finance company that advanced gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromShortTermDebt_c20230329__20230329__us-gaap--DebtInstrumentAxis__custom--CollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zWBKrLABn8pi" title="Gross proceeds">300,000, prior to the deduction of issuance costs in the amount of $<span id="xdx_90D_eus-gaap--DeferredFinanceCostsNet_iI_c20230329__us-gaap--DebtInstrumentAxis__custom--CollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zvuipDOgXIUa" title="Deferred finance costs">12,000. The issuance costs were recognized as a debt discount and would be amortized via the effective interest method. The term of this agreement is 40 weeks. The Company is required to make weekly payments of $<span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPayment_c20230329__20230329__us-gaap--DebtInstrumentAxis__custom--CollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember__us-gaap--AwardDateAxis__custom--FirstFourWeeksMember_zEZGzAxuRTzh" title="Debt instrument periodic payment">5,250 for the first four weeks, and $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20230329__20230329__us-gaap--DebtInstrumentAxis__custom--CollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember__us-gaap--AwardDateAxis__custom--RemainingThirtySixWeeksMember_zRZyXrt1ve67" title="Debt instrument periodic payment">11,083 for the remaining 36 weeks, which is $<span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230329__us-gaap--DebtInstrumentAxis__custom--CollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zHjTbHyPCjOh" title="Long-term debt, gross">420,000 in aggregate. On July 18, 2023, the Company entered into an amendment with the finance company and increased total proceeds borrowed to $<span id="xdx_901_eus-gaap--ProceedsFromShortTermDebt_c20230718__20230718__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember_zOJdQtQmj8xf" title="Gross proceeds">700,000. The proceeds from the amended loan balance were netted against previously outstanding balance of the loan, along with an issuance cost in the amount of $<span id="xdx_901_eus-gaap--DeferredFinanceCostsNet_iI_c20230718__us-gaap--DebtInstrumentAxis__custom--SeriesANotesMember__dei--LegalEntityAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember_zNRDdz6Ss4x2" title="Debt issuance costs in the amount">28,000. The term of this new loan agreement is 40 weeks. The Company is required to make weekly payments of $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_c20230718__20230718__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zKbJAzkfjos1" title="Debt instrument periodic payment">24,500, which is $<span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230718__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zOmk4huqIMDe" title="Long-term debt, gross">980,000 in aggregate. The Company accounted for this amendment as a debt extinguishment and recognized a loss on the amendment of $<span id="xdx_90E_ecustom--LossOnDebtAmendment_iI_c20230718__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zQ0IGjH7wUud" title="Loss on amendment of debt">59,161 in other expenses. The issuance costs on the amended loan were recognized as a debt discount and would be amortized via the effective interest method. During the three and six months ended September 30, 2024, the Company recognized $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_dxL_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zRxqG3OU4Pk2" title="Unamortized issuance cost discount::XDX::-">nil and $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zQDLLKdOKuB5" title="Unamortized issuance cost discount">2,800, respectively, of amortization of discount as accretion and amortization expenses. During the three and six months ended September 30, 2023, the Company recognized $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20230701__20230930__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zX4yXihTF2bg" title="Unamortized issuance cost discount">11,500 and $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_c20230401__20230930__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zU9MC8un6l1h" title="Unamortized issuance cost discount">3,600, respectively, of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $<span id="xdx_904_eus-gaap--AccretionExpense_dxL_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zytV3S3FXh6g" title="Accretion expense::XDX::-">nil and $<span id="xdx_906_eus-gaap--AccretionExpense_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zTZT9ywNh2uf" title="Accretion expense">4,152 accretion expenses, during the three and six months ended September 30, 2024, respectively and $<span id="xdx_902_eus-gaap--AccretionExpense_c20230701__20230930__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_z6CQR606QCwe" title="Accretion expense">100,419 and $<span id="xdx_90E_eus-gaap--AccretionExpense_c20230401__20230930__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zdyt0e1dti32" title="Accretion expense">112,700 during the three and six months ended September 30, 2023, respectively, related to the increase in present value of the loan over its term. During the three and six months ended September 30, 2024, net repayments for the loan amounted to $<span id="xdx_90E_eus-gaap--RepaymentsOfDebt_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zzVCAqnRCCEc" title="Repayments of loan">44,500 and $<span id="xdx_907_eus-gaap--RepaymentsOfDebt_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_z8OPYCXjFgUg" title="Repayments of loan">191,500, respectively. During the three and six months ended September 30, 2023, net repayments for the loan amounted to $<span id="xdx_90A_eus-gaap--RepaymentsOfDebt_c20230701__20230930__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zWOBw9nHnj72" title="Repayments of loan">298,472 and $<span id="xdx_90E_eus-gaap--RepaymentsOfDebt_c20230401__20230930__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zcIevvfTCih1" title="Repayments of loan">762,805, respectively.   In June 2023, the Company entered into a secured revolving account purchase credit and inventory financing facility (the "Revolving Facility") with a revolving loan lender, pursuant to which the lender may from time to time purchase certain discrete account receivables from the Company (with full recourse) or may make loans and provide other financial accommodations, the payment of which are guaranteed and secured by certain assets of the Company. <span id="xdx_904_eus-gaap--LineOfCreditFacilityRevolvingCreditConversionToTermLoanDescription_c20230601__20230630_zKXk0efa2fUe" title="Line of credit facility, revolving credit conversion to term loan, description">In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $1.2 million in financing, and expects to receive the remaining balance as part of normal collection activities. The inventory financing provided by this facility was limited to the lower of $0.3 million, or a 40% maximum of inventory balances. The Revolving Facility was accounted for as a secured borrowing. As of September 30, 2024, and March 31, 2024 the Company had drawn $1,500,529 and $1,286,792, respectively, in accounts receivable financing and $198,000 and $125,000, respectively, in inventory financing with aggregate principal outstanding of $1,698,529 and $1,411,792, respectively. During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $102,485 and $207,718, respectively. During the three and six months ended September 30, 2023, the Company recognized interest expense in the amount of $59,656 and $104,873, respectively. As of September 30, 2024, and March 31, 2024 the Company recorded accrued interest in the amount of $25,369 and $23,879 related to the Revolving Facility.   <span style="font-family: Times New Roman, Times, Serif; font-size:

10pt"> BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   On July 13, 2023, the Company entered into another short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $400,000, prior to the deduction of issuance costs in the amount of $24,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 14 weeks. The Company is required to make weekly payments of $38,705 ($<span id="xdx_90C_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230713__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_znwgZyPkkwqd" title="Debt instrument carrying amount">540,000 in the aggregate). As of September 30, 2024, and March 31, 2024, the principal was fully repaid and discount for this loan was fully amortized. <span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPayment_do_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_z4D9QMFsxV6" title="Debt instrument periodic payment">No repayments were made during the six months ended September 30, 2024.   On August 11, 2023, the Company issued two short term promissory notes ("August 2023 Notes"), each for a principal amount of $250,000, to one investor for aggregate gross proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromShortTermDebt_c20230811__20230811__us-gaap--DebtInstrumentAxis__custom--TwoShortTermPromissoryNotesMember__dei--LegalEntityAxis__custom--OneInvestorMember_z7wKjaZtxx6b" title="Proceeds from promissory notes">500,000. The August 2023 Notes do not accrue formal interest but do contain administrative fees in the aggregate of $75,000. One of the notes matures three months from the issuance date upon which the principal amount of $250,000 and an administrative fee of $25,000 is due. The second note matures six months from the issuance date upon which the principal amount of $250,000 and an administrative fee of $50,000 is due. The administrative fees were accrued as interest expenses for the period of the loans outstanding. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $52,500 and $427,500, respectively. Accrued interest outstanding on the note as of September 30, 2024, and March 31,2024, was $75,000, respectively. During the three and six months ended September 30, 2024, net repayments towards the principal amount of the notes amounted to $250,000 and 375,000, respectively.   On December 8, 2023, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $630,000, prior to the deduction of issuance costs in the amount of $15,750. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 44 weeks. The Company is required to make weekly payments of $19,195 ($<span id="xdx_90D_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231208__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zx5OIRhyqS43" title="Debt instrument carrying amount">844,200 in the aggregate). As of September 30, 2024, and March 31, 2024, the amount of principal outstanding under this amended agreement was $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zMbn1i7QWEbc" title="Debt face amount">37,241 and $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zSBkUSB0Phci" title="Debt face amount">443,185, respectively, and the remaining unamortized issuance cost discount was $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zlAO4oSes1Bi" title="Unamortized issuance cost discount">716 and $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zAoRkESmEKuc" title="Unamortized issuance cost discount">10,023, respectively. During the three and six months ended September 30, 2024, the Company recognized $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zoVFBKQZ8Hoa" title="Adjustment for amortization">4,653 and $<span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zF7Nscyqx3Aj" title="Adjustment for amortization">9,307 of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $<span id="xdx_90F_eus-gaap--AccretionExpense_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zM0m6eTtXzB8" title="Accretion expense">28,560 and $<span id="xdx_905_eus-gaap--AccretionExpense_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zOOZdHjWuxl8" title="Accretion expense">93,127 accretion expenses during the three and six months ended September 30, 2024, related to the increase in present value of the loan over its term. During the three and six months ended September 30, 2024, total repayments for the loan amounted to $<span id="xdx_900_eus-gaap--RepaymentsOfDebt_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zA3lXedFiy4i" title="Repayments of loan">137,585 and $<span id="xdx_908_eus-gaap--RepaymentsOfDebt_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_z4vm1lPc4PTh" title="Repayments of loan">367,925.   During January 2024, the Company entered into a short term loan agreement with an individual lender that resulted in gross proceeds of $140,000 (the "Principal Amount"). The loan has a fixed rate of interest at 12% per annum on the principal amount, payable monthly. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $103,128 and $140,000, respectively. As of September 30, 2024, and March 31, 2024, accrued interest outstanding on the note was $11,231 and $nil, respectively. The loan continues to accrue interest, and total repayments for the loan amounted to $36,872 during the three and six months ended September 30, 2024, respectively. During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $<span id="xdx_900_eus-gaap--InterestExpenseBorrowings_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--ShortTermLoanAgreementMember_z9upc2VUiK56" title="Interest expense related to short term loan">4,235 and $<span id="xdx_902_eus-gaap--InterestExpenseBorrowings_c20240401__20240930__us-gaap--TypeOfArrangementAxis__custom--ShortTermLoanAgreementMember_zvZyYOQDiakb" title="Interest expense related to short term loan">11,231 related to the short term loan.   During February 2024, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20240229__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorOneMember_zzO5IFkUYRb8" title="Debt instrument carrying amount">660,504 (the "Principal Amount"). The note has a fixed rate of interest at <span id="xdx_905_eus-gaap--

DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240201__20240229__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorOneMember_zgRNS9sSRml2" title="Debt instrument interest rate during period">12% per annum on the principal amount, payable monthly. As of September 30, 2024, and March 31, 2024, the amount of principal outstanding on the note was $660,932. As of September 30, 2024, and March 31, 2024, accrued interest outstanding on the note was $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20240930__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorOneMember_zW8q2Cy8hQBe" title="Interest payable">46,908 and $<span id="xdx_903_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorOneMember_zzDaB2fnbDV9" title="Interest payable">7,101, respectively. The note continues to accrue interest, and no repayment demand notification was received from noteholder. During the three and six months ended September 30, 2024, the Company recognized interest expense in the amount of $19,991 and $39,765, respectively, related to the promissory note.   On February 2, 2024, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $700,000, prior to the deduction of issuance costs in the amount of $35,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 35 weeks. The Company is required to make weekly payments of $29,235 ($<span id="xdx_907_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240202__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zTeg8sZxYsY9" title="Debt instrument carrying amount">1,008,000 in the aggregate). As of September 30, 2024, and March 31, 2024, the amount of principal outstanding under this agreement was $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zWbxTjJDEUK6" title="Debt face amount">13,707 and $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_z80cZjfeT2D1" title="Debt face amount">581,105, respectively, and the remaining unamortized issuance cost discount was $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_z6oiubnz8m9b" title="Unamortized issuance cost discount">486 and $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zrz4lJ7stV4l" title="Unamortized issuance cost discount">26,879, respectively. During the three and six months ended September 30, 2024, the Company recognized $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zEoHKdy2OQac" title="Adjustment for amortization">13,196 and $<span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zU6gxm5Cu454" title="Adjustment for amortization">26,393, respectively, of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $<span id="xdx_900_eus-gaap--AccretionExpense_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zjcjlKp3ePai" title="Accretion expense">56,275 and $<span id="xdx_90A_eus-gaap--AccretionExpense_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zx89ohG6yU4g" title="Accretion expense">192,712, respectively, accretion expenses during the three and six months ended September 30, 2024, related to the increase in present value of the loan over its term. During the three and six months ended September 30, 2024, total repayments for the loan amounted to $<span id="xdx_909_eus-gaap--RepaymentsOfDebt_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zBPYaJ1YMmn8" title="Repayments of loan">127,970 and $<span id="xdx_903_eus-gaap--RepaymentsOfDebt_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zEzsannXJCH9" title="Repayments of loan">449,555.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   112755000.12(i) the Outstanding Balance divided by (ii) 75% of the volume weighted average price of the Common Stock for the 5 trading days prior to the Conversion Date (the conversion price).the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company's common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company's common stock being listed on a national securities exchange, in which event the conversion price would be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company's next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest.24.000.75the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company's common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company's common stock being listed on a national securities exchange, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company's next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest.The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company's common shares at the time final closing.The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,500 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes.The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company's common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrants' exercise price was struck at $6.36 per share.230185480880035000001215006215000.120.751057550070000016455322912231871737622484849425187983739213125 00The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company's common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion, redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage.P3Y6.361000009.035417124000010000131250047250034586840000555600126833126680145682The redemption price was determined in accordance to the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note2440813571016285118540456815342220095342253421761832017618320520491023766245912285166841313217094336078215001577208215008215022010888818866 seventy-five percent (75%) of the VWAP for the five (5) Trading Days prior to the Conversion Date, or (ii) eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing.the notes would convert into common stock at the applicable "Mandatory Conversion Price", if either (i) on each of any twenty (20) consecutive Trading Days (the "Measurement Period") (A) the closing price of the Common Stock on the applicable Trading Market is at least $18.00 per share and (B) the dollar value of average daily trades of the Common Stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the Common Stock on the applicable National Exchange on each of the ten (10) consecutive Trading Days following such closing is at least $400,000 per Trading Day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above, seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing.The Company was obligated to issue warrants that accompany the convertible notes and provide 100% warrant coverage. The warrants have a 4-year term from date of issuance and an exercise price that is 200% of the 5-day volume weighted average price of the Company's common shares at the time of final closing.The Company was obligated to pay the placement agent of the first series of Series C Notes a 10% cash fee for the face value of the notes.The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 8% of face value of the notes, with an exercise price that equals to the 5-day volume weighted average price of the Company's common shares at the time final closing.4.182.091278786207361100582918457710516681806061232274951831808661610913450001432700121043175355412104374618228321668167214592978102222257.12-150.036000006000001292812723378087520637808752055110127000020 23-12-31248479215215000027000027000073045000050000300000120005250110834200007000002800024500980000059161280011500360041521004191127004450019150029847 assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $1.2 million in financing, and expects to receive the remaining balance as part of normal collection activities.120000030000015005291286792198000125000169852914117921024852077185965610487325369400000240000P98D387055400000250000500000750002500002500 id="xdx_808_ecustom--BankLoanCreditAgreementTextBlock_zA4htOHTszR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. TERM LOAN AND CREDIT AGREEMENT   Term Loan <span style="font-family: Times New

Roman, Times, Serif; font-size: 10pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2021, the Company entered into a Credit Agreement ("Credit Agreement") with SWK Funding LLC ("Lender"); as part of this, the Company has borrowed $12.4 million, with a maturity date of December 21, 2026. The principal will accrue interest at the LIBOR Rate plus 10.5% per annum (subject to adjustment as set forth in the Credit Agreement). Interest payments are due each February, May, August and November commencing February 15, 2022. Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. The Company and the Lender have negotiated the terms under which the Company will be allowed to extend the interest-only period and delay the start of principal repayment. The negotiated terms indicate principal repayment of $2.4 million ($600,000 per quarter), during the final two years of the term. A current portion of the term loan of $3,000,000 and $2,400,000 was reported in the Company's current liabilities as of September 30, 2024 and March 31, 2024, respectively. Prepayment of amounts owing under the Credit Agreement are allowed under prescribed circumstances. Pursuant to the Credit Agreement the Company is subject to an Origination Fee in the amount of $120,000. Upon Termination of the Credit Agreement, the Company shall pay an Exit Fee of $600,000, along with other fees that may be assessed during the term of the loan. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the loan transaction, the Company paid legal and professional costs directly in connection to the debt financing in the amount of $50,000 in cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total costs directly in connection to the debt financing in the amount of $193,437 (professional fee $48,484; lender's origination fee, due diligence fee, and other expenses in the amount of $144,953) was deducted from the gross proceeds in the amount of $12,000,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also repaid $1,574,068 of existing short-term loan and promissory notes and relevant accrued interests by using the proceeds from the loan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total costs directly in connection to the loan and fair value of warrants was in the amount of $1,042,149. And such costs were accounted as debt discount, and amortized using the effective interest method. The amortization of such debt discount was included in the accretion and amortization expenses. For the three and six months ended September 30, 2024, the amortization of debt discount expense was $52,627 and $104,458 respectively. For the three and six months ended September 30, 2023, the amortization of debt discount expense was $51,724 and $102,666, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During November 2022, unpaid interest of $364,000 was added to the outstanding principal balance, since then interest onwards would be calculated on the updated principal balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total interest expense on the term loan for the three and six months ended September 30, 2024, amounted to $495,783 and $987,135, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had accrued interest payable of $1,107,791 and $795,656, respectively, as of September 30, 2024, and March 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and Lender also entered into a Guarantee and Collateral Agreement ("Collateral Agreement") wherein the Company agreed to secure the Credit Agreement with all of the Company's assets. The Company and Lender also entered into an Intellectual Property Security Agreement dated December 21, 2021 (the "IP Security Agreement") wherein the Credit Agreement is also secured by the Company's right title and interest in the Company's Intellectual Property.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Credit Agreement, the Company issued 57,536 warrants to the Lender, which were fair-valued at $198,713 at issuance (Note 9). The warrants are accounted as part of the debt discount as well as a credit into additional paid-in capital and amortized using the effective interest method.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2024, the Company was not in compliance with certain covenants of the term loan, for which it sought and received relief from the term loan lender.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BIOTRICITY INC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SEPTEMBER 30, 2024 (Unaudited)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Expressed in US dollars)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 1240000020026-12-210.1052022-02-15Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. The Company and the Lender have negotiated the terms under which the Company will be allowed to extend the interest-only period and delay the start of principal repayment.240000060000030000024000001200006000005000019343748484144953120000001574068104214952627104458517241026663640004957839871351107791795(<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. FEDERALLY GUARANTEED LOAN</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Economic Injury Disaster Loan ("EIDL")</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2020, the Company received $370,900 from the U.S. Small Business Administration (SBA) under the captioned program. The loan has a term of 30 years and an interest rate of 3.75% per annum, without the requirement for payment in the first 12 months. The Company may prepay the loan without penalty at will.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the Company received an additional $499,900 from the SBA under the same terms.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, and March 31, 2024, the Company recorded accrued interest of $7,889 and $26,497, respectively, for the EIDL loan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expense on the above loan was $<span id="xdx_903_eus-gaap--InterestExpense_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--EconomicInjuryDisasterLoanMember_z0WUfrRSfWYi"

title="Interest expense">8,231 and $16,372 for the three and six months ended September 30, 2024, respectively, and $8,230 and $16,372 for the three and six months ended September 30, 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 370900The loan has a term of 30 years and an interest rate of 3.75% per annum, without the requirement for payment in the first 12 months.P30Y0.037549990078892649782311637282303 16372<p id="xdx_808_eus-gaap--DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_zhowbNCSyhN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. DERIVATIVE LIABILITIES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company analyzed the compound features of variable conversion and redemption embedded in the preferred shares instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force ("EITF") Issue No. 00-19 and EITF 07-05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value. A roll-forward of activity is presented below for the six months ended September 30, 2024 and 2023:</p> <p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zN0mOP39NJb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> SCHEDULE OF DERIVATIVE LIABILITIES </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240401__20240930_z0BAsbJ84sw2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230401__20230930_zMgvAker92Ri" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">$</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zBv8fjRUV33h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; font-style: italic">Derivative liabilities, beginning of period - March 31</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,435,668</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">759,065</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue_zJuY6j7bSR72" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New issuance [Note 9]</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">649,533</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">642,416</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zUImDVpRIZZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Change in fair value of derivatives during period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">533,126</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(50,033</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--ReductionDueToPreferredSharesConverted_z22nCNYeunml" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Reduction due to preferred shares converted [Note 9]</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(969,150</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConversionOfStockAmountConverted1_iN_di_zp9N7jWB1Tx" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Conversion to common shares</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DerivativeTreatment_zYKb5GhnWsxk" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">End of derivative treatment of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ConversionOfStockAmountModification_zzgti6ucM7Df" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible note modification</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ConversionOfStockAmountRedemption_zFNDihl2XQV3" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible note redemption</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zNjv3heXOhw4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Derivative liabilities, end of period</td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,649,177</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,351,448</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The lattice methodology was used to value the derivative components of Series A Preferred Stock, using the following assumptions during the six months ended September 30, 2024, and 2023:   SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> September 30, 2024 </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> September 30, 2023 </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Dividend yield (%)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjBFEF076g9" title="Derivative liability, measurement input">12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z03Ib3sqAdP4" title="Derivative liability, measurement input">12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate for term (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwtXMbE8dbr7" title="Derivative liability, measurement input">4.1 - <span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zff0NFFgOqZk" title="Derivative liability, measurement input">5.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhokOvIV2u4k" title="Derivative liability, measurement input">4.9 - <span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zL7ReLcNUb2" title="Derivative liability, measurement input">5.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zf2X0Xah5qKg" title="Derivative liability, measurement input">91.2 - <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrOT8B1UbQve" title="Derivative liability, measurement input">132.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHbKKnhhIe42" title="Derivative liability, measurement input">71.9 - <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGz57OZwmAek" title="Derivative liability, measurement input">111.4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSxs5WKd0fw2" title="Derivative liability

remaining term">0.67 - <span id="xdx_90B_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwBP2mWUV8K1" title="Derivative liability remaining term">1.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFWVeIuG6yKh" title="Derivative liability remaining term">0.34 - <span id="xdx_90F_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zl8gcN1Nsnm9" title="Derivative liability remaining term">2.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--DerivativeStockPrice_iI_pid_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_z3FGHUBXpD8b" title="Stock price">0.24 - <span id="xdx_90B_ecustom--DerivativeStockPrice_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zLpGSzRyV7b9" title="Stock price">1.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeStockPrice_iI_pid_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zSNm0xML3oie" title="Stock price">2.14 - <span id="xdx_900_ecustom--DerivativeStockPrice_iI_pid_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_ztwF67UJxQ75" title="Stock price">3.82</td><td style="text-align: left"> </td></tr> </table>   The Monte Carlo simulation methodology was used to value the derivative components of Series B Preferred Stock, using the following assumptions during the six months ended September 30, 2024:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> September 30, 2024 </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> September 30, 2023 </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Dividend yield (%)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKodP0gNqUAg" title="Derivative liability, measurement input">12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfVTw1gVNC6e" title="Derivative liability, measurement input">12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate for term (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z5i4fHeoP8te" title="Derivative liability, measurement input">3.7 - <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zm1UnUxk2uZg" title="Derivative liability, measurement input">5.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zOXHbQILPTN3" title="Derivative liability, measurement input">5.04 - <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPi3leMARqUi" title="Derivative liability, measurement input">5.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zhfwle4rtfXl" title="Derivative liability, measurement input">126.4 - <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLKQQplsGZZf" title="Derivative liability, measurement input">182.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ziSErndNB5F1" title="Derivative liability, measurement input">76.2 - <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zqYitRynhux6" title="Derivative liability, measurement input">119.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6RH38Zh1mW4" title="Derivative liability remaining term">0.97 - <span id="xdx_909_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zztme631rep8" title="Derivative liability remaining term">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfZVep7bUSre" title="Derivative liability remaining term">0.25 - <span id="xdx_909_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlFu0QaOAShe" title="Derivative liability remaining term">0.5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> <span id="xdx_908_ecustom--DerivativeStockPrice_iI_pid_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zvnb7NIioAuh" title="Stock price">0.24 - <span id="xdx_90B_ecustom--DerivativeStockPrice_iI_pid_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zoO32PhKncjg" title="Stock price">1.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--DerivativeStockPrice_iI_pid_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRHSoKg6F6C2" title="Stock price">0.64 - <span id="xdx_907_ecustom--DerivativeStockPrice_iI_pid_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1RmtKgCMChf" title="Stock price">2.14</td><td style="text-align: left"> </td></tr> </table>   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   In addition, the Company recorded derivative liabilities related to the conversion and redemption features of the convertible notes, as well as warrants that were issued in connection with the convertible notes (Note 5). Any noteholder and placement agent warrants that were issued after the finalization of exercise price was accounted for as equity. A roll-forward of activity is presented below for the six months ended September 30, 2024, and 2023: <p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zGG9qNLh96tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240401__20240930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZvyFYnKEis3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230401__20230930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zvvb3i3gY7Z7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zViyTkYrweoa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; font-style: italic">Balance beginning of period – March 31</td><td style="width: 2%"> </td> <td style="width:

1%; text-align: left"> </td><td style="width: 16%; text-align: right">991,866</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,008,216</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue_zU8kP6aXMKid" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New Issuance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,942,004</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConversionOfStockAmountConverted1_iN_di_zDRm3iuWTP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion to common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(490,972</td> <td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zeFIeElFm4E" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(32,515</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(32,635</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--ConversionOfStockAmountRedemption_zlWlTFUt2pW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Convertible note redemption</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,320</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(33,607</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zMHpP9fejU6e" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance end of period – September 30</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">460,059</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,883,978</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <p id="xdx_896_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zORjfG8E3oW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the six months ended September 30, 2024, and 2023, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">September 30, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">September 30, 2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Risk-free rate for term (%)</td><td style="width: 2%"> </td> <td style="width: 28%; text-align: right"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zkUcx7djHRKa" title="Derivative liability, measurement input">4.1 - <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zxPWbGXE2Afb" title="Derivative liability, measurement input">5.2</td><td style="width: 2%"> </td> <td style="width: 28%; text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTXiELTNM2Kf" title="Derivative liability, measurement input">4.2 - <span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zd30O3NkyYLa" title="Derivative liability, measurement input">5.3</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility (%)</td><td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zE352CgY60Nh" title="Derivative liability, measurement input">91.2 - <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zG1Vn0dvw2Fl" title="Derivative liability, measurement input">352.4</td><td> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zYDtRK3SIcmf" title="Derivative liability, measurement input">76.2 - <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ztOd81a1zHi4" title="Derivative liability, measurement input">126.6</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: right"><span id="xdx_90B_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zvbYatX6EUzd" title="Remaining terms">0.25 - <span id="xdx_90C_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z3198FILIY4a" title="Remaining terms">0.5</td><td> </td> <td style="text-align: right"><span id="xdx_90A_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zg8SbwE5JXz6" title="Remaining terms">0.25 - <span id="xdx_908_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuP4fuNdGgZh" title="Remaining terms">1.49</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: right"><span id="xdx_903_ecustom--DerivativeStockPrice_iI_pid_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zxnvFt10ItB4" title="Stock price">0.24 - <span id="xdx_905_ecustom--DerivativeStockPrice_iI_pid_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXJtScIi3V9d" title="Stock price">1.45</td><td> </td> <td style="text-align: right"><span id="xdx_90E_ecustom--DerivativeStockPrice_iI_pid_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zrPAVDPzhuxa" title="Stock price">0.46 - <span id="xdx_90F_ecustom--DerivativeStockPrice_iI_pid_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zOd5cd3waERi" title="Stock price">3.04</td></tr> </table>   SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td colspan="2" id="xdx_493_20240401__20240930_z0BAsbJ84sw2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230401__20230930_zMgvAker92Ri" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">$</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zBv8fjRUV33h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; font-style: italic">Derivative liabilities, beginning of period - March 31</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,435,668</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">759,065</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue_zJuY6j7bSR72" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New issuance [Note 9]</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">649,533</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 642,416 </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zU1mDVpRIZZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Change in fair value of derivatives during period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">533,126</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(50,033</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--ReductionDueToPreferredSharesConverted_z22nCNYeunml" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Reduction due to preferred shares converted [Note 9]</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(969,150</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConversionOfStockAmountConverted1_iN_di_zp9N7jWB1Tx" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Conversion to common shares</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DerivativeTreatment_zYKb5GhnWsxk" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">End of derivative treatment of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ConversionOfStockAmountModification_zzgti6ucM7Df" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom:

1.5pt">Convertible note modification</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ConversionOfStockAmountRedemption_zFNBihl2XQV3" style="display: none; vertical-align: bottom; background-color: White"><td style="text-align: left; padding-bottom: 1.5pt">Convertible note redemption</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zNjv3heXOhw4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Derivative liabilities, end of period</td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,649,177</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,351,448</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1435668759065649533642416533126-50033-9691501649171351448 The lattice methodology was used to value the derivative components of Series A Preferred Stock, using the following assumptions during the six months ended September 30, 2024, and 2023:   SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> September 30, 2024 </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> September 30, 2023 </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Dividend yield (%)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjBFEF076g9" title="Derivative liability, measurement input">12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z03Ib3sqAdP4" title="Derivative liability, measurement input">12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate for term (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwtXMbE8dbr7" title="Derivative liability, measurement input">4.1 - <span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zff0NFFgOqZk" title="Derivative liability, measurement input">5.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhokOvIV2u4k" title="Derivative liability, measurement input">4.9 - <span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zL7ReLcNUb2" title="Derivative liability, measurement input">5.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zf2X0Xah5qKg" title="Derivative liability, measurement input">91.2 - <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrOT8B1UbQve" title="Derivative liability, measurement input">132.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHbKKnhhIe42" title="Derivative liability, measurement input">71.9 - <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGz57OZwmAek" title="Derivative liability, measurement input">111.4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSxs5WKd0fw2" title="Derivative liability remaining term">0.67 - <span id="xdx_90B_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwBP2mWUV8K1" title="Derivative liability remaining term">1.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFWVeIuG6yKh" title="Derivative liability remaining term">0.34 - <span id="xdx_90F_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zl8gcN1Nsnm9" title="Derivative liability remaining term">2.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--DerivativeStockPrice_iI_pid_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_z3FGHUBXpD8b" title="Stock price">0.24 - <span id="xdx_90B_ecustom--DerivativeStockPrice_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zLpGSzRyV7b9" title="Stock price">1.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeStockPrice_iI_pid_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zSNm0xML3oie" title="Stock price">2.14 - <span id="xdx_900_ecustom--DerivativeStockPrice_iI_pid_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_ztwF67UjxQ75" title="Stock price">3.82</td><td style="text-align: left"> </td></tr> </table>   The Monte Carlo simulation methodology was used to value the derivative components of Series B Preferred Stock, using the following assumptions during the six months ended September 30, 2024:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> September 30, 2024 </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> September 30, 2023 </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Dividend yield (%)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKodP0gNqUAg" title="Derivative liability, measurement input">12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfVTw1gVNC6e" title="Derivative liability, measurement input">12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate for term (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z5i4fHeoP8te" title="Derivative liability, measurement input">3.7 - <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zm1UnUxk2uZg" title="Derivative liability, measurement input">5.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zOXHbQILPTN3" title="Derivative liability, measurement input">5.04 - <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPi3IeMARqUi" title="Derivative liability, measurement input">5.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zhfwle4rtfXl" title="Derivative liability, measurement input">126.4 - <span id="xdx_90A_eus-gaap--

DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLKQOplsGZZf" title="Derivative liability, measurement input">182.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ziSErndNB5F1" title="Derivative liability, measurement input">76.2 - <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zqYitRynhux6" title="Derivative liability, measurement input">119.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6RH38Zh1mW4" title="Derivative liability remaining term">0.97 - <span id="xdx_909_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zztme631rep8" title="Derivative liability remaining term">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfZVep7bUSre" title="Derivative liability remaining term">0.25 - <span id="xdx_909_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlFu0QaOAShe" title="Derivative liability remaining term">0.5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--DerivativeStockPrice_iI_pid_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zvnb7NlioAuh" title="Stock price">0.24 - <span id="xdx_90B_ecustom--DerivativeStockPrice_iI_pid_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zoQ32PhKncjg" title="Stock price">1.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--DerivativeStockPrice_iI_pid_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRHSoKg6F6C2" title="Stock price">0.64 - <span id="xdx_907_ecustom--DerivativeStockPrice_iI_pid_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1RmtKgCMChf" title="Stock price">2.14</td><td style="text-align: left"> </td></tr> </table>

12124.15.14.95.291.2132.571.9111.4P0Y8M1DP1Y7M2DP0Y4M2DP2Y3D0.241.142.143.8212123.75.15.045.24126.4182.276.2119.1P0Y11M19DP2YP0Y3MP0Y6M0.241.340.642.

id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zGG9qNLh96tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> SCHEDULE OF DERIVATIVE LIABILITIES   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240401__20240930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZvyFYnKEis3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230401__20230930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zvvb3i3gY7Z7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValue_iS_zViyTkYrweoa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; font-style: italic">Balance beginning of period – March 31</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">991,866</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,008,216</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue_zU8kP6aXMKid" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New Issuance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,942,004</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConversionOfStockAmountConverted1_iN_di_zDRm3iuWTP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion to common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(490,972</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zeFIeEIFm4E" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(32,515</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(32,635</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--ConversionOfStockAmountRedemption_zlWlTFUt2pWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Convertible note redemption</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,320</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(33,607</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zMHpP9feJ0Ge" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance end of period – September 30</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">460,059</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,883,978</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <p id="xdx_896_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zQRjfG8E3oW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the six months ended September 30, 2024, and 2023, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">September 30, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">September 30, 2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Risk-free rate for term (%)</td><td style="width: 2%"> </td> <td style="width: 28%; text-align: right"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zkUcx7djHRKa" title="Derivative liability, measurement input">4.1 - <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zxPWbGXE2Afb" title="Derivative liability, measurement input">5.2</td><td style="width: 2%"> </td> <td style="width: 28%; text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTXiELTNM2Kf" title="Derivative liability, measurement input">4.2 - <span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zd30O3NkvYLa" title="Derivative liability, measurement input">5.3</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility (%)</td><td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zE352CgY60Nh" title="Derivative liability, measurement input">91.2 - <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zG1Vn0dvw2Fl" title="Derivative liability, measurement input">352.4</td><td> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zYDtRK3SIcmf" title="Derivative liability, measurement input">76.2 - <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ztOd81a1zHi4" title="Derivative liability, measurement input">126.6</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: right"><span id="xdx_90B_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zvbYatX6EUzd" title="Remaining terms">0.25 - <span id="xdx_90C_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z3198FILIY4a" title="Remaining terms">0.5</td><td> </td> <td style="text-align: right"><span id="xdx_90A_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zg8SbwE5fXz6" title="Remaining terms">0.25 - <span id="xdx_908_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--

DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuP4fuNdGgZh" title="Remaining terms">1.49</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: right"><span id="xdx_903_ecustom--DerivativeStockPrice_iI_pid_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zxnvFt10ItB4" title="Stock price">0.24 - <span id="xdx_905_ecustom--DerivativeStockPrice_iI_pid_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXJtScIi3Y9d" title="Stock price">1.45</td><td> </td> <td style="text-align: right"><span id="xdx_90E_ecustom--DerivativeStockPrice_iI_pid_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zrPAVDPzhuxa" title="Stock price">0.46 - <span id="xdx_90F_ecustom--DerivativeStockPrice_iI_pid_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zOd5cd3waERi" title="Stock price">3.04</td></tr> </table>
<p id="xdx_896_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zQRjfG8E3oW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the six months ended September 30, 2024, and 2023, using the following assumptions:</p>

	September 30, 2024	September 30, 2023
Risk-free rate for term (%)	4.1 - 5.2	3.54 - 4.2
Volatility (%)	91.2 - 352.4	76.2 - 126.6
Remaining terms (Years)	0.25 - 0.5	0.25 - 0.5
Stock price ($ per share)	0.24 - 1.49	0.46 - 3.04

4.15.24.25.391.2352.476.2126.6P0Y3MP0Y6MP0Y3MP1Y5M26D0.241.450.463.04

STOCKHOLDERS' DEFICIENCY

(a) Authorized and Issued Stock

As at September 30, 2024, the Company is authorized to issue 125,000,000 (March 31, 2024 - 125,000,000) shares of common stock ($0.001 par value), and 10,000,000 (March 31, 2024 - 10,000,000) shares of preferred stock ($0.001 par value), comprised of 20,000 (March 31, 2024 - 20,000) shares designated shares of Series A preferred stock and 600 (March 31, 2024 - 600) shares designated shares of Series B preferred stock.

At September 30, 2024, common shares and shares directly exchangeable into equivalent common shares that were issued and outstanding were 23,023,933 (March 31, 2024 - 9,514,440) shares; these were comprised of 22,863,261 (March 31, 2024 - 9,353,768) shares of common stock and 160,672 (March 31, 2024 - 160,672) exchangeable shares. At September 30, 2024, there were 6,304 (March 31, 2024 - 6,304) shares of Series A Preferred Stock issued and outstanding (March 31, 2024 - 0) shares of Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement as

at September 30, 2024, and March 31, 2024.   (b) Series (A) Preferred Stock   The number of Series A Preferred Stock issued and outstanding as of September 30, 2024, and 2023 was <span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z6Wgn0AROjN1" title="Preferred stock, shares outstanding">200 and <span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zySjFEtsxJxd" title="Preferred stock, shares outstanding">6,304, respectively.   The Series A Preferred Stock is junior to the Company's existing undesignated preferred stock, and unless otherwise set forth in the applicable certificate of designations, shall be junior to any future issuance of preferred stock. The purchase price (the "Purchase Price") for the Series A Preferred Stock to date has been $<span id="xdx_907_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcHmTgU39jci" title="Preferred stock, liquidation preference">1,000 per share. Except as otherwise expressly required by law, the Series A Preferred Stock does not have voting rights and does not have any liquidation rights.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   Preferred Stock Dividends   Dividends shall be paid at the rate of <span id="xdx_909_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ze2xMwyLjdv4" title="Preferred stock dividend rate percentage">12% per annum of the amount of the Series A Preferred Stockholder's (the "Holder") Purchase Price. Dividends shall be paid quarterly unless the Holder and the Company mutually agree to accrue and defer any such dividend.   Conversion   The Series A Preferred Stock is convertible into shares of common stock commencing 24 months after the issuance date of the Series A Preferred Stock; on a monthly basis, up to <span id="xdx_90C_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zPFrO0xjYzIg" title="Debt instrument redemption price percentage">5% of the aggregate amount of the Purchase Price can be converted (subject to adjustment for changes in the Holder's ownership of the underlying Series A Preferred Stock) subsequent to that issuance anniversary. The conversion price is equal to the greater of $0.001 or a 15% discount to the volume-weighted average price ("VWAP") of the Company's common stock five Trading Days immediately prior to the conversion date (the "Conversion Rate). Additionally, subject to certain provisions, the Holder may exchange its Series A Preferred Stock into any common stock financing being conducted by the Company at a 15% discount to the pricing of that financing.   Other Adjustments and Rights   ● The Conversion Rate (and shares issuable upon conversion of the Series A Preferred Stock) will be appropriately adjusted to reflect stock splits, stock dividends business combinations and similar recapitalization.   ● The Holders shall be entitled to a proportionate share of certain qualifying distributions on the same basis as if they were holders of the Company's common stock on an as converted basis.   Company Redemption   The Company may redeem all or part of the outstanding Series A Preferred Stock after one year from the date of issuance by paying an amount equal to the aggregate Purchase Price paid, adjusted for any reduction in Series A Preferred Stock holdings, multiplied by 110% plus accrued dividends.   During the six months ended September 30, 2024, $6,104,444 of Series A Preferred Stock (face value) and $1,071,542 relevant accrued dividend were converted into 8,952,170 common shares. The conversion was accounted as an extinguishment and the difference between the total carrying value of the preferred shares converted, derivative liabilities derecognized and unpaid dividend at the time of conversion ($<span id="xdx_903_eus-gaap--DepositLiabilitiesAccruedInterest_iI_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8sO4RzoLPv6" title="Deposit liabilities, accrued interest">7,984,463), and the fair value of the common shares issued ($<span id="xdx_90B_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLnS3jtBnfU6" title="Stock redeemed or called during period, value">11,039,142), was $<span id="xdx_907_eus-gaap--InvestmentCompanyDividendDistribution_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7BtGHq6HO2c" title="Investment company, dividend distribution">3,054,679 and was recognized as a deemed dividend expense.   (c) Series B Preferred Stock and Mezzanine Equity   On September 19, 2023, the Company entered into a security purchase agreement (the "Purchase Agreement") with an institutional investor (the "Investor") for the issuance and sale of 220 shares of the Company's newly designated Series B Convertible Preferred Stock, at a purchase price of $<span id="xdx_905_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zw3KwFLTx7Mi" title="Preferred stock redemption price per share">9,091 per share of Preferred Stock, and after accounted for other issuance related costs, the net proceeds received was in the amount of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20230918__20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zp4z3AzFN7l1" title="Proceeds from issuance of preferred stock and preference stock">1,900,000.   During the three months ended March 31, 2024, a further <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zkem1PApjj9h" title="Stock issued during period">110 Series B preferred shares were issued for net proceeds of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z2KiGA1Bhtjj" title="Stock issued during period, value">925,000. During the three and six months ended September 30, 2024, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240701__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z49DZHnYXuMd" title="Stock issued during period">55 and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zKVo4MqNb3c6" title="Stock issued during period">220 Series B preferred shares were issued for net proceeds of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240701__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_ztj4vkGNvrs1" title="Stock issued during period, value">420,000 and $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z4Zubh8rWeD" title="Stock issued during period, value">1,732,532, respectively.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited)

(Expressed in US dollars)   Pursuant to the initial Purchase Agreement, on September 19, 2023, the Company filed a certificate of designations of Series B Convertible Preferred Stock (the “Certificate of Designations”) with the Nevada Secretary of State designating <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z0xYEo1IT6o6" title="Preferred stock, shares issued">600 shares of the Company’s shares of Preferred Stock as Series B Convertible Preferred Stock and setting forth the voting and other powers, preferences and relative, participating, optional or other rights of the Preferred Shares. Each share of Series B Preferred Stock has a stated value of $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ztjVRqqGoA08" title="Preferred stock convertible conversion price">10,000 per share.   The Series B Preferred Stock, with respect to the payment of dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company, ranks senior to all capital stock of the Company unless the holders of the majority of the outstanding shares of Series B Preferred Stock consent to the creation of other capital stock of the Company that is senior or equal in rank to the Series B Preferred Stock.   Holders of Series B Preferred Stock will be entitled to receive cumulative dividends (“Dividends”), in shares of common stock or cash on the stated value at an annual rate of <span id="xdx_90F_ecustom--StatedValuePercentage_iI_pid_dp_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zniNk22FocVc" title="Stated value percentage">8% (which will increase to <span id="xdx_90A_ecustom--StatedValuePercentage_iI_pid_dp_uPure_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_z3TWEXdxE9W8" title="Stated value percentage">15% if a Triggering Event (as defined in the Certificate of Designations) occurs. Dividends will be payable upon conversion of the Series B Preferred Stock, upon any redemption, or upon any required payment upon any Bankruptcy Triggering Event (as defined in the Certificate of Designations).   Holders of Series B Preferred Stock will be entitled to convert shares of Series B Preferred Stock into a number of shares of common stock determined by dividing the stated value (plus any accrued but unpaid dividends and other amounts due) by the conversion price. The initial conversion price is $3.50, subject to adjustment in the event the Company sells common stock at a price lower than the then-effective conversion price. Holders may not convert the Series B Preferred Stock to the extent such conversion would cause such holder’s beneficial ownership of common stock to exceed <span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_c20230919__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--OwnershipAxis__custom--BeneficiaryMember_zNbpleyBpbLb" title="Ownership percentage">4.99% of the outstanding common stock. In addition, the Company will not issue shares of common stock upon conversion of the Series B Preferred Stock in an amount exceeding <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--OwnershipAxis__custom--BeneficiaryMember_ztJAMNzJldXb" title="Ownership percentage">19.9% of the outstanding common stock as of the initial issuance date unless the Company receives shareholder approval for such issuances.   Holders may elect to convert shares of Series B Preferred Stock to common stock at an alternate conversion price equal to 80% (or 70% if the Company’s common stock is suspended from trading on or delisted from a principal trading market or if the Company has effected a reverse split of the common stock) of the lowest daily volume weighed average price of the common stock during the Alternate Conversion Measuring Period (as defined in the Certificate of Designations). In the event the Company receives a conversion notice that elects an alternate conversion price, the Company may, at its option, elect to satisfy its obligation under such conversion with payment in cash in an amount equal to 110% of the conversion amount.   The Series B Preferred Stock will automatically convert to common stock upon the 24-month anniversary of the initial issuance date of the Series B Preferred Stock.   At any time after the earlier of a holder’s receipt of a Triggering Event notice and such holder becoming aware of a Triggering Event and ending on the 20th trading day after the later of (x) the date such Triggering Event is cured and (y) such holder’s receipt of a Triggering Event notice, such holder may require the Company to redeem such holder’s shares of Series B Preferred Stock.   Upon any Bankruptcy Triggering Event (as defined in the Certificate of Designations), the Company will be required to immediately redeem all of the outstanding shares of Series B Preferred Stock.   The Company will have the right at any time to redeem all or any portion of the Series B Preferred Stock then outstanding at a price equal to <span id="xdx_902_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20240401__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zTrEcn2QWo2l" title="Debt instrument redemption price percentage">110% of the stated value plus any accrued but unpaid dividends and other amounts due.   Holders of the Series B Preferred Stock will have the right to vote on an as-converted basis with the common stock, subject to the beneficial ownership limitation set forth in the Certificate of Designations.   The Series B Preferred Stock was accounted for as Mezzanine Equity in accordance with ASC 480 - Distinguishing Liabilities from Equity and the embedded conversion and redemption features was separated from the host instrument and recognized as derivative liabilities with change in fair value at each reporting period end recognized in the consolidated statement of operations and comprehensive loss. (Note 8).   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   During the three months ended December 31, 2023, <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKNKLC18aDJ5" title="Stock issued during period shares conversion of convertible securities">40 Series B preferred shares and dividends accrued thereon were converted into <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z67xuBSPto5g" title="Number of shares convertible securities">612,062 common shares. As a result of the conversion, the Company reduced the book value of mezzanine equity by $228,727 and reduced its accrued dividends liability by $16,789. The Company also reduced the fair value of derivative liabilities by $<span id="xdx_90E_ecustom--ReductionDueToPreferredSharesRedeemed_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTG26NXrBrVi" title="Fair value of derivative liabilities">119,359 related to the shares converted. The Company recognized corresponding credits to common share par value and paid in capital.   During the three months ended March 31, 2024, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmOlb7QQKSUl" title="Stock issued during period shares conversion of convertible securities">25 Series B preferred shares and dividends accrued thereon were converted into <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl6399Vtq7d3" title="Number of shares convertible securities">320,321 to be issued common shares. As a result of the conversion, the Company reduced the book value of mezzanine equity by $142,907. The Company also reduced the fair value of derivative liabilities related to the shares converted by $75,523. The Company recognized corresponding credits to be issued common share par value and paid in capital.   During the three and six months ended September 30, 2024, 25 and 50 Series B preferred shares and dividends accrued thereon were converted into 1,091,063 and 1,436,267 common shares, respectively. As a result of the conversion, the Company reduced the book value of mezzanine equity by $142,907 and $285,814 and reduced its accrued dividends liability by $<span id="xdx_904_eus-gaap--

TemporaryEquityDividendsAdjustment_c20240701__20240930_zMtuiigMrBd9" title="Reduced accrued dividends liability">16,219 and $28,438 during the three and six months ended September 30, 2024, respectively. The Company also reduced the fair value of derivative liabilities by $84,076 and $160,672 related to the shares converted during the three and six months ended September 30, 2024, respectively. The Company recognized corresponding credits to common share par value and paid in capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_892_ecustom--ScheduleOfSeriesBPreferredStockForMezzanineEquityTableTextBlock_zLLgD1kAbsHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A roll-forward of activity is presented below for the six months ended September 30, 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240401__20240930_zhkhqlchBpec" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Fiscal Year</p> <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_494_20230401__20230930_zyC4PDvaHylj" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Fiscal Year</p> <p style="margin-top: 0; margin-bottom: 0">2024</p></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">$</td></tr> <tr id="xdx_40B_ecustom--ConvertiblePreferredStock_iS_zQvCWcEYdrN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold; font-style: italic">Balance beginning of period – March 31</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,488,920</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 14%">—</td> <td style="width: 1%"> </td></tr> <tr id="xdx_408_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_zKHO6HcsQktk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net proceeds received pursuant to the issuance of preferred shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,732,532</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"> 1,900,000 </td> <td> </td></tr> <tr id="xdx_405_ecustom--ChangeInFairValueusMeasurementWithReconciliationRecurringBasisLiability_zQ5ktNX8d514" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Recognition of derivative liabilities (Note 8)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(649,533</td><td style="text-align: left">)</td> <td> </td> <td> </td> <td style="text-align: right">(642,416</td> <td>) </td></tr> <tr id="xdx_400_ecustom--ConversionIntoCommonShares_zMfMRoKBrBC7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Conversion into common shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(285,814</td><td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> — </td> <td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_407_ecustom--ConvertiblePreferredStock_iE_zScKYWta4524" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance end of period – September 30</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,286,105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"> 1,257,584 </td> <td style="padding-bottom: 2.5pt"> </td></tr></table>   (d) Share issuances   Share issuances during the six months ended September 30, 2024   During the three and six months ended September 30, 2024, the Company issued <span id="xdx_901_ecustom--IssuanceOfCommonSharesFromSharesToBeIssued_c20240401__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleNoteMember_zo4LgMUhNWV6" title="Issuance of common shares from shares to be issued">287,802 common shares to Series C Convertible Note holders, in relation to shares to be issued obligation as of June 30, 2024, for Series C Convertible Note conversions.   During the three and six months ended September 30, 2024, the Company issued <span id="xdx_90F_ecustom--IssuanceOfCommonSharesFromSharesToBeIssued_dxL_c20240701__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zA8l687hTqvj" title="Issuance of common shares from shares to be issued::XDX::-">nil and <span id="xdx_90D_ecustom--IssuanceOfCommonSharesFromSharesToBeIssued_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zhiGUglARqd2" title="Issuance of common shares from shares to be issued">320,321 common shares to Series B preferred shareholders, respectively, in relation to shares to be issued obligation as of March 2024 for Series B preferred share conversions. During the three and six months ended September 30, 2024, the Company issued another <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240701__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyftuKeMotlg" title="Conversion of mezzanine equity into common shares">1,091,063 and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z5c0PqtGi7ag" title="Conversion of mezzanine equity into common shares">1,436,267 common shares to Series B preferred shareholders for an additional request to convert 25 and 50 Series B preferred shares, respectively (Note 9(c)).   During the three and six months ended September 30, 2024, convertible notes with a face value of $45,000 and $1,432,700, respectively, were converted into 121,043 and 1,753,554 common shares, respectively. As of September 30, 2024, 121,043 shares are recognized as an obligation for shares to be issued relating to the conversion. The fair value of common shares issued during the three and six months ended September 30, 2024, is $74,618 and $2,283,216, respectively, and is determined based on market price upon conversion. Total value of debt settled is in the amount of $68,167 and $2,145,929, respectively, which consisted of the face value of notes converted, accrued interest of $7,810 and $222,257, respectively, and relevant derivative liability of $15,357 and $490,972, respectively. The Company recognized a loss upon conversion of $6,451 and $137,287, respectively, representing the difference between the value of debt settled and fair value of shares issued and to be issued. (Note 5).   During the six months ended September 30, 2024, $6,104,444 of Series A Preferred Stock (face value) and $1,071,542 relevant accrued dividend were converted into 8,952,170 common shares. The conversion was accounted as an extinguishment and the difference between the total carrying value of the preferred shares converted, derivative liabilities derecognized and unpaid dividend at the time of conversion ($<span id="xdx_909_eus-gaap--DepositLiabilitiesAccruedInterest_iI_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziYx4f0knUT6" title="Deposit liabilities, accrued interest">7,984,463), and the fair value of the common shares issued ($<span id="xdx_90F_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zEtLcW9vKHOg" title="Stock redeemed or called during period, value">11,039,142) was $<span id="xdx_907_eus-gaap--InvestmentCompanyDividendDistribution_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZNZPq0gcQrk" title="Investment company, dividend distribution">3,054,679 and was recognized as deemed dividend expense.   The Company issued <span

id="xdx_904_ecustom--IssuanceOfSharesForSettlementOfAccountsPayable_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztOMwtpUysK3" title="Issuance of shares for settlement of accounts payable">1,000,413 common shares in settlement of $<span id="xdx_908_ecustom--IssuanceOfSharesForSettlementOfAccountsPayableValue_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpLBTZeMByn8" title="Issuance of shares for settlement of accounts payable, value">741,316 in amount due to a shareholder which was part of the accounts payable. The Company recognized a loss upon debt extinguishment of $249,093, which was the difference between the accounts payable settled and the fair value of common shares issued. The loss was included as part of the other income (expense) in the Condensed Consolidated Statement of Operations and Comprehensive Loss.   The Company issued 97,811 common shares for net proceeds of $125,227 pursuant to a registration statement filed on May 15, 2024.   In addition, during the six months ended September 30, 2024, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240401__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgC7JzGaJsca" title="Common shares services">70,000 common shares for services received with a fair value of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240401__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zK3zU3F54aYb" title="Issuance of warrants">53,480 which was recognized as a general and administrative expense with a corresponding credit to additional paid-in capital.   Share issuances during the six months ended September 30, 2023   The Company sold 36,897 common shares through use of its registration statement, for gross proceeds of $123,347, raising a net amount of $119,285 after paying for a 3% placement fee and other issuance expenses. In addition, 20,846 shares of common stock were issued to existing holders as a result of make whole provisions associated with the Reverse Split.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   (e) Shares to be issued   Activity during the six months ended September 30, 2024   During the three months ended September 30, 2024, the Company issued <span id="xdx_90A_ecustom--IssuanceOfCommonSharesFromSharesToBeIssued_c20240401__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleNoteMember_zyGPyT40BSK8" title="Issuance of common shares from shares to be issued">287,802 common shares to Series C Convertible Note holders, in relation to shares to be issued obligation as of June 30, 2024, for Series C Convertible Note conversions.   During the six months ended September 30, 2024, the Company issued <span id="xdx_907_ecustom--IssuanceOfCommonSharesFromSharesToBeIssued_c20240401__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrRrOt9sKaO" title="Issuance of common shares from shares to be issued">320,321 common shares to Series B preferred shareholders in relation to shares to be issued obligation as of March 31, 2024, for Series B preferred share conversions.   During the three and six months ended September 30, 2024, convertible notes with a face value of $45,000 and $1,432,700, respectively, were converted into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_zRLXpjVVJ36" title="Converted instrument shares issued">121,043 and <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240401__20240930__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_zJBTNGNMGXck" title="Converted instrument shares issued">1,753,554 common shares, respectively. As of September 30, 2024, <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_ziKDZSR1Z4t3" title="Converted instrument shares issued">121,043 shares are recognized as an obligation for shares to be issued relating to the conversion.   During the three and six months ended September 30, 2024, the Company recorded the obligation for <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--SharesToBeIssuedMember_zD3imrmQZhNg" title="Issuance of shares for services">40,000 and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__custom--SharesToBeIssuedMember_zEHL9XoCO0L1" title="Issuance of shares for services">50,000 shares to be issued with a fair value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--SharesToBeIssuedMember_zTIh9TDrVWL7" title="Shares to be issued with fair value">20,000 and $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pid_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__custom--SharesToBeIssuedMember_zeWYeoV2PMsi" title="Shares to be issued with fair value">27,640 which was recognized as general and administrative expenses.   Activity during the six months ended September 30, 2023   None.   (f) Warrant issuances, exercises and other activity   Warrant exercises and issuances during the six months ended September 30, 2024   None.   Warrant exercises and issuances during the six months ended September 30, 2023   None.   Warrant activity during the six months ended September 30, 2024, is indicated below: SCHEDULE OF WARRANTS OUTSTANDING
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--BrokerWarrantsMember_zcuoLeTgih13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Broker Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--ConsultantWarrantsMember_z940kUZL2za6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Consultant and Noteholder Warrants </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zOnHbvQjsL6a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Warrants Issued on Convertible Notes </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_zPkuQBfw0y92" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_437_c20240401__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zixIhifobVK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">As at March 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">208,927</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td>

<td style="width: 14%; text-align: right">253,994</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">868,098</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">1,331,019</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_433_c20240401__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zEEAiVg5GAE9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,927</td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,331,019</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_zFsePfpAH1q2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_z6b6JsFCRcM1" style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_zNSQoVQu2aYj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Issued</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_433_c20240401__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_zpodeL2MdnFj" style="vertical-align: bottom; background-color: White"> <td>As at September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,331,019</td><td style="text-align: left"> </td></tr> <tr id="xdx_438_c20240401__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_zTGrtT6VilO8" style="display: none; vertical-align: bottom; background-color: White"> <td>Ending balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,331,019</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise Price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$ 2.09 to $22.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$ 2.69 to $14.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_z4NxvHSPkQUg" title="Exercise Price">4.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiration Date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_z5Tgw8rbu9hj" title="Expiration Date">August 2026 to October 2033</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zI8RnK5Luvlk" title="Expiration Date">March 2029 to Dec 2032</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zEK1Tgki2kN6" title="Expiration Date">October 2027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table>   (g) Stock-based compensation   2016 Equity Incentive Plan   On February 2, 2016, the Board of Directors of the Company approved the Company’s 2016 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan shall be equal to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20160202__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_z4gzg0jo8Wb1" title="Share based payment award number of shares authorized">1,241,422 shares ; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 20% of the Company’s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.   During the three and six months ended September 30, 2024, the Company granted 250,000 and 291,559 stock options and during the three and six months ended September 30, 2023, 3,585 stock options, respectively. The Company recorded stock-based compensation of $56,885 and $115,863, respectively, during the three and six months ended September 30, 2024 and $<span id="xdx_907_eus-gaap--

ShareBasedCompensation_c20230701__20230930__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_z2MZbTXgVE26" title="Stock-based compensation">163,335 and $374,515, respectively, during the three months ended September 30, 2023, under selling, general and administrative expenses with corresponding credit to additional paid in capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfdryjWYhEo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the stock option activities during the six months ended September 30:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SCHEDULE OF STOCK OPTION ACTIVITIES</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">2023</td> <td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Number of</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Options</p></td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Weighted Average</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Exercise Price</p></td><td style="text-align: center; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Number of</p> <p style="text-align: center; margin-top: 0; margin-bottom: 0">Options</p> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Weighted Average</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Exercise Price</p> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td> <td> </td> <td colspan="2"> </td><td> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; padding-bottom: 2.5pt">Outstanding at March 31, 2024</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5JHX5H3FUgk" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Number of options, beginning outstanding">1,239,873</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zbqEZyKmCwE" style="padding-bottom: 2.5pt; width: 10%; text-align: right" title="Weighted average exercise price, beginning outstanding">9.39</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right; width: 10%"><p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyadqz5iYgu" style="margin: 0" title="Number of options, beginning outstanding">1,264,890 </td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="padding-bottom: 2.5pt; width: 1%">$</td> <td style="padding-bottom: 2.5pt; text-align: right; width: 10%"><p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfDoie3aqBqg" style="margin: 0" title="Weighted average exercise price, beginning outstanding">9.29</p></td> <td style="padding-bottom: 2.5pt; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsSNl6l5W2gd" style="text-align: right" title="Number of options, beginning outstanding">291,559</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zb6KBUW0AFFk" style="text-align: right" title="Weighted average exercise price, beginning outstanding">1.24</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><p id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDVlmPtjMSYf" style="margin: 0" title="Number of options, beginning outstanding">3,585 </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"><p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zinJ7YajS6Y2" style="margin: 0" title="Weighted average exercise price, beginning outstanding">2.79</p></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znc5OGRHo5w4" style="text-align: right" title="Number of options, beginning outstanding">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNMcB5q93zW1" style="text-align: right" title="Weighted average exercise price, beginning outstanding">—</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"><p id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOlpbxaOVH67" style="margin: 0" title="Number of options, beginning outstanding">— </td> <td> </td> <td> </td> <td>$</td><td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1zRKW9uMtw1" style="text-align: right" title="Number of options, beginning outstanding">(54,219</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBbL1VllDbFj" style="text-align: right" title="Weighted average exercise price, beginning outstanding">12.57</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"><p id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJ1Nu45JRX7k" style="margin: 0" title="Number of options, beginning outstanding">(12,035 </td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right"><p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfD45S5Kd0CJ" style="margin: 0" title="Weighted average exercise price, beginning outstanding">1.61</p></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrBtTcDShaVb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, beginning outstanding">(12,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvbnqMTqE8f" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, beginning outstanding">8.28</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><p id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zl4R18TiQQt5" style="margin: 0" title="Number of options, beginning outstanding">(5,362 </td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">$</td> <td style="padding-bottom: 1pt; text-align: right"><p id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcWqo3NwbNC8" style="margin: 0" title="Weighted average exercise price, beginning outstanding">8.58</p></td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuXmEuOdMCx9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, beginning outstanding">1,464,713</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3V8tGEu7pL7" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, beginning outstanding">7.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><p id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z8ped0z9M6a3" style="margin: 0" title="Number of options, beginning outstanding">1,251,078 </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right"><p id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znEzZlJmNM5j" style="margin: 0" title="Weighted average exercise price, beginning outstanding">9.30 </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The fair value of each option granted is estimated at the time of grant using multi-nominal lattice model using the following assumptions, for each of the respective six months periods ended September 30:   <span id="xdx_8B6_zCbr3oCi1pO7"

style="display: none">SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> September 30, 2024 </td> <td style="padding-bottom: 1pt"> </td> <td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> September 30, 2023 </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Exercise price ($)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">1.2</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">2.79</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.13</td><td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">3.85</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.5-6.5</td><td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">10.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107.7%-109.8</td><td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">117.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield (%)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240401__20240930_zmzs0Oel9ayg" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230401__20230930_zQlLRlhglIB4" style="text-align: right" title="Expected dividend yield">0.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fair value of option ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240930__srt--RangeAxis__srt--MinimumMember_zq7UP0XZXxgl" title="Fair value of option">0.689-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240930__srt--RangeAxis__srt--MaximumMember_zRGEq282XObk" title="Fair value of option">0.733</td><td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">2.30</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected forfeiture (attrition) rate (%)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ExpectedForfeitureAttritionRates_pid_dp_uPure_c20240401__20240930_zwDZgPO0aQCk" style="text-align: right" title="Expected forfeiture (attrition) rate">0</td><td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ExpectedForfeitureAttritionRates_pid_dp_uPure_c20230401__20230930_zZdryIBGdSN2" style="text-align: right" title="Expected forfeiture (attrition) rate">0.00</td><td style="text-align: left"> </td></tr> </table>   2023 Equity Incentive Plan and the Employee Stock Purchase Plans   On March 31, 2023, the Company adopted the 2023 Equity Incentive Plan (the “2023 Plan”). The 2023 Plan authorizes grants of equity-based and incentive cash awards to eligible participants designated by the 2023 Plan’s administrator. The 2023 Plan will be administered by the Compensation Committee of the Company’s Board of Directors (the “Board”). An aggregate of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyThreeEquityIncentivePlanMember_zWCT6J7wHSX2" title="Share based payment award number of shares available for issuance">5,000,000 shares of the Company’s common stock (the “Common Stock”), plus the number of shares available for issuance under the Company’s 2016 Equity Incentive Plan that had not been made subject to outstanding awards, were reserved for issuance under the 2023 Plan. Unless earlier terminated by the Board, the 2023 Plan will remain in effect until all Common Stock reserved for issuance has been issued, provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date of the 2023 Plan.   The Company also adopted the Employee Stock Purchase Plan (the “ESPP”). The ESPP allows eligible employees of the Company and the Company’s designated subsidiaries the ability to purchase shares of the Company’s Common Stock at a discount, subject to various limitations. Under the ESPP, employees will be granted the right to purchase Common Stock at a discount during a series of successive offerings, the duration and timing of which will be determined by the ESPP administrator (the “Administrator”). In no event can any single offering period be longer than 27 months. The purchase price (the “Purchase Price”) for each offering will be established by the Administrator. With respect to an offering under Section 423 of the Internal Revenue Code of 1986 (“Section 423 Offering”), in no case may such Purchase Price be less than the lesser of (i) an amount equal to 85 percent of the fair market value on the commencement date, or (ii) an amount not less than 85 percent of the fair market value the on the purchase date. In the event of financial hardship, an employee may withdraw from the ESPP by providing a request at least 20 Business Days before the end of the offering period (the “Offering Period”). Otherwise, the employee will be deemed to have exercised the purchase right in full as of such exercise date. Upon exercise, the employee will purchase the number of whole shares that the participant’s accumulated payroll deductions will buy at the Purchase Price. If an employee wants to decrease the rate of contribution, the employee must make a request at least 20 Business Days before the end of an Offering Period (or such earlier date as determined by the Administrator). An employee may not transfer any rights under the ESPP other than by will or the laws of descent and distribution. During a participant’s lifetime, purchase rights under the ESPP shall be exercisable only by the participant.   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)
1250000001250000000.001100000001000000000.00120000200006006002302393395144402286326193537681606721606722002006306430443543526526520020063046304410
may elect to convert shares of Series B Preferred Stock to common stock at an alternate conversion price equal to 80% (or 70% if the Company’s common stock is suspended from trading on or delisted from a principal trading market or if the Company has effected a reverse split of the common stock) of the lowest daily volume weighed average price of the common stock during the Alternate Conversion Measuring Period (as defined in the Certificate of Designations). In the event the Company receives a conversion notice that elects an alternate conversion price, the Company may, at its option, elect to satisfy its obligation under such conversion with payment in cash in an amount equal to 110% of the conversion amount.1.1040612062228727167891193592532032114290775232550109106314362671429072858141621928438840761606722 A roll-forward of activity is presented below for the six months ended September 30, 2024: SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240401__20240930_zhkhqlchBpec" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Fiscal Year 2025 </td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_494_20230401__20230930_zyC4PDvaHylj" style="border-bottom: Black 1pt solid; text-align: center"> Fiscal Year 2024 </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td> <td

colspan="3" style="border-bottom: Black 1pt solid; text-align: center">$</td></tr> <tr id="xdx_40B_ecustom--ConvertiblePreferredStock_iS_zQvCWcEYdrN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold; font-style: italic">Balance beginning of period – March 31</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,488,920</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 14%">— </td> <td style="width: 1%"> </td></tr> <tr id="xdx_408_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_zKHO6HcsQktk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net proceeds received pursuant to the issuance of preferred shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,732,532</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"><p style="margin: 0; text-align: right">1,900,000</p></td> <td> </td></tr> <tr id="xdx_405_ecustom--ChangeInFairValueusMeasurementWithReconciliationRecurringBasisLiability_zQ5ktNX8d5l4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Recognition of derivative liabilities (Note 8)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(649,533</td><td style="text-align: left">)</td> <td> </td> <td> </td> <td style="text-align: right">(642,416</td> <td>) </td></tr> <tr id="xdx_400_ecustom--ConversionIntoCommonShares_zMIMRoKBrBC7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Conversion into common shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(285,814</td><td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">—</p></td> <td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_407_ecustom--ConvertiblePreferredStock_iE_zScKYWta4524" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance end of period – September 30</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,286,105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">1,257,584</p></td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> 1488920173253321900000-649533-642416-2858142286105125758428780232032110910631436267255045000143270012104317535541210437461822832166816721459297810222257153574909726451137287610444 id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHjm8Bsl756i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrant activity during the six months ended September 30, 2024, is indicated below:</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>SCHEDULE OF WARRANTS OUTSTANDING</i></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--BrokerWarrantsMember_zcuoLeTgih13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Broker Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--ConsultantWarrantsMember_z940kUZL2za6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Consultant and</p> <p style="margin-top: 0; margin-bottom: 0">Noteholder</p> <p style="margin-top: 0; margin-bottom: 0">Warrants</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zOnHbvQjsL6a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Warrants Issued</p> <p style="margin-top: 0; margin-bottom: 0">on Convertible</p> <p style="margin-top: 0; margin-bottom: 0">Notes</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_zPkuQBfw0y92" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_437_c20240401__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zixIhifobVK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">As at March 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">208,927</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 14%; text-align: right">253,994</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">868,098</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">1,331,019</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_433_c20240401__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zEEAiVg5GAE9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,331,019</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_zFsePfpAH1q2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_z6b6JsECRcM1" style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_zNSQoVQu2aYj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Issued</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_433_c20240401__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_zpodeL2MdnFj" style="vertical-align: bottom; background-color: White"> <td>As at September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,331,019</td><td style="text-align: left"> </td></tr> <tr id="xdx_438_c20240401__20240930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_zTGrtT6ViIO8" style="display: none; vertical-align: bottom; background-color: White"> <td>Ending balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,331,019</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise Price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$ 2.09 to $22.50</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">$ 2.69 to $14.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_z4NxvHSPkQUg" title="Exercise Price">4.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiration Date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_z5Tgw8rbu9hj" title="Expiration Date">August 2026 to October 2033</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zI8RnK5Luvlk" title="Expiration Date">March 2029 to Dec 2032</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zEK1Tqki2kN6" title="Expiration Date">October 2027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> 208927253994868098133101920892725399486809813310192089272539948680981331019208927253994868098133101920892725399486809813310192.0922.502.6914.404.18August 2026 to October 2033March 2029 to Dec 2032October 2027124142225000029155935853585568851158631633353745115<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfdryjWYhEo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the stock option activities during the six months ended September

30:   SCHEDULE OF STOCK OPTION ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">2023</td> <td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> Number of Options </td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> Weighted Average Exercise Price </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"> Number of Options </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"> Weighted Average Exercise Price </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; padding-bottom: 2.5pt">Outstanding at March 31, 2024</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5JHX5H3FUgk" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Number of options, beginning outstanding">1,239,873</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zbqEZyKmCwE" style="padding-bottom: 2.5pt; width: 10%; text-align: right" title="Weighted average exercise price, beginning outstanding">9.39</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right; width: 10%"><p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyadqz5iYgu" style="margin: 0" title="Number of options, beginning outstanding">1,264,890</p></td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="padding-bottom: 2.5pt; width: 1%">$</td> <td style="padding-bottom: 2.5pt; text-align: right; width: 10%"><p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfDoie3aqBqg" style="margin: 0" title="Weighted average exercise price, beginning outstanding">9.29 </td> <td style="padding-bottom: 2.5pt; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsSNl6l5W2gd" style="text-align: right" title="Number of options, beginning outstanding">291,559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zb6KBUW0AFFk" style="text-align: right" title="Weighted average exercise price, beginning outstanding">1.24</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"><p id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDVlmPtjMSYf" style="margin: 0" title="Number of options, beginning outstanding">3,585</p></td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"><p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zinJ7YajS6Y2" style="margin: 0" title="Weighted average exercise price, beginning outstanding">2.79 </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znc5OGRHo5w4" style="text-align: right" title="Number of options, beginning outstanding">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNMcB5q93zW1" style="text-align: right" title="Weighted average exercise price, beginning outstanding">—</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"><p id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOIpbxaOVH67" style="margin: 0" title="Number of options, beginning outstanding">—</p></td> <td> </td> <td>$</td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1zRKW9uMtw1" style="text-align: right" title="Number of options, beginning outstanding">(54,219</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBbL1VllDbFj" style="text-align: right" title="Weighted average exercise price, beginning outstanding">12.57</td><td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"><p id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJ1Nu45JRX7k" style="margin: 0" title="Number of options, beginning outstanding">(12,035</p></td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right"><p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfD4S5Kd0CJl" style="margin: 0" title="Weighted average exercise price, beginning outstanding">1.61 </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrBtTcDShaVb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, beginning outstanding">(12,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvbnqMTqE8f" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, beginning outstanding">8.28</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><p id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zl4R18TiQQt5" style="margin: 0" title="Number of options, beginning outstanding">(5,362</p></td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">$</td> <td style="padding-bottom: 1pt; text-align: right"><p id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcWqo3NwbNC8" style="margin: 0" title="Weighted average exercise price, beginning outstanding">8.58 </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuXmEuOdMCx9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, beginning outstanding">1,464,713</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3V8tGEu7pL7" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, beginning outstanding">7.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><p id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z8ped0z9M6a3" style="margin: 0" title="Number of options, beginning outstanding">1,251,078</p></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right"><p id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230401__20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znEzZIJmNM5j" style="margin: 0" title="Weighted average exercise price, beginning outstanding">9.30 </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> 12398739.39126489909.292915591.2435852.795421912.57120351.61125008.2853628.5814647137.7112510789.30 The fair value of each option granted is estimated at the time of grant using multi-nominal lattice model using the following assumptions, for each of the respective six months periods ended September 30:   SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> September 30, 2024 </td><td style="padding-bottom: 1pt"> </td> <td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> September 30, <span style="font-family:

Times New Roman, Times, Serif; font-size: 10pt">2023 </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Exercise price ($)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">1.2</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left"></td><td style="width: 18%; text-align: right">2.79</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.13</td><td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">3.85</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.5-6.5</td><td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">10.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107.7%-109.8</td><td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">117.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield (%)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240401__20240930_zmzs0Oel9ayg" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230401__20230930_zQlLRlhglIB4" style="text-align: right" title="Expected dividend yield">0.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fair value of option ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.689-0.733</td><td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">2.30</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected forfeiture (attrition) rate (%)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ExpectedForfeitureAttritionRates_pid_dp_uPure_c20240401__20240930_zwDZgPO0aQCk" style="text-align: right" title="Expected forfeiture (attrition) rate">0</td><td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ExpectedForfeitureAttritionRates_pid_dp_uPure_c20230401__20230930_zZdryIBGdSN2" style="text-align: right" title="Expected forfeiture (attrition) rate">0.00</td><td style="text-align: left"> </td></tr> </table> 1.22.790.04130.0385P5Y6MP6Y6MP10Y1.0771.0981.17100.00000.6890.7332.3000.00005000000 10. OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS   The Company has one operating lease primarily for office and administration.   During December 2021, the Company entered into a new lease agreement. The Company paid $85,000 deposit that would be returned at the end of the lease. In December 2022, the Company started a new lease with an additional suite in the same premise as the existing lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When measuring the lease obligations, the Company discounted lease payments using its incremental borrowing rate. The weighted-average-rate applied is 11.4%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89B_ecustom--OperatingLeasesOfLesseeTableTextBlock_zWhrqitLiNN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SCHEDULE OF OPERATING LEASES OBLIGATIONS</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fiscal Year 2024</p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fiscal Year 2023</p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Right of Use Asset</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Beginning balance at March 31</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20240401__20240930_zjgqOHgJ56r6" style="width: 18%; text-align: right" title="Operating lease right-of-use asset, beginning balance">1,221,593</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20230401__20230930_zlSJlKyLnLN4" style="width: 18%; text-align: right" title="Operating lease right-of-use asset, beginning balance">1,587,492</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--OperatingLeaseRightOfUseAssetNewLeases_c20240401__20240930_zdWXKMCrQAhe" style="text-align: right" title="Right of use asset, new leases">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--OperatingLeaseRightOfUseAssetNewLeases_c20230401__20230930_zhrCb0zs4bzk" style="text-align: right" title="Right of use asset, new leases">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20240401__20240930_z80PCXGhLPO1" style="border-bottom: Black 1pt solid; text-align: right" title="Right of use asset, amortization">(198,275</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20230401__20230930_zLZ9oyGrwBPf" style="border-bottom: Black 1pt solid; text-align: right" title="Right of use asset, amortization">(178,320</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance at September 30</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20240401__20240930_z5zRl4DRPZZg" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use asset, ending balance">1,023,318</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20230401__20230930_zSvM4sIczRmf" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use asset, ending balance">1,409,172</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Lease Liability</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Beginning balance at March 31</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_iS_c20240401__20240930_zGzYFIEDfn0e" style="width: 18%; text-align: right" title="Operating lease liability, beginning balance">1,386,486</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLeaseLiability_iS_c20230401__20230930_zQ6ChLxzYim1" style="width: 18%; text-align: right" title="Operating lease liability, beginning balance">1,722,095</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--OperatingLeaseNewLeases_c20240401__20240930_zVkoCiGbz0b4" style="text-align:

right" title="Lease liability, new leases">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--OperatingLeaseNewLeases_c20230401__20230930_zkjtlYc9LoWe" style="text-align: right" title="Lease liability, new leases">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Repayment and interest accretion, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--OperatingLeaseRepaymentAndInterestAccretion_iN_di_c20240401__20240930_zkdgXm9btGu8" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability, repayment and interest accretion, net">(219,283</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--OperatingLeaseRepaymentAndInterestAccretion_iN_di_c20230401__20230930_zJKlVLUH4A0d" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability, repayment and interest accretion, net">(190,864</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance at September 30</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLeaseLiability_iE_c20240401__20240930_zfCJVmvwq0q4" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability, ending balance">1,167,203</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLeaseLiability_iE_c20230401__20230930_zz7WMdfWBTC9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability, ending balance">1,531,231</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> September 30, 2024 </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> March 31, 2024 </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Lease Liability</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Current portion of operating lease liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20240930_zNNKxT35lh4g" style="width: 18%; text-align: right" title="Current portion of operating lease liability">493,190</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20240331_zYdnIDlInUcj" style="width: 18%; text-align: right" title="Current portion of operating lease liability">457,371</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noncurrent portion of operating lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20240930_zzmhFyuZgZB1" style="text-align: right" title="Noncurrent portion of operating lease liability">674,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20240331_ze8GKFjXM2vl" style="text-align: right" title="Noncurrent portion of operating lease liability">929,115</td><td style="text-align: left"> </td></tr> </table>   The operating lease expense was $292,787 for the six months ended September 30, 2024 (2023: $140,759) and included in the selling, general and administrative expenses. Operating cash flows from operating leases amounted to $218,448 and $282,209 during the six months ended September 30, 2024 and September 30, 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_898_ecustom--ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationTableTextBlock_zUWtUbuV6PVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table represents the contractual undiscounted cash flows for lease obligations as at September 30, 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Calendar year</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240930_zlu8Bl5p9Aqi" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">$</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzTPy_z2aoMLp8UZw" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2024</td><td style="width: 2%"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">552,293</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzTPy_zOnODjjxZpqh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,288</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzTPy_z2ixpcCknSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">565,359</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzTPy_zgXxXGa1lTGl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total undiscounted lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,717,940</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zLywtQ14Gkr3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(550,737</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_zVRGol5vOXJh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,167,203</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   850000.114 SCHEDULE OF OPERATING LEASES OBLIGATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> Fiscal Year 2024 </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> Fiscal Year 2023 </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Right of Use Asset</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Beginning balance at March 31</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20240401__20240930_zjggQHgJ56r6" style="width: 18%; text-align: right" title="Operating lease right-of-use asset, beginning balance">1,221,593</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20230401__20230930_zlSJlKyLnLN4" style="width: 18%; text-align: right" title="Operating lease right-of-use asset, beginning balance">1,587,492</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--OperatingLeaseRightOfUseAssetNewLeases_c20240401__20240930_zdWXKMCrQAhe" style="text-align: right" title="Right of use asset, new leases">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--OperatingLeaseRightOfUseAssetNewLeases_c20230401__20230930_zhrCb0zs4bzk" style="text-align: right" title="Right of use asset, new leases">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20240401__20240930_z80PCXGhLPO1" style="border-bottom: Black 1pt solid; text-align: right" title="Right of use asset, amortization">(198,275</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20230401__20230930_zLZ9oyGrwBPf" style="border-bottom: Black 1pt solid; text-align: right" title="Right of use asset, amortization">(178,320</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance at September 30</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20240401__20240930_z5zRl4DRPZZg" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use asset, ending balance">1,023,318</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20230401__20230930_zSvM4slczRmf" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use asset, ending balance">1,409,172</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-

weight: bold">Lease Liability</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Beginning balance at March 31</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_iS_c20240401__20240930_zGzYFIEDfn0e" style="width: 18%; text-align: right" title="Operating lease liability, beginning balance">1,386,486</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLeaseLiability_iS_c20230401__20230930_zQ6ChLxzYim1" style="width: 18%; text-align: right" title="Operating lease liability, beginning balance">1,722,095</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--OperatingLeaseNewLeases_c20240401__20240930_zVkoCiGbz0b4" style="text-align: right" title="Lease liability, new leases">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--OperatingLeaseNewLeases_c20230401__20230930_zkjtlYc9LoWe" style="text-align: right" title="Lease liability, new leases">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Repayment and interest accretion, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--OperatingLeaseRepaymentAndInterestAccretion_iN_di_c20240401__20240930_zkdgXm9btGu8" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability, repayment and interest accretion, net">(219,283</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--OperatingLeaseRepaymentAndInterestAccretion_iN_di_c20230401__20230930_zJKlVLUH4A0d" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability, repayment and interest accretion, net">(190,864</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance at September 30</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLeaseLiability_iE_c20240401__20240930_zfCJVmvwq0q4" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability, ending balance">1,167,203</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLeaseLiability_iE_c20230401__20230930_zz7WMdfWBTC9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability, ending balance">1,531,231</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (Unaudited) (Expressed in US dollars)   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> September 30, 2024 </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> March 31, 2024 </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Lease Liability</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Current portion of operating lease liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20240930_zNNKxT35lh4g" style="width: 18%; text-align: right" title="Current portion of operating lease liability">493,190</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20240331_zYdnIDlInUcj" style="width: 18%; text-align: right" title="Current portion of operating lease liability">457,371</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noncurrent portion of operating lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20240930_zzmhFyuZgZB1" style="text-align: right" title="Noncurrent portion of operating lease liability">674,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20240331_ze8GKFjXM2vl" style="text-align: right" title="Noncurrent portion of operating lease liability">929,115</td><td style="text-align: left"> </td></tr> </table> 12215931587492198275178320102331814091721386486172209521928319086411672031531231493190457371674012991152927871407592184482822092 The following table represents the contractual undiscounted cash flows for lease obligations as at September 30, 2024:   SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Calendar year</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240930_zlu8BlSp9Aqi" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">$</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzTPy_z2aoMLp8UZw" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2024</td><td style="width: 2%"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">552,293</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzTPy_zOnODjjxZpqh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,288</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzTPy_z2ixpcCknSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">565,359</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzTPy_zgXxXGa1lTGl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total undiscounted lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,717,940</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zLywtQ14Gkr3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(550,737</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_zVRGol5vOXJh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,167,203</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5522936002885653591717940550737116720 11. COMMITMENTS AND CONTINGENCIES   There are no claims against the Company that were assessed as significant, which were outstanding as at September 30, 2024 or March 31, 2024 and, consequently, no provision for such has been recognized in the Condensed Consolidated Financial Statements.   12. PROPERTY AND EQUIPMENT   During the year-ended March 31, 2022, the Company purchased leasehold improvements of $12,928 (useful life: 5 years) as well as furniture & fixtures of $16,839 (useful life: 5 years). There were no purchases of property and equipment during the six months ended September 30, 2024, and September 30, 2023. The Company recognized depreciation expense for these assets in the amount of $2,977 and $2,977, respectively, during the six months ended September 30, 2024 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zdFw0a2oi7bb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SCHEDULE OF PROPERTY AND EQUIPMENT</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Cost</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Office</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">equipment</p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Leasehold</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">improvement</p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance at March

31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSghnuoSGHf8" style="width: 16%; text-align: right" title="Cost, beginning balance">16,839</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z4ixaP5SHQnc" style="width: 16%; text-align: right" title="Cost, beginning balance">12,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20240401__20240930_z5ay309t6q0k" style="width: 16%; text-align: right" title="Cost, beginning balance">29,767</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Additions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentAdditions_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zz0WFCJkl8Q6" style="text-align: right" title="Office equipment, additions">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentAdditions_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zA88FJIgXfpf" style="text-align: right" title="Leasehold improvement, additions">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentAdditions_c20240401__20240930_zsIzhR9DVsU9" style="text-align: right" title="Additions">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Disposals</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentDisposals_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zxxAKfp7Izvg" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, disposals">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentDisposals_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z7WScqozBSMb" style="border-bottom: Black 1pt solid; text-align: right" title="Leasehold improvement, disposals">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentDisposals_c20240401__20240930_z9kuZ3L1mhb5" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Balance at September 30, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zYKIS78S05R9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">16,839</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zit35RlKWVhc" style="border-bottom: Black 1pt solid; text-align: right" title="Cost, ending balance">12,928</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20240401__20240930_zlr5UCQtcMI2" style="border-bottom: Black 1pt solid; text-align: right" title="Cost, ending balance">29,767</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> Office equipment </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> Leasehold improvement </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance at March 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zufZWbiwUd6b" style="width: 16%; text-align: right" title="Accumulated depreciation, beginning balance">8,042</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zU4x7Pe3jFAa" style="width: 16%; text-align: right" title="Accumulated depreciation, beginning balance">6,173</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20240401__20240930_zfKSqhollEpd" style="width: 16%; text-align: right" title="Accumulated depreciation, beginning balance">14,215</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation for the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--Depreciation_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zBoMbyuU0FYk" style="text-align: right" title="Office equipment, depreciation">1,683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Depreciation_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zyT4Nw5YfXHh" style="text-align: right" title="Leasehold improvement, depreciation">1,293</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Depreciation_c20240401__20240930_z7YnBhTsgGY8" style="text-align: right" title="Depreciation">2,977</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Disposals</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_ziLdmcM5YOyf" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, disposals">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zmaE1A025Gi1" style="border-bottom: Black 1pt solid; text-align: right" title="Leasehold improvement, disposals">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_c20240401__20240930_zok7IbbmhIeb" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Balance at September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zB5Diww8U8m7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation, ending balance">9,725</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zSme2tJaUSj3" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation, ending balance">7,466</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20240401__20240930_zlBCAex4QTEf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">17,191</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Net book value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Balance at March 31, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iS_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zexJEFKXd7w" style="border-bottom: Black 1pt solid; text-align: right" title="Net book value, beginning balance">8,797</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iS_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaBTkzqhmCn6" style="border-bottom: Black 1pt solid; text-align: right" title="Net book value, beginning balance">6,755</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iS_c20240401__20240930_z6B16OKQUMol" style="border-bottom: Black 1pt solid; text-align: right" title="Net book value, beginning balance">15,552</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Balance at September 30, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iE_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zwfTPcRCnqY8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">7,114</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentNet_iE_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVarnE1bRsKl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">5,462</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iE_c20240401__20240930_zJp73BVghbM9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">12,576</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table>   12928P5Y16839P5Y0029772977 SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Cost</td><td

style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> Office equipment </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> Leasehold improvement </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance at March 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSghnuoSGHf8" style="width: 16%; text-align: right" title="Cost, beginning balance">16,839</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z4ixaP5SHQnc" style="width: 16%; text-align: right" title="Cost, beginning balance">12,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20240401__20240930_z5ay309t6q0k" style="width: 16%; text-align: right" title="Cost, beginning balance">29,767</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Additions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentAdditions_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zz0WFCJkl8Q6" style="text-align: right" title="Office equipment, additions">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentAdditions_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zA88FJIqXfpf" style="text-align: right" title="Leasehold improvement, additions">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentAdditions_c20240401__20240930_zsIzhR9DVsU9" style="text-align: right" title="Additions">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Disposals</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentDisposals_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zxxAKfp7Izvg" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, disposals">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentDisposals_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z7WScgozBSMb" style="border-bottom: Black 1pt solid; text-align: right" title="Leasehold improvement, disposals">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentDisposals_c20240401__20240930_z9kuZ3L1mhb5" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Balance at September 30, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zYKIS78S05R9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">16,839</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zit35RlKWVhc" style="border-bottom: Black 1pt solid; text-align: right" title="Cost, ending balance">12,928</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20240401__20240930_zlr5UCQtcMI2" style="border-bottom: Black 1pt solid; text-align: right" title="Cost, ending balance">29,767</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Office</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">equipment</p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Leasehold</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">improvement</p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance at March 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zufZWbiwUd6b" style="width: 16%; text-align: right" title="Accumulated depreciation, beginning balance">8,042</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zU4x7Pe3jFAa" style="width: 16%; text-align: right" title="Accumulated depreciation, beginning balance">6,173</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20240401__20240930_zfKSqhollEpd" style="width: 16%; text-align: right" title="Accumulated depreciation, beginning balance">14,215</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation for the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--Depreciation_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zBoMbyuU0FYk" style="text-align: right" title="Office equipment, depreciation">1,683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Depreciation_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zyT4Nw5YfXHh" style="text-align: right" title="Leasehold improvement, depreciation">1,293</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Depreciation_c20240401__20240930_z7YnBhTsgGY8" style="text-align: right" title="Depreciation">2,977</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Disposals</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_ziLdmcM5YOyf" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, disposals">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zmaE1A025Gi1" style="border-bottom: Black 1pt solid; text-align: right" title="Leasehold improvement, disposals">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_c20240401__20240930_zok7Ibbmhleb" style="border-bottom: Black 1pt solid; text-align: right" title="Disposals">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Balance at September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zB5Diww8U8m7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation, ending balance">9,725</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zSme2tJaUSj3" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation, ending balance">7,466</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20240401__20240930_zlBCAex4QTEf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">17,191</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Net book value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Balance at March 31, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iS_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zexJEFKXd7w" style="border-bottom: Black 1pt solid; text-align: right" title="Net book value, beginning balance">8,797</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iS_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaBTkzqhmCn6" style="border-bottom: Black 1pt solid; text-align: right" title="Net book value, beginning balance">6,755</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iS_c20240401__20240930_z6B16OKQUMol" style="border-bottom: Black 1pt solid; text-align: right" title="Net book value, beginning balance">15,552</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Balance at September 30, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iE_c20240401__20240930__us-gaap--OfficeEquipmentMember_zwfTPcRCnqY8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">7,114</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom:

1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentNet_iE_c20240401__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVarnE1bRsKl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">5,462</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td> <td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iE_c20240401__20240930_zIp73BVqhbM9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">12,576</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table>

1683912928297671683912928297678042617314215168312932977972574661719187976755155552711454621257 6 13. SUBSEQUENT EVENTS   The Company's management has evaluated subsequent events during the period from October 1 to November 14, 2024, the date the Condensed Consolidated Financial Statements were issued, pursuant to the requirements of ASC 855, and has determined the following material subsequent events: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%">●</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 94%; text-align: justify">During October 2024, the Company issued $<span id="xdx_904_eus-gaap--ProceedsFromUnsecuredNotesPayable_c20241001__20241031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIPcqUIefqJg" title="Unsecured convertible promissory notes">150,000 in unsecured convertible promissory notes to private investors. During November 2024, the Company issued a further $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241101__20241130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertiblePromissoryNotesMember_z6uG4GiRmfv1" title="Shares issues">492,000 in unsecured convertible promissory notes to private investors. These notes mature on their eighteen (<span id="xdx_902_eus-gaap--DebtInstrumentTerm_dtM_c20241101__20241130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertiblePromissoryNotesMember_zRBFCIj0hbjk" title="Issuance date">18) month anniversary of the issuance date, and are convertible at a <span id="xdx_900_ecustom--DebtInstrumentInterestRateStatedDiscountPercentage_iI_dp_uPure_c20241130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertiblePromissoryNotesMember_z2WcvZ2A8OZ4" title="Convertible discount percentage">20% discount to the next qualified financing of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20241130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertiblePromissoryNotesMember_zHHO1Okxwa7j" title="Offering amount">15 million or more, or on note maturity at a $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertiblePromissoryNotesMember_zZfSB4Oe5Ueb" title="Conversion price">0.50 per share conversion price. The notes bear no interest.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> During November 2024, the Company also issued $<span id="xdx_90F_eus-gaap--ProceedsFromUnsecuredNotesPayable_c20241101__20241130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertiblePromissoryNotesMember_zhjzRjfLm453" title="Unsecured convertible promissory notes">169,000 in unsecured promissory notes to private investors. These notes mature on their eighteen (<span id="xdx_900_eus-gaap--DebtInstrumentTerm_dtM_c20241101__20241130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertiblePromissoryNotesMember_zzgEPqneSbdg" title="Issuance date">18) month anniversary of the issuance date. The notes bear an interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20241130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertiblePromissoryNotesMember_z1qcJCp6F464" title="Convertible discount percentage">10% per annum, paid quarterly </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On November 12, 2024, the Company completed an additional transaction with its term lender to receive an additional $635 thousand in term loan proceeds, and interest relief through the capitalization of approximately $945 thousand in interest amounts due on its existing term loan. Concurrent with this, the Company received waiver and forbearance relief on certain term loan covenants and their respective defaults. As part of this arrangement, the Company issued 600,000, 7-year share warrants to the term lender with a strike price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCrUlWVtPUhk" title="Warrants price per share">0.50 per share, and agreed to increase the term loan exit fee to $1.425 million at the end of its 5-year term.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In October 2024, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241001__20241031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertibleRedeemablePreferredStockMember_zc9YSbpALzd2" title="Shares issue">1,197,770 common shares on partial conversion of 25 shares of Series B Convertible Redeemable Preferred Stock, and a further <span id="xdx_904_eus-gaap--Dividends_pn3n3_c20241001__20241031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertibleRedeemablePreferredStockMember_zgJEerhrNxI" title="Accrued dividends">233,441 additional common shares required to complete its conversion obligation of a conversion of 25 shares of Series B Convertible Redeemable Preferred Stock that was triggered on July 11, 2024. During that same period, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20241001__20241031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertibleRedeemablePreferredStockMember_z8jzbVei4qb6" title="Shares issue">100,000 shares of common stock valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_c20241001__20241031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertibleRedeemablePreferredStockMember_zqNunDmf4dYh" title="Consultant contract remuneration">26,000 to a consultant as part of agreed contract remuneration.</td></tr> </table>

150000492000P18M0.20150000000.50169000P18M0.10635000945000600000000000.501425000P5Y1197770233441000100000260 00falsefalsefalsefalse

'

-

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|C>>=PU-QN>G*I$I C^:RTCC6N=IA M#!=S(K-?@,D3V)<;X2<]W=E@EH!O'R0D& B2\[],\2WM-\SV5<7?\B6>DI8E M2YH3MB96^[=?8.#^:0K.A< .0M6H0M6H0V]_U>4E^>,U8?)U <@C8=.4$[!D MZ92\ 1,R3XLB+>9OGNXP$4B[TTAJ;7STI"48+$&4R_ =1O9,C/6!J9^Q=2O M9=K_L4K%$Q@N=29\NR?YA##CXM;BO)3)A< ,* <5Y>!_KH/@DJ&Z$-A!J,(J M5&%M=GQ5Z=*42 MCDZJ+K:]V-V[X!$EDP:*XOW+3"ZNR,6OMB[Q2;O1#'T_/N)P*N;YD6]V&[|[MS[E[I579&MH/,K359_: A4$*V>&9Z,.]K@2^6OSKH2:G=^ T$CRO2) >1ZYTKREVS Z_5 M[<#3#@4BVP^/F1C$[">X;%K96!]+_-3B^";@NN[[K'lCG?"] 9WW<|":S] MCE]R#8*3X$8V"LU?GRTIDXH?G>&T:Q[@ZW4/T- 6-()&"(_:!Y,@\]$;GG-_ MUT# :W40\+0A".WPN&LP2,E&PS4W&B4G9V]GG1,VUP<,'$SIJA#E/K6:K0XU M.GHK?S3?58<=>L>^@RE/2NXQDRPYR,A,0KIV*"/-RL.'DM73=D# 1$ M&0 'AL+W=O_?1|LJ3= MI;-A_%DL 21Z2>)4=)VEE-F5ZXK9$A(B:BR#5#V9,YX0J;I\X8J, XF,4Q*[MON>%;D)HZO0Z9NR1|SIL)6.:PB-'8I4DA+|>0\PV70<[;P-CNEA*/>#V.AE9 MP 3D-'ODJN<6*!%-(!64I8C#O.OT\=4 -[6#L?a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|$)IQ;Z:7<* [1G#R8>O67'XFL%AXFF?[5PU;JFX2H O3,TIT(RM4IE7 M(L5H4=?V335W,'ZMZUU3M.U@\F)Y1/B"I@+%,%>02I+:7#RO/ ,.9)DIX9Z8 M5 6A:2Y5S0Y<&ZCG<\;D6T=/4/P+T/L/4$L#!!0 (%*(;EGX^](}P2@ M Q3 @ 9 >&PO=V]R:W-H965T=YM%51FSU12Y4X$Z-]75*7- 38YD]FSZ2N\P!+V*9:ECR XG;7O/@#$C)7+'T'Z MVP\ZB0V?!4CK+T _UOKY:9 \EMY'42;] K#=I;^\O<^RQQ\ ?DS7]|%#F'[8 M/T:[_#>W^^0AS/))G_[!/^*[^ZSXP<=//S^&=!'7*/OOQR|) M_J^/+\HF?HAV:;S?24ET^\O;S_*/@3Q5BC6.B_PKCI[2VM^E8E|N|OO?BG_8 MFU_>3HI-BK;1.BN,,/_C6W0=;;<%E6_(OTOU[4NCQ8KUOY]UX[CW^=[=D_R0EQ?*Y5_SE MV(&.Z^=O^7A7=/:O69+_-L[7RSY]_>??KUWK[YZF_^/KW_ZR5.3%3Y*F&_:U MK0?7_U=ZIT59&&]3*0B3)"RZY7OI!^F_OVK2N_IZ_/'+-^"POFX+EO33]TI MK[2F2OY^E]VGDK[;1)N>]2WQ^O-+ZSOB]65% 'S,#|W+\5/.Q^]712A^C1X_ M2/+]2E(FBMJS0=?BU;5H_4%2Y./JO[H=)OKK\ZNK& M@(TO5^_;=W/XQO>M;OVY?;?_7.O.GSMT[O#5^UKWQ*L[AYUPW_WAJ_>U'HA7 M-Z*;#])$*5:7YX(^I+[4(/7HJ:]XU]LP3:7]K?0UVZ]_D_[7RW\OV5GTD/Z_ MGHW[|81-^['BY.C']#%<1[^\S<]^TBCY%KW]]+>_R//)3WW=D\0T$M-)S" Q MD\0L$K>)S"$QE\0\$O-)+("P1AF9OI21J4C_=+U_>,BO'HY%Y$KZ>A_F34B? M#G|G/HG_Z#U;^%4(CBTE)*:=L-D1*R[8ON7G+K/)\;^?/WZKUXG!2QKD!IHD M9@W>!YMLUAGO.A5WW2Q+=1DF2=]0Q'[Y"V7],XG7O)Z]0'|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

MU7Q4"RBM.9]>EY=3%=":W;TN@6^>BFH=J/]H%E-8L U7D4A5'+HOY M.27]|.BFO2ON4!2C MJOFH%E!:LZK4Y@(71SR/MS*DTZ7+RTAD3V&RD7;M3%L-.%,[. M%,Y.%
<[.%HII5:X\;]K.=&*-JJ@6IFSSZHL\[PQ7U[MND)GLU7[IL40S4'WP$4U#]5\5 LHK=EGJS2F*DYCCKISB>8R44U3NXG V7S9 M?I?J:*,&JID]NR#/557M]-N>Y7IO-
G:7Z[_9B(8D4!O>;"/I=E]%N7MK#QK&1#4-U714,U#-1#4+U6Q4/MIO8-)P]M MUD>U@-*;9:6*8ZKB.*89[:(DW!X?_?B\>8AW<9HEIRE1]-.C'^)+(C26B6H:
M]NFH9]":B6H6]MFHYJ":BVH>]OFH%E!:H\I,JY#G=$)>$DW1G">]::BFHYJ! M:B;]6:AFHY]#:BZ]>:CFHUI :]T|%2S4=ZN!&@.%=5<5/-0S4>U@-*:E:#* MH4[%
(WUJS9D.I4V4KI/X\;5'5,3:Z$] YE!134QVQQM< M3_O#]F4ZN_Q<,MLWYJZ2PNPX[5WX^+B-U\=HX=_^LE24R4]^N-N$V3YYEJY? MWFEOOB3Q.CHN(/]T)<6W4A0?1Y5]%
[\OIN",PO7]<=C(W;.4/>5GK,_2.V7R MOF@^C=:'8_CHGTFX*2;;T\+G5'I7M'UN, K30W(:L_;+<1:^LJ'WTKO/[X]; MN=[NTWS=-X_%9A0-%3^\/NU.^:#EKKT[Y_;\,/DMRH] 6NSR-
F\KD_Y+7GZ8 M3(HI_TZ?H\>LU+M?3VUM]MMM6/O #?-C4(RMNPGC:;YWN1JE;_[\)DPGDZM) MN1&U0_,3M"^.:GY8#X\E6.[\<5ND_W.(M_%MG%\>&/$NW*WS7USEAV5?3(:^
MR12O[\^[]Z__^?Q%RA=+CO_JOEFOBE>L MN0E2^&;@)E3;$,5W]_5-6-8VX>XX2T0:YJ_&]0=4[]Q\B<;K]R[?F.H3XDW^ MK^CWG(S3RZN6_;?QL^*1JOQ-E&]1^EY*]]OBJK3_7?
BA]XX&FG-'-1?5/%3S M42V@M.992Y5SGXIS[H-F:A<;H\|5T-QZ]=5/TJ>S[D/P:*,&JIFH9O4<$'FJ M*HMN0@/-FJ.:BVH>JOFH%E!:L_]7@?3IH/&!DVB]O]O%Q=,N87[N<;.-[UY]
MN%XLC]X&: A]VAT*M_]V)AHO1S43U2Q4LU'-0347U3Q4\U$MH+1&S9A5\?*9 M> SAXYV.VA<@X7J='([?B611WE[O*828'%LT4$V;=<>Z72SE]AD$V]:!:B:]
M6:76&&XG_V_6GE(9;=5!-1?5/%3S42V@M&8QJ\=&WSJ7,NOL[^=GF#:QN%- MO(VSY]X"@$;!44V;=2/-\DQMO]!UM%$#U4Q4LWH.R'0U62V4=@5 0]ZHVJ*: MAVH^J@64UJP
2E4!Q"'O[SH=0 /?]*:-NL'E^70FMXL!&N1&-1/5K)[C(:L+ M9=DY'4"3W*CFHJ':CZ]!936+ 95DGLF3G)_2:+;*$GR[E\&+P51;C$UN@B@
M46Y4TU'-0#43U2Q4LU'-0347U3Q4\U$MH+1F2:FBW+-3J!.*C0!0UT^TQ4LX;NA(TVZPQMUD6;]5#-1[6 TIH= MN4I@S\0)
[*HCG]S9:HN+N)1M3CF,6#3VZ712#:]::4VK[W>)A\FD\Z]B$&+ M&>BVF:AF#=L%&VW4&=:HBS;IH9)/:@&E-;MR%:&>B0.RY4?P_I"E6;@K4H:] M'19-3J.:5FK-R;0[W;6[T%R=S-
J]%0TZ#VK3&K+Y]B#*&;24.V@I;\AF^8.H M@#]JS7=X%;>;B>-VK0^K]\L/#XK!T>]V-'LWZXX(VGFO7US$0+?)1#7K\N;; M:(/.Y09=M$$/U7Q4"RBMV5FK;-Q,G(U[K;-
>^GQ"\W&HILUZ\G'M'GMQ$0/= M)A/5K,N;;Z,-.I<;=-$&/53S42V@M$:/G5?)M+DXF3;R;5RQ-K:GHIJ&:CJJ M&:AF?H\F]75]=+-L:K,<=+-<5/-0S4>U@-
*:M:0*MLW%P;;&HU:BK[%SN@J M@B;:4$U'-0/53%2S4,U&-0?57%3S4,U'M8#2FO6DBLG-%?)K[#F:D$,U#=5T M5#-0S44U"]5L5'-0S44U#]5 LHK5E5JKS=_,+(J8-
N28B1T<4$3=K-N[-\ M*^I$45=[^Z&]GB57,WDZG;;_MT8WT,QI=KF4)\]T-3*2-7A/[*&D,W27W3YQ M,5-F[<>8O+Z-E.?3V63>:MM_C>S<4Z<.=[,+5/FPN3 I4D[F?KJ#+FT.23$X
MQ>-Q](?>KH#&PU!-0S4=U0Q4,TNM,9?88M%^3-?]66P^6ZQM[\0Z-U@-*:O;^*@:K.3)O'.:W%U052:]TOX6KV>YN:O,YJV'/$UT-ZR^ MW9B]?IP,;=9!-1?
5/%3S42V@M&:OKA)A74Y1E@MET>[DZ$"8J&:CFH-]+]IYJ.:C6D!IS4I0)>?FXN3< MY_:@VHN MJGFHYJ-:0&G-3B>+ M>?
N$O[O88C9KWR0S>A:3Y94ZZ_1M-(_7U^I\,N\,)8.VZ]":BVH>JOFH%E!: MH]0IS?>W6*X2S;GH9U+L9!7J^+@6I3Z3%\+@:!|NO5XG;&]FI4TU!-
M1S4#U4Q4LQ;=8>GDR60RE=O?!J#-.JCFHJ':CZ]!936+"55?&_QG;.5BTK) MU>G[@lZ*@J;\4$U#-1W5#%0S4:,1[+:F=\';=5!-1?5/%3S42V@M&9! MJ?)[B^%SF3<*2O(M7O=?
6XC%T34#S?"AFHYJ![J9J&:56OTL9#'IS#=@HXTZ MJ.:BFH=]/]H%E-8L&5X;S$HG)?MI9OH'%!ZBK-[J8H]]0--*V':AJJZ:AF MH])D:E:I-4XU.C4#'>T.U5Q4\U#-1[6
TIHUHTHS+H0IJ6;-L$\U0_3TD9@; M72Q(34,U'=4,5#-1S4(U&]4<5'-1S4,U']4"2FN6E2HQ!KIU9E^KJUE[U*Z!^V /TIR!>^H.TKR^I11Y MT9Y;Q1^D!=31;;[=]S3BXL+X=*.>-
!)CH]_V:!@1U714,U#-1#5KT1UD[H?> M)Y)Z%NQYP,E!M\Y%-0_5?%0+**U9"*HPXD(<1ASYJ)%8&UT)T# BJNFH9J": M^3U:ISA#B^X,NS_,II-
9^R/2[EFP_7"3@^ZCBVH>JOFH%E!:LP)4^<*%,%_X M/=\&HDE#5-,6W4'LIMUOM72T40/53%2S>@[(K,]K/C2UB&HNJGFHYJ-:0&F- M6K"L4HM+<6KQ.
[_F$ZMZP&J:+L71PR^`9'T?IT'T^2Z)36#S=XTG^D7Z-==!NO MXS!Y%GZQ)VYD='E X>HIJ..@6HFJEFH9J..@VHNJGFHYJ-:0&G-8E/%$I?H ML()+-)*
(:AJJZ:AFH)]):A:JV:CFH)]+:AZJ^:@64%JSJE3)Q:4XN?CWIUV4 MI/?Q8_']QCH_@PGO^]IA3HP\]9T73SY,IJO60X77XO9&5PHTA8AJ!IJ9J&:A MFHUJ#[JY].:AFH]J
:4U*T655UP*@TNGFQ_W^^TFKQ?BZQDR3G6-:AJJZ:AF MH])D:A:JV:CFH)]+:AZJ^:@64%JSGE1!Q24:5%RB0454TU!-1S4#U4Q4LU#- M1C4'U5Q4\U#-1[6 TII5I0HJ+B^-#GF*:
R<=%&LC:XJ:&)QV4W**O-*3_2/KOZ_MP=]?W=4MOWT9CFT:BFH9J..:@:JF:AFH9J-:@ZJN:CFH9J/ M:@&E-:M-%?%<+M'K$#3BB6H:JNFH9J":B6H6]MFHYJ":BVH>]OFH%E!:LZI4
ML=&E.#8Z[($I,3*ZF*!)T64W&/G*=$T]2_9/UX1NH(EJUN#=M=%VG:$'ST6; M]5#-1[6 TAI===U6E/%<74IY1$N==]|/TY65:^,MSPXK-L3T9U314TU'-0#43
MU2Q4LU'-0347U3Q4\U$MH+1F;:D2HRN9O-A8H=%05--034U@-*:546IJHIXQ,K6B>Z]-/DPF[>\PARUF MH-MFHIHU;!=LM%%G6*,NVJB':CZJ!936[,I53'(EC$VUN_* #((8'-UY24TK
MM=8'1;OK=A>:JY-IN^>2&V8.:M,:LOGV(,H9M)2+[]2':CZJ!936[&95>G E MG@/ZM6YVX8:[6!W=U] 48:E=Z&O=A?KZ&AKZ&]2F-63S[4&4,V@I%]U)#]5\ M5
LHK=G7JDS=2IRIZ_2U;?SO0[P)L],Y:?'+:/?*B2Ft:KT,UK=0:$Y;U7&*2 M;1JH9J*:->AXV&B;#JJYJ.:AFH]J :4U*T*5T%N)$WKMZ]7S7*U2$F;1A2<) MQ?
3HDH#&\E!-1S4#U4Q4LTIMV;@(E=LS/Z)M.JCFHJ':CZJ!936+!U5W&XE M'E%1BVXR*=ZE67(X)GCS(A(]/&8OMI:*P.U5Q4\U#-1[6 TIK5HXK5K<2QNC]HQP-
W*&:5FH7;Y2C0S.BFHEJ MUK #8J.-.JCFHJ':CZJ!936* SY]>=+92C^+BH-_IIO\$,*Z2F*[^Z+">'# MO!CD)O&#SBHNV&/K LMI+*>SG,%R)LM99ZYU:=(^N6!;=5C.93F/Y7R6"S'N
M54GD6B41#^MHY/CKH[E>6'M\K4!3>6>N?A=O+D^F^7^M\PBV88/E3):S!A\6 MFVW883F7Y3R6\UDNP+A6)5![JE4 =N<6EPV*S#3LLY[*O,U:OKQG,]R
<:URLBT5D:$Z:A/6O2X3^-,VL;A3;R-LSA*KZ2P/-F(=UF4-YOU M5Q(RQ'7-%??*MP^VV/2'EE>A.!9IV9#F-Y726,UC.9#GK MS#4NZO*/M97<<_F"#HO(2SGLUR
<:V2,]^5%'&2T\ZO7M+L>&>&RWC\\ MAKOGJRJIM8GS*YKXYE!D.?K+'1KF9#F-Y726,UC.9#GKS-5/4-3):#I?K#K5 M!(U_LIS+:.ISS*WJ'># MK'/1@@8Z6B*.=7T\#)_TZ:N"D
M"^CXPH!&.EE.9SF#Y4R6LUC.9CF'Y5R6\UC.9[D XUJE9E4K:-4,EC-9SF(YF^4W,-9ZM[CST.F@I@!TTD^6L0?M@LXTZ@QIUV48]EO-9+L"X5C^NY3GE M"]-TCQZ2Y2PV)R-
IO8S7%]H=WS6[C4[5SDV(ODV;SSI=DTUCHIPU:$]MME%G MT(%SV48]EO-9+L"X5M>L!2SEH2,7CAK&Y0([_C.6C5S*WO*\3[JBVUQ>;'U]%2$YG.8/E3):S M6,YF.8?
E7);S6,YGN0#C6E6D%I^4Q?')XT SM6C")DK72?SX:KI)S(V_I&## MDBBGLYS!*-9IIM$W#^&S%&VC=29E^_/ (B_7H[?2J]]N'Y>N9AV6 MPDP*=U*XS:)D5PR'UH['2-
&_#^&V6&TY^:OT;I](B_S/^%;*[],WUZ=8WM_^ MLE3DQ4]I4XY3*3VDC]%NDS=^F^P?I"PBVMD*5\D=S;1-DZS\^_"HKG=.GXL
M&BN7>PB3WZ*L6/;4GE2V)IV']13=WN9['VW>A/GI>[')D90^;N.LV/MBV?JV MO#__<+M_BM),VH3Q]EGZ5AN#H3,$0X]RCC(7/__\IVQ\$IT_LOYE7#S-|"5\7K'^>K[8^E
MYJIZ2Z7Y-J6WSZ=?WFSCN], FH?\UQG,]R <:U/B=K MF6#YTHSI+V^9_WT/WQ1[@KODW/WU]Q]EP\C535MV,Q[/_T9+/!**>=N>8S MT"MYTGTNJ6=)I7M/KKM0>
[H^D]T%JW<7ININB MG,MR'LOY+!=@7*LRU,*ZLCBL6[)UOAX/UT\E'_//_MO(N$7Y6QZ%^6T[^*D M_@MF-KB+N7DQ49:([]9$7V78=EG-9SF,YG^4"C&L5E%HD5[XPX_FE
M]+_TGW$/!HC;&U]:V,PNRNDL9["R_DL%V!D)KV3:K> MM^!*F76G56[!!B<;9>)[V2(FQQ?%]@4-,KI+&>PG,ER%LO9+.>PG,MR M'LOY+!=@7*L0U5+0RI2]DT'F-Z]93F,YG>4,EC-
9SF(YF^4RG,5R-LLY+.>R MG,=R/LL%&-;] MLWC*'SIQ-+11A^5Y .-:M;26;U4N#$:;A<63<*=O;R[5C=X)Z)>= MDQ VG(IR.LL9+&>RG,5R-LLY+.>RG,=R/LL%&-QG,UR#LNY+.>Q
MG,]R <:UZH92]QOBQ.R?OWCRP[_CA\.#^,))O!7CSVG8H"W*Z2QGL)S]=:Y.5V7HY^>(KC!/HLN7 FQHQ:CG,9R.LL9 M+&>RG,5R-LLY+.>RG,=R/LL%&->]-
;68KCIGKX38P5U13F,YG>4,EC-9SF(Y MF^4;$!)L6MC^\];*87Y726,UC.9#GKS#7& M8UDNEI/\,\ QHNP[+N2SGL9S/<@'&M:I*+=:K7HCUGB^37ON"];^(L*/4HIS& ME<5,GL?
M&&'Y5R6\UC.9[D XUKUHA;,G5X8>O9T MVR2)UON[79P6D^S59Y/KKP[L^+,HI[&4]7G]\O6#3M=/NL*[SI=R>!D]GFS58 MSF0Y]^^@*/)TME)6G4K
)F)15F4YC^5\E@LP[E0)/]:W491I819^^ODA2NZB MZVB[+280/NRRHI':3_/3A]NB4/SX67G[L?-S3?[1E'M^;LD_VGT_=^0?W>// M/U;-?OKY,;R+_#"YBW>IM(UN\TV8?%CD'U1)?'?
_\HI[_YC7KK?2S3[+]@_' MO]Y'X29*B@7RW]_N]]GY'T4#3_ODM^-N?OK_4$L#!!0 (%*(;ED1 S4 M$00 -<0 9 >&PO=V]R:W-H965TZ^CAB562!<$NOV_OI+@")B2JOKFTI"
MGN_SY,.3'T]L\T^\GTA OQ*XI3WC8T0V8UI\G!#$LRO:492^69%68*%;+*U MR3-&\#(W2F(365;73'"4&H->WG?/!CVZ%7&4DGL&^#9),'L>D9CN^@8T7CH> MHO5&]
YST,OPFLR)>,SNF6R9E.T9 MJ*DL*/VI&K?+OF&IB$A,0]$DL/QY(F,2QTI)QO%O*6I4/I5A_?E%_7,^>3F9 M!>9D3,/T5)L^H9G@"59X6TL'NCN*RDGU%%Z(8UY_A?LBK%=Z3'<|!C=
:9& M2S7UD,/,K>7THU1]][E@\FTD[<1@/OXZ"1ZG$S#[#&;WDX?A/[=W7\!T,IQ/ MYF VFMY^D3VSNSGX$!"!HYA_!%?@<1Z #W]^]E"1J!TS++#T-B]\H5>\=<$W MFHH-!Y-
T29:'IJ:,O H?O80_0JV":VQKSH-W\&V;2 M'.J\'\S&KCZ&G>O9K^C-,L*PB-(UF!*9RR!?A5=T=;65C2'G1' P3)?EV]DB MCM98K1ZN^Q*%*T?O2FTG-SS#(>D;FQX)B!XB=
M"K'3IEY#'.<061TQ5H@_@0591VFJQBQPC-.0Z/ 6;MSPSH70[*)U6*F> ;H"-0BIW+)S1-KD:M731PMT>74A MG> ,G3?I=2MZW9/IX80R$?
V7KTX=OT*Q4\N**^A[R.TTLD;$KM@Y4#NRZRCFA S?%M M0V3#)HW6:,^E@?8T4"N-\98QE169.G9D.25/(_H:("T0= 3$\6WYW9L\6L,X M]2)8JM7I.AW7=O=P#W'L[|&P]0XYN*-
I^+M$[*/8NJYCP:,,N>C56./51SZ$ MG081LU;Q)82M\\J9@Y!N4U%43U5O59T/\YJTT3^"-^.BQM[+%"6_+&[D4<4E MJY64M*Y=F1RLJ**+AJ!97E7V.TMH6]LA1
'[W&4L(ZRXCR]4U4V6Z$8LEN2 MHD34+ B-(1=%NE192A&<9Z(X4@U-<]08XD3QV]F[9^]WR9I'.$'/%+!U'$/Z M<8\BLNTHNO+YX@4O5UR^4/UV"I=M6/A@D?::BI)8N
MC,\"_F*T93O/0/9D2LB:+#S..XHF&X0B-./2 8J_#>]A*))&HAG_"D^E3"F% MN\^?[OVL[Z(O4\A0CT2O>,Y7'<53P!PMX#KB+V3[@(K^V-)O1B*6_8)M$:LI
M8+9FG,2%6+0@QDG^#]\+#CL"W3HA,]!<;[+ 3FN0*K$%CG"NQ"D'5=S?N> M@0L@AWZ;DBV@,EJXR8>,?J86O' BY\F(4U&+A8[[H]Y#&$P&(1CV06_X-'I
M]L:3[@!,GH+'46\X>1]' >AU1P^@/QB^CD!_^ (&87#Q]_=\>/P"5P% MB$,9%[7 :X264"X]5<<]36=6IY$9TQU(X0QU%[#0,T0U2_!_? M=$?[534*39H%39]%#9GMC9=9CI=9Y^Z?
F'3WNU!M4NH M]E=0Q2]H]A%4V[%-NW4 M=;\4JA-FH4-F>U!=4]H3BW4,>$P NMDCMF,K!.. MYB#*=N8(PRF.,/^H0NX<(===W6U9V@'SVMR7,F_2+&S(;(^Y6S)W:YD/$&,
MQ^E:TL:"N4C!JS"[1YAO;%MS3?< U]/[2]LWM&G M3=<=U] .OVT5<:;G6)ZS'Q=4Q-FF;ICZ?EQ8$>=:AM:RR[B\G^K.H5A>><01 M;8D3)A;F0BBU6U?,")I?(_(")VEV3IX2+D[=V>-
W+P0E0&B?D$(_RS(HW=Y ME_/_U!+ P04 " !2B&Y9G@#2;L# #C#P &0 'AL+W=O4(E=OM5%QH$&"I3$NF48 SVA4:I-1FKLCD]& M;"?C*
(4[3L0N22C_,8.8'<:]3T/W$?;4.8#^F24T2UX(!^S.XX]O6()H@12 M$;&4<-B,M:EYZ9H*H%;\$\%!'+5)[LJ:L>]Y9Q&,-2.W"&+P94Y!\6/5Q#' M.1/:\5])JE5[YL#C\C/]9^4\.K.F
JY8_#4*9#C6'(T$L*&[6-ZSPKQG M?#Z+A*HEAW*MH1%_)R1+2C!:D$1I\4^?2B&. ,C3#+!*@'4*L%\ ]$I [[4 MNP382IG"%:6#2R6=C#@[$)ZO1K:\H<14:'0_2O-S]R3'V0AQ?-
'SPR7;KE[&IVL[C&Y:NE1]Z[(&D4"[*D MG-/\]#Z0,_+HN>3]WQ]&ND3C\BUTOS1D5AABO6#(@-RR5(:"S-, @CI>1Z@3=[]90Z,3TWB=DGF=D16$]ZNA+?;V"=?5>: @-]
M<,R$!-6$)OD*&M-0/'FZW4^,<]/$]I<_%J9UM[<*TQ%939A^)4R_59A5!OG% M2K?
$IR(D&_R""++A+"&LFHD!4[)H4JO@'AZ)99F.;3LG:C4L:M\=827O\$\GOF&7PG=)YG9$5A/>J81W7AG?*HH)%'>X24#G MURB]L(;.\"28?UUFVL:P?
QK,K6;]IM,7E=,7K4XO\:%ZH]R=;CD4]ZHM9EO9 MWGIUNB1S.R*KJ6@:/U^5QI^.VM*"CK3OE,WMBJVN_M&;WFR]Q<4-#B!C(I(D
MCN@ZBB/YHU"%5]8W]]@EFUNR'2<,IV\81I4O"GGTH^HG ;Y55:0@/MNELB@7 MJM&]4V]^NQD?&9>7A7UYD^:HOR]I7P;I0(SX08IC?,A/CAX45$6'1_4$L#!!0 (%*(;ED1< L#304
M 'XB 9 >&PO=V]R:W-H965T&0:V:EM*'*\V4BYNLFE55?U 8&RC!<8+8WOWWW>XA,&8'!L2OB2 M.>\Y[US,XV%+&.QY]BU>,"?0C\,-XK*V$6),_K>NRL6&#'G_B:A?*3!8\"6\C3
M:*G'ZXC9;AH4^#KI]4P]L+U0FXS2:_-H,N(;X7LAFT]9A-N?^WYXK56!MHR&4+>^.+![[[PG)#1]+G<#!,_Z)==]]A:,C9 MQ((':"L(/#"[+_]CV^(4@]^+8#D :0:T'\E@.8!-
#6:59;:NK*%/1E%?(>B MY&ZIEARD;9-&2S=>F'3CHXCDIYZ,$Y/'Z9?9U=/-#-U_1O.'^_GLX>L_Z.+N M"LW^?+J>W\[NQ](/5TS8GA]_1+^CI\2ZS/.25/":Z
MY:%8Q6@6NLS=C]=ES47AY*7P2P(*/K+U)T1[9XCT2+^FGNGIX10HAQ;M2%,] M^HK>)(S*Q(_S]#8; V'U7G.A*Q4*/FRV4[(T#*MD;XMFP'3M31C%&8,T,R%ZWK)=TU<5SX8
M6E\8]NNM%CI'#9]%01,T>.7%:O[;?JU!,+2!P18Z1PU:A4'KA.'(OO?(6,Q4 MC"-C$43.!X=C(V3YQL@P.#N$^P43$(EM#2 MX+ P.(3'8LE4G8-A71=5>VA8]YVB;MHK#/?4([+7?IK
L0WF21NAHZV/2QR M6PZPX],GE]X;7A8>XDKOP!6T=4B40P(ZO)-0G/ DVMK^AITX<7+-/6N&89"J M-3!U6VL*/C#X4#^P=D*7T4-?Q+#,JJ\N8 (KFL P3MPO%I[#RB!URX)G%M5"
M%*S5E*+>2VW?N4(;'3(D_B=]")OBBX8!2M(P3"E-&#*7&EO5)L#.JR.ZBZ8 M!"LHP3"5@%P)QS9YGG2!*UCQH:!!7YHMB"->I-=(MGS(A:#F5+_$AO=2. M2S!;2S=$<6OZ!.>>-
C)FKETT.>OWJDQ*NH:U'A3D$QIQCF$EJ4$;V5-5$%R1# M%,D0F&3 N07'-IA;;82.FU1,0V"F>0N0DD.Z&5JD^G,'+]"M004W!(;:5CR: M:^Y-,FM8_1T$9VJK3,$+@1=.FN-
H+EBV96'KA\8V*KBG-P#6T]EEX=P:1SC$EIW5K- M\,!$%S1#%FE-_D! MBY;I!H<8.7P3BNS=>'&UV$1QD6X=J%R_Q.?3;"N$DLEV9MS:D>S3&/EL(25[MGRS9;U&VV2$[$7R=
[A=XYD+P(#U<,=ME47*#_'S!N7@Y21(46TXF_P-02P,$ M% @ 4HAN6;"YI[F] P LQ(!D !X;"]W;W)K&ULM5C;;MLX$/T50ET4+"-;KZFMH#$I-FETLBCXPTL@F*HD]
M2=G)WY>49/D2A;4-]<4F*9[#F4/.;,31BK(?? $@T%,2IWQL+(3(SDV3!PM(M,#^C&:3R2419@H7LLKG),P8X+$!);#J6U3,33%++#&Q5C,^:-:"YBDL*,(9XG M"6;/EQ#3U=BPC?7
'9DOA!HPO5&&YW /XB&;,=DS:Y:0))!R0E/$(!H;%_;Y M;W<4H)CQ+X$5WVHCYBSNZ^@250UW%%]"8%[]H5<[M MN@8*^^_H\N;GTT_>?A M>G8SO?V*WOD@,(DYNL6,8;4U[]'?
Z.'>1^_>C\RA5Q9X MNJ&6I6' T34,(=_&FM+@VVUF;?>EH">\A.T.N]0$YEM-IL&=R.-QM@/MZ^ UF M$FX7<$?CC5MO@EOPN:IM I-QS,3S!S2+<2H03D,T_9F33 :80-\^R^GH6D#"
MOS=)7W)WFKE5WCCG&0Y@:,C$P($MP?#>OK%[UL WN(D^X@B\]1ZC=)HF8Z5IDTRO_M2FM['39+TZNEZ6FEF>4L M6,AC@VB$LBHF45:')*Q#LDFJW@N#K-J8TO_?
SO"UUIT8+_W:I][6=Q\D:4!P M\3:&)UE7\.8ST7_AAC/L]_=\/622KS7H1'<'M;N#]/#]59Z0-]N('D$UIAG MM83'!D.;9'Y+9#M"#FLAAW_PW35L4]VR?R6R'8TM:U-56:=E*11SB'*8Q23
M"!K+,#UM%ST#9DUA/=$CCU7O%#MVI=HJ8.UV$E?%L_CC7/@,5J>;4^1+HLIV<\-B1;9?/;8MM51LUVKIWBJ;_QN7-1G0W/]:3X#-BUL1C@*:IZ+\0JY'ZYN7B^*^ M86_\TCZ?E/J1
T*9H+ MP"$P-4$^CR@5ZXY:H+ZG\GX!4$L#!!0 (%*(;EEQ2-9-Z < *92 9 M >&PO=V]R:W-H965TLVP_3?DB#::,C>>8]D[:'S\[Y @IKH^2+4K'OKE M1K!D607EZ[XS&(S[>9(5O?
E%=>Q6S" X5]ZS@MT*4F[S/!%?KMB:/U_V:,_K M@0_9PZ/4! KSBTWRP!9,WFUNA=KK[RG++&=%F?&""+:Z[+VCY_%PH .]$G]E M[+D\V";ZK=QS_E'OQ,O+WD"?
$5NS5&I$HIZ>V#5;KS5)G<>G&MK;Y]2!A]M? MZ4'UYM6;N4]*=LW7?V=+^7C9F_;(D]V2[5I^X,\1J]^0JWDI7Y?5(WFNRPYZ M)-V6DN=UL#]#/"MVS\GG^D("\#'!?"1C6 <-3,XS]@-
&I&=PZ MP#TUP[@,&+\,&+\2,*D#)]=FF-8!TU,#9G7 K)+#]O.K/GPODU\/^X\]__2?R_U.."_PQF63KDKQ/ MA$BT%'\A:\G=PB,___C+15^JI#JTG]8)KG<)G%
<24'+#"_E8$K]8LJ4AWK?' MC[\5'WXCOV,!]-75VE\RY^LENW*LQ/?\Z8Q0YPUQ!L[(=$%."!\.7@WW]&_ MIU*%TU?#?7OX@FVLV8/3PX>F#\,>?I,(Z\E'IX>;LL?V<(^E9\39A5.+$(;[
M[\ZPX@U?NQC;^Y)]VK)"$O])/_[SFRI!8LGR\E_#Z5WM<',S3M_6SLM-DK++ MGKIOE4P\L=[\IQ_H>/"K265(F(>$^4A8@(2%2%B$A,4@6$O'H[V.1S:Z^E[< M2[)2=)+D?
%M(DW2MA*[21<(),Q'P@(D+$3"(B0LWL$F%4RWK9_4/7#+-V]+%VK+&\%3QE;EF0E>$[*1RXDD4SDJBU[;]2H%==5HTB8AX3Y[M'U M?DNIXU(ZWE_OG?Z."TXF0_7?
+A8>%YNZP\%PT"X6'1>CH\F8ZCOI8;D8]%Y:MDAGO)3.V2N9/+8\U3PK"/F>J3F/,I!,KHZM.D# /"?.1L)"Y&P" F+QP:1
MCV;NT%R33?:RG%AE>=Q0O&'Y/1/&1J(5U56=2)B'A/E(6("$A4A8A(3%(%A+ MP].\AJ?8SLX4J6,DS$/"?"0L0,)")"Q"PF(0K*7CV5[',VM=?%>4+-T*MB0I M+YZ8D-G]FI&-
:F)F9SEI%TGPH+8#20B@M M@M)B%*VM5:?1JM.I@LT*I5162LM(:$T\5.ML9%*K-7-GM2)I/O60&DAE!9!
M:3&*UE9KXS=1JPTP_UL[LH4L5:6:*#Y1+=:MN:U:@S#*G50_[W4*=1(@M\ M*'V TD(H+8+28A2MK=/&3Z)V0VFOTXW(4M6Y8F*G6*-2=ZC9@5('9^Y+C4(= M(RC-A]
("*"V$TB(H+4;1VAIMS"5J=Y=.LPJHR?5P3'=[J%\$I?E06@"EA5!: M!*7%*%I;H8V71>UFUJNN ?F/+)C(5 /@BEP?#&)]8$O&\D1OW@JV8D*/&I3F06D^ ME!9
;2&4%D%L8K65G3CI5&KQ3&/5<BQ2P9-'$!I(90606DQBM:>D]]898I=XUH< M#
(F9U&D/[ZI.*,VK::WJTS!4YT.S!E!:"*5%4%],HK6EV1ABCMT04WVT>\GSUA&^S9.PL;;K)!;3Z4%D!I(906 M06DQBM;6?V.R.>!?=3G0GW5!:1Z4YD-I 9060FD1E!:C:&U%-W:<8[?
COG_* MHQW<6=]C8S-E/#MJ.'C0K#Z4%D!I(90606DQBM86;>//.79_[GN&R.S(SG)U MCWIEHYECD"O4K(/2 B@MA-(B*"U&T=IR;M*CG]^3*@TG#^:! M-
BY5M.FK>D_SLL:%NJ906D!E!9":1&4\J-H::DVGIEC]\Q.6:7 CNBLS>EQ M>]4US:'TH'E]"V TD(H+8+28A2M+=#&)'/L)MFN+]U6 :OF/1H%"O7(:IIU
M[]0'3>E#:0&4%D)I$906HVCMA8H:=VQH=\>^XSYO)W:5:DUKW^=?+!WA05Z M4%H I8506@2EQ2C:3JK]@[7IJH4-2U(I4"&POO#!@LJL7U\SCW7OFG<]DNS
M%.QAQI@)%KF0Y8#,C"D^AF$YF;&J8-(BF=(Y-;:KIV%9:$;3$DBY"#NM M5ASFE$LRL,MY?I>;.IBHN30#TFV& G?]D@Y(.[XF@9.;]90-R-/%^Y]S96[?
M!>Y^]N'LK'75:K6>+F]WL8L&O"2A5_SF '%4&!.-MT6KN>=6Q;'.,5KWL$3W MY8E)]SR.[/2U*>A@Y,1+WJ BQ&[KH(3VY%,)AW69#/N9DNMJB8@;L)%ISH)G M*@9D1
4?:PZLC.9<+-UP!P8F2B@=&%NFUDH;1LH7![==#RJXULFY5+]*[2*X M[W$]?0=8]< @%Z(QV"%N8-@OJ#%,RSO;J297@Z^@H&X_+@OK<*KILMVY(6M" M=;-
!QDJG3#=AVF0U-.P+EH$=S:/[(M[46VL:?5CLJF:0W532?C.]"_J>:T-V6OWZ0;%/Q9F<]SFXZL^E K M[%ZSC"^J_B)K#&#J;5R=%H58?A)*G/FDC\XX+!/5[Q@IC1_L=&@5"9V@&D2
M/#-M^&1SY)>FQ2-;F%4Y+3+<<^<$/?_==9XRR305FZ9M[1_S*K_9<=3]5Y:K MWRJ[AKT>ZW?VL9N\.063\2F8/(F:[)V"R>3X348GX+$^>QZ=R;
^"6TQ#AJ,YUP8+NO>C*T+`]0VU+W\Y/64;GPCPV MX("LV[]8RN=YTLRZAX6H9ZW;7R&]=MR"5BF>)K=&A_W8"1)/[=QN((L%K'8@OCU\)22$T6PJY@W[G&D23! M$*A%?XW&,;
(Z,7S\^X,])5&4)'X$,+^#*,(0>!IQ!', 'C DBJKWX,[[*%R] MI\+U?R^'OP%02P,$% @ 4HAN69>*NQS $P(L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7-

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end XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 415 379 1 false 94 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://biotricity.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://biotricity.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://biotricity.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Sheet http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Deficiency (Unaudited) Sheet http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Deficiency (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://biotricity.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995612 - Disclosure - NATURE OF OPERATIONS Sheet http://biotricity.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 9 false false R10.htm 995613 - Disclosure - BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION Sheet http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidation BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION Notes 10 false false R11.htm 995614 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://biotricity.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 11 false false R12.htm 995615 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://biotricity.com/role/AccountsPayableAndAccruedLiabilities ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Notes 12 false false R13.htm 995616 - Disclosure - CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS Notes http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoans CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS Notes 13 false false R14.htm 995617 - Disclosure - TERM LOAN AND CREDIT AGREEMENT Sheet http://biotricity.com/role/TermLoanAndCreditAgreement TERM LOAN AND CREDIT AGREEMENT Notes 14 false false R15.htm 995618 - Disclosure - FEDERALLY GUARANTEED LOAN Sheet http://biotricity.com/role/FederallyGuaranteedLoan FEDERALLY GUARANTEED LOAN Notes 15 false false R16.htm 995619 - Disclosure - DERIVATIVE LIABILITIES Sheet http://biotricity.com/role/DerivativeLiabilities DERIVATIVE LIABILITIES Notes 16 false false R17.htm 995620 - Disclosure - STOCKHOLDERS??? DEFICIENCY Sheet http://biotricity.com/role/StockholdersDeficiency STOCKHOLDERS??? DEFICIENCY Notes 17 false false R18.htm 995621 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS Sheet http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligations OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS Notes 18 false false R19.htm 995622 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://biotricity.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 19 false false R20.htm 995623 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://biotricity.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 20 false false R21.htm 995624 - Disclosure - SUBSEQUENT EVENTS Sheet http://biotricity.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 21 false false R22.htm 995625 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 22 false false R23.htm 995626 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://biotricity.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 995627 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://biotricity.com/role/AccountsPayableAndAccruedLiabilitiesTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Tables http://biotricity.com/role/AccountsPayableAndAccruedLiabilities 24 false false R25.htm 995628 - Disclosure - DERIVATIVE LIABILITIES (Tables) Sheet http://biotricity.com/role/DerivativeLiabilitiesTables DERIVATIVE LIABILITIES (Tables) Tables http://biotricity.com/role/DerivativeLiabilities 25 false false R26.htm 995629 - Disclosure - STOCKHOLDERS??? DEFICIENCY (Tables) Sheet http://biotricity.com/role/StockholdersDeficiencyTables STOCKHOLDERS??? DEFICIENCY (Tables) Tables http://biotricity.com/role/StockholdersDeficiency 26 false false R27.htm 995630 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Tables) Sheet http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsTables OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Tables) Tables http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligations 27 false false R28.htm 995631 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://biotricity.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://biotricity.com/role/PropertyAndEquipment 28 false false R29.htm 995632 - Disclosure - SCHEDULE OF REVENUE RECOGNITION (Details) Sheet http://biotricity.com/role/ScheduleOfRevenueRecognitionDetails SCHEDULE OF REVENUE RECOGNITION (Details) Details 29 false false R30.htm 995633 - Disclosure - SCHEDULE OF INVENTORIES (Details) Sheet http://biotricity.com/role/ScheduleOfInventoriesDetails SCHEDULE OF INVENTORIES (Details) Details 30 false false R31.htm 995634 - Disclosure - SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Sheet http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Details 31 false false R32.htm 995635 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES (Details) Sheet http://biotricity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES (Details) Details 32 false false R33.htm 995636 - Disclosure - BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION (Details Narrative) Sheet http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION (Details Narrative) Details http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidation 33 false false R34.htm 995637 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Sheet http://biotricity.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Details 34 false false R35.htm 995638 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative) Sheet http://biotricity.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative) Details http://biotricity.com/role/AccountsPayableAndAccruedLiabilitiesTables 35 false false R36.htm 995639 - Disclosure - CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS (Details Narrative) Notes http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS (Details Narrative) Details http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoans 36 false false R37.htm 995640 - Disclosure - TERM LOAN AND CREDIT AGREEMENT (Details Narrative) Sheet http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative TERM LOAN AND CREDIT AGREEMENT (Details Narrative) Details http://biotricity.com/role/TermLoanAndCreditAgreement 37 false false R38.htm 995641 - Disclosure - FEDERALLY GUARANTEED LOAN (Details Narrative) Sheet http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative FEDERALLY GUARANTEED LOAN (Details Narrative) Details http://biotricity.com/role/FederallyGuaranteedLoan 38 false false R39.htm 995642 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITIES (Details) Sheet http://biotricity.com/role/ScheduleOfDerivativeLiabilitiesDetails SCHEDULE OF DERIVATIVE LIABILITIES (Details) Details 39 false false R40.htm 995643 - Disclosure - SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS (Details) Sheet http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS (Details) Details 40 false false R41.htm 995644 - Disclosure - SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY (Details) Sheet http://biotricity.com/role/ScheduleOfSeriesBPreferredStockForMezzanineEquityDetails SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY (Details) Details 41 false false R42.htm 995645 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details) Sheet http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails SCHEDULE OF WARRANTS OUTSTANDING (Details) Details 42 false false R43.htm 995646 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITIES (Details) Sheet http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails SCHEDULE OF STOCK OPTION ACTIVITIES (Details) Details 43 false false R44.htm 995647 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS (Details) Sheet

http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS (Details) Details 44 false false R45.htm 995648 - Disclosure - STOCKHOLDERS??? DEFICIENCY (Details Narrative) Sheet http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative STOCKHOLDERS??? DEFICIENCY (Details Narrative) Details http://biotricity.com/role/StockholdersDeficiencyTables 45 false false R46.htm 995649 - Disclosure - SCHEDULE OF OPERATING LEASES OBLIGATIONS (Details) Sheet http://biotricity.com/role/ScheduleOfOperatingLeasesObligationsDetails SCHEDULE OF OPERATING LEASES OBLIGATIONS (Details) Details 46 false false R47.htm 995650 - Disclosure - SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION (Details) Sheet http://biotricity.com/role/ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION (Details) Details 47 false false R48.htm 995651 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Details Narrative) Sheet http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Details Narrative) Details http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsTables 48 false false R49.htm 995652 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 49 false false R50.htm 995653 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://biotricity.com/role/PropertyAndEquipmentTables 50 false false R51.htm 995654 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://biotricity.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://biotricity.com/role/SubsequentEvents 51 false false All Reports Book All Reports btcy-20240930.xsd btcy-20240930_cal.xml btcy-20240930_def.xml btcy-20240930_lab.xml btcy-20240930_pre.xml form10-q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "BTCY", "nsuri": "http://biotricity.com/20240930", "dts": { "schema": { "local": ["btcy-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["btcy-20240930_cal.xml"] }, "definitionLink": { "local": ["btcy-20240930_def.xml"] }, "labelLink": { "local": ["btcy-20240930_lab.xml"] }, "presentationLink": { "local": ["btcy-20240930_pre.xml"] }, "inline": { "local": ["form10-q.htm"] } }, "keyStandard": 303, "keyCustom": 76, "axisStandard": 23, "axisCustom": 0, "memberStandard": 30, "memberCustom": 60, "hidden": { "total": 148, "http://fasb.org/us-gaap/2024": 117, "http://biotricity.com/20240930": 26, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 415, "entityCount": 1, "segmentCount": 94, "elementCount": 681, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1203, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://biotricity.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://biotricity.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R3": { "role": "http://biotricity.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:CommonStockSharesIssued", "span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R4": { "role": "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:CostOfRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R5": { "role": "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "longName": "00000005 - Statement - Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Deficiency (Unaudited)", "shortName": "Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Deficiency (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2023-03-31_us-gaap_PreferredStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-03-31_us-gaap_PreferredStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R6": { "role": "http://biotricity.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://biotricity.com/role/NatureOfOperations", "longName": "995612 - Disclosure - NATURE OF OPERATIONS", "shortName": "NATURE OF OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidation", "longName": "995613 - Disclosure - BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION", "shortName": "BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://biotricity.com/role/SummaryOfSignificantAccountingPolicies", "longName": "995614 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://biotricity.com/role/AccountsPayableAndAccruedLiabilities", "longName": "995615 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoans", "longName": "995616 - Disclosure - CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS", "shortName": "CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://biotricity.com/role/TermLoanAndCreditAgreement", "longName": "995617 - Disclosure - TERM LOAN AND CREDIT AGREEMENT", "shortName": "TERM LOAN AND CREDIT AGREEMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "BTCY:BankLoanCreditAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "BTCY:BankLoanCreditAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://biotricity.com/role/FederallyGuaranteedLoan", "longName": "995618 - Disclosure - FEDERALLY GUARANTEED LOAN", "shortName": "FEDERALLY GUARANTEED LOAN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "BTCY:FederallyGuaranteedLoansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "BTCY:FederallyGuaranteedLoansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://biotricity.com/role/DerivativeLiabilities", "longName": "995619 - Disclosure - DERIVATIVE LIABILITIES", "shortName": "DERIVATIVE LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor":

{ "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://biotricity.com/role/StockholdersDeficiency", "longName": "995620 - Disclosure - STOCKHOLDERS\u2019 DEFICIENCY", "shortName": "STOCKHOLDERS\u2019 DEFICIENCY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligations", "longName": "995621 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS", "shortName": "OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://biotricity.com/role/CommitmentsAndContingencies", "longName": "995622 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://biotricity.com/role/PropertyAndEquipment", "longName": "995623 - Disclosure - PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R21": { "role": "http://biotricity.com/role/SubsequentEvents", "longName": "995624 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "995625 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R23": { "role": "http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "995626 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R24": { "role": "http://biotricity.com/role/AccountsPayableAndAccruedLiabilitiesTables", "longName": "995627 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R25": { "role": "http://biotricity.com/role/DerivativeLiabilitiesTables", "longName": "995628 - Disclosure - DERIVATIVE LIABILITIES (Tables)", "shortName": "DERIVATIVE LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R26": { "role": "http://biotricity.com/role/StockholdersDeficiencyTables", "longName": "995629 - Disclosure - STOCKHOLDERS\u2019 DEFICIENCY (Tables)", "shortName": "STOCKHOLDERS\u2019 DEFICIENCY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "BTCY:ScheduleOfSeriesBPreferredStockForMezzanineEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "BTCY:ScheduleOfSeriesBPreferredStockForMezzanineEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R27": { "role": "http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsTables", "longName": "995630 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Tables)", "shortName": "OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "BTCY:OperatingLeasesOfLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "BTCY:OperatingLeasesOfLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R28": { "role": "http://biotricity.com/role/PropertyAndEquipmentTables", "longName": "995631 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R29": { "role": "http://biotricity.com/role/ScheduleOfRevenueRecognitionDetails", "longName": "995632 - Disclosure - SCHEDULE OF REVENUE RECOGNITION (Details)", "shortName": "SCHEDULE OF REVENUE RECOGNITION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30_custom_TechnologyFeesMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R30": { "role": "http://biotricity.com/role/ScheduleOfInventoriesDetails", "longName": "995633 - Disclosure - SCHEDULE OF INVENTORIES (Details)", "shortName": "SCHEDULE OF INVENTORIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R31": { "role": "http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "longName": "995634 - Disclosure - SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "shortName": "SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R32": { "role": "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails", "longName": "995635 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES (Details)", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2024-09-30_us-gaap_OfficeEquipmentMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "td", "tr", "table", "BTCY:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30_us-gaap_OfficeEquipmentMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "td", "tr", "table", "BTCY:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R33": { "role": "http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "longName": "995636 - Disclosure - BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION (Details Narrative)", "shortName": "BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION

(Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-04-012024-03-31", "name": "BTCY:PlacementFeePercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R34": { "role": "http://biotricity.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "longName": "995637 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "shortName": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:AccountsPayableOtherCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:AccountsPayableOtherCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R35": { "role": "http://biotricity.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative", "longName": "995638 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative)", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:OtherAccountsPayableAndAccruedLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:OtherAccountsPayableAndAccruedLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R36": { "role": "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "longName": "995639 - Disclosure - CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS (Details Narrative)", "shortName": "CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2022-04-012023-03-31", "name": "us-gaap:DebtConversionDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:AmortizationOfDebtDiscountPremium", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R37": { "role": "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative", "longName": "995640 - Disclosure - TERM LOAN AND CREDIT AGREEMENT (Details Narrative)", "shortName": "TERM LOAN AND CREDIT AGREEMENT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2021-12-21", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "span", "p", "BTCY:BankLoanCreditAgreementTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2021-12-212021-12-21", "name": "us-gaap:SubordinatedBorrowingInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "BTCY:BankLoanCreditAgreementTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R38": { "role": "http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative", "longName": "995641 - Disclosure - FEDERALLY GUARANTEED LOAN (Details Narrative)", "shortName": "FEDERALLY GUARANTEED LOAN (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "From2021-12-212021-12-21", "name": "us-gaap:ProceedsFromLoans", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "BTCY:BankLoanCreditAgreementTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2021-05-012021-05-31_custom_EconomicInjuryDisasterLoanMember", "name": "us-gaap:ProceedsFromLoans", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "BTCY:FederallyGuaranteedLoansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R39": { "role": "http://biotricity.com/role/ScheduleOfDerivativeLiabilitiesDetails", "longName": "995642 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITIES (Details)", "shortName": "SCHEDULE OF DERIVATIVE LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "BTCY:ReductionDueToPreferredSharesConverted", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R40": { "role": "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "longName": "995643 - Disclosure - SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS (Details)", "shortName": "SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31_us-gaap_ConvertibleDebtMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R41": { "role": "http://biotricity.com/role/ScheduleOfSeriesBPreferredStockForMezzanineEquityDetails", "longName": "995644 - Disclosure - SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY (Details)", "shortName": "SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "BTCY:ConvertiblePreferredStock", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "BTCY:ScheduleOfSeriesBPreferredStockForMezzanineEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "BTCY:ConvertiblePreferredStock", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "BTCY:ScheduleOfSeriesBPreferredStockForMezzanineEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R42": { "role": "http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails", "longName": "995645 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)", "shortName": "SCHEDULE OF WARRANTS OUTSTANDING (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R43": { "role": "http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails", "longName": "995646 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITIES (Details)", "shortName": "SCHEDULE OF STOCK OPTION ACTIVITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31_us-gaap_StockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R44": { "role": "http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails", "longName": "995647 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS (Details)", "shortName": "SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R45": { "role": "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative", "longName": "995648 - Disclosure - STOCKHOLDERS\u2019 DEFICIENCY (Details Narrative)", "shortName": "STOCKHOLDERS\u2019 DEFICIENCY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:DebtInstrumentRedemptionPricePercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R46": { "role": "http://biotricity.com/role/ScheduleOfOperatingLeasesObligationsDetails", "longName": "995649 - Disclosure - SCHEDULE OF OPERATING LEASES OBLIGATIONS (Details)", "shortName": "SCHEDULE OF OPERATING LEASES OBLIGATIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-03-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "BTCY:OperatingLeasesOfLesseeTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R47": { "role": "http://biotricity.com/role/ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails", "longName": "995650 - Disclosure - SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION (Details)", "shortName": "SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "BTCY:ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "BTCY:ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1,

"baseRef": "form10-q.htm", "first": true, "unique": true } }, "R48": { "role": "http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative", "longName": "995651 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Details Narrative)", "shortName": "OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R49": { "role": "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails", "longName": "995652 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R50": { "role": "http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "995653 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "AsOf2022-03-31", "name": "us-gaap:LeaseholdImprovementsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-03-31", "name": "us-gaap:LeaseholdImprovementsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R51": { "role": "http://biotricity.com/role/SubsequentEventsDetailsNarrative", "longName": "995654 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2021-12-21", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "span", "p", "BTCY:BankLoanCreditAgreementTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-10-012024-10-31_us-gaap_SubsequentEventMember", "name": "us-gaap:ProceedsFromUnsecuredNotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "td", "tr", "table", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://biotricity.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities [Note 4]", "totalLabel": "Total", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r73", "r74"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://biotricity.com/role/AccountsPayableAndAccruedLiabilities"], "lang": { "en-us": { "role": { "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r71", "r74", "r81", "r841"] }, "us-gaap_AccountsPayableOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrent", "crdr": "credit", "calculation": { "http://biotricity.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://biotricity.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Trade and other payables", "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r71"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r792"] }, "us-gaap_AccountsReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetNoncurrent", "crdr": "debit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-term accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent." } } }, "auth_ref": ["r477", "r792"] }, "BTCY_AccreditedInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "AccreditedInvestorsMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accredited Investors [Member]", "documentation": "Accredited Investors [Member]" } } }, "auth_ref": [] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 }, "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows", "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Accretion and amortization expenses [Note 5,6]", "negatedLabel": "Accretion and amortization expenses", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r107"] }, "us-gaap_AccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionExpense", "crdr": "debit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accretion expense", "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations." } } }, "auth_ref": ["r631", "r802"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://biotricity.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r74"] }, "BTCY_AccumulatedDeficitDeemedDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "AccumulatedDeficitDeemedDividend", "crdr": "credit", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Deemed Dividend [Note 9]", "documentation": "Accumulated deficit deemed dividend." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Accumulated depreciation, beginning balance", "periodEndLabel": "Accumulated depreciation, ending balance", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r42", "r169", "r492"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1", "crdr": "debit", "presentation": ["http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Disposals", "label": "Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment", "documentation": "Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": ["http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r185", "r186", "r441", "r442", "r443", "r444", "r445", "r446"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive (loss) / income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r23", "r24", "r95", "r175", "r487", "r516", "r517"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": ["http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r185", "r186", "r441", "r442", "r443", "r444", "r445", "r446"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r3", "r13", "r24", "r415", "r418", "r463", "r512", "r513", "r769", "r770", "r771", "r781", "r782", "r783", "r784"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r718"] }, "BTCY_AdditionalCollateralizedBridgeLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "AdditionalCollateralizedBridgeLoanAgreementMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Additional Collateralized Bridge Loan Agreement [Member]", "documentation": "Additional Collateralized Bridge Loan Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid-in-capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r87", "r653", "r906"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",

```
"localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r528", "r781", "r782", "r783", "r784", "r844", "r909" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r724" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r724" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r724" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r724" ] }, "BTCY_AdjustmentCarryingValueAndPrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "AdjustmentCarryingValueAndPrincipalAmount", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Adjustment carrying value and principal amount", "documentation": "Adjustment carrying value and principal amount." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency" ], "lang": { "en-us": { "role": { "label": "Stock based compensation - ESOP [Note 9]", "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://biotricity.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operations:" } } }, "auth_ref": [] }, "us-gaap_AdministrativeFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdministrativeFeesExpense", "crdr": "debit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Administrative fees", "label": "Administrative Fees Expense", "documentation": "Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost." } } }, "auth_ref": [ "r66", "r569", "r908" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r689", "r700", "r710", "r735" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r692", "r703", "r713", "r738" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r724" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r731" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r693", "r704", "r714", "r731", "r739", "r743", "r751" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "auth_ref": [ "r749" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Adjustment for amortization", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r9", "r101", "r310", "r857" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": [ "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amortization of debt discount expense", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r310", "r635", "r636", "r777", "r857" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r696" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r408" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biotricity.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r132", "r145", "r170", "r201", "r229", "r233", "r247", "r248", "r254", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r409", "r411", "r439", "r482", "r562", "r626", "r627", "r653", "r670", "r808", "r809", "r864" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biotricity.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r164", "r178", "r201", "r254", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r409", "r411", "r439", "r653", "r808", "r809", "r864" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://biotricity.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Total assets at fair value", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r426", "r427", "r645" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r696" ] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [ "r746" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r747" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r742" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r742" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": [ "r742" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r742" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r742" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": [ "r742" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r351", "r352", "r353", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r375", "r376", "r377", "r378", "r379" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": [ "r745" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r744" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r743" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r743" ] }, "BTCY_BankLoanCreditAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biotricity.com/20240930", "localname": "BankLoanCreditAgreementTextBlock", "presentation": [ "http://biotricity.com/role/TermLoanAndCreditAgreement" ], "lang": { "en-us": { "role": { "label": "TERM LOAN AND CREDIT AGREEMENT", "documentation": "Bank Loan Credit Agreement [Text Block]" } } }, "auth_ref": [] }, "BTCY_BeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "BeneficiaryMember", "presentation": [ "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Beneficiary [Member]", "documentation": "Beneficiary [Member]" } } }, "auth_ref": [] }, "BTCY_BrokerWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "BrokerWarrantsMember", "presentation": [ "http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Broker Warrants [Member]", "documentation": "Broker Warrants
```

[Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidation"], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r70", "r108", "r109"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r28", "r167", "r617"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r167"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r845", "r846"] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": ["http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r29"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, beginning of period", "periodEndLabel": "Cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r28", "r104", "r197"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net (increase) decrease in cash during the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r2", "r104"] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashMember", "presentation": ["http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": ["r167"] }, "BTCY_ChangeInFairValueusMeasurementWithReconciliationRecurringBasisLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ChangeInFairValueusMeasurementWithReconciliationRecurringBasisLiability", "crdr": "credit", "presentation": ["http://biotricity.com/role/ScheduleOfSeriesBPreferredStockForMezzanineEquityDetails"], "lang": { "en-us": { "role": { "label": "Recognition of derivative liabilities (Note 8)", "documentation": "Change in fair valueus measurement with reconciliation recurring basis liability." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r722"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative", "http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r161", "r172", "r173", "r174", "r201", "r220", "r221", "r224", "r226", "r231", "r232", "r254", "r279", "r281", "r282", "r283", "r286", "r287", "r318", "r319", "r323", "r326", "r333", "r439", "r521", "r522", "r523", "r524", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r550", "r571", "r590", "r605", "r606", "r607", "r608", "r609", "r759", "r778", "r785"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r172", "r173", "r174", "r231", "r318", "r319", "r321", "r323", "r326", "r331", "r333", "r521", "r522", "r523", "r524", "r637", "r759", "r778"] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails", "http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Exercise Price", "label": "Warrants price per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r334"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants issued", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants shares issues", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees", "presentation": ["http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Expiration Date", "label": "Warrant or Right, Reason for Issuance, Description", "documentation": "Description of reason for issuing warrant or right." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r723"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": ["r723"] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r408"] }, "BTCY_CollateralizedBridgeLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "CollateralizedBridgeLoanAgreementMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collateralized Bridge Loan Agreement [Member]", "documentation": "Collateralized Bridge Loan Agreement [Member]" } } }, "auth_ref": [] }, "BTCY_CollateralizedMerchantFinanceCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "CollateralizedMerchantFinanceCompanyMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collateralized Merchant Finance Company [Member]", "documentation": "Collateralized Merchant Finance Company [Member]" } } }, "auth_ref": [] }, "BTCY_CollateralizedMerchantFinanceCompanyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "CollateralizedMerchantFinanceCompanyOneMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collateralized Merchant Finance Company One [Member]", "documentation": "Collateralized Merchant Finance Company One [Member]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://biotricity.com/role/CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r114", "r271", "r272", "r611", "r797", "r803"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r659", "r660", "r661", "r663",

"r664", "r665", "r666", "r781", "r782", "r784", "r844", "r905", "r909"] }, "us-gaap_CommonStockOtherSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockOtherSharesOutstanding", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, other shares, outstanding", "documentation": "Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, par value", "verboseLabel": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r86"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "verboseLabel": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r86", "r550"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares, issued", "verboseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r86"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r14", "r86", "r550", "r568", "r909", "r910"] }, "BTCY_CommonStockSharesToBeIssued": { "xbrltype": "sharesItemType", "nsuri": "http://biotricity.com/20240930", "localname": "CommonStockSharesToBeIssued", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock shares to be issued", "documentation": "Common stock shares to be issued." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value, 125,000,000 shares authorized as at September 30, 2024, and March 31, 2024, respectively. Issued and outstanding common shares: 22,863,261 and 9,353,768 as at September 30, 2024 and March 31, 2024, respectively, and exchangeable shares of 160,672 outstanding as at September 30, 2024 and March 31, 2024, respectively [Note 9]", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r86", "r485", "r653"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r728"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r727"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r729"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r726"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "COMPREHENSIVE LOSS", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r25", "r181", "r183", "r188", "r478", "r497", "r498"] }, "BTCY_ConsultantWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ConsultantWarrantsMember", "presentation": ["http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Consultant Warrants [Member]", "documentation": "Consultant Warrants [Member]" } } }, "auth_ref": [] }, "BTCY_ConversionIntoCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ConversionIntoCommonShares", "crdr": "credit", "presentation": ["http://biotricity.com/role/ScheduleOfSeriesBPreferredStockForMezzanineEquityDetails", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Conversion into common shares", "verboseLabel": "Conversion of common shares", "documentation": "Conversion into common shares." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Conversion to common shares", "label": "Conversion of Stock, Amount Converted", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r31", "r32", "r33"] }, "BTCY_ConversionOfStockAmountModification": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ConversionOfStockAmountModification", "crdr": "debit", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Convertible note modification", "documentation": "Conversion of stock amount modification." } } }, "auth_ref": [] }, "BTCY_ConversionOfStockAmountRedemption": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ConversionOfStockAmountRedemption", "crdr": "debit", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Convertible note redemption", "documentation": "Conversion of stock amount redemption." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Conversion of preferred stock shares", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r31", "r32", "r33"] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": ["http://biotricity.com/role/DerivativeLiabilitiesTables", "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": ["r116", "r289", "r290", "r300", "r301", "r302", "r306", "r307", "r308", "r309", "r310", "r632", "r633", "r634", "r635", "r636"] }, "BTCY_ConvertibleNoteAndWarrantDerivativeMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ConvertibleNoteAndWarrantDerivativeMember", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Convertible Note and Warrant Derivative [Member]", "documentation": "Convertible Note and Warrant Derivative [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Convertible notes payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": ["r20", "r135", "r874"] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Convertible promissory notes and short term loans [Note 5]", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": ["r74"] }, "BTCY_ConvertibleNotesPayableRemaining": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ConvertibleNotesPayableRemaining", "crdr": "credit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Convertible notes payable remaining", "documentation": "Convertible notes payable remaining." } } }, "auth_ref": [] }, "BTCY_ConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ConvertiblePreferredStock", "crdr": "credit", "presentation": ["http://biotricity.com/role/ScheduleOfSeriesBPreferredStockForMezzanineEquityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance beginning of period \u2013 March 31", "periodEndLabel": "Balance end of period \u2013 September 30", "documentation": "Convertible preferred stock.", "label": "ConvertiblePreferredStock" } } }, "auth_ref": [] }, "BTCY_ConvertiblePreferredStockPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ConvertiblePreferredStockPolicyTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Series B Convertible Preferred Stock", "documentation": "Convertible Preferred Stock [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r98", "r201", "r254", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r439", "r626", "r808"] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r278", "r806"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r278", "r806", "r807"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Debt conversion converted instrument amount", "verboseLabel": "Debt converted amount", "terseLabel": "Instrument amount", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of

```
the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r31", "r33" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Converted instrument shares issued", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r31", "r33" ] }, "us-gaap_DebtConversionDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionDescription", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt conversion description", "documentation": "Description of conversion of original debt instrument in noncash or part noncash transaction." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoans" ], "lang": { "en-us": { "role": { "label": "CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r115", "r199", "r264", "r265", "r266", "r267", "r268", "r277", "r278", "r288", "r294", "r295", "r296", "r297", "r298", "r299", "r304", "r311", "r312", "r314", "r449" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative", "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative", "http://biotricity.com/role/SubsequentEventsDetailsNarrative", "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r20", "r73", "r74", "r133", "r135", "r202", "r289", "r290", "r291", "r292", "r293", "r295", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r632", "r633", "r634", "r635", "r636", "r651", "r779", "r798", "r799", "r800", "r856", "r858" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument carrying amount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r20", "r135", "r315" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r117", "r291" ] }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of conversion terms for debt instrument", "documentation": "Description of conversion terms for debt instrument." } } }, "auth_ref": [ "r50", "r78", "r120", "r121" ] }, "us-gaap_DebtInstrumentDateOfFirstRequiredPayment1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDateOfFirstRequiredPayment1", "presentation": [ "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest payments due date", "documentation": "Date the debt agreement requires the first payment to be made, in YYYY-MM-DD format." } } }, "auth_ref": [ "r20", "r69" ] }, "BTCY_DebtInstrumentDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DebtInstrumentDerivativeLiabilities", "crdr": "debit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument derivative liabilities", "documentation": "Debt instrument derivative liabilities." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDescription", "presentation": [ "http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument description", "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total." } } }, "auth_ref": [ "r20", "r50", "r68", "r73", "r133", "r135", "r449" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative", "http://biotricity.com/role/SubsequentEventsDetailsNarrative", "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt face amount", "verboseLabel": "Debt instrument, face amount", "terseLabel": "Face value", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r289", "r449", "r450", "r633", "r634", "r651" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt face amount", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r302", "r438", "r633", "r634", "r846", "r847", "r848", "r849", "r851" ] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": [ "http://biotricity.com/role/SubsequentEventsDetailsNarrative", "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fee amount", "verboseLabel": "Term loan exit fee", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": [ "r79" ] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument accrued interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": [ "r779" ] }, "BTCY_DebtInstrumentInterestAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DebtInstrumentInterestAmount", "crdr": "credit", "presentation": [ "http://biotricity.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument interest amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument interest rate during period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r76", "r307", "r856" ] }, "BTCY_DebtInstrumentInterestRateStatedDiscountPercentage": { "xbrltype": "percentItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DebtInstrumentInterestRateStatedDiscountPercentage", "presentation": [ "http://biotricity.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible discount percentage" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative", "http://biotricity.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "verboseLabel": "Debt interest rate", "terseLabel": "Convertible discount percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r76", "r290" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://biotricity.com/role/DerivativeLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r202", "r289", "r290", "r291", "r292", "r293", "r295", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r313", "r632", "r633", "r634", "r635", "r636", "r651", "r779", "r856", "r858" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r171", "r632", "r848", "r849" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative", "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative", "http://biotricity.com/role/SubsequentEventsDetailsNarrative", "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r20", "r202", "r289", "r290", "r291", "r292", "r293", "r295", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r632", "r633", "r634", "r635", "r636", "r651", "r779", "r798", "r799", "r800", "r856", "r858" ] }, "us-gaap_DebtInstrumentPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPaymentTerms", "presentation": [ "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument, payment terms", "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment." } } }, "auth_ref": [ "r69", "r77" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument periodic payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r20", "r69" ] }, "BTCY_DebtInstrumentRedeemedByCashPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DebtInstrumentRedeemedByCashPayment", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash payment", "documentation": "Debt instrument redeemed by cash payment." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument redemption price percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r141" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://biotricity.com/role/DerivativeLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r20", "r50", "r54", "r67", "r120", "r121", "r202", "r289", "r290", "r291", "r292", "r293", "r295", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r313", "r632", "r633", "r634", "r635", "r636", "r651", "r779", "r856", "r858" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative", "http://biotricity.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [
```

"http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Unamortized issuance cost discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": ["r811", "r855", "r856", "r858"] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtPolicyTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable and Derivative Instruments", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": ["r11"] }, "BTCY_DebtSettled": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DebtSettled", "crdr": "credit", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Debt settled", "documentation": "Debt settled." } } }, "auth_ref": [] }, "BTCY_DeemedDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DeemedDividends", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Deemed Dividends [Note 9]", "documentation": "Deemed dividends" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Deferred finance costs", "verboseLabel": "Debt financing", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r811", "r855", "r856", "r858"] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenue", "crdr": "credit", "calculation": { "http://biotricity.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://biotricity.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r763"] }, "us-gaap_DepositLiabilitiesAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositLiabilitiesAccruedInterest", "crdr": "credit", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Deposit liabilities, accrued interest", "documentation": "Amount of accrued but unpaid interest on deposit liabilities." } } }, "auth_ref": ["r134"] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Deposits and other receivables", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": ["r768"] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Deposits and other receivables [Note 10]", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r760"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Property and equipment depreciation", "verboseLabel": "Depreciation", "terseLabel": "Depreciation expenses", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r9", "r41"] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 }, "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StatementsOfCashFlows", "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Change in fair value of derivative liabilities [Note 8]", "negatedLabel": "Change in fair value of derivative liabilities", "verboseLabel": "Derivative liability", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": ["r843"] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": ["http://biotricity.com/role/DerivativeLiabilities"], "lang": { "en-us": { "role": { "label": "DERIVATIVE LIABILITIES", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": ["r131", "r413", "r420"] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Derivative liabilities [Note 8]", "verboseLabel": "Derivative liabilities, short-term", "terseLabel": "Derivative liabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r179"] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Derivative liabilities [Note 8]", "label": "Derivative liabilities, long-term", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r179"] }, "BTCY_DerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DerivativeLiability", "crdr": "credit", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Derivative liability", "documentation": "Derivative liability." } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityMeasurementInput", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Derivative liability, measurement input", "documentation": "Value of input used to measure derivative liability." } } }, "auth_ref": ["r428", "r429", "r430"] }, "BTCY_DerivativeLiabilityRemainingTerm": { "xbrltype": "durationItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DerivativeLiabilityRemainingTerm", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Remaining terms", "documentation": "Derivative liability, remaining term (years)." } } }, "auth_ref": [] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r420"] }, "BTCY_DerivativeStockPrice": { "xbrltype": "perShareItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DerivativeStockPrice", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Stock price", "documentation": "Derivative stock price." } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": ["r15", "r57", "r58", "r59", "r60", "r61", "r62", "r63", "r64", "r65", "r420"] }, "BTCY_DerivativeTreatment": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DerivativeTreatment", "crdr": "debit", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "End of derivative treatment of warrants", "documentation": "Derivative treatment." } } }, "auth_ref": [] }, "BTCY_DeviceSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DeviceSalesMember", "presentation": ["http://biotricity.com/role/ScheduleOfRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Device Sales [Member]", "documentation": "Device Sales [Member]" } } }, "auth_ref": [] }, "BTCY_DisclosureFederallyGuaranteedLoanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DisclosureFederallyGuaranteedLoanAbstract", "lang": { "en-us": { "role": { "label": "Federally Guaranteed Loan" } } }, "auth_ref": [] }, "BTCY_DisclosureOperatingLeaseRightofuseAssetsAndLeaseObligationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DisclosureOperatingLeaseRightofuseAssetsAndLeaseObligationsAbstract", "lang": { "en-us": { "role": { "label": "Operating Lease Right-of-use Assets And Lease Obligations", "verboseLabel": "Schedule Of Operating Leases Obligations", "terseLabel": "Schedule Of Contractual Undiscounted Cash Flows For Lease Obligation" } } }, "auth_ref": [] }, "BTCY_DisclosureTermLoanAndCreditAgreementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biotricity.com/20240930", "localname": "DisclosureTermLoanAndCreditAgreementAbstract", "lang": { "en-us": { "role": { "label": "Term Loan And Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Dividends", "crdr": "debit", "presentation": ["http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued dividends", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": ["r6", "r122"] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accrued dividends", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": ["r74", "r81", "r134", "r667", "r873"] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": ["r684"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r682", "r684", "r696"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end

of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r683"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r671"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r684"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r684"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r717"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r674"] }, "BTCY_EarlyPaymentPenaltyProvisionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://biotricity.com/20240930", "localname": "EarlyPaymentPenaltyProvisionPercentage", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Early payment penalty provision percentage", "documentation": "Early payment penalty provision percentage." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "LOSS PER SHARE, BASIC", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r189", "r208", "r209", "r210", "r211", "r212", "r213", "r217", "r220", "r224", "r225", "r226", "r228", "r404", "r407", "r423", "r424", "r479", "r499", "r621"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "LOSS PER SHARE, DILUTED", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r189", "r208", "r209", "r210", "r211", "r212", "r213", "r220", "r224", "r225", "r226", "r228", "r404", "r407", "r423", "r424", "r479", "r499", "r621"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Earnings (Loss) Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r34", "r35", "r227"] }, "BTCY_EconomicInjuryDisasterLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "EconomicInjuryDisasterLoanMember", "presentation": ["http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Economic Injury Disaster Loan [Member]", "documentation": "Economic Injury Disaster Loan [Member]" } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Effect of foreign currency translation", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r854"] }, "BTCY_EighteenMonthAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "EighteenMonthAnniversaryMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Eighteen Month Anniversary [Member]", "documentation": "Eighteen Month Anniversary [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r677"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r673"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r673"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r758"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r673"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r755"] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r696"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] },

```
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified
in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r673" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell
Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r673" ] },
"dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting
Company (SRC)." } } }, "auth_ref": [ "r673" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityTaxIdentificationNumber", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } },
"auth_ref": [ "r673" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers",
"presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is
not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": {
"label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the
Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r756" ] }, "us-gaap_EquityAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref":
[] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative",
"http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails",
"http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": {
"role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained
earnings, etc." } } }, "auth_ref": [ "r14", "r162", "r185", "r186", "r187", "r203", "r204", "r205", "r207", "r212", "r214", "r216", "r230", "r255", "r256", "r261", "r335", "r398",
"r399", "r401", "r402", "r403", "r405", "r406", "r407", "r414", "r415", "r416", "r417", "r418", "r419", "r422", "r441", "r442", "r443", "r444", "r445", "r446", "r451", "r453",
"r463", "r496", "r512", "r513", "r514", "r528", "r590" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r725" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": {
"role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r689", "r700", "r710", "r735" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r686", "r697", "r707", "r732" ] }, "BTCY_ExchangeAgreementMember": { "xbrltype":
"domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ExchangeAgreementMember", "presentation": [
"http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exchange Agreement [Member]", "documentation": "Exchange
Agreement [Member]" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [
"r731" ] }, "BTCY_ExitFees": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ExitFees", "crdr": "debit", "presentation": [
"http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exit fee", "documentation": "Exit Fees." } } }, "auth_ref": []
}, "BTCY_ExpectedForfeitureAttritionRates": { "xbrltype": "percentItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ExpectedForfeitureAttritionRates",
"presentation": [ "http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected
forfeiture (attrition) rate", "documentation": "Expected forfeiture (attrition) rate." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension",
"documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [
"http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants", "documentation": "Amount of
expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r1", "r9" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation":
"Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r302", "r339", "r340", "r341",
"r342", "r343", "r344", "r425", "r427", "r428", "r429", "r430", "r434", "r435", "r437", "r469", "r470", "r471", "r633", "r634", "r639", "r640", "r641", "r645", "r647" ] }, "us-
gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]",
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r302",
"r339", "r344", "r427", "r435", "r469", "r639", "r640", "r641", "r645" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails"
], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable
for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical
or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r302", "r339", "r344", "r427", "r428", "r435", "r470", "r633", "r634", "r639", "r640", "r641", "r645" ] },
"us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member",
"presentation": [ "http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]",
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r302",
"r339", "r340", "r341", "r342", "r343", "r344", "r427", "r428", "r429", "r430", "r435", "r471", "r633", "r634", "r639", "r640", "r641", "r645", "r647" ] },
"BTCY_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue": { "xbrltype": "monetaryItemType", "nsuri":
"http://biotricity.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue", "crdr": "credit", "presentation": [
"http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfDerivativeLiabilitiesDetails" ], "lang": { "en-
us": { "role": { "label": "New issuance [Note 9]", "verboseLabel": "New Issuance", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring
basis liability issue." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "presentation": [
"http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfDerivativeLiabilitiesDetails" ], "lang": { "en-
us": { "role": { "label": "Change in fair value of derivatives during period", "verboseLabel": "Change in fair value of derivative liabilities", "documentation": "Amount of
increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market
participants would use in pricing." } } }, "auth_ref": [ "r850", "r852" ] }, "us-
gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [
"http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfDerivativeLiabilitiesDetails" ], "lang": { "en-
us": { "role": { "periodStartLabel": "Derivative liabilities, beginning of period - March 31", "periodEndLabel": "Derivative liabilities, end of period", "label": "Fair Value,
Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability
measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r431",
"r436" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": {
"role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r302", "r339", "r340", "r341", "r342",
"r343", "r344", "r425", "r427", "r428", "r429", "r430", "r434", "r435", "r437", "r469", "r470", "r471", "r633", "r634", "r639", "r640", "r641", "r645", "r647" ] }, "us-
gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label":
"Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r12" ] },
"BTCY_FederallyGuaranteedLoansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biotricity.com/20240930", "localname":
"FederallyGuaranteedLoansTextBlock", "presentation": [ "http://biotricity.com/role/FederallyGuaranteedLoan" ], "lang": { "en-us": { "role": { "label": "FEDERALLY
GUARANTEED LOAN", "documentation": "Federally Guaranteed Loans [Text Block]" } } }, "auth_ref": [] }, "BTCY_FinanceCharges": { "xbrltype": "monetaryItemType", "nsuri":
"http://biotricity.com/20240930", "localname": "FinanceCharges", "crdr": "debit", "presentation": [
"http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Finance charge", "documentation":
"Finance charges" } } }, "auth_ref": [] }, "BTCY_FinanceCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname":
"FinanceCompanyMember", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": {
"label": "Finance Company [Member]", "documentation": "Finance Company [Member]" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableRevolvingConvertedToTermLoan":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableRevolvingConvertedToTermLoan", "crdr": "debit", "presentation":
[ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Financing receivables",
"documentation": "Amortized cost of revolving financing receivable converted to term loan." } } }, "auth_ref": [ "r257", "r630" ] }, "BTCY_FirstFourWeeksMember": {
"xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "FirstFourWeeksMember", "presentation": [
"http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "First Four Weeks [Member]",
"documentation": "First Four Weeks [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [
"http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Translation", "documentation":
"Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency
financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3)
remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r440" ] },
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r693", "r704", "r714", "r739" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r693",
"r704", "r714", "r739" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r693", "r704", "r714", "r739" ] },
"ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
```

Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r693", "r704", "r714", "r739"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r693", "r704", "r714", "r739"] }, "us-gaap_FurnitureAndFixturesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesGross", "crdr": "debit", "presentation": ["http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Furniture & fixtures", "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": ["r112"] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": ["http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "BTCY_GainLossRecognizedOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "GainLossRecognizedOfDebt", "crdr": "debit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Debt instrument accrued interest", "documentation": "Gain loss recognized of debt", "label": "GainLossRecognizedOfDebt" } } }, "auth_ref": [] }, "BTCY_GainLossUponConvertiblePromissoryNotesConversionAndRedemption": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "GainLossUponConvertiblePromissoryNotesConversionAndRedemption", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "(Gain) loss upon convertible promissory notes conversion and redemption", "documentation": "Gain loss upon convertible promissory notes conversion and redemption." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Gain (loss) upon convertible promissory notes conversion and redemption [Note 9]", "verboseLabel": "Gains losses on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r9", "r44", "r45"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r100"] }, "BTCY_GrossProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "GrossProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Gross proceeds from issuance of common stock", "documentation": "Gross proceeds from issuance of common stock." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "GROSS PROFIT", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r96", "r98", "r144", "r201", "r254", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r439", "r623", "r626", "r786", "r787", "r788", "r789", "r790", "r808"] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Impairment for Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": ["r0", "r113"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS BEFORE INCOME TAXES", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r97", "r137", "r144", "r480", "r494", "r623", "r626", "r786", "r787", "r788", "r789", "r790"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r262", "r269", "r270", "r432", "r433", "r436", "r509", "r511", "r574", "r614", "r646", "r876"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r269", "r270", "r432", "r433", "r436", "r509", "r511", "r574", "r614", "r646", "r876"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Income taxes [Note 3I]", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r149", "r159", "r215", "r216", "r229", "r237", "r248", "r390", "r391", "r400", "r500", "r644"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r184", "r388", "r389", "r392", "r393", "r394", "r397", "r520"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r30", "r196", "r395", "r396"] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts and Other Receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDerivativeLiabilities", "crdr": "debit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Derivative liabilities", "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)." } } }, "auth_ref": ["r776"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Deposits and other receivables", "label": "Increase (Decrease) in Other Receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": ["r8"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": ["r693", "r704", "r714", "r731", "r739", "r743", "r751"] }, "BTCY_IndividualInvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "IndividualInvestorMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Individual Investor [Member]", "documentation": "Individual Investor [Member]" } } }, "auth_ref": [] }, "BTCY_IndividualInvestorOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "IndividualInvestorOneMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Individual Investor One [Member]", "documentation": "Individual Investor One [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": ["r749"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r685", "r754"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r685", "r754"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r685", "r754"] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": {

```
"http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative", "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Unpaid interest", "verboseLabel": "Interest expense", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r229", "r233", "r236", "r238", "r248", "r448", "r626", "r627" ] }, "us-gaap_InterestExpenseBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseBorrowings", "crdr": "debit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest expense related to short term loan", "documentation": "Aggregate amount of interest expense on all borrowings." } } }, "auth_ref": [ "r139", "r140" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r101", "r308", "r316", "r635", "r636" ] }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseOther", "crdr": "debit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest expense", "label": "Interest Expense, Other", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://biotricity.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r192", "r194", "r195" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "verboseLabel": "Interest payable current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r74" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest payable", "verboseLabel": "Accrued interest", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r134", "r873" ] }, "us-gaap_InventoryAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryAdjustments", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Inventory", "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods." } } }, "auth_ref": [ "r40", "r767" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://biotricity.com/role/ScheduleOfInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biotricity.com/role/ScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r766" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://biotricity.com/role/ScheduleOfInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/ScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Inventory [Note 3]", "totalLabel": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r177", "r618", "r653" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r150", "r166", "r176", "r258", "r259", "r260", "r475", "r619" ] }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "calculation": { "http://biotricity.com/role/ScheduleOfInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biotricity.com/role/ScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Raw material", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": [ "r767" ] }, "us-gaap_InvestmentCompanyDividendDistribution": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentCompanyDividendDistribution", "crdr": "debit", "presentation": [ "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment company, dividend distribution", "documentation": "Amount of dividend distribution from ordinary income and capital gain. Excludes distribution for tax return of capital." } } }, "auth_ref": [ "r526", "r527", "r528", "r589" ] }, "BTCY_IssuanceOfCommonSharesFromAtTheMarketTransactionShares": { "xbrltype": "sharesItemType", "nsuri": "http://biotricity.com/20240930", "localname": "IssuanceOfCommonSharesFromAtTheMarketTransactionShares", "presentation": [ "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares from at-the-market transaction [Note 9], shares", "documentation": "Issuance of common shares from at the market transaction shares." } } }, "auth_ref": [] }, "BTCY_IssuanceOfCommonSharesFromAtTheMarketTransactionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "IssuanceOfCommonSharesFromAtTheMarketTransactionValue", "crdr": "credit", "presentation": [ "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares from at-the-market transaction [Note 9]", "documentation": "Issuance of common shares from at the market transaction value." } } }, "auth_ref": [] }, "BTCY_IssuanceOfCommonSharesFromSharesToBeIssued": { "xbrltype": "sharesItemType", "nsuri": "http://biotricity.com/20240930", "localname": "IssuanceOfCommonSharesFromSharesToBeIssued", "presentation": [ "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares from shares to be issued", "documentation": "Issuance of common shares from shares to be issued." } } }, "auth_ref": [] }, "BTCY_IssuanceOfSharesForSettlementOfAccountsPayable": { "xbrltype": "sharesItemType", "nsuri": "http://biotricity.com/20240930", "localname": "IssuanceOfSharesForSettlementOfAccountsPayable", "presentation": [ "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of shares for settlement of accounts payable", "documentation": "Issuance of shares for settlement of accounts payable." } } }, "auth_ref": [] }, "BTCY_IssuanceOfSharesForSettlementOfAccountsPayableValue": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "IssuanceOfSharesForSettlementOfAccountsPayableValue", "crdr": "credit", "presentation": [ "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of shares for settlement of accounts payable, value", "documentation": "Issuance of shares for settlement of accounts payable, value." } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biotricity.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of shares for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r9" ] }, "BTCY_IssuanceOfWarrantsForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "IssuanceOfWarrantsForServices", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biotricity.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants for services", "documentation": "Issuance of warrants for services." } } }, "auth_ref": [] }, "us-gaap_LeaseDepositLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseDepositLiability", "crdr": "credit", "presentation": [ "http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease deposit liability", "documentation": "Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease." } } }, "auth_ref": [ "r460" ] }, "us-gaap_LeaseholdImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsGross", "crdr": "debit", "presentation": [ "http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Leasehold improvements", "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r112" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r112", "r459" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "BTCY_LenderMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "LenderMember", "presentation": [ "http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lender [Member]", "documentation": "Lender [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r456" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://biotricity.com/role/ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biotricity.com/role/ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total undiscounted lease liability", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r458" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://biotricity.com/role/ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biotricity.com/role/ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r458" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://biotricity.com/role/ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biotricity.com/role/ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r458" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://biotricity.com/role/ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biotricity.com/role/ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails" ], "lang": { "en-us": {
```

```
"role": { "label": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r860" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r458" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligations" ], "lang": { "en-us": { "role": { "label": "OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r452" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biotricity.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r20", "r73", "r74", "r75", "r80", "r81", "r82", "r83", "r201", "r254", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r410", "r411", "r412", "r439", "r549", "r622", "r670", "r808", "r864", "r865" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biotricity.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS\u2019 DEFICIENCY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r91", "r136", "r489", "r653", "r780", "r796", "r853" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biotricity.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r75", "r165", "r201", "r254", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r410", "r411", "r412", "r439", "r653", "r808", "r864", "r865" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://biotricity.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Total liabilities at fair value", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r427", "r845" ] }, "us-gaap_LineOfCreditFacilityAnnualPrincipalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAnnualPrincipalPayment", "crdr": "debit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal outstanding", "documentation": "Amount of decrease in debt under credit facility arrangement from principal payment." } } }, "auth_ref": [ "r761", "r762" ] }, "us-gaap_LineOfCreditFacilityCapacityAvailableForTradePurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCapacityAvailableForTradePurchases", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Inventory financing by facility", "documentation": "The maximum amount of borrowing capacity under a line of credit that is available as of the balance sheet date for financing purchases of goods acquired for inventory or imminent delivery to a customer." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityRevolvingCreditConversionToTermLoanDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRevolvingCreditConversionToTermLoanDescription", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit facility, revolving credit conversion to term loan, description", "documentation": "Describes when borrowings outstanding under a line of credit will convert to a term loan, and describes the repayment terms, collateral, and priority (seniority) of the term loan." } } }, "auth_ref": [ "r72", "r79" ] }, "us-gaap_LoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableCurrent", "crdr": "credit", "presentation": [ "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loans payable current portion", "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r74" ] }, "us-gaap_LoansPayableToBankCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableToBankCurrent", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biotricity.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Term loan, current", "documentation": "Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r73", "r546" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermLoansFromBank": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLoansFromBank", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biotricity.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Term loan [Note 6]", "documentation": "Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion." } } }, "auth_ref": [ "r20", "r135", "r546" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://biotricity.com/role/DerivativeLiabilitiesTables", "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r20", "r798", "r799", "r800" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://biotricity.com/role/DerivativeLiabilitiesTables", "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r20", "r43", "r798", "r799", "r800" ] }, "BTCY_LossOnDebtAmendment": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "LossOnDebtAmendment", "crdr": "credit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss on amendment of debt", "documentation": "Loss on debt amendment." } } }, "auth_ref": [] }, "BTCY_LossOnDebtConversion": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "LossOnDebtConversion", "crdr": "debit", "presentation": [ "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss on debt conversion", "documentation": "Loss on debt conversion." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r273", "r274", "r275", "r276", "r347", "r385", "r430", "r474", "r508", "r510", "r518", "r540", "r541", "r596", "r598", "r601", "r602", "r603", "r612", "r613", "r629", "r637", "r642", "r647", "r648", "r649", "r650", "r655", "r810", "r866", "r867", "r868", "r869", "r870", "r871" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r723" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r723" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r847", "r848", "r849" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r847", "r848", "r849" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r647", "r847", "r848", "r849" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r847", "r848", "r849" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r847", "r848", "r849" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r428", "r429", "r430", "r647" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r428", "r429", "r430", "r647" ] }, "BTCY_MezzanineEquityMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "MezzanineEquityMember", "presentation": [ "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency" ], "lang": { "en-us": { "role": { "label": "Mezzanine Equity [Member]", "documentation": "Mezzanine Equity [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r273", "r274", "r275", "r276", "r347", "r385", "r430", "r474", "r508", "r510", "r518", "r540", "r541", "r596", "r598", "r601", "r602", "r603", "r612", "r613", "r629", "r637", "r642", "r647", "r648", "r649", "r655", "r810", "r866", "r867", "r868", "r869", "r870", "r871" ] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ownership percentage", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r742" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r750" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r724" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"NatureOfOperations", "presentation": ["http://biotricity.com/role/NatureOfOperations"], "lang": { "en-us": { "role": { "label": "NATURE OF OPERATIONS", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r151", "r160"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r193"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r104", "r105", "r107"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS BEFORE DIVIDENDS", "label": "Net loss before dividends for the period", "verboseLabel": "Net loss", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r99", "r107", "r138", "r163", "r180", "r182", "r187", "r201", "r206", "r208", "r209", "r210", "r211", "r212", "r215", "r216", "r222", "r254", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r404", "r407", "r424", "r439", "r495", "r570", "r587", "r588", "r668", "r808"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r190", "r208", "r209", "r210", "r211", "r217", "r218", "r223", "r226", "r407"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "BTCY_NewConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "NewConvertibleNoteMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "New Convertible Note [Member]", "documentation": "New Convertible Note [Member]" } } }, "auth_ref": [] }, "BTCY_NewLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "NewLeaseAgreementMember", "presentation": ["http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "New Lease Agreement [Member]", "documentation": "New Lease Agreement [Member]" } } }, "auth_ref": [] }, "BTCY_NewPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "NewPromissoryNoteMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "New Promissory Note [Member]", "documentation": "New Promissory Note [Member]" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": ["r723"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r721"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r720"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r750"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r750"] }, "BTCY_NoncashLeaseExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "NoncashLeaseExpenses", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Non-cash lease expense", "documentation": "Non cash lease expenses." } } }, "auth_ref": [] }, "BTCY_NoteHoldersMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "NoteHoldersMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Note Holders [Member]", "documentation": "Note Holders [Member]" } } }, "auth_ref": [] }, "us-gaap_NotesPayableOtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableOtherPayablesMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Notes Payable, Other Payables [Member]", "documentation": "A written promise to pay a note to a third party." } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": ["http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "BTCY_OneInvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "OneInvestorMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "One Investor [Member]", "documentation": "One Investor [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "TOTAL OPERATING EXPENSES", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "LOSS FROM OPERATIONS", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r144", "r623", "r786", "r787", "r788", "r789", "r790"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Operating lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r859"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://biotricity.com/role/ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails", "http://biotricity.com/role/ScheduleOfOperatingLeasesObligationsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Operating lease liability, beginning balance", "periodEndLabel": "Operating lease liability, ending balance", "totalLabel": "Total", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r455"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/ScheduleOfOperatingLeasesObligationsDetails"], "lang": { "en-us": { "role": { "label": "Operating lease obligations, current [Note 10]", "verboseLabel": "Current portion of operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r455"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/ScheduleOfOperatingLeasesObligationsDetails"], "lang": { "en-us": { "role": { "label": "Operating lease obligations", "verboseLabel": "Noncurrent portion of operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r455"] }, "BTCY_OperatingLeaseNewLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "OperatingLeaseNewLeases", "crdr": "credit", "presentation": ["http://biotricity.com/role/ScheduleOfOperatingLeasesObligationsDetails"], "lang": { "en-us": { "role": { "label": "Lease liability, new leases", "documentation": "Operating lease new leases." } } }, "auth_ref": [] }, "BTCY_OperatingLeaseRepaymentAndInterestAccretion": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "OperatingLeaseRepaymentAndInterestAccretion", "crdr": "credit", "presentation": ["http://biotricity.com/role/ScheduleOfOperatingLeasesObligationsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Lease liability, repayment and interest accretion, net", "documentation": "Repayment and interest accretion.", "label": "Repayment and interest accretion" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/ScheduleOfOperatingLeasesObligationsDetails"], "lang": { "en-us": { "role": { "label": "Operating right of use assets [Note 10]", "periodStartLabel": "Operating lease right-of-use asset, beginning balance", "periodEndLabel":

"Operating lease right-of-use asset, ending balance", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r454"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": ["http://biotricity.com/role/ScheduleOfOperatingLeasesObligationsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Right of use asset, amortization", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r777"] }, "BTCY_OperatingLeaseRightOfUseAssetNewLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "OperatingLeaseRightOfUseAssetNewLeases", "crdr": "debit", "presentation": ["http://biotricity.com/role/ScheduleOfOperatingLeasesObligationsDetails"], "lang": { "en-us": { "role": { "label": "Right of use asset, new leases", "documentation": "Operating lease right of use asset new leases." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted average rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r457", "r652"] }, "BTCY_OperatingLeasesOfLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biotricity.com/20240930", "localname": "OperatingLeasesOfLesseeTableTextBlock", "presentation": ["http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsTables"], "lang": { "en-us": { "role": { "label": "SCHEDULE OF OPERATING LEASES OBLIGATIONS", "documentation": "Operating Leases of Lessee [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "BTCY_OriginationFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "OriginationFeeAmount", "crdr": "debit", "presentation": ["http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Origination fee amount", "documentation": "Origination fee amount." } } }, "auth_ref": [] }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccountsPayableAndAccruedLiabilities", "crdr": "credit", "presentation": ["http://biotricity.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Trade and other payables and accrued liabilities", "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accrued dividends liability", "documentation": "Amount of expenses incurred but not yet paid classified as other." } } }, "auth_ref": ["r134"] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "verboseLabel": "Translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": ["r7", "r13", "r130"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r4", "r496"] }, "BTCY_OtherConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "OtherConvertibleNotesPayableMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Other Convertible Notes Payable [Member]", "documentation": "Other Convertible Notes Payable [Member]" } } }, "auth_ref": [] }, "BTCY_OtherExpenseRegardingLossOnDebtModification": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "OtherExpenseRegardingLossOnDebtModification", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Other expense regarding loss on debt modification", "documentation": "Other expense regarding loss on debt modification." } } }, "auth_ref": [] }, "us-gaap_OtherLoansPayableLongTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLoansPayableLongTerm", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Federally guaranteed loans [Note 7]", "documentation": "Amount of long-term loans classified as other, payable after one year or the operating cycle, if longer." } } }, "auth_ref": ["r20", "r547", "r548"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other income (expense) [Note 9]", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r102"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } } }, "auth_ref": ["r723"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r684"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r691", "r702", "r712", "r737"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": ["r694", "r705", "r715", "r740"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r694", "r705", "r715", "r740"] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": ["r719"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentForManagementFee": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentForManagementFee", "crdr": "credit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Administrative fees", "documentation": "Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP)." } } }, "auth_ref": ["r775", "r861"] }, "us-gaap_PaymentsForProceedsFromProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromProductiveAssets", "crdr": "credit", "presentation": ["http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Purchase of property plant and equipment", "documentation": "The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Debt issuance costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": ["r27"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r722"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r722"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r721"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": ["r724"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r720"] }, "BTCY_PercentageOfPlacementFeeAndOtherIssuanceExpenses": { "xbrltype": "percentItemType", "nsuri": "http://biotricity.com/20240930", "localname": "PercentageOfPlacementFeeAndOtherIssuanceExpenses", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Percentage of placement fee and other issuance expenses", "documentation": "Percentage of placement fee and other issuance expenses." } } }, "auth_ref": [] }, "BTCY_PlacementAgentFeesDescription": { "xbrltype": "stringItemType", "nsuri": "http://biotricity.com/20240930", "localname": "PlacementAgentFeesDescription", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Placement agent fees description", "documentation": "Placement agent fees description." } } }, "auth_ref": [] }, "BTCY_PlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "PlacementAgentMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Placement Agent [Member]", "documentation": "Placement Agent [Member]" } } }, "auth_ref": [] }, "BTCY_PlacementAgentsWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "PlacementAgentsWarrantsMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Placement Agents Warrants [Member]", "documentation": "Placement Agents Warrants [Member]" } } }, "auth_ref": [] }, "BTCY_PlacementFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://biotricity.com/20240930", "localname": "PlacementFeePercentage", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Placement fee percentage", "documentation": "Placement fee percentage" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840"] }, "srt_PlatformOperatorCryptoAssetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":

"PlatformOperatorCryptoAssetLineItems", "presentation": ["http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto Asset [Line Items]" } } }, "auth_ref": ["r263"] }, "srt_PlatformOperatorCryptoAssetTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "PlatformOperatorCryptoAssetTable", "presentation": ["http://biotricity.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto Asset [Table]" } } }, "auth_ref": ["r263"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r721"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r678"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r680"] }, "BTCY_PreferredSharesExtinguishmentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biotricity.com/20240930", "localname": "PreferredSharesExtinguishmentsPolicyTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Preferred Shares Extinguishments", "documentation": "Preferred Shares Extinguishments [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleConversionPrice", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock convertible conversion price", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": ["r320"] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendRatePercentage", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock dividend rate percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": ["r319", "r597", "r599", "r600", "r604"] }, "BTCY_PreferredStockDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "PreferredStockDividends", "crdr": "debit", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "negatedLabel": "Preferred stock dividends", "documentation": "Preferred stock dividends", "label": "PreferredStockDividends" } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendsIncomeStatementImpact", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "negatedLabel": "Preferred Stock Dividends", "label": "Preferred Stock Dividends, Income Statement Impact", "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders." } } }, "auth_ref": [] }, "BTCY_PreferredStockInitialConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://biotricity.com/20240930", "localname": "PreferredStockInitialConversionPrice", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Initial conversion price", "documentation": "Preferred stock initial conversion price." } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreference", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, liquidation preference", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": ["r50", "r51", "r85", "r778", "r812"] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r659", "r660", "r663", "r664", "r665", "r666", "r905", "r909"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "verboseLabel": "Preferred stock convertible conversion price", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r85", "r318"] }, "us-gaap_PreferredStockRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockRedemptionPricePerShare", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Redemption Price Per Share", "verboseLabel": "Preferred stock redemption price per share", "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer." } } }, "auth_ref": ["r49", "r50", "r53"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r85", "r550"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "verboseLabel": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r85", "r318"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r85", "r550", "r568", "r909", "r910"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred stock, value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r85", "r484", "r653"] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Proceeds from convertible debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r26"] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Proceeds from Debt, Net of Issuance Costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": ["r191"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Issuance of common shares, net", "verboseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r5"] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r773"] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/ScheduleOfSeriesBPreferredStockForMezzanineEquityDetails", "http://biotricity.com/role/StatementsOfCashFlows", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of preferred shares, net", "verboseLabel": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Subscriber for a principal amount", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": ["r5"] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative", "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r5"] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Gross proceeds", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r5", "r521"] }, "us-gaap_ProceedsFromLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLeasePayments", "crdr": "debit", "presentation": ["http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases", "documentation": "Amount of cash inflow from lease payment, classified as operating activity." } } }, "auth_ref": ["r461", "r462"] }, "us-gaap_ProceedsFromLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLoans", "crdr": "debit", "presentation": ["http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative", "http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Gross proceeds", "verboseLabel": "Proceeds from loan", "documentation": "Cash received from principal payments made on loans related to operating activities." } } }, "auth_ref": ["r106"] }, "us-gaap_ProceedsFromRepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfDebt", "crdr": "debit", "presentation": ["http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Principal repayments", "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-

gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from convertible debentures, net", "documentation": "Amount of cash inflow (outflow) from long-term debt, finance lease obligation, and mandatorily redeemable capital security." } } }, "auth_ref": ["r772", "r773"] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StatementsOfCashFlows", "http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Proceeds from short term loan and promissory notes, net", "verboseLabel": "Proceeds from short term debt", "terseLabel": "Gross proceeds", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r26"] }, "us-gaap_ProceedsFromUnsecuredNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromUnsecuredNotesPayable", "crdr": "debit", "presentation": ["http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Unsecured convertible promissory notes", "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is uncollateralized (where debt is not backed by the pledge of collateral)." } } }, "auth_ref": ["r26"] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": ["http://biotricity.com/role/ScheduleOfRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://biotricity.com/role/ScheduleOfRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r250", "r476", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r616", "r638", "r654", "r655", "r656", "r657", "r658", "r804", "r805", "r814", "r875", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://biotricity.com/role/ScheduleOfRevenueRecognitionDetails"], "auth_ref": ["r250", "r476", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r616", "r638", "r654", "r655", "r656", "r657", "r658", "r804", "r805", "r814", "r875", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904"] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "presentation": ["http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Professional fee", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": ["r626", "r668", "r907", "r908"] }, "BTCY_PromissoryNoteAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "PromissoryNoteAgreementMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Promissory Note Agreement [Member]", "documentation": "Promissory Note Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAdditions", "crdr": "debit", "presentation": ["http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Additions", "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r10", "r459"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://biotricity.com/role/PropertyAndEquipment"], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r111", "r154", "r157", "r158"] }, "us-gaap_PropertyPlantAndEquipmentDisposals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisposals", "crdr": "credit", "presentation": ["http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Disposals", "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Cost, beginning balance", "periodEndLabel": "Cost, ending balance", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r112", "r168", "r493"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r459"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property and equipment [Note 12]", "periodStartLabel": "Net book value, beginning balance", "periodEndLabel": "Net book value, ending balance", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r10", "r459", "r481", "r493", "r653"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r10", "r154", "r157", "r491"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://biotricity.com/role/PropertyAndEquipmentTables"], "lang": { "en-us": { "role": { "label": "SCHEDULE OF PROPERTY AND EQUIPMENT", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r10"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r112", "r459"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"], "lang": { "en-us": { "role": { "label": "Property and equipment, useful life", "verboseLabel": "Furniture & fixtures useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "BTCY_PurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "PurchaseAgreementMember", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Purchase Agreement [Member]", "documentation": "Purchase Agreement [Member]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r719"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r719"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r273", "r274", "r275", "r276", "r338", "r347", "r376", "r377", "r378", "r385", "r430", "r472", "r473", "r474", "r508", "r510", "r518", "r540", "r541", "r596", "r598", "r601", "r602", "r603", "r612", "r613", "r629", "r637", "r642", "r647", "r648", "r649", "r650", "r655", "r661", "r801", "r810", "r848", "r867", "r868", "r869", "r870", "r871"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails", "http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "auth_ref": ["r273", "r274", "r275", "r276", "r338", "r347", "r376", "r377", "r378", "r385", "r430", "r472", "r473", "r474", "r508", "r510", "r518", "r540", "r541", "r596", "r598", "r601", "r602", "r603", "r612", "r613", "r629", "r637", "r642", "r647", "r648", "r649", "r650", "r655", "r661", "r801", "r810", "r848", "r867", "r868", "r869", "r870", "r871"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": ["r686", "r697", "r707", "r732"] }, "BTCY_RedemptionOfConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "RedemptionOfConvertibleNotes", "crdr": "debit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Redemption of convertible notes", "documentation": "Redemption of convertible notes." } } }, "auth_ref": [] }, "BTCY_ReductionDueToPreferredSharesConverted": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ReductionDueToPreferredSharesConverted", "crdr": "debit", "presentation": ["http://biotricity.com/role/ScheduleOfDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Reduction due to preferred shares converted [Note 9]", "documentation": "Reduction due to preferred shares converted." } } }, "auth_ref": [] }, "BTCY_ReductionDueToPreferredSharesRedeemed": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ReductionDueToPreferredSharesRedeemed", "crdr": "debit", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related to the shares", "documentation": "Reduction due to preferred shares redeemed." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r253", "r346", "r464", "r465", "r483", "r490", "r543", "r544", "r545", "r547",

"r548", "r567", "r569", "r595"] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r253", "r346", "r464", "r465", "r483", "r490", "r543", "r544", "r545", "r547", "r548", "r567", "r569", "r595", "r863"] }, "BTCY_RemainingThirtySixWeeksMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "RemainingThirtySixWeeksMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Remaining Thirty Six Weeks [Member]", "documentation": "Remaining Thirty Six Weeks [Member]" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Repayments of loan", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r774"] }, "us-gaap_RepaymentsOfOtherDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfOtherDebt", "crdr": "credit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Payment redeemed cash", "documentation": "Amount of cash outflow for the payment of debt classified as other." } } }, "auth_ref": ["r103"] }, "BTCY_RepaymentsOfPreferredStockDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "RepaymentsOfPreferredStockDividend", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Preferred Stock Dividend", "documentation": "Repayments of preferred stock dividend.", "label": "RepaymentsOfPreferredStockDividend" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "presentation": ["http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Repayment of short term debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r103"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r387", "r614", "r626", "r872"] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r386"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r687", "r698", "r708", "r733"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": ["r688", "r699", "r709", "r734"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": ["r695", "r706", "r716", "r741"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r167"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r88", "r122", "r488", "r515", "r517", "r525", "r551", "r653"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r162", "r203", "r204", "r205", "r207", "r212", "r214", "r216", "r255", "r256", "r261", "r398", "r399", "r401", "r402", "r403", "r405", "r406", "r407", "r414", "r416", "r417", "r419", "r422", "r451", "r453", "r512", "r514", "r528", "r909"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://biotricity.com/role/ScheduleOfRevenueRecognitionDetails", "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "REVENUE", "verboseLabel": "Total", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r142", "r143", "r229", "r234", "r235", "r246", "r248", "r250", "r251", "r252", "r336", "r337", "r476"] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r572", "r615", "r620"] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r750"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r750"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Net proceeds", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "BTCY_SaleOfStockNumberOfAdditionalSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SaleOfStockNumberOfAdditionalSharesIssuedInTransaction", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of additional shares issued", "documentation": "Sale of stock number of additional shares issued in transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of shares issued", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://biotricity.com/role/AccountsPayableAndAccruedLiabilitiesTables"], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": ["http://biotricity.com/role/DerivativeLiabilitiesTables"], "lang": { "en-us": { "role": { "verboseLabel": "SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": ["r345"] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": ["http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalent [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r408"] }, "BTCY_ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationTableTextBlock", "presentation": ["http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsTables"], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION", "documentation": "Schedule of Contractual Undiscounted Cash Flows For Lease Obligation [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": ["r61"] }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "presentation": ["http://biotricity.com/role/DerivativeLiabilitiesTables"], "lang": { "en-us": { "role": { "label":

"SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS", "documentation": "Tabular disclosure of derivative liabilities at fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "SCHEDULE OF REVENUE RECOGNITION", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": ["r39"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "SCHEDULE OF INVENTORIES", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r22", "r92", "r93", "r94"] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductInformationTable", "presentation": ["http://biotricity.com/role/ScheduleOfRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "BTCY_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES", "documentation": "Schedule Of Property And Equipment Estimated Useful Lives [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://biotricity.com/role/PropertyAndEquipmentDetailsNarrative", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://biotricity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r10", "r459"] }, "BTCY_ScheduleOfSeriesBPreferredStockForMezzanineEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ScheduleOfSeriesBPreferredStockForMezzanineEquityTableTextBlock", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyTables"], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY", "documentation": "Schedule of Series B Preferred Stock for Mezzanine Equity [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r349", "r350", "r351", "r352", "r353", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r375", "r376", "r377", "r378", "r379"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyTables"], "lang": { "en-us": { "role": { "label": "SCHEDULE OF STOCK OPTION ACTIVITIES", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r18", "r19", "r124"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyTables"], "lang": { "en-us": { "role": { "label": "SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r129"] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": ["r73"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r47", "r48", "r50", "r51", "r52", "r54", "r118", "r120", "r121", "r122", "r172", "r173", "r174", "r231", "r318", "r319", "r321", "r323", "r326", "r331", "r333", "r521", "r522", "r523", "r524", "r637", "r759", "r778"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyTables"], "lang": { "en-us": { "role": { "label": "SCHEDULE OF WARRANTS OUTSTANDING", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r55"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r672"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r676"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r675"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r681"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Segment Information", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r239", "r240", "r241", "r242", "r243", "r244", "r245", "r249", "r251", "r624", "r625", "r628"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Selling, general and administrative expenses", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r100"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": ["r842"] }, "BTCY_SeriesAConvertibleNoteHoldersMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SeriesAConvertibleNoteHoldersMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series A Convertible Note Holders [Member]", "documentation": "Series A Convertible Note Holders [Member]" } } }, "auth_ref": [] }, "BTCY_SeriesANoteMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SeriesANoteMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series A Note [Member]", "documentation": "Series A Note [Member]" } } }, "auth_ref": [] }, "BTCY_SeriesANotesMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SeriesANotesMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series A Notes [Member]", "documentation": "Series A Notes [Member]." } } }, "auth_ref": [] }, "BTCY_SeriesANotesOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SeriesANotesOneMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series A Notes One [Member]", "documentation": "Series A Notes One [Member]" } } }, "auth_ref": [] }, "BTCY_SeriesANotesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SeriesANotesTwoMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series A Notes Two [Member]", "documentation": "Series A Notes Two [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": ["r764", "r765", "r813"] }, "BTCY_SeriesBConvertibleRedeemablePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SeriesBConvertibleRedeemablePreferredStockMember", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series B Convertible Redeemable Preferred Stock [Member]", "documentation": "Series B Convertible Redeemable Preferred Stock [Member]" } } }, "auth_ref": [] }, "BTCY_SeriesBNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SeriesBNoteMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series B Note [Member]", "documentation": "Series B Note [Member]" } } }, "auth_ref": [] }, "BTCY_SeriesBNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SeriesBNotesMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series B Notes [Member]", "documentation": "Series B Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-

```
us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r764", "r765", "r813" ] },
"BTCY_SeriesCConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SeriesCConvertibleNoteMember",
"presentation": [ "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series C Convertible Note [Member]",
"documentation": "Series C Convertible Note [Member]" } } }, "auth_ref": [] }, "BTCY_SeriesCNoteMember": { "xbrltype": "domainItemType", "nsuri":
"http://biotricity.com/20240930", "localname": "SeriesCNoteMember", "presentation": [
"http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series C Note [Member]",
"documentation": "Series C Note [Member]" } } }, "auth_ref": [] }, "BTCY_SeriesCNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930",
"localname": "SeriesCNotesMember", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative",
"http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series C Notes [Member]", "documentation": "Series C Notes
[Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SeriesCPreferredStockMember", "presentation": [ "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series C
Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r764", "r765", "r813" ] }, "BTCY_SettlementOfDebt": { "xbrltype":
"monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SettlementOfDebt", "crdr": "credit", "presentation": [
"http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt settlement value", "documentation":
"Settlement of debt." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensation", "crdr": "debit", "calculation": { "http://biotricity.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biotricity.com/role/StatementsOfCashFlows",
"http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock based compensation", "verboseLabel": "Stock-based
compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [
"http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation":
"Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
"presentation": [ "http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected
dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the
option's term." } } }, "auth_ref": [ "r377" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [
"http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility",
"documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-
weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the
share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
} } }, "auth_ref": [ "r376" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [
"http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate",
"documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r378" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails" ],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [ "r349", "r350", "r351", "r352", "r353", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370",
"r371", "r372", "r375", "r376", "r377", "r378", "r379" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [
"http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised", "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "documentation": "Number of non-option equity instruments exercised by
participants." } } }, "auth_ref": [ "r17" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
"presentation": [ "http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired/cancelled", "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations", "documentation": "Number of shares under non-
option equity instrument agreements that were either cancelled or expired." } } }, "auth_ref": [ "r127", "r128" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [
"http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Issued", "documentation": "Net number of non-option equity
instruments granted to participants." } } }, "auth_ref": [ "r16" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
"presentation": [ "http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance",
"periodEndLabel": "Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding,
Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r125",
"r126" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [
"http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based payment award number of shares authorized",
"documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r643" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based payment award number of shares available for
issuance", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of
amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under
the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [
"r56" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation":
[ "http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options, beginning outstanding", "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine
terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual
agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r821" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [
"http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price, beginning outstanding",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
"documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r821" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [
"http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options, beginning outstanding", "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were
cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } },
"auth_ref": [ "r361" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label":
"Number of options, beginning outstanding", "verboseLabel": "Stock options granted", "documentation": "Gross number of share options (or share units) granted during the
period." } } }, "auth_ref": [ "r359" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"presentation": [ "http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of options, beginning
outstanding", "periodEndLabel": "Number of options, beginning outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r355", "r356" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"presentation": [ "http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails",
"http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, beginning
outstanding", "periodEndLabel": "Weighted average exercise price, beginning outstanding", "label": "Fair value of option", "documentation": "Weighted average price at which
grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r355", "r356" ] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [
"r351", "r352", "r353", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r375",
"r376", "r377", "r378", "r379" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [
```

"http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price, beginning outstanding", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r360"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price, beginning outstanding", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r361"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, beginning outstanding", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r359"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Stock Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r348", "r354", "r373", "r374", "r375", "r376", "r379", "r380", "r381", "r382", "r383"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r375"] }, "BTCY_ShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ShareholdersMember", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Shareholders [Member]", "documentation": "Shareholders [Member]" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Shares recognised as obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "BTCY_SharesToBeIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SharesToBeIssued", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Shares to be issued 194,998 and 324,276 shares of common stock as at September 30, 2024 and March 31, 2024, respectively) [Note 9]", "documentation": "Shares to be issued." } } }, "auth_ref": [] }, "BTCY_SharesToBeIssuedMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "SharesToBeIssuedMember", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Shares to be Issued [Member]", "documentation": "Shares To Be Issued [Member]" } } }, "auth_ref": [] }, "BTCY_ShortTermBridgeLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ShortTermBridgeLoanAgreementMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-term Bridge Loan Agreement [Member]", "documentation": "Short-term Bridge Loan Agreement [Member]" } } }, "auth_ref": [] }, "BTCY_ShortTermBridgeLoanAgreementOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ShortTermBridgeLoanAgreementOneMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short Term Bridge Loan Agreement One [Member]", "documentation": "Short Term Bridge Loan Agreement One [Member]" } } }, "auth_ref": [] }, "BTCY_ShortTermCollateralizedBridgeLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ShortTermCollateralizedBridgeLoanAgreementMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-term Collateralized Bridge Loan Agreement [Member]", "documentation": "Short-term Collateralized Bridge Loan Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/FederallyGuaranteedLoanDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": ["r73", "r798", "r799", "r800"] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": ["r71", "r798", "r799", "r800"] }, "BTCY_ShortTermLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ShortTermLoanAgreementMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short Term Loan Agreement [Member]", "documentation": "Short Term Loan Agreement [Member]" } } }, "auth_ref": [] }, "BTCY_ShortTermPromissoryNotesOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ShortTermPromissoryNotesOneMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short Term Promissory Notes One [Member]", "documentation": "Short Term Promissory Notes One [Member]" } } }, "auth_ref": [] }, "BTCY_ShortTermPromissoryNotesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "ShortTermPromissoryNotesTwoMember", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short Term Promissory Notes Two [Member]", "documentation": "Short Term Promissory Notes Two [Member]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r108", "r198"] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://biotricity.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r679"] }, "BTCY_StatedValuePercentage": { "xbrltype": "percentItemType", "nsuri": "http://biotricity.com/20240930", "localname": "StatedValuePercentage", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stated value percentage", "documentation": "Stated value percentage." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/ScheduleOfDerivativeComponentsValuationAssumptionsDetails", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative", "http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r161", "r172", "r173", "r174", "r201", "r220", "r221", "r224", "r226", "r231", "r232", "r254", "r279", "r281", "r282", "r283", "r286", "r287", "r318", "r319", "r323", "r326", "r333", "r439", "r521", "r522", "r523", "r524", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r550", "r571", "r590", "r605", "r606", "r607", "r608", "r609", "r759", "r778", "r785"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r14", "r86", "r89", "r90", "r162", "r185", "r186", "r187", "r203", "r204", "r205", "r207", "r212", "r214", "r216", "r230", "r255", "r256", "r261", "r335", "r398", "r399", "r401", "r402", "r403", "r405", "r406", "r407", "r414", "r415", "r416", "r417", "r418", "r419", "r422", "r441", "r442", "r443", "r444", "r445", "r446", "r451", "r453", "r463", "r496", "r512", "r513", "r514", "r528", "r590"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r203", "r204", "r205", "r230", "r453", "r476", "r519", "r539", "r542", "r543", "r544", "r545", "r547", "r548", "r550", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r563", "r564", "r565", "r566", "r567", "r569", "r572", "r573", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r590", "r662"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r203", "r204", "r205", "r230", "r253", "r453", "r476", "r519", "r539", "r542", "r543", "r544", "r545", "r547", "r548", "r550", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r563", "r564", "r565", "r566", "r567", "r569", "r572", "r573", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r590", "r662"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r690", "r701", "r711", "r736"] }, "BTCY_StockIssuedDuringPeriodShareConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://biotricity.com/20240930", "localname": "StockIssuedDuringPeriodShareConversionOfConvertibleSecurities", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": {

"en-us": { "role": { "label": "Conversion of convertible securities", "verboseLabel": "Number of stock issued during the period convertible, shares", "documentation": "Number of stock issued during the period convertible, shares." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Conversion of mezzanine equity into common shares [Note 9], shares", "label": "Number of stock issued during the period convertible, shares", "terseLabel": "Conversion of mezzanine equity into common shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r14", "r50", "r86", "r89", "r122", "r305"] }, "BTCY_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesOne": { "xbrltype": "sharesItemType", "nsuri": "http://biotricity.com/20240930", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesOne", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Conversion of preferred shares into common shares [Note 9], shares", "documentation": "Stock issued during period shares conversion of convertible securities one." } } }, "auth_ref": [] }, "BTCY_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesTwo": { "xbrltype": "sharesItemType", "nsuri": "http://biotricity.com/20240930", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesTwo", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Conversion of convertible notes into common shares [Note 9], shares", "documentation": "Stock issued during period shares conversion of convertible securities two." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "presentation": ["http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Shares issue", "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "BTCY_StockIssuedDuringPeriodSharesForSettlementOfAccountsPayable": { "xbrltype": "sharesItemType", "nsuri": "http://biotricity.com/20240930", "localname": "StockIssuedDuringPeriodSharesForSettlementOfAccountsPayable", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Issuance of shares for settlement of accounts payable [Note 9], shares", "documentation": "Stock issued during period shares for settlement of accounts payable." } } }, "auth_ref": [] }, "BTCY_StockIssuedDuringPeriodSharesIssuanceOfSharesInLieuOfConvertibleNoteInterest": { "xbrltype": "sharesItemType", "nsuri": "http://biotricity.com/20240930", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesInLieuOfConvertibleNoteInterest", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Convertible notes payable", "documentation": "Stock issued during period shares issuance of shares in lieu of convertible note interest.", "label": "StockIssuedDuringPeriodSharesIssuanceOfSharesInLieuOfConvertibleNoteInterest" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of shares for services [Note 9], shares", "verboseLabel": "Issuance of shares for services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative", "http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of common stock, shares", "verboseLabel": "Issuance of common shares from shares to be issued, shares", "terseLabel": "Stock issued during period", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r14", "r85", "r86", "r122", "r521", "r590", "r606"] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Issuance of common shares from shares to be issued [Note 9], shares", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of common shares to adjust for rounding effect of reverse split, shares", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": ["r14"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Number of options, beginning outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r14", "r85", "r86", "r122", "r360"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Conversion of mezzanine equity into common shares [Note 9]", "verboseLabel": "Conversion of mezzanine equity into common shares", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r14", "r86", "r89", "r90", "r122"] }, "BTCY_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne", "crdr": "credit", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Conversion of preferred shares into common shares [Note 9]", "documentation": "Stock issued during period value conversion of convertible securities one." } } }, "auth_ref": [] }, "BTCY_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesTwo", "crdr": "credit", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Conversion of convertible notes into common shares [Note 9]", "documentation": "Stock issued during period value conversion of convertible securities two." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "crdr": "credit", "presentation": ["http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Consultant contract remuneration", "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "BTCY_StockIssuedDuringPeriodValueForSettlementOfAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "StockIssuedDuringPeriodValueForSettlementOfAccountsPayable", "crdr": "credit", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Issuance of shares for settlement of accounts payable [Note 9]", "documentation": "Stock issued during period value for settlement of accounts payable." } } }, "auth_ref": [] }, "BTCY_StockIssuedDuringPeriodValueIssuanceOfSharesInLieuOfConvertibleNoteInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesInLieuOfConvertibleNoteInterest", "crdr": "credit", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Convertible notes payable", "documentation": "Stock issued during period value issuance of shares in lieu of convertible note interest.", "label": "StockIssuedDuringPeriodValueIssuanceOfSharesInLieuOfConvertibleNoteInterest" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of shares for services [Note 9]", "verboseLabel": "Shares to be issued with fair value", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of common stock", "verboseLabel": "Issuance of common shares from shares to be issued", "terseLabel": "fair value of common shares", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r14", "r85", "r86", "r122", "r528", "r590", "r606", "r669"] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Issuance of common shares from shares to be issued [Note 9]", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": ["http://biotricity.com/role/ScheduleOfStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": ["r661"] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock redeemed or called during period, value", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": ["r14"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 deficiency", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r86", "r89", "r90", "r110", "r552", "r568", "r591", "r592", "r653", "r670", "r780", "r796", "r853", "r909"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 DEFICIENCY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://biotricity.com/role/StockholdersDeficiency"], "lang": { "en-us": { "role": { "verboseLabel": "STOCKHOLDERS\u2019 DEFICIENCY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r119", "r200", "r317", "r319", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r332", "r335", "r421", "r593", "r594", "r610"] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stockholders equity reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": ["r123"] }, "us-gaap_SubordinatedBorrowingInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubordinatedBorrowingInterestRate", "presentation": ["http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Interest rate", "label": "Subordinated Borrowing, Interest Rate", "documentation": "Stated interest rate of the subordinated debt." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r447", "r467"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"SubsequentEventMember", "presentation": ["http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r447", "r467"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r447", "r467"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r447", "r467"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://biotricity.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r447", "r467"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://biotricity.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r466", "r468"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://biotricity.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": ["r730"] }, "BTCY_TechnologyFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "TechnologyFeesMember", "presentation": ["http://biotricity.com/role/ScheduleOfRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Technology Fees [Member]", "documentation": "Technology Fees [Member]" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityAbstract", "presentation": ["http://biotricity.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "MEZZANINE EQUITY" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "crdr": "debit", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Temporary equity value reduction", "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": { "http://biotricity.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://biotricity.com/role/BalanceSheets", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Series B Convertible Redeemable preferred stock, $0.001 par value, 600 shares authorized as of September 30, 2024 and March 31, 2024, respectively, 405 and 265 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively [Note 9]", "periodStartLabel": "Temporary equity, value", "periodEndLabel": "Temporary equity, value", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r279", "r281", "r282", "r283", "r286", "r287", "r384", "r486"] }, "us-gaap_TemporaryEquityDividendsAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityDividendsAdjustment", "crdr": "debit", "presentation": ["http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Reduced accrued dividends liability", "documentation": "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends)." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Series B converible redeemable preferred stock, par value", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": ["r21", "r46"] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesAuthorized", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Series B converible redeemable preferred stock, authorized", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r84"] }, "BTCY_TemporaryEquitySharesConversionOfMezzanineEquityIntoCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://biotricity.com/20240930", "localname": "TemporaryEquitySharesConversionOfMezzanineEquityIntoCommonShares", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Conversion of mezzanine equity into common shares [Note 9], shares", "documentation": "Temporary equity shares conversion of mezzanine equity into common shares." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesIssued", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Series B converible redeemable preferred stock, shares issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r84"] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesOutstanding", "presentation": ["http://biotricity.com/role/BalanceSheetsParenthetical", "http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Series B converible redeemable preferred stock, shares outstanding", "periodStartLabel": "Temporary equity, shares", "periodEndLabel": "Temporary equity, shares", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r84"] }, "BTCY_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://biotricity.com/20240930", "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Issuance of mezzanine equity [Note 9], shares", "documentation": "Temporary equity stock issued during period shares new issues." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "label": "Issuance of mezzanine equity [Note 9]", "documentation": "Value of new stock classified as temporary equity issued during the period." } } }, "auth_ref": [] }, "BTCY_TemporaryEquityValueConversionOfMezzanineEquityIntoCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "TemporaryEquityValueConversionOfMezzanineEquityIntoCommonShares", "crdr": "credit", "presentation": ["http://biotricity.com/role/StatementsOfMezzanineEquityAndStockholdersDeficiency"], "lang": { "en-us": { "role": { "verboseLabel": "Conversion of mezzanine equity into common shares [Note 9]", "documentation": "Temporary equity value conversion of mezzanine equity into common shares.", "label": "TemporaryEquityValueConversionOfMezzanineEquityIntoCommonShares" } } }, "auth_ref": [] }, "BTCY_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "TermLoanMember", "presentation": ["http://biotricity.com/role/TermLoanAndCreditAgreementDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Term Loan [Member]", "documentation": "Term Loan [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r791", "r862"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative", "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative"], "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r722"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r729"] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": ["http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": ["r146", "r147", "r148", "r793", "r794", "r795"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [

```
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r749" ] },
"ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r751" ] },
"dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } },
"auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r752" ] }, "ecd_TrdArrDuration": {
"xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r753" ] },
"ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r753" ] }, "ecd_TrdArrIndName": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } },
"auth_ref": [ "r751" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r751" ] }, "ecd_TrdArrTerminationDate": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r752" ] },
"BTCY_TwentyFourMonthAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname":
"TwentyFourMonthAnniversaryMember", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": {
"role": { "label": "Twenty Four Month Anniversary [Member]", "documentation": "Twenty Four Month Anniversary [Member]" } } }, "auth_ref": [] },
"BTCY_TwoSeriesANotesMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "TwoSeriesANotesMember", "presentation": [
"http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Series A Notes [Member]",
"documentation": "Two Series A Notes [Member]" } } }, "auth_ref": [] }, "BTCY_TwoShortTermPromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri":
"http://biotricity.com/20240930", "localname": "TwoShortTermPromissoryNotesMember", "presentation": [
"http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Short Term Promissory Notes
[Member]", "documentation": "Two Short Term Promissory Notes [Member]" } } }, "auth_ref": [] }, "BTCY_TwoThousandAndSixteenEquityIncentivePlanMember": { "xbrltype":
"domainItemType", "nsuri": "http://biotricity.com/20240930", "localname": "TwoThousandAndSixteenEquityIncentivePlanMember", "presentation": [
"http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2016 Equity Incentive Plan [Member]", "documentation": "2016
Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "BTCY_TwoThousandAndTwentyThreeEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri":
"http://biotricity.com/20240930", "localname": "TwoThousandAndTwentyThreeEquityIncentivePlanMember", "presentation": [
"http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2023 Equity Incentive Plan [Member]", "documentation": "2023
Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "TypeOfArrangementAxis", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative",
"http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligationsDetailsNarrative", "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ],
"lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative
arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r408" ] },
"ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [
"r748" ] }, "BTCY_UnsecuredConvertibblePromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname":
"UnsecuredConvertibblePromissoryNotesMember", "presentation": [ "http://biotricity.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label":
"Unsecured Convertible Promissory Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"label": "Significant accounting estimates and assumptions", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial
statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r36", "r37", "r38", "r152", "r153", "r155", "r156" ] },
"BTCY_VolumeWeightedAveragePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://biotricity.com/20240930", "localname":
"VolumeWeightedAveragePriceOfCommonStockPercent", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ],
"lang": { "en-us": { "role": { "label": "Volume weighted average price of common stock, percent", "documentation": "Volume weighted average price of common stock,
percent." } } }, "auth_ref": [] }, "BTCY_VolumeWeightedAveragePricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://biotricity.com/20240930", "localname":
"VolumeWeightedAveragePricePercentage", "presentation": [ "http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative" ], "lang": { "en-us": { "role": { "label":
"Volume weighted average price percentage", "documentation": "Volume weighted average price percentage." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [
"http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation":
"Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } },
"auth_ref": [ "r659", "r660", "r663", "r664", "r665", "r666" ] }, "BTCY_WarrantOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930",
"localname": "WarrantOneMember", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": {
"role": { "label": "Warrant One [Member]", "documentation": "Warrant One [Member]" } } }, "auth_ref": [] }, "BTCY_WarrantTwoMember": { "xbrltype": "domainItemType",
"nsuri": "http://biotricity.com/20240930", "localname": "WarrantTwoMember", "presentation": [
"http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant Two [Member]",
"documentation": "Warrant Two [Member]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [
"http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants and rights outstanding term",
"documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at
specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and
thirteen days." } } }, "auth_ref": [ "r847", "r848", "r849" ] }, "BTCY_WarrantsDerivative": { "xbrltype": "monetaryItemType", "nsuri": "http://biotricity.com/20240930",
"localname": "WarrantsDerivative", "crdr": "debit", "presentation": [ "http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative" ], "lang": {
"en-us": { "role": { "label": "Warrants derivative", "documentation": "Warrants derivative." } } }, "auth_ref": [] },
"BTCY_WarrantsIssuedOnConversionOfConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://biotricity.com/20240930", "localname":
"WarrantsIssuedOnConversionOfConvertibleNotesMember", "presentation": [ "http://biotricity.com/role/ScheduleOfWarrantsOutstandingDetails" ], "lang": { "en-us": { "role":
{ "label": "Warrants Issued on Conversion of Convertible Notes [Member]", "documentation": "Warrants Issued on Conversion of Convertible Notes [Member]" } } },
"auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": {
"role": { "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED", "documentation": "The average number of shares or units issued and
outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref":
[ "r219", "r226" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": {
"role": { "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC", "documentation": "Number of [basic] shares or units, after adjustment for
contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common
shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r217", "r226" ] }, "BTCY_WorkingCapitalDeficiency": { "xbrltype":
"monetaryItemType", "nsuri": "http://biotricity.com/20240930", "localname": "WorkingCapitalDeficiency", "crdr": "debit", "presentation": [
"http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Working capital deficiency",
"documentation": "Working capital deficiency.", "label": "Working capital deficiency" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label":
"Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written
communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r757" ] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r2": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" },
"r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-
45-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic":
"810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" },
"r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-
1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic":
"825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r15": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
}, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)",
```

"SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role":

"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360",

"Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-6A" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.FF.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r350": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

"Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479341/842-30-25-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479016/842-30-45-5" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479016/842-30-45-7" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-8" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-

50-7" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name":

"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-79" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481639/420-10-35-4" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55",

"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r759": { "role":

"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r820": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",

"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 71 0001493152-24-046028-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-046028-xbrl.zip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lWH7_0F[_V*9]N^?\/_6FH<$F";^_3JF9]O\+C1L"_OWCKNl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

KGV47NQ">RA5X&QX.9)3G&&_ AL%LLEW8I-#N]ZE4,>+I[F M?8P.CF?"4F8SRP7-V23QOE=)4)'R))*0P3+7R(O?*+(_O,]R6AWFCJU7T_UD M#SX<
I/>9X'R))1%)'Q,G\^0\/H)1*LRR?GW'1\SR8YL GD1&RB0B-I?. MHV;_7FY)BKOT'24Q"ZH4-D\RRJU)8-AJTWKU'2LQ2XH%/$_"2@<1,<_'4G&5 M]>L[DJ/$35P%%D8'I/A:+OT-
NTA9/'7N+2^$HZZ2X"T=A M0M';*,/+DW!BW@B_$P"+W20M+,AMSE%(4!@+4'#R))!<5\B6>2SIR%$T4"4, MX#O%5> (603&T)6C>*!:(,"WT)(U M]TP>M1
J3W]$'[9V;!9Q9%OV'<PEDKJ2CZ\$>3R(RR*8C=>659.O.GEQ\-4>^O%EJK1$>S5"20!)?(D8^N(*M!+0 ML[QGWP$=*[;BO!6/$ENB_<%Q-?<8@HC+5X=[?&PW!W77
=^>*@07I)8+,(: MI/H.#&O*M/:DL4F^QXQ2E5F@-*3"_.7V$N44/G?TN$#^39^I9P?>U7EV0'B3 MHOR/5A^ J'$/: KA>S:$YV$$9R.#[$:*[XJEL!?E@6U^G ?P8U MGJU%K&]GFB.I3
!4>XYX\]\CQ_-/M_/0Q1TG@,O;O> D7RN8RQ*@T M'SRM>P5Y"#C!SXB-89%83GB;4ID 2[KU;1=8Y<:$GB=QG8"=TR0,YB+9F)LE ME45P(9P\XW[%OJ0#;2N%5*R7/'FD,XPXJC'M
)@^1):..X4:H. AKDB:]@ MZF"B31MVFQ),%CDBQO&00RRC9(O(11[U"<$6!^U;Z3N8T2)-R]%)CNQ9C*+4
MX60:]KWHNQ=IP5QQ93IPU3PB,M@[KF_^269"WHRCJU3PWG_AHKT9I#W\@*T7 MWHI-/02I1:_O5%7WVG'=S/-D$\X51T^::>,YE.WS=]3'U!BZ]GWFV:UF,,\G M3TJ 6?
4PKPBXA0D F('I[;#2XLOUUK3$67G7OH]*NU<'YOGD20G(Z3# =-+! M3&FP4-:O[]/5'L)!IGD2?9@EUCVN!?-^@[T<[G.Q''M2Y\C09Y@1,KVB&O$ M/?@H[-!WR,\NW$*T7
7K*3S#9\VTPK/@1'5A=&R*+R77&1S=\I4QR,?&WVG+*&,NK/*F=^C:3#(AH)K&"I#D2(ZTD M=0)AF;FUPP<[]>/2U6P/+ "6AVV03Y%TC/\+P@Q+N0:T-5[?AKBZ\K0[\WP5
M>UWU4N%4D=2'.D52IR&%<$Q2*I4<|>_:P?%^%LZ#"Vl6YZJIKHK&LF\M3D'_ MH0YT3%,@1%.0^HK ,3L+U\%^S7@\KH!YR3X=WISOI*<&W\PT..AG2$];^8JR
M^=ZV!^1A) ##B-1CPL(ALT*IVBEHW[>GN5I2](G@263XJ31T=:%V]0AL_ONXOK_ MW3#\Q0OWF@HR4/C.J0(#?25--OG^R*%\&P#?E>,EF8;HA$9!6PV?K&UC55S[M,\
<@[SZG2+D2!3:9_L2I3&M,%D\N>HP.+M+-DKU-NA6;P#YR*+!<.%TM*WPH M#6R3:X>SS/T9A0E
MQ_F;*K/$50":93SQ&OLJIGGA7)+$&9_UKY(XLWT99HP+PF"^Z$CE_7KE@*B:FK=GZ=8=!N31Z>_^,CI!!:A_/ MZ;Y$?0"M$*FT*Z>'1A099M]6PS8]/&EN/M/I&JHP@0=?
('S'21U!E]/C\"#] M6NFS3B2O*J&@@W:,3O3C.Y]QYH"\EY17]53BSJ3R:MB MJ#O'}6, ;)*_Z,+I<5<|T>9.1_M9FZ1&Y=>]%N1P6#IR>C#%("!6A!SN+C#B
MBS<^*\C#E58^,J(W0J>_2+1<(-=TC,NP^G2/$?QCI]E;I&@^$C<;1*L<[YJ/ MOJ._?N8]6W94=4?%Y:T:/$\FS7QP568ZU_S 1W^)35W-9D/E&T:G2D]S M:2*-AAC/:"2OYDMI_B0L --
($MN56]5,2P+/ATL\$>.JL!A^&SY.12(9^%)9 MB6-A*@T?I:FT;!M-\7DUKLB.8S/RLIH\4#]<@@+-^BHJ2PGC62CR39)5&60V MEY>B2@"]7V1E*2Q%929,Y6'+*RSF':\E"&),?
[AU$5E=>6!^O 1SXC)<-(HX MED#?GA21K*16.9\@]^J9AV? @W7A$&XC('DL?W3)=L3<0SV:SK|)CRMA@JL M1K%,!HE>/<=^;D\?
OQDE_@5OH*INBKV)G:,SUK@+E]N,N8H:4\^]\O\A2X M5O_^MY\>[G_\&1!,L.&9C[ZURG7.*X,'SF801"\-QDN6_"*O+7-;Z/D>[B\A M1?X.+.@4'(4H*-+3E^5
G@Q6\&&HJN(R7+OAK_+C5'KJP#WB_)\9EKR%OA C M!S'EJ]5#QI^/Y-E.6N*5JL9.#V,$*;6M7?':MY,OWLYC.>,^P6*"*);?"+_B M_ZZD1>N&1@W6'OHCP#< /J>]"Q-
\YKCB1Q78P^&$^!5/, ,CX7O98 M0G@3$V[Y"2 FD,OTZ5X*8L835X$8DFT7($O<5 POXYM9HZ=9M.4ZOV(T&9>= M[P*[X3W?%Q8SG_'?=
(_8#8@:KK$0X;N,SZ_M(+L!G^=OBM%EW'^^U^E(^?0= M,@(+G:ZK5I#N@ '$U,?X-2M6+H:,LU='7\3Q:DJV[PKV22N0DCB2P?!A00AO M(F)=H4D4V5!@9 *) QICEVKK!!#
<&*_I\]-$,V16LB?;M57C4G$@

8];+^0;94H\8]\&YK\FQ*#BT\C'Y'Q,^C$3[[V8X2*>V554N$VYJQY MR 96!9# :5>;-^@8P"W>0J O48!7?Y)[7)529G5=N;M.9A-& Q'YP1@BM,+
MV:-7G6WW=;7Y&6J;9X^QP/L)8RBD+_3/JA*X'%-;8%?)]/'1@*2I^^Q=>HH M)F)O8A+SQ^*Y.S].%<.W?D*P!IUW%$44;2A89?7L]<0:9D;",E":M,D[C0N3 M-W6G\V7H;FZ*)P24.+?
QYMHXE5BT'G$]:=JO<<9'I"*Z<=-;+N]E%7Z8E>;G MFMZE4&2((SQH'7RJEZ4D3@L,X9_V[. ?YA,W7$*^7_SWPI]-7>T/I6SGT%M&
MJ6#WW@JL*1D\4U\1&[26%N<:U6GD\BNO\C;75X'6;[#*5AF\+<=E#HJT[@X# M.FO$$0_LS_7NR$2:=;\+-5LL,F<1KU>S)?' /JMMKSN,PF6ZO:(@/.!DES9U
MS>,*#5&A[]WB(S%%FRJHO)Y-+E?)?#[,W>/60XF1BVU=M!FZU=T\6.[C68'(M*WR+?$8N-B\7^>3!U;[@ M !?Y'I/K*$J1$WJ;E 7[Z8![HT^Z_OR]IC)E](QFDP07GH7N./0
M:Q_DQRR.<>>Y=!,_V?4IVA8\I37R.9.]0 .XZSY: 89L500)*3"1KR37S* MY#[2+&;C_(ZY59?09*)YJ --A[TQ]I#'>;U(6-5DFM4P&+>+K[F'WF*%1=X@
M7,2X.=1%^7_K7SF4/FI!!VE1#U \0JXX<)4/H,FE&&! 3)"'5E NCOWND%//9#85 $ T M%/+$ZKKLS RGZ4?Q#?K5%3ZQ?O+!#)VD)BN.1>#W_,N!D||$W+=+^;)S.^GU>Y-)
MK]N9SL97_]7ICR>=F]Y__[Z;SH[BT6VR@*2P6*047*!6:\68V!55Z3Y.%5]!A\;?R|[%Y^:S MV3X)@F2(/KN:MI.E2AP!,?P\C1AT _%(3-$Y!U!<1# #SS]#J(,;D
MTZ?:R&OU%.HRCKZB>&O@< ^<6$4UA>GS.WTDEKDEYSK9J[@H*YK5O;VT]0AYHW#XI[KZ'B13X-Z0[HNHDL35!$2N(JT&JUKP0V) M4PPMN>L3[=|)>;D^\7)]XB]U?>+
<\/L3Y[PI^;SFR)>Z;U"<&WZ%XIQWA^+\ MG;Z+FR2SP:6;((^L*7@@YZD8R7*^I,/VN=_37C!6E6:L[W3G : MZ@_:(KZ86";(3:(0+^_$:TABQR/#+\?L&=BW#I0Y1XW([U!T>
M4WQF4H A@4 HO(UZXB>,":RIKS-Q'EVMA0_CXW!RD84Y0XZ*:3O^J9^@B(?3 MOBTUB']/+/1N S>4N9OWFGKN:89F<2E8 MM\(TF,=%-44]-3H/;B#;M^Q
^LB1M7(0!GUJKFG#VYR1VHB&?IPCKS+, MWQ'Q$B#/>4:QNT0'KJ-6>B)/@)?^>8+>?KB9\CJ/'@SS.X37<90TX?B /_;2 M&R5U9-]!%VBT,)$V-&?6)\1?KZ?
6K#OCSLJH+9P'3G5QL\>F>VY3D^/&Z8_OJ,^[T]U1C!(P VZJD.5M1 M^.F_7H>M16,2Y)([_6!_5LQL_2:R7OEV[-]%^__$'Z/>MSL8O\Z^BC]">]\G8 MGB>RC!A(-9FXBI+\|?
ILPJ.O1G_:%MN\QJXX<).: M9^?BA;U]Y(6]]9W!//%&=[1GS;A;]ZG]_VX_2*U_-Y+\[7 ,.!\W9?S+XS3;$D\T&E]WYGZSOHL&)A- MNYN$WYQK2] K; (T"_W""31BX9WXR==^C-
+RAX#X='7]I6+V-]^]_5V4 - MF!DF="^&?2\WQI[0 F^JR9,SG+NCS7W3CE[6"3[8H'4IO <[YCP[6@ _-B>)H WO6?!0^%GH9^5_ST7[/7E31@7X#0CQ(I_L/VOPIZ
MJ#NV!\AUNQT%^W,9)TUCJF\R(%B^5E)/5,U<*J6EEPA<:?G4B80T/D8!EB+I MXG87/@H7VW=21B1A!'D]AG6R]*ETLD22*/PV'G9[D^E__L>GM^?S:!92KF)!< *0".!V$@!OD_:=9U
M3\NPJ9*VO (H::3]>C,\!ARLY?>B.+]-! MMY'6H;B-*7W6(O\:T;CV-]CWHT MO]PMBBD(*;]@RK;1QL*AU$,?;^D]ZO+/_X!"7MIB%)$^2A/\'\S50NPZ)D U80J80%Y-(0ST;C.)P@^NX".:LH
MVQ\,BJ;'?0VS>9(2'J1'F^=CN_0FM^Z:1"5<97CXAVF>2621_\"A2]*V';1) M P$IU.8A(5UN/$O)FWD[7MA<2/*>2U.K1T[:*T "218FR>EBYZBQ$^'OGM/
MW@(C.;H7BS@C./)7#WF<"JI:0J,4"I Y;?X5BHX8Q6B%O'%Y08!\KI9[(=+ MO'+[47Y*P?'Z2]6W@D,5*""1&@.YGW$WHZ\<1*LG-UQO%XPNB9[T[I.T$ 7(MBA"6J&X%C0I(0!8-
<;Z4-ZM*QZ9 =2M85$ "'GYK3'H4+1#RDC[6 %FYW7"! MQ@^'D++#AMG<%TM_P:*W2GB4\5X<&$J_O10,B7&ZK%1>.W(8;H6_T3]P$@#+U MK2!6!0I(I,8$CDSIJ050G$ TXP9BGS/-
UBI1U7P.Y%& E&ASN-SX81330.I\][G+4;'O M39?K6Y?O.E-HQ&PV]^(>=7H9REZB[HH6<3^$W]C!U:Q@C.!"!+>OTID-FS M1S)^*!Q=3=$BBZG3[*)E*&S7"[K@
AVB*I^&6!UW(N#9Y-H$P!'!0761+B" MV=S(R XJ79L;A88A;CRP!9^LVM&10B-FHPEQ4:LX+=RKA OK6%NAQ!V<44 M5*"74==&-D$8('DU^UGV3N^B847IF$Z6.!&2QJB<%'
VQ_TPSJFT= 6MP5)1*FJUTKM"0?EGI7T_1 M[S5&,XP2O'-?1,N0Y&D8/Y!N "@9*FZ^IOF2@^JN./EZ>\Q,[<>E80* ,!)$R;QV'J[M)8CS*BBZW]E'>Y05AX;)XS'A5: ML8),=4 @M1KOQ3
Z9)PCRPJR%,?C05TK:)2% 9"'>K>YI7&)3;_$Q^)0+ 4 M+9#_C+RQ\L 4-V,%I140@>S6[%+9Q\2.'VX#=T&WGGV$G-"C<43;'KAYD0': M<:@V8LWN1M-
7L6&',]8[G4=6Y@OV;XP_'32*QJR%/<>-HSZX@T/|=5X-)LX5[.[9]BY&W4'TZOQ MW6C6ZW;NG.EOG?YP_/NTTQ|^7 1 M'K;TCXB_F$3AL#1R?]R1(^X[D\'U;[.S]V;3CC+HE+>P[1F?W
MP;^]TG01)L!#.,IE*,P R>9R%?#GPB8S*:P#,#\GY]E<890^'M=-,9;GO\ M4(#"?](5*%YK9ZGVMFOMS$4RP$&6=?%91NZRP8J>7%9NJ%XC5O9UG3XOT6F0 M(';UY5W31: _)+]DVV
5:??-VA+Y1,]-9QHC*PWTM%2@]U[.=K#]T(BE QLVR MP(OO_+636>G'7T$E=,;8:0UC6/3^MZ":GC521O-27)G[L3=)F\YM5,;3/K MW.E[:!3(@YI;7*$2Q&^!IR//%66/M)FD"VP
$D:VCU,OO933W;B7"\^+P22KMO0# M\U])%<;9RX9_D;8&#*C\PHWS,H*6E M_\03"XX[8[K&JB AUT]$:,ZIWUO>J=_MA)OXS?Z@AUJ]?!X~FJZHUGA3$]7 M#Z8(;P.7Y@3.
CIRWCCW% &)=K MXA[E.Z;D*AO@H)+DJC03RVK&((,)AHH_*O)J2%76XXI284.2Q|D&3'),-4VD MR4ZJ1LDVU&4U?GCP%V@GK\@UQ2RNZ0Q'981%I+4[RM@U63W'TG)O]
M(I(XE1H8?@US)0(#4F;>6BB(T.??PV -HTYB3RG$8YQ3$!1Z>Q^M"H&[NC\0 MB4>8C()LY0<'QO\I2MR@"I&[NC\0D4>8C//@.8M%MLH"\OQ6%SW%:.%00KN? M IKTFQPCK:
(X]?^DOP=Q;7L8UJ,!J)-VS4U MSE$-!U[2N^,S&\$YC?9+1R\G-B\G-B\G-B\G-B\G-O83^7)B8]:)S_DW\)*8/KZ KYKLZ8 LXJ9IU[B8XOX'K$#81IC(M>A5 L>?
4YBY!#UDP]!\XVQ*)RM81*(O).+.4-5,(QAU8Q3K6^$B,.YG9Q@CW MH[@8/XS_39].?MZDH^&,/+D&K.-1!1=H8%IT:&(;/R7A)4ZN6@YPS^X3].\,
M8^D]DYXDXR=1XIMO|N<|OYY1WRCO2_X_PW*RW2$3\(Q"M?0Y X|E$?D^F26 M-L:-*:+CV+G)P6Z\(_-8>*'S$JR@SV')TS^?*G,=D@Q)1=XK3A4]SD>1MH7<
MF.MFK),>DUV*-5%HJ//P2%YA)@)6<4WAWN+1PJ7&X"#OP^>(^8L1JZP-ZQ", MT: -[:&0(W7R4H9JT1'B\D+S\G4M9K\[2Y,R$.=),7V M[NE.O!]?
^4D2Q>M1E'(..$@#TO5U'4\)!TA4%0RX_FB;]W99?(I9U@6;(KB* M#!VJA 9BK()#>+7F]-DMK705 MO777?#^KL*JN'#Z*'E8Y'!!U^MP+O&>F1^@;_5/5E[=W]2WA4 &,X2Z)&8I7
MLILM4M82@@#!ZW9+ "O8X=<'>+7&W8*FQJ-+L;=-EK=_WA18P]0;,IV?$U 9 M9[T?XNB["^2LB-RRXVE?PW369,2'Z-%X1;0H;<%RRO^9T%NO_@)Q;AU*-V$E
M@2(\H/EH!J/EB8,[GS)5P&O#2DZ%@"!2=5[YW-G#T\9 M?:2Z'T!6;P>0S&Y WT6MKQ_L>RCT>!$8VR*V$' @KXF'CQPW66_U%$1KA"Y1 MB!6;DDCOBMY#1DN6$%@)%LBS-D<(
..+&V2H#IJAANQFF8L*)+F5>PM4/PE: M_+R,GE^CA;?)\O+\A!?F148N%USAK>4R(F=2XS!8%V1JYKN.JZ\L2>G-F^:_M-\"6)9Y8,S=H]F/T87H2[$B_HF?DDIGFTDU(?,N*O/61O]U5>
(CB">^$'NFU,K%;S7RMSDUQCSYJ@*;*$P?G3#TB5?,C=?2TR,#(T,#DS,%]L86(N>&UL[+UMD^,VDB[Z M_4;<_X#CN;%A1U3;_3+C&
<_LGA.]*E5;L54EK:1NK\=QPL$2(17'%*DAJ:J2 M?_T%P'?BE90$9(7LQNZZNY4)/DD^2"2 1.+?__+-D1/.$F#./]{K]Y|^_8K MA*5^] ?1YC^^^K1X,UI<329?
H33S(M\+XPC_QU=1_-7_^=_[_^#R/_\^_IZ M\P;=!#CT_XJNX]6;2;2. X;NO2W^*_](YQX69S\#7WVPCW]E_@F"'&^KN+M M+L09)C D# _XK^M.W[__X@-
Z\,6CW.X[\./DTGU3M/F;9+OWK=]\I/S]_&\5/ MWG.<_)9^NXJW9@TN,B_;IU5K;U_>%O^3J_]I&$2__97^OPOWW[IKO_OKM=K!QUGL31/2]K?!7I19M1:3W[H PZ_0E22\$-
]UP^MM@JE M[VR#G>$DB/UQ- QU5]L1?-)WDNP(YKZUDU8QID7#@+?U+0.^>^.UGOTW M3?P\'O:F&YIG@9WQD'N_7O%[#>]D_WI(_M2#BEXP,8-@O0=(F%!Z8/8$-#$7;
M5>OQJM5N2+UYG/"VTY&1M;GVT@?6\#Y]L_&\'7G ^S]^A\,L+?_E#?T7]A** M?_B5CHUXBZ/L^O32=+I>9/'JM]%+D);/84;^QU<&\M]U#:":HZ2TPDM6FE=1 M2'RWBLE
MLO>A/E+S]772;PU@E&\L]A ^-?PH6H_?\D$@L20EEB"TWB?K'"O M;]RTQO2M%@BW(=&@ 1N.WGO:?/6_F1B*UX@)HE^HZ/_]]^_JIIUP:4::P4F" M?8;]#F\?<"
(Q6"QJDTJLWRB.3 \$8!KDN92K3D3"[MGC4+$B?@=-2#/$H- MJUY(#[WEA^3B8!BEQ|@E5JZ!1NA<#'O(5@=&FI<_?'C+']'XO/JY0'IY%4=D M=IL%#S18\#&9]I
_&9!I8!LVZ'64>91P@QIP3L%C4$M(>8D:#:&ZI;-Q]73Q MV/B?^R IT)64.")_34UB,K&.D[A.!5\8FXD4G%.R#\HN!7-15,M""=,(HFT< MZ8=9@9Q-*EMA=9@4=8&AC P9%\HS.4M#YJ-
'S%S&EWB2IGOL*P9&B:2]X4\) MM1[DA&+.2:#'Q@U83!AE,7K *)>',RB-?#^@"\E>,/,"?Q)=>;L@\T*E]]#H MV/0D1O";7D6IX)Q+@-'O$"1U!$_R(MHS1XPI-H%6^QFGGF^E99V-
>L%B--E>&PLR=BCJG3JPD:95D2/.PS%K,3WS@C M3C+*X%!UCC,OB+ _]I(HB#:IDI2GA=+I7"]}0^=Z!U MAW_W2-/PODD0!YG202MA5E*H%64)91R3@4MM"X-*EE4S,W
^)%BU:/W&JA$ MP_X;J!(ZOP8J%'=.*',TN4FN^M*;9(UV$7^5C.+_.7799"%>+J>1'[P%/A[M+Q2L(2GD;+!("Y-R1RKDG#$Z9%V>,%GD13Z:Q2D+Q$^T*"09AV[I3G0B'WI:
MOUL;=42PJL&F^:/S#RQ#U/VPN8C;ICY+8G^_R]8)\49/P0I+>KM8S%9G5X$L M^[I(QCD3-,#X[58FROIZ(7W>KK[$]\MZZM@5BY).2< M #IDG*^O1!&5/?
>4XQI3CBV\4/7Q!4+6OKP48/79.0D8WUP&J_O!'ZH_!C@A;_+Q<(N?L"@]I*ML<\+1SZ#FW,-,TSGI!L'MDI%J MY GOJ-)A@!'IZ#.4C"DPW0%" MXI?%'C)42YYY&?
PY+HZPW,>9*"")CTKEG. B-OD 6&A&0\:@DYX MP $5\]"2@L>#+C0-#ZA[!-!_.0EB:>9U71D;,8-0GC-D*$EX]P:*E1=5A0R MYW89)$:^8F'K:".;O2KDK#D$%?7/_%@7YP\^]][L]|CY\;)
[_57UTN:^WCZ^!6')) MPJ""!EV7$42\=3[?!C&*W&XCYW_ITOF+('9K.P!U_@)W#8*;;SGDX&#)_:(R)Y4E3 M<904?Z5JE+IG7<4,F!GB0QJ,@KE[=Z#EP'NW4*7";LG$.F
M"#DV$:E3%^25K6T1OOX8ASY630H$0O96LV0 ZV6LKH3S[ZZ$Q2U,+0.'%8YQD2YQL:5J>YMR 1-9J6*&"VPHI1(+.&6."CB\%263?4&%$I2\0
ME3]O2%%4:&MMW:0S[T#KKLG=AXF6-7]B;D+E8/0JSOG3#R=W#( ]8QPSBZBZ/L<11% ;T-D4SL MY0.;3L/:H&8&O1K0U.+,R6&.D:NE7R@AIH4::N>>1RV?R;3M<$/L-Z>/7L?B
M*1,S^(T#)VH%&"0R1,D?0Z%JB.K99U(U!;A. G^#;V,O&FT2C*5':(VU+!;E M-S6A4:!?IP*#4<8XQ;.UC,[6<=)"5=-?:-C
M+VCD[^!ZMAX^[%R^ZC0K0M>$K[H5H5K&^HI0%QZW(E0*.*>%"I5X18@*G3=Z MN@F2-*.SP)\P_DVQE2Z6L^@+Y# ;OH 7R 1A4$2#KLN.6KPZD6'I<'%GBU:;HV>D9OL
LHD1W2()*AT8'#(' M*CVVS)U4M90 >(^?VTY2D?0!$[5YD%D%MGF.620'@RQ[<*)3S-T1ZUIG+<4@]$]9,YWGH!O3QQ^1@DV6$1O&@F3QH%:_PR EZQ2BD-
M@TLF$/G#S(4.RI40T;(SU:IO'#[":PUHQ-[1YZ$&UD>B^[8 0X=#82ONI+;] MZ(Y>*+QB)[IOO%40BG=958(VEPSE0)OKAKR4NP45A; M EM=9%NOY)Q0BN+;.@W8A-
(6Y580RD85'$4&KIF74BN"R)(V\%8J+6 $,X"J M)EX=G]*UW7TO(T>3IJN1_3(_@9K+I21R-J,&KHL+J-S;_G!Q"S1*VMM)94XV]OM(W'19(ZFNO-%>P2Y4&"!6.RNY& M"Y_NH!S]E.
(.4TWD(YU"%@9;] !-"@=$585UYZ>,H\NE_Z&V53UY(RR2I]E(4"E;W5+3 6WLK4FGG_#.&R/&- M2+(HB_VAH0-EUX7B4FZQ- 5L^>5+ _"HH;:M]#*7#N'9 B?E-L=W0D[.UM
M"*'5&AQVFUG_53DF;HNB"G_/_&W'Y WVV UB?ZQ3P[70>]E9"13?VV]CKTZ M'8;PZTH=&@48'#%$R57K*-10KH=*Q=,RZ?BKJ.-HDYD5PA.+6KU6@&V=>"NT M0,XYF0S <4?
IB>B9:N ='U?4F> 4G#K$$,M:C394<%N!AT@0#'E4Z/BI4)VK MSZZ?!N-T[K"7[A.VD#2)=GN=XY&+VV20#G231#)9,#S2 .Q2]2&.F#PH5]0U M9ORRPZL,^]=T.0I' MR3G!
<9TH!+RND-4Y%0K@V6EEK(6J)>H+(-5#:"YM[9 M:Q&G2=9@+OE;S5KREU_G=$-X&$ZO]G@FA .I5'K!^<,$;'A=BLR+PO2+%AY M(6H2X9QN2O.AIX(HV.ZW0N\C^-
W6!Q?"*C]ZZT<0'UZ$B.OYN0S<(&<>I+_= M)!A/(A+]XS3K/2]I&G Y*ND-4XU*(8D>95!/%\<&3>V:BA"F=+PA)E.Y6@LL):50^TS=V!HH M6#(N'KT$L[[3BX]\FDLLBRHQ0T;"K Y;$$]
&%%&2:A6,\>R)3]R[+*/*+>[*N M<1(\L31-51*3L;+%!*:>!C62EPPUG3-N$%S52CTKG4(32LJ[=^LVSG_X@'#] M45NP22!E,257!K&1B-L5@4$2*2X^Z;86/'O*P0M-
C]N85/^3BMI+,%"#K?,* MQ'(P:* &QV41%-+V,J]G>YHQF1K5@Y2)VJL$J09;UX 4R\%@A!H<5_>QD+96 M"T2S9C1(5B
>@QVDNV,SN^VUHR$L,HUH]:/SDD@0\2=E"YESGM8YQ)>!VL M N7M/@(A:YU>"K#]IR$\V^LA-7]T TY2S?D=@)81?"GE+=];ZX2=O<*7:$P M#&(8()1>K,O-'<
LDQ16S4AK.$FPSVZ%5ZZ0*#6L7KBKA]ZZ=E MPL9KE*NC4NT"77HA.[(%),OL(QF5$R\<1?[(WP91D&;YT6FZ2!VEZJ5?0UV; M!.QE3I.*1HI@2-D';9>>A6Y^B+ZEC0IU.*YP1I#?
>UM5&FU;Q";71.":E&K^ M#H8Y E#<7)S\#5&9\\[(EL_Q\C'>IX2'A,>+X(7> DN/&F8'XC2)^R2,I% 4 M9\)ZMF"S'MX TYK%\7JH.Z?6<,Q=YKU_^^Y[E"NA2@LQ/IZ_!&,#?GZ9[))H
MX",(=:*(U+V,5%"3),F()*S!VZ>H._N"'H91+_AI-B]TRQCR66L[>*I8!9 M+V0)A& 018&,6\YBHN5^YMFWM*[B*-V'&7F4G@-R69N;Y$]XS3UQH2 ,/FC0
M"7:\"W%KO"B?,TG3/?:G4;YPEI*IYG3=67E3,&9(*[:X--S$BF7]FX#!O\&X MN\RLZ)BWA.((U6W1=8KN@NOIB'O\BBM=GIONZ/*)>IV5E[.ZNBJ#V5I3[0HY MYYD.&;=WGT<_N:2%"
])NL=FVO534Y@59*K#-"[)$Z) 4Y%4IV&2[*GB3EG)L!S40N0N02X5&--*%3C46NP?4OS//'7? MXR?R_S25*Z325MV?&G++T8E%P=!)C8]S7I4T8N*@BE9T3%&/K6)9AR12C)4B
M0:@$4H]l7?J<.83_1 ;1%?%V?F.&:7S)40IE:V%^;X.JP-I8TSFQ!L'M.JW2 M;RTNG.TNI);O(D_^=A,_?>?C('=;Y ^UMR)_^?4]I!&#S3>6V4=\P6_VZ"7 M%!9ES/>C<1@6-_5HN2(2
MMLT6.> N7WA)4(R1PI-RAFE4URJ!H0U;L;TF89*AL0UYE^3A8*OX4PF#I5 7 MH2&+\N5V]N>(23."4FN M]DG20BT?<>2BUC9E-6"K_5F)' BB:,!QN[:Y>(LHCD:<<90%V>$F"/']7I
I M(A:QQ0T9N)(3W=!!<$$"BLOU9V*(RJ%2I>:TQ6SRP QR#8+ MVC* F" $)F%#+-4,(@HH3:6BZ)1,MZ);NX MD>YP%>^) SQ$9BW5BSPG!<4)*AI M 4G MC!OY/GE1:?&?VR#"
[Z3V"V7MLDL!M\TI@2 @)LG12?A32%Z4?T!4!TTC**IY MW\4]^Y)]G>YHQF1K5@Y2)VJL$J09;UX 4R\%@A!H<5_>QD+96 M"T2S9C1(5B:
MDH?,,G$GA)& %K*F(PN/.F* .OY4 7&IYJ37Y$&YMI.48FZ\3!NDV,7D,O!(MT:=F=2ZYM$M*S.(T*_ISQE1%PLI(0>0L!"DK0DX5%%!$!'F%P$247$^"N* MKG1#0WB4K/.IO2/
ECU$>#&CR!((S+$'P'.5T]R(=N?F7(TP9[$(I1_MO:1 M!:"J;!SX#<8GY@%Q7YCU:R+CHB/3VQ7"V6,!%;7UH&KOS:W=!]?'$) MJ.Y79V*(R3E:C7_)<)2*W?7C-
VLC>Q=.-9"7/X#XNETT_/V,Q>^6O^9/29"1 M)U_%V^T^*G9Y1'F#$CE;7UD]L_SB0B$07U^%C*L;F\NBMK!E6BSB,%@%61!M MLCD,PD\D54B(5N$D ,LV3C M9+I>"T=[E;
M4N@!E^202X(@B18>=X%,@M^L&AHH5T%,QRUM6/GKI!=Y|"J. M*"0%+R$2)P^13C*06E+EBBZYM:#ES9T?K=% "&L\M.W?@3QT46(N,[?^M:. M7/[X9?
5(0&')@02QF&W7+P+9=?]-&\1 44 #CR[CGHJB4=7$@H1ZR-OH@8.,L M"-AH@H -Q"!@8QH$;)P% >5C\Q(AQ"]-'\)@XTF*$RJE;9-" ;G+#X$H**K(M\4E1!J6":AW;%2U9B;-
)M(Z3+7O^#?F#P$])G+6:EBJ855%+D1 (CJB0<64M M\Z)S#6%$I6WS8N\'&?9S,#=!Y$6KP NK\HBB%7&IBC6V&(*OB*.1A\$A,Y < MG7*ULI9AI5B7NK2[E)XG8/R$P__H_@Y6F
OC2/LYVLIHITBM;S=C!D-[';2 MC$08!)U,$$I29ZC2F]^H%BX5BI4P)TSZ'(?[*/,2=I8\$7DFB9Q=YDA@MAG3 M$0+$%#$R"4,J891+NSF@G5>/J((LZQ"$)6#4XI:/:RM!=TYM"V4!
<48)4':& MNZCY4B@DR"2EDG7%AL MO3"\W*=!A%/Y0-21LLL%(<0V%UHB@+@@PB7A A-%I:P3+HRW.-G02T23^#E[M+.JS2FV32-OEAA)RFR-"44!
<4>&3<*940;E.65+7#7E>ZH+B>95%N:4"4T?66^SA#RQA]2C'*'NE5OAE-$O&;E>#S=ES=-+): MT0,1>50>^5XBHI!*V/]M(U+ W-TCG"0((FGAR>\AJ310J6*9-5/"X:0YCV,@
M)AG>2D\[Z%5L.<@4?,DCG3P(-AF"[*'*J;4GUTP144V7U8R;Q>WE(5Y+R\)D M+ #8"8P;$B X(H4E"XN;=P6XJ9VW?PB#U4T8>_)5EI:,Y8IV/+Q.L;Q: ! #
M>%2R$GE,$#%))|__THM^2_:[;'68)?$*8YIEE5;>2K?^9JAMES.]3&JSR4@5 M$,_ZX)4PL&X"-=]X:(Q8+A?S:-(XK>86KWY;/'KD!4[W64I'4),O@JN5+*\
MO6!@0&>30:$!B'H&,&4;#DP3,=4+E"NCAK:C^5E:5P'$_N5ACM<.EO@E MNR0/^DTQPS#0M3U[,S:G.YG3*H(@85^TLJE>BIH-H >:(U8T@7ZAC2#6BNW[
MR_.NLMTC[I%3>KL_3P&Z[.XDP")*9()0XN4+I A$U MQ/3HZE/N[4[*];67/C!S]NF;C>?MAHJ=UKD<18C;(,)T8:*[6:82=$(,#]B0')44 M/()TH2E(0D797Y-
)^/[Y=HM%B,EPOGA+GRTL=1Y-/_C/^Y#YZ\D$9=H^S*2Y(#&2'9V"@Q MVU#7)]%ZF=,DF)$B&,+U09>#G+3,6]US(MWW)>"GDPE#(.R:72%RHHJ70N4(1/NQ0UA%V3B%
[K&R<'8H+$W+:(3?:(P#79 MTOP=##L$H+ILJ$30+_=QAM$']]'0-=[%:4 <8W-\EE@HD;7)#"7<)D6$@F"X MHD+'K?,4LLB+?!2SO=C:F9PV$>WH<-
HD^',8/FO#9JL$R>+,"Vl-8V;9<6+: M"%H5&? >TW#.B3:I[\E7ZN%7FN+N7 L/6NY=:EF@#H8%,_'%*/5N[?NARMA M"*8EF%;+>6BLIIM&!0SKS'#RU5BCS9L,)UOD\=&R<\;-
DGB'D^PP(Y@S,J&D MD\D=7=62!\Y]%9M<,P'?))I*'@S+#$#E5=AR%>;?<"E?^K7W[OW;E,#SZ';+ M+?92/ \VC]ET_2G%S']+WH-&QR;/C. WB:94
,,T$Y1@<9G9/PE_Y+LL<]:IXD2C5IP M$9GW,$T4I1NH@Z%D?\S2%>Y=W@0+L;R\$136K11#WQ_=CWQ7S6N"P3!L,Z'4(NNBN9=%&N
MNSHGTC5,&Z0>/5]\P'H75*G877O7@VXNOS9< MFG50TTRGX&Z50F: ?)FBJP&&;$8PY0L5(=5"<55/-*T<&Z#U"F/'YMJ=F3DQ MQZY+N[YA[+7:&Y -
Q^6<,>S<.?,:O4@?:#J+TS4!.MC(7+G]"&G3 M:(FW]'QR\@#/;$OWG499E@0/^RQ?O)UYBM%L0#L."6=NIH**^D:@DM08.7]3
M3D)CKTO4W!>:DTDEWGKY%A&MCI"0266:E^_X_]Y^^_;M.]3S$O1$SX1=H._? MOD5I7M3#VV>/<1+\3L2]E.;R+,A7Q+3B&?KP]@)1KK(]ICORUA[1AW?Y/UT@
MHKO#K)QT>+A ?S]R;U_OL_E0T']/(#/\^WK0N'#']($6S^X#[89%51'N.0 M3.-3(W>O4K![,EL'O'U"6R8-IDMI(7)89F<]L\?I[?7X_GBW_[PE_?O_OPW M=#V^F5Q-
QO=7[@>"6=EUF6&J8[="2;N)MU*H[7Q;3@P,>^38!'<]OV+?T_\;CK M98(A\4(])GZ;7S'$C[*K A!!UE_1^_<7?_G^P\7[[]\QR1\N/OSIP\6?O_^+ M]-$&0SY+-"_N]V1Q1V$8O?
CQ^[<7W__Y?7?<'_:DDXW[#]GJP/K0VQ\^O&7] MZ')Y[?.O>7&S97R)\W?988)$QD8/4L*CW4+'W]X"R/&!*&]W_^OL&M5:.K#2?5-W"BR9'OL\KG7CCS G\277F[(/.D
MZ8PR::MII&K(K911L:ASDIKAXU)!*VGBW0/_31"]6>4*[FFT6NVW^Y!6R&,; MDK1@<8(?<902PM/Z>5M\&Z?I/K0#;A M-E&TR5QS0YIDU6N!X:WX507CY0?
7ZSEFZSBPMGND^,2)6&E# MO%S"R9F#H]5I"_0?N1\XBGQC*NG5'.T<*HV0;"<*=6"1SA"M=N/Q G5WD]#M_AH!7V?
L;$7,O&2:L&*6OJJ(<6]MAYM+.I,46THR53"#;3^\TNVC%=L^8KM' MB6+W]%K&@L;:?.U@5*VCF;TM7LLA2V4F*-C958'*2@G.8]E8+YO"I*-P#=%(MPSD-^?5% W'8]%.O/?:D7FM?
&R;[Y#>OF*LYYZ'D]A53'=B,U-_,I"6\9DN M9SE^&[MG=&FJ[&ZSNT]L::8)AK.]X&IWR>&$CFV[#"-'G9([!IK$C6H-H(PS MC!HYIG&;ZB 9IPP.50JNF28/#>72H!FF# QE[
(2^8GLT0=^6BW7'-.$?1H5 MT&S3!WTRRD&*ZAJY4#U#.B--1SEI?8(Y S4P/#'3]DYF@Q/#<;=9:@,X188C MOIF$;@IQB/PR#-K:O((7L7$6*
<,UJ;137LD#-8DH7#XI0S01ERZ@!&@]+D0V M4W%**4U6*F\ NLJ:5\@ZIXXA0!5CRO"JF5COW&'E>:K5I:F:0Y-2 M:;OWM"DAMZ]L$XHZ9Y,9/OXB-RJ-&C?_*_OCS=?

5!+=A.'!YO:SB3NW0P8W@['WN7T?/QY M?/|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e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||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l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`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`I>3'+ M%!:>[%ML$6OU-[AR7,:\,'Q77[B*&H)5=>||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

*R6XM&'*Y,;O_QFUS3G_614:V M)%5O E+O*5_W$@I;7E14 .XL)@HD(>75&2'M,N?2"UG6CB@1[M_^\)?W[|[] M[=SI<#EY)U'5A?9IIQ.9=1GAVSA5T_8X>=]743/X-.W""-}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|C_ F':\ CCZ/1;[OGMI_[ZONMZ#6>O=ZQ>RZ!#@|-552WH] MJYL?7C_E!EK@1EF6L M(:-\0WOBAU[%V[XM*#WWME9K?)FZUV5FZ(F&RP.KRV18?HC7<%102 9= M4B*H*^Z<9N88A9=27B FQTKYL$LJH53C*8I\,5"WF@([$ED'U=G$< 7UU]J" M8%BD0L===5]0AS]U9Y9ES?H3\CB4*)S]J-=IGCW$2_"X^9Z80AW^U[>G3_9MS @I4W'2+4Q'UNH.V?E-7](ZEL YMC'^>X*6]36$M-8VR8W>YK4 MI*>A*AB&|L/:)2G51D&ECI)*/P]F(?&TW1<;-SC7-V;K4J;-U=UY4;U1>M;VV?J84>VUF2@YIUI?I%V.Y;KH MN7L.I8\WM#:PW7@K/-K&^RC3CV2UK.4Y?T:ZI7+&]<7)[Z>33\'VTYV/265$ ME,Z\ ]TQN|H3_Q1EHXA>L[3*_R(SVTC5:M34PY@6T0STG#N& 6 %=XPG^T8& M4>]>? G@7IT%V&W@/- (*\@87F PSD'62Q'YQUXB_UID-E!FM'X@]8 >M&A' :N M Q)X!][.N65O"9#79L4[65.DZ%&BF (V@>3 MMNES1/]!KNZAUP>9IYBM:A7"S9#T0&F-4>_'NK.Z3D<HE8;[%67E0%YW MN^FZL5VSP*M]PM8C>@3CV+KFKELJ0 M/U\$2TH?#8W85=Y$7QX+%1W25F&(@]4"+:BDE$/E!W5"-IKD9CUHI!-]CWPY M.FVN9V WY+OE? UK&E[A]F*H9R/31MA8^]C>IBB'-59US;AA>;]&V;(";3R/Z M0LL_DUCS 1N<)3MSOF4=AE012YVNF*^ U&1^8!"0^(I+G(V3YC$CQY6?"$RR6/@QBK M0.SB9Y6";'Q>3@;*9Y8!XS]W*6DQ!"B&CSC)]4@=QW1-0FOJ.LHT7?4P9-:" M@U"@CVF"<,|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lY%1>DZ5[326ZIDCW$NL@785QND_P=,<6P]+-+28FS&DEU'B]3^G% MJSA+1Y'/_GWZ$ 8;]A[3T4.:)61VQV?$'=\F'+=\TB7%#9CM4C!0".- M_:2@#3O4_2&G;H0WJ.#W8*W8/^^3#WC@:_OVDIWQ.!CW, M;F<[U8AW8H\D.VVBE7;G7X1G3S2B\,,LW:&4+M.]DRFNHJH>893[N.DT4 (= M&>E"H=LN,4X7!YG%V;B8YY-Y7UD6KBH.8!#XJ=5=1=PF11G";I4NE !F(&XM M^1)M4/I]3P4"WM <3%S]Q7'\%!{#"GF,8O]KW2E*'>FU("S MBM83+U<3*/\=[>B\("\,%,N^):QOIZE6IU-Z-5]0)G+]:E$('Y'T*OA0&I% MG-P>U5KX51PQX;T7HD_$.Z?L("7VT967/]*;,'Y.T4VXFDRQW3H,U9Z_&&-WWC|-:<3V5.9D*W M?U"NO0Y^7^_)[.TE6S[C\ G?D:[\V)TV']\<.&XKC.[- ;$%;KXO7<@,$K/[3 MJV$U[9W+Y_C(-U.U I'#'1.'4+=HXM4QMHU;0-3O7PU1CWP3,*EY#"?MQM!Q MYH6J>51/U%PA4=H^VC?CXA[S)_=$;4;TXY<5$6U?:=SG;(=#"%GL>YA-PV8;+-?706!1DB6EK2BDE*,EV[]J?'JF#$@]1>3%< M\S#35941H8^,X!4,1J#9.IZL:7KB>X6?* +$?9+Z=_%4F%0O44Z&3'1*^?\7 M?'0>H:=NTIRN*KJQN0V.^XGSUGTX? N<,2T0<3SZ:47B"1UB4_,$WB/A(^$$H MUO-1%7L;U).%]KS[9P?.()C<.V+\K&'ALTW*'?0]#L1I$M0$MQPU\R $[@6.&"D1N.6F81H#"$!@B0[3BP MC?VO)5W7V4VZ-MYK>K#A.|O, 3U6VJ>;Y6E5,TK^(IL_X>LTW?X6PDYL#@O MR3AS\$FA \D;]ZD!Z)H3'/3GG!(F8:N69R5&,R%,(?0UK>#FU-[A?BJ8>K_+ M_YS4L8C:$Z_&;;/- E_NLEP3SFC28\OQ8T9CA/+Q:N2(.Y07B/*!843-O0M6B M)K22ME/G1W"]{4G%X,3F2JY[K_?H50G5=CS",I&=]1N$ M.W@(8:!#,XH=X+1,'!TI$;1HGA:,VG S|4S 3A[0>C30#@NZ01>*/P%PV)N M$ 7)ZO95SXMQGRSE-P6%2WYDN>8D3SX0D4 .IMABP0T.J$Q.5^D8]OK;-4B MZ[%V:1E6: =R4'&B7)%7M&G:I67%:MA:].F%82@ZB^5\.8V8=;W73"4>OW MEG*VS)'[-[%/CS5;1'"K/ RW'K716V;[+)IL.ZY@>V)W\|P:G<^-;S\|&_D1 M%7KTV<:85,&#/O ,HB>'F"3&/"LXLQL "TD['B5QK. *OD.ZS**RO%M_B^ ! M9'7'9*;XNBJK2-QB6 ;2--M9W]QZ-F+PCG:")[C%S02]/=Z2].6@WFZHJP-C M&Z[?^:R9EO2>I3'M?BR;7TMCK,A>@LY\O3!;F=[XK3K> B>L0E+;*'854/?< MF@7'0HKO(F@*]8_A;(-R8H(/'&I*-D>?(]_2E_3A.:)S8FB_'[.25N#-;"/ M]D=T[C "9@BW85 .'VGI@JO?4NM;5C^|WFRS8D?I!Q4"P&;GFNAALC81V"UV K?A M*% [66047C7&33IPPNJES\2SX[,7%Q!%1#J+'XH+*YFFGW#'!]Z2(SZ83_BVQ MCQE2)R@DC^<\@O*=IUD:(2X,3*+4#GR0GL:0G2<<09O@Y-A[2EDK>;DBM MU]G5% [BQ2:O44+KL(&FXU'],IFA1QGV9<3$*Y;1+$B&?5"_B_,_HEZ&+1KO M3Q#K$(%LZMW>]JF$#NW>;(I<|))F!GYLN/0]" -8L8(9KBT%MTQMTA:-!W7' M0H+4>A!%)BU83!OWA^.NSTR&2U%.C%I@6TL,;IQPEW8"^ V%(B*678SZ(Z[^ M-B#38|R!).BF0AFCD_MW!RVNKI\&JI^G^HFFO38(OL6_XKM0N&\W. M-O^/2 M@1FYS6N"K3M8()ETPZT:233:1P(J0W M@;,$/D#$%P(M8-V6?WCNOR^R--[9K<.7$9<5S$3M"N'1?!M21&B%]LV23OQW M2'-8I^6+>*ZU3.[B,I6)3|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|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|+.S|-|=V#-4#"+'9?*]\(^5O?O?_O[?[=731T7 ;; 4>1;&EI M-4VKFM%E53&Q&#]$E3%YAYL!E^H|T>H!YI(- CH4-'_DE:CE_)8SSADK\JIBB M++OX^,(HW7LC\O=_(]R1M_3MAGI$L:W=!1[/MMX\ M7#5(ML!1BOS$6;$HKNHH^YHG;2DN0&AR&94OG[+B#6Y<1-/OGK+T6723=|#B MH:)Q6<+1V^4*8U0^0=1O$/@($5\A_#/-SJG_$)+E=^P4;>[GNJP#)D^>DP&7 M*7BB=84YYL*YTUPS]DD5SCT9U.5OSU&T_2XV"^5ES=@HPX^1X/OOWI.G[&SZ M&.!N].#&I=4*$U0+TM %[61[[Z+KUHG^#-2-;:P.!*C9#5:G0M2]#G#:I7A/ M&MI^%2@3/8ZSJWWZ.%#7BKO6)L.(=$^9>EBG^OY?:#K: 4YSM8J?%T3X99_I M2JR!54'N(QS6#1Y_+X5,|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|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|\.GI563#"26'"3I6$+HX8|HS2': PX?SWGZ M%TWNUI#_5M.#C1"+'B;Q:8]8+ QA2C)"A3R19N^JADH@TG/89R|5TTJO\IN4 MUEHR/U,L_]&%8]'V2=]DUXP|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

"